CONTENT ALERTS FROM

Clinical Infectious Diseases, The Journal of Infectious Diseases, Open Forum Infectious Diseases, and Journal of the Pediatric Infectious Diseases Society

CID, JID, OFID, and JPIIDS content alerts let you receive leading infectious disease research in your inbox the instant new issues and content publish online.

Visit oxford.ly/e-alert_registration to register for New Issue alerts and Advance Article alerts.
Dear Colleagues,

It is our pleasure to welcome you to IDWeek™ 2019! As the IDWeek Program Chairs representing the four societies, we are excited about this year’s conference, showcasing critical advances and the latest science and bench-to-bedside approaches to diagnosis, treatment, and prevention of infectious diseases. Leveraging the expertise of the Program Committee, we are welcoming more presenters and posters than ever before.

IDWeek intentionally incorporates expertise from the membership of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, and the Pediatric Infectious Diseases Society to create the most compelling educational program with the latest scientific advancements. IDWeek is the best opportunity to learn from experts in the field how to implement the newest diagnostic and treatment modalities; apply state-of-the-art science to clinical care; manage current infectious diseases outbreaks; and practice the latest prevention strategies.

IDWeek 2019 is an opportunity to build your strategic network by sharing your passion with others during networking times. After attending sessions, viewing posters and meeting colleagues over the next few days, we hope that all attendees leave IDWeek energized to tackle the important work of improving patients’ lives.

We sincerely hope you enjoy the program as much as we enjoyed creating it. IDWeek is constantly evolving, so if you have suggestions for topics or ideas you would like to see at IDWeek 2020, please tell a staff member. Set your calendars now for IDWeek 2020 scheduled for October 21-25, 2020 in Philadelphia, PA.

With best regards,

Cesar A. Arias, MD, PhD, FIDSA  
IDWeek Chair, IDSA

Kristina A. Bryant, MD, FPIDS  
IDWeek Chair, SHEA

Eric S. Daar, MD  
IDWeek Chair, HIVMA

Roberta L. DeBiasi, MD, MS, FPIDS, FIDSA  
IDWeek Chair, PIDS
The IDWeek partners wish to extend a special Thank You to the following organizations who developed sessions in collaboration with the IDWeek Program Committee (see Allied Partners on page 15 for specific session details):

- American Society of Transplantation
- Centers for Disease Control and Prevention
- European Society of Clinical Microbiology and Infectious Diseases
- European Society for Paediatric Infectious Diseases
- IDSA Clinical Affairs Committee
- IDSA ID Training Program Directors’ Committee
- IDSA Medical Education Community of Practice
- IDSA Education Committee
- IDSA Telehealth Committee
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- National Network of STD Clinical Prevention Training Centers
- Pan-American Society of Infectious Diseases, Brazilian Society of Infectious Diseases
- PIDS Training Programs Committee
- Society of Infectious Diseases Pharmacists

The IDWeek Program Committee would like to extend a special Thank You to the following individuals who generously donated their time and expertise to review abstracts for IDWeek 2019:

Sonali Advani, MBBS, MPH; Yale School of Medicine, New Haven, CT
Majdi Al Hasan, MD; University of South Carolina, Columbia, SC
Upton Allen, MBBS, MSc; Hospital for Sick Children, Toronto, ON
Paul Ambrose, PharmD; Institute for Clinical Pharmacodynamics, Inc., Schenectady, NY
Evan Anderson, MD; Emory University, Atlanta, GA
Marsha Anderson, MD; University of Colorado School of Medicine, Aurora, CO
David Andes, MD; University of Wisconsin Hospital, Madison, WI
Lydia Aoun Barakat, MD; Yale University School of Medicine - Griffin Hospital, Derby, CT
Senu Apewokin, MD; University of Cincinnati, Cincinnati, OH
Monica Ardura, DO, MSc; Nationwide Children's Hospital, Columbus, OH
Cesar Arias, MD, PhD; University of Texas Health Science Center, Houston, TX
Wendy Armstrong, MD; Emory University, Atlanta, GA
David Aronoff, MD; Vanderbilt University Medical Center, Nashville, TN
Ann Avery, MD; MetroHealth Medical Center, Washington, DC
Maja Babic, MD; Cleveland Clinic Foundation, Cleveland, OH
John Baddley, MD, MSPH; University of Alabama At Birmingham, Birmingham, AL
Rajinder Bajwa, MD; Niagara Falls Memorial Medical Center, Niagara Falls, NY
David Banach, MD; University of Connecticut School of Medicine, Farmington, CT
Ritu Banerjee, MD, PhD; Vanderbilt University Medical Center, Nashville, TN
Luis Barroso, MD; Wake Forest Baptist Health, Winston-Salem, NC
Alice Barsoumian, MD; Brooke Army Medical Center, San Antonio, TX
Robert Bednarczyk, PhD; Emory University, Atlanta, GA
Elie Berbari, MD; Mayo Clinic College of Medicine, Rochester, MN
Luiz Bermudez, MD; Oregon State University, Corvallis, OR
Vladimir Berthaud, DTM&H, MD, MPH; Meharry Medical College, Nashville, TN
Adarsh Bhimraj, MD; Cleveland Clinic Foundation, Cleveland, OH
Tiffany Bias, PharmD; Hahnemann University Hospital, Philadelphia, PA
Brian Blackburn, MD; Stanford University School of Medicine, Stanford, CA
Chris Bland, PharmD; University of Georgia College of Pharmacy, Savannah, GA
Anne Blaschke, MD, PhD; University of Utah School of Medicine, Salt Lake City, UT
Karen Bloch, MD, MPH; Vanderbilt University Medical Center, Nashville, TN
Dana Blyth, MD; Brooke Army Medical Center, San Antonio, TX
Erin Bonura, MD; Oregon Health and Science University, Portland, OR
Helen Boucher, MD; Tufts Medical Center, Boston, MA
Beau Bruce, MD, PhD
Kristina A. Bryant, MD; University of Louisville, Louisville, KY
Chloe Bryson-Cahn, MD; University of Washington, Seattle, WA
Steve Burdette, MD; Wright State University, Dayton, OH
Yvonne Burnett, PharmD; St. Louis College of Pharmacy, St. Louis, MO
Angela Campbell, MD; Centers for Disease Control and Prevention, Atlanta, GA
Wesley Campbell, MD, MPH; US Navy, Bethesda, MD
Joseph Carreno, PharmD; Albany College of Pharmacy and Health Sciences, Albany, NY
Karen Carroll, MD; John Hopkins University, Baltimore, MD
Jose Castillo-Mancilla, MD; University of Colorado, Aurora, CO
Kelly Cawcutt, MD, MS; University of Nebraska Medical Center, Omaha, NE
Michelle Cespedes, MD, MS; Icahn School of Medicine at Mount Sinai, New York City, NY
Cody Chastain, MD; Vanderbilt University Medical Center, Nashville, TN
Kartikeya Cheraubuddi, MD; University of Florida College of Medicine, Gainesville, FL
Pearlie Chong, MD; University of Texas Southwestern Medical Center, Dallas, TX
Andrew Chou, MD; Michael E. DeBakey VA Medical Center & Baylor College of Medicine, Houston, TX
Neil Clancy, MD; University of Pittsburgh, Pittsburgh, PA
Susan Coffin, MD, MPH; Children’s Hospital of Philadelphia, Philadelphia, PA
Sue Cohn, MD, MPH; Northwestern University Feinberg School of Medicine, Chicago, IL
Jonathan Colasanti, MD; Emory University Rollins School of Public Health, Druid Hills, GA
Katya Corado, MD; David Geffen School of Medicine at UCLA, Los Angeles, CA
C. Buddy Creech, MD, MPH; Vanderbilt University Medical Center, Nashville, TN
Chris Cnich, MD, PhD; University of Wisconsin, Madison, WI
Eric Daar, MD; Harbor-UCLA Medical Center, West Carson, CA
Inger Damen, MD; Centers for Disease Control and Prevention, Atlanta, GA
Richard Danila, PhD; Minnesota Department of Health, Saint Paul, MN
Michael David, MD, PhD; University of Pennsylvania, Philadelphia, PA
Acknowledgements (continued)

Shandra Day, MD; Ohio State University, Columbus, OH
Robert L. DeBiasi, MD, MS, FIDSA, FPIDS; Children's National Health System/GWU School of Medicine, Washington, DC
Sahera Dirajal-Fargo, DO, MS; UH Rainbow Babies and Children's Hospital, Cleveland, OH
Avika Dixit, MBBS, MPH; Boston Children's Hospital, Boston, MA
Sarah Doernberg, MA, MD; University of California, San Francisco, San Francisco, CA
Yohei Doi, MD, PhD; University of Pittsburgh School of Medicine, Pittsburgh, PA
Kevin Downes, MD; Children's Hospital of Philadelphia, Philadelphia, PA
Lisa Dumkow, PharmD; Mercy Health Saint Mary's, Grand Rapids, MI
Marlene Durand, MD; Massachusetts General Hospital, Boston, MA
Michael Durkin, MD, MPH; Washington University School of Medicine, St. Louis, MO
Kathy Edwards, MD; Monroe Carell, Jr. Children's Hospital at Vanderbilt, Nashville, TN
Nadim El Chakhtoura, MD; Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH
Rana El Feghaly, MD; Children’s Mercy Hospital, Kansas City, MO
Razan El Ramahi, MBBS, University of Nebraska Medical Center, Omaha, NE
Hana El Sahly, MD; Baylor College of Medicine, Houston, TX
Emily Erbelding, MD; NIH: National Institute of Allergy and Infectious Diseases, Bethesda, MD
Joe Eron, MD; University of North Carolina at Chapel Hill, Chapel Hill, NC
Charlesnika Evans, PhD; Northwestern University, Evanston, IL
Carl Fichtbaum, MD; University of Cincinnati College of Medicine, Cincinnati, OH
Tom File, MD; Summa Health System, Akron, OH
Christine Fiske, MD, MPH; Vanderbilt University Medical Center, Nashville, TN
Michelle Floris-Moore, MD, MS; University of North Carolina at Chapel Hill, Chapel Hill, NC
Donald Forthal, MD; University of California, San Francisco, San Francisco, CA
Richard Franco, MD; University of Alabama at Birmingham, Birmingham, AL
Bishara Freij, MD; William Beaumont Hospital, Royal Oak, MI
Bettina Fries, MD; Stony Brook University, Stony Brook, NY
Raj Gandhi, MD; Massachusetts General Hospital, Boston, MA
Anuradha Ganesan, MD; Walter Reed National Military Medical Center, Bethesda, MD
Julia Garcia-Diaz, MD; Ochsner Clinic Foundation, Jefferson, LA
Michael Glickman, MD; Memorial Sloan-Kettering Cancer Center, Manhattan, NY
Roderick Go, DO; Stony Brook University Medical Center, Stony Brook, NY
Marcia Goldberg, MD; Massachusetts General Hospital, Boston, MA
Rachel Gordon, MD, MPH; Columbia University, New York City, NY
Bruno Granwehr, MS, MD; Anderson Cancer Center, Houston, TX
David Greenberg, MD; University of Texas Southwestern, Dallas, TX
Patricia Griffin, MD; Centers for Disease Control and Prevention, Atlanta, GA
Alice Guh, MD; Centers for Disease Control and Prevention, Atlanta, GA
Natasha Halasa, MD; Vanderbilt University Medical Center, Nashville, TN
Kimberly Hanson, MD; University of Utah, Salt Lake City, UT
David Hardy, MD; Johns Hopkins University School of Medicine, Baltimore, MD
Josh Hartzell, MD; Walter Reed National Military Medical Center, Bethesda, MD
Mary Hayden, MD; Rush University Medical Center, Chicago, IL
Randall Hayden, MD; St. Jude Children's Research Hospital, Memphis, TN
Michelle Hecker, MD; MetroHealth Medical Center, Cleveland, OH
Adam Hersh, MD, PhD; University of Utah, Salt Lake City, UT
Lena Heung, MD, PhD; Cedars-Sinai Medical Center, Los Angeles, CA
Elizabeth Hirsch, PharmD; University of Minnesota College of Pharmacy, Minneapolis, MN
Amy Hirsch
Sally Hodder, MD; West Virginia University, Morgantown, WV
Tobias Hohl, MD, PhD; Memorial Sloan-Kettering Cancer Center, Manhattan, NY
Marisa Holubar, MD, MS; Stanford University School of Medicine, Stanford, CA
Misha Huang, MD, MS; University of Colorado, Aurora, CO
David Hyun, MD; The Pew Charitable Trusts, Washington, DC
Kengo Inagaki, MD, University of Mississippi Medical Center, Jackson, MS
Michael Ison, MD, MS; Northwestern University Feinberg School of Medicine, Chicago, IL
Lisa Jackson, MD; Kaiser Permanente Washington, Seattle, WA
Andrew Jameson, MD; Mercy Health Physician Partners, Grand Rapids, MI
Erica Johnson, MD; Johns Hopkins University School of Medicine, Baltimore, MD
James Johnson, MD, University of Minnesota School of Medicine, Minneapolis, MN
Bruce Jones, PharmD; St. Joseph's/Candler Health System, Savannah, GA
Robin Jump, MD, PhD; Case Western Reserve University, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH
Sarah Kabbani, MD; Centers for Disease Control and Prevention, Atlanta, GA
Mini Kamboj, MD; Memorial Sloan-Kettering Cancer Center, Manhattan, NY
David Kaufman, MD; Cumberland Internal Medicine, Vineland, NJ
Marla Keller, MD; Albert Einstein College of Medicine, Bronx, NY
Colleen Kelley, MD, MPH; Emory University, Atlanta, GA
Emily Kendall, MD; Johns Hopkins University School of Medicine, Baltimore, MD
Rachel Kenney, PharmD; Henry Ford Hospital, Detroit, MI
Larry Kociolek, MD, MSc; Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
Sophia Koo, MD, MSc; Brigham and Women’s Hospital, Boston, MA
Jennie Kwon, DO, MS; Washington University School of Medicine, St. Louis, MO
Tahaniyat Lalani, MBBS; Uniform Services University of the Health Sciences, Bethesda, MD
Raphy Landovitz, MD, MSc; University of California, Los Angeles, Los Angeles, CA
Mike Lane, MD, MPH, MSC; Washington University School of Medicine, St. Louis, MO
Ebbing Lautenbach, MD, MPH, MS; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Jennifer Le, MA, PharmD; University of California San Diego, San Diego, CA
Francesca Lee, MD; University of Texas Southwestern Medical Center, Dallas, TX
Stu Levitz, MD; University of Massachusetts Medical Center, Worcester, MA
Michael Lin, MD, MPH; Rush University Medical Center, Chicago, IL
David Lindholm, MD
Daniel Livorsi, MD, MSc; University of Iowa, Iowa City, IA
Vera Luther, MD; Wake Forest School of Medicine, Winston-Salem, NC
John Lynch, MD, MPH; Harborview Medical Center and University of Washington, Seattle, WA
Ann Macintyre, DO
Theresa Madaline, MD; Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY
Shelley Magill, MD, PhD; Centers for Disease Control and Prevention, Atlanta, GA
Barbara Mahon, MD, MPH; Centers for Disease Control and Prevention, Atlanta, GA
Monica Mahoney, PharmD; Beth Israel Deaconess Medical Center, Boston, MA
Jasmine Marcelin, MD, University of Nebraska Medical Center, Omaha, NE
continued on next page
Acknowledgements (continued)

Emily Martin, PhD; University of Michigan School of Public Health, Ann Arbor, MI
Amy Mathers, MD; University of Virginia, Charlottesville, VA
Celia Maxwell, MD; Howard University College of Medicine, Washington, DC
Dana Mazo, MD; Mount Sinai Queens, Astoria, NY
Danya McManus, PharmD; Yale New Haven Health, New Haven, CT
Kathleen McManus, MD, MS; University of Virginia, Charlottesville, VA

Candice McNeil, MD, MPH; Wake Forest School of Medicine, Winston-Salem, NC
Sanjay Mehta, MD; University of California San Diego, San Diego, CA
Sapna Mehta, MD; New York University School of Medicine, New York City, NY
André Mélençon, MD, MSc; Parkview Physicians Group, Fort Wayne, IN
Michael Melia, MD; Johns Hopkins School of Medicine, Baltimore, MD
Alfredo Mená Lora, MD; University of Illinois at Chicago, Chicago, IL
Lina Meng, PharmD; Stanford Hospital, Stanford, CA
Julia Messina, MD; Duke University, Durham, NC
Rachel Miller, MD; Duke University, Durham, NC

John Mills, MD; University of Michigan, Ann Arbor, MI
Jose Miro MD, PhD; Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) - University of Barcelona, Barcelona, Spain
Christopher Moore, MD; University of Virginia, Charlottesville, VA
Caitlin Moran, MD; Emory University School of Medicine, Atlanta, GA

William Muller, MD, PhD; Northwestern University, Chicago, IL
Flor Munoz, MD; Baylor College of Medicine, Houston, TX
David Mushatt, MD, MPH; Tulane University School of Medicine, New Orleans, LA
Susanna Naggie, MD; Duke University Medical Center, Duke Clinical Research Institute, Durham, NC

Jeniel Nett, MD; University of Wisconsin, Madison, WI
Natalie Neu, MD; Columbia University, New York City, NY
Kathy Neuzil, MD, MPh; University of Maryland School of Medicine, Baltimore, MD
Priya Nori, MD; Montefiore Medical Center, Bronx, NY
Josh Nosanchuk, MD; Albert Einstein College of Medicine, Bronx, NY

Chris Ohl, MD; Wake Forest University School of Medicine, Winston-Salem, NC
John O’Horo, MD, MPH; Mayo Clinic College of Medicine, Rochester, MN

Nora Oliver, MD, MPh; Emory University, Atlanta, GA
Veterans Affairs Medical Center, Atlanta, GA
Luis Ostrosky-Zeichner, MD; McGovern Medical School at UTHealth, Houston, TX
Tara Palmore, MD; National Institutes of Health, Bethesda, MD
Dimple Patel, PharmD; Morristown Medical Center, Morristown, NJ
Payal Patel, MD, MPh; University of Michigan, Ann Arbor, MI
Andrew Pavia, MD; University of Utah, Salt Lake City, UT
Frederico Perez, MD, MS; Case Western Reserve University, Cleveland, OH
Steve Pergram, MD; Wake Forest University School of Medicine, Winston-Salem, NC
Sarah Perloff, DO; Albert Einstein Medical Center, Bronx, NY
Anna Person, MD; Vanderbilt University School of Medicine, Nashville, TN
Lindsay Petty, MD; Michigan Medicine, Ann Arbor, MI
Varun Phadke, MD; Emory University, Atlanta, GA
Jennifer Phillips, MD, PhD; Washington University School of Medicine, St. Louis, MO
Mario Poljak, MD, PhD; University of Ljubljana, Slovenia
Kyle Popovich, MD; Rush University Medical Center, Chicago, IL
Paul Pottinger, MD; University of Washington, Seattle, WA
Karen Ravin, MD; Nemours Alfred I. duPont Hospital for Children, Wilmington, DE
Sujan Reddy, MD, MSc; Centers for Disease Control and Prevention, Atlanta, GA

Mona Rigaud, MD; NYU Langone-Brooklyn, Brooklyn, NY

María Rodríguez-Barradas, MD, Michael E. DeBakey VA Medical Center, Houston, TX
Nadine Rouphael, MD; Emory University, Atlanta, GA
Theresa Rowe, DO; Northwestern University Feinberg School of Medicine, Chicago, IL
Eric Sachinwalla, MD; Einstein Medical Center Philadelphia, Philadelphia, PA
Rafik Samuel, MD; Temple University School of Medicine, Philadelphia, PA
John Sanders, MD, MPH; Wake Forest University School of Medicine, Winston-Salem, NC
Roberto Santos, MD, MSc; Children’s of Mississippi, University of Mississippi Medical Center, Jackson, MS
Patrice Savard, MD, MSc; Centre hospitalier de l’Université de Montréal, Montréal, Canada
Jennifer Schuster, MD, MSc; Children’s Mercy Hospitals and Clinics, Kansas City, MO
Brian Schwartz, MD; University of California, San Francisco, San Francisco, CA
David Schwartz, MD; Stroger Hospital of Cook County, Chicago, IL

Hyman Scott, MD, MPH; University of California, San Francisco, San Francisco, CA
Cynthia Sears, MD; Johns Hopkins School of Medicine, Baltimore, MD
Isaac See, MD; Centers for Disease Control and Prevention, Atlanta, GA
Sam Shelburne, MD, PhD; MD Anderson Cancer Center, Houston, TX
Erica Sheny, MD, PhD; Massachusetts General Hospital, Boston, MA
Masako Shimamura, MD; Nationwide Children’s Hospital, Columbus, OH
Kari Simonsen, MD; University of Nebraska Medical Center, Omaha, NE
Dawd Siraj, MD; University of Nebraska Medical Center, Omaha, NE
Jessica Snowden, MD; University of Arkansas for Medical Sciences, Little Rock, AR
Geeta Sood
Paul Spearman, MD; Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Kevin Spicer, MD; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Steven Shaefer Spires, MD; Duke University School of Medicine, Durham, NC
Emily Spivak, MD; University of Utah School of Medicine, Salt Lake City, UT
Victoria Staller, MD; University of Louisville, Louisville, KY
Michael Stevens, MD, MPH; Virginia Commonwealth University School of Medicine, Richmond, VA
Usma Stiefel, MD; Cleveland VA Medical Center; Case Western Reserve University, Cleveland, OH

Luke Strnad, MD; Oregon Health and Sciences University, Portland OR
Geetha Suleyman, MD; University of Toledo Medical Center, Toledo, OH
Sankar Swaminathan, MD; University of Utah School of Medicine, Salt Lake City, UT
Keipp Talbot, MD, MPH; Vanderbilt University Medical Center, Nashville, TN
Thomas Talbot, MD, MPH; Vanderbilt University School of Medicine, Nashville, TN

Vincent Tam, PharmD; University of Houston College of Pharmacy, Houston, TX
Tina Tan, MD; Feinberg School of Medicine - Northwestern University, Chicago, IL
Michael Tekippe, MD, PhD; Advocate Children’s Hospital, Oak Lawn, IL
George Thompson, MD; University of California, Davis, Davis, CA
Nicola Thompson, MSc, PhD; Centers for Disease Control and Prevention, Atlanta, GA
Samad Tirimizi, PharmD; Yale New Haven Hospital, New Haven, CT
Jeffrey Tornehim, MD, MPH; Johns Hopkins University School of Medicine, Baltimore, MD

Harrys Torres, MD; University of Texas MD Anderson Cancer Center, Houston, TX
Acknowledgements (continued)

Virginia Triant, MD; Massachusetts General Hospital, Boston, MA
Snigdha Vallabhaneni, MD; Centers for Disease Control and Prevention, Atlanta, GA
Roberto Viau, MD; Tufts Medical Center, Boston, MA
Richard Watkins, MD; Cleveland Clinic Akron General, Akron, OH
Jill Weatherhead, MD; Baylor College of Medicine, Houston, TX

Robert Weinstein, MD; Rush University Medical Center, Chicago, IL
Sharon Weissman, MD; University of South Carolina/Palmetto Health, Columbia, SC
Zachary Willis, MD, MPH; University of North Carolina, Chapel Hill, NC
Laila Woc-Colburn, MD; Baylor College of Medicine, Houston, TX
Joshua Wolfe, MBBS; St. Jude Children’s Research Hospital, Memphis, TN
Karen Wong

Rebekah Wrenn, PharmD; Duke University Hospital, Durham, NC
Vincent Young, MD, PhD; University of Michigan Medical School, Ann Arbor, MI
Heather Yun, MD; Brooke Army Medical Center, San Antonio, TX
Gary Zeitlin, MD; White Plains Medical Associates, White Plains, NY
Andrea Zimmer, MD; University of Nebraska Medical Center, Omaha, NE

The IDWeek Program Committee would like to extend a special Thank You to the following individuals who generously donated their time and expertise to review cases for IDWeek 2019:

Elisabeth Adderson, MD; St. Jude Children’s Research Hospital, Memphis, TN
Wendy Armstrong, MD; Emory University, Atlanta, GA
Jennifer Babik, MD, PhD; University of California, San Francisco, San Francisco, CA
Nesli Basgoz, MD; Massachusetts General Hospital, Boston, MA
Christy Beneri, DO; Stony Brook University Medical Center, Stony Brook, NY
Samina Bhumra, MD; Indiana University School of Medicine, Indianapolis, IN
Karen Bloch, MD, MPH; Vanderbilt University Medical Center, Nashville, TN
Emily Blumberg, MD; Hospital of the University of Pennsylvania, Philadelphia, PA
Erin Bonura, MD; Oregon Health and Science University, Portland, OR
Andres Camacho-Gonzalez, MD, MSC; Emory University, Atlanta, GA
Maria Carrillo-Marquez, MD; University of Tennessee Health Science Center, Memphis, TN
Jose Castillo-Mancilla, MD; University of Colorado, Aurora, CO
Henry Chambers, MD; University of California San Francisco, San Francisco, CA
Natasha Chida, MD, MSPH; Johns Hopkins University, Baltimore, MD

Jacqueline Chu, MD; Massachusetts General Hospital, Boston, MA
Seth Cohen, MD, MS; University of Washington, Seattle, WA
Annabelle de St. Maurice, MD, MPH; UCLA David Geffen School of Medicine, Los Angeles, CA
Carlos del Rio, MD; Emory University, Atlanta, GA
Ozlem Equils, MD; Cedars-Sinai Medical Center/Pfizer, Los Angeles, CA
Jessica Ericson, MD; Penn State Hershey, Hershey, PA
Raj Gandhi, MD; Massachusetts General Hospital, Boston, MA
Scott James, MD; University of Alabama at Birmingham, Birmingham, AL
Christina Lancioni, MD; Oregon Health and Science University, Portland, OR
Catherine Liu, MD; Fred Hutchinson Cancer Research Center, Seattle WA
Michael Melia, MD; Johns Hopkins School of Medicine, Baltimore, MD
Angela Myers, MD, MPH; Children’s Mercy Hospital, Kansas City, MO
Laura Norton, MD; University of Minnesota Medical School, Minneapolis, MN
Grant Paulsen, MD; Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Sarah Perloff, DO; Albert Einstein Medical Center, Philadelphia, PA
Varun Phadke, MD; Emory University, Atlanta, GA
Paul Pottinger, MD; University of Washington, Seattle, WA
Gail Reid, MD, MSC; Loyola University Chicago, Stritch School of Medicine, Maywood, IL
David Rimland, MD; Emory University School of Medicine, Atlanta, GA
Julia Rosebush, DO; University of Chicago Medical Center, Chicago, IL
Andi Shane, MD, MPH, MSC; Emory University School of Medicine, Atlanta, GA
Luke Strnad, MD; Oregon Health and Science University, Portland, OR
Sarah Turbett, MD; Massachusetts General Hospital, Boston, MA
Rolando Ulloa-Gutierrez, MD; Hospital Nacional de Niños “Dr. Carlos Sáenz Herrera”, San José, Costa Rica
Angela Veesenmeyer, MD, MPH; Valley Children’s Healthcare, Madera, CA
Rebecca Wallihan, MD; Nationwide Children’s Hospital, Columbus, OH
James Wood, MD, MSC; Indiana University School of Medicine, Indianapolis, IN
Jumi Yi, MD; UCSF Children’s Benioff Oakland, Oakland, CA
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome Letter</td>
<td>3</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>4</td>
</tr>
<tr>
<td><strong>General Information</strong></td>
<td>10</td>
</tr>
<tr>
<td>Headquarters Office</td>
<td>10</td>
</tr>
<tr>
<td>Certificate of Attendance</td>
<td>10</td>
</tr>
<tr>
<td>Childcare and Nursing Mothers</td>
<td>10</td>
</tr>
<tr>
<td>IDWeek Booth / Society Booths</td>
<td>10</td>
</tr>
<tr>
<td>IDSA-HIVMA-PIDS Advocacy Education Breakfast</td>
<td>10</td>
</tr>
<tr>
<td>Newsroom</td>
<td>10</td>
</tr>
<tr>
<td>Smoking Policy</td>
<td>10</td>
</tr>
<tr>
<td>IDWeek Mobile App</td>
<td>10</td>
</tr>
<tr>
<td>IDWeek Digital Session Library</td>
<td>10</td>
</tr>
<tr>
<td><strong>IDWeek 2019 Program Committee</strong></td>
<td>11</td>
</tr>
<tr>
<td><strong>Program Information</strong></td>
<td>12</td>
</tr>
<tr>
<td>IDWeek Description</td>
<td>12</td>
</tr>
<tr>
<td>Accreditation Statement for Physicians</td>
<td>12</td>
</tr>
<tr>
<td>Accreditation Statement for Pharmacists</td>
<td>12</td>
</tr>
<tr>
<td>ACCME Guidelines for Moderators</td>
<td>12</td>
</tr>
<tr>
<td>Credit Designation Statement</td>
<td>12</td>
</tr>
<tr>
<td>ABIM MOC Statement</td>
<td>12</td>
</tr>
<tr>
<td>Claim CME/CPE/MOC Credit</td>
<td>12</td>
</tr>
<tr>
<td>Continuing Education Credit for Pharmacists</td>
<td>12</td>
</tr>
<tr>
<td>Faculty Disclosures</td>
<td>13</td>
</tr>
<tr>
<td>Commercial Support Statement</td>
<td>13</td>
</tr>
<tr>
<td>Scientific Sessions and Room Capacity</td>
<td>13</td>
</tr>
<tr>
<td>BugBash - Opening Reception</td>
<td>13</td>
</tr>
<tr>
<td><strong>IDWeek Partnering Societies’ Board of Directors</strong></td>
<td>211</td>
</tr>
<tr>
<td>IDWeek Partnering Societies Business Meetings</td>
<td>13</td>
</tr>
<tr>
<td>Hot Breakfast and Hot Topics: IDSA &amp; HIVMA in 2019</td>
<td>13</td>
</tr>
<tr>
<td>PIDS Business Meeting</td>
<td>13</td>
</tr>
<tr>
<td>SHEA President’s Reception &amp; Business Meeting</td>
<td>13</td>
</tr>
<tr>
<td>Abstracts</td>
<td>13</td>
</tr>
<tr>
<td>Speaker Ready Room</td>
<td>14</td>
</tr>
<tr>
<td><strong>IDWeek Supporters</strong></td>
<td>14</td>
</tr>
<tr>
<td>Allied Partners</td>
<td>15</td>
</tr>
<tr>
<td><strong>Plenaries</strong></td>
<td>17</td>
</tr>
<tr>
<td>Opening Plenary Session</td>
<td>17</td>
</tr>
<tr>
<td>Closing Plenary Session</td>
<td>18</td>
</tr>
<tr>
<td>Named Lectures</td>
<td>20</td>
</tr>
<tr>
<td>Awards Presentation Schedule</td>
<td>27</td>
</tr>
<tr>
<td>IDSA Society Awards</td>
<td>28</td>
</tr>
<tr>
<td>SHEA Society Awards</td>
<td>36</td>
</tr>
<tr>
<td>HIVMA Leadership Awards</td>
<td>42</td>
</tr>
<tr>
<td>PIDS Society Awards</td>
<td>45</td>
</tr>
<tr>
<td>Abstract Awards</td>
<td>46</td>
</tr>
<tr>
<td><strong>CME/CPE/MOC Credit Tracker</strong></td>
<td>56</td>
</tr>
<tr>
<td><strong>Schedule-at-a-Glance</strong></td>
<td>61</td>
</tr>
<tr>
<td><strong>IDWeek 2019 Program Tracks</strong></td>
<td>65</td>
</tr>
<tr>
<td><strong>Scientific Sessions</strong></td>
<td>75</td>
</tr>
<tr>
<td>Oral Abstract Sessions</td>
<td>145</td>
</tr>
<tr>
<td>Poster Abstract Sessions</td>
<td>153</td>
</tr>
<tr>
<td><strong>IDWeek Partnering Societies’ Board of Directors</strong></td>
<td>211</td>
</tr>
</tbody>
</table>
General Information

Headquarters Office
The IDWeek Headquarters Office is located in Room 156 of the Walter E. Washington Convention Center.

Certificate of Attendance
Attendees may obtain certificates of attendance at the IDWeek Information Booth or after the meeting at www.idweek.org. The IDWeek Information Booth can be found outside of Salons ABC and GHI.

Childcare and Nursing Mothers
For childcare services at the meeting, please contact your hotel concierge.

Two nursing mothers’ lounges are available during the meeting hours located in the North L Street Lobby in the Middle Building (near Room 140A) and in the South L Street Lobby in the South Building (near 103B). Only nursing mothers and their infants are permitted in this room. Water and temporary refrigeration for storage will be available for your convenience.

IDWeek Booth / Society Booths
All attendees are invited to stop by the IDSA booth and the individual societies’ booths in the Exhibit Hall to learn more about the meeting and membership in IDWeek’s partnering societies. New this year, visit the IDSA and HIVMA policy team at the Advocacy Dome located in the Grand Lobby near Registration to learn more about how you can participate in IDSA and HIVMA advocacy to advance IDSA and HIVMA’s policy priorities. This includes signing up for the IDSA and HIVMA Member Advocacy Program to stay informed and to connect with your members of Congress in support of federal policies for ID and HIV physicians, scientists, patients, and public health. Please visit the individual booths to get the latest news from DC. You can also join and become a member on site or renew your membership. Stop by and say hello!

IDSA-HIVMA-PIDS Advocacy Education Breakfast
The Advocacy Education Breakfast session highlights the work of IDSA, HIVMA, and PIDS members to improve federal policy for ID and HIV physicians, scientists, patients and public health. IDSA, HIVMA, and PIDS member advocates will share their experiences participating in the IDSA and HIVMA Big IDea Advocacy Day, Congressional district meetings, and other advocacy activities to highlight the importance of educating members of Congress about ID and HIV legislative policy priorities. IDSA, HIVMA, and PIDS members will share information about the key elements of effective advocacy and current opportunities for members to get involved. Speaker remarks will touch on IDSA and HIVMA federal legislative priorities. CME credit is available.

Newsroom
The Newsroom is located in room 158 of the Walter E. Washington Convention Center. Press conferences will be held on selected abstracts. Interviews with authors can also be arranged for the media.

Smoking Policy
Smoking is prohibited at IDWeek.

IDWeek Mobile App
- Browse for IDWeek 2019 in the Apple App Store or Google Play Store to download.
- Registered attendees may download the IDWeek mobile application for their iPhone, iPad, or Android devices for free.
- Participate in the Interactive Sessions with the mobile app, which will be used as the audience response system.
- The mobile app helps you navigate event details, connect with other attendees, view full abstracts and posters, and search the list of exhibiting companies.
- Authenticate the app using the email address you used to register for IDWeek and your confirmation ID (found on the front of your badge).

View the App for the following information:
- Moderator and Presenter Information
- Attendees with Disabilities
- Badge Policies
- Baggage and Coat Check
- Lost and Found
- Financial Disclosures

IDWeek Digital Session Library
- View sessions in premier format from your Mac, PC, smartphone, or tablet.
- The recordings feature high-quality digital audio and visuals.
- All sessions will include synchronized speaker slides, animations, procedural videos, and pointer movements displayed at the event.
- Access the digital library through the IDWeek app or online at www.idweek.org.
- Access will be free for all scientific attendees.
- There will be an opportunity to claim CME for sessions not attended in person.
Chairs:
Cesar Arias, MD, PhD, FIDSA, Vice-Chair, IDSA; University of Texas Health Science Center at Houston, Houston, TX
Kristina A. Bryant, MD, FPIDS, Vice-Chair, SHEA; University of Louisville, Louisville, KY
Eric Daar, MD Harbor-UCLA, Vice-Chair, HIVMA; Medical Center, Torrance, CA
Roberta L. DeBiasi, MD, MS, FIDSA, FPIDS, Vice-Chair, PIDS; Children’s National Health System/GWU School of Medicine, Washington, DC

Vice Chairs:
Inger Damon, MD, PhD, FIDSA, Vice-Chair, IDSA; Centers for Disease Control and Prevention, Atlanta, GA
Thomas R. Talbot, III, MD, MPH, FIDSA, FSHEA, Vice-Chair, SHEA; Vanderbilt University School of Medicine, Nashville, TN
Virginia Triant, MD, MPH, FIDSA, Vice-Chair, HIVMA; Massachusetts General Hospital, Boston, MA
Natasha B. Halasa, MD, MPH, FIDSA, FPIDS, Vice-Chair, PIDS; Vanderbilt University Medical Center, Nashville, TN

Members:
Wendy Armstrong, MD, FIDSA; Emory University School of Medicine, Atlanta, GA
Adarsh Bhimraj, MD, FIDSA; Cleveland Clinic Foundation, Cleveland, OH
Karen C. Carroll, MD, FIDSA; Johns Hopkins University School of Medicine, Baltimore, MD
Pearlie P. Chong, MD; University of Texas Southwestern Medical Center, Dallas, TX
Yohei Doi, MD, PhD; University of Pittsburgh School of Medicine, Pittsburgh, PA
Hana M. El Sahly, MD, FIDSA; Baylor College of Medicine, Houston, TX
Emily Erbelding, MD; National Institutes of Health, Bethesda, MD
Michelle Floris-Moore, MD; University of North Carolina at Chapel Hill, Chapel Hill, NC
Michael S. Gluckman, MD; Memorial Sloan-Kettering Cancer Center, New York, NY
Marcia Goldberg, MD, FIDSA; Massachusetts General Hospital, Boston, MA
Patricia Griffin, MD, FIDSA; Centers for Disease Control and Prevention, Atlanta, GA
Randall Hayden, MD; St. Jude Children’s Research Hospital, Memphis, TN
Tobias M. Hohl, MD, PhD, FIDSA; Memorial Sloan Kettering Cancer Center, New York, NY

David Hyun, MD; The Pew Charitable Trusts, McLean, VA
Robin L. Jump, MD, PhD; Case Western Reserve University, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH
Ebbing Lautenbach, MD, FIDSA, FSHEA; University of Pennsylvania School of Medicine, Philadelphia, PA
John B. Lynch, III, MD, MPH; University of Washington, Seattle, WA
Shelley Magill, MD, PhD; Centers for Disease Control and Prevention, Atlanta, GA
Rachel Miller, MD, FIDSA; Duke University Medical Center, Durham, NC
Jose M. Miro, MD, PhD; University of Barcelona, Barcelona, Spain
Susanna Naggie, MD, MHS, FIDSA; Duke University Medical Center, Duke Clinical Research Institute, Durham, NC
Kathleen M. Neuzil, MD, MPH, FIDSA; University of Maryland School of Medicine, Baltimore, MD
Joshua Nosanchuk, MD, FIDSA; Albert Einstein College of Medicine, Bronx, NY
Christopher A. Ohl, MD, FIDSA; Wake Forest School of Medicine, Winston-Salem, NC
Tara Palmore, MD; NIAID, Bethesda, MD
Andrew T. Pavia, MD, FIDSA, FSHEA; University of Utah, Salt Lake City, UT
Mario Poljak, MD; University of Ljubljana, Ljubljana, Slovenia
Samuel Shelburne, MD, PhD, FIDSA; MD Anderson Cancer Center, Houston, TX
Vincent Tam, PharmD, FIDSA; University of Houston College of Pharmacy, Houston, TX
Laila E. Woc-Colburn, MD, FIDSA; Baylor College of Medicine, Houston, TX
Heather Yun, MD, FIDSA; Brooke Army Medical Center, Houston, TX

Ex-officio:
Cynthia Sears, MD, FIDSA, IDSA President; Johns Hopkins University School of Medicine, Baltimore, MD
Tom M. File, Jr., MD, FIDSA, FSHEA, IDSA President-Elect; Summa Health System, Northeast Ohio Medical University, Akron, OH
Chris Busky, CAE, Chief Executive Officer, IDSA, Arlington, VA
Sandra Vura Harwood, CMP, Meeting Secretariat, IDWeek, Arlington, VA
Kristy WeinsHEL, MBA, Executive Director, SHEA, Arlington, VA
Andrea Weddle, MSW, Executive Director, HIVMA, Arlington, VA
Terri Christene Phillips, MSA, Executive Director, PIDS, Arlington, VA

Infectious Diseases Society of America
www.idsociety.org
The Society for Healthcare Epidemiology of America
www.shea-online.org
HIV Medicine Association
www.hivma.org
Pediatric Infectious Diseases Society
www.pids.org

IDWeek 2019 | 1300 Wilson Blvd., Suite 300, Arlington, VA 22209 | 703-740-4961
info@idweek.org | www.idweek.org
IDWeek Description

IDWeek 2019 is a joint meeting of IDSA, SHEA, HIVMA, and PIDS, focusing on the theme — Advancing Science, Improving Care — and featuring the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek is geared toward healthcare professionals in infectious diseases and healthcare epidemiology and prevention, including researchers, clinicians, quality and patient safety practitioners, epidemiologists, and public health officials, as well as, those who see HIV and pediatric patients. There are no prerequisites for attendance. The meeting will provide state-of-the-art science and clinical care updates on key topics and issues. It is a must-attend meeting.

IDWeek Objectives

• Update infectious diseases clinicians and investigators with state-of-the-art developments in the field, including timely reviews of recent advances in clinical care and research, and original reports of clinical, translational, and basic research.
• Bridge the widening gaps among the fields of infectious diseases clinical practice, clinical research, epidemiological and health services research, translational research, and basic research.
• Promote multi-disciplinary dialogue and collaboration among clinicians and investigators, thus facilitating advances in the prevention, diagnosis, and treatment of infectious diseases.

Accreditation Statement for Physicians

The Infectious Diseases Society of America (IDSA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Accreditation Statement for Pharmacists

The continuing education activities for pharmacists have been developed through a joint providership of ProCE, Inc. and the Infectious Diseases Society of America (IDSA). ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Numbers 0221-9999-19-301-L04-P through 0221-9999-19-434-L06-P have been assigned to these live knowledge-based and application-based sessions (initial release date October 1-6, 2019). This conference is acceptable for up to 36.25 contact hours (3.625 CEUs) in states that recognize ACPE providers. The registration fee covers the cost of CE credits. CE Statements will be issued by the Infectious Diseases Society of America (IDSA) at the conclusion of the conference. Participants must complete an evaluation for each session they attended to receive pharmacy CE credit. The deadline for completing the evaluations is Monday, November 25, 2019.

ProCE will upload all ID Week CPE credits to NABP CPE Monitor accounts between November 18 and November 30, 2019.

ACCME Guidelines for Moderators

In accordance with ACCME guidelines, and to ensure balanced presentations, at least one IDWeek Program Committee member will serve as a moderator of each session.

Credit Designation Statement

IDSA designates this live activity for a maximum of 37.25 AMA PRA Category 1 Credits™. The core IDWeek sessions are designated for 25.25 credit hours and premeeting workshops are an additional 12. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABIM MOC Statement

Successful completion of this CME activity enables the participant to earn up to 25.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

IDWeek 2019 physician participation information will be shared with ABIM through ACCME PARS.

Claim CME/CPE/MOC Credit

Statements of credit must be claimed either at the CME Pavilion or online after the meeting. Attendees will be required to complete a short evaluation for every session for which credit is claimed. The deadline to claim credit is November 25, 2019. Attendees must attend each selected session in its entirety to receive CME/CPE/MOC credit. Partial credit is not available.

Continuing Education Credit for Pharmacists

Pharmacy credit will be available for select sessions at IDWeek Week 2019. Please refer to the CME/CPE/MOC Credit Tracker on pages 56 - 60 for a detailed list and ACPE number assigned to each applicable session. Pharmacists must attend each select session in its entirety to receive CPE credit.
Faculty Disclosures

In accordance with the ACCME Standards for Commercial Support, IDWeek must provide balance, objectivity, and scientific rigor in all sponsored educational activities accredited for CME. The intent of the disclosures is to provide the audience with information on which they can make their own independent judgments pertaining to program content. IDWeek requires all faculty to disclose relevant financial relationships that they or a spouse/partner have, or have had, within the past 12 months with companies or commercial supporters of any products/services that are related to the research being presented at IDWeek (for example, employee, grants, research support, speaker, sponsors, stockholder, etc.). In addition to verbal and written disclosures, faculty are required to provide on the first slide of PowerPoint presentations any significant financial interest(s)/relationship(s) or note that there is “Nothing to disclose.” These disclosures can be found on the IDWeek App.

Commercial Support Statement

IDWeek and ProCE, Inc. follow and support the ACCME/ACPE guidelines for commercial support.

Scientific Sessions and Room Capacity

Scientific sessions will be held at the Walter E. Washington Convention Center. For floor plans and maps please check the meeting app. IDWeek has made every effort to assign sessions to the appropriate room. Attendance is on a first-come, first-served basis and we ask that attendees use all available seating before standing. We apologize in advance if attendance exceeds available seating.

BugBash - Opening Reception

The IDWeek BugBash - Opening Reception will be held on Wednesday, October 2 from 5:15 - 6:30 p.m. in the Ballroom ABC Reception Area, immediately following the Opening Plenary Session. Mingle with colleagues and talk to poster presenters whose research has been specially selected by each of the partner societies. This event is open to all registered attendees.

IDWeek Partnering Societies Business Meetings

Hot Breakfast and Hot Topics: IDSA & HIVMA in 2019
Join IDSA President Dr. Cynthia Sears and HIVMA Chair Dr. W. David Hardy on Friday, October 4, 2019 from 7 - 8 a.m. in room 143 ABC for breakfast and the premiere of an inspiring video highlighting the pivotal initiatives launched in 2019 and your fellow members who are leading them. Open to all.

PIDS Business Meeting
Join PIDS Leadership for the PIDS Business Meeting on Thursday, October 3, 2019 from 5:45 - 6:45 p.m. in the Walter E. Washington Convention Center, Room 202AB. Leaders will provide an update on PIDS activities and recognize newly elected leadership and Society Awardees. We hope to see you there!

SHEA President’s Reception & Business Meeting
Join SHEA Leadership for SHEA’s Business Meeting on Thursday, October 3, 2019 from 6:00 - 7:30 p.m. in the Renaissance Congressional Ballroom ABC. SHEA’s newly elected leadership will be announced along with a wrap up of SHEA’s activities for the past year. SHEA will present the SHEA Research Scholar Grant and the top fundraisers of the Race Against Resistance. Please join us as we discuss SHEA’s successful year!

Abstracts

Abstracts are available online through the Interactive Program Planner at www.idweek.org. An app is available for mobile devices to access abstracts. See the IDWeek Mobile App for details.

IDWeek 2019 abstracts will be published as an online supplement to Open Forum Infectious Diseases (OFID), the open access journal from IDSA. They will be permanently archived as part of the journal and will be accessible to all journal readers, not only meeting attendees or society members.
Speaker Ready Room

Check-in is required for all speakers. All speakers must use PowerPoint presentations. Speakers should check-in at the onsite Speaker Ready Room at least 24 hours prior to presentation time. Please bring an electronic copy of your presentation. The Speaker Ready Room will be located adjacent to room 103A in the Walter E. Washington Convention Center. In the Speaker Ready Room, you can review your presentation and approve the file to be uploaded to the central server. Professional audiovisual consultants and IDWeek staff will be available for assistance. Computers in the Speaker Ready Room will be configured with hardware and software exactly like the ones in the meeting rooms and will allow you to preview your presentation, identify problems, and make corrections as necessary before your presentation. All speakers are requested to leave a version of the PowerPoint presentation in the Speaker Ready Room for posting in the IDWeek digital library after the meeting.

Speaker Ready Room Hours of Operation:

Monday, September 30 ............. 2:00 - 6:00 p.m.
Tuesday, October 1 ................. 7:00 a.m. - 6:00 p.m.
Wednesday, October 2 .......... 7:00 a.m. - 6:00 p.m.
Thursday, October 3 .............. 7:00 a.m. - 6:00 p.m.
Friday, October 4 ................. 7:00 a.m. - 6:00 p.m.
Saturday, October 5 .......... 7:00 a.m. - 6:00 p.m.
Sunday, October 6 ............... 7:00 - 9:00 a.m.

IDWeek Supporters

IDWeek gratefully acknowledges the support of the following companies:

Diamond Patron
Gilead Sciences, Inc.

Platinum Patron
ViiV Healthcare

Gold Patron
Astellas
BioFire Diagnostics, LLC

Silver Patron
Nabriva Therapeutics

Bronze Patron
Healix, LLC
Alleged Partners

- **American Society of Transplantation**
  INTERACTIVE
  Challenging Cases in Transplant ID
  Saturday, October 5, 10:30 - 11:45 a.m.

- **Centers for Disease Control and Prevention**
  SYMPOSIUM
  Unsolved or Uncontrolled: Public Health Challenges in Resistant Pathogens
  Thursday, October 3, 10:30 - 11:45 a.m.
  Enterovirus-Associated Neurologic Disease
  Thursday, October 3, 1:45 - 3 p.m.
  New Worries about Group A Streptococcal Disease
  Thursday, October 3, 1:45 - 3 p.m.
  Advances in RSV: Preparing for Future RSV Vaccines and Immunoprophylaxis Products
  Saturday, October 5, 10:30 - 11:45 a.m.
  Antivirals and Use of PCR Testing for Respiratory Viruses
  Saturday, October 5, 1:45 - 3 p.m.
  HPV Update
  Saturday, October 5, 3:15 - 4:30 p.m.

- **European Society for Paediatric Infectious Diseases**
  INTERACTIVE
  Diagnosis and Management of Congenital CMB on Both Sides of the Pond (Joint PIDS/ESPID)
  Saturday, October 5, 10:30 - 11:45 a.m.

- **IDSA Clinical Affairs Committee**
  SYMPOSIUM
  I'm Better Than You and I Can Prove It: Quality Metrics and ID
  Friday, October 4, 3:15 - 4:30 p.m.
  MEET THE PROFESSOR
  OPAT Update
  Saturday, October 5, 8 - 9 a.m.
  SYMPOSIUM
  ID Physicians in a Value-Based World
  Saturday, October 5, 1:45 - 3 p.m.

- **IDSA ID Training Program Directors**
  PRE-MEETING WORKSHOP
  Fellows' Day Workshop
  Wednesday, October 2, 8 a.m. - noon

- **IDSA Medical Education Workgroup**
  INTERACTIVE
  Educating Healthcare Students and Trainees about Stewardship
  Thursday, October 3, 3:15 - 4:30 p.m.
  SYMPOSIUM
  Using Technology to Enhance Teaching and Learning
  Friday, October 4, 10:30 - 11:45 a.m.
  MEET THE PROFESSOR
  Leveraging Social Media for Professional Success
  Saturday, October 5, 8 - 9 a.m.

- **IDSA Telehealth Committee**
  SYMPOSIUM
  Success Stories in Telehealth
  Saturday, October 5, 3:15 - 4:30 p.m.

- **Infectious Diseases Society of China**
  SYMPOSIUM
  Tick-Tac-Toe: Tick-Borne Infections Upping the Game
  Saturday, October 5, 10:30 - 11:45 a.m.

- **Japanese Association of Infectious Diseases**
  SYMPOSIUM
  Antimicrobial Resistance and Stewardship Across the Globe
  Wednesday, October 2, 1:30 - 3:15 p.m.

- **Mycoses Study Group Education and Research Consortium**
  MEET THE PROFESSOR
  Top Papers in Medical Mycology
  Friday, October 4, 8 - 9 a.m.

- **National Institute of Allergy and Infectious Diseases**
  PRE-MEETING WORKSHOP
  Research Training Programs and Grant Writing Strategies for ID Physician-Scientists
  Tuesday, October 1, 1 - 5 p.m.

- **National Institutes of Health**
  SYMPOSIUM
  The Role of Public Health in Precision Medicine
  Thursday, October 3, 3:15 - 4:30 p.m.
  The Influence of Climate Change on Infectious Diseases
  Friday, October 4, 1:45 - 3 p.m.
  Update on Strategies ID Clinicians Can Use to Treat Opioid Use Disorder
  Saturday, October 5, 10:30 - 11:45 a.m.

- **National Network of STD Clinical Prevention Training Centers**
  SYMPOSIUM
  STIs in the HIV Care Setting: An Interactive Case-Based Approach
  Thursday, October 3, 3:15 - 4:30 p.m.

- **Pan-American Society of Infectious Diseases and the Brazilian Society of Infectious Diseases**
  SYMPOSIUM
  South of the Border: Important Diseases You Can Not Miss
  Friday, October 4, 10:30 - 11:45 a.m.

- **PIDS Training Programs Committee**
  PRE-MEETING WORKSHOP
  Pediatric Fellows' Day Workshop
  Wednesday, October 2, 7:45 a.m. - noon

- **Society of Infectious Diseases Pharmacists**
  MEET THE PROFESSOR
  Experience and Challenges with Vancomycin Monitoring by AUC
  Thursday, October 3, 8 - 9 a.m.
  SYMPOSIUM
  Optimizing PK/PD of New Antibiotics Against MDR Organisms
  Saturday, October 5, 10:30 - 11:45 a.m.
Plenaries

Opening Plenary Session: From Outbreaks to -Oomics: Revolutionizing the Infectious Diseases Landscape in the Age of Big Data

Wednesday, October 2, 2019
3:45 - 5:15 p.m.
Walter E. Washington Convention Center: Ballroom ABC

How Genomics Is Revolutionizing Biomedicine Across Disciplines, Across Continents

Francis S. Collins, MD, PhD was appointed the 16th Director of the National Institutes of Health (NIH) by President Barack Obama and confirmed by the Senate. He was sworn in on August 17, 2009. On June 6, 2017, President Donald Trump announced his selection of Dr. Collins to continue to serve as the NIH Director. In this role, Dr. Collins oversees the work of the largest supporter of biomedical research in the world, spanning the spectrum from basic to clinical research. Dr. Collins is a physician-geneticist noted for his landmark discoveries of disease genes and his leadership of the international Human Genome Project, which culminated in April 2003 with the completion of a finished sequence of the human DNA instruction book. He served as director of the National Human Genome Research Institute at NIH from 1993-2008. Before coming to NIH, Dr. Collins was a Howard Hughes Medical Institute investigator at the University of Michigan. He is an elected member of the National Academy of Medicine and the National Academy of Sciences, was awarded the Presidential Medal of Freedom in November 2007, and received the National Medal of Science in 2009.

Outbreak Response in the Genomic and Information Age

Pardis Sabeti, MD, DPhil is a Professor at Harvard University, the Harvard School of Public Health, the Broad Institute of Harvard and MIT, and a Howard Hughes Medical Institute Investigator. Her computational genomic lab has contributed to widely varying fields — including human evolutionary biology, viral sequencing, information theory, rural disease surveillance and education efforts in West Africa. They aim to create comprehensive approaches for detecting, containing, and treating deadly infectious diseases, including Lassa virus, Ebola virus, Zika virus, and Babesiosis microtia. She has invested in capacity building and education throughout, enabling the first diagnosis of Ebola in Sierra Leone and Nigeria, training over seventy African scientists through summer-long educational programs, and establishing genome centers in West Africa. Dr. Sabeti completed her undergraduate degree at MIT, her graduate work at Oxford University as a Rhodes Scholar, and her medical degree summa cum laude from Harvard Medical School as a Soros Fellow. Sabeti has received numerous awards and honors including World Economic Forum (WEF) Young Global Leader, National Geographic Emerging Explorer, the National Academy of Sciences Richard Lounsbery Award, Smithsonian American Ingenuity Award for Natural Science, TIME magazine “Person of the Year” as one of the Ebola fighters, TIME magazine’s 100 Most Influential. She is also the host of ‘Against All Odds’ included as part of AP stats classes nationwide, and is the lead singer of the rock band Thousand Days.

continued on next page
Closing Plenary Session: All About Vaccines: The Individual, the Community, the World

Sunday, October 6, 2019
9:15 - 10:45 a.m.
Walter E. Washington Convention Center: Ballroom ABC

Neglected Disease and Vaccine Diplomacy in a Time of War, Political Instability, Antiscience, and Climate Change

Peter Jay Hotez, MD, PhD is Dean of the National School of Tropical Medicine and Professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine where he is also the Director of the Texas Children's Center for Vaccine Development (CVD) and Texas Children's Hospital Endowed Chair of Tropical Pediatrics. He is also University Professor at Baylor University, and Fellow in Disease and Poverty at the James A Baker III Institute for Public Policy, as well as the Health Policy Scholar in the Baylor Center for Medical Ethics and Health Policy. Dr. Hotez is an internationally-recognized physician-scientist in neglected tropical diseases and vaccine development. As head of the Texas Children's CVD, he leads the only product development partnership for developing new vaccines for hookworm infection, schistosomiasis, leishmaniasis, Chagas disease, and SARS/MERS, diseases affecting hundreds of millions of children and adults worldwide. In 2006 at the Clinton Global Initiative he co-founded the Global Network for Neglected Tropical Diseases to provide access to essential medicines for hundreds of millions of people. He obtained his undergraduate degree in molecular biophysics from Yale University in 1980 (phi beta kappa), followed by a Ph.D. degree in biochemistry from Rockefeller University in 1986, and an MD from Weil Cornell Medical College in 1987. Dr. Hotez has authored more than 450 original papers and is the author of Forgotten People, Forgotten Diseases (ASM Press) and Blue Marble Health: An Innovative Plan to Fight Diseases of the Poor amid Wealth (Johns Hopkins University Press). Dr. Hotez served previously as President of the American Society of Tropical Medicine and Hygiene and he is founding Editor-in-Chief of PLoS Neglected Tropical Diseases. He is an elected member of the National Academy of Medicine and the American Academy of Arts & Sciences. In 2011 he was awarded the Abraham Horwitz Award for Excellence in Leadership in Inter-American Health by the Pan American Health Organization of the WHO. In 2014-16 he served in the Obama Administration as US Envoy, focusing on vaccine diplomacy initiatives between the US Government and countries in the Middle East and North Africa. In 2018 he was appointed by the US State Department to serve on the Board of Governors for the US Israel Binational Science Foundation, and is frequently called upon to testify before US Congress. He has served on infectious disease task forces for two consecutive Texas Governors. For these efforts in 2017 he was named by FORTUNE Magazine as one of the 34 most influential people in health care, while in 2018 he received the Sustained Leadership Award from Research!America. Most recently as both a vaccine scientist and autism Dad he has led national efforts to defend vaccines and to serve as an ardent champion of vaccines going up against a growing national "antivaxx" threat. His newest book, Vaccines Did Not Cause Rachel's Autism (Johns Hopkins Press) was published in 2018. Dr. Hotez appears frequently on television (including BBC, CNN, Fox News, and MSNBC), radio, and in newspaper interviews (including the New York Times, USA Today, Washington Post, and Wall Street Journal).
Vaccines for Emerging Infectious Disease Threats: From Science to Implementation

Anthony S. Fauci, MD, FIDSA is Director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health, where he oversees an extensive research portfolio focused on infectious and immune-mediated diseases. He serves as one of the key advisors to the White House and Department of Health and Human Services on global HIV/AIDS issues, and on initiatives to bolster medical and public health preparedness against emerging infectious disease threats. He is the winner of numerous prestigious awards including the Presidential Medal of Freedom, the National Medal of Science and the Lasker Award for Public Service.

Developing Vaccines for Poverty-Related Diseases: A New Global Public Health Model

Penny M. Heaton, MD is the Chief Executive Officer of the Bill & Melinda Gates Medical Research Institute (Gates MRI), a non-profit biotechnology organization that applies translational science to combat diseases that disproportionately impact the poor in low- and middle-income countries. Dr. Heaton leads the institute’s work to capitalize on new strategies and partnerships to optimize therapeutics, vaccines and monoclonal antibody candidates, accelerate progress from the lab to the clinic and develop them through proof of concept in target populations. The mission of the Gates MRI is to advance or develop products that will help eradicate malaria, accelerate the end of the tuberculosis epidemic, prevent diarrheal deaths from occurring in children and improve maternal and neonatal health outcomes. Prior to this role, Dr. Heaton served as Director of the Bill & Melinda Gates Foundation’s Vaccine Development and Surveillance team, which provided strategic and technical support to the foundation’s vaccine development programs against several diseases including HIV, TB, malaria, pneumonia, enteric diseases, and polio. She has more than 15 years of experience leading vaccine clinical research and development for companies including Novartis, Merck and Novavax. Dr. Heaton began her career at the U.S. Centers for Disease Control and Prevention conducting diarrheal disease surveillance and investigating outbreaks of foodborne and diarrheal diseases, influencing her life-long passion for vaccine development. Notably, Dr. Heaton co-developed RotaTeq® during her time at Merck & Co., Inc., a rotavirus vaccine which has been licensed in more than 100 countries and universally recommended by the World Health Organization for infants worldwide. A graduate of the University of Louisville School of Medicine in Kentucky, Dr. Heaton is board-certified in Pediatrics and Pediatric Infectious Diseases. She is a member of the Pediatric Infectious Diseases Society and a fellow of the American Academy of Pediatrics.
Named Lectures

2019 Edward H. Kass Lecture

Thursday, October 3, 2019: 9:15 - 10 a.m.
Walter E. Washington Convention Center: Ballroom ABC

EDWARD H. KASS, MD, was one of the founding leaders of IDSA. He served as the Society’s seventh president in 1970 as well as the Society’s secretary from 1964 to 1967. He helped to create not only IDSA, but also the Channing Memorial Laboratory and the International Congress on Infectious Diseases. Dr. Kass was instrumental in securing IDSA’s role in publishing The Journal of Infectious Diseases, and he developed the concept for Reviews of Infectious Diseases – now Clinical Infectious Diseases. Not only was he a pioneer in the study of infection, he was an advocate for social justice and passionate about addressing poverty, racism and discrimination. Dr. Kass held the positions of William Ellery Channing Professor of Medicine at Harvard Medical School and director of the Channing Laboratory at Harvard Medical School and Brigham and Women’s Hospital. In his memory, IDSA maintains the annual Edward H. Kass Lectureship in the History of Medicine and the Kass Awards, which assist medical students and residents with travel expenses to IDWeek. The first Kass Lectureship was given in 1991 by Theodore E. Woodward, MD.

2019 Featured Lecturer

Epidemic Infectious Diseases and Creation of the Infectious Diseases Discipline

Herbert L DuPont, MD, MACP, FIDSA is Professor of Infectious Diseases and Epidemiology at the University of Texas School of Public Health, the Mary W. Kelsey Chair of Medical Sciences and Professor of Internal Medicine at The University of Texas McGovern Medical School. He is Professor of Infectious Diseases at MD Anderson Cancer Center, Clinical Professor of Medicine, Baylor College of Medicine.

In the Infectious Diseases Society of America he served as Councilor 1978-1981, Secretary 1982-1987, President-Elect 1988-1989 and President 1989-1990. He also served as President of the National Foundation for Infectious Diseases, the American Clinical and Climatological Association and was the Founding President of the International Society of Travel Medicine.

Honors from universities include the Distinguished Achievement Award, Ohio Wesleyan University, the Distinguished Medical Achievement Award from Emory University Medical School, honorary doctorate from the University of Zurich, the University of Texas President’s Scholar Award for Research, the Regents’ Outstanding Teaching Award from The University of Texas System and given the title Distinguished Teaching Professor of the University of Texas System.

Honors from professional societies include Maxwell Finland Award for Scientific Achievement (the National Foundation for Infectious Diseases), Laureate Award (Texas Chapter, the American College of Physicians [ACP]), and the Alexander Fleming Award for Lifetime Achievement in Infectious Diseases (Infectious Diseases Society of America).

He has authored or co-authored 744 scientific publications (396 peer-reviewed original science publications and 348 peer-reviewed scientific reviews or book chapters) and edited or written 19 books dealing with enteric and infectious diseases.

Past Lecturers

<table>
<thead>
<tr>
<th>Year</th>
<th>Lecturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>Henry Masur</td>
</tr>
<tr>
<td>2017</td>
<td>James M. Hughes</td>
</tr>
<tr>
<td>2016</td>
<td>John Perfect</td>
</tr>
<tr>
<td>2015</td>
<td>Karen C. Carroll</td>
</tr>
<tr>
<td>2014</td>
<td>Janet Gilsdorf</td>
</tr>
<tr>
<td>2013</td>
<td>Peter Hotez</td>
</tr>
<tr>
<td>2012</td>
<td>Elaine Larson</td>
</tr>
<tr>
<td>2011</td>
<td>Larry Pickering</td>
</tr>
<tr>
<td>2010</td>
<td>Richard Wenzel</td>
</tr>
<tr>
<td>2009</td>
<td>Paul A. Volberding</td>
</tr>
<tr>
<td>2008</td>
<td>Arturo Casadevall</td>
</tr>
<tr>
<td>2007</td>
<td>David Relman</td>
</tr>
<tr>
<td>2006</td>
<td>Wafa El-Sadr</td>
</tr>
<tr>
<td>2005</td>
<td>Constance Benson</td>
</tr>
<tr>
<td>2004</td>
<td>Lucy Tompkins</td>
</tr>
<tr>
<td>2003</td>
<td>Seymour J. Klebanoff</td>
</tr>
<tr>
<td>2002</td>
<td>Stanley A. Plotkin</td>
</tr>
<tr>
<td>2001</td>
<td>John G. Bartlett</td>
</tr>
<tr>
<td>2000</td>
<td>Walter E. Stamm</td>
</tr>
<tr>
<td>1999</td>
<td>Sharon L. Hillier</td>
</tr>
<tr>
<td>1998</td>
<td>Martin J. Blaser</td>
</tr>
<tr>
<td>1997</td>
<td>Judith Wasserheit</td>
</tr>
<tr>
<td>1996</td>
<td>Charles S. Bryan</td>
</tr>
<tr>
<td>1995</td>
<td>Alfred Evans</td>
</tr>
<tr>
<td>1994</td>
<td>Jay Sanford</td>
</tr>
<tr>
<td>1993</td>
<td>Floyd Denny</td>
</tr>
<tr>
<td>1992</td>
<td>Allan Brandt</td>
</tr>
<tr>
<td>1991</td>
<td>Theodore E. Woodward</td>
</tr>
</tbody>
</table>
Named Lectures (continued)

2019 Caroline B. Hall Lectureship

Thursday, October 3, 2019: 3:15 - 4:30 p.m.
Walter E. Washington Convention Center: Salon ABC

The lectureship is dedicated to and honors Caroline B. Hall, MD, a world-renowned pediatrician, teacher, researcher, and a founding member of PIDS. Dr. Hall held the position of professor of pediatrics and medicine at the University of Rochester School of Medicine for over 40 years. She was a leader in pediatric infectious diseases for her groundbreaking and prolific research on respiratory syncytial virus, human herpesvirus 6, and other respiratory viral pathogens and authored over 500 peer-reviewed publications. Her contributions significantly enhanced our understanding of diverse respiratory viral infections and resulted in the development of diagnostic and management guidelines for infections that continue to be important clinical references. Dr. Hall served as the fifth president of PIDS and was the society's historian. She was a member of the Institute of Medicine and the Royal College of Physicians and received numerous honors, including the Distinguished Physician and Distinguished Service awards from PIDS, the IDSA John F. Enders Lectureship, the Pan American Society for Virology Award, and the Robert M. Chanock Lifetime Achievement Award.

2019 Featured Lecturer

Clinical Evolution of Infants with Antenatal Zika Virus Exposure - Lessons Learned from Rio de Janeiro

Karin Nielsen, MD, MPH is Professor of Pediatrics in the Division of Infectious Diseases at UCLA Mattel Children’s Hospital and a member of the UCLA faculty since 1996. She is also an attending physician for Pediatric Infectious Diseases at the UCLA Ronald Reagan Medical Center and co-director of the Care4Families HIV clinic at UCLA. Dr. Nielsen was born and raised in Rio de Janeiro where she obtained medical training from the University of Rio de Janeiro and completed a pediatric residency at the Hospital dos Servidores do Estado. She then came to Los Angeles where she completed a clinical and research fellowship in Pediatric Infectious Diseases at UCLA and obtained a Master's degree in Public Health/ Epidemiology at the same institution. Dr. Nielsen's main area of research has been in the area of HIV, TB and congenital infections and she is also very interested in tropical and neglected infectious diseases. Dr. Nielsen has led innumerable collaborative research studies in Brazil and in the U.S, as well as other countries in the Americas, sub-Saharan Africa, and Asia. Her work has focused on prevention of HIV transmission from mother to child and between couples, as well as treatment of this disease and other infections in children, adolescents and adults. Much of this work has been completed through large multicenter prospective clinical trials. Dr. Nielsen has very strong longstanding research collaborations in Brazil and received the Diaspora Award in Medical Sciences from the Government of Brazil in recognition of her contributions. During the Zika epidemic of 2015-16 she joined efforts with leading experts from the Arboviral Diseases Division at the Fundação Oswaldo Cruz and the Fiocruz Maternal-Pediatric Hospital, Instituto Fernandes Figueira both in Rio de Janeiro, to investigate the pathogenesis of ZIKA virus transmission during pregnancy and characterize the repercussions of antenatal Zika exposure in children. In the U.S., Dr. Nielsen leads a large study of early treatment of HIV infection in at risk youth in Los Angeles and New Orleans. Much of her work has been funded by the NIH including the NIAID, NICHD, and the Fogarty Institute, as well as the NIH networks, IMPAACT, ATN, HPTN and ACTG. Dr. Nielsen has mentored an extensive number of medical students, residents, fellows, graduate students and postdoctoral scholars from all over the globe. She is an active clinician licensed in both the U.S. and in Brazil.

Past Lecturers

2018  Ruth Karron
2017  Janet Englund
2016  Octavio Ramilo
2015  John V. Williams

continued on next page
Joseph E. Smadel, MD, MA, DSci, was a physician and investigator who created a bridge between basic laboratory science and the clinician, making significant contributions to the knowledge of psittacosis, vaccinia, variola, myxomatosis, and viral encephalitis. During World War II, Dr. Smadel led a study of control measures of typhus fever in Egypt and southern Italy. Dr. Smadel served at the Department of Virus and Rickettsial Diseases of the Army Medical School, Walter Reed Army Institute of Research and National Institutes of Health (NIH). He held the position of chief of virology and rickettsiology in the Division of Biologic Standards at NIH until his death. The Joseph E. Smadel Lecture is intended to honor someone who has made a significant impact in public health.

Gail Bolan, MD is Director of the Division of STD Prevention at the Centers for Disease Control and Prevention (CDC). A graduate of Dartmouth Medical School, she completed her training in internal medicine at the University of Virginia, in infectious diseases at Tufts New England and Stanford Medical Centers and in medical epidemiology as a CDC EIS officer in the Respiratory and Special Pathogens Branch. Prior to joining CDC, she served as the Chief of the STD Control Branch at the California Department of Public Health. As a leader in the field of STD Prevention, Dr. Bolan is recognized for her contributions in applied STD prevention research and implementation of science-based STD programs. Dr. Bolan has over 150 scientific publications. She has served on the CDC HIV/STD Prevention Advisory Committee and OID Board of Scientific Counselors, the Executive Committee of ASTDA, and Board of Directors of NCSD and ASHA.

Past Lecturers

<table>
<thead>
<tr>
<th>Year</th>
<th>Lecturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>Monica M. Farley</td>
</tr>
<tr>
<td>2017</td>
<td>Ruth Lynfield</td>
</tr>
<tr>
<td>2016</td>
<td>Patricia Griffin</td>
</tr>
<tr>
<td>2015</td>
<td>Bruno Moonen*</td>
</tr>
<tr>
<td>2014</td>
<td>Robert Weinstein</td>
</tr>
<tr>
<td>2013</td>
<td>Myron S. Cohen</td>
</tr>
<tr>
<td>2012</td>
<td>Diane Havlir</td>
</tr>
<tr>
<td>2011</td>
<td>William Schaffner</td>
</tr>
<tr>
<td>2010</td>
<td>Kathleen Neuzil</td>
</tr>
<tr>
<td>2009</td>
<td>Myron Levine</td>
</tr>
<tr>
<td>2008</td>
<td>Jane E. Koehler</td>
</tr>
<tr>
<td>2007</td>
<td>Kathryn M. Edwards</td>
</tr>
<tr>
<td>2006</td>
<td>Allan R. Ronald</td>
</tr>
<tr>
<td>2005</td>
<td>Lyle Peterson</td>
</tr>
<tr>
<td>2004</td>
<td>Eric Otteson</td>
</tr>
<tr>
<td>2003</td>
<td>Didier Raoul</td>
</tr>
<tr>
<td>2002</td>
<td>Donald A. Henderson</td>
</tr>
<tr>
<td>2001</td>
<td>Karl M. Johnson</td>
</tr>
<tr>
<td>2000</td>
<td>Anne Schuchat</td>
</tr>
<tr>
<td>1999</td>
<td>Lou H. Miller</td>
</tr>
<tr>
<td>1998</td>
<td>Thomas Wellems</td>
</tr>
<tr>
<td>1997</td>
<td>Brett Finlay</td>
</tr>
<tr>
<td>1996</td>
<td>Scott B. Halstead</td>
</tr>
<tr>
<td>1995</td>
<td>David T. Dennis</td>
</tr>
<tr>
<td>1994</td>
<td>Roy Anderson</td>
</tr>
<tr>
<td>1993</td>
<td>Richard Guerrant</td>
</tr>
<tr>
<td>1992</td>
<td>Alfred Sommer</td>
</tr>
<tr>
<td>1991</td>
<td>Charles Carpenter</td>
</tr>
<tr>
<td>1990</td>
<td>Zervil Cohen</td>
</tr>
<tr>
<td>1989</td>
<td>Thomas Grayston</td>
</tr>
<tr>
<td>1988</td>
<td>P. Frederick Sparling</td>
</tr>
<tr>
<td>1987</td>
<td>Jack M. Gwaltney</td>
</tr>
<tr>
<td>1986</td>
<td>Richard T. Johnson</td>
</tr>
<tr>
<td>1985</td>
<td>Franklin A. Neva</td>
</tr>
<tr>
<td>1984</td>
<td>Maurice R. Hilleman</td>
</tr>
<tr>
<td>1983</td>
<td>Garrison Rapmund</td>
</tr>
<tr>
<td>1982</td>
<td>Richard B. Hornick</td>
</tr>
<tr>
<td>1981</td>
<td>Baruj Benacerraf</td>
</tr>
<tr>
<td>1980</td>
<td>Robert M. Chanock</td>
</tr>
<tr>
<td>1979</td>
<td>Philip K. Russell</td>
</tr>
<tr>
<td>1978</td>
<td>Philip Y. Paterson</td>
</tr>
<tr>
<td>1977</td>
<td>D. Carleton Gajdusek</td>
</tr>
</tbody>
</table>
Named Lectures (continued)

2019 SHEA Lectureship

Friday, October 4, 2019: 4:45 - 6 p.m.
Walter E. Washington Convention Center: Ballroom ABC

The SHEA Lectureship award is given annually to recognize the career contributions of a senior investigator in healthcare epidemiology and infection prevention and control. Awardees have shown leadership through notable contributions to the science of healthcare epidemiology, demonstration of ongoing dedication to advancing the field, demonstration of mentorship, and dedication to SHEA and its mission to prevent healthcare-associated infections.

2019 Featured Lecturer

Oh the Places We Can Go!

Trish M. Perl, MD, MSc, FIDSA, FSHEA, currently serves as the Jay P. Sanford Professor of Medicine and the Chief of Infectious Diseases at the University of Texas Southwestern Medical School and Medical Center. Dr. Perl received her Bachelor of Arts and medical degree from the University of North Carolina at Chapel Hill and a Master of Science degree from McGill University in Montreal, Canada. She completed a residency in internal medicine at McGill University and a fellowship in infectious diseases and clinical epidemiology at the University of Iowa in Iowa City, Iowa.

She rose through the ranks at Johns Hopkins University and Health System to become a Professor of Medicine and Pathology in the School of Medicine in Baltimore, Maryland, and in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. As the Hospital Epidemiologist of the Johns Hopkins Hospital between 1996 and 2011, she built the Infection Prevention and Hospital Epidemiology’s reputation as a leader and innovator in the field. She became the Senior Epidemiologist for The Johns Hopkins Health System and the University and again was instrumental in implementing important institutional policies that impacted the hospitals, university and affiliates. She is a clinician and enjoys seeing patients and has extensive practical and research experience in the field of healthcare associated infections and resistant and epidemiologically significant organisms and is recognized globally for her innovation and research in the field and the use of research knowledge in the healthcare setting. Dr. Perl is a former President of the Society of Hospital Epidemiologists of America (SHEA) and has served on advisory panels for the IOM, the CDC and WHO and been a consultant to the NIH and ARHQ. She was the Courage Fund Visiting Professor in 2008-10 at the National University of Singapore. An active researcher, Dr. Perl has been a principal and co-principal investigator on multiple studies funded by the CDC, the Veteran’s Affairs Administration and BARDA over the years. She has authored or coauthored over 300 peer-reviewed articles. In addition, she has written multiple chapters and contributed to guidelines and policies relevant to healthcare associated infections at the institutional, state and federal level. She has been asked to help with management of international outbreaks including SARS and MERS CoV and consults with international governments on guideline development and strategies to prevent healthcare associated infections and antimicrobial resistance.

Dr. Perl’s presentation, titled “Oh the Places We Can Go!,” will focus on the challenges of determining how to best answer important questions in healthcare epidemiology and how to implement innovative solutions.

Past Lecturers

<table>
<thead>
<tr>
<th>Year</th>
<th>Lecturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>Jane E. Patterson</td>
</tr>
<tr>
<td>2017</td>
<td>Neil Fishman</td>
</tr>
<tr>
<td>2016</td>
<td>Daniel Sexton</td>
</tr>
<tr>
<td>2015</td>
<td>Richard Platt</td>
</tr>
<tr>
<td>2014</td>
<td>Lisa Saiman</td>
</tr>
<tr>
<td>2013</td>
<td>Denise Cardo</td>
</tr>
<tr>
<td>2012</td>
<td>William Rutala</td>
</tr>
<tr>
<td>2011</td>
<td>Victoria Fraser</td>
</tr>
<tr>
<td>2010</td>
<td>David Henderson</td>
</tr>
<tr>
<td>2009</td>
<td>Elaine Larson</td>
</tr>
<tr>
<td>2008</td>
<td>Didier Pittet</td>
</tr>
<tr>
<td>2007</td>
<td>Dale Gerding</td>
</tr>
<tr>
<td>2006</td>
<td>C. Glen Mayhall</td>
</tr>
<tr>
<td>2005</td>
<td>Robert Weinstein</td>
</tr>
<tr>
<td>2004</td>
<td>Lindsay Nicole</td>
</tr>
<tr>
<td>2003</td>
<td>William Jarvis</td>
</tr>
<tr>
<td>2001</td>
<td>William Scheckler</td>
</tr>
<tr>
<td>2000</td>
<td>Walter Hierholzer</td>
</tr>
<tr>
<td>1999</td>
<td>Dennis Maki</td>
</tr>
<tr>
<td>1998</td>
<td>John E. Mcgowan</td>
</tr>
<tr>
<td>1997</td>
<td>Richard Wenzel</td>
</tr>
<tr>
<td>1996</td>
<td>William Schaffner</td>
</tr>
<tr>
<td>1995</td>
<td>Philip S. Brachman</td>
</tr>
<tr>
<td>1993</td>
<td>John V. Benett</td>
</tr>
</tbody>
</table>

continued on next page
The Stanley A. Plotkin Lecture in Vaccinology is presented annually to an individual who has made significant contributions to the field of vaccinology or areas of related science that have impacted the lives of children and the specific area of pediatric infectious diseases.

Immunizing Women to Protect their Newborn Infants: The New Normal?

Scott Halperin, MD is Professor of Pediatrics and Microbiology and Immunology at Dalhousie University in Halifax, Nova Scotia. He was educated in the United States, completing his undergraduate degree in Biology at Stanford University and his medical degree at Cornell University. His postgraduate residency training was in pediatrics at the University of Virginia and his fellowship in pediatric infectious diseases at the University of Virginia and the University of Minnesota. He has lived in Halifax since 1985 where, as the Director of the Canadian Center for Vaccinology and the Nominated Principal Investigator of the Canadian Immunization Research Network, he has played a foundational role in the establishment of these and other Canadian collaborative research networks undertaking evaluative vaccine research. Dr. Halperin is a former Canadian Institutes of Health Research/Wyeth Pharmaceuticals Clinical Research Chair in Vaccines. His research focuses on the diagnosis, treatment, and prevention of pertussis and other vaccine-preventable diseases.

Past Lecturers

<table>
<thead>
<tr>
<th>Year</th>
<th>Lecturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>Gary S. Marshall</td>
</tr>
<tr>
<td>2017</td>
<td>Peter F. Wright</td>
</tr>
<tr>
<td>2016</td>
<td>Larry K. Pickering</td>
</tr>
<tr>
<td>2016</td>
<td>Carol J. Baker</td>
</tr>
<tr>
<td>2015</td>
<td>Neal A. Halsey</td>
</tr>
<tr>
<td>2014</td>
<td>Eugene D. Shapiro</td>
</tr>
<tr>
<td>2013</td>
<td>Anne A. Gershon</td>
</tr>
<tr>
<td>2012</td>
<td>John B. Robbins</td>
</tr>
<tr>
<td>2011</td>
<td>David I. Bernstein</td>
</tr>
<tr>
<td>2010</td>
<td>Dan Granoff</td>
</tr>
<tr>
<td>2009</td>
<td>James A. Cherry</td>
</tr>
<tr>
<td>2008</td>
<td>Paul A. Offit</td>
</tr>
<tr>
<td>2007</td>
<td>Kathryn M. Edwards</td>
</tr>
<tr>
<td>2006</td>
<td>Walter A. Orenstein</td>
</tr>
<tr>
<td>2005</td>
<td>Samuel L. Katz</td>
</tr>
<tr>
<td>2004</td>
<td>Stanley A. Plotkin</td>
</tr>
</tbody>
</table>
JOHN F. ENDERS, PhD, served as the second president of IDSA. Dr. Enders and two of his colleagues received the 1954 Nobel Laureate in Medicine for their discovery of the ability of poliomyelitis viruses to grow in cultures of various types of tissue. This discovery led to the development of vaccines against polio, measles, rubella, and mumps, as well as other advances. For almost 15 years, he worked in Dr. Hans Zinnser’s department at Harvard where his early use of tissue cultures for the growth of viruses in vitro began in collaboration with Dr. Zinnser. Dr. Enders received numerous awards in addition to the Nobel Prize, including the Albert Lasker Award of the American Public Health Association, Germany’s Koch Medal, and the Cameron Prize of the University of Edinburgh. He received the Presidential Medal of Freedom and honorary degrees from many universities. Dr. Enders has been described as “one of the most modest, magnificent men in the history of sciences.” His contributions also include major advances in the field of genetics, links between viruses and cancer, and insights into the pattern and process of tumor growth, and are noted among the most important of the 20th century. The John F. Enders Distinguished Lecture in Medical Virology, which bears his name, was first given in 1988 by Thomas Weller, MD.

2019 Featured Lecturer

Preventing Viral Infections after Transplantation: Triumphs, Challenges and Opportunities

Michael Boeckh, MD, PhD, is the Head of the Infectious Disease Sciences Program, Vaccine and Infectious Disease Division, at Fred Hutchinson Cancer Research Center, and a Professor of Medicine, Division of Allergy and Infectious Diseases, at the University of Washington. He received his MD and PhD degrees from the Freie Universität Berlin, Germany, and trained in internal medicine at the Benjamin Franklin Hospital in Berlin, Germany, and in infectious diseases at the University of Washington. He is an expert in viral infections in the immunocompromised host. Dr. Boeckh is a Fellow of the Infectious Disease Society of America and the current chair of the American Society of Transplantation and Cellular Therapy (ASTCT) Transplant Infectious Disease Special Interest Group. He conducts laboratory research, observational studies as well as clinical trials of all phases, and has authored more than 300 peer-reviewed articles, review articles, practice guidelines and book chapters. He is the co-editor of the Transplant Infectious Disease textbook (4th edition). His CMV research is focused on immune reconstitution after transplantation, viral kinetics, transmission of CMV, and disease management in the immunocompromised patient population. Recently, he also initiated studies to determine the role of CMV reactivation on the outcome of immunocompetent patients with sepsis and respiratory failure. His respiratory virus research focuses on the association of respiratory viruses and airflow obstruction, the adaptive immune response to respiratory viruses, viral dissemination and gene expression signatures as biomarkers for disease severity, as well as management strategies.
MAXWELL FINLAND, MD, DSci, served as the first president of IDSA. His prestigious medical career spanned more than 50 years at Harvard University and Boston City Hospital. He was internationally recognized for his study of the incidence and character of infectious diseases and their specific treatments. Dr. Finland’s unbiased judgment on the role of antimicrobial agents in medical treatment was universally respected.

He is credited with influencing pioneering studies of antibiotic therapy and the treatment for pneumonia and respiratory injuries linked to exposure to noxious gases. He was noted as establishing early identification of new infectious hazards and the emergence of dangerous new infections in hospitalized patients. The Maxwell Finland Lecture, which bears his name, was first given in 1972 by Theodore E. Woodward, MD.

MAXWELL FINLAND, MD, DSci, served as the first president of IDSA. His prestigious medical career spanned more than 50 years at Harvard University and Boston City Hospital. He was internationally recognized for his study of the incidence and character of infectious diseases and their specific treatments. Dr. Finland’s unbiased judgment on the role of antimicrobial agents in medical treatment was universally respected.

He is credited with influencing pioneering studies of antibiotic therapy and the treatment for pneumonia and respiratory injuries linked to exposure to noxious gases. He was noted as establishing early identification of new infectious hazards and the emergence of dangerous new infections in hospitalized patients. The Maxwell Finland Lecture, which bears his name, was first given in 1972 by Theodore E. Woodward, MD.
Awards Presentation Schedule

**IDSA Society Awards**

**IDSA Alexander Fleming Award for Lifetime Achievement**
W. Michael Scheld, MD, FIDSA
Wednesday, October 2, at 3:45 p.m. in Walter E. Washington Convention Center: Ballroom ABC

**IDSA Society Citation**
Brian S. Schwartz, MD
Steven K. Schmitt, MD, FIDSA
Saturday, October 5, 9:15 a.m. in Walter E. Washington Convention Center: Ballroom ABC

**IDSA Watanakunakorn Clinician Award**
Virginia D. Banks, MD, MBA, FIDSA
Thursday, October 5, at 9:15 a.m. in Walter E. Washington Convention Center: Ballroom ABC

**IDSA Clinical Teacher Award**
William L. Salzer, MD
Saturday, October 5, at 9:15 a.m. in Walter E. Washington Convention Center: Ballroom ABC

**IDSA Oswald Avery Award for Early Achievement**
Nasia Safdar, MD, PhD, MS, FIDSA, FSHEA
Saturday, October 5, 9:15 a.m. in Walter E. Washington Convention Center: Ballroom ABC

**IDSA Walter E. Stamm Mentor Award**
David L. Thomas, MD, MPH, FIDSA
Thursday, October 3, at 4:45 p.m. in Walter E. Washington Convention Center: Ballroom ABC

**IDSA D.A. Henderson Award**
Catherine M. Wilfert, MD, FIDSA
Thursday, October 3, 9:15 a.m. in Walter E. Washington Convention Center: Ballroom ABC

**SHEA Society Awards**

**SHEA Senior Scholarship Award**
Robert A. Weinstein, MD, FIDSA, FSHEA
Wednesday, October 2, at 3:45 p.m. in Walter E. Washington Convention Center: Ballroom ABC

**SHEA Advanced Practice Infection Preventionist Award**
Loretta Litz Fauerbach, MS, FSHEA, FAPIC, CIC
Friday, October 4, at 4:30 p.m. in Walter E. Washington Convention Center: Ballroom ABC

**SHEA Antibiotic Stewardship Scholarship Award**
Jeffrey S. Gerber, MD, PhD
Friday, October 4, at 4:30 p.m. in Walter E. Washington Convention Center: Ballroom ABC

**SHEA Mentor Scholar Award**
Keith Kaye, MD, MPH, FIDSA, FSHEA
Friday, October 4, at 4:30 p.m. in Walter E. Washington Convention Center: Ballroom ABC

**SHEA Mid-Career Scholarship Award**
Daniel Morgan, MD, MS, FIDSA, FSHEA
Friday, October 4, at 4:30 p.m. in Walter E. Washington Convention Center: Ballroom ABC

**SHEA Pediatric Scholarship Award**
Judith Guzman-Cottrill, DO, FSHEA
Friday, October 4, at 4:30 p.m. in Walter E. Washington Convention Center: Ballroom ABC

**SHEA International Award**
Jaffar A. Al -Tawfiq, MD, FACP, FIDSA, FSHEA
Friday, October 4, at 4:30 p.m. in Walter E. Washington Convention Center: Ballroom ABC

**SHEA Barry Farr Award**
Gonzalo Bearman MD, MPH, FACP, FIDSA, FSHEA
Friday, October 4, at 4:30 p.m. in Walter E. Washington Convention Center: Ballroom ABC

**SHEA William Jarvis Award**
Pinyo Rattanaumpawan, MD, PHD
Friday, October 4, at 4:30 p.m. in Walter E. Washington Convention Center: Ballroom ABC

**SHEA Sue Bradley Reviewer Award**
Joseph Mylotte, MD
Friday, October 4, at 4:30 p.m. in Walter E. Washington Convention Center: Ballroom ABC

**HIVMA Leadership Awards**

**HIVMA Clinical Educator Award**
Carlos del Rio, MD, FIDSA
Wednesday, October 2, at 3:45 p.m. in the Walter E. Washington Convention Center: Ballroom ABC

**HIVMA Research Award**
Andrea Ciaranello, MD, MPH, FIDSA
Thursday, October 3, at 4:45 p.m. in the Walter E. Washington Convention Center: Ballroom ABC

**PIDS Society Awards**

**PIDS Distinguished Service Award**
David W. Kimberlin, MD, FPIDS
Wednesday, October 2, at 3:45 p.m. in Walter E. Washington Convention Center: Ballroom ABC
IDSA Alexander Fleming Award for Lifetime Achievement

Presented on Wednesday, October 2, at 3:45 p.m., in Walter E. Washington Convention Center: Ballroom ABC

W. Michael Scheld, MD, FIDSA, an accomplished scientist and scholar whose research has greatly expanded our knowledge of serious life-threatening infections including infective endocarditis, bacterial meningitis, and sepsis, is the recipient of IDSA's 2019 Alexander Fleming Award for Lifetime Achievement. This award recognizes a career that reflects major contributions to the acquisition and dissemination of knowledge about infectious diseases.

Over his 40 years as an investigator and educator, Dr. Scheld's work using molecular tools and animal models has greatly contributed to the understanding of the pathogenesis and pathophysiology of multiple serious infections. The recipient of more than 100 research grants over his career, his impact has extended from the bench to the bedside, influencing recommendations for treatment. Dr. Scheld's elucidations of the mechanisms of central nervous system inflammation in meningitis led to clinical trials with corticosteroids, which are now accepted adjunctive therapies in both children and adults. His use of experimental animal models of sepsis have led to clinical trials of interventions in sub-Saharan Africa, including early fluid resuscitation in patients with severe sepsis, which was shown to reduce mortality.

Dr. Scheld is the Bayer-Gerald L. Mandell Professor of Infectious Diseases, a professor of medicine, and a clinical professor of neurosurgery at the University of Virginia School of Medicine, where he has also served as the director of the Pfizer Initiative in International Health. He has contributed more than 230 peer-reviewed publications to the literature; has edited more than 15 books, including Infections of the Central Nervous System, considered a gold standard in the field; and has served on the editorial boards of several journals. A skilled educator, he has received multiple teaching and faculty awards in addition to numerous other honors.

A past president of IDSA, Dr. Scheld formed and was a member of the Society's Antimicrobial Availability Task Force, established to help address the concerning drop in antibiotic development by the pharmaceutical industry in the face of increasing drug resistance. He has served on IDSA's annual meeting program committee and the panels that authored clinical practice guidelines for the management of bacterial meningitis, encephalitis, and healthcare-associated ventriculitis and meningitis. He has also served as chair of the American Board of Internal Medicine's Subspecialty Board on Infectious Diseases. Dr. Scheld received his medical degree from Cornell University Medical College and completed his internship, residency, and fellowship in infectious diseases at the University of Virginia before joining the faculty there.

Dr. Scheld's four decades of seminal research, scholarship, and teaching have had a tremendous and lasting impact on the field, on our knowledge of multiple serious life-threatening infections, and on those he has collaborated with and taught. The Society is proud to honor him with the 2019 Alexander Fleming Award for Lifetime Achievement.
IDSA D.A. Henderson Award

Presented on Thursday, October 3, 9:15 a.m., in Walter E. Washington Convention Center: Ballroom ABC

Catherine M. Wilfert, MD, FIDSA, a driving force behind the effort to drastically reduce mother-to-child transmission of HIV in the U.S. and globally, is the recipient of IDSA's 2019 D.A. Henderson Award for Outstanding Contributions to Public Health. Named to honor the memory of Dr. Henderson, who led the successful eradication of smallpox, this award recognizes a lifetime of achievement in public health.

A relentless advocate for the treatment and prevention of HIV in infants, Dr. Wilfert has made many seminal contributions in this area during her long career. These include leading the development of treatments for children infected with HIV and leading the effort to prevent mother-to-child transmission of HIV in North Carolina, which resulted in a 90 percent reduction in just 3 years, followed by similar efforts to reduce perinatal HIV transmission across the U.S. and around the world, leading to a 47 percent decrease in new infections globally. Her influential, peer-reviewed publications related to these efforts have appeared in the New England Journal of Medicine, Lancet, JAMA, The Journal of Infectious Diseases, and numerous other important journals.

A professor of pediatrics and microbiology and division chief of pediatric ID in the Department of Pediatrics at Duke University School of Medicine for many years until the mid-1990s, Dr. Wilfert joined the Elizabeth Glaser Pediatric AIDS Foundation as its scientific director in 1996. She spent many months of each year working in Africa, designing and implementing strategies to interfere with mother-to-child transmission. Her studies involving the use of nevirapine in infected mothers and the substitution of formula for mother's milk were the basis for policy changes, including at the World Health Organization. An effective ambassador globally for pediatric AIDS prevention and treatment, Dr. Wilfert has received several awards, and has been a mentor to hundreds of physicians, inspiring others with her strong commitment to public health and public service.

Professor emerita of pediatrics and microbiology at Duke, Dr. Wilfert is a past president of IDSA and was elected to the Institute of Medicine in 1999. She has served on many national boards and committees, including the Board of Scientific Counselors for the National Center for Infectious Diseases at the Centers for Disease Control and Prevention, the Office of AIDS Research Advisory Committee, and the Fogarty International Center Advisory Board. She received her medical degree from Harvard Medical School and completed an internship at Boston City Hospital, residency at North Carolina Baptist Hospital in Winston-Salem, and fellowship training at Harvard and Children's Hospital Medical Center in Boston.

Dr. Wilfert has been a world leader in the tremendous progress that has been made in the reduction of perinatal HIV transmission. IDSA is proud to recognize her great achievements with the 2019 D.A. Henderson Award.
IDSA Society Citation

Presented on Saturday, October 5, 9:15 a.m., in Walter E. Washington Convention Center: Ballroom ABC

Brian S. Schwartz, MD, a nationally recognized leader in infectious diseases medical education, is the recipient of a 2019 IDSA Society Citation. First awarded in 1977, this is a discretionary award given in recognition of exemplary contribution to IDSA, an outstanding discovery in the field of infectious diseases, or a lifetime of outstanding achievement.

As increasing numbers of physicians seek careers in medical education and as the ID specialty works to attract applicants to the field, Dr. Schwartz’s efforts to enhance ID medical education have been particularly critical. He has been instrumental in the development of a robust medical education track that now runs throughout IDWeek. Entering its fifth year, the program has grown to include Meet the Professor sessions and symposia, an abstract category with posters and an oral abstract session, a coaching program for junior faculty clinician educators, and videos providing teaching instruction to IDWeek speakers to help them deliver effective presentations. He has also led efforts to enhance preclinical microbiology education, an important opportunity to interest medical students in careers in ID.

A past member of IDSA’s Education Committee, Dr. Schwartz served as the founding chair of the Society’s Medical Education Work Group, and, with others, has been leading efforts to launch IDSA’s Medical Education Community of Practice, the organization’s first community of practice. The group will support IDSA members to become better teachers of all learner groups, and will support and advocate for the career development of clinician educators, with the end goal of helping to recruit the best and brightest to the field of ID.

Dr. Schwartz is an associate professor of clinical medicine at the University of California, San Francisco (UCSF), where he serves as vice chief of clinical affairs for the Division of Infectious Diseases and as director of the ID fellowship program, in addition to holding several teaching roles, where he has had a great impact on students and trainees. He was elected into the Haile T. Debas Academy of Medical Educators at his institution, and he has received several additional honors for teaching and mentoring, including the Gold-Headed Cane Endowed Teaching Chair in Internal Medicine at UCSF. After earning his medical degree from Rush Medical College, Dr. Schwartz completed his internship and residency training at Massachusetts General Hospital and Boston Children’s Hospital, followed by fellowships in infectious diseases and clinical pharmacology at UCSF.

A collaborative innovator, Dr. Schwartz has played a leading role in driving IDSA’s efforts to support ID medical education and to develop it as an area of concentration. His accomplishments will impact students, residents, fellows, and ID fellows for years to come. IDSA is delighted to add a 2019 Society Citation to his long list of accomplishments.
Steven K. Schmitt, MD, FIDSA, a leading voice for the appropriate recognition of the value of the infectious diseases specialist, is the recipient of a 2019 IDSA Society Citation. First awarded in 1977, this is a discretionary award given in recognition of exemplary contribution to IDSA, an outstanding discovery in the field of infectious diseases, or a lifetime of outstanding achievement.

For more than a decade, Dr. Schmitt has represented IDSA and its members with several key advisory committees of the American Medical Association, including those that define reimbursement value for all the procedures that ID clinicians perform, making effective representation crucial for the specialty. As chair of IDSA's Value of ID Specialists Task Force, he led the group's efforts resulting in two seminal publications in Clinical Infectious Diseases: The first, in 2014, reported data demonstrating the value of ID physician consultation in the care of hospitalized Medicare beneficiaries. The second, in 2019, provided similar data for privately insured patients under the age of 65. The two studies have formed the backbone of efforts to demonstrate the value of ID physicians to the systems where they practice.

A past member of IDSA's Board of Directors, Dr. Schmitt has served on or led several additional Society committees, including the Clinical Affairs Committee, the Governance Task Force, the Guidelines Task Force, the Quality Improvement Task Force, the ID Specialty Recruitment Task Force, and the vertebral osteomyelitis guidelines panel. He is also a member of IDSA’s Leadership Institute Work Group. A leadership and management training program designed exclusively for mid-career ID and HIV specialists, the inaugural leadership institute was held earlier this year, the start of a critical effort to enable the next generation of ID physician leaders. He has served on multiple additional committees at the state level and at his institution.

Dr. Schmitt is as staff physician in the Department of Infectious Disease at the Cleveland Clinic, where is also head of the Section of Bone and Joint Infections. An associate professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, he received his medical degree from the University of Cincinnati College of Medicine, followed by residency and ID fellowship training at the Cleveland Clinic.

Whether hearing him speak to fellows at IDSA's Clinical Fellows Meeting, to lawmakers on Capitol Hill on behalf of members and patients, or at state, regional, and national meetings for invited lectures, Dr. Schmitt's passionate advocacy for ID physicians and their value is readily apparent. For his efforts on multiple fronts to successfully advance recognition of the value of the ID specialist, the Society is delighted to recognize him with a 2019 Society Citation.
IDSA Watanakunakorn Clinician Award

Presented on Thursday, October 3, 4:45 p.m., in Walter E. Washington Convention Center: Ballroom ABC

Virginia D. Banks, MD, MBA, FIDSA, who has made sustained contributions to the field and the next generation of ID specialists, is the recipient of IDSA's 2019 Watanakunakorn Clinician Award. Named to honor the memory of Chatrchai Watanakunakorn, this award is presented by the IDSA Education and Research Foundation to recognize an IDSA member or fellow for outstanding achievement in the clinical practice of infectious diseases.

An infectious diseases physician with Northeast Ohio Infectious Disease Associates in Youngstown, Dr. Banks is the former director of infectious diseases at the University of Pittsburgh Medical Center’s Horizon Health System in western Pennsylvania, where she was the only ID specialist for two counties with extremely busy clinical services for 15 years. She is nationally known for providing leadership and innovative solutions for infection control in hospitals. As chair and vice chair of internal medicine and as a member of several committees at Horizon, Dr. Banks developed comprehensive care systems, effective outreach activities, creative educational programs, and rigorous clinical studies.

An active partner for many years with the National Medical Association, the nation’s largest and oldest organization representing African American physicians and their patients, Dr. Banks has provided expertise in HIV treatment and prevention, influenza, immunization, and hepatitis C, among other topics, and has contributed to the organization’s projects throughout the country. She has also served as an associate professor of clinical internal medicine at the Northeast Ohio University College of Medicine; director of the Wound Care Center at the University of Pittsburgh Medical Center’s Horizon Health System, where she was also chair of the infection control committee; and as director of the Division of Infectious Diseases at Allegheny General Hospital in Pittsburgh.

Dr. Banks has contributed to IDSA in many ways, including as co-chair of the Professional Development and Equity Committee and as a member of the Education Committee. She has served on HIVMA’s Nominations Committee and Minority Fellowship Committee. Earlier this year, she was named to IDSA’s newly established Leadership Development Committee, which will develop and oversee the process of identifying and coaching qualified pools of applicants to serve as volunteer leaders. After earning her medical degree from Case Western Reserve University School of Medicine, Dr. Banks completed an internship at the Cleveland Clinic, followed by residency and ID fellowship training at University Hospitals of Cleveland. She also earned an MBA from Youngstown State University. She has received several awards and honors throughout her long career.

Recognized for her expertise, leadership, thoughtfulness, and concern for patients, Dr. Banks is a widely admired ID specialist known for her dedication to the field and its future. The Society is pleased to recognize her with the 2019 Watanakunakorn Award.
IDSA Clinical Teacher Award

William L. Salzer, MD, who has supervised hundreds of students, residents, and fellows over nearly three decades, is the recipient of IDSA's 2019 Clinical Teacher Award. This award honors a career dedicated to teaching clinical infectious diseases to fellows, residents, and medical students and recognizes excellence as a clinician and motivation to teach the next generation of physicians.

A professor of clinical medicine at the University of Missouri School of Medicine, where he joined the faculty in 1992, Dr. Salzer is director of the Division of Infectious Diseases and has been the director of the ID fellowship program since 2004. Passionate about patient care, physician training, medical education, community outreach, and mentorship, he has contributed greatly to the patient-based learning curriculum as a case and exam writer; he has done so since the curriculum, in which students collaboratively learn from real clinical cases, was introduced at the University of Missouri 25 years ago. In his decades of service, he has become a legendary teacher and mentor to students, several of whom are now faculty members at his own institution.

Arriving early to the office and among the last to leave each day, Dr. Salzer is readily available to answer student questions and to respond to pressing educational needs, including when expert lectures are needed on short notice. Listed among Best Doctors in America for 2009-2010, Dr. Salzer has received more than 30 teaching awards, including the Jane Hickman Teaching Award, the highest honor in medical education bestowed by the University of Missouri, in 2018. Graduating medical students, by vote, have selected him to serve either as the investiture marshall—who hoods all graduates as they receive their diplomas—or as a commencement speaker eight times.

Dr. Salzer serves on IDSA's Fellows In-Training Exam Test Writing Subcommittee and previously served on the Education Committee for the Society’s annual meeting. A member of several medical school and hospital committees, he also serves as a board member and medical director for Spectrum Health Care, originally founded in 1992 as the Regional AIDS Interfaith Network, which focuses on providing compassionate care to patients. Dr. Salzer received his medical degree from New Jersey Medical School in Newark, followed by an internship, residency, and chief residency at North Carolina Baptist Hospital in Winston-Salem. He completed an ID fellowship and a National Cancer Institute post-doctoral research fellowship at the Bowman Gray School of Medicine in Winston-Salem.

During his many years of tireless dedication to teaching the physicians of the future, Dr. Salzer has become a true legend among students, residents, fellows, and colleagues at the University of Missouri and beyond. IDSA is pleased to add the 2019 Clinical Teacher Award to his impressive record of achievements.

continued on next page
IDSA Oswald Avery Award for Early Achievement

Presented on Saturday, October 5 at 9:15 a.m., in Walter E. Washington Convention Center: Ballroom ABC

Nasia Safdar, MD, PhD, MS, FIDSA, FSHEA, an internationally recognized leader in healthcare-associated infection prevention research, is the recipient of IDSA’s 2019 Oswald Avery Award for Early Achievement. This honor recognizes members or fellows of IDSA age 45 or younger who have demonstrated outstanding achievements in an area of infectious diseases.

Dr. Safdar uses multidisciplinary approaches, including human factors ergonomics, mathematical modeling, clinical trials, implementation science, and bench-based microbiome research to tackle *C. difficile* infection prevention comprehensively. Her transformative and innovative work has changed the paradigm for effective *C. difficile* prevention in many healthcare systems and has been incorporated into national guidelines. An avid believer that research must be applied in real-world settings to have an impact on patient outcomes, Dr. Safdar has created a network of healthcare facilities that participate in the active adoption, evaluation, and dissemination of research findings. Her contributions to implementation science have resulted in greater adoption of evidence-based practices for infection prevention, narrowing the gap between evidence generation and practice.

A leading authority on systems engineering approaches to infection prevention, Dr. Safdar has received a Presidential Early Career Award for Scientists and Engineers—the highest honor bestowed by the U.S. government on outstanding scientists and engineers beginning their independent careers—and a National Institutes of Health Director’s New Innovator Award, given to highly creative investigators. A frequently cited and prolific author whose work includes approximately 300 peer-reviewed articles and other publications, Dr. Safdar is a professor in the Division of Infectious Diseases and vice chair for research in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, and also serves as hospital epidemiologist at University of Wisconsin Health. In addition, she is the associate chief of staff for research at the William S. Middleton Memorial Veterans Hospital and remains an active clinician.

An invited speaker to multiple national and international scientific meetings who has presented widely, Dr. Safdar is a past chair and vice chair of the SHEA Research Committee and currently serves as chair of the committee updating IDSA’s catheter-related bloodstream infection management guideline. She received her medical degree from Aga Khan University Medical College in Pakistan and completed residency training, followed by fellowships in infectious diseases and women’s health, at the University of Wisconsin, where she also earned an MS degree in population health sciences and a PhD in clinical research.

In recognition of her strong leadership as a physician-scientist in healthcare-associated infection prevention research, specifically in the area of *C. difficile* infection, and in bridging the gap between research and clinical practice, IDSA is delighted to honor Dr. Safdar with the 2019 Oswald Avery Award for Early Achievement.
IDSA Walter E. Stamm Mentor Award

Presented on Thursday, October 3, 4:45 p.m., in Walter E. Washington Convention Center: Ballroom ABC

Dr. Thomas is the Stanhope Bayne Jones Professor of Medicine in the Johns Hopkins University School of Medicine, where he also serves as chief of the Division of Infectious Diseases, and is a professor in the Department of Epidemiology at the Johns Hopkins University Bloomberg School of Public Health. He has played a large role in mentoring many of the current ID leaders in the field of hepatitis C virus (HCV) infection, where his own important contributions have advanced our understanding of the disease’s epidemiology and natural history. Forming training plans collaboratively with those he mentors based on their interests, Dr. Thomas has helped numerous trainees and junior faculty at his own institution and elsewhere achieve their goals by providing support, guidance, honest advice, and opportunities.

His trainees have received more than $100 million in National Institutes of Health-funded awards and have authored more than 1,200 peer-reviewed publications in journals including Science, Lancet, the New England Journal of Medicine, and JAMA. They include those now serving as tenure-track faculty, full professors, or in other leadership roles at institutions across the country. Dr. Thomas has also served as director of research at the Infectious Diseases Institute in Kampala, Uganda, which in addition to providing free medical and social services for HIV-infected patients also offers training for physicians and nurses from across sub-Saharan Africa.

The recipient of a 2014 Society Citation from IDSA, Dr. Thomas co-led the joint panel of specialists representing the Society and the American Association for the Study of Liver Diseases to develop timely, evidence-based, consensus recommendations for HCV screening, treatment, and management. After earning a medical degree from West Virginia University School of Medicine, he completed his internship and residency training at Wake Forest University School of Medicine and a fellowship in infectious diseases at Johns Hopkins. He also received a master of public health degree from the Johns Hopkins University Bloomberg School of Public Health.

A leader in the field of viral hepatitis who strongly believes in the importance of fostering the next generation of ID clinicians and researchers, Dr. Thomas has nurtured the careers of numerous trainees with his skilled mentorship. IDSA is delighted to recognize him with the 2019 Walter E. Stamm Mentor Award.
SHEA Senior Scholarship Award

Robert A. Weinstein, MD, FIDSA, FSHEA, is the recipient of the 2019 SHEA Senior Scholar Award recognizing his work as a senior investigator in infection prevention and healthcare epidemiology over the course of his career.

Dr. Weinstein is the C. Anderson Hedberg MD Professor of Internal Medicine, Rush University Medical Center; Chief Academic Officer; Chairman Emeritus, Department of Medicine, Cook County Health and Hospitals System (formerly Cook County Hospital); and Founding Chief Operating Officer, the outpatient Ruth M. Rothstein CORE Center for the Prevention, Care, and Research of Infectious Diseases— all in Chicago, IL.

Dr. Weinstein attended Cornell University and Cornell University Medical College; was a medical house officer at Barnes Hospital/Washington University; and trained in Infectious Diseases and Epidemiology in the CDC’s EIS Program and at the University of Chicago.

Dr. Weinstein’s clinical and research interests have focused on healthcare-acquired infections (particularly the epidemiology, costs, microbiome, and prevention of antimicrobial resistance and infections in intensive care units), rapid HIV testing, and healthcare costs and outcomes for patients with HIV/AIDS.

Dr. Weinstein is a past-president of the Society for Healthcare Epidemiology of America (SHEA), a past-chair of the CDC’s Healthcare Infection Control Practices Advisory Committee (HICPAC), a past member of the IDSA Board of Directors, and a past member of the CDC’s National Center for Infectious Disease Board of Scientific Counselors and Chair of that Board’s Antimicrobial Resistance Working Group. Dr. Weinstein currently is a member of the Presidential Advisory Committee on Combating Antimicrobial Resistant Bacteria. He was a recipient of the National Association of Public Hospitals and Health Systems 1999 Clinical Research Award, the 2005 recipient of the SHEA Lectureship Award, and the 2008 recipient of the SHEA Mentor Award, and was honored with a Lifetime Achievement Award from the CDC in 2010, the Infectious Disease Society of America (IDSA) Walter Stamm Mentor Award in 2012, the IDSA Joseph Smadel Named Lecture in 2014, and the 2017 Rush University Mentor of the year. Dr. Weinstein has published over 350 peer-reviewed scientific articles, over 50 book chapters, 2 books, and over 25 CDs and internet educational materials.

SHEA is thrilled to recognize the contributions of Dr. Weinstein with the 2019 SHEA Senior Scholarship Award for his ongoing career contributions to healthcare epidemiology and infection prevention.
Loretta Litz Fauerbach, MS, FSHEA, FAPIC, CIC, is the recipient of the 2019 SHEA Advanced Practice Infection Preventionist Award based on her career achievements in infection prevention. Ms. Fauerbach currently serves as the Lead Infection Preventionist for Fauerbach & Associates, LLC. Ms. Fauerbach was the Director of Infection Prevention & Control for Shands Hospital at the University of Florida for 28 years. In 2007 Ms. Fauerbach received APIC’s, “Carole DeMille Lifetime Achievement Award” for her contributions and achievements in the field of infection prevention and control. Ms. Fauerbach just completed her term as member of the Healthcare Infection Control Practice Advisory Committee (HICPAC). She is the managing editor the AHE Practice Guidance for Health Care Environmental Cleaning (fall 2019). Ms. Fauerbach was a member of the SHEA spring conference committees (2017-2018) and is currently a member of the SHEA's Membership Task Force. She has served on the APIC's Board of Directors and multiple APIC committees and served as a member and co-chair of APIC's Nominating and Awards Committee. In 2002, Ms. Fauerbach testified before the Institute of Medicine on APIC’s behalf related to healthcare associated infection data. Ms. Fauerbach has served as APIC’s liaison to AAMI, HICPAC, FDA and IDSA during which multiple sentinel guidelines were produced by those agencies/associations. She was APIC’s leader for the SHEA/APIC/ CDC Communication Network. Ms. Fauerbach represented APIC on the Joint Commission’s expert panels for the monographs on hand hygiene, influenza vaccination, and Tdap vaccination. She also participated in the Joint Commission Task Force to identify Opportunities to bridge gaps between respiratory protection guidance and practice in US health care in 2018. She serves as a member of the Advisory Board of the Florida Department of Health, HAI Prevention Program 2009-2019 and the Advisory Board of the FMQA on Antimicrobial Stewardship Advisory Board 2017-2019. Ms. Fauerbach has presented at regional and national meetings and authored multiple articles which have been published in peer-reviewed journals. She was a section editor of *The APIC Text of Infection Control and Epidemiology* and author of two chapters; a chapter author of “APIC’s Elimination Guide: Guide to Preventing Clostridium difficile Infections”; and a chapter author for *The Joint Commission/APIC Infection Prevention and Control Workbook*.

For her years of dedication and overall contributions and commitment to excellence in the field of infection prevention, that SHEA is pleased to award Loretta Litz Fauerbach the 2019 Advanced Practice Infection Preventioist Award.
SHEA Society Awards (continued)

SHEA Antibiotic Stewardship Scholarship Award

Presented on Friday, October 4, at 4:30 p.m., in Walter E. Washington Convention Center: Ballroom ABC

SHEA is pleased to award, Jeffrey S. Gerber, MD, PhD, the 2019 SHEA Antibiotic Stewardship Scholarship Award for his contributions as an investigator and practitioner to antibiotic stewardship program and research.

Dr. Gerber is associate professor of pediatrics and epidemiology at the University of Pennsylvania Perelman School of Medicine and Attending Physician in the Division Infectious Diseases at Children’s Hospital of Philadelphia (CHOP). Dr. Gerber is medical director of the CHOP Antimicrobial Stewardship Program; associate director of the CHOP Center for Pediatric Clinical Effectiveness; senior scholar in the Penn Center for Clinical Epidemiology and Biostatistics; and a member of the American Academy of Pediatrics Committee on Infectious Diseases, for which he is chair of the Antimicrobial Resistance and Stewardship Subcommittee. His research focuses on the epidemiology and outcomes of antimicrobial use in children, in both hospital and ambulatory settings, and is funded by NIH, PCORI, AHRQ, and CDC.

SHEA is pleased to recognize Dr. Gerber for his commitment to Antibiotic Stewardship with the 2019 SHEA Antibiotic Stewardship Scholarship Award.

SHEA Mentor Scholar Award

Presented on Friday, October 4, at 4:30 p.m., in Walter E. Washington Convention Center: Ballroom ABC

Keith Kaye, MD, MPH, FIDSA, FSHEA, is this year’s recipient for the 2019 SHEA Mentor Scholar Award for his commitment to mentoring fellows and junior faculty.

Dr. Kaye is a Professor of Medicine in the Division of Infectious Diseases and Department of Medicine at University of Michigan Medical School. He is the Director of Research for the Division of Infectious Diseases. Dr. Kaye’s particular academic interests and skills include the prevention and management of healthcare-associated infections including those due to multi-drug resistant pathogens; antimicrobial stewardship; infections in the older adults; and surgical site infection.

Dr. Kaye received his medical degree from the University of Pennsylvania and completed his Internal Medicine residency and Infectious Diseases fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School in Boston, MA. During fellowship, Dr. Kaye earned a Master’s in Public Health from the Harvard School of Public Health. Dr. Kaye has authored over 250 peer-reviewed articles and 18 book chapters. Dr. Kaye has dedicated his entire career to infection prevention and antimicrobial stewardship and served as the Corporate Medical Director for Infection Prevention at Detroit Medical Center (DMC) from 2008-2016 and as Corporate VP of Quality and Patient Safety at DMC from 2012-2016. He is the Past President of the Society for Health Epidemiology of America (SHEA). He is recognized as an expert in healthcare epidemiology and antimicrobial resistance and has been invited to speak on these topics at venues throughout the world. Some of his most noteworthy work pertains to the polymyxin antimicrobials, nephrotoxic antibiotics discovered in the 1950s that have recently taken on growing recognition and importance due their high level of activity against practically untreatable multi-drug resistant (MDR) Gram-negative bacilli. He currently is the PI on 2 NIH-funded trials evaluating the treatment of infections due to extremely-drug resistant (XDR) Gram-negative bacteria with polymyxins. Dr. Kaye also conducts cutting edge research pertaining to infection prevention and is currently the PI on an AHRQ-funded trial evaluating the impact UV disinfection of patient rooms on the acquisition of infection due to Clostridium difficile and MDR pathogens in hospitals.

Dr. Kaye is extremely passionate about mentorship and has remained committed to developing trainees and junior faculty into independent and productive physicians, pharmacists and epidemiologists. He has mentored more than 50 trainees and faculty members, many of whom have risen to leadership positions in areas of quality improvement, research and clinical care in healthcare epidemiology, antimicrobial stewardship and infectious diseases in the United States and also around the world. Several of Dr. Kaye’s mentees are actively involved in SHEA and are emerging leaders in the Society as well. SHEA is pleased to recognize the mentoring achievements of Dr. Kaye with the 2019 SHEA Mentor Scholar Award.
### SHEA Mid-Career Scholarship Award

**Daniel Morgan MD, MS**, is this year’s 2019 SHEA Mid-Career Scholarship Award for his contributions during his career in infection prevention and healthcare epidemiology science and practice. Dr. Morgan is a physician and epidemiologist in Baltimore, Maryland. He is a Professor of Epidemiology and Medicine at the University of Maryland School of Medicine and Chief Hospital Epidemiologist at the Baltimore VAMC. His research explores infection prevention and medical overuse. This includes pragmatic issues related to the control of infectious diseases in the hospital and patient safety, including the best use of patient isolation, hand hygiene compliance, prevention of MRSA, C. diff and CRE, multicenter infection prevention studies and antimicrobial stewardship. He was a founding member and past Director of the Society for Healthcare Epidemiology of America (SHEA) Research Network and served on the Board of Directors of SHEA as well as many SHEA committees.

On a NIH New Innovator award for “exceptional scientists pursuing highly innovative approaches to major challenges” he is exploring clinician understanding of risk in relation to testing and treatment decisions. This has been incorporated into his efforts towards diagnostic stewardship or making appropriate testing easier for clinicians.

His work is funded through the US NIH, CDC and AHRQ.

---

### SHEA Pediatric Scholarship Award

**Judith Guzman-Cottrill, DO, FSHEA**, was selected at the 2019 SHEA Pediatric Scholarship Award Recipient recognizing her contributions to the fields of pediatric infection prevention. Dr. Guzman-Cottrill is a Professor of Pediatrics in the Division of Infectious Diseases and Department of Pediatrics at Oregon Health and Science University, where she served as Hospital Epidemiologist and Medical Director of Infection Prevention for Doernbecher Children’s Hospital from 2004-2015.

For over a decade, Dr. Guzman-Cottrill has been an active contributor to the field of pediatric infection prevention. In 2011, she was Chair of a statewide NICU collaborative for CLABSI prevention. This led to serving as a faculty leader in an HRET-funded national CLABSI prevention collaborative from 2012-2013. In 2013, Dr. Guzman-Cottrill established a partnership with Ronald McDonald House Charities to develop and publish the 2013 SHEA Guideline, *Infection Prevention and Control in Residential Facilities for Pediatric Patients and Their Families*, which has since been considered the standard operations reference document for over 360 Ronald McDonald Houses worldwide. From 2017-2018, Dr. Guzman-Cottrill served as a faculty member on the CDC/Vermont Oxford Network “Choosing Antibiotics Wisely” national QI collaborative. Most recently, Dr. Guzman-Cottrill and Dr. Kristina Bryant (PIDS President) co-edited the first edition of the “Handbook of Pediatric Infection Prevention and Control,” the first pediatric-specific infection prevention reference book of its kind.

In 2015, Dr. Guzman-Cottrill partnered with Oregon’s public health HAI program, becoming the state’s Ebola & Emerging Pathogen Preparedness Medical Director. This work has allowed her to develop ways to strengthen collaboration between healthcare facilities and state HAI prevention programs, with specific focus on antibiotic use and resistance (AUR) reporting to the National Healthcare Safety Network (NHSN), pediatric *C. difficile* epidemiology, and early detection of infectious diseases in the Emergency Department setting. She remains an active partner with the Oregon HAI and Health Security, Preparedness, and Response (HSPR) programs. From 2016-2018, Dr. Guzman-Cottrill served as Advisory Panel Chair of the CDC/SHEA Outbreak Response Training Program. She is currently Chair of the SHEA Public Health Task Force. Since July 2019, Dr. Guzman-Cottrill began serving as a member of the CDC Healthcare Infection Control Practices Advisory Committee (HICPAC).

Dr. Guzman-Cottrill has been a SHEA member since 2005, and a member of the SHEA Pediatric Leadership Council since 2008. From 2014-2016, she was the PIDS Liaison on the SHEA Board of Trustees. Dr. Guzman-Cottrill was a member of the SHEA Education & Research Foundation from 2015-2017, when she developed the annual *Race Against Resistance* fundraiser which has since raised over $45,000 towards antibiotic stewardship educational scholarships. She has served on the SHEA Education Committee and Guidelines Committee and was Chair of the SHEA 2019 Spring Conference. She currently serves as a Councilor on the SHEA Board of Trustees.

For her contributions to SHEA and pediatrics infection prevention, we are pleased to present Dr. Guzman-Cottrill with the 2019 SHEA Pediatric Scholarship Award.

---

For her contributions to SHEA and pediatrics infection prevention, we are pleased to present Dr. Guzman-Cottrill with the 2019 SHEA Pediatric Scholarship Award.
SHEA is pleased to award, Jaffar A. Al-Tawfiq, MD, FACP, FIDSA, FSHEA, the 2019 SHEA International Scholarship Award for his contributions as an investigator and practitioner to international infection prevention.

Dr. Jaffar A. Al-Tawfiq, is a consultant of internal medicine and infectious diseases at Johns Hopkins Aramco Healthcare in Dhahran, Saudi Arabia. He completed his medical school at King Faisal University School of Medicine, Kingdom of Saudi Arabia (KSA). He then completed the internal medicine residency at Indiana University School of Medicine, Indianapolis, Indiana. He subsequently completed Infectious Diseases Fellowship at the same university.

During his Infectious Diseases fellowship, Dr. Al-Tawfiq worked extensively on the pathogenesis of *Haemophilus ducreyi* and the mechanism of the immune response to the various genes. In 1998, he completed a diploma in Tropical Medicine and Hygiene (DTM&H) at London School of Tropical Medicine and Hygiene and was awarded a diploma in TM&H by the Royal College of Physician of London. He also completed an Improvement Advisor certification program from IHI, Boston, USA and a clinical teacher certificate from Toronto University, Toronto, Canada. He had participated in many international conferences and presented at various regional and local seminars. Dr. Al-Tawfiq received many publication awards.

Since 2012, Dr. Al-Tawfiq was involved in the management and control of the emerging MERS-CoV in Saudi Arabia. He worked closely with the Saudi Ministry of Health (MOH) and international academic organization to control multiple outbreaks of MERS-CoV. Dr. Al-Tawfiq was a member of the Saudi MERS-CoV scientific committee and was a member of the Saudi ministry of health to the Republic of Korea to advice on the control of MERS outbreak.

During his academic career, Dr. Al-Tawfiq had published extensively in multiple journals. He has been involved in many projects that were designed to decrease healthcare associated infections such as ventilator-associated pneumonia. He recently was awarded by the Saudi Center for patient safety an award for his work on reducing central line associated blood stream infections. His work was selected from a thousand projects in the KSA. In addition, he has worked tirelessly to promote hand hygiene and other quality improvement initiatives.

SHEA is pleased to recognize Dr. Al-Tawfiq for his commitment to infection prevention with the 2019 SHEA International Scholarship Award.

The Editors of Infection Control and Hospital Epidemiology (ICHE) selected the following manuscript to receive the Barry Farr Award for most outstanding domestic clinical study published in ICHE in 2018: “Impact of Discontinuing Contact Precautions for Methicillin-Resistant *Staphylococcus aureus* and Vancomycin-Resistant Enterococcus: An Interrupted Time Series Analysis.” ICHE 2018 39(6): 676-682.

The study aimed to investigate the impact of discontinuing contact precautions among patients infected or colonized with methicillin-resistant *Staphylococcus aureus* (MRSA) or vancomycin-resistant Enterococcus (VRE) on rates of healthcare-associated infection (HAI). Researchers used a single-center, quasi-experimental study conducted between 2011 and 2016.

The study found that discontinuation of contact precautions for patients infected or colonized with MRSA or VRE, when combined with horizontal infection prevention measures was not associated with an increased incidence of MRSA and VRE device-associated infections. This approach may represent a safe and cost-effective strategy for managing these patients.

Lead author Gonzalo Bearman MD, MPH, FACP, FIDSA, FSHEA, is the Chair of the Division of Infectious Diseases, Professor of Medicine and the Associate Hospital Epidemiologist at the Virginia Commonwealth University Health System. He is a graduate of Colgate University (BA), SUNY at Buffalo School of Medicine and Biomedical Sciences (MD) and Columbia University (MPH). He currently serves as a councilor on the SHEA Board of Trustees. Other authors on the study were Salma Abbas, Nadia Masroor, Kakotan Sanogo, Ginger Vanhoozer, Kaila Cooper, Michelle Doll, Michael P. Stevens and Michael B. Edmond.
**SHEA Society Awards (continued)**

### SHEA William Jarvis Award

The Editors of *Infection Control and Hospital Epidemiology* (ICHE) selected the following manuscript to receive the William Jarvis Award for most outstanding international clinical study published in ICHE in 2018: "A noninferiority cluster randomized controlled trial in antibiotic post prescription review and authorization by trained general pharmacists and infectious disease clinical fellows." ICHE 2018; 39 (10):1154-1162.

Pinyo Rattanaumpawan MD, MSCE, PhD

The study set out to compare the effectiveness of antibiotic post prescription review and authorization (PPRA) determined by infectious disease (ID) clinical fellows with that of trained general pharmacists. Using a noninferiority cluster-randomized controlled trial in 6 general medical wards at Siriraj Hospital in Bangkok, Thailand. The study enrolled all patients in the study wards who received 1 or more doses of the targeted antibiotics: piperacillin/tazobactam, imipenem/cilastatin, and meropenem. The study confirmed the noninferiority of pharmacist PPRA in terms of favorable clinical response; however, noninferiority in targeted antibiotic consumption could not be established. Therefore, using trained general pharmacists rather than ID clinical fellows could be an alternative in a resource-limited setting.

Lead author Pinyo Rattanaumpawan MD, MSCE, PhD works in the Division of Infectious Diseases and Tropical Medicine, Department of Medicine, and serves as a Faculty of Medicine at Siriraj Hospital, Mahidol University in Thailand.

### Sue Bradley Reviewer Award

SHEA on behalf of our scientific journal, *Infection Control and Hospital Epidemiology* (ICHE), is pleased to recognize Joseph M. Mylotte, MD with the inaugural Sue Bradley Reviewer Award. This award is presented as a thank you to recognize the time and effort of the ICHE reviewer who has completed the most on time reviews based on ICHE’s editorial process. Dr. Mylotte received a Doctor of Medicine degree from the School of Medicine, University at Buffalo in 1973. He completed a residency in Internal Medicine and a fellowship in Infectious Diseases at the University at Buffalo. He was a full-time faculty member of the School of Medicine, Department of Medicine, Division of Infectious Diseases, University at Buffalo from 1980 to 2010 retiring with the rank of Professor with tenure. From 1988 to 2010 he also was an infection control consultant for several hospitals and nursing homes in Western New York State.

Dr. Mylotte served as an attending physician on the Acute Geriatrics Service at Erie County Medical Center, Buffalo, NY from July 1997 to January 2006; he was the director of the unit from 2000-2006. Beginning in 2004 he was a part-time attending on a post-acute unit of a nursing home. From 2006 until 2015 he was a full-time attending physician for several nursing homes in Western New York primarily doing post-acute care. He also served as a medical director for several nursing homes. He retired from the practice of medicine in July 2015.

Dr. Mylotte is a Fellow of the Infectious Diseases Society of America, Fellow, Society for Healthcare Epidemiology of America, and Fellow, American College of Physicians. We appreciate Dr. Mylotte’s service to SHEA and thank him for his efforts in support of ICHE.
Carlos del Rio, MD, FIDSA, who has been actively engaged in research and education in HIV care for nearly 30 years, is the recipient of the 2019 HIVMA Clinical Educator Award. This award recognizes HIVMA members who have demonstrated significant achievement in the area of clinical care and provider education.

The Hubert Professor and Chair of the Hubert Department of Global Health in the Rollins School of Public Health at Emory University and a professor of medicine in the Emory University School of Medicine, Dr. del Rio has made countless contributions to medical teaching and training. In addition to training residents and fellows at Emory, where he consistently receives rave reviews, he has had a prominent role in educating clinicians as a highly sought-after speaker at clinical and scientific meetings and as a conference organizer. His updates as a member of the core faculty and the Board of Directors of the International Antiviral Society-USA have provided authoritative information on advances in care for many HIV clinicians.

A recognized leader in the area of the HIV care continuum and providing care to vulnerable populations, Dr. del Rio has influenced the practice of thousands of care providers through his activities as a member of the U.S. Department of Health and Human Services Panel for Antiretroviral Guidelines for Adults and Adolescents. As a media spokesperson, he has educated the public and his colleagues on timely medical and public health topics through hundreds of interviews with national and international media outlets, providing balanced and informed comments. An early adopter of social media who has lectured on its educational uses, he has effectively used Twitter and other platforms to inform, share newly presented or published findings in real time, and provide insightful commentary on pressing public health challenges to a wide audience. Dr. del Rio has now become actively engaged in addressing the opioid epidemic and has devoted time and efforts to educate ID clinicians on this important topic.

For 17 years, Dr. del Rio was the principal investigator of Emory’s AIDS International Training and Research Program, which was devoted to developing training opportunities in public health and HIV research for trainees from the Republic of Georgia, Mexico, Vietnam, Ethiopia, Rwanda, and Zambia. A past chair and member of the HIVMA Board of Directors and a past member of the IDSA Education Committee, he has published nearly 350 peer-reviewed publications and has received many honors, including election to the National Academy of Medicine. He received a medical degree from Universidad La Salle in Mexico City and completed his residency, chief residency, and ID fellowship training at Emory University.

For his passionate commitment to education, advancing HIV care, and improving the lives of the most vulnerable, which have reached all corners of the globe, HIVMA is honored to recognize Dr. del Rio with the 2019 HIVMA Clinical Educator Award.
Andrea Ciaranello, MD, MPH, FIDSA, a skilled physician-scientist committed to identifying effective approaches to care for HIV-infected women and children, is the recipient of the 2019 HIVMA Research Award. This award recognizes members who have made outstanding contributions to HIV medicine in clinical or basic research early in their careers.

Dr. Ciaranello, an associate professor of medicine at Harvard Medical School and an ID physician at Massachusetts General Hospital, leads the Maternal-Child Health research program within the hospital’s Cost-Effectiveness of Preventing AIDS Complications (CEPAC) modeling group. She has developed novel computer simulation models to address critical clinical and policy questions in the care of women with HIV and their children. Her team has generated an impressive portfolio of widely-cited, high-impact research focused on perinatal infection, care for HIV-exposed and HIV-infected children, and HIV treatment and prevention among adolescents living with or at risk of infection. Her work has had a significant impact on health policy and has influenced care and treatment guidelines locally, nationally, and internationally.

The principal investigator or leading co-investigator on successfully funded awards from numerous entities, including the National Institutes of Health, amfAR, and the World Health Organization, Dr. Ciaranello serves as co-chair of the U.S. Department of Health and Human Services Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. She is the lead author for recommendations on preferred antiretroviral regimens during pregnancy and is a member of the UNAIDS Technical Reference Group for Pediatric HIV Modeling and Estimates.

As the founding director of the Perinatal Infectious Disease Clinic at Massachusetts General Hospital, Dr. Ciaranello provides care for patients with HIV and other infections during pregnancy and continues to see patients once weekly in the outpatient HIV/ID clinic. In addition to her own significant research contributions informing public health policy, she has demonstrated a strong commitment to developing the next generation of researchers as a highly sought-after mentor and serves as a teaching attending for students, residents, and fellows on the ID consult and internal medicine inpatient services.

After earning her medical degree from Yale University School of Medicine, Dr. Ciaranello completed a residency and chief residency in internal medicine at the University of California, Davis, followed by clinical and research fellowship training in infectious diseases at Brigham and Women’s Hospital and Massachusetts General Hospital. She also received a master of public health degree from the Harvard School of Public Health. For her pioneering work in the area of HIV cost-effectiveness research, which has impacted the care of women and children around the world, HIVMA is delighted to honor Dr. Ciaranello with the 2019 HIVMA Research Award.
HIVMA Clinical Fellows

**Sunny Lai, MD**  
Thomas Jefferson University Hospital  
Philadelphia, PA  
Mentor: Lisa Spacek, MD, PhD

Dr. Sunny Lai is pursuing HIV clinical training at the Jefferson Infectious Disease Associates (part of the Jefferson Health system), the Kendig Comprehensive HIV Primary Care Clinic, and the Mazzoni Center under the mentorship of Lisa A. Spacek, MD, PhD. Dr. Lai is eager to further her training in HIV, along with addiction, LGBTQ health, and advocacy. Her desire to pursue training in HIV is driven by firsthand experience with the disproportionate impact of HIV on marginalized communities and is committed to improving care and advancing health equity through direct patient care, inclusive collaboration, advocacy, and the arts. Dr. Lai completed her residency in Family and Community Medicine at Thomas Jefferson University. She received her medical degree from the University of California, San Francisco and Master of Public Health from Johns Hopkins Bloomberg School of Public Health.

**Lin Mel, MD**  
Ponce de Leon Center  
Emory University/Grady Health System  
Atlanta, GA  
Mentors: Aley Kalapila, MD and Minh Nguyen, MD

Dr. Lin Mel's primary training site is the Ponce De Leon Center with Grady Health Systems under the mentorship of Drs. Aley Kalapila, MD, and Minh Ly Nguyen, MD. He became interested in the HIV epidemic and its history in college and pursued a family residency in Atlanta so that he could explore training opportunities in HIV primary care. He's excited to deepen his understanding of the HIV epidemic in Atlanta and the South through the HIVMA Clinical Fellowship. Dr. Mel received his medical degree from Virginia Commonwealth University and completed his residency in Family Medicine at Emory University.
PIDS Distinguished Service Award

Presented on Wednesday, October 2, at 3:45 p.m., in Walter E. Washington Convention Center: Ballroom ABC

David W. Kimberlin, MD, FPIDS, Sergio Stagno Endowed Chair in Pediatric Infectious Diseases, Vice Chair for Clinical and Translational Research and Co-Director of the Division of Pediatric Infectious Diseases at the University of Alabama at Birmingham, has been selected as the 2019 recipient of the Pediatric Infectious Diseases Society (PIDS) Distinguished Service Award. This award recognizes a Society member who has made outstanding contributions to the specialty of pediatric infectious diseases.

Dr. Kimberlin is a Past-President of PIDS. Dr. Kimberlin is Editor of the 2021 AAP Report of the Committee on Infectious Diseases (Red Book), and he has previously served as Editor of the 2018 and 2015 editions. Dr. Kimberlin served as a member of the American Academy of Pediatrics (AAP) Committee on Infectious Diseases (COID) from 2005-2011 and is an Associate Editor for the 6th edition of Principles and Practice of Pediatric Infectious Diseases.

Dr. Kimberlin's work has focused on the diagnosis and management of numerous viral infections in children. Through studies he led together with colleagues in the Collaborative Antiviral Study Group, David has defined diagnostic and management approaches to neonatal herpes simplex virus infection and congenital CMV infection. As the leading expert in herpesvirus infections of infants, David has served on numerous government and medical society panels and has published widely. David is often consulted by his peers in pediatric ID around the world to assist in the management of challenging clinical cases and he always willingly provides consultation. In this way, David not only is recognized as a global expert in herpesvirus infections, but as a global ambassador for the specialty of pediatric infectious diseases.

Dr. Kimberlin's contributions to our understanding and novel treatment approaches of herpesvirus and other infections of children are unparalleled and are an inspiration to all our members. PIDS is proud to honor Dr. Kimberlin with the Distinguished Service Award.

PIDS Society Awards

PIDS presents several Society Awards during their business meeting. The PIDS Distinguished Physician and Young Investigator Awards will be presented at the PIDS Foundation Dinner.

Antimicrobial Stewardship Fellowship Award
Hall Award for a Clinically Innovative Research Paper by a Junior Investigator
Horizon Therapeutics Fellowship Award

Pichichero Family Foundation Research Development, Vaccines for Children Initiative Award in Pediatric Infectious Diseases
PIDS-St. Jude Children's Research Hospital Fellowship Award in Basic and Translational Science
Stanley & Susan Plotkin and Sanofi Pasteur Fellowship Award
Abstract Awards

IDWeek Program Committee Choice Awards

This award recognizes up to four of the best abstracts overall. IDWeek’s Program Committee selected the following recipients based on outstanding scientific research:

Alan Gross, PharmD; University of Illinois, Chicago, IL - Presentation #1895: “Serious Antibiotic-Related Adverse Effects Following Unnecessary Dental Prophylaxis in the United States” Session: 201: SHEA Featured Oral Abstract, Friday, October 4, 4:45 - 5 p.m.

Styliani Karanika, MD; Boston University, Boston, MA - Presentation #976: “Development and Validation of a Risk Score for Predicting Cardiovascular Events in HIV-Infected Patients” Session: 126: Suppressed but Still at Risk: Comorbidities, Friday, October 4, 10:30 - 10:45 a.m.

Ayesha Khan, BSC; McGovern Medical School, Houston, TX - Presentation #903: “Resensitization to β-lactams in Enterococci Depends on Penicillin-Binding Protein (PBP) Mislocalization and Is Mediated by a Single Protein That Modulates Cell Membrane (CM) Adaptation to Daptomycin (DAP)” Session: 100: IDSA Featured Oral Abstract, Thursday, October 3, 5:05 - 5:20 p.m.

Anne Rowley, MD; Northwestern University, Chicago, IL - Presentation #1876: “A Hepacivirus-Like Protein is Targeted by the Antibody Response to Kawasaki Disease (KD)” Session: 196: Pediatric Emerging Viral Diseases, Friday, October 4, 4:15 - 4:30 p.m.

IDWeek Diagnostic Awards

The IDWeek Award for top abstracts submitted in diagnostics is intended to recognize the best abstract in the category of diagnostics. The IDWeek Program Committee selected the recipients based on outstanding scientific research in the field of diagnostics.

Matthew Cheng, MD; Brigham and Women’s Hospital, Boston, MA - Presentation #847: “The Effect of Antimicrobial Administration on Blood Culture Positivity in Patients with Severe Manifestations of Sepsis” Session: 84: Novel Insights into Bacteremia and Endocarditis, Thursday, October 3, 1:45 - 2 p.m.

Catherine Hogan, MD, MSc; Stanford University School of Medicine, Stanford, CA, United States - Presentation #1791: “Novel Metabolomics Approach for the Diagnosis of Respiratory Viruses Directly from Nasopharyngeal Specimens” Session: 170: Viral Diagnostics, Friday, October 4, 12:15 - 1:30 p.m.

Rose Lee, MD, MSPH; Boston Children’s Hospital, Boston, MA - Presentation #1832: “Development of an Ultrasensitive Field-Applicable Plasmodium falciparum Assay for Malaria Diagnosis and Eradication” Session: 183: Innovative Diagnostics, Friday, October 4, 2:15 - 2:30 p.m.
Abstract Awards (continued)

**IDWeek Investigator Awards**

The Investigator Awards are intended to recognize the work of investigators in practice for less than 15 years, whose submitted abstracts are accepted for presentation at IDWeek. Selection was based on the quality of the scientific merit of the nominee’s accepted abstract. Each IDWeek sponsoring society has chosen one outstanding abstract from a member in their specialty to highlight. Following are the awardees for IDWeek 2019:

**PIDS Awardee:**
**Angela Campbell, MD;** Centers for Disease Control and Prevention, Atlanta, GA - Presentation #899: “Influenza Vaccine Effectiveness against Laboratory-Confirmed Influenza in Children Hospitalized with Respiratory Illness in the United States, 2016-17 and 2017-18 Seasons” Session: 99: Vaccines I - Influenza and RSV, Thursday, October 3, 3:30 - 3:45 p.m.

**SHEA Awardee:**
**James McKinell, MD;** LA BioMed at Harbor-UCLA Medical Center, Torrance, CA - Presentation #893: “The SHIELD Orange County Project: A Decolonization Strategy in 35 Hospitals and Nursing Homes Reduces Multi-Drug Resistant Organism (MDRO) Prevalence in a Southern California Region” Session: 98: To Decolonize or Not to Decolonize: Do We Still Need to Ask the Question, Thursday, October 3, 3:15 - 3:30 p.m.

**HIVMA Awardee:**
**Kathleen McManus, MD, MSCR;** University of Virginia, Charlottesville, VA - Presentation #883: “Evidence from a Multistate Cohort: Enrollment in Affordable Care Act Qualified Health Plans Results in Viral Suppression” Session: 96: HIV Viral Suppression or Bust, Thursday, October 3, 3:15 - 3:30 p.m.

**IDSA Awardee:**
**Ann Woolley, MD, MPH;** Brigham and Women’s Hospital, Boston, MA - Presentation #87: “Heart and Lung Transplants from HCV-Viremic Donors to Uninfected Patients - Longer-Term Follow-Up” Session: 33: Transplant ID, Thursday, October 3, 10:30 - 10:45 a.m.
IDWeek International Investigator Awards

The IDWeek International Investigator Awards are intended to recognize and support the work of individuals outside the United States and Canada who are either currently in training or who have been in practice for five years or less, and have an abstract accepted for presentation at IDWeek. The grant selection was based on scientific merit of the submitted abstract. Following are the awardees for 2019 IDWeek:

Otto Helve, MD, PhD; Children’s Hospital, Pediatric Research Center, Helsinki University Hospital, University of Helsinki, Finland, Helsinki, Uusimaa, Finland - Presentation #2843: “Maternal Fecal Transplantation to Infants Born by Cesarean Section-Safety and Feasibility” Session: 295: Microbiome Science, Saturday, October 5, 1:45 - 2 p.m.

Eduardo Perez Alba, MD; Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico - Presentation #1789: “Frequency of Chikungunya, Dengue and Zika Virus in Acute Febrile Illness in Paired Urine and Serum Samples in Mexico.” Session: 170: Viral Diagnostics, Friday, October 4, 12:15 - 1:30 p.m.


Suguru Takeuchi, MD; Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan - Presentation #1788: “The Utility of Next-Generation Sequencing for Detection of Candidate Pathogens in Bronchoalveolar Lavage Fluid from Pediatric Patients with Respiratory Failure” Session: 170: Viral Diagnostics, Friday, October 4, 12:15 - 1:30 p.m.

Monica Liliana Vargas Ardila, DVM; Universidad Nacional de Colombia; Molecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Distrito Capital de Bogota, COL - Presentation #1827: “Genetic Characterization of Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Associated with the Development of Reduced Susceptibility to Vancomycin from Latin America” Session: 182: Emergent Mechanisms of Resistance and How to Prevent Them, Friday, October 4, 2:15 - 2:30 p.m.

Ilan Youngster, MD, MMSc; Shamir Medical Center, Israel., Nes Ziona, HaMerkaz, ISR - Presentation #90: “Fecal Microbiota Transplantation in Metastatic Melanoma Patients Resistant to Anti-PD-1 Treatment” Session: 33: Transplant ID, Thursday, October 3, 11:15 - 11:30 a.m.

PIDS Awardee:
Fausto Martin Ferolla, MD; Hospital de Niños “Dr. Ricardo Gutiérrez”, Buenos Aires, Buenos Aires, Argentina - Presentation #2332: “Low Serum Vitamin D Levels are Related to Life-Threatening Respiratory Syncytial Virus Infection in Previously Healthy Infants” Session: 247: Clinical Virology/Viral Epidemiology, Saturday, October 5, 12:15 - 1:30 p.m.

HIVMA Awardee:
Itai M’yambo Magodoro, MBBS, MMSc, MSc; Harvard TH Chan School of Public Health, Cape Town, Western Cape, ZAF - Presentation #844: “Engagement in HIV Care as an Avenue to Primary Care in Rural South Africa: Results from the Vukuzazi Population Health Platform” Session: 82: Global Health: Outbreaks, Controls, and Genetics, Thursday, October 3, 2:15 - 2:30 p.m.

SHEA Awardee:
Takashi Matono, MD, PhD; Iizuka Hospital, Iizuka, Fukuoka, Japan - Presentation #2041: “Impact of an Infectious Disease Specialist-led Post-prescription Carbapenem Intervention in a Large Japanese Tertiary Hospital: A Before-after Cohort Study” Session: 236: Antibiotic Stewardship: Global, Saturday, October 5, 12:15 - 1:30 p.m.

IDSA Awardee:
Maria Smatti, MSc; Qatar University, Doha, Ad Dawhah, QAT - Presentation #1833: “Measuring Influenza HA Stem-Specific ADCC in Human Sera Using Novel Stabilized Stem Nanoparticle Probes” Session: 183: Innovative Diagnostics, Friday, October 4, 2:30 - 2:45 p.m.
The Guerrant International Travel Grants are awarded to fund travel to IDWeek from low- and lower-middle income countries (based on the World Bank’s definition). A limited number of grants up to $1,600 are available to participants whose abstracts are accepted. The following are the recipients who have received this award for 2019:

**Guerrant International Travel Grants**

**Ajay Chopra, MD MBBS;** Base Hospital Delhi Cantt, New Delhi, Delhi, India - Presentation #1345: “Randomized Control Trial to evaluate the Clinical and Cytokine response profile to Oral Thalidomide in Leprosy patients with Erythema Nodosum Leprosum” Session: 153: Mycobacteria, Friday, October 4, 12:15 - 1:30 p.m.

**Manisha Gupta, MD,DipRCPath;** SGPGI, Lucknow, Uttar Pradesh, India - Presentation #1790: “Single centre experience and lessons learnt from management of Nipah virus outbreak in India” Session: 170: Viral Diagnostics, Friday, October 4, 12:15 - 1:30 p.m.


**George Varghese, MD,DNB, DTMH, FRCP, FIDSA;** Christian Medical College, Vellore, Tamil Nadu, India - Presentation #1655: “Performance of Molecular and Serologic Tests for the Diagnosis of Scrub Typhus” Session: 164: Stepping off your Doorstep - Global Health, Friday, October 4, 12:15 - 1:30 p.m.

**Paul Yonga, MBChB, MScPH, MRCP Edin.;** Baringo County Referral Hospital/Fountain Health Care Hospital, Nairobi, Nairobi Area, Kenya - Presentation #1319: “Events of Disengagement from HIV care and Subsequent Reengagement in a Kenyan Pastoralist Community: Frequency, Determinants, and Patient Views” Session: 151: HIV: Care Continuum, Friday, October 4, 12:15 - 1:30 p.m.

The Guerrant International Travel Grants are awarded to fund travel to IDWeek from low- and lower-middle income countries (based on the World Bank’s definition). A limited number of grants up to $1,600 are available to participants whose abstracts are accepted. The following are the recipients who have received this award for 2019:
Abstract Awards (continued)

Kass Awards

The Kass Awards were established to honor the achievements of Edward H. Kass, a past IDSA president and leader in infectious diseases research. Grants in the amount of $750 are awarded to medical students, residents, or house officers who have demonstrated excellence in research in infectious diseases and allied fields. Following are the recipients of this award for 2019:

**Amalia Aldredge, MD;** Emory University, Atlanta, GA - Presentation #980: “Effects of Integrase Strand-Transfer Inhibitor Use on Lipids, Glycemic Control, and Insulin Resistance in the Women’s Interagency HIV Study (WIHS)” Session: 126: Suppressed but Still at Risk: Comorbidities, Friday, October 4, 11:30 AM - 11:45 a.m.

**Sarah Battle, MD;** University of South Carolina/Prisma Health Richland Hospital, West Columbia, SC - Presentation #851: “Validation of Quick Pitt Bacteremia Score in Patients with *Staphylococcus aureus* Bloodstream Infection” Session: 84: Novel Insights into Bacteremia and Endocarditis, Thursday, October 3, 2:45 - 3 p.m.

**Morgan Birabaharan, BS;** Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Leesport, PA - Presentation #340: “Prevalence of Type II Diabetes Mellitus Among Patients Living with HIV in the United States” Session: 44: HIV Complications: Cardiovascular, Metabolic, and other Complications, Thursday, October 3, 12:15 - 1:30 p.m.

**Jennifer Crook, BS, BA;** Vanderbilt University Medical Center, Nashville, TN - Presentation #1793: “Clinical Outcomes among Febrile Infants Before and After Implementation of BioFire®FilmArray®Panels” Session: 170: Viral Diagnostics, Friday, October 4, 12:15 - 1:30 p.m.

**Michael Dieterle, BS;** University of Michigan Medical School, Ann Arbor, MI - Presentation #76: “Validation of Systemic Inflammatory Mediators as Biomarkers for Severity and Adverse Outcomes in *Clostridium difficile* Infection” Session: 31: Not Just Your Everyday Diarrhea, Thursday, October 3, 10:30 - 10:42 a.m.

**Mackenzie Keintz, MD;** University of Nebraska Medical Center, Omaha, NE - Presentation #966: “A Closer Look at Antibiotic Prescribing for Upper Respiratory Illnesses (URI) in People with HIV Compared to People without HIV” Session: 124: Out of the Box and Out of the Hospital: Stewardship Outpatient Services, Friday, October 4, 10:30 - 10:45 a.m.

**James Ray Lim, MD;** Beaumont Hospital, Ferndale, MI - Presentation #853: “Epidemiology of Groups A, C, and G Beta-Hemolytic Streptococcal Pharyngitis” Session: 85: Pediatric Bacterial Diseases, Thursday, October 3, 2 - 2:15 p.m.

**Qaasim Mian, MD, MBA;** University of Alberta, Edmonton, AB - Presentation #842: “Social Resistance Fuels Ebola Transmission in the Eastern Democratic Republic of Congo” Session: 82: Global Health: Outbreaks, Controls, and Genetics, Thursday, October 3, 1:45 - 2 p.m.

**Nathan Pincus, BS;** Northwestern University, Chicago, IL - Presentation #2453: “Prolonged Local Epidemic of an XDR *P. aeruginosa* Subclade of High-Risk Clonal Complex 298” Session: 257: HAI: Outbreaks, Saturday, October 5, 12:15 - 1:30 p.m.

**Qianjing (Jenny) Xia, BA;** Weill Cornell Medicine, New York, NY - Presentation #1886: “N1, N12-Diacetylspermine as Potential Urinary Biomarker to Monitor Treatment Response and Bacterial Load in Pulmonary Tuberculosis” Session: 198: Tuberculosis: Stigma, Diagnosis, and Treatment, Friday, October 4, 4:15 - 4:30 p.m.
Abstract Awards (continued)

**IDWeek Trainee Awards**

Each IDWeek partnering society has chosen one outstanding abstract from a member in their specialty. These abstracts are recognized as the top submissions from trainees. Following are the awardees for IDWeek 2019:

**IDSA Trainee:**
Mohammad Al-Shaer, PharmD; University of Florida, Gainesville, FL

**HIVMA Trainee:**
Lauren Collins, MD; Emory University School of Medicine, Atlanta, GA

**PIDS Trainee:**
Yamini Mandelia, MD; Cleveland Clinic, Cleveland, OH

**SHEA Trainee:**
Margaret Omatsone, MD; Medical Center of Central Georgia, Navicent Health, Macon GA

In addition to the above awards to trainees, IDWeek Trainee Awards are awarded to trainees who submitted excellent research. The 2019 IDWeek recipients are listed below:

Emily Abdoler, MD; University of Michigan, Ann Arbor, MI
Ahmed Abdul Azim, MD; Beth Israel Deaconess Medical Center, Boston, MA
Jacinda Abdul-Mutakkibbar, PharmD, AAHIVP; Wayne State University, Detroit, MI
Ancil Abney, MD; University of Minnesota, Minneapolis, MN
Ruth Adekunle, MD; Emory University, Atlanta, GA
Faran Ahmad, MBBS; Creighton University Medical Center, Omaha, NE
Okan Akay, MD; University of Maryland Medical Center, Baltimore, MD
Nina Akbar, MD; University of Rochester Medical Center, Rochester, NY
Fatima Al Dhaheri, MBBS; Boston Children’s Hospital, Harvard Medical School, Boston, MA
Owen Albin, MD; Michigan Medicine, Ann Arbor, MI
Leslie-Ann Alexander, MD; Beth Israel Deacooned Medical Center, Boston, MA
Sara Alosaimy, PharmD, BCPS; Wayne State University, Detroit, MI
Hend Al-Saleh, MD; Saint Michael’s Medical Center, Newark, NJ
Ayesha Appa, MD; UCSF at Zuckerberg San Francisco General, San Francisco, CA
Haley Appaneal, PharmD; Providence Veterans Affairs Medical Center, Providence, RI
Kamile Arikan, MD; Keçiören Research and Training Hospital, Ankara Province, Turkey
Mariam Assi, MD; Virginia Commonwealth University Health System, Richmond, VA
Lindsay Avery, PharmD; Hartford Hospital, Hartford, CT
Hesham Awadh, MD; University of Texas Health Science Center at Houston/MD Anderson Cancer Center, Houston, TX
Dierdre Axell-House, MD; Baylor College of Medicine, Houston, TX
Nancy Azab, MBCH; Stony Brook University Hospital, Stony Brook, NY
Ashaur Azhar, MD; Louisiana State University Health Sciences Center, New Orleans, LA
Ahmed Babiker, MBBS; University of Pittsburgh, Pittsburgh, PA
Samuel Bailin, MD; Vanderbilt University Medical Center, Nashville, TN
Archana Balamohan, MD; Cohen Children's Medical Center of New York, Northwell Health, Queens, NY
Kasturi Banerjee, PhD; Stony Brook University, Stony Brook, NY
Ruba Barbar, MD; St. Jude Children’s Research Hospital, Memphis, TN
Jillian Baron, MD, MPH; Hospital of the University of Pennsylvania, Philadelphia, PA
Nicolas Barros, MD; Massachusetts General Hospital, Boston, MA
Ana Berbel Caban, MD; Icahn School of Medicine at Mount Sinai, New York City, NY
Isha Bhatt, MD; SUNY Downstate Medical Center, Brooklyn, NY
Monica Bianchini, PharmD, MPH; Henry Ford Hospital, Detroit, MI
Seth Blumberg, MD PhD; NYU Langone Health, New York, NY
Emily Bodo, PharmD; Rhode Island Infectious Diseases Research Program
Brian Bohn, PharmD; Cleveland Clinic, Cleveland, OH
Michael Bozzella, DO, MS, Children’s National Health System, Washington, DC
Stephanie Brooks, MD; Nationwide Children's Hospital, Columbus, OH
Jacqueline Burnell, MD; Temple University Hospital, Philadelphia, PA
Julianne Burns, MD; Children’s Hospital of Philadelphia, Philadelphia, PA
Kelly Byrne, MD; Vanderbilt University Medical Center, Nashville, TN
Ilknur Çağlar, MD; Dr. Behçet Uz Children’s Hospital, Izmir, Turkey
Edison Cano Cevallos, MD; Mayo Clinic, Rochester, MN
Travis Carlson, PharmD; University of Houston College of Pharmacy, Houston, TX
Douglas Challener, MD; Mayo Clinic, Rochester, MN
Amy Chang, MD PharmD; Stanford University, Stanford, CA
Sharon Chi, DO, George Washington University, Washington, DC

continued on next page
### Abstract Awards (continued)

<table>
<thead>
<tr>
<th>ID Week Trainee Awards (continued)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robbie Christian, PharmD; VA Northeast Ohio Healthcare System, Cleveland, OH</td>
</tr>
<tr>
<td>Emily Ciccone, MD, MHS; University of North Carolina School of Medicine, Chapel Hill, NC</td>
</tr>
<tr>
<td>Eva Clark, MD, PhD; Baylor College of Medicine, Houston, TX</td>
</tr>
<tr>
<td>Lee Connor, MD; Washington University, St. Louis, MO</td>
</tr>
<tr>
<td>Joseph Cooper, MD; Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY</td>
</tr>
<tr>
<td>Jaclyn Cusumano, PharmD; Providence VA Medical Center/University of Rhode Island, Providence, RI</td>
</tr>
<tr>
<td>Steven Dahl, MD; Children’s Mercy, Kansas City, MO</td>
</tr>
<tr>
<td>Keerti Dantuluri, MD; Vanderbilt University Medical Center, Nashville, TN</td>
</tr>
<tr>
<td>Daniela de Lima Corvino, MD; Jackson Memorial Hospital, Miami, FL</td>
</tr>
<tr>
<td>Peter DeJonge, MPH; University of Michigan School of Public Health, Ann Arbor, MI</td>
</tr>
<tr>
<td>Catherine DeVoe, MD; University of California, San Francisco, San Francisco, CA</td>
</tr>
<tr>
<td>Alejandro Diaz, MD; Nationwide Children’s Hospital, Columbus, OH</td>
</tr>
<tr>
<td>Emma Dishner, MD, MPH; MD Anderson/Baylor College of Medicine, Houston, TX</td>
</tr>
<tr>
<td>Yosuke Ebisu, MD; Jackson Memorial Hospital/Miami Transplant Institute, University of Miami Miller School of Medicine, Miami, FL</td>
</tr>
<tr>
<td>Lourdes Eguiguren, MD; Stanford University, Stanford, CA</td>
</tr>
<tr>
<td>Lynn El Haddad, PhD; University of Texas MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>Matthew Enriquez, MD; University of Chicago Medicine, Chicago, IL</td>
</tr>
<tr>
<td>Selvi Ersoy, B.S., MA, PhD; Los Angeles Biomedical Research Institute, Los Angeles, CA</td>
</tr>
<tr>
<td>Nouman Farooq, MD; Texas Tech University Health Sciences Center, Lubbock, TX</td>
</tr>
<tr>
<td>Lauren Fontana, DO; Oregon Health &amp; Science University, Portland, OR</td>
</tr>
<tr>
<td>Teresa Fox, MD; University of Minnesota, Minneapolis, MN</td>
</tr>
<tr>
<td>Denise Marie Francisco, MD; Baylor College of Medicine, Houston, TX</td>
</tr>
<tr>
<td>Daniel Friedman, MD; University of Alberta, Edmonton, AB</td>
</tr>
<tr>
<td>Risa Fuller, MD; Icahn School of Medicine at Mount Sinai, New York City, NY</td>
</tr>
<tr>
<td>Daisuke Furukawa, MD; David Geffen School of Medicine at UCLA, Los Angeles, CA</td>
</tr>
<tr>
<td>Althea Gabrellas, MD; University of Utah Hospital, Salt Lake City, UT</td>
</tr>
<tr>
<td>Cristina Garcia, MD; University of South Florida, Tampa, FL</td>
</tr>
<tr>
<td>G. Taylor George, MD; Ohio State University, Columbus, OH</td>
</tr>
<tr>
<td>Benjamin Gern, MD; Seattle Children’s Hospital, Seattle, WA</td>
</tr>
<tr>
<td>Christian Gill, PharmD; Henry Ford Hospital, Detroit, MI</td>
</tr>
<tr>
<td>Tarvinder Gilota, MD; State University of New York Upstate Medical University, Syracuse, NY</td>
</tr>
<tr>
<td>Shana Glesson, MD; Yale School of Medicine, New Haven, CT</td>
</tr>
<tr>
<td>James Go, PharmD; University of Kentucky HealthCare, Lexington, KY</td>
</tr>
<tr>
<td>Erin Goldman, DO; Wayne State University, Detroit, MI</td>
</tr>
<tr>
<td>Jaime Gonzalez, MD; Stony Brook University Hospital, Stony Brook, NY</td>
</tr>
<tr>
<td>Sara Gore, MD; Oregon Health &amp; Science University, Portland, OR</td>
</tr>
<tr>
<td>Siddhi Gupta, DO; Wake Forest Baptist Medical Center, Winston Salem, NC</td>
</tr>
<tr>
<td>Pooja Gurram, MBBS; Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>Michael Haden, MD; Ohio State University, Columbus, OH</td>
</tr>
<tr>
<td>Leena Hamadeh, PharmD; Advocate Christ Medical Center, Oak Lawn, IL</td>
</tr>
<tr>
<td>Ahmed Hamdi, MD; Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>Gavin Harris, MD; University of Pittsburgh School of Medicine, Pittsburgh, PA</td>
</tr>
<tr>
<td>Julia Haston, MD; Emory University School of Medicine, Atlanta, GA</td>
</tr>
<tr>
<td>Timothy Hatlen, MD; Harbor-UCLA Medical Center, West Carson, CA</td>
</tr>
<tr>
<td>Khezar Hayat, MPhil; Xian Jiatong University, China</td>
</tr>
<tr>
<td>Edwin Hayes, MD; University of South Carolina, Columbia, SC</td>
</tr>
<tr>
<td>Shaina Hecht, MD; Nationwide Children’s Hospital, Columbus, OH</td>
</tr>
<tr>
<td>Michael Hendrix, MD; Barnes Jewish Hospital, St. Louis, MO</td>
</tr>
<tr>
<td>Cami Hilsendager, MD; Oregon Health &amp; Science University, Portland, OR</td>
</tr>
<tr>
<td>Jenna Holmen, MD; UCSF Benioff Children’s Hospital Oakland, Oakland, CA</td>
</tr>
<tr>
<td>Babak Hooshmand, MD; Ascension St. John Hospital, Detroit, MI</td>
</tr>
<tr>
<td>Lucy Horton, MD, MPH; UC San Diego Medical Center, San Diego, CA</td>
</tr>
<tr>
<td>Joel Howard, MD; University of Utah, Salt Lake City, UT</td>
</tr>
<tr>
<td>Jessica Howard-Anderson, MD; Emory University, Atlanta, GA</td>
</tr>
<tr>
<td>Kristen Hysell, MD; Massachusetts General Hospital, Boston, MA</td>
</tr>
<tr>
<td>Saki Ikeda, MD; Baylor College of Medicine, Houston, TX</td>
</tr>
<tr>
<td>Alison Ivey, PharmD; WakeMed Health &amp; Hospitals, Raleigh, NC</td>
</tr>
<tr>
<td>Christopher Jackson, PharmD Candidate; University of Texas Health Science Center/University of Texas at Austin College of Pharmacy, Austin, TX</td>
</tr>
<tr>
<td>Niyati Jakharia, MBBS; University of Maryland, Baltimore, MD</td>
</tr>
</tbody>
</table>
Abstract Awards (continued)

<table>
<thead>
<tr>
<th>IDWeek Trainee Awards (continued)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joyce Johnsrud, MD; University of Arkansas for Medical Sciences, Little Rock, AR</td>
</tr>
<tr>
<td>Trahern Jones, MD; University of Utah School of Medicine, Salt Lake City, UT</td>
</tr>
<tr>
<td>Rajendra Karnatak, MBBS; University of Nebraska Medical Center, Omaha, NE</td>
</tr>
<tr>
<td>Sophie Katz, MD; Vanderbilt University Medical Center, Nashville, TN</td>
</tr>
<tr>
<td>Ju Hee Katzman, MD; University of South Florida, Tampa, FL</td>
</tr>
<tr>
<td>Aamir Kazi, MBBS; Rush University Medical Center, Chicago, Illinois</td>
</tr>
<tr>
<td>Razieh Kebriaei, PhD; Wayne State University, Detroit, MI</td>
</tr>
<tr>
<td>Sarwat Khalil, MD; Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>Sheena Knights, MD; University of Texas Southwestern Medical Center, Dallas, TX</td>
</tr>
<tr>
<td>Takaaki Kobayashi, MD; University of Iowa Carver College of Medicine, Iowa City, IA</td>
</tr>
<tr>
<td>Rebecca Kumar, MD; Northwestern University, Evanston, IL</td>
</tr>
<tr>
<td>Jessica Kumar, DO; Northeast Ohio VA Healthcare System, Cleveland, OH</td>
</tr>
<tr>
<td>Frances Lahrman, DO; Washington University School of Medicine, St. Louis, MO</td>
</tr>
<tr>
<td>Jason Lake, MD, MPH; Washington University Medical School, St. Louis, MO</td>
</tr>
<tr>
<td>Raynell Lang, MD; College of Medicine, University of Calgary, Calgary, AB</td>
</tr>
<tr>
<td>Alexander Lankowski, MD; University of Washington, Seattle, WA</td>
</tr>
<tr>
<td>Matthew Lee, MD; Beth Israel Deaconess Medical Center, Boston, MA</td>
</tr>
<tr>
<td>Dorothy Ling, MBBS; Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, NC</td>
</tr>
<tr>
<td>Baoming Liu, MD, PhD; Johns Hopkins School of Medicine, Baltimore, MD</td>
</tr>
<tr>
<td>Jiajun Liu, PharmD; Midwestern University/Northwestern Memorial Hospital, Chicago, IL</td>
</tr>
<tr>
<td>Elizabeth Lloyd, MD; University of Michigan, Ann Arbor, MI</td>
</tr>
<tr>
<td>Harold Lochner, MD; University of Florida Jacksonville, Jacksonville, FL</td>
</tr>
<tr>
<td>Derek MacFadden, MD; University of Toronto, Toronto, ON</td>
</tr>
<tr>
<td>Alexandre Malek, MD; University of Texas- McGovern Medical School/MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>Nikola Markoski, PharmD, MBA; Northwestern Memorial Hospital, Chicago, IL</td>
</tr>
<tr>
<td>Anne-Grete Martson, MSc Clin Pharm; University Medical Center Groningen, University of Groningen, Groningen, Netherlands</td>
</tr>
<tr>
<td>Samantha Mathews, MD; Dartmouth-Hitchcock Medical Center, Lebanon, NH</td>
</tr>
<tr>
<td>Sarah McGuffin, MD; University of Washington, Seattle, WA</td>
</tr>
<tr>
<td>Katherine Mersinger, PharmD; Hospital of the University of Pennsylvania, Philadelphia, PA</td>
</tr>
<tr>
<td>Alexander Milgrom, MD; University of South Carolina School of Medicine, Columbia, SC</td>
</tr>
<tr>
<td>William Justin Moore, PharmD; Northwestern Medicine, Chicago, IL</td>
</tr>
<tr>
<td>Taylor Morrisette, PharmD; University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Denver, CO</td>
</tr>
<tr>
<td>Jennifer Mulliken, MD; University of California, San Francisco Medical Center, San Francisco, CA</td>
</tr>
<tr>
<td>Hannah Nam, MD; Northwestern Memorial Hospital, Chicago, IL</td>
</tr>
<tr>
<td>Tamara Naraw, MD; Memorial Sloan Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>Margaret Newman McCort, MD; University of Chicago Medicine, Chicago, IL</td>
</tr>
<tr>
<td>David Nguyen, MD; Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH</td>
</tr>
<tr>
<td>Susan Nichols, MD; Brody School of Medicine at East Carolina University, Greenville, NC</td>
</tr>
<tr>
<td>Afua Ntem-Mensah, MbChB; University of Maryland Medical Center, Baltimore, MD</td>
</tr>
<tr>
<td>Meredith Oliver, PharmD; University of Utah Health, Salt Lake City, UT</td>
</tr>
<tr>
<td>Stephanie Pankow, DO; University of Texas at Houston, Houston, TX</td>
</tr>
<tr>
<td>Tommy Parraga Acosta; MD, Henry Ford Hospital, Detroit, MI</td>
</tr>
<tr>
<td>Ami Patel, MD, MPH; NYU Langone Health, New York, NY</td>
</tr>
<tr>
<td>Courtney Pearson, MD; University of Arkansas for Medical Sciences, Little Rock, AR</td>
</tr>
<tr>
<td>Carlos Perez-Lopez, MD; University of South Florida Morsani College of Medicine, Tampa, FL</td>
</tr>
<tr>
<td>Najwa Pervin, MD; Southern Illinois University School of Medicine, Springfield, IL</td>
</tr>
<tr>
<td>Jordan Polistico, MD; Detroit Medical Center, Detroit, MI</td>
</tr>
<tr>
<td>Leila Posch, MD; Children’s Hospital of Philadelphia, Philadelphia, PA</td>
</tr>
<tr>
<td>Varvara Probst, MD; Vanderbilt University, Nashville, TN</td>
</tr>
<tr>
<td>Mireia Puig-Asensio; MD, PHD, University of Iowa Hospitals &amp; Clinics</td>
</tr>
<tr>
<td>Alfredo Puing, MD; University of Texas Southwestern Medical Center</td>
</tr>
<tr>
<td>Mohammad Rai, MD,PhD; University of Cincinnati Medical Center</td>
</tr>
<tr>
<td>Jennifer Rathe, MD, PhD; University of Washington, Seattle Children’s Hospital, Seattle, WA</td>
</tr>
<tr>
<td>Adriana Rauseo, MD; Washington University at St. Louis, St. Louis, MO</td>
</tr>
</tbody>
</table>

continued on next page
### Abstract Awards (continued)

<table>
<thead>
<tr>
<th>Award</th>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lindsey Rearigh, DO</td>
<td>University of Nebraska Medical Center, Omaha, NE</td>
<td></td>
</tr>
<tr>
<td>Ryan Rochat, MD, PhD, GEMS</td>
<td>Texas Children’s Hospital, Baylor College of Medicine, Houston, TX</td>
<td></td>
</tr>
<tr>
<td>Ralph Rogers, MD</td>
<td>Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI</td>
<td></td>
</tr>
<tr>
<td>France Emilie Roy, MD</td>
<td>Institut Universitaire de Cardiologie et de pneumologie de Québec, Québec City, QC</td>
<td></td>
</tr>
<tr>
<td>Ariana Saatchi, BASc</td>
<td>University of British Columbia, Vancouver, BC</td>
<td></td>
</tr>
<tr>
<td>Srishti Saha, MBBS, MD</td>
<td>Mayo Clinic, Rochester, MN</td>
<td></td>
</tr>
<tr>
<td>Youssef Said, MD</td>
<td>Children’s Cancer Hospital - Egypt/National Cancer Institute, Cairo, Egypt</td>
<td></td>
</tr>
<tr>
<td>Aki Sakurai, MD</td>
<td>University of Texas Health Science Center, McGovern Medical School</td>
<td></td>
</tr>
<tr>
<td>Sarah Sansom, DO</td>
<td>Rush University Medical Center, Chicago, IL</td>
<td></td>
</tr>
<tr>
<td>Julia Sapozhnikov, PharmD</td>
<td>Froedtert &amp; the Medical College of Wisconsin, Wauwatosa, WI</td>
<td></td>
</tr>
<tr>
<td>Moumita Sarker, MD</td>
<td>University of Rochester Medical Center, Rochester, NY</td>
<td></td>
</tr>
<tr>
<td>Jessica Seidelman, MD, MPH</td>
<td>Duke University, Durham, NC</td>
<td></td>
</tr>
<tr>
<td>Amy Sherman, MD</td>
<td>Emory University, Atlanta, GA</td>
<td></td>
</tr>
<tr>
<td>FNU Shweta, MBBS</td>
<td>Mayo Clinic, Rochester, MN</td>
<td></td>
</tr>
<tr>
<td>Anna Sick-Samuels, MD, MPH</td>
<td>Johns Hopkins University School of Medicine, Baltimore, MD</td>
<td></td>
</tr>
<tr>
<td>Brandon Smith, MD, PharmD</td>
<td>University of Pittsburgh Medical Center, Pittsburgh, PA</td>
<td></td>
</tr>
<tr>
<td>Suthanya Sornprom, MD</td>
<td>Dartmouth-Hitchcock Medical Center, Lebanon, NH</td>
<td></td>
</tr>
<tr>
<td>Julie Steinbrink, MD</td>
<td>Duke University, Durham, NC</td>
<td></td>
</tr>
<tr>
<td>Eric Stone, MD</td>
<td>Mayo Clinic, Rochester, MN</td>
<td></td>
</tr>
<tr>
<td>Jonathan Sun, DO</td>
<td>University of Pittsburgh, Pittsburgh, PA</td>
<td></td>
</tr>
<tr>
<td>Sadia Syed, MBBS</td>
<td>Mayo Clinic College of Medicine, Rochester, MN</td>
<td></td>
</tr>
<tr>
<td>Aviva Szigeti, MD</td>
<td>State University of New York Downstate Medical Center, Brooklyn, NY</td>
<td></td>
</tr>
<tr>
<td>Melinda Tanabe, MD</td>
<td>University of Texas Medical Branch, Galveston, TX</td>
<td></td>
</tr>
<tr>
<td>Jeanette Tavares, DO</td>
<td>Nationwide Children’s Hospital, Columbus, OH</td>
<td></td>
</tr>
<tr>
<td>Greg Matthew Teo, MD</td>
<td>University of South Florida, Tampa, FL</td>
<td></td>
</tr>
<tr>
<td>Anupa Thampy, MD</td>
<td>Christian Medical College, Vellore, Vellore, IN</td>
<td></td>
</tr>
<tr>
<td>Mary Theoktisto, MD</td>
<td>University of Texas Health Science Center San Antonio, San Antonio, TX</td>
<td></td>
</tr>
<tr>
<td>Christine Thomas, DO</td>
<td>Loyola University Medical Center, Hines, IL</td>
<td></td>
</tr>
<tr>
<td>S Throneberry, MD</td>
<td>University of Utah, Salt Lake City, UT</td>
<td></td>
</tr>
<tr>
<td>Jessica Tischendorf, MD, MS</td>
<td>University of Wisconsin School of Medicine and Public Health, Madison, WI</td>
<td></td>
</tr>
<tr>
<td>Farrell Tobolowsky, DO, MS</td>
<td>University of Colorado, Denver, CO</td>
<td></td>
</tr>
<tr>
<td>Polina Trachuk, MD</td>
<td>Montefiore Medical Center, Bronx, NY</td>
<td></td>
</tr>
<tr>
<td>Erlinda Ulloa, MD, MSc</td>
<td>Children’s Hospital of Philadelphia, Philadelphia, PA</td>
<td></td>
</tr>
<tr>
<td>Nirima Vadlamudi, BA, BS, MPH</td>
<td>University of British Columbia, Vancouver, BC</td>
<td></td>
</tr>
<tr>
<td>Kristen Valencia Deray, MD</td>
<td>Baylor College of Medicine and Texas Children’s Hospital, Houston, TX</td>
<td></td>
</tr>
<tr>
<td>Cara Varley, MD, MPH</td>
<td>Oregon Health &amp; Science University, Portland, OR</td>
<td></td>
</tr>
<tr>
<td>Matthew Vogt, MD, PhD</td>
<td>Vanderbilt University Medical Center, Nashville, TN</td>
<td></td>
</tr>
<tr>
<td>Francis Wadskier Montagne, MD</td>
<td>Montefiore Medical Center, Bronx, NY</td>
<td></td>
</tr>
<tr>
<td>Jeremey Walker, MD</td>
<td>University of Alabama in Birmingham, Birmingham, AL</td>
<td></td>
</tr>
<tr>
<td>Lorne Walker, MD, PhD</td>
<td>UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA</td>
<td></td>
</tr>
<tr>
<td>Melissa White, PharmD</td>
<td>Hospital of the University of Pennsylvania, Philadelphia, PA</td>
<td></td>
</tr>
<tr>
<td>Julie Wohrley, MD</td>
<td>University of Chicago, Chicago, IL</td>
<td></td>
</tr>
<tr>
<td>Teena Xu, MD</td>
<td>Baylor College of Medicine, Houston, TX</td>
<td></td>
</tr>
<tr>
<td>Michael Yarrington, MD</td>
<td>Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, NC</td>
<td></td>
</tr>
<tr>
<td>Alexandra Yonts, MD</td>
<td>Children’s National Medical Center/George Washington University School of Medicine, Washington, DC</td>
<td></td>
</tr>
<tr>
<td>Dima Youssef, MD</td>
<td>Ascension St. John Hospital; Detroit, MI</td>
<td></td>
</tr>
<tr>
<td>Yorgo Zahlanie, MD</td>
<td>University of Texas Southwestern Medical Center, Dallas, TX</td>
<td></td>
</tr>
<tr>
<td>Dannel Zamora, MD</td>
<td>University of Washington, Seattle, WA</td>
<td></td>
</tr>
<tr>
<td>Ahmed Zaqout, MD</td>
<td>Hamad Medical Corporation, Doha, Qatar</td>
<td></td>
</tr>
<tr>
<td>Helen Zhang, MD</td>
<td>University of Pennsylvania, Philadelphia, PA</td>
<td></td>
</tr>
<tr>
<td>Jason Zucker, MD, MS</td>
<td>Columbia University Irving Medical Center, New York, NY</td>
<td></td>
</tr>
<tr>
<td>Sydney Agnello, DO</td>
<td>Ohio State University, Columbus, OH</td>
<td></td>
</tr>
<tr>
<td>Ambreen Allana, MBBS</td>
<td>University of Texas Houston/MD Anderson Cancer Center, Houston, TX</td>
<td></td>
</tr>
<tr>
<td>Shannon Andrews, MD</td>
<td>University of Minnesota, Minneapolis, MN</td>
<td></td>
</tr>
<tr>
<td>Tomefa Asempa, PharmD</td>
<td>Hartford Hospital, Hartford, CT</td>
<td></td>
</tr>
<tr>
<td>Danielle Avila, MD</td>
<td>University of Alabama at Birmingham, Birmingham, AL</td>
<td></td>
</tr>
<tr>
<td>Maymonah Belal, MD</td>
<td>Stony Brook University Hospital, Stony Brook, NY</td>
<td></td>
</tr>
<tr>
<td>Sara Beiga, MD</td>
<td>University of Alberta, Edmonton, AB</td>
<td></td>
</tr>
</tbody>
</table>
IDWeek Trainee Awards (continued)

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swati Bhargava, MD</td>
<td>University at Buffalo, Buffalo, NY</td>
</tr>
<tr>
<td>Paul Blair, MD, MSPH, MHS</td>
<td>Johns Hopkins, Baltimore, MD</td>
</tr>
<tr>
<td>Nicolo Cabrera, MD</td>
<td>University of Texas Health Science Center, Houston, TX</td>
</tr>
<tr>
<td>Natalia Castillo Almeida, MD</td>
<td>Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>Kevin Davis, MD</td>
<td>University of Arkansas for Medical Sciences, Little Rock, AR</td>
</tr>
<tr>
<td>Megan Donahue, MD</td>
<td>Walter Reed National Military Medical Center, Bethesda, MD</td>
</tr>
<tr>
<td>Augusto Dulanto Chiang, MD</td>
<td>Bacterial Pathogenesis and Resistance Unit, NIAID</td>
</tr>
<tr>
<td>Lauren Dutcher, MD</td>
<td>University of Pennsylvania, Philadelphia, PA</td>
</tr>
<tr>
<td>Sami El-Dalati, MD</td>
<td></td>
</tr>
<tr>
<td>Zerelda Esquer Garrigos, MD</td>
<td>Mayo Clinic College of Medicine, Rochester, MN</td>
</tr>
<tr>
<td>Ronnie Gravett, MD</td>
<td>University of Alabama at Birmingham, Birmingham, AL</td>
</tr>
<tr>
<td>Smitha Gudipati, MD</td>
<td>Henry Ford Health System, Detroit, MI</td>
</tr>
<tr>
<td>Giorgos Hadjivassiliou, MBBS</td>
<td>University of Alabama at Birmingham, Birmingham, AL</td>
</tr>
<tr>
<td>Hannah Imlay, MD</td>
<td>University of Washington Medical Center, Seattle, WA</td>
</tr>
<tr>
<td>Alina Iovleva, MD</td>
<td>University of Pittsburgh Medical Center, Pittsburgh, PA</td>
</tr>
<tr>
<td>Michael Kessler, MD</td>
<td>University of Wisconsin School of Medicine and Public Health, Madison, WI</td>
</tr>
<tr>
<td>John Kiley, MD</td>
<td>Brooke Army Medical Center, Fort Sam Houston, TX</td>
</tr>
<tr>
<td>David Kline, MD</td>
<td>Brooke Army Medical Center, Fort Sam Houston, TX</td>
</tr>
<tr>
<td>Anish Krishnan, PharmD</td>
<td>Windsor Regional Hospital, Windsor, ON</td>
</tr>
<tr>
<td>Morgan Manley, DO</td>
<td>San Antonio Military Medical Center, San Antonio, TX</td>
</tr>
<tr>
<td>Jen Manne-Goehler, MD, DSc</td>
<td>Massachusetts General Hospital, Boston, MA</td>
</tr>
<tr>
<td>Randy McCreery, MD</td>
<td>University of Nebraska Medical Center, Omaha, NE</td>
</tr>
<tr>
<td>Ryan Miller, DO</td>
<td>Cleveland Clinic Foundation, Cleveland, OH</td>
</tr>
<tr>
<td>Anita Modi, MD</td>
<td>Cleveland Clinic Foundation, Cleveland, OH</td>
</tr>
<tr>
<td>Mark Murphy, DO</td>
<td>Cincinnati Children's Hospital Medical Center, Cincinnati, OH</td>
</tr>
<tr>
<td>Minh-Vu Nguyen, MD, MSc</td>
<td>University of California, Davis Health and School of Medicine, Sacramento, CA</td>
</tr>
<tr>
<td>Sobia Nizami, MBBS</td>
<td>NYU Langone Medical Center, New York City, NY</td>
</tr>
<tr>
<td>Kwendolyn Pais, PhD</td>
<td>Midwestern University, Downers Grove, IL</td>
</tr>
<tr>
<td>Michael Peluso, MD</td>
<td>University of California, San Francisco, San Francisco, CA</td>
</tr>
<tr>
<td>Donald Perry, MD, MS, MPH</td>
<td>University of Michigan, Ann Arbor, MI</td>
</tr>
<tr>
<td>Melissa Reimer-McAtee, MD</td>
<td>University of Texas Health Sciences Center, Houston, TX</td>
</tr>
<tr>
<td>Avnish Sandhu, Doctor of Osteopathic Medicine</td>
<td>Detroit Medical Center, Wayne State University, Detroit, MI</td>
</tr>
<tr>
<td>Sena Sayood, MD</td>
<td>Washington University School of Medicine, Seattle, WA</td>
</tr>
<tr>
<td>Maroun Sfeir, MD, MPH, MS</td>
<td>Massachusetts General Hospital, Boston, MA</td>
</tr>
<tr>
<td>Aditya Shah, MBBS</td>
<td>Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>Madeeha Shams, MBBS, MS</td>
<td>Infectious Diseases Department</td>
</tr>
<tr>
<td>Jacqueline Sherbuk, MD</td>
<td>University of Virginia, Charlottesville, VA</td>
</tr>
<tr>
<td>Anat Stern, MD</td>
<td>Memorial Sloan Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>Joel Szela, DO</td>
<td>Beaumont Hospital, Royal Oak, Royal Oak, MI</td>
</tr>
<tr>
<td>Beth Thielen, MD, PhD</td>
<td>University of Minnesota, Minneapolis, MN</td>
</tr>
<tr>
<td>Michelle Ting, PharmD</td>
<td>St. Joseph's Hospital and Medical Center, Phoenix, AZ</td>
</tr>
<tr>
<td>Amit Vahia, MD MPH</td>
<td>Henry Ford Hospital, Detroit, MI</td>
</tr>
<tr>
<td>Olivia Van Gerwen, MD, MPH</td>
<td>University of Alabama at Birmingham, Birmingham, AL</td>
</tr>
<tr>
<td>Angela Villamagna, MD</td>
<td>Oregon Health and Science University, Portland, OR</td>
</tr>
<tr>
<td>Mohamad Yasmin, MD</td>
<td>Case Western Reserve University, Cleveland, OH</td>
</tr>
</tbody>
</table>
Use the CME/CPE/MOC Tracker below as a guide to track the sessions you’ve attended, then go to www.idweek.org to enter your sessions, complete a short evaluation for each session, and claim CME/CPE/MOC credit. In accordance with ACCME guidelines, and to ensure balanced presentations, at least one IDWeek Program Committee member will serve as a moderator of each session. IDSA, in conjunction with ProCE, Inc. will offer pharmacists continuing pharmacy education (CPE) credit for select sessions. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

<table>
<thead>
<tr>
<th>Attended</th>
<th>Session #</th>
<th>Session Title</th>
<th>CME/MOC Credits</th>
<th>Universal Program Number (for CPE credit)</th>
</tr>
</thead>
<tbody>
<tr>
<td>✓</td>
<td>PW01</td>
<td>The Vincent T. Andriole ID Board Review Course</td>
<td>Maximum of 7.5 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-302-L01-P</td>
</tr>
<tr>
<td></td>
<td>PW02</td>
<td>Best Practices for Antimicrobial Stewardship Programs ($)</td>
<td>Maximum of 7.5 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-301-L04-P</td>
</tr>
<tr>
<td></td>
<td>PW03</td>
<td>Research Training Programs and Grant Writing Strategies for ID Physician-Scientists</td>
<td>Maximum of 4 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-304-L04-P</td>
</tr>
<tr>
<td></td>
<td>PW04</td>
<td>Medication Assisted Treatment Waiver Course</td>
<td>Maximum of 4 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-303-L01-P</td>
</tr>
<tr>
<td></td>
<td>PW07</td>
<td>TB Workshop</td>
<td>Maximum of 4 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-308-L01-P</td>
</tr>
<tr>
<td></td>
<td>PW08</td>
<td>Hepatitis C Workshop</td>
<td>Maximum of 4 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-306-L01-P</td>
</tr>
<tr>
<td></td>
<td>PW09</td>
<td>Infectious Diseases ABIM Recertification: Self-Evaluation of Medical Knowledge, IDSA Module: General Infectious Diseases 2019</td>
<td>Maximum of 15 AMA PRA Category 1 Credits™</td>
<td>No CPE Credit</td>
</tr>
<tr>
<td></td>
<td>PW10</td>
<td>How to Use EBM/GRADE to Develop Guidelines</td>
<td>Maximum of 4 AMA PRA Category 1 Credits™</td>
<td>No CPE Credit</td>
</tr>
<tr>
<td></td>
<td>PW11</td>
<td>Expanding Antibiotic Stewardship into Outpatient Settings</td>
<td>Maximum of 4 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-305-L04-P</td>
</tr>
<tr>
<td></td>
<td>PW12</td>
<td>Introductory Training for Clinical Performance Improvement</td>
<td>Maximum of 4 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-307-L04-P</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>Challenging Cases in Pediatric Infectious Diseases</td>
<td>Maximum of 1.75 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-313-L01-P</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>Antimicrobial Resistance and Stewardship Across the Globe</td>
<td>Maximum of 1.75 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-312-L04-P</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>Conundrums in Diagnosis and Management of Diarrhea</td>
<td>Maximum of 1.75 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-314-L01-P</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>If I Built a Hospital: Designing to Optimize Infection Prevention</td>
<td>Maximum of 1.75 AMA PRA Category 1 Credits™</td>
<td>No CPE Credit</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>2019 Measles Outbreak</td>
<td>Maximum of 1.75 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-315-L01-P</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>Practical Guide to the Infectious Diseases and Opioid Use Disorder Syndemic: Regional Responses</td>
<td>Maximum of 1.75 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-311-L01-P</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>What’s Hot in ID + HIV</td>
<td>Maximum of 1.75 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-310-L02-P</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>Opening Plenary: From Outbreaks to -Omics: Revolutionizing the Infectious Diseases Landscape in the Age of Big Data</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-316-L04-P</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>The Big IDEA: Making the Case to Policymakers for ID and HIV Priorities</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-317-L02-P</td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>Career Navigation and Negotiation for the Infectious Diseases Practitioner</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-322-L04-P</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>Case-Based Approach to the 2018 IDSA Guidelines on Neurocysticercosis</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-319-L01-P</td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>Critical and Flexible Partnerships: Investigation of Hospital Outbreaks</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>No CPE Credit</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>Experience and Challenges with Vancomycin Monitoring by AUC</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-320-L01-P</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>Infection Prevention and Stewardship in Long-Term Care</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-321-L04-P</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>Moving it Forward: Closing the Gender Gap</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-323-L04-P</td>
</tr>
<tr>
<td></td>
<td>17</td>
<td>Our Most Difficult HIV Cases</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-318-L01-P</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>Updates on Interferon-Gamma Release Assay Performance</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>No CPE Credit</td>
</tr>
<tr>
<td>Attended</td>
<td>Session #</td>
<td>Session Title</td>
<td>CME/MOC Credits</td>
<td>Universal Program Number (for CPE credit)</td>
</tr>
<tr>
<td>---------</td>
<td>-----------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------------------------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>✔️</td>
<td>19</td>
<td>Edward H. Kass Lecture</td>
<td>Maximum of 0.75 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-324-L04-P</td>
</tr>
<tr>
<td>✔️</td>
<td>20</td>
<td>Diagnostic Clinical Cases</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-328-L04-P</td>
</tr>
<tr>
<td>✔️</td>
<td>21</td>
<td>Behavioral Approaches to Antibiotic Stewardship</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-330-L04-P</td>
</tr>
<tr>
<td>✔️</td>
<td>22</td>
<td>Clinical Reasoning from Education to Practice</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-331-L04-P</td>
</tr>
<tr>
<td>✔️</td>
<td>23</td>
<td>Clinical Trials That Might Change Your Practice</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-332-L04-P</td>
</tr>
<tr>
<td>✔️</td>
<td>24</td>
<td>Help or Hype? Update on Biomarkers in Management of Adult and Pediatric Infectious Diseases</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-383-L01-P</td>
</tr>
<tr>
<td>✔️</td>
<td>25</td>
<td>HIV State-of-the-Art</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-327-L02-P</td>
</tr>
<tr>
<td>✔️</td>
<td>26</td>
<td>New Effectors of TB Immunity: Beyond CD4 T-Cells</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>No CPE Credit</td>
</tr>
<tr>
<td>✔️</td>
<td>27</td>
<td>One Health and Global Health Security</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-325-L04-P</td>
</tr>
<tr>
<td>✔️</td>
<td>28</td>
<td>Unsolved or Uncontrolled: Public Health Challenges in Resistant Pathogens</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-326-L04-P</td>
</tr>
<tr>
<td>✔️</td>
<td>29</td>
<td>Vaccination and Immunocompromised Hosts: Recommendations and Knowledge Gaps</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-333-L06-P</td>
</tr>
<tr>
<td>✔️</td>
<td>30</td>
<td>Antimicrobial Stewardship in Compromised Hosts</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-336-L04-P</td>
</tr>
<tr>
<td>✔️</td>
<td>31</td>
<td>Applying Contact Precautions: What's the Best Approach to Reduce Transmission?</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>No CPE Credit</td>
</tr>
<tr>
<td>✔️</td>
<td>32</td>
<td>Challenging HIV Cases</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-335-L02-P</td>
</tr>
<tr>
<td>✔️</td>
<td>33</td>
<td>Clinical Interpretation and Use of Metagenomic-based Infectious Disease Diagnostics</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-334-L04-P</td>
</tr>
<tr>
<td>✔️</td>
<td>34</td>
<td>Enterovirus-Associated Neurologic Disease</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>No CPE Credit</td>
</tr>
<tr>
<td>✔️</td>
<td>35</td>
<td>Head Scratching Cases of MDR Gram-Negatives Other than Enterobacteriales</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-337-L01-P</td>
</tr>
<tr>
<td>✔️</td>
<td>36</td>
<td>New Science Behind Chronic Pulmonary Infectious Diseases</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>No CPE Credit</td>
</tr>
<tr>
<td>✔️</td>
<td>37</td>
<td>New Worries about Group A Streptococcal Disease</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-339-L04-P</td>
</tr>
<tr>
<td>✔️</td>
<td>38</td>
<td>Vaccine Hesitancy</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-340-L06-P</td>
</tr>
<tr>
<td>✔️</td>
<td>39</td>
<td>Who Owns Sepsis Anyway?</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-338-L04-P</td>
</tr>
<tr>
<td>✔️</td>
<td>40</td>
<td>Clinical Controversies</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-349-L01-P</td>
</tr>
<tr>
<td>✔️</td>
<td>41</td>
<td>Educating Healthcare Students and Trainees about Stewardship</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-344-L04-P</td>
</tr>
<tr>
<td>✔️</td>
<td>42</td>
<td>Drug Resistant Gonorrhea: The Future is Here</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-343-L01-P</td>
</tr>
<tr>
<td>✔️</td>
<td>43</td>
<td>Innovative Methods in Healthcare Epidemiology and Antimicrobial Stewardship</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-342-L04-P</td>
</tr>
<tr>
<td>✔️</td>
<td>44</td>
<td>Meeting the Full Potential of DAA Therapies for HCV</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-348-L01-P</td>
</tr>
<tr>
<td>✔️</td>
<td>45</td>
<td>Non-Antibiotic Approaches to Treating Transplant-Associated Infections</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-341-L01-P</td>
</tr>
<tr>
<td>✔️</td>
<td>46</td>
<td>STIs in the HIV Care Setting: An Interactive Case-Based Approach</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-346-L02-P</td>
</tr>
<tr>
<td>✔️</td>
<td>47</td>
<td>The Role of Public Health in Precision Medicine</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-347-L04-P</td>
</tr>
<tr>
<td>✔️</td>
<td>48</td>
<td>What Every ID Physician Should Know: Bridging Innate Immune Responses to Immune Memory</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>No CPE Credit</td>
</tr>
<tr>
<td>✔️</td>
<td>49</td>
<td>Edward B. Hall Lecture: Antenatal Zika Virus Exposure</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-345-L01-P</td>
</tr>
<tr>
<td>Attended</td>
<td>Session #</td>
<td>Session Title</td>
<td>CME/MOC Credits</td>
<td>Universal Program Number (for CPE credit)</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>101</td>
<td>Joseph E. Smadel Lecture</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-350-L01-P</td>
</tr>
<tr>
<td></td>
<td>102</td>
<td>Alternative Strategies to Monitor CMV Reactivation After Transplantation</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-355-L01-P</td>
</tr>
<tr>
<td></td>
<td>103</td>
<td>Left Ventricular Assist Device-associated Infections</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-358-L01-P</td>
</tr>
<tr>
<td></td>
<td>104</td>
<td>Cefazolin vs. Nafcillin for MSSA Infections: Pro-Con Debate</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-359-L01-P</td>
</tr>
<tr>
<td></td>
<td>105</td>
<td>Challenging STIs in Patients with HIV</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-364-L02-P</td>
</tr>
<tr>
<td></td>
<td>106</td>
<td>Compensation Disparities Across Gender</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>No CPE Credit</td>
</tr>
<tr>
<td></td>
<td>107</td>
<td>Displaced: Infectious Disease Impacts on Refugee and Migrant Populations</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-356-L04-P</td>
</tr>
<tr>
<td></td>
<td>108</td>
<td>From Inactive to Reactive: When and How to Treat HBV Infection</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-357-L01-P</td>
</tr>
<tr>
<td></td>
<td>109</td>
<td>Medical Director 101: Practical Guidance for the ID Specialist new to Infection Prevention and Antibiotic Stewardship Program Leadership</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-353-L01-P</td>
</tr>
<tr>
<td></td>
<td>110</td>
<td>Practicing Diagnostic Stewardship: Tools You can Use Today in Your Hospital</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-351-L04-P</td>
</tr>
<tr>
<td></td>
<td>111</td>
<td>Top Papers in Medical Mycology</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-352-L04-P</td>
</tr>
<tr>
<td></td>
<td>112</td>
<td>Special Session</td>
<td>Maximum of 0.75 AMA PRA Category 1 Credits™</td>
<td>No CPE Credit</td>
</tr>
<tr>
<td></td>
<td>113</td>
<td>Mano-a-Mano V: Pediatric Infectious Diseases</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-361-L01-P</td>
</tr>
<tr>
<td></td>
<td>114</td>
<td>Opening Pandora’s Chest: A Case Based Multidisciplinary Approach to Chronic Pulmonary Infections and Their Mimics</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-364-L01-P</td>
</tr>
<tr>
<td></td>
<td>115</td>
<td>Bacterial Persisters and Nonculturable Forms: Basic Biology and Therapeutic Susceptibility</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-366-L01-P</td>
</tr>
<tr>
<td></td>
<td>116</td>
<td>Clinical Controversies in HIV Antiretroviral Therapy</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-365-L02-P</td>
</tr>
<tr>
<td></td>
<td>117</td>
<td>Influenza Vaccines</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-363-L06-P</td>
</tr>
<tr>
<td></td>
<td>118</td>
<td>Phages to the Rescue</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-368-L01-P</td>
</tr>
<tr>
<td></td>
<td>119</td>
<td>South of the Border: Important Diseases You Can Not Miss</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-367-L01-P</td>
</tr>
<tr>
<td></td>
<td>120</td>
<td>Tackling the Big Beasts of Healthcare Epidemiology</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-360-L01-P</td>
</tr>
<tr>
<td></td>
<td>121</td>
<td>Using Technology to Enhance Teaching and Learning</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-362-L04-P</td>
</tr>
<tr>
<td></td>
<td>122</td>
<td>A Day with the Hospital Epidemiologist’s Pager, Part II: Even More Challenging Cases in Infection Prevention</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>No CPE Credit</td>
</tr>
<tr>
<td></td>
<td>123</td>
<td>Our Toughest Mycobacterial Cases</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-371-L01-P</td>
</tr>
<tr>
<td></td>
<td>124</td>
<td>Immunization: Beyond the Guidelines</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-377-L06-P</td>
</tr>
<tr>
<td></td>
<td>125</td>
<td>Antibiotic Stewardship: Special Surgical Populations</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-370-L01-P</td>
</tr>
<tr>
<td></td>
<td>126</td>
<td>Big Beasts I</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-374-L01-P</td>
</tr>
<tr>
<td></td>
<td>127</td>
<td>Case-Based Guideline Update</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-369-L01-P</td>
</tr>
<tr>
<td></td>
<td>128</td>
<td>Hot Topics in Pediatric Infectious Diseases</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-372-L04-P</td>
</tr>
<tr>
<td></td>
<td>129</td>
<td>Mycobiome and Invasive Fungal Infections</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-375-L04-P</td>
</tr>
<tr>
<td></td>
<td>130</td>
<td>Populations with Disparities in the HIV Care Cascade</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-373-L02-P</td>
</tr>
<tr>
<td></td>
<td>131</td>
<td>The Influence of Climate Change on Infectious Diseases</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-376-L04-P</td>
</tr>
<tr>
<td>Attended</td>
<td>Session #</td>
<td>Session Title</td>
<td>CME/MOC Credits</td>
<td>Universal Program Number (for CPE credit)</td>
</tr>
<tr>
<td>---------</td>
<td>-----------</td>
<td>-------------------------------------------------------------------------------</td>
<td>------------------------------------------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td></td>
<td>186</td>
<td>Challenging Cases in Infectious Diseases</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-384-L04-P</td>
</tr>
<tr>
<td></td>
<td>187</td>
<td>Big Beasts II</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-386-L01-P</td>
</tr>
<tr>
<td></td>
<td>188</td>
<td>Cutting Edge in Pediatric Osteomyelitis: Basic Scientist, ID Clinician, and Orthopedist</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-329-L04-P</td>
</tr>
<tr>
<td></td>
<td>189</td>
<td>HIV Prevention</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-382-L02-P</td>
</tr>
<tr>
<td></td>
<td>190</td>
<td>I’m Better Than You and I Can Prove It: Quality Metrics and ID</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-387-L04-P</td>
</tr>
<tr>
<td></td>
<td>191</td>
<td>Influential Publications in Healthcare Epidemiology, 2019</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-381-L04-P</td>
</tr>
<tr>
<td></td>
<td>192</td>
<td>The Fungus Among Us</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-385-L01-P</td>
</tr>
<tr>
<td></td>
<td>193</td>
<td>The State of HCV Elimination</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-380-L01-P</td>
</tr>
<tr>
<td></td>
<td>194</td>
<td>Vaccines and Antimicrobial Resistance</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-379-L06-P</td>
</tr>
<tr>
<td></td>
<td>195</td>
<td>When the Transplant ID Physician Needs to “Phone a Friend”</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-378-L01-P</td>
</tr>
<tr>
<td></td>
<td>200</td>
<td>Ending HIV as an Epidemic: An Update and Discussion</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-389-L02-P</td>
</tr>
<tr>
<td></td>
<td>202</td>
<td>SHEA Lecture (Trish Perl)</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-390-L04-P</td>
</tr>
<tr>
<td></td>
<td>203</td>
<td>Stanley A. Plotkin Lectureship in Vaccinology</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-388-L06-P</td>
</tr>
<tr>
<td></td>
<td>204</td>
<td>Are the New Non-Molecular Assays Better for Diagnosis of Clostridiodes difficile Toxin Tests</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-396-L01-P</td>
</tr>
<tr>
<td></td>
<td>205</td>
<td>Burning Questions on Hot Topics in Transplant ID</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-397-L01-P</td>
</tr>
<tr>
<td></td>
<td>206</td>
<td>Fighting the TB Epidemic in Children and Adolescents: Game-Changing Advances in Pediatric TB</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-398-L01-P</td>
</tr>
<tr>
<td></td>
<td>207</td>
<td>Infectious Complications of Immunomodulatory Biologic Agents: Risk Assessment, Diagnosis, and Management</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-400-L01-P</td>
</tr>
<tr>
<td></td>
<td>208</td>
<td>Leveraging Social Media for Professional Success</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-393-L04-P</td>
</tr>
<tr>
<td></td>
<td>209</td>
<td>OPAT Update</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-399-L01-P</td>
</tr>
<tr>
<td></td>
<td>210</td>
<td>Registration Trials versus Clinical Practice: Challenges Associated with Newly Approved Antimicrobials</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-394-L04-P</td>
</tr>
<tr>
<td></td>
<td>211</td>
<td>Teamwork Collaboration and Antimicrobial Stewardship</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-395-L04-P</td>
</tr>
<tr>
<td></td>
<td>213</td>
<td>Updates from NHSN and the HICPAC NHSN Work Group</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-392-L04-P</td>
</tr>
<tr>
<td></td>
<td>215</td>
<td>John F. Enders Lecture</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-401-L04-P</td>
</tr>
<tr>
<td></td>
<td>216</td>
<td>Challenging Cases in Transplant ID</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-403-L01-P</td>
</tr>
<tr>
<td></td>
<td>217</td>
<td>Diagnosis and Management of Congenital CMV on Both Sides of the Pond: UK and Europe</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-408-L01-P</td>
</tr>
<tr>
<td></td>
<td>218</td>
<td>The Embers that Keep Smoldering: A Case-Based Multidisciplinary Approach to Prosthetic Joint Infections</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-410-L01-P</td>
</tr>
<tr>
<td></td>
<td>219</td>
<td>Advances in RSV: Preparing for Future RSV Vaccines and Immunoprophylaxis Products</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-409-L01-P</td>
</tr>
<tr>
<td></td>
<td>220</td>
<td>Co-Morbidities and Aging</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-407-L02-P</td>
</tr>
<tr>
<td></td>
<td>221</td>
<td>Nurturing Young Leaders in Antimicrobial Stewardship: Year One of the LEAP Fellowship</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-411-L04-P</td>
</tr>
<tr>
<td></td>
<td>222</td>
<td>Optimizing PK/PD of New Antibiotics Against MDR Organisms</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-402-L01-P</td>
</tr>
</tbody>
</table>

continued on next page
<table>
<thead>
<tr>
<th>Attended</th>
<th>Session #</th>
<th>Session Title</th>
<th>CME/MOC Credits</th>
<th>Universal Program Number (for CPE credit)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>223</td>
<td>Tick-Tac-Toe: Tick-Borne Infections Upping the Game</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-404-L01-P</td>
</tr>
<tr>
<td></td>
<td>224</td>
<td>Update on Strategies ID Clinicians Can Use to Treat Opioid Use Disorder</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-405-L01-P</td>
</tr>
<tr>
<td></td>
<td>225</td>
<td>US Military Research Advancing Global Health</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-406-L04-P</td>
</tr>
<tr>
<td></td>
<td>226</td>
<td>A Focus on Personal Protective Equipment: How to Optimize Use to Prevent HAIs</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>No CPE Credit</td>
</tr>
<tr>
<td></td>
<td>227</td>
<td>Antivirals and Use of PCR Testing for Respiratory Viruses</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-412-L01-P</td>
</tr>
<tr>
<td></td>
<td>228</td>
<td>Back to Basics in Transplant ID</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-418-L01-P</td>
</tr>
<tr>
<td></td>
<td>229</td>
<td>Collaborating with Public Health Partners to Improve Antibiotic Use</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-419-L04-P</td>
</tr>
<tr>
<td></td>
<td>231</td>
<td>Controversial Topics in HIV Clinical Care</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-415-L02-P</td>
</tr>
<tr>
<td></td>
<td>232</td>
<td>Diagnostic Updates: Clinical Mycology</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-414-L01-P</td>
</tr>
<tr>
<td></td>
<td>233</td>
<td>ID Physicians in a Value-Based World</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>No CPE Credit</td>
</tr>
<tr>
<td></td>
<td>234</td>
<td>Impact of Early Life Microbiome Disruptions in the Child</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-416-L01-P</td>
</tr>
<tr>
<td></td>
<td>235</td>
<td>Maternal Immunization: Progress and Challenges</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-417-L06-P</td>
</tr>
<tr>
<td></td>
<td>236</td>
<td>The Etiology of Community-Acquired Pneumonia: How Appropriate are Current Guidelines?</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-413-L01-P</td>
</tr>
<tr>
<td></td>
<td>237</td>
<td>This Year’s Innovations in Pediatric Infectious Diseases</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-424-L01-P</td>
</tr>
<tr>
<td></td>
<td>238</td>
<td>Diagnosis and Management of Cryptococcal Meningitis</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-427-L01-P</td>
</tr>
<tr>
<td></td>
<td>239</td>
<td>Hot Topics in Pediatric Infection Prevention</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-425-L04-P</td>
</tr>
<tr>
<td></td>
<td>240</td>
<td>HPV Update</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-426-L06-P</td>
</tr>
<tr>
<td></td>
<td>241</td>
<td>Innovative Models for Retention in HIV Care</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-420-L02-P</td>
</tr>
<tr>
<td></td>
<td>242</td>
<td>Laboratory Diagnosis and Susceptibility Testing of Non-Tuberculous Mycobacteria</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-421-L01-P</td>
</tr>
<tr>
<td></td>
<td>243</td>
<td>Mechanistic Basis of Action and Resistance of B-Lactam/B-Lactamase Inhibitors</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-423-L01-P</td>
</tr>
<tr>
<td></td>
<td>244</td>
<td>Opportunistic Infections in the ICU: From Pathophysiology to Practical Approaches</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-422-L01-P</td>
</tr>
<tr>
<td></td>
<td>245</td>
<td>Success Stories in Telehealth</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-429-L04-P</td>
</tr>
<tr>
<td></td>
<td>246</td>
<td>The Compromised Immunocompromised</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-428-L01-P</td>
</tr>
<tr>
<td></td>
<td>247</td>
<td>Maxwell Finland Lecture</td>
<td>Maximum of 0.5 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-430-L04-P</td>
</tr>
<tr>
<td></td>
<td>248</td>
<td>ID BugBowl</td>
<td>Maximum of 0.75 AMA PRA Category 1 Credits™</td>
<td>No CPE Credit</td>
</tr>
<tr>
<td></td>
<td>249</td>
<td>A Precision Approach to the Management of Early Onset Neonatal Sepsis</td>
<td>Maximum of 1.0 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-432-L01-P</td>
</tr>
<tr>
<td></td>
<td>250</td>
<td>Hot Topics in Outpatient Antimicrobial Therapy of Infective Endocarditis</td>
<td>Maximum of 1.0 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-433-L01-P</td>
</tr>
<tr>
<td></td>
<td>251</td>
<td>How our Minds Respond to our Microbiome</td>
<td>Maximum of 1.0 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-431-L04-P</td>
</tr>
<tr>
<td></td>
<td>252</td>
<td>Closing Plenary: All About Vaccines: The Individual, the Community, the World</td>
<td>Maximum of 1.5 AMA PRA Category 1 Credits™</td>
<td>0221-9999-19-434-L06-P</td>
</tr>
</tbody>
</table>
Schedule-at-a-Glance

**Tuesday, October 1**

8 a.m. - 5 p.m. **PRE-MEETING WORKSHOP**
- The Vincent T. Andriole ID Board Review Course ($) - Salon GHI
- Best Practices for Antimicrobial Stewardship Programs ($) - Salon ABC

1 - 5 p.m. **PRE-MEETING WORKSHOP**
- Research Training Programs and Grant Writing Strategies for ID Physician-Scientists ($) - 102 AB
- Medication Assisted Treatment Waiver Course ($) - 103 AB

2 - 7 p.m. **REGISTRATION**

---

**Wednesday, October 2**

7 a.m. - 7 p.m. **REGISTRATION**

7:45 a.m. - 12 p.m. **PRE-MEETING WORKSHOP**
- Pediatric Fellows' Day Workshop - 152 AB

8 a.m. - 12 p.m. **PRE-MEETING WORKSHOP**
- Fellows' Day Workshop - 151 AB
- TB Workshop ($) - 103 AB
- Hepatitis C Workshop ($) - 201
- How to Use EBM/GRADE to Develop Guidelines ($) - 102 AB
- Expanding Antibiotic Stewardship into Outpatient Settings - 143 ABC
- Introductory Training for Clinical Performance Improvement - 147 AB

6 a.m. - 12:30 p.m. **PRE-MEETING WORKSHOP**
- Infectious Diseases ABIM Recertification: Self-Evaluation of Medical Knowledge, IDSA Module: General Infectious Diseases 2019 ($) - 150 AB

1:30 - 3:15 p.m. **INTERACTIVE**
- Challenging Cases in Pediatric Infectious Diseases - 146 ABC SYMPOSIUM
- Antimicrobial Resistance and Stewardship Across the Globe - 202 AB
- Conundrums in Diagnosis and Management of Diarrhea - 145 AB
- If I Built a Hospital: Designing to Optimize Infection Prevention - Salon ABC
- 2019 Measles Outbreak - Salon GHI
- Practical Guide to the Infectious Diseases and Opioid Use Disorder Syndemic: Regional Responses - 207 AB
- What's Hot in ID + HIV - Ballroom ABC

3:45 - 5:15 p.m. **PLENARY SESSION**
- Opening Plenary - Ballroom ABC

6 - 7:30 p.m. **RECEPTION**
- BugBash - Opening Reception - Salon ABC

6:30 - 8 p.m. **MED ED COP EVENT**
- Med Ed COP Event - 102 & 103 AB

---

**Thursday, October 3**

6:30 a.m. - 4 p.m. **REGISTRATION**

7 - 8 a.m. **REGISTRATION**
- Women in ID Breakfast - 143 ABC

7:30 - 9 a.m. **MEET THE PROFESSOR**
- The Big Idea: Making the Case to Policymakers for ID and HIV Priorities - 102 AB

8 - 9 a.m. **MEET THE PROFESSOR**
- Career Navigation and Negotiation for the Infectious Diseases Practitioner - 152 AB
- Case-Based Approach to the 2018 IDSA Guidelines on Neurocysticercosis - 206
- Critical and Flexible Partnerships: Investigation of Hospital Outbreaks - 204 ABC
- Experience and Challenges with Vancomycin Monitoring by AUC - 150 AB
- Infection Prevention and Stewardship in Long-Term Care - 201
- Moving it Forward: Closing the Gender Gap - 144 ABC
- Our Most Difficult HIV Cases - 147 AB

($$) – Additional Fee Applies

---

**9:15 - 10 a.m.**
- Updates on Interferon-Gamma Release Assay Performance - 151 AB

**10:30 - 11:45 a.m.**
- Edward H. Kass Lecture - Ballroom ABC

---

**12:15 - 12:45 p.m.**
- RAPID FIRE POSTER

**12:15 - 1:30 p.m.**
- POSTER ABSTRACT
- Bacteremia, CLABSI, and Endovascular Infections - Hall B +C
- Transplant ID: Bloodstream Infections - Hall B +C
- Diagnostics: Sequencing & Typing - Hall B +C
- Fungal Diagnostics - Hall B +C
- Hepatitis - Hall B +C
- HIV Complications: Bone Complications - Hall B +C
- HIV Complications: Cancer - Hall B +C
- HIV Complications: Cardiovascular, Metabolic, and other Complications - Hall B +C
- HIV Complications: Hepatitis Co-Infections - Hall B +C
- HIV Complications: Neurologic Complications - Hall B +C
- HIV Complications: Opportunistic Infections - Hall B +C
- Infections of Joints - Hall B +C
- Inflammation and Infectious Diseases - Hall B +C
- Sexually Transmitted Infections - Hall B +C
- Soft Tissue and Skin Infections - Hall B +C
- HA: MDRO - GNR Epidemiology, ESBL Producers - Hall B +C
- HA: MDRO - GNR Epidemiology, Other - Hall B +C
- HA: MDRO - GNR Epidemiology, CRE - Hall B +C
- HA: MDRO - GNR Transmission - Hall B +C
- HA: MDRO - GNR Treatment - Hall B +C
- HA: MDRO - GNR Prevention - Hall B +C
- HA: MDRO - GNR Surveillance - Hall B +C
- HA: MDRO: General - Hall B +C
- HA: MDRO - GNR Epidemiology, Acinetobacter - Hall B +C
- HA: MRSA Epidemiology - Hall B +C
- HA: MRSA Prevention - Hall B +C
- HA: VRE Epidemiology - Hall B +C
- HA: Pediatric - Hall B +C
- Mechanisms of Antimicrobial Resistance - Hall B +C
- Molecular and Genomic Epidemiology of Resistant Pathogens - Hall B +C
- New Diagnostics - Hall B +C

---

**Continued on Next Page**

Final Program IDWeek 2019 • 61
### Friday, October 4

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 a.m. - 4 p.m.</td>
<td>Registration: Hot Breakfast and Hot Topics: IDSA &amp; HIVMA in 2019</td>
</tr>
<tr>
<td>7 - 8 a.m.</td>
<td>Hot Breakfast and Hot Topics: IDSA &amp; HIVMA in 2019- 143 ABC</td>
</tr>
<tr>
<td>8 - 9 a.m.</td>
<td>Meet the Professor</td>
</tr>
<tr>
<td></td>
<td>Alternative Strategies to Monitor CMV Reactivation After Transplantation - 150 AB</td>
</tr>
<tr>
<td></td>
<td>Left Ventricular Assist Device-associated Infections - 209 ABC</td>
</tr>
<tr>
<td></td>
<td>Ketoconazole vs. Nafcillin for MSSA Infections: Pro-Con Debate - 151 AB</td>
</tr>
<tr>
<td></td>
<td>Challenging STIs in Patients with HIV - 103 AB</td>
</tr>
<tr>
<td></td>
<td>Compensatory Disparities Across Gender - 152 AB</td>
</tr>
<tr>
<td></td>
<td>Displaced: Infectious Disease Impacts on Refugee and Migrant Populations - 144 ABC</td>
</tr>
<tr>
<td></td>
<td>From Inactive to Reactive: When and How to Treat HBV Infection - 147 AB</td>
</tr>
<tr>
<td></td>
<td>Medical Director 101: Practical Guidance for the ID Specialist new to Infection Prevention and Antibiotic Stewardship Program Leadership - 206</td>
</tr>
<tr>
<td></td>
<td>Practicing Diagnostic Stewardship: Tools You can Use Today in Your Hospital - 201</td>
</tr>
<tr>
<td></td>
<td>Top Papers in Medical Mycology - 204 ABC</td>
</tr>
</tbody>
</table>

### 1:45 - 3 p.m.
- **Syposium**
  - Novel Antimicrobials and Approaches Against Resistant Bugs - Hall B +C
  - What’s New in Clinical Practice? - Hall B +C
  - Interesting Cases from the IDWeek Call for Cases - Hall B +C
- **Oral Abstract**
  - Antimicrobial Stewardship in Compromised Hosts - 150 AB
  - Applying Contact Precautions: What’s the Best Approach to Reduce Transmission? - Salon GHI
  - Challenging HIV Cases - 146 ABC
  - Clinical Interpretation and Use of Metagenomic-based Infectious Disease Diagnostics - Salon ABC
  - Enterovirus-Associated Neurologic Disease - 207 AB
  - Head Scratching Cases of MDR Gram-Negatives Other than Enterobacteriales - Ballroom ABC
  - New Science Behind Chronic Pulmonary Infectious Diseases - 152 AB
  - New Worries about Group A Streptococcal Disease - 145 AB
  - Vaccine Hesitancy - 202 AB
  - Who Owns Sepsis Anyway? - 151 AB
- **Interactive**
  - Clinical Controversies - Ballroom ABC
  - Educating Healthcare Students and Trainees about Stewardship - 150 AB
- **Symposium**
  - Drug Resistant Gonorrhea: The Future is Here - 146 ABC
  - Innovative Methods in Healthcare Epidemiology and Antimicrobial Stewardship - 145 AB
  - Meeting the Full Potential of DAA Therapies for HCV - 207 AB
  - Non-Antibiotic Approaches to Treating Transplant-Associated Infections - 202 AB
  - STIs in the HIV Care Setting: An Interactive Case-Based Approach - Salon GHI
  - The Role of Public Health in Precision Medicine - 152 AB
  - What Every ID Physician Should Know: Bridging Inmate Immune Responses to Immune Memory - 151 AB
- **Named Lecture**
  - Caroline B. Hall Lecture: Antenatal Zika Virus Exposure - Salon ABC
- **Oral Abstract**
  - HIV Viral Suppression or Bust - 144 ABC
  - Innovations in Clinical Practice - 147 AB
  - To Decolonize or Not to Decolonize: Do We Still Need to Ask the Question - 204 ABC
  - Vaccines I - Influenza and RSV - 206
- **Awards Session**
  - Awards Session - Ballroom ABC
- **Named Lecture**
  - Joseph E. Smadel Lecture - Ballroom ABC
- **Oral Abstract**
  - IDSA Featured Oral Abstract - Ballroom ABC
- **PIDS Business Meeting**
  - PIDS Business Meeting - 202 AB
- **6 - 7 p.m.**
  - **IDEA incubator**
    - IDEA Incubator - Ballroom ABC
  - **Shea Business Meeting & Reception**
    - SHEA Business Meeting & Reception - Renaissance - Congressional Ballroom ABC
- **Career Fair**
  - Career Fair - Level 300 Foyer
Schedule-at-a-Glance (continued)

1:45 - 3 p.m.
INTERACTIVE
A Day with the Hospital Epidemiologist’s Pager, Part II: Even More Challenging Cases in Infection Prevention - 202 AB
Our Toughest Mycobacterial Cases - Salon GHI
Immunization: Beyond the Guidelines - 207 AB
SYMPOSIUM
Antibiotic Stewardship: Special Surgical Populations - 151 AB
Big Beasts I - Ballroom ABC
Case-Based Guideline Update - Salon ABC
Hot Topics in Pediatric Infectious Diseases - 146 ABC
Mycobiome and Invasive Fungal Infections - 145 AB
Populations with Disparities in the HIV Care Cascade - 152 AB
The Influence of Climate Change on Infectious Diseases - 150 AB

3:15 - 4:30 p.m.
INTERACTIVE
Challenging Cases in Infectious Diseases - Ballroom ABC

SYMPOSIUM
Big Beasts II - 146 AB
Cutting Edge in Pediatric Osteomyelitis: Basic Scientist, ID Clinician, and Orthopedist - 150 AB
HIV Prevention - 145 AB
I’m Better Than You and I Can Prove It: Quality Metrics and ID - Salon GHI

4:30 - 4:45 p.m.
ORAL ABSTRACT
Influential Publications in Healthcare Epidemiology, 2019 - Salon ABC
The Fungus Among Us - 151 AB
The State of HCV Elimination - 202 AB
Vaccines and Antimicrobial Resistance - 152 AB
When the Transplant ID Physician Needs to “Phone a Friend” - 207 AB

4:45 - 5 p.m.
AWARDS SESSION
Awards Session - ORAL ABSTRACT

4:45 - 6 p.m.
SYMPOSIUM
Ending HIV as an Epidemic: An Update and Discussion - 146 ABC
NAMED LECTURE
SHEA Lecture (Trish Perl) - Ballroom ABC
Stanley A. Plotkin Lectureship in Vaccinology - Salon GHI

Saturday, October 5
6:30 a.m. - 4 p.m.
REGISTRATION
MEET THE PROFESSOR
Are the New Non-Molecular Assays Better for Diagnosis of Clostridiodes difficile Toxin Tests - 150 AB
 Burning Questions on Hot Topics in Transplant ID - 152 AB
 Fighting the TB Epidemic in Children and Adolescents: Game-Changing Advances in Pediatric TB - 103 AB
 Infectious Complications of Immunomodulatory Biologic Agents: Risk Assessment, Diagnosis, and Management - 209 ABC
 Leveraging Social Media for Professional Success - 143 ABC
 OPAT Update - 204 ABC
 Registration Trials versus Clinical Practice: Challenges Associated with Newly Approved Antimicrobials - 144 ABC
 Teamwork! Collaboration and Antimicrobial Stewardship - 201
 The Who, What, Why, When of the GeoSentinel Surveillance Network and Emerging Infectious Diseases - 147 AB
 Updates from NHSN and the HICPAC NHSN Work Group - 206
 Rapid Diagnostics and Resistance: Making Sense of Now and the Future Part 2 - Ballroom ABC

9:15 - 10 a.m.
NAMED LECTURE
John F. Enders Lecture - Ballroom ABC

10:30 - 11:45 a.m.
INTERACTIVE
Challenging Cases in Transplant ID - Salon GHI
Diagnosis and Management of Congenital CMB on Both Sides of the Pond (Joint PIDS/ESPID) - 151 AB
The Embers that Keep Smoldering: A Case-Based Multidisciplinary Approach to Prosthetic Joint Infections - Ballroom ABC
SYMPOSIUM
Advances in RSV: Preparing for Future RSV Vaccines and Immunoprophylaxis Products - Salon ABC
Co-Morbidities and Aging - 145 AB
Fostering Young Leadership Across Public Health and Academic Medicine: Year One of the LEAP Fellowship - 152 AB
Optimizing PK/PD of New Antibiotics Against MDR Organisms - 146 ABC
Tick-Tac-Toe: Tick-Borne Infections Upping the Game - 150 AB
Update on Strategies ID Clinicians Can Use to Treat Opioid Use Disorder - 207 AB
US Military Research Advancing Global Health - 202 AB

continued on next page
### Schedule-at-a-Glance (continued)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15 - 1:30 p.m.</td>
<td><strong>POSTER ABSTRACT</strong>&lt;br&gt;- Antibiotic Stewardship: Adverse Effects - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Antibiotic Stewardship: Antifungals - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Antibiotic Stewardship: C. difficile - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Antibiotic Stewardship: Diagnostics and Diagnostic Stewardship - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Antibiotic Stewardship: Global - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Antibiotic Stewardship: Long-Term Care - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Antibiotic stewardship: Non-Inpatient Settings - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Antibiotic Stewardship: Nursing - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Antibiotic Stewardship: Regional - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Antibiotic Stewardship: Sepsis - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Antifungals - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Bacterial Diagnostics - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Bacterial Respiratory Infections - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Biomarkers of Infectious Diseases - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Clinical Outcomes of Infections with Resistant Organisms - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Clinical Virology/Viral Epidemiology - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Congenital Infections - CMV and HSV - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- HAI: C. difficile - Diagnostic Stewardship - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- HAI: C. difficile - Diagnostic Testing - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- HAI: C. difficile - Epidemiology - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- HAI: C. difficile - Prevention - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- HAI: C. difficile - Treatment - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- HAI: Epidemiology Methods - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- HAI: Miscellaneous - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- HAI: Outbreaks - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- HAI: Surveillance - Molecular Epidemiology - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- HAI: Surveillance, General - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- HAI: Surveillance, International - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- HAI: Surveillance, Regional - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- HIV: Antiretroviral Therapy - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- HIV: ART Resistance &amp; Adherence - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- HIV: Pathogenesis - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- HIV: Pediatric - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Medical Education: Medical School to Practice - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Microbiome, Antibiotics, and Pathogenesis - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Neonatal Infections - non CMV/HSV - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Pathogenesis and Host-Response Interactions - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Pediatric Respiratory Infections - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Pediatric Respiratory Viral Infections - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Studies of Treatment and Prevention of Viral Disease - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Transplant ID: Bacterial Infections - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Transplant ID: C. difficile - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Transplant ID: Malignancy and Neutropenia - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Transplant ID: Parasitic Infections - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Vaccines: Bacterial - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Vaccines: Influenza - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Vaccines: Viral Non Influenza - Hall B +C</td>
</tr>
<tr>
<td></td>
<td>- Viral Pathogenesis - Hall B +C</td>
</tr>
</tbody>
</table>

### April 11: Saturday

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.</td>
<td><strong>REGISTRATION</strong>&lt;br&gt;- MINI-SYMPOSIUM - A Precision Approach to the Management of Early Onset Neonatal Sepsis - 201</td>
</tr>
<tr>
<td>9:00 a.m.</td>
<td>- Hot Topics in Outpatient Antimicrobial Therapy of Infective Endocarditis - 206</td>
</tr>
<tr>
<td>9:15 a.m.</td>
<td>- How our Minds Respond to our Microbiome - 202 AB</td>
</tr>
<tr>
<td>9:45 a.m.</td>
<td><strong>PLENARY SESSION</strong>&lt;br&gt;- Closing Plenary - Ballroom ABC</td>
</tr>
<tr>
<td>10:00 a.m.</td>
<td>- Viral Respiratory Diseases - Hall B +C</td>
</tr>
<tr>
<td>10:15 a.m.</td>
<td>- Zika Virus Infection - Hall B +C</td>
</tr>
<tr>
<td>10:30 a.m.</td>
<td><strong>SYMPOSIUM</strong>&lt;br&gt;- A Focus on Personal Protective Equipment: How to Optimize Use to Prevent HAIs - 146 ABC</td>
</tr>
<tr>
<td></td>
<td>- Antivirals and Use of PCR Testing for Respiratory Viruses - 151 AB</td>
</tr>
<tr>
<td></td>
<td>- Back to Basics in Transplant ID - 202 AB</td>
</tr>
<tr>
<td></td>
<td>- Collaborating with Public Health Partners to Improve Antibiotic Use - Salon ABC</td>
</tr>
<tr>
<td></td>
<td>- Controversial Topics in HIV Clinical Care - Salon GHI</td>
</tr>
<tr>
<td></td>
<td>- Diagnostic Updates: Clinical Mycology - 207 AB</td>
</tr>
<tr>
<td></td>
<td>- ID Physicians in a Value-Based World - 152 AB</td>
</tr>
<tr>
<td></td>
<td>- Impact of Early Life Microbiome Disruptions in the Child - 150 AB</td>
</tr>
<tr>
<td></td>
<td>- Maternal Immunization: Progress and Challenges - 145 AB</td>
</tr>
<tr>
<td></td>
<td>- The Etiology of Community-Acquired Pneumonia: How Appropriate are Current Guidelines? - Ballroom ABC</td>
</tr>
<tr>
<td>1:00 p.m.</td>
<td><strong>ORAL ABSTRACT</strong>&lt;br&gt;- Clinical Trials that May Change your Practice - 144 ABC</td>
</tr>
<tr>
<td></td>
<td>- Late Breaker Oral Abstract Session 3 - 209 ABC</td>
</tr>
<tr>
<td></td>
<td>- Microbiome Science - 147 AB</td>
</tr>
<tr>
<td></td>
<td>- New Insights into MDRO Gram-Negatives - 204 ABC</td>
</tr>
<tr>
<td></td>
<td>- Pediatric Viral and Fungal Diseases - 206</td>
</tr>
<tr>
<td>5:00 p.m.</td>
<td><strong>AWARDS SESSION</strong>&lt;br&gt;- Awards Session -</td>
</tr>
<tr>
<td>5:30 p.m.</td>
<td>- Maxwell Finland Lecture - Ballroom ABC</td>
</tr>
<tr>
<td>6:00 p.m.</td>
<td>- ID BugBowl - Ballroom ABC</td>
</tr>
</tbody>
</table>
# IDWeek 2019 Program Tracks

<table>
<thead>
<tr>
<th>Pres #</th>
<th>Session Name</th>
<th>Pres Room</th>
<th>Adult ID</th>
<th>Pediatric ID</th>
<th>Global ID</th>
<th>Trainee ID</th>
<th>Epi/Infection Control</th>
<th>HIV/STD</th>
<th>Investigative</th>
<th>Transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Tuesday, October 1</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8 a.m. - 5 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Pre-meeting Workshop</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PW01                           The Vincent T. Andriole ID Board Review Course</td>
<td>Salon GHI</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>PW02                           Best Practices for Antimicrobial Stewardship Programs ($)</td>
<td>Salon ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 - 5 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Pre-meeting Workshop</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PW03                           Research Training Programs and Grant Writing Strategies for ID Physician-Scientists</td>
<td>102 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>PW04                           Medication Assisted Treatment Waiver Course</td>
<td>103 AB</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td><strong>Wednesday, October 2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7:45 a.m. - 12 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Pre-meeting Workshop</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PW06                           Pediatric Fellows’ Day Workshop</td>
<td>152 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>8 a.m. - 12 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Pre-meeting Workshop</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PW05                           Fellows’ Day Workshop</td>
<td>151 AB</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>PW07                           TB Workshop</td>
<td>103 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>PW08                           Hepatitis C Workshop</td>
<td>201</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>PW10                           How to Use EBM/GRADE to Develop Guidelines</td>
<td>102 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>PW11                           Expanding Antibiotic Stewardship into Outpatient Settings</td>
<td>143 ABC</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>PW12                           Introductory Training for Clinical Performance Improvement</td>
<td>147 AB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8 a.m. - 12:30 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Pre-meeting Workshop</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PW09                           Infectious Diseases ABIM Recertification: Self-Evaluation of Medical Knowledge, IDSA Module: General Infectious Diseases 2019</td>
<td>150 AB</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>**1:30 - 3:15 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Interactive</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1                              Challenging Cases in Pediatric Infectious Diseases</td>
<td>146 ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>2                              Antimicrobial Resistance and Stewardship Across the Globe</td>
<td>202 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>3                              Conundrums in Diagnosis and Management of Diarrhea</td>
<td>145 AB</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>4                              If I Built a Hospital: Designing to Optimize Infection Prevention</td>
<td>Salon ABC</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>5                              2019 Measles Outbreak</td>
<td>Salon GHI</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>
|        | 6                              Practical Guide to the Infectious Diseases and Opioid Use Disorder Syndemic: Regional Responses | 207 AB | ✓        |              |            |            |                        |         |               | ✓          | continued on next page
## IDWeek 2019 Program Tracks (continued)

<table>
<thead>
<tr>
<th>Pres #</th>
<th>Session Name</th>
<th>Pres Room</th>
<th>Adult ID</th>
<th>Pediatric ID</th>
<th>Global ID</th>
<th>Trainee ID</th>
<th>Epi/Infection Control</th>
<th>HIV/TB/STD</th>
<th>Investigative</th>
<th>Transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>What’s Hot in ID + HIV</td>
<td>Ballroom ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:45 - 5:15 p.m.</td>
<td>Plenary Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Opening Plenary</td>
<td>Ballroom ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Thursday, October 3

#### 7 - 8 a.m.

8
Women in ID Breakfast | 143 ABC | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |

#### 7 - 9 a.m.

10
The Big IDEa: Making the Case to Policymakers for ID and HIV Priorities | 102 AB | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |

#### 8 - 9 a.m.

Meet the Professor

11
Career Navigation and Negotiation for the Infectious Diseases Practitioner | 152 AB | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |

12
Case-Based Approach to the 2018 IDSA Guidelines on Neurocysticercosis | 206 | ✓ | ✓ | ✓ |

13
Critical and Flexible Partnerships: Investigation of Hospital Outbreaks | 204 ABC | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |

14
Experience and Challenges with Vancomycin Monitoring by AUC | 150 AB | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |

15
Infection Prevention and Stewardship in Long-Term Care | 201 | ✓ | ✓ | ✓ | ✓ |

16
Moving it Forward: Closing the Gender Gap | 144 ABC | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |

17
Our Most Difficult HIV Cases | 147 AB | ✓ | ✓ | ✓ | ✓ |

18
Updates on Interferon-Gamma Release Assay Performance | 151 AB | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |

#### 9:15 - 10 a.m.

Named Lecture

19
Edward H. Kass Lecture | Ballroom ABC | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |

#### 10:30 - 11:45 a.m.

Interactive

20
Diagnostic Clinical Cases | 146 ABC | ✓ | ✓ | ✓ |

Symposium

21
We’re Part of the Problem: How ID Killed Antibiotic Development | 151 AB | ✓ | ✓ | ✓ | ✓ |

22
Behavioral Approaches to Antibiotic Stewardship | 202 AB | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |

23
Clinical Reasoning from Education to Practice | 143 ABC | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |

24
Clinical Trials That Might Change Your Practice | Ballroom ABC | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |

25
Help or Hype? Update on Biomarkers in Management of Adult and Pediatric Infectious Diseases | 207 AB | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
## IDWeek 2019 Program Tracks (continued)

<table>
<thead>
<tr>
<th>Pres #</th>
<th>Session Name</th>
<th>Pres Room</th>
<th>Adult ID</th>
<th>Pediatric ID</th>
<th>Global ID</th>
<th>Trainee ID</th>
<th>Epid/Infection</th>
<th>HIV/TB/STD</th>
<th>Investigative</th>
<th>Transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>HIV State-of-the-Art</td>
<td>Salon GHI</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>New Effectors of TB Immunity: Beyond CD4 T-Cells</td>
<td>152 AB</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>One Health and Global Health Security</td>
<td>145 AB</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>Unsolved or Uncontrolled: Public Health Challenges in Resistant Pathogens</td>
<td>150 AB</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Vaccination and Immunocompromised Hosts: Recommendations and Knowledge Gaps</td>
<td>Salon ABC</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Oral Abstract**

| 31     | Not Just Your Everyday Diarrhea                                               | 144 ABC        | ✔        |              |           |             |                |            |               |            |
| 32     | Surveillance in Healthcare-Associated Infections                             | 147 AB         | ✔        | ✔           |           |             |                |            |               |            |
| 33     | Transplant ID                                                                 | 204 ABC        | ✔        | ✔           |           |             |                |            |               |            |
| 34     | Viral Infections - Host, Pathogen, and Impact of Intervention                 | 206            | ✔        | ✔           |           |             |                |            |               |            |

**12:15 - 12:45 p.m.**

**Oral Abstract**

| 35     | Rapid Fire Poster Session: Antimicrobial Resistance                          | Hall B +C - Arena 2 | ✔        |              |           |             |                |            |               |            |
| 36     | Rapid Fire Poster Session: Diagnostics                                       | Hall B +C - Arena 1 | ✔        |              |           |             |                |            |               |            |

**1:45 - 3 p.m.**

**Symposium**

| 71     | Antimicrobial Stewardship in Compromised Hosts                               | 150 AB         | ✔        | ✔           |           | ✔          |                | ✔          |               |            |
| 72     | Applying Contact Precautions: What’s the Best Approach to Reduce Transmission? | Salon GHI      | ✔        | ✔           |           | ✔          |                | ✔          |               |            |
| 73     | Challenging HIV Cases                                                        | 146 ABC        | ✔        | ✔           |           |             |                |            |               |            |
| 74     | Clinical Interpretation and Use of Metagenomic-based Infectious Disease Diagnostics | Salon ABC | ✔        | ✔           |           |             |                |            |               |            |
| 75     | Enterovirus-Associated Neurologic Disease                                     | 207 AB         | ✔        | ✔           |           | ✔          |                | ✔          |               |            |
| 76     | Head Scratching Cases of MDR Gram-Negatives Other than Enterobacteriales     | Ballroom ABC   | ✔        | ✔           |           |             |                | ✔          |               |            |
| 77     | New Science Behind Chronic Pulmonary Infectious Diseases                     | 152 AB         | ✔        | ✔           |           | ✔          |                | ✔          |               |            |
| 78     | New Worries about Group A Streptococcal Disease                              | 145 AB         | ✔        | ✔           |           |             |                | ✔          |               |            |
| 79     | Vaccine Hesitancy                                                            | 202 AB         | ✔        | ✔           |           | ✔          |                | ✔          |               |            |
| 80     | Who Owns Sepsis Anyway?                                                       | 151 AB         | ✔        | ✔           |           | ✔          |                | ✔          |               |            |

**Oral Abstract**

<p>| 81     | <strong>Clostridium difficile</strong>                                                     | 144 ABC        | ✔        |              |           |             |                |            |               |            |
| 82     | Global Health: Outbreaks, Controls, and Genetics                             | 147 AB         | ✔        | ✔           |           |             |                | ✔          |               |            |
| 83     | Late Breaker Oral Abstract Session 1                                         | 209 ABC        | ✔        |              |           |             |                |            |               |            |</p>
<table>
<thead>
<tr>
<th>Pres #</th>
<th>Session Name</th>
<th>Pres Room</th>
<th>Adult ID</th>
<th>Pediatric ID</th>
<th>Global ID</th>
<th>Trainee ID</th>
<th>Epi/Infection Control</th>
<th>HIV/TB/STD</th>
<th>Investigative</th>
<th>Transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td>84</td>
<td>Novel Insights into Bacteremia and Endocarditis</td>
<td>204 ABC</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>85</td>
<td>Pediatric Bacterial Diseases</td>
<td>206</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>3:15 - 4:30 p.m. Interactive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>86</td>
<td>Clinical Controversies</td>
<td>Ballroom  ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>87</td>
<td>Educating Healthcare Students and Trainees about Stewardship</td>
<td>150 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:15 - 4:30 p.m. Symposium</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>88</td>
<td>Drug Resistant Gonorrhea: The Future is Here</td>
<td>146 ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>89</td>
<td>Innovative Methods in Healthcare Epidemiology and Antimicrobial Stewardship</td>
<td>145 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>90</td>
<td>Meeting the Full Potential of DAA Therapies for HCV</td>
<td>207 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>91</td>
<td>Non-Antibiotic Approaches to Treating Transplant-Associated Infections</td>
<td>202 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>92</td>
<td>STIs in the HIV Care Setting: An Interactive Case-Based Approach</td>
<td>Salon GHI</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>93</td>
<td>The Role of Public Health in Precision Medicine</td>
<td>152 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>94</td>
<td>What Every ID Physician Should Know: Bridging Innate Immune Responses to Immune Memory</td>
<td>151 AB</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Named Lecture</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>Caroline B. Hall Lecture: Antenatal Zika Virus Exposure</td>
<td>Salon ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral Abstract</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>HIV Viral Suppression or Bust</td>
<td>144 ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>97</td>
<td>Innovations in Clinical Practice</td>
<td>147 AB</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>98</td>
<td>To Decolonize or Not to Decolonize: Do We Still Need to Ask the Question</td>
<td>204 ABC</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>Vaccines I - Influenza and RSV</td>
<td>206</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:45 - 5:45 p.m. Named Lecture</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>101</td>
<td>Joseph E. Smadel Lecture</td>
<td>Ballroom  ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:05 - 5:20 p.m. Oral Abstract</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>IDSA Featured Oral Abstract</td>
<td>Ballroom  ABC</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>
### IDWeek 2019 Program Tracks (continued)

#### Friday, October 4

<table>
<thead>
<tr>
<th>Pres #</th>
<th>Session Name</th>
<th>Pres Room</th>
<th>Adult ID</th>
<th>Pediatric ID</th>
<th>Global ID</th>
<th>Trainee ID</th>
<th>Ep/Infection Control</th>
<th>HIV/STD</th>
<th>Investigative Transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td>102</td>
<td>Alternative Strategies to Monitor CMV Reactivation After Transplantation</td>
<td>150 AB</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>103</td>
<td>Left Ventricular Assist Device-associated Infections</td>
<td>209 ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>104</td>
<td>Cefazolin vs. Nafcillin for MSSA Infections: Pro-Con Debate</td>
<td>151 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>105</td>
<td>Challenging STIs in Patients with HIV</td>
<td>103 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>106</td>
<td>Compensation Disparities Across Gender</td>
<td>152 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>107</td>
<td>Displaced: Infectious Disease Impacts on Refugee and Migrant Populations</td>
<td>144 ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>108</td>
<td>From Inactive to Reactive: When and How to Treat HBV Infection</td>
<td>147 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>109</td>
<td>Medical Director 101: Practical Guidance for the ID Specialist new to Infection Prevention and Antibiotic Stewardship Program Leadership</td>
<td>206</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>110</td>
<td>Practicing Diagnostic Stewardship: Tools You can Use Today in Your Hospital</td>
<td>201</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>111</td>
<td>Top Papers in Medical Mycology</td>
<td>204 ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

#### 9:15 - 10 a.m.

**Special Session**

- 112: Special Session
  - Room: Ballroom
    - AB: ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓

#### 10:30 - 11:45 a.m.

**Interactive**

- 113: Mano-a-Mano V: Pediatric Infectious Diseases
  - Room: Salon GHI
    - AB: ✓ ✓

- 114: Opening Pandora’s Chest: A Case Based Multidisciplinary Approach to Chronic Pulmonary Infections and Their Mimics
  - Room: Salon ABC
    - AB: ✓ ✓ ✓

**Symposium**

- 115: Bacterial Persisters and Nonculturable Forms: Basic Biology and Therapeutic Susceptibility
  - Room: 152 AB
    - AB: ✓ ✓ ✓ ✓ ✓ ✓

- 116: Clinical Controversies in HIV Antiretroviral Therapy
  - Room: 145 AB
    - AB: ✓ ✓ ✓

- 117: Influenza Vaccines
  - Room: 146 ABC
    - ABC: ✓ ✓ ✓ ✓ ✓ ✓ ✓

- 118: Phages to the Rescue
  - Room: 202 AB
    - AB: ✓ ✓ ✓

- 119: Rapid Diagnostics and Resistance: Making Sense of Now and the Future Part 1
  - Room: Ballroom ABC
    - ABC: ✓ ✓ ✓

- 120: South of the Border: Important Diseases You Can Not Miss
  - Room: 150 AB
    - AB: ✓ ✓ ✓ ✓

- 121: Tackling the Big Beasts of Healthcare Epidemiology
  - Room: 207 AB
    - AB: ✓ ✓ ✓ ✓ ✓

- 122: Using Technology to Enhance Teaching and Learning
  - Room: 143 ABC
    - ABC: ✓ ✓ ✓ ✓ ✓ ✓

*continued on next page*
# IDWeek 2019 Program Tracks (continued)

<table>
<thead>
<tr>
<th>Pres #</th>
<th>Session Name</th>
<th>Pres Room</th>
<th>Adult ID</th>
<th>Pediatric ID</th>
<th>Global ID</th>
<th>Trainee ID</th>
<th>Epi/Infection Control</th>
<th>HIV/TB/STD</th>
<th>Investigative</th>
<th>Transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral Abstract</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>123</td>
<td>Advances in Sexually Transmitted and UTIs</td>
<td>144 ABC</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>124</td>
<td>Out of the Box and Out of the Hospital: Stewardship Outpatient Services</td>
<td>147 AB</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>125</td>
<td>Pathogenesis and Inflammatory Response</td>
<td>204 ABC</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>126</td>
<td>Suppressed but Still at Risk: Comorbidities</td>
<td>206</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>12:15 - 12:45 p.m.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Interactive</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>127</td>
<td>Rapid Fire Poster Session: HIV</td>
<td>Hall B +C - Arena 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>128</td>
<td>Rapid Fire Poster Session: Transplant/Immunocompromised ID</td>
<td>Hall B +C - Arena 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1:45 - 3 p.m.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Symposium</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>171</td>
<td>A Day with the Hospital Epidemiologist's Pager, Part II: Even More Challenging Cases in Infection Prevention</td>
<td>202 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>172</td>
<td>Our Toughest Mycobacterial Cases</td>
<td>Salon GHI</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>173</td>
<td>Immunization: Beyond the Guidelines</td>
<td>207 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>3:15 - 4:30 p.m.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Interactive</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>181</td>
<td>Advances in CNS Infections</td>
<td>144 ABC</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>182</td>
<td>Emergent Mechanisms of Resistance and How to Prevent Them</td>
<td>147 AB</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>183</td>
<td>Innovative Diagnostics</td>
<td>204 ABC</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>184</td>
<td>Late Breaker Oral Abstract Session 2</td>
<td>209 ABC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>185</td>
<td>Staph aureus: New Perspectives on an Old Foe</td>
<td>206</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Symposium</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>186</td>
<td>Challenging Cases in Infectious Diseases</td>
<td>Ballroom ABC</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>187</td>
<td>Big Beasts II</td>
<td>146 ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*FRIDAY*
### IDWeek 2019 Program Tracks (continued)

<table>
<thead>
<tr>
<th>Pres #</th>
<th>Session Name</th>
<th>Pres Room</th>
<th>Adult ID</th>
<th>Pediatric ID</th>
<th>Global ID</th>
<th>Trainee ID</th>
<th>Epi/Infection Control</th>
<th>HIV/TBD</th>
<th>Investigative</th>
<th>Transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td>188</td>
<td>Cutting Edge in Pediatric Osteomyelitis: Basic Scientist, ID Clinician, and Orthopedist</td>
<td>150 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>189</td>
<td>HIV Prevention</td>
<td>145 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>190</td>
<td>I’m Better Than You and I Can Prove It: Quality Metrics and ID</td>
<td>Salon GHI</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>191</td>
<td>Influential Publications in Healthcare Epidemiology, 2019</td>
<td>Salon ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>192</td>
<td>The Fungus Among Us</td>
<td>151 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>193</td>
<td>The State of HCV Elimination</td>
<td>202 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>194</td>
<td>Vaccines and Antimicrobial Resistance</td>
<td>152 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>195</td>
<td>When the Transplant ID Physician Needs to “Phone a Friend”</td>
<td>207 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>

**Oral Abstract**

<table>
<thead>
<tr>
<th>Pres #</th>
<th>Session Name</th>
<th>Pres Room</th>
<th>Adult ID</th>
<th>Pediatric ID</th>
<th>Global ID</th>
<th>Trainee ID</th>
<th>Epi/Infection Control</th>
<th>HIV/TBD</th>
<th>Investigative</th>
<th>Transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td>196</td>
<td>Pediatric Emerging Viral Diseases</td>
<td>144 ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>197</td>
<td>Stewardship Success Stories</td>
<td>147 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>198</td>
<td>Tuberculosis: Stigma, Diagnosis, and Treatment</td>
<td>204 ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>199</td>
<td>What’s New and Happening in Public Health</td>
<td>206</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>

**4:45 - 5 p.m. Oral Abstract**

<table>
<thead>
<tr>
<th>Pres #</th>
<th>Session Name</th>
<th>Pres Room</th>
<th>Adult ID</th>
<th>Pediatric ID</th>
<th>Global ID</th>
<th>Trainee ID</th>
<th>Epi/Infection Control</th>
<th>HIV/TBD</th>
<th>Investigative</th>
<th>Transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td>201</td>
<td>SHEA Featured Oral Abstract</td>
<td>Ballroom ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**4:45 - 6 p.m. Symposium**

<table>
<thead>
<tr>
<th>Pres #</th>
<th>Session Name</th>
<th>Pres Room</th>
<th>Adult ID</th>
<th>Pediatric ID</th>
<th>Global ID</th>
<th>Trainee ID</th>
<th>Epi/Infection Control</th>
<th>HIV/TBD</th>
<th>Investigative</th>
<th>Transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td>200</td>
<td>Ending HIV as an Epidemic: An Update and Discussion</td>
<td>146 ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Named Lecture**

<table>
<thead>
<tr>
<th>Pres #</th>
<th>Session Name</th>
<th>Pres Room</th>
<th>Adult ID</th>
<th>Pediatric ID</th>
<th>Global ID</th>
<th>Trainee ID</th>
<th>Epi/Infection Control</th>
<th>HIV/TBD</th>
<th>Investigative</th>
<th>Transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td>202</td>
<td>SHEA Lecture (Trish Perl)</td>
<td>Ballroom ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>203</td>
<td>Stanley A. Plotkin Lectureship in Vaccinology</td>
<td>Salon GHI</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>
## IDWeek 2019 Program Tracks (continued)

<table>
<thead>
<tr>
<th>Pres #</th>
<th>Session Name</th>
<th>Pres Room</th>
<th>Adult ID</th>
<th>Pediatric ID</th>
<th>Global ID</th>
<th>Trainee ID</th>
<th>Epi/Infection Control</th>
<th>HIV/TB/STD</th>
<th>Investigative</th>
<th>Transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Saturday, October 5</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 - 9 a.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Meet the Professor</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>204</td>
<td>Are the New Non-Molecular Assays Better for Diagnosis of <em>Clostridiodes difficile</em> Toxin Tests</td>
<td>150 AB</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>205</td>
<td>Burning Questions on Hot Topics in Transplant ID</td>
<td>152 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>206</td>
<td>Fighting the TB Epidemic in Children and Adolescents: Game-Changing Advances in Pediatric TB</td>
<td>103 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>207</td>
<td>Infectious Complications of Immunomodulatory Biologic Agents: Risk Assessment, Diagnosis, and Management</td>
<td>209 ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>208</td>
<td>Leveraging Social Media for Professional Success</td>
<td>143 ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>209</td>
<td>OPAT Update</td>
<td>204 ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>210</td>
<td>Registration Trials versus Clinical Practice: Challenges Associated with Newly Approved Antimicrobials</td>
<td>144 ABC</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>211</td>
<td>Teamwork! Collaboration and Antimicrobial Stewardship</td>
<td>201</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>212</td>
<td>The Who, What, Why, When of the GeoSentinel Surveillance Network and Emerging Infectious Diseases</td>
<td>147 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>213</td>
<td>Updates from NHSN and the HICPAC NHSN Work Group</td>
<td>206</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>214</td>
<td>Rapid Diagnostics and Resistance: Making Sense of Now and the Future Part 2</td>
<td>Ballroom ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>9:15 - 10 a.m.</strong></td>
<td><strong>Named Lecture</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>215</td>
<td>John F. Enders Lecture</td>
<td>Ballroom ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td><strong>10:30 - 11:45 a.m.</strong></td>
<td><strong>Interactive</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>216</td>
<td>Challenging Cases in Transplant ID</td>
<td>Salon GHI</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>217</td>
<td>Diagnosis and Management of Congenital CMB on Both Sides of the Pond (Joint PIDS/ESPID)</td>
<td>151 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>218</td>
<td>The Embers that Keep Smoldering: A Case-Based Multidisciplinary Approach to Prosthetic Joint Infections</td>
<td>Ballroom ABC</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Symposium</strong></td>
<td><strong>219</strong></td>
<td>Advances in RSV: Preparing for Future RSV Vaccines and Immunoprophylaxis Products</td>
<td>Salon ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>220</td>
<td>Co-Morbidities and Aging</td>
<td>145 AB</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>221</td>
<td>Nurturing Young Leaders in Antimicrobial Stewardship: Year One of the LEAP Fellowship</td>
<td>152 AB</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
IDWeek 2019 Program Tracks (continued)

<table>
<thead>
<tr>
<th>Pres #</th>
<th>Session Name</th>
<th>Pres Room</th>
<th>Adult ID</th>
<th>Pediatric ID</th>
<th>Global ID</th>
<th>Trainee ID</th>
<th>HIV/TB/STD</th>
<th>Investigative</th>
<th>Transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td>222</td>
<td>Optimizing PK/PD of New Antibiotics Against MDR Organisms</td>
<td>146 ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>223</td>
<td>Tick-Tac-Toe: Tick-Borne Infections Upping the Game</td>
<td>150 AB</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>224</td>
<td>Update on Strategies ID Clinicians Can Use to Treat Opioid Use Disorder</td>
<td>207 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>225</td>
<td>US Military Research Advancing Global Health</td>
<td>202 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Oral Abstract**

| 226    | Advances/in/ID/Med/Ed                                                         | 206       | ✓        | ✓            |           |            |             |               |            |
| 227    | Novel Antimicrobials and Approaches Against MDR Organisms                    | 144 ABC   | ✓        | ✓            |           | ✓          |             |               |            |
| 228    | Pediatric Stewardship                                                        | 204 ABC   |           | ✓            | ✓         | ✓          |             |               |            |
| 229    | The End of AIDS Starts with Prevention                                       | 147 AB    | ✓        | ✓            | ✓         | ✓          |             |               |            |

**12:15 - 12:45 p.m.**

**Oral Abstract**

| 230    | Rapid Fire Poster Session: Outbreaks                                          | Hall B +C - Arena 2 | ✓        | ✓            | ✓         | ✓          |             |               |            |
| 231    | Rapid Fire Poster Session: Vaccines                                          | Hall B +C - Arena 1 |           | ✓            | ✓         | ✓          |             |               |            |

**1:45 - 3 p.m.**

**Symposium**

| 283    | A Focus on Personal Protective Equipment: How to Optimize Use to Prevent HAIs | 146 ABC   | ✓        | ✓            | ✓         | ✓          |             |               |            |
| 284    | Antivirals and Use of PCR Testing for Respiratory Viruses                     | 151 AB    | ✓        | ✓            | ✓         | ✓          |             |               |            |
| 285    | Back to Basics in Transplant ID                                              | 202 AB    | ✓        | ✓            | ✓         | ✓          |             |               |            |
| 286    | Collaborating with Public Health Partners to Improve Antibiotic Use           | Salon ABC | ✓        | ✓            | ✓         | ✓          | ✓           |               |            |
| 287    | Controversial Topics in HIV Clinical Care                                     | Salon GHI | ✓        | ✓            | ✓         | ✓          |             |               |            |
| 288    | Diagnostic Updates: Clinical Mycology                                         | 207 AB    | ✓        | ✓            | ✓         | ✓          |             |               |            |
| 289    | ID Physicians in a Value-Based World                                          | 152 AB    | ✓        | ✓            | ✓         | ✓          | ✓           |               |            |
| 290    | Impact of Early Life Microbiome Disruptions in the Child                      | 150 AB    | ✓        | ✓            | ✓         | ✓          |             |               |            |
| 291    | Maternal Immunization: Progress and Challenges                               | 145 AB    | ✓        | ✓            | ✓         | ✓          |             |               |            |
| 292    | The Etiology of Community-Acquired Pneumonia: How Appropriate are Current Guidelines? | Ballroom ABC | ✓        | ✓            | ✓         | ✓          |             |               |            |

**Oral Abstract**

| 293    | Clinical Trials that May Change your Practice                                 | 144 ABC   | ✓        | ✓            | ✓         |           |             |               |            |
| 294    | Late Breaker Oral Abstract Session 3                                          | 209 ABC   |           | ✓            | ✓         | ✓          |             |               |            |
| 295    | Microbiome Science                                                            | 147 AB    | ✓        | ✓            |           | ✓          |             |               |            |
| 296    | New Insights into MDRO Gram-Negatives                                         | 204 ABC   | ✓        | ✓            |           | ✓          |             |               |            |
| 297    | Pediatric Viral and Fungal Diseases                                           | 206       | ✓        | ✓            | ✓         | ✓          |             |               |            |

continued on next page
# IDWeek 2019 Program Tracks (continued)

<table>
<thead>
<tr>
<th>Pres #</th>
<th>Session Name</th>
<th>Pres Room</th>
<th>Adult ID</th>
<th>Pediatric ID</th>
<th>Global ID</th>
<th>Trainee ID</th>
<th>Epi/Infection Control</th>
<th>HIV/TB/STD</th>
<th>Investigative</th>
<th>Transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:15 - 4:30 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Interactive</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>298</td>
<td>This Year’s Innovations in Pediatric Infectious Diseases</td>
<td>207 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Symposium</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>299</td>
<td>Diagnosis and Management of Cryptococcal Meningitis</td>
<td>Ballroom ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>300</td>
<td>Hot Topics in Pediatric Infection Prevention</td>
<td>152 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>301</td>
<td>HPV Update</td>
<td>151 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>302</td>
<td>Innovative Models for Retention in HIV Care</td>
<td>150 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>303</td>
<td>Laboratory Diagnosis and Susceptibility Testing of Non-Tuberculous Mycobacteria</td>
<td>Salon ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>304</td>
<td>Mechanistic Basis of Action and Resistance of B-Lactam/B-Lactamase Inhibitors</td>
<td>Salon GHI</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>305</td>
<td>Opportunistic Infections in the ICU: From Pathophysiology to Practical Approaches</td>
<td>146 ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>306</td>
<td>Success Stories in Telehealth</td>
<td>145 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>307</td>
<td>The Compromised Immuno-compromised Host</td>
<td>202 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oral Abstract</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>308</td>
<td>Fungi: Blood, Sweat, and Genes</td>
<td>144 ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>309</td>
<td>Glass Half Full or Half Empty? Trends in Antimicrobial Prescribing</td>
<td>147 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>310</td>
<td>Hepatitis C: Progress on Elimination and Treatment</td>
<td>204 ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>311</td>
<td>Vaccination II - Other</td>
<td>206</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:45 - 5:15 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Named Lecture</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>312</td>
<td>Maxwell Finland Lecture</td>
<td>Ballroom ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>5:15 - 6:00 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>313</td>
<td>ID BugBowl</td>
<td>Ballroom ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td><strong>Sunday, October 6</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 - 9 a.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mini-Symposium</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>314</td>
<td>A Precision Approach to the Management of Early Onset Neonatal Sepsis</td>
<td>201</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>315</td>
<td>Hot Topics in Outpatient Antimicrobial Therapy of Infective Endocarditis</td>
<td>206</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>316</td>
<td>How our Minds Respond to our Microbiome</td>
<td>202 AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>9:15 - 10:45 a.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Plenary Session</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>317</td>
<td>Closing Plenary</td>
<td>Ballroom ABC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>
PW01. Pre-meeting Workshop
The Vincent T. Andriole ID Board Review Course ($)
Tuesday, 8 a.m. – 5 p.m. Salon GHI

Objectives: At the conclusion of this session, participants will be able to:
- discuss and apply updated information on diagnosis and treatment of sexually transmitted infections
- assess and apply current trends in diagnosis and treatment of Tuberculosis and other mycobacteria
- discuss the diagnosis and treatment of Rickettsial and other tick-borne diseases
- discuss common parasitic disease infections including their diagnosis and treatment
- recognize and apply in diagnostic and therapeutic ways the epidemiologic, tempo, and sign/symptom features of important bacterial infections
- assess and apply components of effective infection control/prevention programs
- discuss the most common non-infectious causes of elevated temperature
- identify and apply characteristic pharmacologic and clinical features of antimicrobial agents used in treating the spectrum of clinical infections
- discuss and apply updated information on nervous system infections and their non-infectious mimics
- assess and apply current trends in HIV care

Intended Audience: Clinicians, Infectious Diseases Physicians

Moderators:
PATTY WRIGHT, MD; Vanderbilt University Medical Center, Nashville, TN
GEORGE KARAM, MD; Louisiana State Univ Med Sch, Baton Rouge, LA

Speakers:
(W1) 8:15 a.m. Sexually Transmitted Diseases
KHALIL GHANEM, MD, PHD, FIDSA; Johns Hopkins, Baltimore, MD

(W2) 8:50 a.m. TB and Other Mycobacteria
LISA Y. ARMITIGE, MD, PHD; Heartland National TB Center, San Antonio, TX

(W3) 9:25 a.m. Vectorborne Infections
CHRIS OHL, MD, FIDSA; Wake Forest School of Medicine, Winston Salem, NC

(W4) 10:15 a.m. Parasitic Diseases
PHILIP BUDGE, MD, PHD; Washington University, St. Louis, MO

(W5) 10:50 a.m. Bacterial Syndrome Pearls
SOUHA S. KANJ, MD, FIDSA; American University of Beirut Medical Center, Beirut, Lebanon

(W6) 11:25 a.m. Infection Control/Prevention
CATHERINE S. O’NEAL, MD; Louisiana State University Health Baton Rouge, Baton Rouge, LA

(W7) 1:00 p.m. Non-Infectious Causes of Elevated Temperature
BARBARA TAYLOR, MD, MS, FIDSA; University of Texas Health Science Center San Antonio, TX

PW02. Pre-meeting Workshop
Best Practices for Antimicrobial Stewardship Programs ($)
Tuesday, 8 a.m. – 5 p.m. 207 AB

Objectives: At the conclusion of this session, participants will be able to:
- evaluate components of effective antimicrobial stewardship programs and implement interventions in their healthcare setting
- review and apply strategies for implementing process and outcomes measures
- apply antimicrobial stewardship interventions for unique populations and across healthcare settings
- critically assess available data, including pharmacy and microbiology data, needed to support antimicrobial stewardship in their institution

Intended Audience: Hospital Epidemiologists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Microbiologists, Nurses, Pharmacists, Public Health Practitioners

Moderators:
JASON NEWLAND, MD, MED, FPIDS; Washington University, St. Louis, MO
EMILY S. SPIVAK, MD, MHS, FIDSA; University of Utah, Salt Lake City, UT

Speakers:
(W13) 8:00 a.m. A Syndrome-Specific Stewardship Intervention Focusing on Asymptomatic Bacteriuria (ASB)
TIMOTHY C. JENKINS, MD; Denver Health Medical Center, University of Colorado School of Medicine, Denver, CO

8:25 a.m. Q&A
Scientific Sessions (continued)

(W14) 8:35 a.m. Clinical and Formulary Considerations for New Agents to Treat Resistant Gram-negative Bacteria: A Stewardship Perspective
ERIN K. MCCREARY, PHARMD, BCPS, BCIDP; University of Pittsburgh, Pittsburgh, PA

9:00 a.m. Q&A

(W15) 9:10 a.m. Vancomycin AUC Dosing
MARISA HOLUBAR, MD, MS; Stanford University School of Medicine, Stanford, CA

9:35 a.m. Q&A

(W16) 10:00 a.m. Panel Discussion: Oral Versus IV Antibiotics for Serious Infections Including Osteomyelitis, Bacteremia and Endocarditis
EMILY S. SPIVAK, MD, MHS, FIDSA; University of Utah School of Medicine, Salt Lake City, UT
TIMOTHY C. JENKINS, MD; Denver Health Medical Center, University of Colorado School of Medicine, Denver, CO

(W17) 10:45 a.m. Group Work: Developing an Elevator Speech to Promote and Obtain Resources for Your Stewardship Program
JOHN B. LYNCH, MD; University of Washington, Seattle, WA

(W18) 11:30 a.m. Lunch

(W19) 1:15 p.m. Penicillin Allergy Assessment and Interventions
REBEKAH WRENN, PHARMD, BCPS; Duke University, Durham, NC

1:40 p.m. Q&A

1:50 p.m. Update on National Stewardship Activities
ARJUN SRIWASAN, MD, FSHEA; Centers for Disease Control and Prevention, Atlanta, GA

2:15 p.m. Q&A

(W20) 2:25 p.m. Group Work: Utilizing the SAAR to Improve Antibiotic Use in Your Hospital
EDWARD A. STENHEJEM, MD, MSC; Intermountain Healthcare, Salt Lake City, UT

3:00 p.m. Discussion/Report Out

3:15 p.m. Break

(W21) 3:30 p.m. Antimicrobial Stewardship at Discharge
PRIYA NORI, MD; Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY

3:55 p.m. Q&A

(W22) 4:05 p.m. Financial Analysis of your ASP
SARAH K. PARKER, MD; Children’s Hospital Colorado, Aurora, CO

4:30 p.m. Q&A

(W23) 4:40 p.m. Wrap up and Final Thoughts
EMILY S. SPIVAK, MD, MHS, FIDSA; University of Utah, Salt Lake City, UT
JASON NEWLAND, MD, MED, FPIDS; Washington University, St. Louis, MO

Maximum of 7.5 hours of AMA PRA Category 1 Credit™
ACPE 7.5 knowledge-based contact hours of pharmacy CE; 0221-9999-19-301-L04-P

Adult ID/Investigative ID/Trainee

PW03. Pre-meeting Workshop
Research Training Programs and Grant Writing Strategies for ID Physician-Scientists ($) 
Tuesday, 1 – 5 p.m. 102 AB

Objectives: At the conclusion of this session, participants will be able to:
• examine career paths for ID physician-scientists in government, academia, and industry and determine the best research opportunities for individual applicants
• list the categories of grant mechanisms (what they are and which career stages they are intended to support) and successful grantmanship strategies, including specific aims development
• explain how to set the best trajectory for a successful ID physician-scientist career, reduce inefficiency, and build best practices by refining career pathways and aligning training goals with those pathways

Intended Audience: Fellows, Members-in-Training, Medical Students and Residents

Speakers:

(W26) 1:00 p.m. Types of Research Training and Career Development Mechanisms
SHAWN DREW GAILLARD, PHD; Bethesda, MD
ROSEMARY MCKAIG, PHD, MPH; Bethesda, MD

(W27) 1:45 p.m. Intro to Research Careers at the VA
THERESA GLEASON, PHD; Washington, DC
MARK H. ROLTSCH, PHD; Washington, DC
JANE K. BATTLES, PHD; Washington, DC

(W28) 2:30 p.m. Intro to Research Careers in Industry
CHRISTINE C. GINOCCHIO, PHD, MT(ASCP); Durham, NC

(W29) 3:15 p.m. Grant-Writing Strategies
JATIN M. VYAS, MD, FIDSA; Boston, MA
ROSEMARY MCKAIG, PHD, MPH; Bethesda, MD

(W30) 4:00 p.m. Physician-Scientist Panel
JATIN M. VYAS, MD, FIDSA; Boston, MA
UPINDER SINGH, MD, FIDSA; CA
LINDEN HU, MD, FIDSA; Boston, MA
MARIA L. ALCAIDE, MD, FIDSA; University of Miami Miller School of Medicine, Miami, FL

4:30 p.m. Table Talks and Small Group Breakouts

Maximum of 4 hours of AMA PRA Category 1 Credit™
ACPE 4 knowledge-based contact hours of pharmacy CE; 0221-9999-19-304-L04-P

Adult ID/HIV/TB/STD

PW04. Pre-meeting Workshop
Medication Assisted Treatment Waiver Course ($) 
Tuesday, 1 – 5 p.m. 103 AB

Objectives: At the conclusion of this session, participants will be able to:
• complete the training required to apply for a waiver to prescribe buprenorphine to their patients with opioid dependence (addiction)
• identify and assess patients who are appropriate for treatment with buprenorphine
• use the knowledge concerning the use of buprenorphine to manage opioid dependence in the outpatient setting
• discuss the psychiatric and medical co-morbidities associated with opioid addiction

Intended Audience: Clinicians, Healthcare Workers, HIV Clinicians, HIV Specialists, Infection Preventionists, Infectious Diseases Physicians

Moderators and Instructors:
JOSHUA A. BAROCAS, MD; Boston University, Boston, MA
LAURA FANUCCHI, MD, MPH; University of Kentucky, Lexington, KY

Speakers:
(W31) 1:00 p.m. Overview: Opioid Use Disorder Treatment with Buprenorphine/Naloxone
(W32) 1:40 p.m. Patient Evaluation
(W33) 2:30 p.m. Specialty Topics
(W34) 3:00 p.m. Case Study
(W35) 3:15 p.m. Medication Assisted Treatment Clinical Application
(W36) 3:45 p.m. Case Study
(W37) 4:00 p.m. Urine Drug Testing
(W38) 4:20 p.m. Case Study
(W39) 4:35 p.m. Overview of Clinical Tools
(W40) 4:45 p.m. Completing the Notification of Intent Waiver Form

Maximum of 4 hours of AMA PRA Category 1 Credit™

ACPE 4 knowledge-based contact hours of pharmacy CE; 0221-9999-19-303-L01-P

Scientific Sessions (continued)

• A Man with Newly-Diagnosed ATLL and Sudden-Onset Respiratory Distress
SAMAN NEMATOLLahi, MD; Johns Hopkins, Baltimore, MD

(W43) 8:15 a.m. When the Answer Lies in the Name
TULIP JHAPERI, MD; Tufts Medical Center, Boston, MA

(W44) 8:30 a.m. Rash in an Immunocompromised Patient
JESSICA MARAIA Hughes, MD; University of Ottawa, Ottawa, ON

(W45) 8:45 a.m. An Otherwise Healthy Man with Unrelenting Headaches
PANKAJ PAL, MD, PhD; Beth Israel Deaconess Medical Center, Boston, MA

(W46) 9:00 a.m. A Young Woman with Lupus Presenting in Late Winter with Cough
JOSE A. MORILLAS, MD; Cleveland Clinic Foundation, Cleveland, OH

(W47) 9:15 a.m. A Man with a Kidney Transplant Presents with Subacute Diplopia
LUIS PARRA-RODRIGUEZ, MD; John H. Stroger Jr. Hospital of Cook County, Chicago, IL

(W48) 9:30 a.m. A Progressive Uterating Facial Lesion in a Ugandan Man with HIV
ELIZABETH ANNE GULLEEN, MD; University of Virginia, Johnston, IA

(W49) 10:00 a.m. Antimicrobial Stewardship
NEIL FISHMAN, MD, FSHEA; Hospital of the University of Pennsylvania, Philadelphia, PA

(W50) 10:00 a.m. Careers in Industry
JOEL GALLANT, MD, MPH, FIDSA; Gilead Sciences Inc., Foster City, CA

(W51) 10:00 a.m. Clinical Practice
SEEKA MEHTA, MD, MSC; Johns Hopkins, Baltimore, MD

(W52) 10:00 a.m. Global Health
(W53) 10:00 a.m. Healthcare Epidemiology and Infection Control
TRISH M. PERL, MD, MSC, FIDSA, FSHEA; University of Texas Southwestern, Dallas, TX

(W54) 10:00 a.m. Medical Education
BRIAN SCHWARTZ, MD; University of California, San Francisco, San Francisco, CA

(W55) 10:00 a.m. Careers in Public Health
SARAH KABBANI, MD, MSC; Centers for Disease Control and Prevention, Atlanta, GA

(W56) 10:00 a.m. Research-Based Careers
AMITA GUPTA, MD; Johns Hopkins, Baltimore, MD

ROBERT T. SCHOOLEY, MD, FIDSA; University of California, San Diego, San Diego, CA

PW05. Pre-meeting Workshop
Fellows’ Day Workshop ($)
Wednesday, 8 a.m. – noon 151 AB

Objectives: At the conclusion of this session, participants will be able to:
• discuss challenging infectious disease cases and approaches to differential diagnosis
• describe career pathways in at least two different infectious disease fields
• develop an initial action plan in pursuit of a post-fellowship position

Intended Audience: Fellows, Members-in-Training, Medical Students and Residents

Moderators:
RAJESH GANDHI, MD, FIDSA; Harvard Medical School
MICHAEL MELIA, MD; Johns Hopkins, Baltimore, MD

Speakers:
(W41) 8:00 a.m. ID Images Expert Panelists
SARAH TURBET
NATASHA CHIDA
CARLOS DEL RIO, MD, FIDSA; Rollins School of Public Health of Emory University, Decatur, GA

STUART COHEN, MD, FIDSA, FSHEA; University of California, Davis, Sacramento, CA
Scientific Sessions (continued)

(W57) 10:00 a.m.  **Transplant/Oncology Infectious Diseases**  
RICARDO M. LA HOZ, MD; University of Texas Southwestern, Dallas, TX  
BARBARA D. ALEXANDER, MD, MHS, FIDSA; Duke University, Durham, NC  

No CME is offered for this session.  
No CPE credit is offered for this session.

Pediatric ID/Trainee

PW06. Pre-meeting Workshop  
**Pediatric Fellows’ Day Workshop ($)**  
Wednesday, 7:45 a.m. – noon  152 AB

**Objectives:** At the conclusion of this session, participants will be able to:  
• discuss challenging infectious disease cases and approaches to patient management  
• summarize career opportunities and pathways to achieve professional goals  
• review common questions and best practices for interviewing for your first job  

**Intended Audience:** Fellows, Members-in-Training, Medical Students and Residents

**Moderators:**  
C. BUDDY CREECH, MD, MPH; Vanderbilt University Medical Center, Nashville, TN  
TANVI SHARMA, MD, MPH; Boston Children’s Hospital, Boston, MA

**Speakers:**  
7:45 a.m.  **Welcome and Introductions**  
WELCOME AND INTRODUCTIONS  
STEVEN DAHL, MD; Children’s Mercy Hospital, Kansas City, MO

(W58) 7:50 a.m.  **The Face is the Mirror of the Mind**  
STEVEN DAHL, MD; Children’s Mercy Hospital, Kansas City, MO

(W59) 8:05 a.m.  **10 Months-old Girl with Mastoiditis**  
KEVIN P. O’CALLAGHAN, MB, BCH, BAO; Children’s Hospital of Philadelphia, Philadelphia, PA

(W60) 8:20 a.m.  **An Acutely Large Tongue**  
ANDREW HAYNES, MD; Children’s Hospital Colorado, Aurora, CO

(W61) 8:35 a.m.  **The Case of the Wandering Eye**  
ANDREW S. HANDEL, MD; Stony Brook Children’s Hospital, Stony Brook, NY

(W62) 8:50 a.m.  **Twists and Turns**  
AYELET ROSENTHAL, MD, MSC; Stanford University, Palo Alto, CA

(W63) 9:05 a.m.  **18mo Female with Fever and Pancytopenia**  
ANGELIQUE ELENI BOUTZOUKAS, MD; Nationwide Children’s Hospital, Columbus, OH

(W64) 9:25 a.m.  **Best Practices for Developing Your CV and Cover Letter**  
KATHLEEN MCGANN

(W65) 10:00 a.m.  **Career in Transplant**  
JASON NEWLAND, MD, MEd, FPIDS; Washington University, St. Louis, MO

(W66) 10:00 a.m.  **Global Health/Clinical Trials**  
KARIN NIELSEN-SAINES, MD; David Geffen UCLA School of Medicine, Los Angeles, CA

(W67) 10:00 a.m.  **Public Health**  
MONIQUE FOSTER

(W68) 10:00 a.m.  **Transplant Medicine**  
DANIEL DULEK, MD; Vanderbilt University Medical Center, Nashville, TN  

No CME is offered for this session.  
No CPE credit is offered for this session.

Pediatric ID/Trainee

PW07. Pre-meeting Workshop  
**TB Workshop ($)**  
Wednesday, 8 a.m. – noon  103 AB

**Objectives:** At the conclusion of this session, participants will be able to:  
• review the latest diagnostics tools for TB  
• apply treatment risk-based treatment strategies for treating latent TB in the US  
• recognize the role of malnutrition in TB management and outcomes  
• integrate the latest evidence-based strategies for management of TB infection  

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists, Vaccinologists

**Moderators:**  
HANA M. EL SAHLY, MD; Baylor College of Medicine, Houston, TX  
SOUMYA CHATTERJEE, MD; Saint Louis University, St. Louis, MO

**Speakers:**  
(W69) 8:00 a.m.  **Advances in Tuberculosis Diagnostics: Implications for the Clinicians and the Researchers**  
ANNA M. MANDALAKAS, MD, PHD; Baylor College of Medicine, Houston, TX

(W70) 9:00 a.m.  **Latent TB in the US**  
SOUMYA CHATTERJEE, MD; Saint Louis University, St. Louis, MO

(W71) 10:00 a.m.  **Malnutrition and TB**  
NATASHA HOCHBERG, MD, MPH; Boston Medical Center, Boston, MA

(W72) 11:00 a.m.  **Challenging Cases in TB**  
MAUNANK SHAH, MD, PHD; Johns Hopkins, Baltimore, MD

Maximum of 4 hours of AMA PRA Category 1 Credit™  
ACPE 4 application-based contact hours of pharmacy CE; 0221-9999-19-308-L01-P

Pediatric ID/Trainee

PW08. Pre-meeting Workshop  
**Hepatitis C Workshop ($)**  
Wednesday, 8 a.m. – noon  201

**Objectives:** At the conclusion of this session, participants will be able to:  
• discuss how to design the treatment options for HCV patients according to their RAVS, treatment experience, HCV genotype, and disease stage
• compare methods for staging liver disease
• distinguish steatosis from steatohepatitis
• explain how to diagnose common liver diseases

**Intended Audience:** Clinicians, HIV Clinicians, HIV Specialists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Pharmacists

**Moderators:**
ELIOT GODOFSKY, MD, FIDSA; University Hepatitis Center, Bradenton, FL
DAVID THOMAS, MD, FIDSA; Johns Hopkins, Baltimore, MD

**Speakers:**

- **(W73) 8:00 a.m.** Introduction
  ELIOT GODOFSKY, MD, FIDSA; University Hepatitis Center, Bradenton, FL

- **(W74) 8:10 a.m.** Staging Liver Disease
  DAVID THOMAS, MD, FIDSA; Johns Hopkins, Baltimore, MD

- **(W75) 8:30 a.m.** Treatment and Retreatment
  DAVID L. WYLES, MD, FIDSA; Denver Health, Denver, CO

- **(W76) 9:00 a.m.** Beyond Treatment: Substance Abuse and Other Post SVR Issues
  OLUWASEUN FALADE-NWULIA, MBBS, MPH; Johns Hopkins, Baltimore, MD

- **(W77) 9:30 a.m.** Top 5 Mistakes ID Docs Make with the Liver
  DOUGLAS T. DIETERICH, MD; Mount Sinai Health System, New York, NY

- **(W78) 9:30 a.m.** HBV: Current and Future Treatment
  CHLOE THIO, MD, FIDSA; Johns Hopkins, Baltimore, MD

**Maximum of 4 hours of AMA PRA Category 1 Credit™**

**ACPE 4 knowledge-based contact hours of pharmacy CE; 0221-9999-19-306-L01-P**

---

**PW09. Pre-meeting Workshop**

**Infectious Diseases ABIM Recertification: Self-Evaluation of Medical Knowledge, IDSA Module: General Infectious Diseases 2019 ($)**

Wednesday, 8 a.m. – 12:30 p.m. 150 AB

**Objectives:** At the conclusion of this session, participants will be able to:
• identify gaps in infectious diseases medical knowledge where further study is needed for board preparation and patient management
• improve competence in the area of infectious diseases medicine regarding diagnosis, treatments, and other aspects of patient management
• evaluate and revise patient management strategies
• improve clinical decision-making skills in infectious diseases medicine

**Intended Audience:** Clinicians, Infectious Diseases Pediatricians, Infectious Diseases Physicians

**Moderators and Instructors:**
CHRIS OHL, MD; Wake Forest School of Medicine, Winston Salem, NC

**Maximum of 4 hours of AMA PRA Category 1 Credit™**

**ACPE 4 knowledge-based contact hours of pharmacy CE; 0221-9999-19-306-L01-P**

---

**PW10. Pre-meeting Workshop**

**How to Use EBM/GRADE to Develop Guidelines ($)**

Wednesday, 8 a.m. – noon 102 AB

**Objectives:** At the conclusion of this session, participants will be able to:
• explain the guideline development process utilized by IDSA including: initiation of guidelines, scope, question formulation, searching for evidence, evidence synthesis, and recommendation development using Grading of Recommendation Assessment, Development and Evaluation framework (GRADE) methods
• discuss GRADE methods as a means to rate the quality/certainty of the underlying evidence and the grading of the strength and direction of recommendation

**Intended Audience:** Clinicians, Fellows, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Medical Students and Residents, Members-in-Training, Researchers, Scientists, Vaccinologists

**Moderators:**
PAUL ALEXANDER, PHD; Infectious Diseases Society of America, Arlington, VA
REED SIEMIENIEK, MD; Infectious Diseases Society of America, Arlington, VA

**Instructor:**
YNGVE FALCK-YTTER, MD, AGAF; Case Western Reserve University, Cleveland, OH

- 8:00 a.m. Welcome and Course Overview
- 8:05 a.m. Creating Trustworthy Clinical Practice Guidelines: From Asking the Right Questions to Building a Methodologically Rigorous Foundation
  PAUL ALEXANDER, PHD; Infectious Diseases Society of America, Arlington, VA
- 8:30 a.m. GRADE Overview: Rating Down and Rating Up
- 10:00 a.m. Exercise: Otitis Media – Rate the GRADE
- 10:30 a.m. Overview: Evidence-to-Decision Framework
- 10:45 a.m. Balancing Outcomes: Patients’ Values and Preferences
- 11:00 a.m. Exercise: Hepatitis C – From Evidence to Recommendation
- 11:30 a.m. Questions, Practical Considerations of Guideline Development
- 11:45 a.m. Adjourn

**Maximum of 4 hours of AMA PRA Category 1 Credit™**

No CPE credit is offered for this session.
### PW11. Pre-meeting Workshop

**Expanding Antibiotic Stewardship into Outpatient Settings ($)**

**Wednesday, 8 a.m. – noon 143 ABC**

**Objectives:** At the conclusion of this session, participants will be able to:
- describe a framework and key targets for implementing outpatient antibiotic stewardship
- develop approaches to data collection and/or data systems to facilitate tracking and reporting of outpatient antibiotic use
- identify currently available antibiotic prescribing quality measures that can be used by a health care system or individual providers to assess progress
- recommend interventions to improve antibiotic prescribing, such as prescriber audit and feedback, behavioral modification strategies, and communication training
- identify partnerships and policies to facilitate stewardship activities

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Medical Students and Residents, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists

**Moderators:**
- LAURI HICKS, DO; Centers for Disease Control and Prevention, Atlanta, GA
- DAVID Y. HYUN, MD; The Pew Charitable Trusts, Washington, DC

**Speakers:**
- **Morning Edition: Introduction and Workshop Overview**
  - LAURI HICKS, DO; Centers for Disease Control and Prevention, Atlanta, GA

- **All Things Considered: Outpatient Antibiotic Use and the Core Elements of Outpatient Antibiotic Stewardship**
  - KATHERINE E. FLEMING-DUTRA, MD; Centers for Disease Control and Prevention, Atlanta, GA

- **How I Built This: Personal Experiences from Inpatient Stewards Expanding Their Influence to the Outpatient Setting**
  - EDWARD A. STENEHJEM, MD, MSC; Intermountain Healthcare, Salt Lake City, UT
  - LISA DUMKOW, PHARMD, BCPS, BCIDP; Mercy Health Saint Mary's, Grand Rapids, MI

- **Marketplace: Tracking and Reporting of Outpatient Antibiotic Use and Quality Measures**
  - JEFFREY GERBER, MD, PHD; Children's Hospital of Philadelphia, Philadelphia, PA
  - KATIE RICHARDS, MPH; Health Quality Innovators, Richmond, VA

**Break**

### PW12. Pre-meeting Workshop

**Introductory Training for Clinical Performance Improvement**

**Wednesday, 8 a.m. – noon 147 AB**

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss various performance improvement methodologies and their relation to traditional scientific methods
- utilize standard performance improvement tools for chartering, team building, discovery, rapid cycle change, and run and control charts for displaying data
- discuss why ID physicians pursuing performance improvement, antimicrobial stewardship, and infection control and prevention are well-positioned for leadership roles
- develop a performance improvement research manuscript according to best practices
- identify appropriate outlets for publication and presentation for performance improvement research
- identify appropriate grant funding opportunities for performance improvement research

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, HIV Clinicians, HIV Specialists, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians

**Speakers:**
- **Introduction to Performance Improvement**
  - THERESA MADALINE, MD, FIDSA, FSHEA; University of Iowa Hospitals and Clinics, Iowa City, IA

- **Performance Improvement Tools and Data Management**
  - FRAN GRIFFIN, RRT MPA; Fran Griffin & Associates LLC, Neptune, NJ

- **ID Physicians as Performance Improvement Leaders**
  - MICHAEL EDMOND, MD, MPA, MPH, MBA, FIDSA, FSHEA; University of Iowa Hospitals and Clinics, Iowa City, IA
1. Interactive

**Challenging Cases in Pediatric Infectious Diseases**
Wednesday, 1:30 – 3:15 p.m. 146 ABC

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss the clinical presentation and diagnostics of challenging cases in infectious diseases
- describe atypical presentations of certain Infectious Diseases
- discuss clinical presentations mimicking Infectious Diseases

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Medical Students and Residents, Pharmacists

**Interactive Moderators:**
- MORVEN S. EDWARDS, MD, FIDSA; Baylor College of Medicine, Houston, TX
- PIA S. PANNARAJ, MD, MPH; Children’s Hospital Los Angeles, Los Angeles, CA

**Panelists:**
- SHANNON ROSS, MD, MSPH, FIDSA; University of Alabama at Birmingham, Birmingham, AL
- ALISON TRIBBLE, MD; University of Michigan, Ann Arbor, MI
- MATTHEW KRONMAN, MD, MSCE; Seattle Children’s Hospital, Seattle, WA
- BENJAMIN HANISCH, MD; Children’s National Health System, Washington, DC

Maximum of 1.75 hours of AMA PRA Category 1 Credit™
ACPE 1.75 knowledge-based contact hours of pharmacy CE; 0221-9999-19-312-L04-P

2. Symposium

**Antimicrobial Resistance and Stewardship Across the Globe**

*Co-organized with the Japanese Association of Infectious Diseases*

Wednesday, 1:30 – 3:15 p.m. 202 AB

**Objectives:** At the conclusion of this session, participants will be able to:
- summarize the status of global antimicrobial stewardship efforts
- discuss activities in promoting and implementing antimicrobial stewardship in Japan, the Eastern Mediterranean and Mexico
- describe the landscape of antimicrobial resistance and trends in Asia, the Eastern Mediterranean and Central America

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Microbiologists, Pharmacists, Public Health Practitioners

Moderators:
- CHRIS OHL, MD; Wake Forest School of Medicine, Winston Salem, NC
- KAZUHIRO TATEDA, PHD; Toho University, Tokyo, Japan

Speakers:
1. 1:30 p.m. **CDC’s Core Elements of Antibiotic Stewardship Programs in Resource-Limited Settings**
   RACHEL SMITH, MD, MPH; Centers for Disease Control and Prevention, Decatur, GA

2. 1:55 p.m. **Controlling MDROs Through Stewardship in Asia: Initiatives in Japan**
   MASAHIRO ISHIKANE, MD, PHD; National Center for Global Health and Medicine Hospital, Shinjuku, Tokyo, Japan

3. 2:20 p.m. **Antimicrobial Resistance and Stewardship in the Eastern Mediterranean**
   BASSIM ZAYED, MD, MPH; AMR/IPC Unit, WHO/EMRO, Cairo, Egypt

4. 2:45 p.m. **Opportunities and Challenges in Implementing Antimicrobial Stewardship: Experience in Mexico.**
   ANAHI DRESER, MD, PHD; National Institute of Public Health, Mexico, Cuernavaca, Mexico

Maximum of 1.75 hours of AMA PRA Category 1 Credit™
ACPE 1.75 knowledge-based contact hours of pharmacy CE; 0221-9999-19-312-L04-P

3. Symposium

**Conundrums in Diagnosis and Management of Diarrhea**

Wednesday, 1:30 – 3:15 p.m. 145 AB

**Objectives:** At the conclusion of this session, participants will be able to:
- interpret laboratory tests for diarrhea
- manage patients with diarrheal disease
- recommend therapy for diarrheal disease

**Intended Audience:** Academicians, Clinicians, Fellows, Members-in-Training

**Moderator:**
- KAREN C. CARROLL, MD, FIDSA; Johns Hopkins University School of Medicine, Baltimore, Maryland

**Speakers:**
5. 1:30 p.m. **Management of Clostridium difficile Infection**
   STUART JOHNSON, MD, FIDSA; Hines VA Hospital, Hines, IL

6. 2:05 p.m. **Viral Gastroenteritis in the Clinic and ED: Test or Not?**
   MATTHEW BINNICKER, PHD; Mayo Clinic, Rochester, MN

7. 2:40 p.m. **Cyclospora: Epidemiology, Diagnosis and Treatment**
   ANNE STRAILY, DVM, MPH, DACVPM; Centers for Disease Control and Prevention, Atlanta, GA
4. Symposium
If I Built a Hospital: Designing to Optimize Infection Prevention
Wednesday, 1:30 – 3:15 p.m. 151 AB

Objectives: At the conclusion of this session, participants will be able to:
- discuss how design of hospitals air handling affects nosocomial infection risk
- appreciate potential benefits of newer and innovative strategies to reduce infection risk from air handling system
- discuss how design of water infrastructure affects nosocomial infection risk
- appreciate potential benefits of newer and innovative design strategies to reduce infection risk from water systems
- discuss how design of hospitals and hospital layout affect nosocomial infection risk
- appreciate potential benefits of newer and innovative hospital design strategies to reduce infection risk
- appreciate potential benefits of antimicrobial surfaces and innovative environmental disinfection strategies to reduce infection risk

Intended Audience: Epidemiologists, Fellows, Members-in-Training, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Microbiologists, Nurses, Pharmacists

Moderators:
TARA N. PALMORE, MD; National Institutes of Health, Bethesda, MD
COSTI SIFRI, MD, FIDSA; University of Virginia, Charlottesville, VA

Speakers:
(8) 1:30 p.m. The Ideal Infection Prevention Hospital: Air Handling
SHELLY L. MILLER, PHD; University of Colorado Boulder, Boulder, CO

(9) 1:55 p.m. The Ideal Infection Prevention Hospital: Water Systems
SARAH S. LEWIS, MD; Duke University, Durham, NC

(10) 2:20 p.m. The Ideal Infection Prevention Hospital: Layout and Design
CRAIG ZIMRING; Georgia Tech School of Architecture, Atlanta, GA

(11) 2:45 p.m. The Ideal Infection Prevention Hospital: Antimicrobial Surfaces
DAVID J. WEBER, MD, MPH; University of North Carolina, Chapel Hill, NC

5. Symposium
2019 Measles Outbreak
Wednesday, 1:30 – 3:15 p.m. Salon GHI

Objectives: At the conclusion of this session, participants will be able to:
- describe the details of the most recent measles outbreak in the United States in the context of recent US outbreaks, vaccination rates, and exemptions
- describe the background and status of recent international measles outbreaks, including the current Ukraine outbreak
- list specific infection control measures that are necessary when transferring and evaluating patients with potential measles exposure, infection, or complications and
- utilize practical measures to notify, screen and identify patients presenting to institutions and offices with possible measles, as well as ascertain health care worker presumptive immunity and/or required measures to document presumptive immunity


Moderators:
ROBERTA DEBIASI, MD, MS, FIDSA, FPIDS; Children’s National Health System, Washington, DC
KRISTINA A. BRYANT, MD, FPIDS; University of Louisville, Louisville, KY

Speakers:
(12) 1:30 p.m. US Outbreak: Summary of US Epi Data in General and Specific NYC Outbreak
JANE ZUCKER, MD, FIDSA; Department of Health and Mental Hygiene, Queens, NY

(13) 1:50 p.m. European Outbreak Update
SOTIRIOS TSIODRAS, MD, MSC, PHD; National & Kapodistrian University of Athens, Medical School, Athens Greece, Athens, Attiki, Greece

(14) 2:10 p.m. General Infection Control/Hospital and Office-based Preparedness
LISA MARAGAKIS, MD, MPH; Johns Hopkins, Baltimore, MD

(15) 2:35 p.m. Occupational Health Practical Issues: Ensuring Staff Immunity
HILARY BABCOCK, MD, MPH, FIDSA, FSHEA; Washington University School of Medicine, St. Louis, MO

(16) 3:00 p.m. Panel Q&A

6. Symposium
Practical Guide to the Infectious Diseases and Opioid Use Disorder Syndemic: Regional Responses
Wednesday, 1:30 – 3:15 p.m. 207 AB

No CPE credit is offered for this session.
**Objectives:** At the conclusion of this session, participants will be able to:
- recognize the leadership role for infectious diseases and HIV providers in responding to the U.S. opioid and other drug epidemics
- describe practical responses and evolving best practices in preventing and treating infections in persons who use opioids and other drugs and with opioid use disorders
- summarize key features important to effective responses to preventing and treating infections in persons who use opioids and those with opioid use disorders as well as other drugs

**Intended Audience:** Academicians, Clinicians, Health Care Workers, HIV Clinicians, HIV Specialists, Infectious Diseases Physicians, Nurses, Pharmacists, Public Health Practitioners

**Moderators:**
SANDRA ANN SPRINGER, MD; Yale University, New Haven, CT
JOSHUA A. BAROCAS, MD; Boston University, Boston, MA

**Speakers:**
(17) 1:30 p.m.  
- **Optimizing Outcomes through Multidisciplinary Inpatient Teams: Lessons from Kentucky**
  ALICE THORNTON, MD; University of Kentucky, Lexington, KY

(18) 1:55 p.m.  
- **Harm Reduction and Partnering with the Community: Lessons from Maine**
  KINNA THAKARAR, DO, MPH; Maine Medical Center/Tufts University School of Medicine, Portland, ME

(19) 2:20 p.m.  
- **Strategies for Assuming Outpatient ID/Opioid Use Disorder Care: Lessons from Denver**
  HERMIONE HURLEY, MBCHB; Denver Health, Denver, CO

(20) 2:45 p.m.  
- **Improving Screening and Treatment in Correctional Settings: Lessons from Massachusetts**
  ALYSSE GAIL WURCEL, MD, MS; Tufts Medical Center, Boston, MA

**Scientific Sessions (continued)**

**8. Plenary**

**Opening Plenary Session: From Outbreaks to -omics: Revolutionizing the Infectious Diseases Landscape in the Age of Big Data**

Wednesday, 3:45 – 5:15 p.m.  
Ballroom ABC

**Objectives:** At the conclusion of this session, participants will be able to:
- describe recent advances in the field of genomics and how they are accelerating research in a broad range of applications
- examine the implications of these advances for the diagnosis, treatment, and prevention of infectious diseases and other disorders around the globe
- list the ways in which genomic information can be used in response to emerging epidemics
- recognize the advantages of novel CRISPR-based diagnostics in combatting infectious disease outbreaks, which include direct detection from non-invasive bodily fluids, visual read-out requiring only a heat block for equipment, rapid assay development in response to an emerging outbreak, and SNP detection

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, HIV Clinicians, HIV Specialists, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Physicians, Infectious Diseases Specialists, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists, Vaccinologists

**Moderators:**
CESAR A. ARIAS, MD, MSC, PHD, FIDSA; University of Texas Health Science Center, Houston, TX
WENDY ARMSTRONG, MD, FIDSA; Emory University, Decatur, GA

**Speakers:**
(21) 1:30 p.m.  
- **What’s Hot in ID Clinical Science**
  HELEN BOUCHER, MD, FIDSA; Tufts Medical Center, Boston, MA

(22) 1:55 p.m.  
- **What’s Hot in ID Basic Science**
  DAVID A. RELMAN, MD, FIDSA; Stanford University, Palo Alto, CA

(23) 2:20 p.m.  
- **What’s Hot in HIV Basic Science**
  COLLEEN KELLEY, MD, MPH; Emory University, Decatur, GA

(24) 2:45 p.m.  
- **What’s Hot in HIV Clinical Science**
  W. DAVID HARDY, MD, AAHIVS; Johns Hopkins University School of Medicine, Baltimore, MD

**Maximum of 1.75 hours of AMA PRA Category 1 Credit™**

ACPE 1.75 knowledge-based contact hours of pharmacy CE; 0221-9999-19-311-L01-P

**HIV/TB/STD/Pediatric ID/Adult ID/Epi/Infection Control/Investigative ID/Transplant ID/Global ID/Trainee**

**7. Symposium**

**What’s Hot in ID + HIV**

Wednesday, 1:30 – 3:15 p.m.  
Ballroom ABC

**Objectives:** At the conclusion of this session, participants will be able to:
- review what is new in the field of infectious diseases using basic and clinical science
- describe what is new in the field of clinical and epidemiological sciences in HIV
- review what is new in the field of basic science and pathogenesis of HIV infection

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, HIV Clinicians, HIV Specialists, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Physicians, Infectious Diseases Specialists, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists, Vaccinologists

**Moderators:**
CESAR A. ARIAS, MD, MSC, PHD, FIDSA; University of Texas Health Science Center, Houston, TX
INGER DAMON, MD, PHD, FIDSA; Centers for Disease Control and Prevention, Atlanta, GA
### Scientific Sessions (continued)

**Speakers:**

3:45 p.m.  **Introductory Remarks**  
CESAR A. ARIAS, MD, MSC, PHD, FIDSA;  
University of Texas Health Science Center,  
Houston, TX

**SHEA Senior Scholar Award**  
Introductory Remarks: HILARY BABCOCK,  
MD, MPH, FIDSA, FSHEA; Washington  
University School of Medicine, St. Louis, MO

**AWARDEE:** ROBERT A. WEINSTEIN, MD,  
FIDSA, SHEA; Rush University Medical  
Center, Chicago, IL

**PIDS Distinguished Service Award**  
Introductory Remarks: PAUL SPEARMAN,  
MD, FIDSA; Cincinnati Children’s Hospital  
Medical Center, Cincinnati, OH

**AWARDEE:** DAVID W. KIMBERLIN,  
MD, FFIDSA; University of Alabama at  
Birmingham, Birmingham, AL

**PIDS Alexander Fleming Award for  
Lifetime Achievement**  
Introductory Remarks: CYNTHIA L. SEARS,  
MD, FIDSA; Johns Hopkins University  
School of Medicine, Baltimore, MD

**AWARDEE:** W. MICHAEL SCHELD, MD,  
FIDSA; University of Virginia Health System,  
Charlottesville, VA

**IDSA Alexander Fleming Award for  
Lifetime Achievement**

**HIVMA Clinical Educator Award**

**Introductory Remarks:** W. DAVID HARDY,  
MD, AAHIVS; Johns Hopkins University  
School of Medicine, Baltimore, MD

**AWARDEE:** CARLOS DEL RIO, MD, FIDSA;  
Rollins School of Public Health of Emory  
University, Decatur, GA

8:00 a.m.  **Welcome and Introductions**  
AMANDA JEZEK; Infectious Diseases Society of America,  
Arlington, VA

8:05 a.m.  **The Big IDea IDSA-HIVMA Advocacy Hill Day: Lessons Learned**  
PREETI N. MELANI, MD; University of  
Michigan, Ann Arbor, MI

8:20 a.m.  **The Big IDea: How to Be An ID/HIV Resource to Congress**  
PREETI N. MELANI, MD; University of  
Michigan, Ann Arbor, MI

No CME is offered for this session.

No CPE credit is offered for this session.

<table>
<thead>
<tr>
<th>HIV/TB/STD/Pediatric ID/Adult ID/Epi/Infection Control/Investigative ID/Transplant ID/Global ID/Trainee</th>
</tr>
</thead>
</table>

### Maximum of 1 hour of AMA PRA Category 1 Credit™

ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-19-316-L04-P

<table>
<thead>
<tr>
<th>HIV/TB/STD/Pediatric ID/Adult ID/Epi/Infection Control/Investigative ID/Transplant ID/Global ID/Trainee</th>
</tr>
</thead>
</table>

### 9. Women in ID Breakfast

Thursday, 7 – 8:00 a.m.  143 ABC

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, HIV Clinicians, HIV Specialists, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Lab Personnel, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists, Vaccinologists

---

**Objectives:** At the conclusion of this session, participants will be able to:

- identify opportunities for educating members of Congress and other key policymakers and advocating for infectious disease and HIV policy priorities
- describe strategies for effectively communicating with policymakers to develop relationships with policymakers and their staff and to advance policy priorities
- describe the guidelines regarding advocacy and policy education by individuals who receive federal grant funding or work for a local or state health department or other agencies

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, HIV Clinicians, HIV Specialists, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Lab Personnel, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists, Vaccinologists

**Moderators:**

AMANDA JEZEK; Infectious Diseases Society of America, Arlington, VA
ANDREA WEDDLE, MSW; HIV Medicine Association, Arlington, VA

**Speakers:**

8:00 a.m.  **Welcome and Introductions**  
AMANDA JEZEK; Infectious Diseases Society of America, Arlington, VA

8:05 a.m.  **The Big IDea IDSA-HIVMA Advocacy Hill Day: Lessons Learned**  
PREEVI N. MELANI, MD; University of  
Michigan, Ann Arbor, MI

8:20 a.m.  **The Big IDea: How to Be An ID/HIV Resource to Congress**  
PREEVI N. MELANI, MD; University of  
Michigan, Ann Arbor, MI

---

**Scientific Sessions (continued)**

**10. The Big IDea: Making the Case to Policymakers for ID and HIV Priorities**

Thursday, 7:30 – 9:00 a.m.  102 AB

**Objectives:** At the conclusion of this session, participants will be able to:

- identify opportunities for educating members of Congress and other key policymakers and advocating for infectious disease and HIV policy priorities
- describe strategies for effectively communicating with policymakers to develop relationships with policymakers and their staff and to advance policy priorities
- describe the guidelines regarding advocacy and policy education by individuals who receive federal grant funding or work for a local or state health department or other agencies

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, HIV Clinicians, HIV Specialists, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Lab Personnel, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists, Vaccinologists

**Moderators:**

AMANDA JEZEK; Infectious Diseases Society of America, Arlington, VA
ANDREA WEDDLE, MSW; HIV Medicine Association, Arlington, VA

**Speakers:**

8:00 a.m.  **Welcome and Introductions**  
AMANDA JEZEK; Infectious Diseases Society of America, Arlington, VA

8:05 a.m.  **The Big IDea IDSA-HIVMA Advocacy Hill Day: Lessons Learned**  
PREEVI N. MELANI, MD; University of  
Michigan, Ann Arbor, MI

8:20 a.m.  **The Big IDea: How to Be An ID/HIV Resource to Congress**  
PREEVI N. MELANI, MD; University of  
Michigan, Ann Arbor, MI
11. Meet the Professor
Career Navigation and Negotiation for the Infectious Diseases Practitioner
Thursday, 8 – 9 a.m. 152 AB

Objectives: At the conclusion of this session, participants will be able to:
• describe the fundamental approach to negotiation and how to anticipate barriers
• recognize how gender and emotion impact negotiation style
• create a career mission statement and identify steps to creating a five-year career plan

Intended Audience: Members-in-Training

Speakers:
(30) 8:00 a.m. Career Navigation for the ID Practitioner
ARCHANA CHATTERJEE, MD, PHD, FIDSA; University of South Dakota, Sanford School of Medicine, Sioux Falls, SD

(31) 8:00 a.m. Negotiation
SHANTA M. ZIMMER, MD; University of Colorado, Denver, CO

12. Meet the Professor
Case-Based Approach to the 2018 IDSA Guidelines on Neurocysticercosis
Thursday, 8 – 9 a.m. 206

Objectives: At the conclusion of this session, participants will be able to:
• summarize the major treatment and diagnostic tenets of the IDSA Neurocysticercosis Guidelines

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Infectious Diseases Physicians, Infectious Diseases Pediatricians, Microbiologists, Researchers, Scientists

Speakers:
(32) 8:00 a.m. Challenging Neurocysticercosis Cases: Application of Guidelines and Beyond
CHRISTINA COYLE, MD; Albert Einstein College of Medicine, Bronx, NY

(33) 8:00 a.m. Challenging Neurocysticercosis Cases: Application of Guidelines and Beyond
A CLINTON WHITE, JR., MD, FIDSA; University of Texas Medical Branch, Galveston, TX

13. Meet the Professor
Critical and Flexible Partnerships: Investigation of Hospital Outbreaks
Thursday, 8 – 9 a.m. 204 ABC

Objectives: At the conclusion of this session, participants will be able to:
• demonstrate, through case examples, sequence-based investigations of hospital outbreaks
• describe how real-time laboratory analyses can accelerate and inform outbreak investigations

Intended Audience: Clinicians, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Microbiologists, Nurses, Pharmacists

Speakers:
(34) 8:00 a.m. Meet the Professor - Speaker 1
ERIN H. GRAF, PHD, D(ABMM); Children's Hospital of Philadelphia, Philadelphia, PA

(35) 8:00 a.m. Meet the Professor - Speaker 2
JULIA S. SAMMONS, MD, MSCE; Children's Hospital of Philadelphia, Philadelphia, PA

No CPE credit is offered for this session.

14. Meet the Professor
Experience and Challenges with Vancomycin Monitoring by AUC
Co-organized with the Society of Infectious Diseases Pharmacists
Thursday, 8 – 9 a.m. 150 AB

Objectives: At the conclusion of this session, participants will be able to:
• differentiate vancomycin monitoring by trough and AUC
• formulate an institution-specific strategy to monitor vancomycin therapy
• evaluate the impact of optimal vancomycin therapy on patient outcomes


Moderators:
JASON M. POGUE, PHARMD, BCPS, BCIDP; University of Michigan, Ann Arbor, MI
VINCENT TAM, PHARMD, FIDSA; University of Houston, Houston, TX

Speakers:
(36) 8:00 a.m. Adult Experience
WILLIAM L. MUSICK, PHARMD; Houston Methodist Hospital, Houston, TX

(37) 8:00 a.m. Pediatric Experience
JENNIFER LE, PHARMD, MAS; University of California, San Diego, La Jolla, CA
15. Meet the Professor
Infection Prevention and Stewardship in Long-Term Care

Thursday, 8 – 9 a.m. 201

Objectives: At the conclusion of this session, participants will be able to:
• discuss effective strategies for post-acute and long-term care settings to implement antibiotic stewardship and infection prevention and control strategies programs

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Microbiologists, Nurses, Pharmacists, Public Health Practitioners

Moderator:
ROBIN L. JUMP, MD, PHD; Case Western Reserve University, Cleveland, OH

Speakers:
(38) 8:00 a.m. A Medical Center Director’s Perspective
DAVID A. NACE, MD, MPH; University of Pittsburgh, Pittsburgh, PA

(39) 8:00 a.m. Public Health Perspective
NIMALIE D. STONE, MD, MS; Centers for Disease Control and Prevention, Atlanta, GA

HIV/TB/STD/Adult ID/Epi/Infection Control/Trainee

16. Meet the Professor
Moving it Forward: Closing the Gender Gap

Thursday, 8 – 9 a.m. 144 ABC

Objectives: At the conclusion of this session, participants will be able to:
• describe the scope of gender disparities in medicine
• discuss the changes that are needed to achieve gender workforce equity in medicine, with a focus on the Be Ethical Campaign
• identify specific strategies to enhance career success and satisfaction


Speakers:
(40) 8:00 a.m. Moving it Forward: Closing the Gender Gap
JULIE SILVER, MD; Harvard Medical School, Boston, MA

HIV/TB/STD/Pediatric ID/Adult ID/Epi/Infection Control/Transplant ID/Global ID/Trainee

17. Meet the Professor
Our Most Difficult HIV Cases

Thursday, 8 – 9 a.m. 147 AB

Objectives: At the conclusion of this session, participants will be able to:
• identify key aspects of managing antiretroviral therapy in HIV-infected patients who are treatment experienced and/or have co-occurring conditions
• evaluate different strategies and options in selecting an antiretroviral treatment regimen for HIV-infected patients

Intended Audience: HIV Clinicians, HIV Specialists

Moderator:
VIRGINIA TRIANT, MD, MPH, FIDSA; Massachusetts General Hospital, Boston, MA

Speakers:
(42) 8:00 a.m. Our Most Difficult HIV Cases
MARIA C. RODRIGUEZ BARRADAS, MD, FIDSA; Michael E. DeBakey VAMC, Houston, TX

(43) 8:00 a.m. Our Most Difficult HIV Cases
JUDITH A. ABERG, MD; Icahn School of Medicine at Mount Sinai; Mount Sinai Health System, New York, NY

HIV/TB/STD/Adult ID/Trainee

18. Meet the Professor
Updates on Interferon-Gamma Release Assay Performance

Thursday, 8 – 9 a.m. 151 AB

Objectives: At the conclusion of this session, participants will be able to:
• describe differences in currently available interferon gamma release assays
• summarize recent literature on the use of interferon gamma release assays in pediatric populations
• determine in which groups of patients an IGRA is preferable to a tuberculin skin test

Intended Audience: Clinicians, Epidemiologists, HIV Clinicians, HIV Specialists, Hospital Epidemiologists, Infectious Diseases Physicians, Lab Personnel, Microbiologists, Public Health Practitioners

Moderator:
HEATHER YUN, MD, FIDSA; San Antonio Military Medical Center; Uniformed Services University of the Health Sciences, San Antonio, TX

Pediatric ID/Adult ID/Epi/Infection Control/Trainee

Maximum of 1 hour of AMA PRA Category 1 Credit™
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-19-320-L01-P

Maximum of 1 hour of AMA PRA Category 1 Credit™
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-19-323-L04-P

Maximum of 1 hour of AMA PRA Category 1 Credit™
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-19-318-L01-P
19. Named Lecture

**Edward H. Kass Lecture: Evolution of ID Meetings in the U.S.**

*Thursday, 9:15 – 10:00 a.m. Ballroom ABC*

**Objectives:** At the conclusion of this session, participants will be able to:
- describe the factors involved with and timing of the creation of infectious diseases as a medical specialty
- discuss evolution of annual ID meetings in the U.S. over the last 60 years
- predict the characteristics of the next pandemic infection after SARS, swine flu, Ebola and Zika

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, HIV Clinicians, HIV Specialists, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Lab Personnel, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists, Vaccinologists

**Moderator:** CESAR A. ARIAS, MD, MSC, PHD, FIDSA; University of Texas Health Science Center, Houston, TX

**Speaker:**

(46) **9:15 a.m.**

**Epidemic Infectious Diseases and Creation of the Infectious Diseases Discipline**

HERBERT DUPONT, MD; UT School of Public Health, Houston, TX

Maximum of 0.75 hours of *AMA PRA Category 1 Credit™*

ACPE 0.75 knowledge-based contact hours of pharmacy CE; 0221-9999-19-324-L04-P

20. Interactive

**Diagnostic Clinical Cases**

*Thursday, 10:30 – 11:45 a.m. 146 ABC*

**Objectives:** At the conclusion of this session, participants will be able to:
- explain the selection and interpretation of microbiologic testing to solve case-based diagnostic dilemmas in clinical infectious diseases
- synthesize laboratory and clinical data to resolve the differential diagnosis of complex clinical infectious disease cases

**Intended Audience:** Academicians, Clinicians, Fellows, Members-in-Training, Health Care Workers, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Lab Personnel, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Investigators, Scientists, Vaccinologists

21. Symposium

**We’re Part of the Problem: How ID Killed Antibiotic Development**

*Thursday, 10:30 – 11:45 a.m. 151 AB*

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Medical Students and Residents, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists

**Moderators:**

HELEN BOUCHER, MD, FIDSA; Tufts Medical Center, Boston, MA

VANCE G. FOWLER, JR., MD, MHS, FIDSA; Duke University, Durham, NC

**Speakers:**

(47) **10:30 a.m. TBD 352**

(48) **10:30 a.m. TBD 351**

(49) **10:30 a.m. TBD 350**

No CME is offered for this session.

No CPE credit is offered for this session.

22. Symposium

**Behavioral Approaches to Antibiotic Stewardship**

*Thursday, 10:30 – 11:45 a.m. 202 AB*

**Objectives:** At the conclusion of this session, participants will be able to:
- review and discuss human factors engineering approaches
- characterize IKEA effect strategies in stewardship
- discuss advantages and disadvantages of handshake stewardship approaches

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Pharmacists, Public Health Practitioners

**Moderators:**

HELEN BOUCHER, MD, FIDSA; Tufts Medical Center, Boston, MA

VANCE G. FOWLER, JR., MD, MHS, FIDSA; Duke University, Durham, NC

**Speakers:**

(47) **10:30 a.m. TBD 352**

(48) **10:30 a.m. TBD 351**

(49) **10:30 a.m. TBD 350**

No CME is offered for this session.

No CPE credit is offered for this session.
Scientific Sessions (continued)

Moderators:
EBBIN LAUTENBACH, MD, MPH, MSCE, FIDSA, FSHEA; University of Pennsylvania, Philadelphia, PA
JULIE SZYMczak, PHD; University of Pennsylvania, Philadelphia, PA

Speakers:
(50) 10:30 a.m.  Human Factors Engineering in Antibiotic Stewardship
MICHAEL PULIA, MD, MS; University of Wisconsin School of Medicine and Public Health, Madison, WI

(51) 10:55 a.m.  Leveraging the IKEA Effect for Stewardship
JONNE J. SIKKENS, MD, MSC, PHD; VU University Medical Center, Amsterdam, the Netherlands

(52) 11:20 a.m.  Handshake Stewardship: the Benefits of an In-person Approach
SARAH K. PARKER, MD; Children’s Hospital Colorado, Aurora, CO

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-330-L04-P

23. Symposium
Clinical Reasoning from Education to Practice
Thursday, 10:30 – 11:45 a.m.  143 ABC

Objectives: At the conclusion of this session, participants will be able to:
• describe the language and conceptual framework of clinical reasoning
• compare and contrast heuristics and biases commonly encountered in the context of infectious diseases case
• apply the clinical reasoning framework to diagnose, assess, and coach learners


Moderators:
JOSH NOSANCHUK, MD, FIDSA; Albert Einstein College of Medicine, Bronx, NY
BRIAN SCHWARTZ, MD; University of California, San Francisco, San Francisco, CA

Speakers:
(53) 10:30 a.m.  Clinical Reasoning from Education to Practice - Speaker #1
CARLOS M. ISADA, MD; Cleveland Clinic Foundation, Cleveland, OH

(54) 10:30 a.m.  Clinical Reasoning from Education to Practice - Speaker #2
GURPREET DHALIWAL, MD; University of California, San Francisco, San Francisco, CA

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-19-331-L04-P

24. Symposium
Clinical Trials That Might Change Your Practice
Thursday, 10:30 – 11:45 a.m.  Ballroom ABC

Objectives: At the conclusion of this session, participants will be able to:
• discuss clinical trials in mycology that might have an impact on clinical practice
• discuss clinical trials in bacteriology that might have an impact on clinical practice
• discuss clinical trials in virology that might have an impact on clinical practice

Intended Audience: Academicians, Clinicians, Fellows, Members-in-Training, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Researchers, Scientists

Moderators:
NADINE ROUPHAEL, MD, FIDSA; Emory University, Atlanta, GA
HANA M. EL SAHLY, MD; Baylor College of Medicine, Houston, TX

Speakers:
(55) 10:30 a.m.  Clinical Trials in Fungal Diseases that Might Change Your Practice
RICHARD J. HAMILL, MD, FIDSA; Baylor College of Medicine, Houston, TX

(56) 10:55 a.m.  Clinical Trials in Bacterial Diseases that Might Change Your Practice
DAVID VAN DUIN, MD, PHD, FIDSA; University of North Carolina, Chapel Hill, NC

(57) 11:20 a.m.  Clinical Trials in Viral Diseases that Might Change Your Practice
ROBIN AVERY, MD, FIDSA; Johns Hopkins, Baltimore, MD

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-332-L04-P

25. Symposium
Help or Hype? Update on Biomarkers in Management of Adult and Pediatric Infectious Diseases
Thursday, 10:30 – 11:45 a.m.  207 AB

Objectives: At the conclusion of this session, participants will be able to:
• discuss the advantages and limitations of procalcitonin in the management of sepsis and critically-ill adults and children
• evaluate the current evidence for use of procalcitonin for diagnosis and management of lower respiratory tract infections and the febrile infant
• describe biomarkers in the pipeline for the diagnosis and management of infectious diseases

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Pharmacists, Researchers

Moderator:
DAVID Y. HYUN, MD; The Pew Charitable Trusts, Washington, DC

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-333-L04-P
Speakers:

(58) 10:30 a.m.  Procalcitonin as a Marker for Sepsis - A Useful Test or the Best We Have?  
KEVIN J. DOWNES, MD; Children’s Hospital of Philadelphia, Philadelphia, PA

(59) 10:55 a.m.  Procalcitonin and Common Febrile Illnesses: Hype or Help?  
TODD A. FLORIN, MD, MSCE; Ann & Robert H Lurie Children’s Hospital of Chicago, Chicago, IL

(60) 11:20 a.m.  The Next Generation of ID Host Response Biomarkers  
EPHRAIM L. TSALIK, MD, MHS, PHD, FIDSA; Duke University, Durham, NC

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-383-L01-P

26. Symposium  
HIV State-of-the-Art  
Thursday, 10:30 – 11:45 a.m.  Salon GHI

Objectives: At the conclusion of this session, participants will be able to:
• evaluate the use of long-acting therapy in patients with HIV
• discuss new treatment options available for people living with HIV or vulnerable to HIV
• describe the state of generic antiretrovirals and their effect on HIV treatment in the U.S.

Intended Audience: HIV Clinicians, HIV Specialists

Moderator:  
ERIC DAAR, MD; Harbor-UCLA, Los Angeles, CA

Speakers:

(61) 10:30 a.m.  Long Acting Therapy on the Immediate Horizon  
JOE ERON, MD; University of North Carolina, Chapel Hill, NC

(62) 10:55 a.m.  Two Drug Therapy  
BABAFEMI O. TAIWO, MBBS; Northwestern University, Chicago, IL

(63) 11:20 a.m.  ARV Cost Containment in the Era of Generics  
TIM HORN, MS; NASTAD, Washington, DC

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-327-L02-P

27. Symposium  
New Effectors of TB Immunity: Beyond CD4 T-Cells  
Thursday, 10:30 – 11:45 a.m.  152 AB

Objectives: At the conclusion of this session, participants will be able to:
• identify the contributions, both proven and hypothesized, for antibodies in host defense against TB infection
• distinguish between the contributions of neutrophils and adaptive T-cell immunity in TB defense

28. Symposium  
One Health and Global Health Security  
Thursday, 10:30 – 11:45 a.m.  145 AB

Objectives: At the conclusion of this session, participants will be able to:
• describe the development and application of One Health methods for the advancement of global health problem solving and emerging infectious diseases
• discuss the spatial and temporal aspects of infectious disease epidemiology to support the rational implementation of disease control and intervention strategies
• illustrate the role of wildlife movement in disease introduction; the emergence of novel zoonotic viruses lethal to humans such as Nipah, Hendra, SARS, and Avian Influenza in the One Health concept

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Nurses, Public Health Practitioners, Researchers

Moderator:  
LAILA WOC-COLBURN, MD, FIDSA; Baylor College of Medicine, Houston, TX

Speakers:

(67) 10:30 a.m.  TBD 397  
ELLEN CARLIN, DVM; EcoHealth Alliance, New York, NY

(68) 10:55 a.m.  A One Health Approach to the Study and Prevention of Nipah Virus Transmission in Bangladesh  
EMILY S. GURLEY, PHD, MPH; Johns Hopkins, Baltimore, MD

• define the importance of Type I Interferon and IL1-Beta in determining TB susceptibility and disease severity


Moderator:  
MICHAEL S. GLICKMAN, MD, FIDSA, FAAM; Memorial Sloan Kettering, New York, NY

Speakers:

(64) 10:30 a.m.  Cytokine and Lipid mediator Crosstalk in M. Tuberculosis Host Defense  
KATRIN MAYER-BARBER, PHD; National Institute of Allergy and Infectious Diseases, Bethesda, MD

(65) 10:55 a.m.  New Insights into the Role of Humoral Immunity in TB Defense  
BABAK JAVID, MB, BCHIR, PHD, MRCP; Tsinghua University School of Medicine, Haidian Qu, Beijing Shi, China

(66) 11:20 a.m.  Beyond Pus: Neutrophils in Host Defense Against Tuberculosis  
CHRISTINA STALLINGS, PHD; Washington University, St. Louis, MO

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
No CPE credit is offered for this session.

PEDIATRIC ID/ADULT ID/EPIDEMIOLOGY/INFECTION CONTROL/GLOBAL ID/TRAINEE
Scientific Sessions (continued)

(69)  11:20 a.m.  TBD 399  
CHRISTINE KREUDER JOHNSON, BS, VMD, MPVM, PhD; UC Davis School of Veterinary Medicine, Davis, CA

Maximum of 1.25 hours of AMA PRA Category 1 Credit™  
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-325-L04-P

29. Symposium  
Unsolved or Uncontrolled: Public Health Challenges in Resistant Pathogens  
Co-organized with the Centers for Disease Control and Prevention  
Thursday, 10:30 – 11:45 a.m.  150 AB

Objectives: At the conclusion of this session, participants will be able to:
- describe the impact of rapid global dissemination of antimicrobial resistance on US surveillance and public health response
- describe clinically important resistance in Salmonella strains isolated from food and from food-producing animals
- identify emerging fungal pathogens with important resistance to antifungals

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Nurses, Public Health Practitioners, Researchers, Scientists

Moderators:  
PATRICIA GRIFFIN, MD, FIDSA; Centers for Disease Control and Prevention, Decatur, GA  
LOUISE FRANCOIS WATKINS, MD, MPH; Centers for Disease Control and Prevention, Atlanta, GA

Speakers:  
(70)  10:30 a.m.  Around the World in Less Than 80 days: The Rise and Rapid Global Spread of Antimicrobial Resistance in Enteric Pathogens  
LOUISE FRANCOIS WATKINS, MD, MPH; Centers for Disease Control and Prevention, Atlanta, GA

(71)  10:55 a.m.  What’s on the Menu? Multidrug-Resistant Salmonella in the Food Chain  
CINDY R. FRIEDMAN, MD; Centers for Disease Control and Prevention, Atlanta, GA

(72)  11:20 a.m.  More Fungus Among Us: How Can We Control the Spread of Emerging Resistance?  
TOM M. CHILLER, MD, MPHTM; Centers for Disease Control and Prevention, Atlanta, GA

Pediatric ID/Adult ID/Investigative ID/Transplant ID/Trainee

30. Symposium  
Vaccination and Immunocompromised Hosts: Recommendations and Knowledge Gaps  
Thursday, 10:30 – 11:45 a.m.  Salon ABC

Objectives: At the conclusion of this session, participants will be able to:
- summarize advances in the use of vaccines in immunocompromised hosts
- explain important gaps in knowledge of the use of vaccines in immunocompromised hosts
- explain the risks of vaccines in immunocompromised hosts


Moderator:  
ANDREW PAVIA, MD, FIDSA, FSHEA; University of Utah, Salt Lake City, UT, USA

Speakers:  
(73)  10:30 a.m.  Immunization of Hematopoietic Stem Cell Transplant Recipients - 2019 Update  
DEEPAK KUMAR, MD, MSC, FRCPC; University Of Toronto, Toronto, ON, Canada

(74)  10:55 a.m.  Vaccination in Solid Organ Transplantation  
LARA DANZIGER-ISAKOV, MD, MPH; Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

(75)  11:20 a.m.  Cancer and Biologic Immunosuppressants  
ALEXANDRA FREEMAN, MD; National Institute of Allergy and Infectious Diseases, Bethesda, MD

Maximum of 1.25 hours of AMA PRA Category 1 Credit™  
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-333-L06-P

31. Oral Abstract  
Not Just Your Everyday Diarrhea  
Thursday, 10:30 – 11:45 a.m.  144 ABC

Objectives for all IDWeek Oral Abstract Sessions: ALL IDWeek Oral Abstract Session objectives coincide with the IDWeek meeting objectives and are available online at www.idweek.org.

Intended Audience for all IDWeek Oral Abstract Sessions:  
Academicians, Clinicians, Epidemiologists, Fellows, Health Care Workers, HIV Clinicians, HIV Specialists, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Lab Personnel, Medical Students and Residents, Members-in-Training, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists, Vaccinologists

Moderators:  
SEEMA JAIN, MD, FIDSA; California Department of Public Health, Richmond, CA  
JENNIE H. KWON, DO, MSCI; Washington University, St. Louis, MO
Speakers:
(76) 10:30 a.m. Validation of Systemic Inflammatory Mediators as Biomarkers for Severity and Adverse Outcomes in Clostridium difficile Infection  
MICHAEL G. DIETERLE, BS; University of Michigan Medical School, Ann Arbor, MI
SCOTT C. OLSON, MD; Marshfield Clinic Research Institute, Marshfield, WI
(79) 11:07 a.m. Mucosal Interferon (IFN) Responses in Infants with Respiratory Syncytial Virus (RSV) Infection to Inform Live Attenuated Vaccine (LAV) Development  
JEANETTE TAVERAS, DO; Nationwide Children’s Hospital, Grandview Heights, OH
(81) 11:31 a.m. Oral Norovirus Vaccination in Humans Induces Plasmablast B Cell Expansion and Follicular T-Cell Activation Comparable to Natural Infection  
ROBERTO MATEO, PHD; Vaxart, Inc, San Francisco, CA
(83) 10:45 a.m. During A Million Patient-Days of Surveillance, Low Levels of Infection Prevention Staff Correlated with Higher Rates of Some Healthcare-Associated Infections  
ARTHUR W. BAKER, MD, MPH; Duke University, Durham, NC
(84) 11:00 a.m. Evaluation of the NHSN Standardized Infection Ratio (SIR) Risk Adjustment for HO-CDI in Oncology and ICU Patients in General Acute Care Hospitals  
CHRISTOPHER R. POLAGE, MD, MAS; Duke University, Durham, NC
(85) 11:15 a.m. Use of Dual Statistical Process Control Charts for Early Detection of Surgical Site Infection Outbreaks at a Community Hospital Network  
ARTHUR W. BAKER, MD, MPH; Duke University, Durham, NC
(86) 11:30 a.m. Opioid Analgesics are Associated with Increased Clostridioides difficile Infection Risk in a National Cohort of Veterans  
ERIC H. YOUNG, PHARM; University of Texas at Austin, San Antonio, TX

No CME is offered for this session.
No CPE credit is offered for this session.

32. Oral Abstract
Surveillance in Healthcare-Associated Infections  
Thursday, 10:30 – 11:45 a.m. 147 AB

Moderators:
DAVID BANACH, MD, FIDSA; UConn Health, Farmington, CT
JANE SIEGEL, MD, FIDSA, FSHEA, California Public Health Department, Richmond, CA

Speakers:
(87) 10:30 a.m. Heart and Lung Transplants from HCV-Viremic Donors to Uninfected Patients - Longer-Term Follow-Up  
ANN E. WOOLLEY, MD, MPH; Brigham and Women’s Hospital, Boston, MA
(91) 11:30 a.m. Differential Impact of Cytomegalovirus (CMV) Donor (D) Serostatus on Rates and Kinetics of CMV Viremia among CMV Seropositive Recipients (R+) of Ex-vivo T-cell Depleted (TCD) and Unmodified (CONV) Hematopoietic Cell Transplants (HCT).  
ANAT STERN, MD; Memorial Sloan Kettering, New York, NY
34. Oral Abstract

**Viral Infections - Host, Pathogen, and Impact of Intervention**

Thursday, 10:30 – 11:45 a.m. 206

### Moderators:
SANKAR SWAMINATHAN, MD, MS, FIDSA; University of Utah School of Medicine, Salt Lake City, UT
NORA T. OLIVER, MD, MPH; Emory University, Atlanta, GA

### Speakers:

- **(92) 10:30 a.m.** Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017-2019
  ANGELA BRANCHE, MD; University of Rochester, Rochester, NY

- **(93) 10:42 a.m.** Trends in the Laboratory Detection of Rotavirus Before and After Implementation of Routine Rotavirus Vaccination — United States, 2000-2018
  BENJAMIN D. HALLOWELL, PHD, MPH; Centers for Disease Control and Prevention, Atlanta, GA

- **(94) 10:55 a.m.** Pneumonia Severity Scores Poorly Predict Severe Outcomes Among Adults Hospitalized with Influenza.
  JOSHUA DOYLE, MD, PHD; Centers for Disease Control and Prevention, Decatur, GA

- **(95) 11:07 a.m.** Impact of Influenza-Like Illnesses on Academic and Work Performance on a College Campus
  ANNE EMANUELS, MPH; University of Washington, Seattle, WA

- **(97) 11:31 a.m.** Competition Experiments for the Baloxavir-Resistant I38T Influenza A Mutant
  GUY BOIVIN, MD; Centre Hospitalier Universitaire de Québec, Quebec, QC, Canada

No CME is offered for this session.
No CPE credit is offered for this session.
Nonsusceptible *Staphylococcus Aureus* Populations Associated with Tricuspid-Valve Infective Endocarditis
CHRISTOPHER R. MILLER, BA; Wayne State University, Detroit, MI
(101) 12:30 p.m.

TOMEFA E. ASEMPA, PHARMD; Hartford Hospital, Hartford, CT
(102) 12:35 p.m.

XIN YIN, MPH; Penn State College of Medicine, Hummelstown, PA
(99) 12:40 p.m.

The Accessory Genome in Enterococcal Bacteremia: Results from the Vancomycin-Resistant Enterococcal Bacteremia Outcomes Study (VENOUS)
SHELBY SIMAR, MPH; University of Texas Health Science Center, Houston, TX

36. Rapid Fire Poster
Rapid Fire Poster Session: Diagnostics
Thursday, 12:15 – 12:45 p.m. Hall B +C - Arena 1

Moderator:
PATRICIA SIMNER, PHD; Johns Hopkins, Baltimore, MD

Speakers:
(103) 12:15 p.m. Clinical Outcomes among Febrile Infants Before and After Implementation of BioFire® FilmArray® Panels
JENNIFER CROOK, BS, BA; Vanderbilt University Medical Center, Nashville, TN
(106) 12:20 p.m. Rapid Antimicrobial Susceptibility Testing using ATP Luminescence and Machine Learning Methods
SHUNSUKE KAWABE, PHD; Hitachi, Ltd., Kokubunji-shi, Tokyo, Japan
(107) 12:25 p.m. Impact of Accelerate Pheno™ Rapid Blood Culture Detection System with Real Time Notification versus Standard Antibiotic Stewardship on Clinical Outcomes in Bacteremic Patients
COURTNEY PEARSON, MD; University of Arkansas for Medical Sciences, Little Rock, AR
(104) 12:30 p.m. Performance Characteristics of an FDA Cleared Multiplex Panel for the Rapid Identification of Fungal Pathogens from Positive Blood Culture
SEAN ZHANG, MD, PHD; Johns Hopkins, Baltimore, MD
(105) 12:35 p.m. Randomized Clinical Trial Evaluating Clinical Impact of RAPid IDentification and Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia (RAPIDS-GN)
RITU BANERJEE, MD, PHD; Vanderbilt University Medical Center, Nashville, TN
(108) 12:40 p.m. Carbapenem Resistant Klebsiella (CRK) Bloodstream Infections (BSIs) are Caused by Bacterial Populations that are Genotypically and Phenotypically Diverse
MINH-HONG NGUYEN, MD; University of Pittsburgh, Pittsburgh, PA

No CME is offered for this session.
No CPE credit is offered for this session.

71. Symposium
Antimicrobial Stewardship in Compromised Hosts
Thursday, 1:45 – 3 p.m. 150 AB

Objectives: At the conclusion of this session, participants will be able to:
- identify unique challenges and opportunities in antimicrobial stewardship in solid organ transplant patients
- identify unique challenges and opportunities in antimicrobial stewardship in stem cell transplant patients
- identify unique challenges and opportunities in antimicrobial stewardship in burn patients

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Microbiologists, Public Health Practitioners, Researchers, Scientists

Moderators:
LILIAN M. ABBO, MD, FIDSA; University of Miami Miller School of Medicine & Jackson Health System, Miami, FL
KRISTINA BRYANT, MD, FPIDS; University of Louisville, Louisville, KY

Speakers:
(809) 1:45 p.m. Antimicrobial Stewardship in Solid Organ Transplant Patients
JUDITH A. ANESI, MD; University of Pennsylvania, Philadelphia, PA
(810) 2:10 p.m. Antimicrobial Stewardship in Stem Cell Transplant Patients
ELLA ARIZA, MD, FIDSA; The University of Texas MD Anderson Cancer Center, Houston, TX
(811) 2:35 p.m. Antimicrobial Stewardship in Burn Patients
ANNE LACHIEWICZ, MD, MPH; University of North Carolina, Chapel Hill, NC

Maximum of 1.25 hours of AMA PRA Category 1 Credit™ ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-336-L04-P
Scientific Sessions (continued)

72. Symposium
**Applying Contact Precautions: What’s the Best Approach to Reduce Transmission?**
Thursday, 1:45 – 3 p.m.  
Salon GHI

**Objectives:** At the conclusion of this session, participants will be able to:
- explain the reasons for focusing infection prevention efforts primarily on methicillin-resistant *Staphylococcus aureus* versus all *Staphylococcus aureus*
- determine the justification for focusing contact precautions based on patient characteristics versus based on the pathogen of interest

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Members-in-Training, Health Care Workers, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Microbiologists, Public Health Practitioners, Researchers

**Moderator:**
EBBING LAUTENBACH, MD, MPH, MSCE, FIDSA, FSHEA; University of Pennsylvania, Philadelphia, PA

**Speakers: (812)** 1:45 p.m.  
**It’s All About the “R” – Prevention Efforts Should Focus on MRSA**
MARTIN EVANS, MD; Veterans Affairs, Lexington, KY

(813) 2:04 p.m.  
**The “R” Don’t Mean a Thing – Prevention Efforts Should Include all Staphylococcus aureus**
USHAA STIEFEL, MD, FIDSA; Cleveland VA Medical Center, Shaker Heights, OH

(814) 2:23 p.m.  
**Targeting Contact Precautions: It’s about the Patient**
MARY-CLAIRES ROGHMANN, MD, MS, FIDSA, FSHEA; University of Maryland, Baltimore, MD

(815) 2:42 p.m.  
**Targeting Contact Precautions: It’s about the Pathogen**
PATRICIA W. STONE, PHD, FAAN; Columbia University School of Nursing, New York, NY

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**

No CPE credit is offered for this session.

73. Symposium
**Challenging HIV Cases**
Thursday, 1:45 – 3 p.m.  
146 ABC

**Objectives:** At the conclusion of this session, participants will be able to:
- identify complicating factors in patients with HIV
- apply strategies to address treatment complications in patients with HIV
- choose between different treatment strategies for managing patients with HIV

**Intended Audience:** HIV Clinicians, HIV Specialists

**Interactive Moderators:**
JEFF LENNOX, MD, FIDSA; Grady Memorial Hospital/Emory University School of Medicine, Atlanta, GA
ANNA PERSON, MD; Vanderbilt University Medical Center, Nashville, TN

**Panelists:**
RAJESH GANDHI, MD, FIDSA; Harvard Medical School, Boston, MA
BABAFEMI O. TAIWO, MBBS; Northwestern University, Chicago, IL
MICHELLE CESPEDES, MD, MS; Icahn School of Medicine at Mount Sinai; Mount Sinai Health System, New York, NY

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**

ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-19-335-L02-P

74. Symposium
**Clinical Interpretation and Use of Metagenomic-based Infectious Disease Diagnostics**
Thursday, 1:45 – 3 p.m.  
Salon ABC

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss how metagenomic-based tests can be applied to syndromic testing and understand the strengths and limitations of current approaches
- recognize challenges in the regulation of Metagenomic-based Infectious Disease Diagnostics
- discuss the promise and pitfalls of metagenomic sequencing for PJI pathogen identification
- discuss the future role of metagenomic sequencing in PJI pathogen investigations

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Lab Personnel, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists

**Moderator:**
KAREN C. CARROLL, MD, FIDSA; Johns Hopkins University School of Medicine, Baltimore, MD

**Speakers:**
(816) 1:45 p.m.  
**FDA Perspective on Metagenomic Sequencing in Infectious Diseases**
STEVE GITTERMAN, MD; Food and Drug Administration, Silver Spring, MD

(817) 2:10 p.m.  
**Prosthetic Joint Infections**
MATTHEW J. THOENDEL, MD, PHD; Mayo Clinic, Rochester, MN

(818) 2:35 p.m.  
**Respiratory Infections**
ROBERT SCHLABERG, MD, MPH; University of Utah, Salt Lake City, UT

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-334-L04-P
75. Symposium

**Enterovirus-Associated Neurologic Disease**
*Co-organized with the Centers for Disease Control and Prevention*

**Objectives:** At the conclusion of this session, participants will be able to:
- explain the epidemiology of acute flaccid myelitis
- discuss the spectrum of clinical disease associated with AFM
- list new associations of AFM with laboratory findings
- describe the clinical spectrum of neurologic diseases associated with enterovirus infections

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Lab Personnel, Microbiologists, Researchers, Scientists

**Moderators:**
INGER DAMON, MD, PHD, FIDSA; Centers for Disease Control and Prevention, Atlanta, GA
SUSAN GERBER, MD; Centers for Disease Control and Prevention, Atlanta, GA

**Speakers:**
- (822) 1:45 p.m. **Acute Flaccid Myelitis - National Perspective**
  MANISHA PATEL, MD, MS; Centers for Disease Control and Prevention, Atlanta, GA

- (823) 2:10 p.m. **Clinical Spectrum of Enterovirus-Associated Neurologic Disease**
  KEVIN MESSACAR, MD; University of Colorado, Aurora, CO

- (824) 2:35 p.m. **Update in Pathogenesis Including Biomarkers and Animal Models**
  STEVE OBERSTE; Centers for Disease Control and Prevention, Atlanta, GA

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**

76. Symposium

**Head Scratching Cases of MDR Gram-Negatives Other than Enterobacteriales**

**Objectives:** At the conclusion of this session, participants will be able to:
- describe key mechanisms underlying MDR
- recognize the differences among the lactose-non-fermenting organisms of clinical relevance
- identify and apply treatment options of MDR organisms in clinical practice

**Intended Audience:** Clinicians, Epidemiologists, Fellows, Members-in-Training, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Microbiologists, Pharmacists

**Moderator:**
MARCIA B. GOLDBERG, MD, FIDSA; Massachusetts General Hospital, Boston, MA

**Speakers:**
- (825) 1:45 p.m. **A Revised Landscape of the Cystic Fibrosis Lung**
  STEVEN ROWE, MD, MSPH; University of Alabama at Birmingham, Birmingham, AL

- (826) 2:10 p.m. **Advances in Invasive Aspergillus Infection**
  DON SHEPPARD, MD; McGill University, Montreal, QC, Canada

- (827) 2:35 p.m. **New Insights into Local Pulmonary Immunity to Mycobacterium Tuberculosis**
  JOANNE L. FLYNN, PHD; University of Pittsburgh, Pittsburgh, PA

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**

77. Symposium

**New Science Behind Chronic Pulmonary Infectious Diseases**

**Objectives:** At the conclusion of this session, participants will be able to:
- describe recent new insights into the distribution of cells in human tissues, including the lung, that primarily mediate the abnormalities found in cystic fibrosis
- describe recent advances in our understanding of the mechanisms involved in invasive infection due to Aspergillus species
- describe recent new insights into processes underlying pulmonary infection due to tuberculosis
- describe recent findings relating to the mechanisms underlying chronic pulmonary infection in cystic fibrosis and chronic pulmonary infection due to Aspergillus species or tuberculosis

**Intended Audience:** Academicians, Fellows, Members-in-Training, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Lab Personnel, Microbiologists, Researchers, Scientists, Vaccinologists

**Moderator:**
MARCIA B. GOLDBERG, MD, FIDSA; Massachusetts General Hospital, Boston, MA

**Speakers:**
- (828) 1:45 p.m. **Acute Flaccid Myelitis - National Perspective**
  MANISHA PATEL, MD, MS; Centers for Disease Control and Prevention, Atlanta, GA

- (829) 2:10 p.m. **Clinical Spectrum of Enterovirus-Associated Neurologic Disease**
  KEVIN MESSACAR, MD; University of Colorado, Aurora, CO

- (830) 2:35 p.m. **Update in Pathogenesis Including Biomarkers and Animal Models**
  STEVE OBERSTE; Centers for Disease Control and Prevention, Atlanta, GA

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**

No CPE credit is offered for this session.
78. Symposium
New Worries about Group A Streptococcal Disease
\textit{Co-organized with the Centers for Disease Control and Prevention}

\textbf{Thursday, 1:45 – 3 p.m.} \ 145 AB

\textbf{Objectives:} At the conclusion of this session, participants will be able to:

- explain the basis and options for different approaches to contact management
- define Group A Streptococcal carriage, its role in the epidemiology of streptococcal disease, and gaps in knowledge regarding transmission
- describe key risk groups that have contributed to the recently changing epidemiology of invasive Group A Streptococcal infections in the United States


\textbf{Moderator:} PATRICIA GRIFFIN, MD, FIDSA; Centers for Disease Control and Prevention, Decatur, GA

\textbf{Speakers:}

\begin{itemize}
  \item (828) 1:45 p.m. Recent Canadian Experience with Invasive Group A Streptococcal Disease and Guidelines for Post-Exposure Prophylaxis
    MONIKA NAUS, MD; BC CENTRE FOR DISEASE CONTROL, VANCOUVER, BC, Canada

  \item (829) 2:10 p.m. Solving the Enigma: Contribution of Carriage to Group A Streptococcal Epidemiology and Transmission
    ANTHONY R. FLORES, MD, MPH, PHD; McGovern Medical School, Houston, TX

  \item (830) 2:35 p.m. Changing Epidemiology of Invasive Group A Streptococcal Disease in the United States
    CHRIS VAN BENEDEN, MD, MPH; Centers for Disease Control and Prevention, Atlanta, GA
\end{itemize}

\textbf{Speakers:}

\begin{itemize}
  \item (831) 1:45 p.m. Vaccine Hesitancy and Policy: What Happens When States Change Their Immunization Policies
    SAAD OMER, MBBS, MPH, PHD; Emory University, Atlanta, GA

  \item (832) 2:10 p.m. Vaccine Hesitancy and the Media: Sources of Information for Parents or “Fake News”
    LENA SUN, MS; The Washington Post, Washington, DC

  \item (833) 2:35 p.m. Vaccine Hesitancy Countermeasures for Providers: Best Practices
    EVE DUBE, PHD; Inspq, Quebec, Quebec, Canada
\end{itemize}

\textbf{Moderator:} ANDREW PAVIA, MD, FIDSA, FSHEA; University of Utah, Salt Lake City, UT

\textbf{Speakers:}

\begin{itemize}
  \item (831) 1:45 p.m. Vaccine Hesitancy and Policy: What Happens When States Change Their Immunization Policies
    SAAD OMER, MBBS, MPH, PHD; Emory University, Atlanta, GA

  \item (832) 2:10 p.m. Vaccine Hesitancy and the Media: Sources of Information for Parents or “Fake News”
    LENA SUN, MS; The Washington Post, Washington, DC

  \item (833) 2:35 p.m. Vaccine Hesitancy Countermeasures for Providers: Best Practices
    EVE DUBE, PHD; Inspq, Quebec, Quebec, Canada
\end{itemize}

\textbf{Moderator:} ANDREW PAVIA, MD, FIDSA, FSHEA; University of Utah, Salt Lake City, UT

\textbf{Speakers:}

\begin{itemize}
  \item (831) 1:45 p.m. Vaccine Hesitancy and Policy: What Happens When States Change Their Immunization Policies
    SAAD OMER, MBBS, MPH, PHD; Emory University, Atlanta, GA

  \item (832) 2:10 p.m. Vaccine Hesitancy and the Media: Sources of Information for Parents or “Fake News”
    LENA SUN, MS; The Washington Post, Washington, DC

  \item (833) 2:35 p.m. Vaccine Hesitancy Countermeasures for Providers: Best Practices
    EVE DUBE, PHD; Inspq, Quebec, Quebec, Canada
\end{itemize}

\textbf{Moderator:} ANDREW PAVIA, MD, FIDSA, FSHEA; University of Utah, Salt Lake City, UT

\textbf{Speakers:}

\begin{itemize}
  \item (831) 1:45 p.m. Vaccine Hesitancy and Policy: What Happens When States Change Their Immunization Policies
    SAAD OMER, MBBS, MPH, PHD; Emory University, Atlanta, GA

  \item (832) 2:10 p.m. Vaccine Hesitancy and the Media: Sources of Information for Parents or “Fake News”
    LENA SUN, MS; The Washington Post, Washington, DC

  \item (833) 2:35 p.m. Vaccine Hesitancy Countermeasures for Providers: Best Practices
    EVE DUBE, PHD; Inspq, Quebec, Quebec, Canada
\end{itemize}

\textbf{Moderator:} ANDREW PAVIA, MD, FIDSA, FSHEA; University of Utah, Salt Lake City, UT

\textbf{Speakers:}

\begin{itemize}
  \item (831) 1:45 p.m. Vaccine Hesitancy and Policy: What Happens When States Change Their Immunization Policies
    SAAD OMER, MBBS, MPH, PHD; Emory University, Atlanta, GA

  \item (832) 2:10 p.m. Vaccine Hesitancy and the Media: Sources of Information for Parents or “Fake News”
    LENA SUN, MS; The Washington Post, Washington, DC

  \item (833) 2:35 p.m. Vaccine Hesitancy Countermeasures for Providers: Best Practices
    EVE DUBE, PHD; Inspq, Quebec, Quebec, Canada
\end{itemize}

\textbf{Moderator:} ANDREW PAVIA, MD, FIDSA, FSHEA; University of Utah, Salt Lake City, UT

\textbf{Speakers:}

\begin{itemize}
  \item (831) 1:45 p.m. Vaccine Hesitancy and Policy: What Happens When States Change Their Immunization Policies
    SAAD OMER, MBBS, MPH, PHD; Emory University, Atlanta, GA

  \item (832) 2:10 p.m. Vaccine Hesitancy and the Media: Sources of Information for Parents or “Fake News”
    LENA SUN, MS; The Washington Post, Washington, DC

  \item (833) 2:35 p.m. Vaccine Hesitancy Countermeasures for Providers: Best Practices
    EVE DUBE, PHD; Inspq, Quebec, Quebec, Canada
\end{itemize}

\textbf{Moderator:} ANDREW PAVIA, MD, FIDSA, FSHEA; University of Utah, Salt Lake City, UT

\textbf{Speakers:}

\begin{itemize}
  \item (831) 1:45 p.m. Vaccine Hesitancy and Policy: What Happens When States Change Their Immunization Policies
    SAAD OMER, MBBS, MPH, PHD; Emory University, Atlanta, GA

  \item (832) 2:10 p.m. Vaccine Hesitancy and the Media: Sources of Information for Parents or “Fake News”
    LENA SUN, MS; The Washington Post, Washington, DC

  \item (833) 2:35 p.m. Vaccine Hesitancy Countermeasures for Providers: Best Practices
    EVE DUBE, PHD; Inspq, Quebec, Quebec, Canada
\end{itemize}

\textbf{Moderator:} ANDREW PAVIA, MD, FIDSA, FSHEA; University of Utah, Salt Lake City, UT

\textbf{Speakers:}

\begin{itemize}
  \item (831) 1:45 p.m. Vaccine Hesitancy and Policy: What Happens When States Change Their Immunization Policies
    SAAD OMER, MBBS, MPH, PHD; Emory University, Atlanta, GA

  \item (832) 2:10 p.m. Vaccine Hesitancy and the Media: Sources of Information for Parents or “Fake News”
    LENA SUN, MS; The Washington Post, Washington, DC

  \item (833) 2:35 p.m. Vaccine Hesitancy Countermeasures for Providers: Best Practices
    EVE DUBE, PHD; Inspq, Quebec, Quebec, Canada
\end{itemize}

\textbf{Moderator:} ANDREW PAVIA, MD, FIDSA, FSHEA; University of Utah, Salt Lake City, UT

\textbf{Speakers:}

\begin{itemize}
  \item (831) 1:45 p.m. Vaccine Hesitancy and Policy: What Happens When States Change Their Immunization Policies
    SAAD OMER, MBBS, MPH, PHD; Emory University, Atlanta, GA

  \item (832) 2:10 p.m. Vaccine Hesitancy and the Media: Sources of Information for Parents or “Fake News”
    LENA SUN, MS; The Washington Post, Washington, DC

  \item (833) 2:35 p.m. Vaccine Hesitancy Countermeasures for Providers: Best Practices
    EVE DUBE, PHD; Inspq, Quebec, Quebec, Canada
\end{itemize}
Scientific Sessions (continued)

(835) 2:10 p.m.  Challenges with Sepsis in Post-Acute Care Settings: Recognition, Response and Regulatory Influences  
THERESA ROWE; Northwestern University, Chicago, IL

(836) 2:35 p.m.  Sepsis and Antimicrobial Stewardship: Right Drug, Right on Time  
DEVERICK J. ANDERSON, MD, MPH, FIDSA, FSHEA; Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, NC

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-338-L04-P

81. Oral Abstract  
Clostridium difficile  
Thursday, 1:45 – 3 p.m.  144 ABC

Moderators:  
SURBHI LEEKHA, MBBS, MPH; University of Maryland, Baltimore, MD  
HANA HAKIM, MD, MS, CIC; St. Jude Children’s Research Hospital, Memphis, TN

Speakers:  
(837) 1:45 p.m.  Prior Hospitalizations Among Cases of Community-Associated Clostridioides difficile Infection—10 U.S. States, 2014 - 2015  
KELLY M. HATFIELD, MSPH; Centers for Disease Control and Prevention, Atlanta, GA

(838) 2:00 p.m.  Oral Vancomycin Prophylaxis Works!  
NICHOLAS W. VAN HISE, PHARMD; Metro Infectious Disease Consultants, Burr Ridge, IL

(839) 2:15 p.m.  Effect of Clostridioides difficile (C. difficile) Toxin Test Reporting on Clinical Treatment and Outcomes of Toxin-Negative PCR-Positive Patients at Five California Hospitals  
CHRISTOPHER R. POLAGE, MD, MAS; Duke University, Durham, NC

(840) 2:30 p.m.  Clinical Failure Rates Associated with Hemin-Induced Metronidazole Resistance in Clostridioides difficile  
ANNE J. GONZALES-LUNA, PHARMD; University of Houston, Houston, TX

(841) 2:45 p.m.  Implications of C. difficile Treatment on Environmental Contamination: A Randomized Controlled Trial with Microbiologic, Environmental, and Molecular Outcomes  
NICHOLAS A. TURNER, MD, MHSC; Duke University, Durham, NC

No CME is offered for this session.  
No CPE credit is offered for this session.

82. Oral Abstract  
Global Health: Outbreaks, Controls, and Genetics  
Thursday, 1:45 – 3 p.m.  147 AB

Moderators:  
HEATHER YUN, MD, FIDSA; San Antonio Military Medical Center; Uniformed Services University of the Health Sciences, San Antonio, TX  
QAASIM MIAN, MD, MBA; University of Alberta, Edmonton, AB, Canada

Speakers:  
(842) 1:45 p.m.  Social Resistance Fuels Ebola Transmission in the Eastern Democratic Republic of Congo  
QAASIM MIAN, MD, MBA; University of Alberta, Edmonton, AB, Canada

(843) 2:00 p.m.  The PALM Consortium: A Multi-Center, Multi-Outbreak Randomized Controlled Trial of Ebola Virus Disease Therapeutics  
SABUE MULANGU, MD; Institut National de Recherche Biomedicales, Kinshasa, Kinshasa, COD

(844) 2:15 p.m.  Engagement in HIV Care as an Avenue to Primary Care in Rural South Africa: Results from the Vukuzazi Population Health Platform  
ITAI M’YAMBO MAGODORO, MBBS, MMSC, MSC; Harvard TH Chan School of Public Health, Cape Town, Western Cape, South Africa

(845) 2:30 p.m.  Children with Clinical Plasmodium falciparum Infection Have Increased Sharing of Haplotypes with Household Members as well as Temporally-Proximal, Symptomatic Peers  
CODY S. NELSON, PHD; Duke University, Durham, NC

(846) 2:45 p.m.  Postnatally Acquired Zika Virus (ZIKV) Infection in Infants and Young Children in Guatemala: Serologic and Neurodevelopmental (ND) Evaluation  
FLOR M. MUNOZ, MD; Baylor College of Medicine, Houston, TX

No CME is offered for this session.  
No CPE credit is offered for this session.

83. Oral Abstract  
Late Breaker Oral Abstract Session 1  
Thursday, 1:45 – 3 p.m.  209 ABC

No CME is offered for this session.  
No CPE credit is offered for this session.
84. Oral Abstract

**Novel Insights into Bacteremia and Endocarditis**

Thursday, 1:45 – 3 p.m. 204 ABC

**Moderators:**
RAZAN EL RAMAHI, MBBS; University of Nebraska Medical Center, Omaha, NE
KELLY CAWCUTT, MD, MS; University of Nebraska Medical Center, Omaha, NE

**Speakers:**
(847) 1:45 p.m. The Effect of Antimicrobial Administration on Blood Culture Positivity in Patients with Severe Manifestations of Sepsis
MATTHEW P. CHENG, MD; Brigham and Women's Hospital, Boston, MA

(848) 2:00 p.m. Low-Bioavailability Versus High-Bioavailability Oral Antibiotics for the Definitive Treatment of Enterobacteriaceae Bacteremia from Suspected Urine Source in Hospitalized Veterans
JESSE D. SUTTON, PHARMD; Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, UT

(849) 2:15 p.m. Reduced CIED Infections with an Antibacterial Envelope: Microbiologic Analysis of the WRAP-IT Study
MUHAMMAD R. SOHAIL, MD, FIDSA; Mayo Clinic, Rochester, MN

(850) 2:30 p.m. Outcomes of Patients Discharged on Parenteral Ceftriaxone Compared to Oxacillin or Cefazolin in Methicillin Susceptible *Staphylococcus aureus* (MSSA) Bloodstream Infections.
LEE ERIK CONNOR, MD; Washington University, St. Louis, MO

(851) 2:45 p.m. Validation of Quick Pitt Bacteremia Score in Patients with *Staphylococcus aureus* Bacteremia
SARAH ELIZABETH. BATTLE, MD; University of South Carolina/Prisma Health Richland Hospital, West Columbia, SC

No CME is offered for this session.
No CPE credit is offered for this session.

85. Oral Abstract

**Pediatric Bacterial Diseases**

Thursday, 1:45 – 3 p.m. 206

**Moderators:**
NADA HARIK, MD; Children's National Health System, Washington, DC
KRISTINA G. HULTEN, PHD; Baylor College of Medicine, Houston, TX

**Speakers:**
(852) 1:45 p.m. The Cefazolin Inoculum Effect and Methicillin-Susceptible *Staphylococcus aureus* Osteoarticular Infections in Children: Does it Matter?
JONATHAN C. MCNEIL, MD; Baylor College of Medicine, Pearland, TX

Epidemiology of Groups A, C, and G Beta-Hemolytic Streptococcal Pharyngitis
JAMES RAY MATA. LIM, MD; Beaumont Hospital, Ferndale, MI

Impact of Antimicrobial Stewardship and Rapid Diagnostics in Children with *Staphylococcus aureus* Bacteremia
STEPHANIE N. WELCH, PHARMD; Atrium Health, Charlotte, NC

Evolution of Group B Streptococcal Capsular Type V Invasive Infections in Neonates and Young Infants: A Whole Genome Sequencing Study
ANTHONY R. FLORES, MD, MPH, PHD; McGovern Medical School, Houston, TX

Invasive *Haemophilus influenzae* disease in Children: A Canadian Multi-Centre Study on Emerging Serotypes
CRAIG FRANKEL, MD; Western University, London, ON, Canada

No CME is offered for this session.
No CPE credit is offered for this session.

86. Interactive

**Clinical Controversies**

Thursday, 3:15 – 4:30 p.m. Ballroom ABC

**Objectives:** At the conclusion of this session, participants will be able to:
- list and describe the risks and benefits of providing oral therapy for uncomplicated *Staphylococcus aureus* bacteremia
- identify the rationale for not selecting fluoroquinolones as first-line therapy

**Intended Audience:** Academicians, Clinicians, Fellows, HIV Clinicians, HIV Specialists, Infectious Diseases Physicians, Medical Students and Residents, Members-in-Training, Pharmacists

**Moderators:**
PATRICK P. JOSEPH, MD, FIDSA; University of California, San Francisco, San Ramon, CA
SUSAN BLEASDALE, MD, FIDSA; University of California, San Francisco, San Ramon, CA

**Debate Style Speakers:**
(857) 3:15 p.m. Should Fluoroquinolones Be Abandoned As First Line Therapy For Anything?
JENNIFER PISANO, MD; University of Chicago, Chicago, IL

(858) 3:15 p.m. Should Fluoroquinolones Be Abandoned As First Line Therapy For Anything?
MATTHEW SCARBOROUGH, MRCP, FRCPATH, PHD; Oxford University Hospitals, UK, Headington, Oxford, UK

(859) 3:15 p.m. Oral Therapy For Uncomplicated *Staphylococcus aureus* Bacteremia
PATTY WRIGHT, MD; Vanderbilt University Medical Center, Nashville, TN
87. Interactive
Educating Healthcare Students and Trainees about Stewardship
Co-organized with the IDSA Medical Education Workgroup
Thursday, 3:15 – 4:30 p.m.  150 AB

Objectives: At the conclusion of this session, participants will be able to:
• discuss components of an effective curriculum for educating students and trainees on the principles and practice of antimicrobial stewardship
• discuss how to implement elements of antibiotic stewardship education for students and trainees in your healthcare institution
• list available curriculum and training resources for teaching antimicrobial stewardship principles and practice to students and trainees

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Hospital Epidemiologists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Microbiologists, Nurses, Pharmacists

Moderators:
CHRIS OHL, MD; Wake Forest School of Medicine, Winston Salem, NC
VERA LUTHER, MD, FIDSA; Wake Forest Baptist Health System, Winston Salem, NC

Panlists:
ALICE BARSOUMIAN, MD, FIDSA; Brooke Army Medical Center, San Antonio, TX
RICHARD H. DREW, PHARMD, MS; Duke University, Durham, NC
JAMES B. CUTRELL, MD, FIDSA; University of Texas Southwestern, Dallas, TX

89. Symposium
Innovative Methods in Healthcare Epidemiology and Antimicrobial Stewardship
Thursday, 3:15 – 4:30 p.m.  145 AB

Objectives: At the conclusion of this session, participants will be able to:
• discuss the use of interrupted time series design and other analytic methods in quality improvement evaluations
• describe how contact patterns within facilities influence dissemination of emerging pathogens
• describe the VA experience in using large datasets to drive antimicrobial stewardship efforts

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Pharmacists, Public Health Practitioners, Researchers, Scientists

Moderator:
SHELLEY S. MAGILL, MD, PHD; Centers for Disease Control and Prevention, Atlanta, GA

88. Symposium
Drug Resistant Gonorrhea: The Future is Here
Thursday, 3:15 – 4:30 p.m.  146 ABC

Objectives: At the conclusion of this session, participants will be able to:
• discuss the epidemiology of Neisseria gonorrhoeae infections
• review current and novel treatment options for gonococcal infections
• discuss the current prospects for a gonococcal vaccine

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, HIV Clinicians, HIV Specialists, Infectious Diseases Physicians, Vaccinologists
90. Symposium

Meeting the Full Potential of DAA Therapies for HCV
Thursday, 3:15 – 4:30 p.m. 207 AB

Objectives: At the conclusion of this session, participants will be able to:
• discuss novel approaches to use of HCV positive donor organs in the DAA era
• discuss emerging data of treatment of HCV in pregnancy and safety of DAA in pregnant women
• discuss treatment approaches to acute HCV infection in MSM

Intended Audience: Academicians, Clinicians, Infectious Diseases Physicians, Infectious Diseases Pediatricians

Moderators:
SUSANNA NAGGIE, MD, FIDSA; Duke University, Durham, NC
DAVID L. WYLES, MD, FIDSA; Denver Health, Denver, CO

Speakers:
(870) 3:15 p.m. HCV positive donor to negative recipient organ transplant: Is There Anything we can’t do?
RAYMOND CHUNG, MD; Massachusetts General Hospital, Boston, MA

(871) 3:40 p.m. Test and Treat in Pregnancy: Are we There Yet?
CATHERINE CHAPPELL, MD, MSC; University of Pittsburgh, Pittsburgh, PA

(872) 4:05 p.m. HCV Treatment as Prevention in MSM: Challenges and Opportunities
ANNE BOEREKAMPS, MD; Erasmus Medical Center, Rotterdam, the Netherlands

91. Symposium

Non-Antibiotic Approaches to Treating Transplant-Associated Infections
Thursday, 3:15 – 4:30 p.m. 202 AB

Objectives: At the conclusion of this session, participants will be able to:
• review the safety and effectiveness of using bacteriophage therapy for multidrug-resistant bacterial infections in transplant recipients
• evaluate the feasibility of integrating virus-specific T-cell therapy into the day-to-day management of transplant patients
• discuss issues surrounding using fecal microbiota transplantation in the transplant population


Moderators:
PAMELA CHONG, MD, MSCR; University of Texas Southwestern, Dallas, TX

Speakers:
(873) 3:15 p.m. What is the Rage with Bacteriophage (Therapy)?
SAIMA ASLAM, MD, MS; University of California, San Diego, San Diego, CA

(874) 3:40 p.m. Virus-Specific T-cell Therapy in Transplantation: Adopting into Clinical Practice
RAJIV KHANNA, PHD, FAHMS; QIMR Berghofer Medical Research Institute, Herston, Australia

(875) 4:05 p.m. Transplanting Fecal Microbiota: Friend or Foe?
ANDREW Y. KOH, MD; University of Texas Southwestern, Dallas, TX
93. Symposium
The Role of Public Health in Precision Medicine
Co-organized with the National Institutes of Health
Thursday, 3:15 – 4:30 p.m. 152 AB

Objectives: At the conclusion of this session, participants will be able to:
- list three ways that new tools in big data can improve health outcomes
- describe how precision medicine can influence infectious disease outcomes


Moderators:
EMILY ERBE LDING, MD, FIDSA; National Institutes of Health, Rockville, MD
KELLY GEBO, MD, MPH; Johns Hopkins, Baltimore, MD

Speakers:
(876) 3:15 p.m. TBD 484
WAFAA EL-SADR, MD, MPH, FIDSA; ICAP at Columbia University, New York, NY

(877) 3:40 p.m. TBD 485
KELLY GEBO, MD, MPH; Johns Hopkins, Baltimore, MD

(880) 4:05 p.m. TBD 486
GREGORY L. ARMSTRONG, MD; Centers for Disease Control and Prevention, Atlanta, GA

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE;
0221-9999-19-347-L04-P

95. Named Lecture
Caroline B. Hall Lecture: Antenatal Zika Virus Exposure
Thursday, 3:15 – 4:30 p.m. Salon ABC

Objectives: At the conclusion of this session, participants will be able to:
- define the potential sequelae of antenatal zika virus exposure and the clinical evolution of these sequelae in infants over time
- describe the clinical evolution of these sequelae over time
- apply specific lessons learned from follow-up of a cohort of infants with antenatal Zika exposure in Rio de Janeiro


Moderators:
ROBERTA DEBIASI, MD, MS, FIDSA, FPIDS; Children’s National Health System, Washington, DC
PAUL SPEARMAN, MD, FIDSA; Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

Speaker:
(882) 3:15 p.m. Clinical Evolution of Infants with Antenatal Zika Virus Exposure - Lessons Learned from Rio de Janeiro
KAREN NIELSEN-SAINES, MD, MPH; David Geffen UCLA School of Medicine, Los Angeles, CA

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE;
0221-9999-19-345-L01-P
### Scientific Sessions (continued)

| Adult ID/Pediatric ID/HIV/TB/STD/Global ID | 96. Oral Abstract

**HIV Viral Suppression or Bust**

Thursday, 3:15 – 4:30 p.m. 144 ABC

**Moderators:**

- ANNA PERSON, MD; Vanderbilt University Medical Center, Nashville, TN
- BABAFEMI O. TAIWO, MBBS; Northwestern University, Chicago, IL

**Speakers:**

- **(883) 3:15 p.m.** Evidence from a Multistate Cohort: Enrollment in Affordable Care Act Qualified Health Plans Results in Viral Suppression
  - KATHLEEN A. MCMANUS, MD, MSCR; University of Virginia, Charlottesville, VA

- **(884) 3:30 p.m.** Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies
  - PAULA TEICHNER, PHARMD; ViiV Healthcare, Research Triangle Park, NC

- **(885) 3:45 p.m.** HIV-1 Treatment Failure and Extensive Drug Resistance in Perinatally-Infected Children Failing First-Line Antiretroviral Therapy in Western Kenya
  - SABINA HOLLAND, MD; Brown University, Providence, RI

| Adult ID/Pediatric ID/Epi/Infection Control | 97. Oral Abstract

**Innovations in Clinical Practice**

Thursday, 3:15 – 4:30 p.m. 147 AB

**Moderators:**

- THOMAS M. FILE, JR., MD, FIDSA; Summa Health System, Akron, OH
- ANN MACINTYRE, DO, FIDSA; Miami, FL

**Speakers:**

- **(888) 3:15 p.m.** Impact of Mandatory Infectious Diseases Consult on All-Cause Inpatient Mortality
  - GREGORY D. HUHN, MD; The Ruth M. Rothstein CORE Center, Chicago, IL

| Adult ID | 98. Oral Abstract

**To Decolonize or Not to Decolonize: Do We Still Need to Ask the Question**

Thursday, 3:15 – 4:30 p.m. 204 ABC

**Moderators:**

- KYLE POPOVICH, MD, MS, FIDSA, FSHEA; Rush University Medical Center, Chicago, IL
- DAVID HAM, MD, MPH; Centers for Disease Control and Prevention, Atlanta, GA

**Speakers:**

- **(893) 3:15 p.m.** The SHIELD Orange County Project: A Decolonization Strategy in 35 Hospitals and Nursing Homes Reduces Multi-Drug Resistant Organism (MDRO) Prevalence in a Southern California Region
  - JAMES A. MCKINNELL, MD; LA BioMed at Harbor-UCLA Medical Center, Torrance, CA

- **(894) 3:30 p.m.** Universal Decolonization in Nursing Homes: Effect of Chlorhexidine and Nasal Povidone-Iodine on Prevalence of MultiDrug-Resistant Organisms (MDROs) in the PROTECT Trial
  - LOREN G. MILLER, MD, MPH, FIDSA; Harbor UCLA, Torrance, CA

- **(895) 3:45 p.m.** Impact of Measurement and Results Feedback of Chlorhexidine Gluconate (CHG) Skin Concentrations in Medical Intensive Care Unit (MICU) Patients Receiving CHG Bathing
  - YOONA RHEE, MD, SCM; Rush University Medical Center, Chicago, IL

No CME is offered for this session.
No CPE credit is offered for this session.
A Safe, More Cost-Effective Protocol—Universal Decolonization versus MRSA Screening and Contact Precautions

JACQUELINE WHITAKER, RN, MS, LHRM, CPHQ, CIC; AdventHealth, Tampa, FL

Prevalence of Candida auris at Body Sites, Characterization of Skin Microbiota, and Relation of Chlorhexidine Gluconate (CHG) Skin Concentration to C. auris Detection among Patients at a High-Prevalence Ventilator-Capable Skilled Nursing Facility (vSNF) with Established CHG Bathing

MARY K. HAYDEN, MD, FIDSA, FSHEA; Rush University Medical Center, Chicago, IL

Influenza Vaccination Reduces Risk of Severe Outcomes Among Adults Hospitalized with Influenza A(H1N1)pdm09, FluSurv-NET, 2013-2018

SHIKHA GARG, MD, MPH; Centers for Disease Control and Prevention, Atlanta, GA

Influenza Vaccine Effectiveness against Laboratory-Confirmed Influenza in Children Hospitalized with Respiratory Illness in the United States, 2016-17 and 2017-18 Seasons

ANGELA P. CAMPBELL, MD, FIDSA; Centers for Disease Control and Prevention, Atlanta, GA


JESSIE R. CHUNG, MPH; Centers for Disease Control and Prevention, Atlanta, GA

MEDI8897 Prevents Serious RSV Disease in Healthy Preterm Infants

MARY PAMELA GRIFFIN, MD; AstraZeneca, Gaithersburg, MD

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of a Single Immunization of Ad26.RSV.preF against RSV Infection in a Viral Challenge Model in Healthy Adults

JOHN DEVINCENZO, MD; University of Tennessee School of Medicine, Memphis, TN

Resensitization to β-lactams in Enterococci Depends on Penicillin-Binding Protein (PBP) Mislocalization and Is Mediated by a Single Protein That Modulates Cell Membrane (CM) Adaptation to Daptomycin (DAP)

AYESHA KHAN, BSC; McGovern Medical School, Houston, TX

Elusive Elimination of STDs in the 21st Century: Why Smallpox and Not the Great Pox

GAIL A. BOLAN, MD; Centers for Disease Control and Prevention, Atlanta, GA

No CME is offered for this session.
No CPE credit is offered for this session.
Scientific Sessions (continued)

**Special Session**
**IDea Incubator**
Thursday, 6 – 7 p.m.  
Ballroom ABC

**102. Meet the Professor**
**Alternative Strategies to Monitor CMV Reactivation After Transplantation**
Friday, 8 – 9 a.m.  
150 AB

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss the potential role of quantification of torque teno virus as an innovative predictive biomarker for risk of infection in transplant recipients and other immunocompromised individuals
- discuss the ability of CMV T-cell response assays to predict CMV reactivation and its outcome in transplant recipients and other immunocompromised individuals

**Intended Audience:** Clinicians, Fellows, Members-in-Training, HIV Clinicians, HIV Specialists, Infectious Diseases Physicians, Microbiologists

**Speakers:**
(905) 8:00 a.m.  
**Torque TENV0RUS Viral Load as a Novel Biomarker of the Net State of Immunosuppression after Transplant**
CAMILLE KOTTON, MD; Massachusetts General Hospital, Boston, MA

(906) 8:00 a.m.  
**Cytomegalovirus T-Cell Response Assays**
ROY F. CHEMALY, MD, MPH, FACP, FIDSA; University of Texas MD Anderson Cancer Center, Houston, TX

Maximum of 1 hour of **AMA PRA Category 1 Credit™**
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-19-355-L01-P

**Pediatric ID/Adult ID/Transplant ID/Trainee**

**103. Meet the Professor**
**Left Ventricular Assist Device-associated Infections**
Friday, 8 – 9 a.m.  
209 ABC

**Objectives:** At the conclusion of this session, participants will be able to:
- list essential components of the evaluation and diagnosis of infections associated with left ventricular assist devices (LVADs)
- discuss multidisciplinary management of LVAD-associated infections, including medical and surgical approaches
- discuss the management of LVAD-associated infections when removal of the device is not feasible

**Intended Audience:** Academicians, Clinicians, Fellows, Members-in-Training, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Microbiologists, Nurses, Pharmacists

**Speakers:**
(907) 8:00 a.m.  
**Diagnosing and Managing LVAD-Related Infections**
CHETAN PATEL; Duke University, Durham, NC

(908) 8:00 a.m.  
**Diagnosing and Managing LVAD-Related Infections**

**Pediatric ID/Adult ID/Transplant ID/Trainee**

**104. Meet the Professor**
**Cefazolin vs. Nafcillin for MSSA Infections: Pro-Con Debate**
Friday, 8 – 9 a.m.  
151 AB

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss the clinical approach using nafcillin vs cefazolin for deep-seated MSSA infections
- review the available data favoring one antibiotic over to treat invasive MSSA infections
- analyze data related to the cefazolin inoculum effect in an area of high prevalence

**Intended Audience:** Academicians, Clinicians, Fellows, Members-in-Training, Health Care Workers, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Microbiologists, Nurses, Pharmacists

**Speakers:**
(909) 8:00 a.m.  
**Cefazolin versus Nafcillin for MSSA Infections: Pro-Con Discussion**
ESTEBAN C. NANNINI, MD; Facultad Ciencias Médicas - Universidad Nacional de Rosario, Rosario, Argentina

(910) 8:00 a.m.  
**Cefazolin versus Nafcillin for MSSA Infections: Pro-Con Discussion**
SARAH B. DOERNBERG, MD, MAS; University of California, San Francisco, San Francisco, CA

Maximum of 1 hour of **AMA PRA Category 1 Credit™**
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-19-359-L01-P

**HIV/TB/STD/Adult ID**

**105. Meet the Professor**
**Challenging STIs in Patients with HIV**
Friday, 8 – 9 a.m.  
103 AB

**Objectives:** At the conclusion of this session, participants will be able to:
- identify key aspects of the medical evaluation, diagnosis and treatment of STIs in patients with HIV
- evaluate different strategies and options in managing complicated STIs in patients with HIV

**Intended Audience:** Academicians, Clinicians, Fellows, Members-in-Training, Health Care Workers, HIV Clinicians, HIV Specialists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Nurses, Pharmacists, Public Health Practitioners

**Moderator:**
ERIC DAAR, MD; Harbor-UCLA, Los Angeles, CA
106. Meet the Professor
Compensation Disparities Across Gender
Friday, 8 – 9 a.m. 152 AB

Objectives: At the conclusion of this session, participants will be able to:
• compare compensation by gender
• identify causes of disparity of compensation by gender
• list ways to correct compensation disparity


Speakers:
(913) 8:00 a.m. Compensation Disparities Across Gender
ALICE KIM, MD; Cleveland Clinic, Cleveland, OH

(914) 8:00 a.m. Compensation Disparities Across Gender
ANN MACINTYRE, DO, FIDSA; Miami, FL

Maximum of 1 hour of AMA PRA Category 1 Credit™
No CPE credit is offered for this session.

107. Meet the Professor
Displaced: Infectious Disease Impacts on Refugee and Migrant Populations
Friday, 8 – 9 a.m. 144 ABC

Objectives: At the conclusion of this session, participants will be able to:
• recognize the impact of infectious diseases on refugee and migrant health
• describe specific causes of infectious disease morbidity in these populations
• summarize high yield interventions to mitigate this impact in settings where care is delivered

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Nurses, Public Health Practitioners, Researchers

Moderators:
HEATHER YUN, MD, FIDSA; San Antonio Military Medical Center; Uniformed Services University of the Health Sciences, San Antonio, TX
LUCY E. HORTON, MD, PHD; University of California, San Diego, San Diego, CA

Speakers:
(915) 8:00 a.m. “Displaced: Infectious Disease Impacts on Refugee and Migrant Populations”
RICHARD MURPHY, MD, MPH; LA BioMed at Harbor-UCLA Medical Center, Torrance, CA

(916) 8:00 a.m. “Displaced: Infectious Disease Impacts on Refugee and Migrant Populations”
MARTIN CETRON, MD; Centers for Disease Control and Prevention, Atlanta, GA

Maximum of 1 hour of AMA PRA Category 1 Credit™
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-19-356-L04-P
109. Meet the Professor
**Medical Director 101: Practical Guidance for the ID Specialist new to Infection Prevention and Antibiotic Stewardship Program Leadership**
Friday, 8 – 9 a.m. 206

**Objectives:** At the conclusion of this session, participants will be able to:
- describe important strategies for serving as the Hospital Epidemiologist/Medical Director of the Infection Prevention program
- describe important strategies for serving as the Medical Director of an Antibiotic Stewardship Program

**Intended Audience:** Clinicians, Fellows, Members-in-Training, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Physicians

**Speakers:**
- (919) 8:00 a.m. **Practical Guidance for the ID Specialist New to Infection Prevention**
  LOUISE DEMBRY, MD, MS, MBA, FIDSA, FSHEA; Yale University, New Haven, CT
- (920) 8:00 a.m. **Practical Guidance for the ID Specialist New to Antibiotic Stewardship Program Leadership**
  EMILY S. SPIVAK, MD, MHS, FIDSA; University of Utah, Salt Lake City, UT

**Maximum of 1 hour of AMA PRA Category 1 Credit™**
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-19-353-L04-P

110. Meet the Professor
**Practicing Diagnostic Stewardship: Tools You Can Use Today in Your Hospital**
Friday, 8 – 9 a.m. 201

**Objectives:** At the conclusion of this session, participants will be able to:
- describe elements of a successful diagnostic stewardship program
- list 6 instances where diagnostic stewardship has improved patient care or healthcare economics
- discuss how to implement elements of a diagnostic stewardship program in your healthcare system

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Lab Personnel, Microbiologists

**Speakers:**
- (921) 8:00 a.m. **Reducing Unnecessary Tests: Opportunities in Pediatric**
  ANGELA MYERS, MD, MPH; Children’s Mercy Hospital, Kansas City, MO
- (922) 8:00 a.m. **Reducing Unnecessary Tests: Opportunities in Adults**

**Maximum of 1 hour of AMA PRA Category 1 Credit™**
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-19-352-L04-P

111. Meet the Professor
**Top Papers in Medical Mycology**
*Co-organized with the Mycoses Study Group Education and Research Consortium*
Friday, 8 – 9 a.m. 204 ABC

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss the year’s important clinical advances and biomedical discoveries in mycology that have the potential to impact clinical care and foster new research
- discuss strategies to apply new data to further discovery or clinical practices in mycology
- describe new scientific and clinical findings in mycology

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, HIV Clinicians, HIV Specialists, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Lab Personnel, Microbiologists, Researchers, Scientists

**Moderator:**
JOSH NOSANCHUK, MD, FIDSA; Albert Einstein College of Medicine, Bronx, NY

**Speakers:**
- (923) 8:00 a.m. **Top Papers in Medical Mycology**
  JOHN R. PERFECT, MD; Duke University, Durham, NC
- (924) 8:00 a.m. **Top Papers in Medical Mycology**
  MARISA H. MICELI, MD, FIDSA; University of Michigan, Ann Arbor, MI

**Maximum of 1 hour of AMA PRA Category 1 Credit™**
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-19-351-L04-P

112. Special Session
**Special Session**
Friday, 9:15 – 10:00 a.m. Ballroom ABC

**Objectives:** At the conclusion of this session, participants will be able to:

**Speakers:**
- (925) 9:15 a.m. TBD 445
  CME credit pending
  No CPE credit is offered for this session.
113. Interactive
Mano-a-Mano V: Pediatric Infectious Diseases
Friday, 10:30 – 11:45 a.m. Salon GHI

Objectives: At the conclusion of this session, participants will be able to:
• discuss how pre-transplant viral infections impacts post-transplant outcomes
• discuss how pre-transplant viral infections do not affect post-transplant outcomes
• discuss the pros of reverse syphilis algorithms
• discuss the cons of reverse syphilis screening algorithms
• describe when to use steroids for children who have an abnormal ECHO and Kawasaki Disease
• explain when to use Infliximab for children who have an abnormal ECHO and Kawasaki Disease

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Hospital Administrators, Infectious Diseases Pediatricians, Infectious Diseases Physicians; Researchers

Moderators:
TARA L. GREENHOW, MD; Kaiser Permanente Northern California, San Francisco, CA
NATASHA B. HALASA, MD, MPH; Vanderbilt University Medical Center, Nashville, TN

Debate Style Speakers:
(926) 10:30 a.m. Pre-Transplant Resp Viral Infection Impacts Post-Transplant Outcomes Infection: PRO
ALPANA WAGHMARE, MD; University of Washington, Seattle, WA
(927) 10:42 a.m. Pre-Transplant Resp Viral Infection Impacts Post-Transplant Outcomes Infection: CON
FLOR M. MUNOZ, MD; Baylor College of Medicine, Houston, TX
(928) 10:54 a.m. Reverse Syphilis Screening Algorithms: PRO
PABLO J. SANCHEZ, MD, FIDSA; Nationwide Children's Hospital, Columbus, OH
(929) 11:04 a.m. Reverse Syphilis Screening Algorithms: CON
LAURA H. BACHMANN, MD, FIDSA; Centers for Disease Control and Prevention, Atlanta, GA
(930) 11:16 a.m. Use of Steroids versus Infliximab in Kawasaki Disease for an Abnormal ECHO: PRO Steroids
PREETI JAGGI, MD; Emory University, Atlanta, GA
(931) 11:28 a.m. Use of Steroids versus Infliximab in Kawasaki Disease for an Abnormal ECHO: PRO Infliximab
JANE BURNS, MD, FIDSA; University of California, San Diego, La Jolla, CA

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-361-L01-P

114. Interactive
Opening Pandora's Chest: A Case Based Multidisciplinary Approach to Chronic Pulmonary Infections and Their Mimics
Friday, 10:30 – 11:45 a.m. Salon ABC

Objectives: At the conclusion of this session, participants will be able to:
• describe the diagnostic approach to patients with chronic lung infections and their mimics
• identify the radiological characteristics on CT chest that differentiate the spectrum of etiologies causing chronic lung infections
• discuss how to choose the appropriate management strategy including antimicrobial combinations, duration of therapy, and when not to treat

Intended Audience: Academicians

Moderators:
LUCILEIA JOHNSON, MD, MS; Cleveland Clinic, Beachwood, OH
CHADI A. HAGE, MD; Indiana University, Indianapolis, IN

Panelists:
ANNE O'DONNELL, MD; Georgetown University Medical Center, Washington, DC
RUCHI YADAV; Cleveland Clinic, Cleveland, OH
CHARLES L. DALEY, MD; National Jewish Health, Denver, CO
KIEREN MARR, MD; Johns Hopkins University, Baltimore, MD

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-19-364-L01-P

115. Symposium
Bacterial Persisters and Nonculturable Forms: Basic Biology and Therapeutic Susceptibility
Friday, 10:30 – 11:45 a.m. 152 AB

Objectives: At the conclusion of this session, participants will be able to:
• discuss new models for the discovery of compounds against MRSA
• describe new approaches for drug discovery
• discuss the challenges associated with the discovery of compounds with activity against persister cells


Moderator:
MICHAEL S. GLICKMAN, MD, FIDSA, FAAM; Memorial Sloan Kettering, New York, NY

Speakers:
(932) 10:30 a.m. Therapeutic Targeting of S. aureus Persisters
ELEFTHERIOS MYLONAKIS, MD, PHD, FIDSA; Brown University, Providence, RI
(933) 10:55 a.m. Role of Cholera Biofilms in the Infection Lifecycle
FITNAT YILDIZ; University of California, Santa Cruz, Santa Cruz, CA
### Scientific Sessions (continued)

<table>
<thead>
<tr>
<th>Session Number</th>
<th>Time</th>
<th>Title</th>
<th>Location</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>(934)</td>
<td>11:20 a.m.</td>
<td><strong>Differentially Detectable Mtb in Treatment Resistance and Relapse</strong></td>
<td>KOHTA SAITO, MD, MPH; Weill Cornell Medicine, New York, NY</td>
<td>Maximum of 1.25 hours of AMA PRA Category 1 Credit™ ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-366-L01-P</td>
</tr>
<tr>
<td>(935)</td>
<td>10:30 a.m.</td>
<td><strong>Clinical Controversies in HIV Antiretroviral Therapy</strong></td>
<td></td>
<td>zano ASLAM, MD, MS; University of California, San Diego, San Diego, CA</td>
</tr>
<tr>
<td>(936)</td>
<td>10:49 a.m.</td>
<td><strong>Same Day Therapy - PRO</strong></td>
<td>MONICA GANDHI, MD, MPH; University of California, San Francisco, San Francisco, CA</td>
<td></td>
</tr>
<tr>
<td>(937)</td>
<td>11:08 a.m.</td>
<td><strong>ARV Treatment for Women of Child Bearing Age</strong></td>
<td>THOMAS P. GIORDANO, MD, MPH, FIDSA; Baylor College of Medicine, Houston, TX</td>
<td></td>
</tr>
<tr>
<td>(938)</td>
<td>11:27 a.m.</td>
<td><strong>ARV Treatment for Women of Child Bearing Age</strong></td>
<td>SUSAN ELLEN E. COHN, MD, MPH, FIDSA; Northwestern University, Park Ridge, IL</td>
<td></td>
</tr>
<tr>
<td>(939)</td>
<td>10:30 a.m.</td>
<td><strong>Influenza Vaccine and Indirect Protection: Optimizing the Impact of Influenza Vaccine</strong></td>
<td>MEAGAN FITZPATRICK, PHD; University of Maryland, Baltimore, MD</td>
<td>Maximum of 1.25 hours of AMA PRA Category 1 Credit™ ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-363-L06-P</td>
</tr>
<tr>
<td>(940)</td>
<td>10:55 a.m.</td>
<td><strong>Current Influenza Vaccines: Are We Ready for Different Vaccines for Different Populations?</strong></td>
<td>LISA GROHSKOPF, MD, PHD; Centers for Disease Control and Prevention, Atlanta, GA</td>
<td></td>
</tr>
<tr>
<td>(941)</td>
<td>11:20 a.m.</td>
<td><strong>New Insights On Vaccine-Induced Protection</strong></td>
<td>MATT WET MEMOLI, MD, MS; National Institutes of Health, Bethesda, MD</td>
<td></td>
</tr>
<tr>
<td>(942)</td>
<td>10:30 a.m.</td>
<td><strong>The Rationale for Using Phages as Therapeutic Weapons</strong></td>
<td>JASON GILL, MSC, PHD; Texas A&amp;M University, College Station, TX</td>
<td></td>
</tr>
<tr>
<td>(943)</td>
<td>10:55 a.m.</td>
<td><strong>Phage Lysins Effectively Target MDR ESKAPE Pathogens</strong></td>
<td>VINCENT A. FISCHETTI, PHD; Rockefeller University, New York, NY</td>
<td></td>
</tr>
<tr>
<td>(944)</td>
<td>11:20 a.m.</td>
<td><strong>Clinical Experiences with Phage Therapy</strong></td>
<td>SAIMA ASLAM, MD, MS; University of California, San Diego, San Diego, CA</td>
<td></td>
</tr>
</tbody>
</table>
119. Symposium
Rapid Diagnostics and Resistance: Making Sense of Now and the Future Part 1
Friday, 10:30 – 11:45 a.m. Ballroom ABC

Speakers:
(945) 10:30 a.m. Roche
(946) 10:30 a.m. BacterioScan
(947) 10:30 a.m. LifeScale
(948) 10:30 a.m. Selux
(949) 10:30 a.m. Specific Diagnostics
(950) 10:30 a.m. Accelerate
(951) 10:30 a.m. Klaris

No CME is offered for this session.
No CPE credit is offered for this session.

120. Symposium
South of the Border: Important Diseases You Can Not Miss
Co-organized with API and BSID
Friday, 10:30 – 11:45 a.m. 150 AB

Objectives: At the conclusion of this session, participants will be able to:
• describe the main presentations of diseases that are endemic in Latin America but are rarely seen in the USA but are emerging in North America
• discuss major parasitic diseases that affect immunocompromised patients
• review the state of the art of the management of malaria in Latin America and list the current challenges in the diagnostic and treatment of Paracoccidiodomycosis
• list the current challenges in the diagnostic and treatment of Paracoccidiodomycosis

Intended Audience: Academicians, Clinicians, Fellows, Members-in-Training, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Microbiologists, Nurses, Scientists

Moderators:
DUILIO S. NUNEZ, MD; IPS Hospital Central, Asunción, Paraguay
SERGIO CIMERMAN, MD, PHD; Brazilian Society of Infectious Diseases, Sao Paulo, Brazil

Speakers:
(952) 10:30 a.m. Paracoccidiodomycosis: An Update
FLAVIO QUEIROZ-TELLES, MD, PHD; Hospital de Clinicas, Federal University of Parana, Curitiba, Brazil

(953) 10:55 a.m. Malaria State of the Art
ARLENE DENT, MD, PHD; Rainbow Babies/Children's Hospital, Cleveland, OH

(954) 11:20 a.m. Parasitosis in Immunocompromised Hosts
CARLOS SEAS, MD; Universidad Peruana Cayetano Heredia, Lima, Peru

121. Symposium
Tackling the Big Beasts of Healthcare Epidemiology
Friday, 10:30 – 11:45 a.m. 207 AB

Objectives: At the conclusion of this session, participants will be able to:
• explain methods for preventing spread of Candida auris
• discuss the value of surveillance and prevention of central line infections in the outpatient setting
• discuss the importance of preventing MDRO transmission across healthcare settings

Intended Audience: Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Public Health Practitioners

Moderator:
TARA N. PALMORE, MD; National Institutes of Health, Bethesda, MD

Speakers:
(955) 10:30 a.m. Tracking and Preventing Complications of Central Lines in Outpatient Settings
VINEET CHOPRA, MD, MSC; Medicine, Ann Arbor, MI

(956) 10:55 a.m. There and Back Again: The Role of Post-Acute-Care and Care Transitions in Controlling the Spread of MDROs
GHINWA DUMYATI, MD, FSHEA; Center for Disease Control and Prevention, Atlanta, GA

(957) 11:20 a.m. Infection Control Measures for the Prevention and Control of Candida Auris
SNIGDHA VALLABHANENI, MD, MPH; Centers for Disease Control and Prevention, Atlanta, GA

HIV/TB/STD/Pediatric ID/Adult ID/Epi/Infection Control/Investigative ID/Trainee

122. Symposium
Using Technology to Enhance Teaching and Learning
Co-organized with the IDSA Medical Education Workgroup
Friday, 10:30 – 11:45 a.m. 143 ABC

Objectives: At the conclusion of this session, participants will be able to:
• identify strategies to improve learning including spaced learning, audience response and gamification
• compare and contrast technology tools that can facilitate active learning
• acquire at least one skill useful for teaching adult learners

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, HIV Clinicians, HIV Specialists, Hospital Administrators, Hospital Epidemiologists, Infection....
Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists, Vaccinologists

**Moderators:**
CHRIS OHL, MD; Wake Forest School of Medicine, Winston Salem, NC
BRIAN SCHWARTZ, MD; University of California, San Francisco, San Francisco, CA

**Speakers:**
(958) 10:30 a.m.  **Technology that Can Facilitate Active Learning**
JENNIFER O. SPICER, MD, MPH; Emory University, Atlanta, GA

(959) 10:55 a.m.  **Strategies for Active Learning and Increased Retention**
ERIN BONURA, MD, MCR; Oregon Health & Science University, Portland, OR

(960) 11:20 a.m.  **Technology in Action: Specific Examples in the Classroom and at the Bedside**
ANOOP AGRAWAL, MD; Baylor College of Medicine, Houston, TX

---

**Objectives for all IDWeek Oral Abstract Sessions:**

**ALL IDWEEK Oral Abstract Session objectives coincide with the IDWEEK meeting objectives and are available online at www.idweek.org.**

**Intended Audience for all IDWEEK Oral Abstract Sessions:**

Academicians, Clinicians, Epidemiologists, Fellows, Health Care Workers, HIV Clinicians, HIV Specialists, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Lab Personnel, Medical Students and Residents, Members-in-Training, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists, Vaccinologists

**Moderators:**
ANURADHA GANESAN, MBBS, MPH; Infectious Disease Clinical Research Program and the Henry M. Jackson Foundation for the Advancement of Military Medicine and Walter Reed National Military Medical Center, Bethesda, MD
MICHAEL MELIA, MD; Johns Hopkins, Baltimore, MD

**Speakers:**
(961) 10:30 a.m.  **Prevalence and Macrolide Resistance of *Mycoplasma genitalium* After Initiation of HIV Preexposure Prophylaxis**
JENS VAN PRAET, MD, PhD; AZ Sint-Jan Brugge-Oostende AV, Brugge, West-Vlaanderen, Belgium

(962) 10:45 a.m.  **Trends in Cervical Pre-Cancers by Race and Ethnicity During the Human Papillomavirus Vaccine Era, HPV Vaccine Impact Monitoring Project (HPV-IMPACT), United States, 2008-2016**

---

**124. Oral Abstract**

**Out of the Box and Out of the Hospital: Stewardship Outpatient Services**
Friday, 10:30 – 11:45 a.m.  147 AB

**Moderators:**
KAVITA K. TRIVEDI, MD; Trivedi Consults, LLC, Berkeley, CA
ZACHARY I. WILLIS, MD, MPH; University of North Carolina, Chapel Hill, NC

**Speakers:**
(966) 10:30 a.m.  **A Closer Look at Antibiotic Prescribing for Upper Respiratory Illnesses (URI) in People with HIV Compared to People without HIV**
MACKENZIE R. KEINTZ, MD; University of Nebraska Medical Center, Omaha, NE

(967) 10:45 a.m.  **Concordance of Antibiotic Prescribing with the Proposed American Dental Association Acute Oral Infection Guidelines within Veterans Affairs (VA) Dentistry**
DANIEL CARLSEN, PHARMD; Edward Hines, Jr. VA Hospital, Chicago, IL

(968) 11:00 a.m.  **Effect of Outpatient Antibiotic Ordering Restrictions on Antibiotic Prescribing Patterns at a State-Wide VA Health Care System**
ROHINI DAVE, PHARMD; VA Maryland Health Care System, Baltimore, MD

(969) 11:15 a.m.  **Antibiotic Prescribing in a Large Retail Health Clinic Chain: Opportunities for Stewardship**
KATHERINE E. FLEMING-DUTRA, MD; Centers for Disease Control and Prevention, Atlanta, GA

---

**Adult ID/Pediatric ID/Epi/Infection Control**

**123. Oral Abstract**

**Advances in Sexually Transmitted and UTIs**
Friday, 10:30 – 11:45 a.m.  144 ABC

**Moderators:**
JULIA GARGANO, PHD; Centers for Disease Control and Prevention, Atlanta, GA

**Speakers:**
(963) 11:00 a.m.  **Extragenital Chlamydia and Gonorrhea Among Females Visiting an STD Clinic**
MICHAELA MAYNARD, MPH; Miriam Hospital/Brown University, Providence, RI

(964) 11:15 a.m.  **Journey to Zero Harm: Eliminating Catheter Associated Urinary Tract Infections (CAUTIs) for 12 Consecutive Months at Two Community Hospitals**
LEONARDO GIRIO-HERRERA, DO; University of Maryland Upper Chesapeake Health, Timonium, MD

(965) 11:30 a.m.  **The Efficacy of Oral Beta-lactam Antibiotics as Step-down Therapy for Acute Pyelonephritis**
ATHENA L. V. HOBBS, PHARMD, BCIDP; Baptist Memorial Hospital-Memphis, Memphis, TN

---

No CME is offered for this session.
No CPE credit is offered for this session.
125. Oral Abstract
Pathogenesis and Inflammatory Response
Friday, 10:30 – 11:45 a.m.

Modera tors:
JENNIFER PHILIPS, MD, PHD; Washington University, St. Louis, MO
ROBERT A. BONOMO, MD, FIDSA; Louis Stokes Cleveland VA Medical Center, Cleveland, OH

Speakers:
(971) 10:30 a.m. The Role of Inflammation and Innate Effectors in Passive Immunization for Acinetobacter baumannii Infections
TRAVIS B. NIELSEN, PHD; Loyola University Chicago, Forest Park, IL

(972) 10:45 a.m. A Mycobacterium Tuberculosis Secreted Lipid Triggers Cough Through a Neuronal Cough Receptor
MICHAEL SHILOH, MD, PHD; University of Texas Southwestern, Dallas, TX

(973) 11:00 a.m. Single-Cell RNA Sequencing Analysis of Zika Virus Infection in Human Stem Cell-Derived Cerebral Organoids
KAREN OCWIEJA, MD, PHD; Boston Children's Hospital, Somerville, MA

(974) 11:15 a.m. PD-1 Immune Checkpoint Blockade Improves Survival and Promotes Fungal Clearance in an Immunosuppressed Murine Invasive Pulmonary Aspergillosis (IPA) Model
SEBASTIAN WURSTER, MD; University of Texas MD Anderson Cancer Center, Houston, TX

(975) 11:30 a.m. Roles of Type I and III Interferon in Severe Pathogenesis of Human Metapneumovirus
JOHN V. WILLIAMS, MD; University of Pittsburgh, Pittsburgh, PA

126. Oral Abstract
Suppressed but Still at Risk: Comorbidities
Friday, 10:30 – 11:45 a.m.

Moderators:
CARL FICH TENBAUM, MD; University of Cincinnati, Cincinnati, OH
CAITLIN MORAN, MD; Emory University, Atlanta, GA

Speakers:
(976) 10:30 a.m. Development and Validation of a Risk Score for Predicting Cardiovascular Events in HIV-Infected Patients
STYLIANI KARANIKIA, MD; Boston University, Boston, MA

(977) 10:45 a.m. The Prevalence and Burden of Non-AIDS Co-Morbidities in Women with or At-Risk for HIV Infection in the United States
LAUREN F. COLLINS, MD; Emory University School of Medicine, and Grady Healthcare System, Atlanta, GA

(978) 11:00 a.m. Changes in BMI Associated with Antiretroviral Regimens in Treatment-Experienced, Virologically Suppressed Individuals Living with HIV
KARAM MOUNZER, MD; Philadelphia FIGHT, Philadelphia, PA

(979) 11:15 a.m. BMI and ASCVD Risk Score Changes in Virologically Suppressed Patients with HIV Switching from TDF to TAF Containing ART
JASON J. SCHAFER, PHARMD, MPH; Jefferson College of Pharmacy, Philadelphia, PA

No CME is offered for this session.
No CPE credit is offered for this session.
127. Rapid Fire Poster
Rapid Fire Poster Session: HIV
Friday, 12:15 – 12:45 p.m.  Hall B +C - Arena 2

Moderator:
CARLOS DEL RIO, MD, FIDSA; Rollins School of Public Health of Emory University, Decatur, GA

Speakers:
(984) 12:15 p.m.
Perceptions of and Preferences for Oral or Long-Acting Injectable Antiretroviral Treatment Regimens in the United States and Canada
CINDY GARRIS, MSPH; ViiV Healthcare, Chapel Hill, NC

(983) 12:20 p.m.
Association of Structural Stigma Due to Sexual Orientation and HIV Diagnosis/PrEP Use in the United States: An Ecological Analysis
NGUYEN K. TRAN, MPH; Drexel University Dornsife School of Public Health, Philadelphia, PA

(981) 12:25 p.m.
Exploring the Prevalence and Characteristics of Weight Gain and other Metabolic Changes in Patients with HIV Infection Switching to Integrase Inhibitor Containing ART
MATTY ZIMMERMAN; Jefferson College of Pharmacy, Philadelphia, PA

(982) 12:30 p.m.
Association of Maternal ARV Use with Microcephaly in HIV-Exposed Uninfected Children
PAIGE L. WILLIAMS, PhD; Harvard TH Chan School of Public Health, Boston, MA

(986) 12:35 p.m.
Inpatient Initiation of ART Improves Short Term Mortality in People Living with HIV
JAMIE CAMPBELL, DO; Atrium Health, Charlotte, NC

(985) 12:40 p.m.
Trans Females Receiving Gender-Affirming Surgical Referrals are More Likely to Have Durable Virologic Suppression at Whitman-Walker Health, 2008-2017
DEBORAH GOLDSTEIN, MD; Whitman-Walker Institute, Washington, DC

128. Rapid Fire Poster
Rapid Fire Poster Session: Transplant/Immunocompromised ID
Friday, 12:15 – 12:45 p.m.  Hall B +C - Arena 1

Moderator:
STEVEN A. PERGAM, MD, MPH; Fred Hutchinson Cancer Research Center; University of Washington, Seattle, WA

Speakers:
(987) 12:15 p.m.
Adherence and Immunogenicity of Early Vaccination in Pediatric Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Recipients
DANA DANINO, MD; Nationwide Children's Hospital, Bexley, OH

(988) 12:20 p.m.
Role of Human Bocavirus Respiratory Tract Infection in Hematopoietic Cell Transplant Recipients
CHIKARA OGIMI, MD; Seattle Children's Hospital, Seattle, WA

(991) 12:25 p.m.
Hepatitis C-Infected Donors and Hepatitis C-Infected Recipients: Analysis of Renal Transplant Outcomes
HAYLEY CROSSMAN, MD; University of California, San Francisco, San Francisco, CA

(992) 12:30 p.m.
Epidemiology of Invasive Mycoplasma and Ureaplasma Infections Early after Lung Transplantation
ARTHUR W. BAKER, MD, MPH; Duke University, Durham, NC

(989) 12:35 p.m.
Clinical Prediction Tool for Multidrug-Resistant Organisms among Deceased Donors at the Time of Donor Evaluation
JUDITH A. ANESI, MD; University of Pennsylvania, Philadelphia, PA

(990) 12:40 p.m.
Microbiome and Cumulative Antibiotic Use as Predictors of Stenotrophomonas maltophilia Infection in Patients with Acute Myeloid Leukemia Receiving Remission-Induction Chemotherapy
SAMUEL L. AITKEN, PHARMD; University of Texas MD Anderson Cancer Center, Houston, TX

No CME is offered for this session.
No CPE credit is offered for this session.

171. Interactive
A Day with the Hospital Epidemiologist’s Pager, Part II: Even More Challenging Cases in Infection Prevention
Friday, 1:45 – 3 p.m.  202 AB

Objectives: At the conclusion of this session, participants will be able to:

• discuss approaches to various infection prevention challenges encountered in a complex healthcare facility
• examine unusual scenarios in infection prevention in which there is limited evidence or guidelines re: recommended practices
• express an appreciation for the ingenuity of healthcare worker behaviors that, though well-intended, may have potential harm

**Intended Audience:** Clinicians, Epidemiologists, Fellows, Members-in-Training, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Nurses

**Moderator:**
TOM TALBOT, III, MD, MPH, FIDSA, FSHEA; Vanderbilt University Medical Center, Nashville, TN

**Panelists:**
MARCI DREES, MD, MS, FSHEA; Christiana Care Health System, Newark, DE
EMILY LANDON, MD; University of Chicago, Chicago, IL
MATT LINAM, MD, MS; Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, GA
DAVID K. WARREN, MD, MPH, FIDSA, FSHEA; Washington University, St. Louis, MO

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**
No CPE credit is offered for this session.

**172. Interactive**

**Our Toughest Mycobacterial Cases**

Friday, 1:45 – 3 p.m.  
Salon GHI

**Objectives:** At the conclusion of this session, participants will be able to:
• discuss the diagnosis and treatment of nontuberculous mycobacterial (NTMB) infections
• illustrate the diverse presentation of mycobacterial diseases presentations
• describe the different strategies for treatment of tuberculosis in the era of MDR and XDR

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, HIV Clinicians, HIV Specialists, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Nurses, Public Health Practitioners

**Moderators:**
LAILA WOC-COLBURN, MD, FIDSA; Baylor College of Medicine, Houston, TX
HEATHER YUN, MD, FIDSA; San Antonio Military Medical Center; Uniformed Services University of the Health Sciences, San Antonio, TX

**Panelists:**
ANNIE F. KIZILBASH, MD, MPH, FIDSA; Texas Center for Infectious Disease, San Antonio, TX
MAUNANK SHAH, MD, PHD; Johns Hopkins University, Baltimore, MD
LUCILEIA JOHNSON, MD, MS; Cleveland Clinic, Beachwood, OH

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-377-L06-P

**173. Interactive**

**Immunization: Beyond the Guidelines**

Friday, 1:45 – 3 p.m. 207 AB

**Objectives:** At the conclusion of this session, participants will be able to:
• list different approaches to challenging pediatric vaccine questions
• describe new ways of addressing difficult questions regarding vaccines for older adults
• explain the expert’s approach to challenging questions in vaccines for travelers

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Nurses, Pharmacists, Public Health Practitioners, Researchers, Vaccinologists

**Moderator:**
ANDREW PAVIA, MD, FIDSA, FSHEA; University of Utah, Salt Lake City, UT

**Panelists:**
KENNETH SCHMADER, MD; Duke and Durham VA Medical Centers, Durham, NC
JAMES CAMPBELL, MD; University of Maryland School of Medicine, Baltimore, MD
NOREEN HYNES, MD, MPH, DTM&H; Johns Hopkins University School of Medicine, Baltimore, MD

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-377-L06-P

**174. Symposium**

**Antibiotic Stewardship: Special Surgical Populations**

Friday, 1:45 – 3 p.m. 151 AB

**Objectives:** At the conclusion of this session, participants will be able to:
• discuss infection prevention and treatment strategies for individuals undergoing urologic, ENT and neurosurgical procedures
• discuss antibiotic prophylaxis strategies for individuals undergoing urologic, ENT and neurosurgical procedures

**Intended Audience:** Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Microbiologists, Nurses, Pharmacists

**Moderator:**
ROBIN L. JUMP, MD, PHD; Case Western Reserve University, Cleveland, OH

**Speakers:**
(1798) 1:45 p.m.  
BPH and Elevated PSA, Meet ASP:  Urologic Procedures
PATRICK N A HARRIS, PHD, DTMH, MRCP, FRACP, FRCPA; Pathology Queensland/
Scientific Sessions (continued)

175. Symposium
Big Beasts I
Friday, 1:45 – 3 p.m.
Ballroom ABC

Objectives: At the conclusion of this session, participants will be able to:
- state the key diagnostic and treatment paradigms for malaria
- describe how CMV infections are prevented, diagnosed, and treated in transplant patients
- discuss how community associated MRSA became widely distributed outside of health care settings

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Microbiologists, Researchers, Scientists

Moderator:
SAMUEL A. SHELBURNE, MD, PHD, FIDSA; University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:
(1801) 1:45 p.m.  Malaria: Updates in Diagnosis and Treatment
JESSICA LIN, MD, MSCR; University of North Carolina, Chapel Hill, NC
(1802) 2:10 p.m.  ‘CMV- Taming the Troll of Transplantation’
DEEPALI KUMAR, MD, MSC, FRCP; University Of Toronto, Toronto, ON, Canada
(1803) 2:35 p.m.  The Rise and Fall of Community-Associated MRSA
PAUL J. PLANET, MD, PHD; Sackler Institute for Comparative Genomics, American Museum of Natural History; Children’s Hospital of Philadelphia, Philadelphia, PA

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-370-L01-P

176. Symposium
Case-Based Guideline Update
Friday, 1:45 – 3 p.m.
Salon ABC

Objectives: At the conclusion of this session, participants will be able to:
- indicate appropriate management of catheter-related infections
- indicate appropriate management of babiesiosis
- indicate appropriate management of bone and joint infections in pediatrics

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, HIV Clinicians, HIV Specialists, Hospital Administrators, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Medical Students and Residents, Microbiologists, Nurses, Pharmacists, Researchers, Scientists

Moderators:
THOMAS M. FILE, JR., MD, FIDSA; Summa Health System, Akron, OH
SUZANNE F. BRADLEY, MD, FIDSA, FSHEA; University of Michigan, Ann Arbor, MI

Speakers:
(1804) 1:45 p.m.  Human Babesiosis
PETER J. KRAUSE, MD, FIDSA; Yale School of Public Health and Yale School of Medicine, New Haven, CT
(1805) 2:10 p.m.  Bone and Joint Infections in Pediatrics
CHARLES R. WOODS, MD, MS, FIDSA, FSHEA; University of Tennessee College of Medicine - Chattanooga, Lookout Mountain, TN
(1806) 2:35 p.m.  Catheter-Related Infections
NASIA SAFDAR, MD, PHD; University of Wisconsin, Madison, WI

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-19-369-L01-P

177. Symposium
Hot Topics in Pediatric Infectious Diseases
Friday, 1:45 – 3 p.m.
146 ABC

Objectives: At the conclusion of this session, participants will be able to:
- summarize and apply the key findings of the year’s highest impact publications in Pediatric Infectious Diseases
- describe notable, recent manuscripts in pediatric infectious diseases


Moderators:
ADAM HERSH, MD, PHD; University of Utah, Salt Lake City, Utah
TINA Q. TAN, MD, FIDSA; Feinberg School of Medicine, Northwestern University, Chicago, IL

Speakers:
(1807) 1:45 p.m.  Hot Topics in Pediatric Infectious Diseases
RITU BANERJEE, MD, PHD; Vanderbilt University Medical Center, Nashville, TN
(1808) 2:04 p.m.  Hot Topics in Pediatric Infectious Diseases
WILLIAM J. MULLER, MD, PHD; Northwestern University, Chicago, IL

HIV/TB/STD/Pediatric ID/Adult ID/Epi/Infection Control/Global ID/Trainee
Scientific Sessions (continued)

178. Symposium
**Mycobiome and Invasive Fungal Infections**
Friday, 1:45 – 3 p.m. 145 AB

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss the composition, diversity, and anatomic location of endogenous human fungal communities
- demonstrate an understanding of methods to measure, classify, and analyze human fungal communities by culture-independent methods
- state the impact of human fungal communities on immune function and susceptibility to invasive mycoses

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Lab Personnel, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists, Vaccinologists

**Moderators:**
TOBIAS HOHL, MD, PHD, FIDSA; Memorial Sloan Kettering, New York, NY
ANNA R. HUPPLER, MD; Medical College of Wisconsin, Milwaukee, WI

**Speakers:**
(1811) 1:45 p.m. **Clinical Implications of Emerging Fungal-Host Interactions**
MIHAÍ NETEA, MD, PHD; Radboud University Medical Center, Nijmegen, the Netherlands

(1812) 2:10 p.m. **Candida Intestinal Colonization and Bloodstream Infections**
BING ZHAI, PHD; Memorial Sloan Kettering, New York, NY

(1813) 2:35 p.m. **Human Fungal Communities**
JOSEPH PETROSINO; Baylor College of Medicine, Houston, TX

**179. Symposium**
**Populations with Disparities in the HIV Care Cascade**
Friday, 1:45 – 3 p.m. 152 AB

**Objectives:** At the conclusion of this session, participants will be able to:
- describe effective strategies for preventing HIV and improving treatment outcomes for transgender individuals
- identity approaches to improve the delivery of HIV prevention and care to individuals who are justice-involved
- discuss strategies to improve HIV prevention for adolescents

**Intended Audience:** Academicians, Clinicians, Fellows, Members-in-Training, Health Care Workers, HIV Clinicians, HIV Specialists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Nurses, Pharmacists, Public Health Practitioners

**Moderator:**
VIRGINIA TRIANT, MD, MPH, FIDSA; Massachusetts General Hospital, Boston, MA

**Speakers:**
(1814) 1:45 p.m. **HIV in Justice-Involved Individuals**
ANK E. NIJHAWAN, MD, MPH; University of Texas Southwestern, Dallas, TX

(1815) 2:10 p.m. **HIV Prevention in Adolescents and Young Adults**
ANNE M. NEILAN, MD, MPH; Massachusetts General Hospital, Boston, MA

(1816) 2:35 p.m. **Improving Prevention and Care for Transgender Individuals**
ASA RADIX, MD, MPH; Callen-Lorde Community Health Center, New York, NY

180. Symposium
**The Influence of Climate Change on Infectious Diseases**
*Co-organized with the National Institutes of Health*
Friday, 1:45 – 3 p.m. 150 AB

**Objectives:** At the conclusion of this session, participants will be able to:
- list three ways that the changing climate poses a threat to human health
- describe actions that a physician can take to protect health in the face of global warming threats

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, HIV Clinicians, HIV Specialists, Hospital Administrators, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Medical Students and Residents, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists

**Speakers:**
(1809) 2:23 p.m. **Hot Topics in Pediatric Infectious Diseases-Speaker 3**
WEI LI A. KOAY, MBBS, MSC; Children’s National Health System, Washington, DC

(1810) 2:42 p.m. **Hot Topics in Pediatric Infectious Diseases-Speaker 4**
JOSEPH B. CANTEY, MD; University of Texas Health San Antonio, San Antonio, TX

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-372-L04-P

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-375-L04-P

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-373-L02-P

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-19-375-L04-P
### Scientific Sessions (continued)

<table>
<thead>
<tr>
<th>Moderator(s)</th>
<th>Time</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
</table>
| EMILY ERBELDING, MD, FIDSA; National Institutes of Health, Rockville, MD  
YUKARI C. MANABE, MD; Johns Hopkins, Baltimore, MD | 1:45 p.m. | Climate Change and Infectious Diseases: A View from The Arctic | JAY C. BUTLER, MD, FIDSA; Alaska Department of Health and Social Services, Anchorage, AK |
| | 2:10 p.m. | Climate Change, Vectors and Infectious Diseases: What’s Happening? | CHARLES (BEN) BEARD, MS, PHD; Centers for Disease Control and Prevention, Fort Collins, CO |
| | 2:35 p.m. | Physician Response to Climate Change | MONA SARFATY, MD, MPH; George Mason University Center for Climate Change Communication, Chevy Chase, MD |
| | 1:45 p.m. | Optimizing Beta-lactam Therapy in Surgical Intensive Care Unit Patients Using Therapeutic Drug Monitoring | MOHAMMAD H. AL-SHAER, PHARMd; University of Florida, Gainesville, FL |
| | 2:00 p.m. | Impact of Rapid Diagnostics and Ceftazidime-Avibactam on Mortality After Bacteremia Caused by Carbapenem-Resistant Enterobacteriaceae | MICHAEL J. SATLIN, MD, MS, FIDSA; Weill Cornell Medicine, New York, NY |
| | 2:15 p.m. | Genetic Characterization of Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Associated with the Development of Reduced Susceptibility to Vancomycin from Latin America | MONICA LILIANA VARGAS ARDILA, DVM; Universidad Nacional de Colombia; Molecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Distrito Capital de Bogota, Colombia |
| | 2:30 p.m. | Bedaquiline Resistance in Mycobacterium intracellulare is Mediated by the Transcriptional Repressor MmpT5 | DAVID ALEXANDER, PHD; Cadham Provincial Laboratory, Winnipeg, MB, Canada |
| | 2:45 p.m. | The Paradox of KPC Bearing Strains of Klebsiella pneumoniae with the D179Y Substitution: Resistance to Ceftazidime/Avibactam (CAZ) and Susceptibility to Meropenem (MEM) | ROBERT A. BONOMO, MD, FIDSA; Louis Stokes Cleveland VA Medical Center, Cleveland, OH |

**No CME is offered for this session.  
No CPE credit is offered for this session.**

### 182. Oral Abstract

**Emergent Mechanisms of Resistance and How to Prevent Them**

Friday, 1:45 – 3 p.m.  
147 AB

<table>
<thead>
<tr>
<th>Moderator(s)</th>
<th>Time</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
</table>
| AMY MATHERS, MD, D(ABMM); University of Virginia, Charlottesville, VA  
SAMUEL L. AITKEN, PHARMd; The University of Texas MD Anderson Cancer Center, Houston, TX | 1:45 p.m. | Efficacy of Pulse-Taper Corticosteroid Adjunctive Therapy for Refractory Non-HIV Cryptococcal Meningoencephalitis | SEHER ANJUM, MD; National Institutes of Health, Bethesda, MD |
| | 2:00 p.m. | Evaluation of Cerebrospinal Fluid White Blood Cell Count Criteria for Use of the BioFire® FilmArray® Meningitis/Encephalitis Panel in Immunocompetent Patients | RANDY MCCREERY, MD; University of Nebraska Medical Center, Omaha, NE |
| | 2:15 p.m. | Decreased JC Virus-Specific Antibody-Dependent Cellular Cytotoxicity in HIV-Seropositive PML Survivors | CHEN SABRINA TAN, MD, FIDSA; Beth Israel Deaconess Medical Center, Boston, MA |
| | 2:30 p.m. | Incidence of Meningoencephalitis in the Absence of CSF Pleocytosis | SHANKAR UPADHYAYULA, MD, MRCPCH; Akron Children’s Hospital, Peninsula, OH |
| | 2:45 p.m. | Herpes Simplex Encephalitis: Outcomes From a 10-Year Retrospective Single-Center Case Series | CHRISTINA A. SNIDER, BA; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, University Heights, OH |

**No CME is offered for this session.  
No CPE credit is offered for this session.**
### Scientific Sessions (continued)

<table>
<thead>
<tr>
<th>Adult ID/Investigative ID</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>183. Oral Abstract</strong></td>
</tr>
<tr>
<td><strong>Innovative Diagnostics</strong></td>
</tr>
<tr>
<td><strong>Friday, 1:45 – 3 p.m.</strong></td>
</tr>
<tr>
<td><strong>204 ABC</strong></td>
</tr>
<tr>
<td><strong>Moderators:</strong></td>
</tr>
<tr>
<td>ROBIN PATEL, MD, FIDSA; Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>SOPHIA KOO, MD, MSC; Brigham and Women’s Hospital, Boston, MA</td>
</tr>
<tr>
<td><strong>Speakers:</strong></td>
</tr>
<tr>
<td>(1830) 1:45 p.m.</td>
</tr>
<tr>
<td>ROBY P. BHATTACHARYYA, MD, PHD; Massachusetts General Hospital, Boston, MA</td>
</tr>
<tr>
<td>(1831) 2:00 p.m.</td>
</tr>
<tr>
<td>DAVID E. GREENBERG, MD, FIDSA; University of Texas Southwestern, Dallas, TX</td>
</tr>
<tr>
<td>(1832) 2:15 p.m.</td>
</tr>
<tr>
<td>ROSE LEE, MD, MSPH; Boston Children’s Hospital, Boston, MA</td>
</tr>
<tr>
<td>(1833) 2:30 p.m.</td>
</tr>
<tr>
<td>MARIA K. SMATTI, MSC; Qatar University, Doha, Ad Dawhah, Qatar</td>
</tr>
<tr>
<td>(1834) 2:45 p.m.</td>
</tr>
<tr>
<td>SARWAT KHALIL, MD; Mayo Clinic, Rochester, MN</td>
</tr>
</tbody>
</table>

No CME is offered for this session.
No CPE credit is offered for this session.

<table>
<thead>
<tr>
<th>Pediatric ID/Adult ID/Trainee</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>184. Oral Abstract</strong></td>
</tr>
<tr>
<td><strong>Late Breaker Oral Abstract Session 2</strong></td>
</tr>
<tr>
<td><strong>Friday, 1:45 – 3 p.m.</strong></td>
</tr>
<tr>
<td><strong>209 ABC</strong></td>
</tr>
<tr>
<td><strong>No CME is offered for this session.</strong></td>
</tr>
<tr>
<td><strong>No CPE credit is offered for this session.</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adult ID/Pediatric ID/Epi/Infection Control</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>185. Oral Abstract</strong></td>
</tr>
<tr>
<td><strong>Staph aureus: New Perspectives on an Old Foe</strong></td>
</tr>
<tr>
<td><strong>Friday, 1:45 – 3 p.m.</strong></td>
</tr>
<tr>
<td><strong>206</strong></td>
</tr>
<tr>
<td><strong>Moderators:</strong></td>
</tr>
<tr>
<td>SHANDRA R. DAY, MD; Ohio State University Wexner Medical Center, Columbus, OH</td>
</tr>
<tr>
<td>GONZALO BEARMAN, MD, MPH, FACP, FIDSA, FSHEA; Virginia Commonwealth University Health System, Richmond, VA</td>
</tr>
</tbody>
</table>

### Speakers:

**1835** 1:45 p.m. **High Burden of Invasive *Staphylococcus aureus* Disease Among Native Americans on the White Mountain Apache Tribal Lands**
CATHERINE SUTCLIFFE, PHD, SCM; Johns Hopkins, Baltimore, MD

**1836** 2:00 p.m. **Genomic Epidemiology of Methicillin-Susceptible *Staphylococcus aureus* Colonization and Infection Among US Army Trainees at Fort Benning, Georgia**
JASON BENNETT, MD, MSPH; Walter Reed Army Institute of Research, Silver Spring, MD

**1837** 2:15 p.m. **Considerations for a Targeted Approach to Contact Precautions for Patients with MRSA in Hospitals: A Multicenter Cohort Study to Identify High-Risk Patient Characteristics and Healthcare Personnel Interactions**
LYNDSEY M. O’HARA, PHD, MPH; University of Maryland, Baltimore, MD

**1838** 2:30 p.m. **Bare Below the Elbows versus Sleeved Attire: a Pilot Study Comparing Microbial Flora of Healthcare Workers**
MARIAM ASSI, MD; Virginia Commonwealth University Health System, Richmond, VA

**1839** 2:45 p.m. **Contact Precautions’ Effects on MRSA Transmission in Department of Veterans Affairs Hospitals**
KARIM KHADER, PHD; IDEAS Center of Innovation, VA Salt Lake City Health Care System, Salt Lake City, UT

No CME is offered for this session.
No CPE credit is offered for this session.

### 186. Interactive

**Challenging Cases in Infectious Diseases**
Friday, 3:15 – 4:30 p.m. **Ballroom ABC**

**Objectives:** At the conclusion of this session, participants will be able to:
- develop a differential diagnosis for complex cases with suspected infections
- differentiate infectious from noninfectious causes of inflammatory syndromes

**Intended Audience:** Academicians, Clinicians, Fellows, Members-in-Training, HIV Clinicians, HIV Specialists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Microbiologists, Pharmacists

**Moderators:**
HENRY F. CHAMBERS, MD, FIDSA; University of California, San Francisco, San Francisco, CA
NESLI BASGOZ, MD, FIDSA; Massachusetts General Hospital, Boston, MA

**Panelists:**
TBD SPEAKER
Scientific Sessions (continued)

Speakers:
(1840) 3:15 p.m. 40 Year Old Transgender Woman with Rapidly Progressing Dementia and Myoclonus
KELLY ANNE JOHNSON, MD, MPH; University of California, San Francisco, San Francisco, CA

(1841) 3:30 p.m. PUO Serendipity
PRUTHU NARENDRA DHEKANE, MD; Apollo Hospital, Chennai, India, Pune, Maharashtra, India

(1842) 3:45 p.m. An Unusual Cause of Brain and Liver Abscesses in an Immunocompetent Woman
BERNARDO A. MARTINEZ-GUERRA, MD; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico

(1843) 4:00 p.m. A Case of Fulminant Liver Failure in an Immunosuppressed Returning Traveller
MUGE CEVIK; University of St. Andrews, Edinburgh, Scotland

(1844) 4:15 p.m. An Unusual Case of Paraplegia in a Pediatric Patient
ALESSIO MESINI, MD; Genoa University, Genova, Italy

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-386-L01-P

187. Symposium
Big Beasts II
Friday, 3:15 – 4:30 p.m. 146 ABC

Objectives: At the conclusion of this session, participants will be able to:
• discuss recent updates to guidelines for assessment and management of diabetic foot infections and describe strategies to optimize outcomes
• discuss epidemiology and current best practices for diagnosis and treatment of Salmonella, Shiga toxin-producing E. coli, and Norovirus gastrointestinal infection
• discuss epidemiology and current best practices for diagnosis and management of Clostridioides difficile infection in children
• describe strategies for assessment and diagnosis of vision-threatening infections and optimal management of ocular infections


Moderators:
MICHELLE FLORIS-MOORE, MD, MS; University of North Carolina, Chapel Hill, NC
ANDI L. SHANE, MD, MPH; Vanderbilt University Medical Center, Nashville, TN

Speakers:
(1846) 3:40 p.m. Ocular Infections
MARLENE L. DURAND, MD; Harvard Medical School, Boston, MA

(1845) 3:15 p.m. Top Four Beasts in Acute Gastroenteritis
ANDI L. SHANE, MD, MPH, MSC, FIDSA, FPIDS; Emory University, Atlanta, GA

(1847) 4:05 p.m. Diabetic Foot Infection
EDGAR JG PETERS, MD, PHD; Amsterdam University Medical Center, Amsterdam, Noord-Holland, the Netherlands

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-384-L04-P

188. Symposium
Cutting Edge in Pediatric Osteomyelitis: Basic Scientist, ID Clinician, and Orthopedist
Friday, 3:15 – 4:30 p.m. 150 AB

Objectives: At the conclusion of this session, participants will be able to:
• explain the concepts of bone homeostasis and osteo-immunologic crosstalk
• discuss optimal time for surgical interventions for osteomyelitis
• discuss how to diagnose and optimally treat osteomyelitis

Intended Audience: Academicians, Clinicians, Fellows, Infectious Diseases Pediatricians, Infectious Diseases Physicians

Moderators:
NATASHA B. HALASA, MD, MPH; Vanderbilt University Medical Center, Nashville, TN
PRANITA TAMMA, MD, MHS; Johns Hopkins, Baltimore, MD

Speakers:
(1848) 3:15 p.m. Bone Homeostasis and Osteo-Immunologic Crosstalk in the Setting of Pediatric Osteomyelitis
JIM CASSAT, MD, PHD; Vanderbilt University Medical Center, Nashville, TN

(1849) 3:40 p.m. Surgical Controversies in Pediatric Osteomyelitis
NATHAN DONALDSON, DO; Children’s Hospital Colorado, Aurora, CO

(1850) 4:05 p.m. Optimizing Diagnosis and Antimicrobial Treatment of Pediatric Osteomyelitis
SARAH K. PARKER, MD; Children’s Hospital Colorado, Aurora, CO

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-329-L04-P

189. Symposium
HIV Prevention
Friday, 3:15 – 4:30 p.m. 145 AB

Objectives: At the conclusion of this session, participants will be able to:
• identify effective approaches to HIV prevention in women of color
• discuss the state of innovation in HIV prevention interventions
• evaluate interventions at the community level to reduce new HIV infections

Moderators:
MICHELLE FLORIS-MOORE, MD, MS; University of North Carolina, Chapel Hill, NC
ANDI L. SHANE, MD, MPH; Vanderbilt University Medical Center, Nashville, TN

Speakers:
(1846) 3:40 p.m. Ocular Infections
MARLENE L. DURAND, MD; Harvard Medical School, Boston, MA

(1845) 3:15 p.m. Top Four Beasts in Acute Gastroenteritis
ANDI L. SHANE, MD, MPH, MSC, FIDSA, FPIDS; Emory University, Atlanta, GA

(1847) 4:05 p.m. Diabetic Foot Infection
EDGAR JG PETERS, MD, PHD; Amsterdam University Medical Center, Amsterdam, Noord-Holland, the Netherlands

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-384-L04-P
### Scientific Sessions (continued)

**Intended Audience:** Academicians, Clinicians, Fellows, Members-in-Training, Health Care Workers, HIV Clinicians, HIV Specialists, Infection Preventionists, Infectious Diseases Physicians, Infectious Diseases Physicians, Nurses, Pharmacists, Public Health Practitioners

**Moderator:**
WENDY ARMSTRONG, MD, FIDSA; Emory University, Decatur, GA

**190. Symposium**

**I'm Better Than You and I Can Prove It: Quality Metrics and ID**

Friday, 3:15 – 4:30 p.m.  
Salon GHI

**Objectives:** At the conclusion of this session, participants will be able to:
- describe the use of quality metrics that apply to specific infectious diseases
- discuss the role of metrics in improving the care of patients with infectious diseases

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians

**Moderators:**
DAVID CLASSEN, MD; Pascal Metrics, Washington, DC  
JOHN B. LYNCH, MD; University of Washington, Seattle, WA

**Speakers:**
(1851) 3:15 p.m.  
**Prevention in Women**  
ANANDI N. SETH, MD, MS; Emory University, Atlanta, GA

(1852) 3:40 p.m.  
**Prevention Strategies on the Horizon**  
CRAIG HENDRIX, MD; Johns Hopkins, Baltimore, MD

(1853) 4:05 p.m.  
**Community-Based Prevention Implementation**  
SUSANNE DOBLECKI-LEWIS, MD, MSPH, FIDSA; University of Miami, Miami, FL

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-382-L02-P

**191. Symposium**

**Influential Publications in Healthcare Epidemiology, 2019**

Friday, 3:15 – 4:30 p.m.  
Salon ABC

**Objectives:** At the conclusion of this session, participants will be able to:
- describe the impactful publications in the field of infection control, antimicrobial stewardship, and public health from the past year

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Nurses, Pharmacists, Public Health Practitioners, Researchers

**Moderators:**
TOM TALBOT, III, MD, MPH, FIDSA, FSHEA; Vanderbilt University Medical Center, Nashville, TN  
LATANIA K. LOGAN, MD, MSPH; Rush University Medical Center, Chicago, IL

**Speakers:**
(1857) 3:15 p.m.  
**Influential Publications in Infection Control in the Past Year**  
LISA SAIMAN, MD, MPH; Columbia University Irving Medical Center, New York, NY

(1858) 3:40 p.m.  
**Influential Publications in Antibiotic Stewardship in the Past Year**  
MELINDA M. NEUHAUSER, PHARMD, FSHEA; FSHEA; Vanderbilt University Medical Center, Nashville, TN

(1859) 4:05 p.m.  
**Influential Publications in Public Health and Emerging Pathogens from the Past Year**  
JOHN A. JERNIGAN, MD, MS; Centers for Disease Control and Prevention, Atlanta, GA

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-381-L04-P

**192. Symposium**

**The Fungus Among Us**

Friday, 3:15 – 4:30 p.m.  
151 AB

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss diagnostic and treatment approaches to mold infections, sporotrichosis, and coccidioidomycosis
- identify patient groups and risk factors for these infections
- list experimental vaccine approaches for these infections

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Lab Personnel, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists, Vaccinologists

**Speakers:**
(1854) 3:15 p.m.  
**Pending QI Regulations and How They Will Impact You**  
DALE W. BRATZLER, DO, MPH, FIDSA; Oklahoma University Health Sciences Center, Oklahoma City, OK

(1855) 3:40 p.m.  
**Review of the QIC Manuscript: “How Do You Measure Up?”**  
JOSHUA C. EBY, MD; University of Virginia, Charlottesville, VA

(1856) 4:05 p.m.  
**Update on QI Measures for CDI and the SHEA Compendium**  
MICHAEL LANE, MD, MPH, MSC; Washington University, St. Louis, MO

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-387-L04-P
193. Symposium
The State of HCV Elimination
Friday, 3:15 – 4:30 p.m.

Objectives: At the conclusion of this session, participants will be able to:
• discuss WHO goals for HCV elimination
• discuss country level treatment strategies for HCV infection
• discuss the goals for HCV elimination in the US

Moderators:
SUSANNA NAGGIE, MD, FIDSA; Duke University, Durham, NC
DAVID THOMAS, MD, FIDSA; Johns Hopkins, Baltimore, MD

Speakers:
(1863) 3:15 p.m. Strategy for HCV Elimination in the United States
TAMMY BECKHAM; U.S. Department of Health & Human Services, Washington, DC

(1864) 3:40 p.m. Novel Testing and Treatment Models of Care for HCV Infection
JOSEPH S. DOYLE, MBBS, MPH, PHD, FRACP; Burnet Institute, Alfred Health and Monash University, Melbourne, Victoria, Australia

(1865) 4:05 p.m. “Meeting WHO Goals for HCV Elimination One Country at a Time”
JEFFREY LAZARUS; ISGlobal, Barcelona, Spain

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-380-L06-P

195. Symposium
When the Transplant ID Physician Needs to “Phone a Friend”
Friday, 3:15 – 4:30 p.m.

Objectives: At the conclusion of this session, participants will be able to:
• describe the clinical settings associated with challenging, but frequently encountered infections in transplant candidate and recipients: drug-resistant CMV infections
• discuss the diagnostic complexities related to drug-resistant CMV infection
• formulate management strategies for drug-resistant CMV infections

### Scientific Sessions (continued)

**Moderators:**
- PEARLIE P. CHONG, MD, MSCR; University of Texas Southwestern, Dallas, TX
- LYNNE STRASFELD, MD; Oregon Health & Science University, Portland, OR

**Speakers:**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1869</td>
<td>How I Treat Resistant CMV Infections in Transplant Patients</td>
<td>RAYMUND R. RAZONABLE, MD, FIDSA; Mayo Clinic, Rochester, MN</td>
</tr>
<tr>
<td>1870</td>
<td>Managing Challenging Fungal Infections: Art or Science?</td>
<td>FERNANDA P. SILVEIRA, MD, MS, FIDSA; University of Pittsburgh, Pittsburgh, PA</td>
</tr>
<tr>
<td>1871</td>
<td>Optimizing Transplant Readiness in the Setting of Infection with MDROs</td>
<td>VALERIE WATERS, MD; Hospital for Sick Children, Toronto, ON, Canada</td>
</tr>
</tbody>
</table>

Maximum of 1.25 hours of AMA PRA Category 1 Credit™

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-1378-L01-P

---

### 196. Oral Abstract

**Pediatric Emerging Viral Diseases**

**Friday, 3:15 – 4:30 p.m.** 144 ABC

**Moderators:**
- ROBERTA DEBIASI, MD, MS, FIDSA, FPIDS; Children’s National Health System, Washington, DC
- WILLIAM J. MULLER, MD, PhD; Northwestern University, Chicago, IL

**Speakers:**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1872</td>
<td>Neurodevelopment in Apparently Normal Infants from Zika Virus Positive Pregnancies</td>
<td>SARAH B. MULKEY, MD, PhD; Children’s National Health System, Rockville, MD</td>
</tr>
<tr>
<td>1873</td>
<td>Pregnancy &amp; birth outcomes among Colombian women with Zika virus disease in 3 Surveillance Sites, Proyecto Vigilancia de Embarazadas con Zika</td>
<td>MARGARET (PEGGY) HONEIN, PHD; Centers for Disease Control and Prevention, Atlanta, GA</td>
</tr>
<tr>
<td>1874</td>
<td>Comparison of the Risk of Birth Defects in Live Births from Pregnant Women Infected and not Infected by Zika Virus in Guadeloupe, 2016-2017</td>
<td>BRUNO HOEN, MD, PhD; University Hospital of Nancy, Vandoeuvre Les Nancy, Lorraine, France</td>
</tr>
<tr>
<td>1875</td>
<td>La Crosse Virus Neuroinvasive Disease in Children: A Contemporary Review and Evaluation for Predictors of Disease Severity</td>
<td>ANGELIQUE ELENI. BOUTZOUKAS, MD; Nationwide Children’s Hospital, Columbus, OH</td>
</tr>
</tbody>
</table>

---

### 197. Oral Abstract

**Stewardship Success Stories**

**Friday, 3:15 – 4:30 p.m.** 147 AB

**Moderators:**
- TREVOR C. VAN SCOONEVELD, MD, FACP; University of Nebraska Medical Center, Omaha, NE
- MIRIAN DAL BEN, MD, MSC; Hospital Sírio Libanês, Sao Paulo, Brazil

**Speakers:**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1876</td>
<td>A Hepacivirus-Like Protein is Targeted by the Antibody Response to Kawasaki Disease (KD)</td>
<td>ANNE ROWLEY, MD; Northwestern University, Chicago, IL</td>
</tr>
</tbody>
</table>

No CME is offered for this session.
No CPE credit is offered for this session.
198. Oral Abstract

**Tuberculosis: Stigma, Diagnosis, and Treatment**
Friday, 3:15 – 4:30 p.m. 204 ABC

**Moderators:**
JEFFREY TORNHEIM, MD, MPH; Johns Hopkins, Baltimore, MD
EMILY A. KENDALL, MD, PHD; Johns Hopkins, Baltimore, MD

**Speakers:**
(1882) 3:15 p.m.  **Tuberculosis in the Department of Veterans Affairs: Missed Opportunities for Prevention**
GINA ODA, MS, CIC; Department of Veterans Affairs, Palo Alto, CA

(1883) 3:30 p.m.  **Factors Associated with Stigma toward Isoniazid-Preventative Therapy in a Rural Community of South Africa**
CARLO F. FOPIANO PALACIOS, MD; University of Maryland, Baltimore, MD

(1884) 3:45 p.m.  **Clinical Outcomes among Patients with Drug-Resistant Tuberculosis receiving Bedaquiline or Delamanid Containing Regimens**
RUSSELL R. KEMPKER, MD, MSC, FIDSA; Emory University, Atlanta, GA

(1885) 4:00 p.m.  **T-Helper 1 (Th1) Production of Interferon Gamma (IFN-γ) is Directly Inhibited by TGFβ Within Pulmonary Mycobacterium tuberculosis (Mt) Granulomas**
BENJAMIN H. GERN, MD; Seattle Children's Hospital, Seattle, WA

(1886) 4:15 p.m.  **N1, N12-Diacetylspermine as Potential Urinary Biomarker to Monitor Treatment Response and Bacterial Load in Pulmonary Tuberculosis**
QIANJING (JENNY) XIA, BA; Weill Cornell Medicine, New York, NY

No CME is offered for this session.
No CPE credit is offered for this session.

199. Oral Abstract

**What’s New and Happening in Public Health**
Friday, 3:15 – 4:30 p.m. 206

**Moderators:**
PATRICIA GRIFFIN, MD, FIDSA; Centers for Disease Control and Prevention, Decatur, GA
EMILY ERBELDING, MD, FIDSA; National Institutes of Health, Rockville, MD

**Speakers:**
(1887) 3:15 p.m.  **Estimating the Burden of Waterborne Disease in the United States**
SARAH COLLIER, MPH; Centers for Disease Control and Prevention, Atlanta, GA

(1888) 3:30 p.m.  **A Nationwide Outbreak of Invasive Pneumococcal Disease (IPD) Caused by a Novel Streptococcus pneumoniae Serotype 2 (SP2) Clone in the PCV13 Era, in Israel**
RON DAGAN, MD, FIDSA; Ben-Gurion University of the Negev, Beer Sheva, HaDarom, Israel

(1889) 3:45 p.m.  **Clinical Features Distinguishing Enterovirus A71 and Enterovirus D68-Associated Acute Flaccid Myelitis in Colorado, 2013-2018**
KEVIN MESSCAR, MD; University of Colorado, Aurora, CO

(1890) 4:00 p.m.  **Missed Clinical Opportunities to Prevent Infections and Treat Substance Use Disorder (SUD) in People Who Inject Drugs (PWID)**
ANA C. BARDOSSY, MD; Centers for Disease Control and Prevention, Decatur, GA

(1891) 4:15 p.m.  **Invasive Group A Streptococcus Infections Among Residents of Multiple Nursing Homes—Denver, Colorado, 2017–2018**
OSATOHAMWEN IDUBOR, MD, MHS, CHES; Centers for Disease Control and Prevention, Atlanta, GA

No CME is offered for this session.
No CPE credit is offered for this session.

200. Symposium

**Ending HIV as an Epidemic: An Update and Discussion**
Friday, 4:45 – 6 p.m. 146 ABC

**Objectives:** At the conclusion of this session, participants will be able to:
- review key components of the administration’s Ending the HIV Epidemic initiative
- discuss the status of implementation of the Ending the HIV Epidemic initiative
- identify opportunities to engage in local efforts to end HIV as an epidemic

**Intended Audience:** Academicians, Clinicians, Fellows, Members-in-Training, Health Care Workers, HIV Clinicians, HIV Specialists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Nurses, Pharmacists, Public Health Practitioners

**Speakers:**
(1892) 4:45 p.m.  TBD 353
(1893) 4:45 p.m.  TBD 355
(1894) 4:45 p.m.  TBD 354

Maximum of 1.25 hours of AMA PRA Category 1 Credit™ ACPE 1.25 knowledge-based contact hours of pharmacy CE;
0221-9999-19-389-L02-P

201. Oral Abstract

**SHEA Featured Oral Abstract**
Friday, 4:45 – 5:00 p.m. Ballroom ABC

**Moderators:**
HILARY BABCOCK, MD, MPH, FIDSA; FSHEA; Washington University School of Medicine, St. Louis, MO
202. Named Lecture
SHEA Lecture
Friday, 4:45 – 6 p.m. Ballroom ABC

Objectives: At the conclusion of this session, participants will be able to:
- analyze the outstanding infection prevention questions that are relevant for your healthcare setting
- construct innovative solutions to meet the challenges of these patient safety questions
- integrate solutions with the entire healthcare team to change practice


Moderator: HILARY BABCOCK, MD, MPH, FIDSA, FSHEA; Washington University School of Medicine in St. Louis, St. Louis, MO

Speaker: (1896) 4:45 p.m. Oh the Places We Can Go!
TRISH M. PERL, MD, MSC, FIDSA, FSHEA; University of Texas Southwestern, Dallas, TX

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-390-L04-P

203. Named Lecture
Stanley A. Plotkin Lectureship in Vaccinology
Friday, 4:45 – 6 p.m. Salon GHI

Objectives: At the conclusion of this session, participants will be able to:
- describe the rationale for and mechanism of maternal immunization to protect newborn infants from infectious diseases
- describe current vaccines utilized for maternal immunization and data regarding safety and efficacy
- list future targeted infectious diseases for which maternal vaccination may be useful

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Nurses, Public Health Practitioners, Researchers, Scientists, Vaccinologists

Moderators:
ROBERTA DEBIASI, MD, MS, FIDSA, FPIDS; Children’s National Health System, Washington, DC
PAUL SPEARMAN, MD, FIDSA; Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

Speaker: (1897) 4:45 p.m. Immunizing Women to Protect their Newborn Infants: The New Normal?
SCOTT HALPERIN, MD; IWK Hlth Ctr, Halifax, NS, Canada

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-388-L06-P

204. Meet the Professor
Are the New Non-Molecular Assays Better for Diagnosis of Clostridiodes difficile Toxin Tests
Saturday, 8 – 9 a.m. 150 AB

Objectives: At the conclusion of this session, participants will be able to:
- appraise the performance of the newer non-molecular platforms for the detection of C difficile toxins in patient specimens
- discuss the challenges in distinguishing C difficile colonization from disease

Intended Audience: Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Lab Personnel, Microbiologists, Nurses, Pharmacists, Public Health Practitioners

Moderator: KAREN C. CARROLL, MD, FIDSA; Johns Hopkins University School of Medicine, Baltimore, MD

Maximum of 1 hour of AMA PRA Category 1 Credit™
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-19-396-L01-P

Pediatric ID/Adult ID/Transplant ID/Trainee

205. Meet the Professor
Burning Questions on Hot Topics in Transplant ID
Saturday, 8 – 9 a.m. 152 AB

Objectives: At the conclusion of this session, participants will be able to:
- identify common clinical dilemmas and questions that arise during the infectious diseases care of solid organ transplant and hematopoietic stem cell transplant recipients
- discuss evidence-based management approaches to these transplant infectious diseases clinical dilemmas and questions
- evaluate nuances in the practice of transplant infectious diseases

206. Meet the Professor
Fighting the TB Epidemic in Children and Adolescents: Game-Changing Advances in Pediatric TB
Saturday, 8 – 9 a.m. 103 AB

Objectives: At the conclusion of this session, participants will be able to:
• discuss how to improve delivery of preventive therapy to TB contacts
• describe the challenges posed by the TB epidemic in children/adolescents globally

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Health Care Workers, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians

Speakers:
(1900) 8:00 a.m. Pediatric TB Contact Tracing: Can We Improve Delivery of Preventive Therapy to TB Contacts?
ANNA M. MANDALAKAS, MD, PHD; Baylor College of Medicine, Houston, TX

(1901) 8:00 a.m. Meeting the Challenges Posed by the TB Epidemic in Children/Adolescents Globally
CHRISTY BENERI, DO; Stony Brook Children’s Hospital, Stony Brook, NY

Maximum of 1 hour of AMA PRA Category 1 Credit™ ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-19-397-L01-P

207. Meet the Professor
Infectious Complications of Immunomodulatory Biologic Agents: Risk Assessment, Diagnosis, and Management
Saturday, 8 – 9 a.m. 209 ABC

Objectives: At the conclusion of this session, participants will be able to:
• describe key elements for assessing risk of infection prior to initiation of immunomodulatory biologic drugs
• review major infections associated with immunomodulatory drugs


Speakers:
(1902) 8:00 a.m. Infectious Complications of Immunomodulatory Biologic Agents
KEVIN L. WINTHROP, MD, MPH; Oregon Health & Science University, Portland, OR

(1903) 8:00 a.m. Infectious Complications of Immunomodulatory Biologic Agents
CASSANDRA CALABRESE, DO; Cleveland Clinic Foundation, Cleveland, OH

Maximum of 1 hour of AMA PRA Category 1 Credit™ ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-19-400-L01-P

208. Meet the Professor
Leveraging Social Media for Professional Success
Co-organized with the IDSA Medical Education Workgroup
Saturday, 8 – 9 a.m. 143 ABC

Objectives: At the conclusion of this session, participants will be able to:
• recognize individual online identities
• manage risks and benefits of social media utilization
• define best practices for social media engagement and participate in hands-on social media use


Speakers:
(1904) 8:00 a.m. Leveraging Social Media for Professional Success
KELLY CAWCUTT, MD, MS; University of Nebraska Medical Center, Omaha, NE
JASMINE R. MARCELIN, MD; University of Nebraska Medical Center, Omaha, NE

Maximum of 1 hour of AMA PRA Category 1 Credit™ ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-19-393-L04-P

209. Meet the Professor
OPAT Update
Saturday, 8 – 9 a.m. 204 ABC

Objectives: At the conclusion of this session, participants will be able to:
• discuss the current state of outpatient parenteral antimicrobial therapy (OPAT)
211. Meet the Professor

**Teamwork! Collaboration and Antimicrobial Stewardship**

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss roles for hospitalists in antimicrobial stewardship programs
- discuss roles for nurses in antimicrobial stewardship programs

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Microbiologists, Nurses, Pharmacists, Public Health Practitioners

**Speakers:**

(1909) 8:00 a.m. **Collaborating with Hospitalists**
VALERIE M. VAUGHN, MD, MSC; Michigan Medicine, Ann Arbor, MI

(1910) 8:00 a.m. **Collaborating with Nurses**
ELIZABETH MONSEES, PHD, MBA, RN, CIC, FAPIC; Children’s Mercy Hospital, Kansas City, MO

**Maximum of 1 hour of AMA PRA Category 1 Credit™**
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-19-395-L04-P

Pediatric ID/Adult ID/Epi/Infection Control/Global ID/Trainee

212. Meet the Professor


**Objectives:** At the conclusion of this session, participants will be able to:
- describe the GeoSentinel Surveillance network- what it is and significance for infectious diseases physicians
- disseminate relevant information and suggested response options for new or acutely emerging infections, including potential bio-terrorism threats to the network of GeoSentinel clinicians and other collaborating networks
- explain how to maintain an international communications and data collection network of travel and tropical medicine clinics on all continents (except Antarctica) by tracking geographic and temporal trends in infectious diseases among travelers and migrants

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, HIV Clinicians, Lab Personnel, Microbiologists, Nurses, Scientists

**Speakers:**

(1911) 8:00 a.m. **The Who, What, Why, When of the GeoSentinel Surveillance Network and Emerging Infectious Diseases**
DAVID H. HAMER, MD, FIDSA; Boston University, Boston, MA

**Maximum of 1 hour of AMA PRA Category 1 Credit™**
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-19-394-L04-P

Pediatric ID/Adult ID/Epi/Infection Control/Global ID/Trainee
213. Meet the Professor

Updates from NHSN and the HICPAC NHSN Work Group
Saturday, 8 – 9 a.m.

Objectives: At the conclusion of this session, participants will be able to:
- discuss upcoming changes to the National Healthcare Safety Network
- describe the role of the NHSN HICPAC Work Group and list updates from the Work Group

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists

Speakers:
(1913) 8:00 a.m. Updates from NHSN
ANDREA BENIN, MD; Connecticut Children’s Medical Center, Farmington, CT

(1914) 8:00 a.m. Updates from the NHSN HICPAC Work Group
DEBORAH S. YOKOE, MD, MPH, FIDSA, FSHEA; University of California, San Francisco, San Francisco, CA

Maximum of 1 hour of AMA PRA Category 1 Credit™
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-19-391-L04-P

214. Meet the Professor

Rapid Diagnostics and Resistance: Making Sense of Now and the Future Part 2
Saturday, 8 – 9 a.m.

Speakers:
(1915) 8:00 a.m. Cepheid
(1916) 8:00 a.m. Biofire
(1917) 8:00 a.m. GenMark
(1918) 8:00 a.m. OpGen
(1919) 8:00 a.m. T2 Biosystems
(1920) 8:00 a.m. Hardy Diagnostics/NG Biotech

No CME is offered for this session.
No CPE credit is offered for this session.
217. Interactive

Diagnosis and Management of Congenital CMV on Both Sides of the Pond: UK and Europe

Co-organized with the European Society for Paediatric Infectious Diseases

Saturday, 10:30 – 11:45 a.m. 151 AB

Objectives: At the conclusion of this session, participants will be able to:
- discuss universal maternal and infant screening for congenital CMV infections in UK and Europe
- discuss the management and antiviral treatment for congenital CMV infections in infants in treated the UK and Europe
- explain the benefits and challenges related to maternal vaccination


Moderators:
DELANE SHINGADIA, MBCHB, FRCPCH; Great Ormond Street Hospital, London, England, UK
PAUL SPEARMAN, MD, FIDSA; Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Speakers:
(1922) 10:30 a.m. Diagnosis and Management of Congenital CMV on Both Sides of the Pond: UK and Europe
DAVID KIMBERLIN, MD, FIDSA, FPIDS; University of Alabama at Birmingham, Birmingham, AL

(1923) 10:30 a.m. Diagnosis and Management of Congenital CMV on Both Sides of the Pond: UK and Europe
HERMIONE LYALL, MD; Imperial College Healthcare NHS Trust, London, UK

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-408-L01-P

218. Interactive

The Embers that Keep Smoldering: A Case-Based Multidisciplinary Approach to Prosthetic Joint Infections

Saturday, 10:30 – 11:45 a.m. Ballroom ABC

Objectives: At the conclusion of this session, participants will be able to:
- describe the accuracy and yield of clinical presentation, blood-tests and synovial fluid-tests in the diagnosis of indolent prosthetic joint infections
- identify the high-yield imaging characteristics of prosthetic joint infections and their mimics
- discuss the indications for and limitations of surgical management of prosthetic joint infections

Intended Audience: Clinicians, Fellows, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Microbiologists, Pharmacists

Interactive Moderators:
DOUGLAS R. OSMON, MD, FIDSA; Mayo Clinic, Rochester, MN
STEVEN K. SCHMITT, MD, FIDSA; Cleveland Clinic, Cleveland, OH

Panelists:
SANDRA B. NELSON, MD; Massachusetts General Hospital, Boston, MA
ANGELA HEWLETT, MD, MS, FIDSA; University of Nebraska Medical Center, Omaha, NE
CLAUS SIMPFENDORFER, MD; Cleveland Clinic, Cleveland, OH
KENNETH URISH, MD, PHD; University of Pittsburgh, Pittsburgh, PA

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-19-410-L01-P

219. Symposium

Advances in RSV: Preparing for Future RSV Vaccines and Immunoprophylaxis Products

Co-organized with the Centers for Disease Control and Prevention

Saturday, 10:30 – 11:45 a.m. Salon ABC

Objectives: At the conclusion of this session, participants will be able to:
- explain the epidemiology and molecular features of RSV A and B in the U.S. and globally
- discuss correlates of protection in children and adults
- describe RSV disease severity and mortality


Moderators:
INGER DAMON, MD, PHD, FIDSA; Centers for Disease Control and Prevention, Atlanta, GA
SUSAN GERBER, MD; Centers for Disease Control and Prevention, Atlanta, GA

Panelists:
STEVEN K. SCHMITT, MD, FIDSA; Cleveland Clinic, Cleveland, OH
DOUGLAS R. OSMON, MD, FIDSA; Mayo Clinic, Rochester, MN
KARL RAY, MD; University of Washington, Seattle, WA
EMILY SCHNEIDER, MD; University of Alabama at Birmingham, Birmingham, AL

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-19-403-L01-P

Speakers:
(1922) 10:30 a.m. Approaches to Measuring RSV Disease Burden (and Why it Matters)
GAYLE LANGLEY, MD, MPH; Centers for Disease Control and Prevention, Atlanta, GA

(1925) 10:55 a.m. RSV A, B and Molecular Features in the U.S. and Throughout the World
HELEN Y. CHU, MD, MPH; University of Washington, Seattle, WA

(1926) 11:20 a.m. Updates on Correlates of Protection Among Children and Adults
EDWARD E. WALSH, MD; University of Rochester, Rochester, NY
Scientific Sessions (continued)

220. Symposium
Co-Morbidities and Aging
Saturday, 10:30 – 11:45 a.m. 145 AB

Objectives: At the conclusion of this session, participants will be able to:
• describe co-morbidities common in people living with HIV as they age
• review key strategies for managing the care of older individuals with HIV
• assess clinical services and health care delivery infrastructure that are responsive to the unique needs of older individuals with HIV


Moderator:
VIRGINIA TRIANT, MD, MPH, FIDSA; Massachusetts General Hospital, Boston, MA

Speakers:
(1927) 10:30 a.m. Epidemiology of Aging-Related Co-morbidities in HIV Disease
KATHLEEN FITCH, MSN; Massachusetts General Hospital, Boston, MA

(1928) 10:55 a.m. A Geriatrician's Approach to People Aging with HIV
EUGENIA SIEGLER, MD; Weill Cornell Medicine, New York, NY

(1929) 11:20 a.m. Implementation of an HIV and Aging Clinical Program
MEREDITH GREENE, MD; University of California, San Francisco, San Francisco, CA

221. Symposium
Fostering Young Leadership Across Public Health and Academic Medicine: Year One of the LEAP Fellowship
Saturday, 10:30 – 11:45 a.m. 152 AB

Objectives: At the conclusion of this session, participants will be able to:
• describe innovative methods to address antibiotic stewardship in partnership with public health collaborators

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators,

Nurses, Pharmacists, Public Health Practitioners, Researchers

Moderator:
TOM TALBOT, III, MD, MPH, FIDSA, FSHEA; Vanderbilt University Medical Center, Nashville, TN
SUJAN REDDY, MD, MSC; Centers for Disease Control and Prevention, Atlanta, GA

Speakers:
(1930) 10:30 a.m. LEAP Scholar Presentation 1
JENNIFER BLUMENTHAL, MD; Boston Children's Hospital, Boston, MA

(1931) 10:48 a.m. LEAP Scholar Presentation 2
GABRIELA ANDUJAR VAZQUEZ, MD; Tufts Medical Center, Boston, MA

(1932) 11:06 a.m. LEAP Scholar Presentation 3
DANA PEPE, MD, MPH; Yale University, New Haven, CT

(1933) 11:25 a.m. LEAP Scholar Presentation 4
MILNER STAUB, MD; Vanderbilt University Medical Center, Nashville, TN

222. Symposium
Optimizing PK/PD of New Antibiotics Against MDR Organisms
Co-organized with the Society of Infectious Diseases Pharmacists
Saturday, 10:30 – 11:45 a.m. 146 ABC

Objectives: At the conclusion of this session, participants will be able to:
• assess the impact of infections due to MDR organisms on patient outcomes
• distinguish the merits of new antibiotics
• formulate effective treatment strategies for infections due to MDR organisms

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Lab Personnel, Microbiologists, Pharmacists, Public Health Practitioners, Researchers, Scientists

Moderators:
VINCENT TAM, PHARMD, FIDSA; University of Houston, Houston, TX
ELIZABETH B. HIRSCH, PHARMD; University of Minnesota, Minneapolis, MN

Speakers:
(1934) 10:30 a.m. Beta-lactam beta-lactamase Inhibitor Combinations
MARC H. SCHEETZ, PHARMD, MSC; Midwestern University/Northwestern Memorial Hospital, Chicago, IL

(1935) 10:55 a.m. Plazomicin: Novel Once-daily Aminoglycoside
KAMILIA ABDELRAOUF, PHD; Center for Anti-Infective Research and Development/ Hartford Hospital, Hartford, CT
### 223. Symposium

**Tick-Tac-Toe: Tick-Borne Infections Upping the Game**

**Co-organized with the Infectious Diseases Society of China**

**Saturday, 10:30 – 11:45 a.m.**

**150 AB**

**Objectives:** At the conclusion of this session, participants will be able to:

- review the epidemiology of emerging tick-borne Infections in the US
- discuss clinical and diagnostic features of tick-borne infections
- review diagnostic and clinical features of Severe Fever with Thrombocytopenia Syndrome

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Infectious Diseases Physicians

**Moderators:**

- J. STEPHEN DUMLER, MD; Uniformed Services University of the Health Sciences, Bethesda, MD
- HANA M. EL SAHLY, MD; Baylor College of Medicine, Houston, TX

**Speakers:**

- GUI-QIANG (JOHN) WANG, MD; Peking University First Hospital, Beijing, China
- ANNE PIANTADOSI, MD, PHD; Massachusetts General Hospital, Decatur, GA

**Speakers:**

- (1936) 11:20 a.m. **New Tetracycline Derivatives** *(Omadacycline and Eravacycline)*
  ALEXANDER LEPAK, MD; University of Wisconsin, Madison, WI

  Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**
  ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-402-L01-P

  **Epi/Infection Control/Global ID/Trainee**

**224. Symposium**

**Update on Strategies ID Clinicians Can Use to Treat Opioid Use Disorder**

**Co-organized with the National Institutes of Health**

**Saturday, 10:30 – 11:45 a.m.**

**207 AB**

**Objectives:** At the conclusion of this session, participants will be able to:

- describe how ID physicians can enact systems changes to improve outcomes in opiate use disorders

**Intended Audience:** Academicians, Clinicians, Fellows, Members-in-Training, Health Care Workers, HIV Clinicians, HIV Specialists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Nurses, Pharmacists, Public Health Practitioners

**Moderators:**

- LAURA W. CHEEVER, MD, FIDSA; Health Resources and Services Administration, Germantown, MD
- EMILY EMBERLING, MD, FIDSA; National Institutes of Health, Rockville, MD

**Speakers:**

- (1940) 11:20 a.m. **Integrating Responses at the Intersection of Opioid Use Disorder and Infectious Diseases**
  CARLOS DEL RIO, MD, FIDSA; Rollins School of Public Health of Emory University, Decatur, GA

  Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**
  ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-405-L01-P

  **Pediatric ID/Adult ID/Global ID/Trainee**

**225. Symposium**

**US Military Research Advancing Global Health**

**Saturday, 10:30 – 11:45 a.m.**

**202 AB**

**Objectives:** At the conclusion of this session, participants will be able to:

- describe the role of the Multidrug-Resistant organism Repository and Surveillance Network in the Combating Antibiotic Resistant Bacteria National Action Plan
- recognize the contributions of Department of Defense research toward Ebola vaccine development
- discuss the role of US military research programs in the development of FDA approved antimalarial drugs

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, HIV Clinicians, HIV Specialists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Lab Personnel, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists, Vaccinologists

**Moderators:**

- HEATHER YUN, MD, FIDSA; San Antonio Military Medical Center; Uniformed Services University of the Health Sciences, San Antonio, TX
- DANA M. BLYTH, MD; Brooke Army Medical Center, San Antonio, TX
### Scientific Sessions (continued)

<table>
<thead>
<tr>
<th>Speakers:</th>
<th>(1943) 10:30 a.m.</th>
<th>MDR Surveillance Systems and Strategies</th>
<th>PAIGE WATERMAN, MD; OSTP/WRAIR, Bethesda, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(1944) 10:55 a.m.</td>
<td>Ebola Vaccine Development</td>
<td>JULIE AKE, MD, MSC; Walter Reed Army Institute of Research, Laurel, MD</td>
</tr>
<tr>
<td></td>
<td>(1945) 11:20 a.m.</td>
<td>Advances in Malaria Therapeutics</td>
<td>MARK FUKADA; AFIRMS, Silver Spring, MD</td>
</tr>
</tbody>
</table>

Maximum of 1.25 hours of AMA PRA Category 1 Credit™

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-406-L04-P

| 226. Oral Abstract | Advances/in/ID/Med/Ed | Saturday, 10:30 – 11:45 a.m. |

#### Objectives for all IDWeek Oral Abstract Sessions: ALL IDWeek Oral Abstract Session objectives coincide with the IDWeek meeting objectives and are available online at [www.idweek.org](http://www.idweek.org).

#### Intended Audience for all IDWeek Oral Abstract Sessions:
Academicians, Clinicians, Epidemiologists, Fellows, Health Care Workers, HIV Clinicians, HIV Specialists, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Lab Personnel, Medical Students and Residents, Members-in-Training, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists, Vaccinologists

<table>
<thead>
<tr>
<th>Moderators:</th>
<th>ERIN BONURA, MD, MCR; Oregon Health &amp; Science University, Portland, OR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>WENDY STEAD, MD; Beth Israel Deaconess Medical Center, Boston, MA</td>
</tr>
</tbody>
</table>

#### Speakers:

<table>
<thead>
<tr>
<th>(1946) 10:30 a.m.</th>
<th>An Exploratory Study of the Therapeutic Reasoning Underlying Antimicrobial Selection</th>
<th>EMILY ABDOLER, MD; University of Michigan, San Francisco, CA</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1947) 10:45 a.m.</td>
<td>Educational Impact of a Hybrid Infectious Diseases Rotation for Internal Medicine Residents</td>
<td>JAMES B. CUTRELL, MD; University of Texas Southwestern, Dallas, TX</td>
</tr>
<tr>
<td>(1948) 11:00 a.m.</td>
<td>Impact of @WuidQ, a Free Open-Access Medical Education Twitter Resource, on Infectious Disease Learning and Teaching</td>
<td>GEROME V. ESCOTA, MD; Washington University, St. Louis, MO</td>
</tr>
<tr>
<td>(1949) 11:15 a.m.</td>
<td>Putting Out Fires: Assessing Burnout within an Infectious Diseases Fellowship at an Academic Medical Center</td>
<td>LESLIE-ANN ALEXANDER, MD; Beth Israel Deaconess Medical Center, Dorchester, MA</td>
</tr>
<tr>
<td>(1950) 11:30 a.m.</td>
<td>Intentional Intergroup Experiential Education in an HIV/Infectious Diseases Clinic</td>
<td>CAROLINE DERRICK, PHARMD; University of South Carolina, Columbia, SC</td>
</tr>
</tbody>
</table>

No CME is offered for this session.
No CPE credit is offered for this session.

#### 227. Oral Abstract

**Novel Antimicrobials and Approaches Against MDR Organisms**

Saturday, 10:30 – 11:45 a.m. 144 ABC

#### Moderators:
WILLIAM R. MILLER, MD; Center for Antimicrobial Resistance and Microbial Genomics, UTHHealth, Houston, TX
JOSE M. MUNITA, MD; Genomics and Resistant Microbes (GeRM) Group, Millennium Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Region Metropolitana, Chile

#### Speakers:

<table>
<thead>
<tr>
<th>(1951) 10:30 a.m.</th>
<th>Extended Infusions of Beta-lactam Antibiotics are Feasible and May Improve Mortality in the Pediatric Population</th>
<th>TRACY N. ZEMBLES, PHARMD; Children’s Hospital of Wisconsin, Menomonee Falls, WI</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1952) 10:45 a.m.</td>
<td>Bacteriophage Treatment Improves Survival of Mice Infected with Carbapenem-Resistant <em>Klebsiella pneumoniae</em></td>
<td>SHAYLA HESSE, MD; National Cancer Institute, Rockville, MD</td>
</tr>
<tr>
<td>(1953) 11:00 a.m.</td>
<td>VE303, a Rationally Designed Bacterial Consortium for Prevention of Recurrent <em>Clostridiodes difficile</em> (C. difficile) infection (rCDI), Stably Restores the Gut Microbiota after Vancomycin (Vanco)-Induced Dysbiosis in Adult Healthy Volunteers (HV)</td>
<td>DMITRI BOBILEV, MD; Vedanta Biosciences, Cambridge, MA</td>
</tr>
<tr>
<td>(1954) 11:15 a.m.</td>
<td>In Vivo Efficacy of Delayed Therapy with the Novel Inositol Acyltransferase Inhibitor Fosmanogepix (APX001) in a Murine Model of Candida Auris Invasive Candidiasis</td>
<td>NATHAN P. WIEDERHOLD, PHARMD, FIDSA; University of Texas Health San Antonio, San Antonio, TX</td>
</tr>
<tr>
<td>(1955) 11:30 a.m.</td>
<td>Novel Compound Reverses Vancomycin Resistance in Vancomycin Resistant <em>Enterococci</em> (VRE)</td>
<td>KENNETH ONYEDIIBE, MBBS, MSC, FWACP, FMCPATH; Purdue Institute for Immunology, Inflammation &amp; Infectious Diseases, Purdue University, West Lafayette, IN</td>
</tr>
</tbody>
</table>

No CME is offered for this session.
No CPE credit is offered for this session.
228. Oral Abstract
Pediatric Stewardship
Saturday, 10:30 – 11:45 a.m. 204 ABC

Moderators:
NISHA THAMPI, MD MSC; Children’s Hospital of Eastern Ontario, Ottawa, ON, Canada
PHILIP ZACHARIAH, MD, MS; Columbia University Irving Medical Center, New York, NY

Speakers:
(1956) 10:30 a.m. Reduction in Endotracheal Aspirate Cultures after Implementation of a Diagnostic Stewardship Intervention in a Pediatric Intensive Care Unit
ANNA SICK-SAMUELS, MD, MPH; Johns Hopkins, Baltimore, MD

(1957) 10:45 a.m. Impact of Beta-Lactam Antibiotic Allergy on Antimicrobial Use, Clinical Outcomes, and Costs for Hospitalized Children
TRAHERN WALLACE. JONES, MD; University of Utah, Salt Lake City, UT

(1958) 11:00 a.m. Assessment of Guideline-Concordant Antimicrobial Prescribing in Urgent Care Centers
JANET WU, PHARMD, BCIDP; Cleveland Clinic, Cleveland, OH

(1959) 11:15 a.m. Parent Satisfaction and Antibiotic Prescribing for Pediatric Respiratory Infections by Telemedicine
CHARLES B. FOSTER, MD; Cleveland Clinic Children’s, Cleveland, OH

(1960) 11:30 a.m. Lost in Translation-Comparing Rates of Outpatient Antibiotic Use in Three Metrics
CHRISTOPHER PRESTEL, MD; Centers for Disease Control and Prevention, Decatur, GA

No CME is offered for this session.
No CPE credit is offered for this session.

229. Oral Abstract
The End of AIDS Starts with Prevention
Saturday, 10:30 – 11:45 a.m. 147 AB

Moderators:
MICHELLE CESPEDES, MD, MS; Icahn School of Medicine at Mount Sinai; Mount Sinai Health System, New York, NY
JENNIFER BLUMENTHAL, MD; Boston Children’s Hospital, Boston, MA

Speakers:
(1961) 10:30 a.m. Grindr™ on Screen Activity on iPhones Correlates with HIV Risk and Substance Use in Men Who Have Sex with Men, San Diego
MARTIN HOENIGL, MD; University of California, San Diego, San Diego, CA

(1962) 10:45 a.m. Renal Outcomes for Participants Taking F/TAF versus F/TDF for HIV PrEP in the DISCOVER Trial

No CME is offered for this session.
No CPE credit is offered for this session.
269 Pathogenesis and Host-Response Interactions
270 Pediatric Respiratory Infections
271 Pediatric Respiratory Viral Infections
272 Studies of Treatment and Prevention of Viral Disease
273 Transplant ID: Bacterial Infections
274 Transplant ID: C. diff
275 Transplant ID: Malignancy and Neutropenia
276 Transplant ID: Parasitic Infections
277 Vaccines: Bacterial
278 Vaccines: Influenza
279 Vaccines: Viral Non-Influenza
280 Viral Pathogenesis
281 Viral Respiratory Diseases
282 Zika Virus Infection

230. Rapid Fire Poster
Rapid Fire Poster Session: Outbreaks
Saturday, 12:15 – 12:45 p.m. Hall B +C - Arena 2

Moderator:
JAMES M. HUGHES, MD, FIDSA; Emory University, Decatur, GA

Speakers:
(1966) 12:15 p.m. Response to a Cluster of Haemophilus influenzae Serotype A Cases in a Small Alaska Community, 2018
LEISHA NOLEN, MD, PHD; Centers for Disease Control and Prevention, Anchorage, AK

(1968) 12:20 p.m. Legionellosis Cluster Associated with Direct and Indirect Hot Tub Exposure — West Virginia, 2018
JARED R. RISPENS, MD, REHS/RS; Centers for Disease Control and Prevention, Atlanta, GA

(1969) 12:25 p.m. Pediatric Mumps during the 2015–2017 Mumps Resurgence in the United States
MARIEL MARLOW, PHD, MPH; Centers for Disease Control and Prevention, Atlanta, GA

(1967) 12:30 p.m. Prolonged Local Epidemic of an XDR P. aeruginosa Subclone of High-Risk Clonal Complex 298
NATHAN B. PINCUS, BS; Northwestern University, Chicago, IL

(1971) 12:35 p.m. What's Lurking in the Drain? Serial Transmission of NDM-1 Klebsiella pneumoniae to Patients Admitted 9 months Apart to the Same ICU Room
BECKY A. SMITH, MD; Duke University, Durham, NC

(1970) 12:40 p.m. Healthcare-Associated Pediatric Cutaneous Mucormycosis at Texas Children's Hospital, 2012-2019
LUCILA MARQUEZ, MD, MPH; Baylor College of Medicine, Houston, TX

No CME is offered for this session.
No CPE credit is offered for this session.

231. Rapid Fire Poster
Rapid Fire Poster Session: Vaccines
Saturday, 12:15 – 12:45 p.m. Hall B +C - Arena 1

Moderator:
KATHRYN M. EDWARDS, MD; Vanderbilt University Medical Center, Nashville, TN

Speakers:
SARA S. KIM, MPH; ORISE; US Centers for Disease Control and Prevention, Atlanta, GA

(1975) 12:20 p.m. Immunogenicity of Inactivated Influenza Vaccines Given Early versus Late after Pediatric Allogeneic Hematopoietic Cell Transplantation
JENNIFER E. SCHUSTER, MD; Children’s Mercy Hospital, Kansas City, MO

(1974) 12:25 p.m. Meningococcal Vaccination among Patients Newly Diagnosed at High-Risk for Meningococcal Disease in the US
COSMINA HOGEA, PHD; GSK, Philadelphia, PA

(1972) 12:35 p.m. A Cohort Analysis of Completion of the Pediatric Measles-Mumps-Rubella-Varicella Series in the United States
MANJIRI D. PAWASKAR, PHD; Merck & Co., Inc., Kenilworth, NJ

(1973) 12:40 p.m. Uptake and Safety of Measles-Mumps-Rubella (MMR) Vaccine in Adolescents and Adults in the Vaccine Safety Datalink
KAYLA E. HANSON, MPH; Marshfield Clinic Research Institute, Marshfield, WI

No CME is offered for this session.
No CPE credit is offered for this session.

283. Symposium
A Focus on Personal Protective Equipment: How to Optimize Use to Prevent HAIs
Saturday, 1:45 – 3 p.m. 146 ABC

Objectives: At the conclusion of this session, participants will be able to:
• list the key considerations in design and selection of personal protective equipment
• learn the importance of correcting errors of donning and doffing
• describe ways in which experience with Ebola virus infection has improved routine practices with personal protective equipment

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Microbiologists, Public Health Practitioners, Researchers, Scientists, Vaccinologists
284. Symposium
Antivirals and Use of PCR Testing for Respiratory Viruses
Co-organized with the Centers for Disease Control and Prevention
Saturday, 1:45 – 3 p.m. 151 AB

Objectives: At the conclusion of this session, participants will be able to:
• explain how laboratory testing for respiratory viruses can impact antibiotic usage
• list antivirals for respiratory viruses
• discuss current approaches to laboratory testing for respiratory virus vaccines

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians

Moderators:
INGER DAMON, MD, PhD, FIDSA; Centers for Disease Control and Prevention, Atlanta, GA
SUSAN GERBER, MD; Centers for Disease Control and Prevention, Atlanta, GA

Speakers:
(2810) 1:45 p.m. Current Approaches to Laboratory Testing for Respiratory Viruses
RICHARD L. HODINKA, PHD; University of South Carolina, Greenville, SC
(2811) 2:10 p.m. Respiratory Virus PCR Testing and Antibiotic Use: Potential for Impact
EVAN J. ANDERSON, MD; Emory University, Atlanta, GA
(2812) 2:35 p.m. Updates on Antivirals-Not Just Influenza
FLOR M. MUNOZ, MD; Baylor College of Medicine, Houston, TX

285. Symposium
Back to Basics in Transplant ID
Saturday, 1:45 – 3 p.m. 202 AB

Objectives: At the conclusion of this session, participants will be able to:
• generate a differential diagnosis for the febrile transplant recipient and formulate a diagnostic approach
• construct an approach to the initial evaluation and management of pneumonia in transplant recipients
• review important dermatologic conditions encountered in transplant recipients that are relevant to the infectious disease clinician

Intended Audience: Academicians, Fellows, Members-in-Training, Infectious Diseases Pediatricians, Infectious Diseases Physicians

Moderators:
RACHEL MILLER, MD, FIDSA; Duke University, Durham, NC
REUBEN J. ARASARATNAM, MD, MPH; University of Texas Southwestern, Dallas, TX

Speakers:
(2813) 1:45 p.m. Thoughtfully Approaching Pneumonia in the Transplant Recipient
DANIEL R. KAUL, MD; University of Michigan, Ann Arbor, MI
(2814) 2:10 p.m. The Evaluation of Unexplained Fever After Transplantation
EMILY A. BLUMBERG, MD; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
(2815) 2:35 p.m. A Dermatology Primer for the Transplant ID Physician
KAROLYN WANAT, MD; Medical College of Wisconsin, Milwaukee, WI
Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Pharmacists, Public Health Practitioners, Researchers, Scientists

Moderator:
SHELLEY S. MAGILL, MD, PHD; Centers for Disease Control and Prevention, Atlanta, GA

Speakers:
(2816) 1:45 p.m. Implementing a Toolkit to Improve Antimicrobial Use in California Emergency Departments
ERIN EPSON, MD; California Department Of Public Health, Richmond, CA

(2817) 2:10 p.m. Public Health Partnership to Implement a Tele-Antimicrobial Stewardship Program in Washington State
MARISA A. D’ANGELI, MD, MPH; Washington State Department of Health, Shoreline, WA

(2818) 2:35 p.m. Helping Hospitals Improve Antibiotic Use Through the NHSN AUR Module: The Tennessee Experience
CHRISTOPHER D. EVANS, PHARMD; Tennessee Department of Health, Nashville, TN

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-419-L04-P

287. Symposium
Controversial Topics in HIV Clinical Care
Saturday, 1:45 – 3 p.m. Salon GHI

Objectives: At the conclusion of this session, participants will be able to:
• assess the pros and cons of HIV providers serving as specialist consultants versus HIV primary care providers
• discuss the pros and cons of routine anal cancer screening in patients with HIV


Moderator:
WENDY ARMSTRONG, MD; Emory University, Decatur, GA

Speakers:
(2819) 1:45 p.m. Anal Cancer Screening - PRO
JOEL PALEFSKY, MD; University of California, San Francisco, San Francisco, CA

(2820) 2:04 p.m. Anal Cancer Screening - CON
TIMOTHY WILKIN, MD, MPH, FIDSA; Weill Cornell Medicine, New York, NY

(2821) 2:23 p.m. HIV Specialist as PCP
MELANIE A. THOMPSON, MD; AIDS Research Consortium of Atlanta, Atlanta, GA

(2822) 2:42 p.m. HIV Specialist as Consultant
MICHAEL SAAG, MD, FIDSA; University of Alabama at Birmingham, Birmingham, AL

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-19-415-L02-P

288. Symposium
Diagnostic Updates: Clinical Mycology
Saturday, 1:45 – 3 p.m. 207 AB

Objectives: At the conclusion of this session, participants will be able to:
• explain the application of new methodologies, including MALDI-TOF, for the diagnosis of Candidemia
• explain how to optimally utilize fungal biomarker assays and susceptibility testing for the diagnosis and management of clinically relevant fungal infections
• explain new diagnostic approaches to the detection of invasive mold infections


Moderators:
RANDALL HAYDEN, MD; St. Jude Children's Research Hospital, Memphis, TN
BARBARA D. ALEXANDER, MD, MHS, FIDSA; Duke University, Durham, NC

Speakers:
(2823) 1:45 p.m. New Approaches to Diagnosis of Candidemia
MAURIZIO SANGUINETTI, MD; Università Cattolica del S. Cuore, Rome, Italy

(2824) 2:10 p.m. Use and Misuse of Fungal Biomarkers
BARBARA D. ALEXANDER, MD, MHS, FIDSA; Duke University, Durham, NC

(2825) 2:35 p.m. New Approaches to the Diagnosis of Invasive Mold Infections
SOPHIA KOO, MD, MSC; Brigham and Women's Hospital, Boston, MA

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-414-L01-P

289. Symposium
ID Physicians in a Value-Based World
Co-organized with the IDSA Clinical Affairs Committee
Saturday, 1:45 – 3 p.m. 152 AB

Objectives: At the conclusion of this session, participants will be able to:
• cite results of recent IDSA compensation survey
• define value of ID promotional material
• recognize the state of the ID specialty

Intended Audience: Clinicians

Moderators:
THOMAS M. FILE, JR., MD, FIDSA; Summa Health System, Akron, OH
### 290. Symposium
**Impact of Early Life Microbiome Disruptions in the Child**
Saturday, 1:45 – 3 p.m. 150 AB

**Objectives:** At the conclusion of this session, participants will be able to:
- state the evidence for and compare benefit and risk of vaginal microbiome seeding in C-section delivered newborns
- describe the long term effects of prenatal/perinatal/early neonatal antimicrobial exposure on childhood obesity, atopy and autoimmunity
- summarize current data regarding the association between the infant intestinal microbiome and necrotizing enterocolitis
- apply current data to understand current and future approaches to treatment of necrotizing enterocolitis

**Intended Audience:** Academicians, Clinicians, Fellows, Members-in-Training, Health Care Workers, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Microbiologists, Nurses, Researchers, Scientists

**Moderators:**
- ROBERTA DEBIASI, MD, MS, FIDSA, FPIDS; Children’s National Health System, Washington, DC
- ATHENA P. KOURTIS, MD, PHD, MPH, FIDSA; Centers for Disease Control and Prevention, Atlanta, GA

**Speakers:**
- (2829) 1:45 p.m. Vaginal Microbiome Seeding in C-section Delivered Newborns: What is the Evidence and Comparison of Benefit and Risk
  NOEL T. MUELLER, PhD, MPH, FAHA; Johns Hopkins University School of Medicine, Baltimore, MD
- (2830) 2:10 p.m. Association of the Intestinal Microbiome with Necrotizing Enterocolitis and Approaches to Treatment
  ANDI L. SHANE, MD, MPH, MSC; Emory University, Atlanta, GA

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
No CPE credit is offered for this session.

### 291. Symposium
**Maternal Immunization: Progress and Challenges**
Saturday, 1:45 – 3 p.m. 145 AB

**Objectives:** At the conclusion of this session, participants will be able to:
- summarize advances in the development and use of maternal vaccines
- examine on-going challenges associated with maternal immunization programs

**Intended Audience:** Academicians, Clinicians, Fellows, Members-in-Training, Health Care Workers, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists, Vaccinologists

**Moderators:**
- KATHY NEUZIL, MD, MPH; University of Maryland School of Medicine, Baltimore, MD
- RUTH KARRON, MD; Johns Hopkins, Baltimore, MD

**Speakers:**
- (2832) 1:45 p.m. Maternal Immunization for Influenza and Pertussis
  HELEN Y. CHU, MD, MPH; University of Washington, Seattle, WA
- (2833) 2:10 p.m. RSV and Other New Vaccines to Protect Women and Infants
  FLOR M. MUNOZ, MD; Baylor College of Medicine, Houston, TX
- (2834) 2:35 p.m. Ethical Considerations for the Involvement of Pregnant Women in Vaccine Studies
  RUTH FADEN, PHD, MPH; Johns Hopkins, Baltimore, MD

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-417-L06-P

### 292. Symposium
**The Etiology of Community-Acquired Pneumonia: How Appropriate are Current Guidelines?**
Saturday, 1:45 – 3 p.m. Ballroom ABC

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss current knowledge on the etiology of CAP
- list the strengths and pitfalls of current CAP treatment guidelines
- explain the correlations between new diagnostic platforms and antibiotic use

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians

**Moderators:**
- DANIEL M. MUSHER, MD, FIDSA; Baylor College of Medicine, Houston, TX

**Speakers:**
- (2826) 1:45 p.m. Results of IDSA Compensation Survey
  ANURAG N. MALANI, MD, FIDSA, FSHEA; St. Joseph Mercy Health System Ann Arbor, Ann Arbor, MI
- (2827) 2:10 p.m. Value of ID Promotional Material Update
  SUSAN BLEASDALE, MD, FIDSA; University of Illinois, Chicago, IL
- (2828) 2:35 p.m. The State of Infectious Diseases Specialty
  STUART CLARK; Advisory Board, Washington, DC

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-416-L01-P

---

**Pediatric ID/Adult ID/Global ID/Trainee**

**290. Symposium**

**Impact of Early Life Microbiome Disruptions in the Child**
Saturday, 1:45 – 3 p.m. 150 AB

**Objectives:**

- state the evidence for and compare benefit and risk of vaginal microbiome seeding in C-section delivered newborns
- describe the long term effects of prenatal/perinatal/early neonatal antimicrobial exposure on childhood obesity, atopy and autoimmunity
- summarize current data regarding the association between the infant intestinal microbiome and necrotizing enterocolitis
- apply current data to understand current and future approaches to treatment of necrotizing enterocolitis

**Intended Audience:**
- Academicians
- Clinicians
- Fellows
- Members-in-Training
- Health Care Workers
- Infection Preventionists
- Infectious Diseases Pediatricians
- Infectious Diseases Physicians
- Investigators
- Microbiologists
- Nurses
- Researchers
- Scientists

**Moderators:**
- ROBERTA DEBIASI, MD, MS, FIDSA, FPIDS; Children’s National Health System, Washington, DC
- ATHENA P. KOURTIS, MD, PHD, MPH, FIDSA; Centers for Disease Control and Prevention, Atlanta, GA

**Speakers:**
- (2829) 1:45 p.m. Vaginal Microbiome Seeding in C-section Delivered Newborns: What is the Evidence and Comparison of Benefit and Risk
  NOEL T. MUELLER, PhD, MPH, FAHA; Johns Hopkins University School of Medicine, Baltimore, MD
- (2830) 2:10 p.m. Association of the Intestinal Microbiome with Necrotizing Enterocolitis and Approaches to Treatment
  ANDI L. SHANE, MD, MPH, MSC; Emory University, Atlanta, GA

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
No CPE credit is offered for this session.

**291. Symposium**

**Maternal Immunization: Progress and Challenges**
Saturday, 1:45 – 3 p.m. 145 AB

**Objectives:**

- summarize advances in the development and use of maternal vaccines
- examine on-going challenges associated with maternal immunization programs

**Intended Audience:**
- Academicians
- Clinicians
- Fellows
- Members-in-Training
- Health Care Workers
- Hospital Administrators
- Hospital Epidemiologists
- Infection Preventionists
- Infectious Diseases Pediatricians
- Infectious Diseases Physicians
- Nurses
- Pharmacists
- Public Health Practitioners
- Researchers
- Scientists
- Vaccinologists

**Moderators:**
- KATHY NEUZIL, MD, MPH; University of Maryland School of Medicine, Baltimore, MD
- RUTH KARRON, MD; Johns Hopkins, Baltimore, MD

**Speakers:**
- (2832) 1:45 p.m. Maternal Immunization for Influenza and Pertussis
  HELEN Y. CHU, MD, MPH; University of Washington, Seattle, WA
- (2833) 2:10 p.m. RSV and Other New Vaccines to Protect Women and Infants
  FLOR M. MUNOZ, MD; Baylor College of Medicine, Houston, TX
- (2834) 2:35 p.m. Ethical Considerations for the Involvement of Pregnant Women in Vaccine Studies
  RUTH FADEN, PHD, MPH; Johns Hopkins, Baltimore, MD

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-417-L06-P

**292. Symposium**

**The Etiology of Community-Acquired Pneumonia: How Appropriate are Current Guidelines?**
Saturday, 1:45 – 3 p.m. Ballroom ABC

**Objectives:**

- discuss current knowledge on the etiology of CAP
- list the strengths and pitfalls of current CAP treatment guidelines
- explain the correlations between new diagnostic platforms and antibiotic use

**Intended Audience:**
- Academicians
- Clinicians
- Epidemiologists
- Fellows
- Members-in-Training
- Health Care Workers
- Infection Preventionists
- Infectious Diseases Pediatricians
- Infectious Diseases Physicians
- Investigators
- Microbiologists
- Nurses
- Researchers
- Scientists

**Moderators:**
- DANIEL M. MUSHER, MD, FIDSA; Baylor College of Medicine, Houston, TX
294. Oral Abstract

Late Breaker Oral Abstract Session 3
Saturday, 1:45 – 3 p.m.

Moderators:
VINCENT B. YOUNG, MD, PHD; University of Michigan, Ann Arbor, MI
LUIZ BERMUDEZ, MD, FSHEA; Oregon State University, Portland, OR

Speakers:

(2843) 1:45 p.m. Maternal Fecal Transplantation to Infants Born by Cesarean Section: Safety and Feasibility
OTTO HELVE, MD, PHD; Children’s Hospital, Pediatric Research Center, Helsinki University Hospital, University of Helsinki, Finland, Helsinki, Uusimaa, Finland

(2844) 2:00 p.m. Butyrogenic Bacteria after Acute Graft Versus Host Disease Associate with the Development of Steroid Refractory GVHD
JONATHAN L. GOLOB, MD, PHD; University of Michigan, Ann Arbor, MI

(2845) 2:15 p.m. Oral Antibiotic Use and Risk of Colorectal Cancer in the United Kingdom, 1989-2012: A Matched Case-Control Study
JIAJIA ZHANG, MD, MPH; Johns Hopkins, Baltimore, MD

(2846) 2:30 p.m. Perirectal Samples for Analysis of the Gut Microbiota as a Predictive Tool for Multidrug-Resistant Organism (MDRO) Acquisition in Nursing Facility (NF) Patients
JOYCE WANG, PHD; University of Michigan, Ann Arbor, MI

(2847) 2:45 p.m. Comparative Genomics and Clonal Tracking of Multidrug-Resistant Uropathogens Implicates the Fecal Microbiome as a Potential Reservoir for Recurrent Urinary Tract Infections
JEAN A. VAN WYK, MB,CHB; ViIV Healthcare, Brentford, England

No CME is offered for this session.
No CPE credit is offered for this session.
JENNIE H. KWON, DO, MSCI; Washington University, St. Louis, MO

No CME is offered for this session.
No CPE credit is offered for this session.

**Adult ID/Epi/Infection Control**

**296. Oral Abstract**

**New Insights into MDRO Gram-Negatives**

Saturday, 1:45 – 3 p.m.  204 ABC

**Moderators:**
MICHAEL Y. LIN, MD, MPH; Rush University Medical Center, Chicago, IL
L SILVIA MUNOZ-PRICE, MD, PHD; Medical College of Wisconsin, Milwaukee, WI

**Speakers:**
(2848)  1:45 p.m. Spatial Distribution of Community-Acquired Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Infections and its Association With Sewer Overflows in Middle Georgia
MARGARET OMATSONE, MD; Medical Center of Central Georgia, Navicent Health, Macon GA, Macon, GA

(2849)  2:00 p.m. Gut Microbiota Differences at the Time of Medical Intensive Care Unit (MICU) Admission Are Associated with Acquisition of Multidrug-Resistant Organisms (MDROs) Among Patients Not Already Colonized with an MDRO
CHRISTINE BASSIS, PHD; University of Michigan, Ann Arbor, MI

SAMEER S. KADRI, MD, MS, FIDSA; National Institutes of Health, Bethesda, MD

(2851)  2:30 p.m. Impact of Antimicrobial Resistant Gram-Negative Bloodstream Infections on Outcomes Among Pediatric Hospitalizations in the United States, 2009-2016
ALICEN B. SPAULDING, PHD, MPH; Children’s Minnesota Research Institute, Minneapolis, MN

(2852)  2:45 p.m. Epidemiology of Emerging Carbapenemase-Producing Organisms (CPO) in Chicago, Illinois, 2013-2018
STEPHANIE R. BLACK, MD, MSC; Chicago Department of Public Health, Chicago, IL

No CME is offered for this session.
No CPE credit is offered for this session.

**Pediatric ID/Investigative ID/Global ID**

**297. Oral Abstract**

**Pediatric Viral and Fungal Diseases**

Saturday, 1:45 – 3 p.m.  206

**Moderators:**
ASUNCION MEJIAS, MD, PHD, MSCS; Nationwide Children’s Hospital, Columbus, OH
PAUL K. SUE, MD; University of Texas Southwestern, Dallas, TX

**Speakers:**
(2853)  1:45 p.m. Innate Immune Response in Serum and Cerebrospinal Fluid of Neonates and Infants Infected with Parechovirus-A3 and Enteroviruses
RIE HABUKA, MD; Niigata University, Niigata, Niigata, Japan

(2854)  2:00 p.m. Enterovirus D68 Infections in Pediatric Patients in Central Ohio: Clinical Characteristics of a new Outbreak in 2018
ALEJANDRO DIAZ, MD; Nationwide Children’s Hospital, Columbus, OH

(2855)  2:15 p.m. Respiratory Syncytial Virus Neutralizing Antibodies in Cord Blood and Serum from Infants up to 2 Years of Age in a Multinational Prospective Study
JOSEPH B. DOMACHOWSKE, MD; SUNY Upstate Medical University, Syracuse, NY

(2856)  2:30 p.m. Salvaging High-Value Catheters: Antifungal Lock Therapy for Candidal Central Catheter Infections in a Pediatric Cohort
LORNE W. WALKER, MD, PHD; UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA

(2857)  2:45 p.m. A Statistical Model to Predict Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation Patients
MUAYAD ALALI, MD; University of Chicago, Chicago, IL

No CME is offered for this session.
No CPE credit is offered for this session.

**Pediatric ID/Global ID/Trainee**

**298. Interactive**

**This Year’s Innovations in Pediatric Infectious Diseases**

Saturday, 3:15 – 4:30 p.m.  207 AB

**Objectives:** At the conclusion of this session, participants will be able to:
• discuss the year’s most important innovations and guidelines that address controversies in pediatric clinical care and data
• apply insights into etiology, epidemiology, pathophysiology, diagnostics, treatment and prevention of infections in children and adolescents

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Nurses, Researchers, Scientists, Vaccinologists
300. Symposium
Hot Topics in Pediatric Infection Prevention
Saturday, 3:15 – 4:30 p.m.  152 AB

Objectives: At the conclusion of this session, participants will be able to:
• review upcoming changes to NHSN neonatal/pediatric healthcare-associated infection definitions
• explain how to implement evidence-based practices for the prevention of surgical site infections after scoliosis repair
• describe measures to prevent the transmission of respiratory viruses in pediatric long-term facilities

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Microbiologists, Nurses, Public Health Practitioners

Moderator:
JOSHUA K. SCHAFFZIN, MD, PHD; Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

Speakers:
(2861) 3:15 p.m. Improving Infection Surveillance Definitions in Pediatrics: An Update from NHSN
LATASHA POWELL; Centers for Disease Control and Prevention, Atlanta, GA

(2862) 3:40 p.m. More than “Just a Virus”: Lessons Learned from Adenovirus Outbreaks in Pediatric Long-Term Care.
LISA MCHUGH, PHD, MPH; New Jersey Department of Health, Trenton, NJ

(2863) 4:05 p.m. Straight Talk: Preventing Surgical Site Infections after Scoliosis Repair.
NATALIE NEU, MD, MPH; Columbia University Irving Medical Center, New York, NY

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-425-L04-P

301. Symposium
HPV Update
Co-organized with the Centers for Disease Control and Prevention
Saturday, 3:15 – 4:30 p.m.  151 AB

Objectives: At the conclusion of this session, participants will be able to:
• describe epidemiology of human papilloma virus infections
• recognize the science behind planning for global elimination of cervical cancer
• review the immunology of HPV vaccines


Speakers:
(2858) 3:15 p.m. Advances in Antifungal Therapy of Cryptococcal Infections
OLIVIER LORTHOLARY, MD; Hospital Avicenne, Bobigny, France

(2859) 3:40 p.m. HIV Therapy and Cryptococcosis: When to Start, What to Start With, and How to Manage IRIS
DAVID R. BOULWARE, MD, MPH, CTROPMED, FIDSA; University of Minnesota, Minneapolis, MN

(2860) 4:05 p.m. Epidemiology, Clinical Manifestations, and Prognosis of Cryptococcal Meningitis
NINA SINGH, MD; VA Medical Center, Pittsburgh, PA

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-427-L01-P
Scientific Sessions (continued)

Moderators:
INGER DAMON, MD, PHD, FIDSA; Centers for Disease Control and Prevention, Atlanta, GA
LAURI MARKOWITZ, MD; Centers for Disease Control and Prevention, Atlanta, GA
ELIZABETH R. UNGER, PHD, MD; Centers for Disease Control and Prevention, Atlanta, GA

Speakers:
(2864) 3:15 p.m. 
Modelling HPV Natural History and Vaccine Impact-Informing Policy and Acceleration of Global Elimination of Cervical Cancer
MARC BRISSON, PHD; Université Laval, Quebec, QC, Canada

(2865) 3:40 p.m.
HPV Vaccine Mechanisms-Explaining the Basis for Unexpected Effectiveness of Current Formulations and Horizon for New Vaccines
JOHN T. SCHILLER, PHD; National Cancer Institute, Bethesda, MD

(2866) 4:05 p.m.
Questions in HPV Epidemiology-Latency, Reactivation and Risk in Older Ages
RACHEL L. WINER, PHD, MPH; University of Washington, Seattle, WA

302. Symposium
Innovative Models for Retention in HIV Care
Saturday, 3:15 – 4:30 p.m. 150 AB

Objectives: At the conclusion of this session, participants will be able to:
• discuss current guidelines and methods for the detection of susceptibility and resistance among the non-tuberculous mycobacteria
• discuss updates in emerging non-tuberculous mycobacteria and assess their potential impact in the clinical laboratory setting
• describe the optimum methods for detection and identification of nontuberculous mycobacteria
• list the recommended testing strategies for susceptibility and resistance detection among non-tuberculous mycobacteria


Moderator:
KAREN C. CARROLL, MD, FIDSA; Johns Hopkins University School of Medicine, Baltimore, Maryland

Speakers:
(2867) 3:15 p.m.
Emerging Non-Tuberculous Mycobacteria
CHRISTINE Y. TURENNE, PHD, DABMM, FCCM; University of Manitoba, Winnipeg, MB, Canada

(2870) 3:15 p.m. 
Lessons from RLS: Community Based Retention Strategies
INGRID V. BASSETT, MD, MPH, FIDSA; Massachusetts General Hospital, Cambridge, MA

(2871) 3:40 p.m.
Diagnostic Methods for Detection and Identification of Non-Tuberculous Mycobacteria
EMMANUELLE CAMBAU; Assistance Publique Hopitaux De Paris, Paris, France

(2872) 4:05 p.m.
Update on Susceptibility Testing and Resistance among NTM
BARTHA A. BROWN-ELLIOTT, MS; University of Texas Health Science Center at Tyler, Tyler, TX

303. Symposium
Laboratory Diagnosis and Susceptibility Testing of Non-Tuberculous Mycobacteria
Saturday, 3:15 – 4:30 p.m. Salon ABC

Objectives: At the conclusion of this session, participants will be able to:
• discuss current guidelines and methods for the detection of susceptibility and resistance among the non-tuberculous mycobacteria
• discuss updates in emerging non-tuberculous mycobacteria and assess their potential impact in the clinical laboratory setting
• describe the optimum methods for detection and identification of nontuberculous mycobacteria
• list the recommended testing strategies for susceptibility and resistance detection among non-tuberculous mycobacteria


Moderator:
WENDY ARMSTRONG, MD; Emory University, Decatur, GA

Speakers:
(2868) 3:40 p.m. 
Retention in HIV Care: What is the Evidence in the US?
THOMAS P. GIORDANO, MD, MPH, FIDSA; Baylor College of Medicine, Houston, TX

(2869) 4:05 p.m. 
Lessons from RLS: Structural/Clinic Changes to Enhance Retention
ELVIN GENG, MD, MPH; Washington University, St. Louis, MO

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-420-L01-P

Pediatric ID/Adult ID/Trainee

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-420-L01-P
304. Symposium
Mechanistic Basis of Action and Resistance of B-Lactam/B-Lactamase Inhibitors
Saturday, 3:15 – 4:30 p.m.  Salon GHI

Objectives: At the conclusion of this session, participants will be able to:
- summarize the epidemiology of carbapenemase-producing organisms
- identify mechanisms of resistance to newer BLBIs
- review recent advances in the development of inhibitors of metallo-beta-lactamases

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Lab Personnel, Microbiologists, Pharmacists, Public Health Practitioners, Researchers, Scientists

Moderators:
YOHEI DOI, MD, PHD; University of Pittsburgh, Pittsburgh, PA
MARIA F. MOJICA, PHD; Case Western Reserve University, Cleveland, OH

Speakers:
(2873) 3:15 p.m. Genetic Basis of Carbapenemase Dissemination
ALESSANDRA CARATTOLI, PHD; Sapienza University of Rome, Rome, Italy

(2874) 3:40 p.m. Inhibitors Against Metallo-Beta-Lactamases
ALEJANDRO J. VILA, PHD; Instituto de Biología Molecular y Celular de Rosario (IBR), Rosario, Santa Fe, Argentina

(2875) 4:05 p.m. Avibactam and Vaborbactam Resistance
RYAN K. SHIELDS, PHARMD, MS; University of Pittsburgh, Pittsburgh, PA

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-423-L01-P

305. Symposium
Opportunistic Infections in the ICU: From Pathophysiology to Practical Approaches
Saturday, 3:15 – 4:30 p.m. 145 AB

Objectives: At the conclusion of this session, participants will be able to:
- discuss the pros and cons of gastrointestinal tract decolonization as a strategy to prevent hospital acquired infections
- contrast various approaches to using biomarkers in the diagnosis and treatment of critically ill patients with suspected infection
- identify useful strategies for diagnosing and treating critically ill, immunocompromised with suspected or proven infections

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Microbiologists, Researchers, Scientists

Moderators:
JOHN B. LYNCH, MD; University of Washington, Seattle, WA
JAVEED SIDDIQUI, MD, MPH; TeleMed2U, Roseville, CA

Speakers:
(2879) 3:15 p.m. Models of Telemedicine Service in ID
RIMA ABDUL-MASSIH, MD; University of Pittsburgh, Pittsburgh, PA

(2880) 3:15 p.m. Telemedicine and Antimicrobial Stewardship
CHRIS CRNICH, MD, PHD, FIDSA; University of Wisconsin, Madison, WI

(2881) 3:15 p.m. ID Telehealth Best Practices: Veterans’ Administration
JAMIE MORANO, MD, MPH; University of South Florida, Morsani College of Medicine, Tampa, FL

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-19-429-L04-P
307. Symposium
The Compromised Immunocompromised
Saturday, 3:15 – 4:30 p.m. 202 AB

Objectives: At the conclusion of this session, participants will be able to:
• demonstrate the added infection risks associated with the use of newer immunotherapies in organ transplantation and oncology
• review updates in HIV and transplantation
• discuss the impact of aging and immunosenescence on infection risk in transplantation


Moderators:
RACHEL MILLER, MD, FIDSA; Duke University, Durham, NC
NINA M. CLARK, MD, FIDSA; Loyola University Chicago Stritch School of Medicine, Maywood, IL

Speakers:
(2882) 3:15 p.m. Keeping up with the Nibs and the Mabs: New Therapies, New Risks?
MICHAIL LIONAKIS, MD, SCD; National Institute of Allergy and Infectious Diseases, Bethesda, MD

(2883) 3:15 p.m. Transplant and HIV Infection: Hoping for a Game Changer
CHRISTINE DURAND, MD; Johns Hopkins, Baltimore, MD

(2884) 3:15 p.m. Infection and the Aging Transplant Recipient: Does Immune Senescence Increase Infection Risk?
JOANNA SCHAENMAN, MD; David Geffen UCLA School of Medicine, Los Angeles, CA

No CME is offered for this session.
No CPE credit is offered for this session.

308. Oral Abstract
Fungi: Blood, Sweat, and Genes
Saturday, 3:15 – 4:30 p.m. 144 ABC

Moderators:
JENIEL E. NETT, MD, PHD; University of Wisconsin, Madison, WI
CORNELIUS J. CLANCY, MD; University of Pittsburgh, Pittsburgh, PA

Speakers:
(2885) 3:15 p.m. A Host Transcriptional Signature for Accurate Diagnosis of Candidemia in the Hospital Setting
JULIE M. STEINBRINK, MD; Duke University, Durham, NC

(2886) 3:30 p.m. Retrospective Case-Control Study of the Performance of the Karius Test, a Plasma Microbial Cell-Free DNA Next-Generation Sequencing Test, to Detect Invasive

(2887) 3:45 p.m. Identifying Candida albicans Transcription Factors (TFs) That Regulate Pathogenesis of Intra-Abdominal Candidiasis (IAC) by Screening a Deletion Mutant Library
CORNELIUS J. CLANCY, MD; University of Pittsburgh, Pittsburgh, PA

(2888) 4:00 p.m. STAT4 Mutation in Three Generations with Disseminated Coccidioidomycosis (DCM) Also Exhibits Increased Susceptibility to Coccidioidal Infection in Transfected Mice
JOHN N. GALGIANI, MD, FIDSA; University of Arizona, Tucson, AZ

(2889) 4:15 p.m. Skin Niche Conditions Trigger C. auris to Form Robust Biofilms that Resist Desiccation
JENIEL E. NETT, MD, PHD; University of Wisconsin, Madison, WI

309. Oral Abstract
Glass Half Full or Half Empty? Trends in Antimicrobial Prescribing
Saturday, 3:15 – 4:30 p.m. 147 AB

Moderators:
JASMINE R. MARCELIN, MD; University of Nebraska Medical Center, Omaha, NE
JASON M. POGUE, PHARMD, BCPS, BCIDP; University of Michigan, Ann Arbor, MI

Speakers:
(2890) 3:15 p.m. Antibiotic Overuse at Discharge in Hospitalized Patients with Bacteriuria or Treated for Pneumonia: A Multi-Hospital Cohort Study
VALERIE M. VAUGHN, MD, MSC; Michigan Medicine, Ann Arbor, MI

(2891) 3:30 p.m. Trends in Inpatient Antibiotic Use in U.S. Hospitals, 2012-2017
JAMES BAGGS, PHD; Centers for Disease Control and Prevention, Atlanta, GA

(2892) 3:45 p.m. The Relationship Between Inpatient and Post-discharge Antimicrobial Use at the Hospital-Level Across an Integrated Healthcare Network
DANIEL J. LIVORSI, MD, MSC; University of Iowa, Iowa City, IA

(2893) 4:00 p.m. The Michigan Hospital Medicine Safety Consortium: Improving Patient Care by Reducing Excessive Antibiotic Use in Patients Hospitalized with Community-Acquired Pneumonia
TEJAL N. GANDHI, MD; University of Michigan, Ann Arbor, MI
### Scientific Sessions (continued)

**310. Oral Abstract**  
**Hepatitis C: Progress on Elimination and Treatment**  
Saturday, 3:15 – 4:30 p.m.  
204 ABC

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2895)</td>
<td>3:15 p.m.</td>
<td>Threats to Successful Elimination of Viral Hepatitis: Results from the Nationwide Treatment as Prevention for Hepatitis C (TraP HepC) Program in Iceland</td>
<td>MAGNUS GOTTFREDSSON, MD, PHD; Landspitali University Hospital, Reykjavik, Hofuoborgarsvaoio, Iceland</td>
</tr>
<tr>
<td>(2896)</td>
<td>3:27 p.m.</td>
<td>Reduction in Liver-Related Mortality Among HCV Infected Persons is Driven by Attainment of SVR Independent of the Regimen Used: Results from the ERCHIVES Cohort</td>
<td>ADEEL A. BUTT, MD, MS, FIDSA; Weill Cornell Medicine, Doha, Ad Dawhah, Qatar</td>
</tr>
<tr>
<td>(2897)</td>
<td>3:39 p.m.</td>
<td>Collocated Buprenorphine is Associated with Improved HCV Visit Adherence in People Who Inject Drugs (PWID): Data From the ANCHOR Study</td>
<td>ELANA S. ROSENTHAL, MD; University of Maryland, Washington, DC</td>
</tr>
<tr>
<td>(2898)</td>
<td>3:51 p.m.</td>
<td>Achieving Hepatitis C SVR12 of 95% in Mono-Infected Patients with Severe Comorbidities Using Volunteer Staff and Minimal Clinic Visits and Phlebotomy</td>
<td>CHARLES M. VAN DER HORST, MD, FIDSA; Open Door Clinic of Urban Ministries of Wake County, Chapel Hill, NC</td>
</tr>
<tr>
<td>(2899)</td>
<td>4:03 p.m.</td>
<td>Decreased Hepatitis C Virus-Associated Mortality in the U.S. 2014-2017 after New Oral Direct-Acting Antiviral Era.</td>
<td>ZAINAB WASTI, MD; Drexel University College of Medicine, Philadelphia, PA</td>
</tr>
<tr>
<td>(2900)</td>
<td>4:15 p.m.</td>
<td>High Rates of Experienced and Witnessed Opioid Overdose in PWID Receiving HCV Treatment: Data from the ANCHOR Study</td>
<td>SARAH KATTAKUZH, MD; University of Maryland, Washington, DC</td>
</tr>
</tbody>
</table>

### 311. Oral Abstract**  
**Vaccination II - Other**  
Saturday, 3:15 – 4:30 p.m.  
206

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2901)</td>
<td>3:15 p.m.</td>
<td>Measles in the United States During the Postelimination Era, 2017-2019</td>
<td>PAUL GASTANADUY, MD, MPH; Centers for Disease Control and Prevention, Atlanta, GA</td>
</tr>
<tr>
<td>(2902)</td>
<td>3:30 p.m.</td>
<td>Pertussis Antibody Levels in Preterm Infants After Maternal Tdap Immunization During Pregnancy</td>
<td>C. MARY HEALY, MD; Baylor College of Medicine, Houston, TX</td>
</tr>
<tr>
<td>(2903)</td>
<td>3:45 p.m.</td>
<td>Post PCV13 Dynamics of Non-Vaccine Serotype (NVT): Disproportionate Increase of the Additional PCV20 Candidate Serotypes in Respiratory and Invasive Disease in Young Children</td>
<td>SHALOM BEN-SHIMOL, MD; Soroka University Med Ctr and Ben-Gurion University, Beer Sheva, HaDarom, Israel</td>
</tr>
<tr>
<td>(2904)</td>
<td>4:00 p.m.</td>
<td>Protective Efficacy of Nucleic Acid Vaccines Against Transmission of Zika Virus During Pregnancy in Mice</td>
<td>BRETT W. JAGGER, MD, PHD; Washington University, St. Louis, MO</td>
</tr>
<tr>
<td>(2905)</td>
<td>4:15 p.m.</td>
<td>Long-term Immunological Persistence of the Adjuvanted Recombinant Zoster Vaccine: Clinical Data and Mathematical Modeling</td>
<td>ANNE SCHUIND, MD; GSK, Rockville, MD</td>
</tr>
</tbody>
</table>

No CME is offered for this session.  
No CPE credit is offered for this session.

### 312. Named Lecture**  
**Maxwell Finland Lecture: Prosthetic Joint Infection**  
Saturday, 4:45 – 5:15 p.m.  
Ballroom ABC

**Objectives:** At the conclusion of this session, participants will be able to:  
- describe the microbiology of and the role of biofilms in prosthetic joint infection  
- discuss diagnostic approaches to prosthetic joint infection  
- summarize new technologies for diagnosis of culture-negative prosthetic joint infection

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, HIV Clinicians, HIV Specialists, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Lab Personnel, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists, Vaccinologists
313. Special Session
ID BugBowl
Saturday, 5:15 – 6:00 p.m.  Ballroom ABC
The IDBugBowl is a Jeopardy-style quiz game being organized for IDWeek 2019 in Washington, D.C. and is specifically geared toward fellows, residents and medical students, but all attendees are invited.
Objectives: At the conclusion of this session, participants will be able to:
- discuss antibiotic treatment approaches to early onset sepsis diagnostics including markers of immune response, molecular pathogen detection, and algorithms that incorporate vital signs
- recognize when to consider and the optimal treatment approach for important viral causes of neonatal sepsis including disseminated enterovirus, parechovirus, and respiratory viruses
- discuss antibiotic treatment approaches to early onset sepsis with integration of antibiotic stewardship

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Infectious Diseases Pediatricians, Infectious Diseases Physicians
Moderator: ROBIN PATEL, MD; Mayo Clinic, Rochester, MN

314. Mini-Symposium
A Precision Approach to the Management of Early Onset Neonatal Sepsis
Sunday, 8 – 9 a.m. 201
Objectives: At the conclusion of this session, participants will be able to:
- discuss the utility of and innovations in neonatal sepsis diagnostics including markers of immune response, molecular pathogen detection, and algorithms that incorporate vital signs
- recognize when to consider and the optimal treatment approach for important viral causes of neonatal sepsis including disseminated enterovirus, parechovirus, and respiratory viruses
- discuss antibiotic treatment approaches to early onset sepsis with integration of antibiotic stewardship

Intended Audience: Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Infectious Diseases Pediatricians, Infectious Diseases Physicians
Moderator: DAVID Y. HYUN, MD; The Pew Charitable Trusts, Washington, DC
Speakers:
(2907) 8:00 a.m.  Threading the Needle: Precision Treatment Approaches for Early Onset Sepsis
JOSEPH B. CANTEY, MD; University of Texas Health San Antonio, San Antonio, TX

(2908) 8:20 a.m.  Viral Causes of Neonatal Sepsis
JENNIFER E. SCHUSTER, MD; Children’s Mercy Hospital, Kansas City, MO

(2909) 8:40 a.m.  Novel Diagnostics for Early Onset Sepsis
LEENA B. MITHAL, MD, MSCI; Northwestern University, Chicago, IL

315. Mini-Symposium
Hot Topics in Outpatient Antimicrobial Therapy of Infective Endocarditis
Sunday, 8 – 9 a.m. 206
Objectives: At the conclusion of this session, participants will be able to:
- describe the role of oral therapy in outpatient treatment of endocarditis
- describe the implications of IV drug use in outpatient management of endocarditis

Moderators:
JOSE MIRO, MD, PHD; Institut d’Investigacions Biomèdiques August Pi i Sunyer - (IDIBAPS) - University of Barcelona, Barcelona, Spain
VIVIAN CHU, MD; Duke University, Durham, NC

Speakers:
(2910) 8:00 a.m.  Oral Therapy for Infective Endocarditis
KASPER IVERSEN; Rigshospitalet, Copenhagen, Denmark

(2911) 8:30 a.m.  Outpatient Antimicrobial Therapy for People Who Inject Drugs (PWID) with Infective Endocarditis (IE)
STEVEN M. GORDON, MD, FIDSA, FSHEA; Cleveland Clinic Foundation, Cleveland, OH

316. Mini-Symposium
How Our Minds Respond to Our Microbiome
Sunday, 8 – 9 a.m. 202AB
Objectives: At the conclusion of this session, participants will be able to:
- demonstrate new knowledge on the microbiome
- interpret emerging literature on the gut/brain axis
- report gut/brain axis concepts to patients

Intended Audience: Academicians, Clinicians, Fellows, Members-in-Training, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Microbiologists, Pharmacists, Researchers, Scientists
Moderators:
CYNTHIA L. SEARS, MD, FIDSA; Johns Hopkins University School of Medicine, Baltimore, MD
LARRY PICKERING, MD, FIDSA; Emory University, Atlanta, GA

Speakers:
(2912) 8:00 a.m.  Gut Microbiome, Brain, and Behavior in Health and Disease
## Scientific Sessions (continued)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Location</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2913) 8:30 a.m.</td>
<td>Microbiome and Stroke Recovery</td>
<td>Ballroom</td>
<td>HELEN VUONG; University of California, Los Angeles, CA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>VENUGOPAL VENNA, PHD; McGovern Medical School, Houston, TX</td>
</tr>
</tbody>
</table>

Maximum of 1 hour of **AMA PRA Category 1 Credit**

ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-19-431-L04-P

### 317. Plenary

**Closing Plenary Session: All About Vaccines: The Individual, the Community, the World**

Sunday, 9:15 – 10:45 a.m. Ballroom ABC

**Objectives:** At the conclusion of this session, participants will be able to:
- report on the re-emergence of neglected diseases due to modern 21st century forces of war, political instability, antiscience, urbanization, and climate change, and the new vaccines required to combat these conditions
- describe key enabling technologies for the discovery and development of vaccines for emerging infectious diseases
- describe this new era in which state-of-the art vaccines are being developed to improve the lives of families in in the world’s most impoverished countries

**Intended Audience:** Academicians, Clinicians, Epidemiologists, Fellows, Members-in-Training, Health Care Workers, HIV Clinicians, HIV Specialists, Hospital Administrators, Hospital Epidemiologists, Infection Preventionists, Infectious Diseases Pediatricians, Infectious Diseases Physicians, Investigators, Lab Personnel, Microbiologists, Nurses, Pharmacists, Public Health Practitioners, Researchers, Scientists, Vaccinologists

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Location</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2914) 9:15 a.m.</td>
<td>Neglected Disease and Vaccine Diplomacy in a Time of War, Political Instability, Antiscience, and Climate Change</td>
<td>Ballroom</td>
<td>PETER J. HOTEZ, MD, PHD; Baylor College of Medicine, Houston, TX</td>
</tr>
<tr>
<td>(2915) 9:45 a.m.</td>
<td>Vaccines for Emerging Infectious Disease Threats: From Science to Implementation</td>
<td>Ballroom</td>
<td>ANTHONY S. FAUCI, MD; National Institute of Allergy and Infectious Diseases, Bethesda, MD</td>
</tr>
<tr>
<td>(2916) 10:15 a.m.</td>
<td>Developing Vaccines for Poverty-Related Diseases: A New Global Public Health Model</td>
<td>Ballroom</td>
<td>PENNY M. HEATON, MD; Bill &amp; Melinda Gates Medical Research Institute, Cambridge, MA</td>
</tr>
</tbody>
</table>

Maximum of 1.5 hours of **AMA PRA Category 1 Credit**

ACPE 1.5 knowledge-based contact hours of pharmacy CE; 0221-9999-19-434-L06-P
Oral Abstract Sessions

Adult ID

31. Oral Abstract Session
Not Just Your Everyday Diarrhea
Thursday, 10:30 - 11:45 a.m.

76 Validation of Systemic Inflammatory Mediators as Biomarkers for Severity and Adverse Outcomes in Clostridium difficile Infection


78 Oral Norovirus Vaccination in Humans Induces Plasmablast B Cell Expansion and Follicular T-Cell Activation Comparable to Natural Infection

79 Mucosal Interferon (IFN) Responses in Infants with Respiratory Syncytial Virus (RSV) Infection to Inform Live Attenuated Vaccine (LAV) Development

80 Opioid analgesics are associated with increased Clostridioides difficile infection risk in a national cohort of veterans

81 Azithromycin-Nonsusceptible Salmonella Newport Infections Associated with Mexican-style Soft Cheese and Beef —United States, 2018-2019

Adult ID/Pediatric ID/Epi/Infection Control

32. Oral Abstract Session
Surveillance in Healthcare-Associated Infections
Thursday, 10:30 - 11:45 a.m.

82 First Five Years of Experience with the Illinois Extensively Drug Resistant Organism (XDRO) Registry and Implementation of Automated Alerting

83 During A Million Patient-Days of Surveillance, Low Levels of Infection Prevention Staff Correlated with Higher Rates of Some Healthcare-Associated Infections

84 Evaluation of the NHNSN Standardized Infection Ratio (SIR) Risk Adjustment for HO-CDI in Oncology and ICU Patients in General Acute Care Hospitals

85 Use of Dual Statistical Process Control Charts for Early Detection of Surgical Site Infection Outbreaks at a Community Hospital Network

86 Ventilator-Associated Pneumonia in Trauma Intensive Care Unit, a Dilemma in Quality Metrics

Adult ID/Pediatric ID/Transplant ID

33. Oral Abstract Session
Transplant ID
Thursday, 10:30 - 11:45 a.m.

87 Heart and Lung Transplants from HCV-Viremic Donors to Uninfected Patients - Longer-Term Follow-Up

88 Public Health Service (PHS) Increased-Risk Factors in Organ Donors: A Review of the OPTN ad hoc Disease Transmission Advisory Committee (DTAC)

89 Efficacy and Tolerability of Voriconazole (VOR) versus Isavuconazole (ISA) Prophylaxis (px) in Preventing Invasive Fungal Infections (IFI) in Lung Transplant Recipients (LTR)

90 Fecal Microbiota Transplantation in Metastatic Melanoma Patients Resistant to Anti-PD-1 Treatment

91 Differential Impact of Cytomegalovirus (CMV) Donor (D) Serostatus on Rates and Kinetics of CMV Viremia among CMV Seropositive Recipients (R+) of Ex-vivo T-cell Depleted (TCD) and Unmodified (CONV) Hematopoietic Cell Transplants (HCT).

Adult ID/Pediatric ID

34. Oral Abstract Session
Viral Infections - Host, Pathogen, and Impact of Intervention
Thursday, 10:30 - 11:45 a.m.

92 Incidence of Respiratory Syncytial Virus Infection among Hospitalized Adults, 2017-2019

93 Trends in the Laboratory Detection of Rotavirus Before and After Implementation of Routine Rotavirus Vaccination — United States, 2000-2018

94 Pneumonia Severity Scores Poorly Predict Severe Outcomes Among Adults Hospitalized with Influenza.

95 Impact of Influenza-Like Illnesses on Academic and Work Performance on a College Campus

96 Human Papilloma Viruses associated diseases in a cohort of patients with Idiopathic CD4 Lymphopenia

97 Competition Experiments for the Baloxavir-Resistant I38T Influenza A Mutant

Adult ID/Pediatric ID/Epi/Infection Control

35. Rapid Fire Poster
Rapid Fire Poster Session: Antimicrobial Resistance
Thursday, 12:15 - 12:45 p.m.

98 Distinct, Segregated Daptomycin-Susceptible and Daptomycin-Nonsusceptible Staphylococcus Aureus Populations Associated with Tricuspid-Valve Infective Endocarditis

99 The Accessory Genome in Enterococcal Bacteremia: Results from the Vancomycin-Resistant Enterococcal Bacteremia Outcomes Study (VENOUS)

100 Recurrence of Infection and Emergence of Drug Resistance After Treatment with Meropenem/Vaborbactam Compared to Ceftazidime/Avibactam in Carbapenem-Resistant Enterobacteriaceae Infections


Adult ID/Pediatric ID/Transplant ID

36. Rapid Fire Poster
Rapid Fire Poster Session: Diagnostics
Thursday, 12:15 - 12:45 p.m.

103 Clinical Outcomes among Febrile Infants Before and After Implementation of BioFire® FilmArray® Panels

104 Performance Characteristics of an FDA Cleared Multiplex Panel for the Rapid Identification of Fungal Pathogens from Positive Blood Culture

105 Randomized Clinical Trial Evaluating Clinical Impact of RAPid IDentification and Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia (RAPIDS-GN)
<table>
<thead>
<tr>
<th>Oral Abstract Sessions (continued)</th>
</tr>
</thead>
<tbody>
<tr>
<td>106. Rapid Antimicrobial Susceptibility Testing using ATP Luminiscence and Machine Learning Methods</td>
</tr>
<tr>
<td>108. Carbapenem Resistant Klebsiella (CRK) Bloodstream Infections (BSIs) are Caused by Bacterial Populations that are Genotypically and Phenotypically Diverse</td>
</tr>
</tbody>
</table>
| **81. Oral Abstract Session**  
*Clostridium difficile*  
**Thursday, 1:45 - 3 p.m.** |
| 838. Oral Vancomycin Prophylaxis Works! |
| 839. Effect of *Clostridioides difficile* (C. difficile) Toxin Test Reporting on Clinical Treatment and Outcomes of Toxin-Negative PCR-Positive Patients at Five California Hospitals |
| 840. Clinical Failure Rates Associated with Hemin-Induced Metronidazole Resistance in *Clostridioides difficile* |
| 841. Implications of *C. difficile* Treatment on Environmental Contamination: A Randomized Controlled Trial with Microbiologic, Environmental, and Molecular Outcomes |
| **82. Oral Abstract Session**  
*Global Health: Outbreaks, Controls, and Genetics*  
**Thursday, 1:45 - 3 p.m.** |
| 843. The PALM Consortium: A Multi-Center, Multi-Outbreak Randomized Controlled Trial of Ebola Virus Disease Therapeutics |
| 844. Engagement in HIV care as an Avenue to Primary Care in Rural South Africa: Results from the Vukuzazi Population Health Platform |
| 845. Children with Clinical *Plasmodium falciparum* Infection Have Increased Sharing of Haplotypes with Household Members as well as Temporally-Proximal, Symptomatic Peers |
| 846. Postnatally Acquired Zika Virus (ZIKV) Infection in Infants and Young Children in Guatemala: Serologic and Neurodevelopmental (ND) Evaluation |
| **83. Oral Abstract Session**  
**Late Breaker Oral Abstract Session 1**  
**Thursday, 1:45 - 3 p.m.** |
| **84. Oral Abstract Session**  
**Novel Insights into Bacteremia and Endocarditis**  
**Thursday, 1:45 - 3 p.m.** |
| 847. The Effect of Antimicrobial Administration on Blood Culture Positivity in Patients with Severe Manifestations of Sepsis |
| 848. Low-Bioavailability Versus High-Bioavailability Oral Antibiotics for the Definitive Treatment of Enterobacteriaceae Bacteremia from Suspected Urine Source in Hospitalized Veterans |
| 849. Reduced CIED Infections with an Antibacterial Envelope: Microbiologic Analysis of the WRAP-IT Study |
| 850. Outcomes of Patients Discharged on Parenteral Ceftriaxone Compared to Oxacillin or Cefazolin in Methicillin Susceptible *Staphylococcus aureus* (MSSA) Bloodstream Infections. |
| 851. Validation of Quick Pitt Bacteremia Score in Patients with *Staphylococcus Aureus* Bloodstream Infection |
| **85. Oral Abstract Session**  
**Pediatric Bacterial Diseases**  
**Thursday, 1:45 - 3 p.m.** |
| 852. The Cefazolin Inoculum Effect and Methicillin-Susceptible *Staphylococcus aureus* Osteoarticular Infections in Children: Does it Matter? |
| 853. Epidemiology of Groups A, C, and G Beta-Hemolytic Streptococcal Pharyngitis |
| 854. Impact of Antimicrobial Stewardship and Rapid Diagnostics in Children with *Staphylococcus aureus* Bacteremia |
| 855. Evolution of Group B Streptococcal Capsular Type V Invasive Infections in Neonates and Young Infants: A Whole Genome Sequencing Study |
| 856. Invasive *Haemophilus Influenzae* disease in Children: A Canadian Multi-Centre Study on Emerging Serotypes |
| **86. Oral Abstract Session**  
**HIV Viral Suppression or Bust**  
**Thursday, 3:15 - 4:30 p.m.** |
| 883. Evidence from a Multistate Cohort: Enrollment in Affordable Care Act Qualified Health Plans Results in Viral Suppression |
| 884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies |
| 885. HIV-1 Treatment Failure and Extensive Drug Resistance in Perinatally-Infected Children Failing First-Line Antiretroviral Therapy in Western Kenya |
| 886. Pregnancy Outcomes Following Raltegravir Exposure |
| 887. High Rates of Virologic Suppression Achieved in HIV-1–Infected Adults Rapidly Starting Antiretroviral Therapy (ART) With the Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease |
Oral Abstract Sessions (continued)

Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial

97. Oral Abstract Session
Innovations in Clinical Practice
Thursday, 3:15 - 4:30 p.m.

888 Impact of Mandatory Infectious Diseases Consult on All-Cause Inpatient Mortality and 30-day Readmission in Patients with Severe Sepsis
889 Impact of an Infectious Disease Telehealth (IDt) Service on S. aureus Bacteremia (SAB) Outcomes in 15 Small Community Hospitals
890 Bridging the Gap to Help Address the Opioid Crisis: A Novel Model of Care to Integrate Substance Use, Mental Health, and Infectious Disease Services
891 Epidemiology and Outcomes of Sepsis in Previously Healthy Patients
892 Risk Factors for Adverse Events in Children Receiving Outpatient Antibiotic Therapy

98. Oral Abstract Session
To Decolonize or Not to Decolonize: Do We Still Need to Ask the Question
Thursday, 3:15 - 4:30 p.m.

893 The SHIELD Orange County Project: A Decolonization Strategy in 35 Hospitals and Nursing Homes Reduces Multi-Drug Resistant Organism (MDRO) Prevalence in a Southern California Region
894 Universal Decolonization in Nursing Homes: Effect of Chlorhexidine and Nasal Povidone-Iodine on Prevalence of MultiDrug-Resistant Organisms (MDROs) in the PROTECT Trial
895 Impact of Measurement and Results Feedback of Chlorhexidine Gluconate (CHG) Skin Concentrations in Medical Intensive Care Unit (MICU) Patients Receiving CHG Bathing
896 A Safe, More Cost-Effective Protocol-Universal Decolonization versus MRSA Screening and Contact Precautions
897 Prevalence of Candida auris at Body Sites, Characterization of Skin Microbiota, and Relation of Chlorhexidine Gluconate (CHG) Skin Concentration to C. auris Detection among Patients at a High-Prevalence Ventilator-Capable Skilled Nursing Facility (vSNF) with Established CHG Bathing

99. Oral Abstract Session
Vaccines I - Influenza and RSV
Thursday, 3:15 - 4:30 p.m.

898 Influenza Vaccination Reduces Risk of Severe Outcomes among Adults Hospitalized with Influenza A(H1N1) pdm09, FluSurv-NET, 2013-2018
899 Influenza Vaccine Effectiveness against Laboratory-Confirmed Influenza in Children Hospitalized with Respiratory Illness in the United States, 2016-17 and 2017-18 Seasons
901 MED8897 Prevents Serious RSV Disease in Healthy Preterm Infants
902 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of a Single Immunization of Ad26. RSV,preF against RSV Infection in a Viral Challenge Model in Healthy Adults

100. Oral Abstract Session
IDSA Featured Oral Abstract
Thursday, 5:05 - 5:20 p.m.

903 Resensitization to β-lactams in Enterococci Depends on Penicillin-Binding Protein (PBP) Mislocalization and Is Mediated by a Single Protein That Modulates Cell Membrane (CM) Adaptation to Daptomycin (DAP)

123. Oral Abstract Session
Advances in Sexually Transmitted and UTIs
Friday, 10:30 - 11:45 a.m.

961 Prevalence and Macrolide Resistance of Mycoplasma genitalium after Initiation of HIV Preexposure Prophylaxis
962 Trends in Cervical Pre-Cancers by Race and Ethnicity during the Human Papillomavirus Vaccine Era, HPV Vaccine Impact Monitoring Project (HPV-IMPACT), United States, 2008-2016
963 Exogenous Chlamydia and Gonorrhea among Females Visiting an STD Clinic
964 Journey to Zero Harm: Eliminating Catheter Associated Urinary Tract Infections (CAUTIs) for 12 Consecutive Months at Two Community Hospitals
965 The Efficacy of Oral Beta-lactam Antibiotics as Step-down Therapy for Acute Pyelonephritis

124. Oral Abstract Session
Out of the Box and Out of the Hospital: Stewardship Outpatient Services
Friday, 10:30 - 11:45 a.m.

966 A Closer Look at Antibiotic Prescribing for Upper Respiratory Illnesses (URI) in People with HIV Compared to People without HIV
967 Concordance of Antibiotic Prescribing with the Proposed American Dental Association Acute Oral Infection Guidelines within Veterans Affairs (VA) Dentistry
968 Effect of Outpatient Antibiotic Ordering Restrictions on Antibiotic Prescribing Patterns at a State-Wide VA Health Care System
969 Antibiotic Prescribing in a Large Retail Health Clinic Chain: Opportunities for Stewardship
970 Antibiotic Use Variability Among U.S. Nursing Homes-2016
125. Oral Abstract Session
Pathogenesis and Inflammatory Response
Friday, 10:30 - 11:45 a.m.

971 The Role of Inflammation and Innate Effectors in Passive Immunization for *Acinetobacter baumannii* Infections
972 A Mycobacterium Tuberculosis Secreted Lipid Triggers Cough Through a Neuronal Cough Receptor
973 Single-Cell RNA Sequencing Analysis of Zika Virus Infection in Human Stem Cell-Derived Cerebral Organoids
974 PD-1 Immune Checkpoint Blockade Improves Survival and Promotes Fungal Clearance in an Immunosuppressed Murine Invasive Pulmonary Aspergillosis (IPA) Model
975 Roles of Type I and III Interferon in Severe Pathogenesis of Human Metapneumovirus

126. Oral Abstract Session
Suppressed but Still at Risk: Comorbidities
Friday, 10:30 - 11:45 a.m.

976 Development and Validation of a Risk Score for Predicting Cardiovascular Events in HIV-Infected Patients
977 The Prevalence and Burden of Non-AIDS Co-Morbidities in Women with or At-Risk for HIV Infection in the United States
978 Changes in BMI Associated with Antiretroviral Regimens in Treatment-Experienced, Virologically Suppressed Individuals Living with HIV
979 BMI and ASCVD Risk Score Changes in Virologically Suppressed Patients with HIV Switching from TDF to TAF Containing ART
980 Effects of Integrase Strand-Transfer Inhibitor Use on Lipids, Glycemic Control, and Insulin Resistance in the Women’s Interagency HIV Study (WIHS)

127. Rapid Fire Poster
Rapid Fire Poster Session: HIV
Friday, 12:15 - 12:45 p.m.

981 Exploring the Prevalence and Characteristics of Weight Gain and other Metabolic Changes in Patients with HIV Infection Switching to Integrase Inhibitor Containing ART
982 Association of Maternal ARV Use with Microcephaly in HIV-Exposed Uninfected Children
983 Association of Structural Stigma Due to Sexual Orientation and HIV Diagnosis/PrEP Use in the United States: An Ecological Analysis
984 Perceptions of and Preferences for Oral or Long-Acting Injectable Antiretroviral Treatment Regimens in the United States and Canada
985 Trans Females Receiving Gender-Affirming Surgical Referrals are More Likely to Have Durable Virologic Suppression at Whitman-Walker Health, 2008-2017
986 Inpatient Initiation of ART Improves Short Term Mortality in People Living with HIV

128. Rapid Fire Poster
Rapid Fire Poster Session: Transplant/Immunocompromised ID
Friday, 12:15 - 12:45 p.m.

987 Adherence and Immunogenicity of Early Vaccination in Pediatric Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Recipients
988 Role of Human Bocavirus Respiratory Tract Infection in Hematopoietic Cell Transplant Recipients
989 Clinical Prediction Tool for Multidrug-Resistant Organisms among Deceased Donors at the Time of Donor Evaluation
990 Microbiome and Cumulative Antibiotic Use as Predictors of *Stenotrophomonas maltophilia* Infection in Patients with Acute Myeloid Leukemia Receiving Remission-Induction Chemotherapy
991 Hepatitis C-Infected Donors and Hepatitis C-Infected Recipients: Analysis of Renal Transplant Outcomes
992 Epidemiology of Invasive *Mycoplasma* and *Ureaplasma* Infections Early after Lung Transplantation

181. Oral Abstract Session
Advances in CNS Infections
Friday, 1:45 - 3 p.m.

1820 Efficacy of Pulse-Taper Corticosteroid Adjunctive Therapy for Refractory Non-HIV Cryptococcal Meningoencephalitis
1821 Evaluation of Cerebrospinal Fluid White Blood Cell Count Criteria for Use of the BioFire® FilmArray® Meningitis/Encephalitis Panel in Immunocompetent Patients
1822 Decreased JC Virus-Specific Antibody-Dependent Cellular Cytotoxicity in HIV-Seropositive PML Survivors
1823 Incidence of Meningoencephalitis in the Absence of CSF Pleocytosis
1824 Herpes Simplex Encephalitis: Outcomes From a 10-Year Retrospective Single-Center Case Series

182. Oral Abstract Session
Emergent Mechanisms of Resistance and How to Prevent Them
Friday, 1:45 - 3 p.m.

1825 Optimizing Beta-lactam Therapy in Surgical Intensive Care Unit Patients Using Therapeutic Drug Monitoring
1826 Impact of Rapid Diagnostics and Ceftazidime-Avibactam on Mortality after Bacteremia Caused by Carbapenem-Resistant Enterobacteriaceae
1827 Genetic Characterization of Methicillin-Resistant *Staphylococcus aureus* (MRSA) Isolates Associated with the Development of Reduced Susceptibility to Vancomycin from Latin America
1828 Bedaquiline Resistance in *Mycobacterium intracellulare* is Mediated by the Transcriptional Repressor MmpT5
1829 The Paradox of KPC Bearing Strains of *Klebsiella pneumoniae* with the D179Y Substitution: Resistance to Ceftazidime/Avibactam (CZA) and Susceptibility to Meropenem (MEM)
### Oral Abstract Sessions (continued)

| Adult ID/Investigative ID | 183. Oral Abstract Session  
**Innovative Diagnostics**  
Friday, 1:45 - 3 p.m. | 1876 A Hepacivirus-Like Protein is Targeted by the Antibody Response to Kawasaki Disease (KD)  
Adult ID/Pediatric ID/Epi/Infection Control |
|---|---|---|
| 1830 Single-Cell Transcriptional Profiling Reveals an Immune Cell State Signature of Bacterial Sepsis | 1877 Evaluation of Antibiotic Utilization after Introduction of a Dedicated Infectious Diseases-Critical Care Medicine Service in Critical Care Units | 197. Oral Abstract Session  
**Stewardship Success Stories**  
Friday, 3:15 - 4:30 p.m. |
| 1831 Machine Learning Approaches to Predicting Resistance in *Pseudomonas aeruginosa* | 1878 Impact of Antibiotic Stewardship Rounds in the Intensive Care Setting; a Prospective Cluster-Randomized Crossover Study | 1877 Evaluation of Antibiotic Utilization after Introduction of a Dedicated Infectious Diseases-Critical Care Medicine Service in Critical Care Units |
| 1832 Development of an Ultrasensitive Field-Applicable *Plasmodium falciparum* Assay for Malaria Diagnosis and Eradication | 1879 A 20/20 Vision: Successful Integration of a Prescribing Dashboard for Outpatient Antimicrobial Stewardship to Target 20% Reduction by Year 2020 | 1877 Evaluation of Antibiotic Utilization after Introduction of a Dedicated Infectious Diseases-Critical Care Medicine Service in Critical Care Units |
| 1833 Measuring Influenza HA Stem-Specific ADCC in Human Sera Using Novel Stabilized Stem Nanoparticle Probes | 1880 Reducing Antibiotic Prescribing for Acute Bronchitis in Outpatient Settings using a Multifaceted Approach | 1877 Evaluation of Antibiotic Utilization after Introduction of a Dedicated Infectious Diseases-Critical Care Medicine Service in Critical Care Units |
| 184. Oral Abstract Session  
**Late Breaker Oral Abstract Session 2**  
Friday, 1:45 - 3 p.m. | 184. Oral Abstract Session  
**Late Breaker Oral Abstract Session 2**  
Friday, 1:45 - 3 p.m. | 1882 Tuberculosis in the Department of Veterans Affairs: Missed Opportunities for Prevention |
| Adult ID/Pediatric ID/Epi/Infection Control | Adult ID/Pediatric ID/Epi/Infection Control | 1883 Factors Associated with Stigma toward Isoniazid-Preventative Therapy in a Rural Community of South Africa |
| 185. Oral Abstract Session  
**Staph aureus: New Perspectives on an Old Foe**  
Friday, 1:45 - 3 p.m. | 185. Oral Abstract Session  
**Staph aureus: New Perspectives on an Old Foe**  
Friday, 1:45 - 3 p.m. | 1884 Clinical Outcomes among Patients with Drug-Resistant Tuberculosis receiving Bedaquiline or Delamanid Containing Regimens |
| 1835 High Burden of Invasive *Staphylococcus aureus* Disease Among Native Americans on the White Mountain Apache Tribal Lands | 1836 Genomic Epidemiology of Methicillin-Susceptible *Staphylococcus aureus* Colonization and Infection among US Army Trainees at Fort Benning, Georgia | 1885 T-Helper 1 (Th1) Production of Interferon Gamma (IFN&gamma;) is Directly Inhibited by TGF&beta;: Within Pulmonary *Mycobacterium tuberculosis* (Mt) Granulomas |
| 1837 Considerations for a Targeted Approach to Contact Precautions for Patients with MRSA in Hospitals: A Multicenter Cohort Study to Identify High-Risk Patient Characteristics and Healthcare Personnel Interactions | 1838 Bare Below the Elbows versus Sleeved Attire: a Pilot Study Comparing Microbial Flora of Healthcare Workers | 1886 N1, N12-Diacetylspermine as Potential Urinary Biomarker to Monitor Treatment Response and Bacterial Load in Pulmonary Tuberculosis |
| 1839 Contact Precautions' Effects on MRSA Transmission in Department of Veterans Affairs Hospitals | 184. Oral Abstract Session  
**Late Breaker Oral Abstract Session 2**  
Friday, 1:45 - 3 p.m. | 1887 Estimating the Burden of Waterborne Disease in the United States |
| 186. Oral Abstract Session  
**Pediatric Emerging Viral Diseases**  
Friday, 3:15 - 4:30 p.m. | 186. Oral Abstract Session  
**Pediatric Emerging Viral Diseases**  
Friday, 3:15 - 4:30 p.m. | 1888 A Nationwide Outbreak of Invasive Pneumococcal Disease (IPD) Caused by a Novel *Streptococcus Pneumoniae* Serotype 2 (SP2) Clone in the PCV13 Era, in Israel |
| 1872 Neurodevelopment in Apparently Normal Infants from Zika Virus Positive Pregnancies | 1873 Pregnancy & birth outcomes among Colombian women with Zika virus disease in 3 Surveillance Sites, Proyecto Vigilancia de Embarazadas con Zika | 1889 Clinical Features Distinguishing Enterovirus A71 and Enterovirus D68-Associated Acute Flaccid Myelitis in Colorado, 2013-2018 |
| 1874 Comparison of the Risk of Birth Defects in Live Births from Pregnant Women Infected and not Infected by Zika Virus in Guadeloupe, 2016-2017 | 1875 La Crosse Virus Neuroinvasive Disease in Children: A Contemporary Review and Evaluation for Predictors of Disease Severity | 1890 Missed Clinical Opportunities to Prevent Infections and Treat Substance Use Disorder (SUD) in People Who Inject Drugs (PWID) |
| 1876 A Hepacivirus-Like Protein is Targeted by the Antibody Response to Kawasaki Disease (KD) | 1877 Evaluation of Antibiotic Utilization after Introduction of a Dedicated Infectious Diseases-Critical Care Medicine Service in Critical Care Units | 1882 Tuberculosis in the Department of Veterans Affairs: Missed Opportunities for Prevention |
| 1878 Impact of Antibiotic Stewardship Rounds in the Intensive Care Setting; a Prospective Cluster-Randomized Crossover Study | 1879 A 20/20 Vision: Successful Integration of a Prescribing Dashboard for Outpatient Antimicrobial Stewardship to Target 20% Reduction by Year 2020 | 1883 Factors Associated with Stigma toward Isoniazid-Preventative Therapy in a Rural Community of South Africa |
| 1880 Reducing Antibiotic Prescribing for Acute Bronchitis in Outpatient Settings using a Multifaceted Approach | 1881 The Agency for Healthcare Research and Quality (AHRQ) Safety Program for Improving Antibiotic Use: Results from a National Antibiotic Stewardship Intervention of 402 United States (US) Hospitals | 1884 Clinical Outcomes among Patients with Drug-Resistant Tuberculosis receiving Bedaquiline or Delamanid Containing Regimens |
| 1885 T-Helper 1 (Th1) Production of Interferon Gamma (IFN&gamma;) is Directly Inhibited by TGF&beta;: Within Pulmonary *Mycobacterium tuberculosis* (Mt) Granulomas | 1886 N1, N12-Diacetylspermine as Potential Urinary Biomarker to Monitor Treatment Response and Bacterial Load in Pulmonary Tuberculosis | 1887 Estimating the Burden of Waterborne Disease in the United States |
| 1888 A Nationwide Outbreak of Invasive Pneumococcal Disease (IPD) Caused by a Novel *Streptococcus Pneumoniae* Serotype 2 (SP2) Clone in the PCV13 Era, in Israel | 1889 Clinical Features Distinguishing Enterovirus A71 and Enterovirus D68-Associated Acute Flaccid Myelitis in Colorado, 2013-2018 | 1890 Missed Clinical Opportunities to Prevent Infections and Treat Substance Use Disorder (SUD) in People Who Inject Drugs (PWID) |
Oral Abstract Sessions (continued)

1891  Invasive Group A Streptococcus Infections Among Residents of Multiple Nursing Homes—Denver, Colorado, 2017–2018

201. Oral Abstract Session
SHEA Featured Oral Abstract
Friday, 4:45 - 5 p.m.

1895  Serious Antibiotic-Related Adverse Effects Following Unnecessary Dental Prophylaxis in the United States

226. Oral Abstract Session
Advances/in/ID/Med/Ed
Saturday, 10:30 - 11:45 a.m.

1946  An Exploratory Study of the Therapeutic Reasoning Underlying Antimicrobial Selection
1947  Educational Impact of a Hybrid Infectious Diseases Rotation for Internal Medicine Residents
1948  Impact of @WuidQ, a Free Open-Access Medical Education Twitter Resource, on Infectious Disease Learning and Teaching
1949  Putting Out Fires: Assessing Burnout within an Infectious Diseases Fellowship at an Academic Medical Center
1950  Intentional Interprofessional Experiential Education in an HIV/Infectious Diseases Clinic

227. Oral Abstract Session
Novel Antimicrobials and Approaches Against MDR Organisms
Saturday, 10:30 - 11:45 a.m.

1951  Extended Infusions of Beta-lactam Antibiotics are Feasible and May Improve Mortality in the Pediatric Population
1952  Bacteriophage Treatment Improves Survival of Mice Infected with Carbapenem-Resistant Klebsiella pneumoniae
1953  VE303, a Rationally Designed Bacterial Consortium for Prevention of Recurrent Clostridioides difficile (C. Difficile) infection (rCDI), Stably Restores the Gut Microbiota after Vancomycin (Vanco)-Induced Dysbiosis in Adult Healthy Volunteers (HV)
1954  In Vivo Efficacy of Delayed Therapy with the Novel Inositol Acyltransferase Inhibitor Fosmanogepix (APX001) in a Murine Model of Candida Auris Invasive Candidiasis
1955  Novel Compound Reverses Vancomycin Resistance in Vancomycin Resistant Enterococci (VRE)

228. Oral Abstract Session
Pediatric Stewardship
Saturday, 10:30 - 11:45 a.m.

1956  Reduction in Endotracheal Aspirate Cultures after Implementation of a Diagnostic Stewardship Intervention in a Pediatric Intensive Care Unit

1957  Impact of Beta-Lactam Antibiotic Allergy on Antimicrobial Use, Clinical Outcomes, and Costs for Hospitalized Children
1958  Assessment of Guideline-Concordant Antimicrobial Prescribing in Urgent Care Centers
1959  Parent Satisfaction and Antibiotic Prescribing for Pediatric Respiratory Infections by Telemedicine
1960  Lost in Translation-Comparing Rates of Outpatient Antibiotic Use in Three Metrics

229. Oral Abstract Session
The End of AIDS Starts with Prevention
Saturday, 10:30 - 11:45 a.m.

1961  Grindr™ on Screen Activity on iPhones Correlates with HIV Risk and Substance Use in Men Who Have Sex with Men, San Diego
1962  Renal Outcomes for Participants Taking F/TAF versus F/TDF for HIV PrEP in the DISCOVER Trial
1965  PrEP On the Go! Implementation Mobile PrEP, STI, and HIV Prevention Services in South Florida

230. Rapid Fire Poster
Rapid Fire Poster Session: Outbreaks
Saturday, 12:15 - 12:45 p.m.

1966  Response to a Cluster of Haemophilus influenzae Serotype A Cases in a Small Alaska Community, 2018
1967  Prolonged Local Epidemic of an XDR P. aeruginosa Subclone of High-Risk Clonal Complex 298
1968  Legionellosis Cluster Associated with Direct and Indirect Hot Tub Exposure — West Virginia, 2018
1969  Pediatric Mumps during the 2015–2017 Mumps Resurgence in the United States
1970  Healthcare-Associated Pediatric Cutaneous Mucormycosis at Texas Children’s Hospital, 2012-2019
1971  What’s Lurking in the Drain? Serial Transmission of NDM-1 Klebsiella pneumoniae to Patients Admitted 9 months Apart to the Same ICU Room

231. Rapid Fire Poster
Rapid Fire Poster Session: Vaccines
Saturday, 12:15 - 12:45 p.m.

1972  A Cohort Analysis of Completion of the Pediatric Measles-Mumps-Rubella-Varicella Series in the United States
1973  Uptake and Safety of Measles-Mumps-Rubella (MMR) Vaccine in Adolescents and Adults in the Vaccine Safety Datalink
1974  Meningococcal Vaccination among Patients Newly Diagnosed at High-Risk for Meningococcal Disease in the US
Oral Abstract Sessions (continued)

1975  Immunogenicity of Inactivated Influenza Vaccines Given Early versus Late after Pediatric Allogeneic Hematopoietic Cell Transplantation

Adult ID/HIV/TB/STD/Investigative ID

293. Oral Abstract Session
Clinical Trials that May Change your Practice
Saturday, 1:45 - 3 p.m.

2838 Safety and Immunogenicity of a gp120-CD4 Chimeric Subunit Vaccine: A Phase 1a Randomized Controlled Trial
2839 Efficacy, Pharmacokinetics (PK), and Safety Profile of Suvratoxumab (MEDI4893), a Staphylococcus aureus Alpha Toxin (AT)-Neutralizing Human Monoclonal Antibody in Mechanically Ventilated Patients in Intensive Care Units; Results of the Phase 2 SAATELLITE Study Conducted by the Public-Private COMBACTE Consortium.
2840 Long Term Efficacy, Safety and Durability of CAB and RPV as Two Drug Oral Maintenance Therapy – LATTE Week 312 Results
2841 A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate (TZD) and Linezolid (LZD) for Treatment of Ventilated Gram-Positive (G+) Nosocomial Pneumonia
2842 Durable Efficacy of Two-Drug Regimen (2DR) of Dolutegravir (DTG) plus Lamivudine (3TC) in Antiretroviral Treatment-Naïve Adults with HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies

294. Oral Abstract Session
Late Breaker Oral Abstract Session 3
Saturday, 1:45 - 3 p.m.

Adult ID/Investigative ID

295. Oral Abstract Session
Microbiome Science
Saturday, 1:45 - 3 p.m.

2843 Maternal Fecal Transplantation to Infants Born by Cesarean Section-Safety and Feasibility
2844 Butyrogenic Bacteria after Acute Graft Versus Host Disease Associate with the Development of Steroid Refractory GVHD
2845 Oral Antibiotic Use and Risk of Colorectal Cancer in the United Kingdom, 1989-2012: A Matched Case-Control Study
2846 Perirectal Samples for Analysis of the Gut Microbiota as a Predictive Tool for Multidrug-Resistant Organism (MDRO) Acquisition in Nursing Facility (NF) Patients
2847 Comparative Genomics and Clonal Tracking of Multidrug-Resistant Uropathogens Implicates the Fecal Microbiome as a Potential Reservoir for Recurrent Urinary Tract Infections

Adult ID/HIV/TB/STD/Investigative ID

296. Oral Abstract Session
New Insights into MDRO Gram-Negatives
Saturday, 1:45 - 3 p.m.

2848 Spatial Distribution of Community-Acquired Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Infections and its Association With Sewer Overflows in Middle Georgia
2849 Gut Microbiota Differences at the Time of Medical Intensive Care Unit (MICU) Admission Are Associated with Acquisition of Multidrug-Resistant Organisms (MDROs) among Patients Not Already Colonized with an MDRO
2852 Epidemiology of Emerging Carbapenemase-Producing Organisms (CPO) in Chicago, Illinois, 2013-2018

Pediatric ID/Investigative ID/Global ID

297. Oral Abstract Session
Pediatric Viral and Fungal Diseases
Saturday, 1:45 - 3 p.m.

2853 Innate Immune Response in Serum and Cerebrospinal Fluid of Neonates and Infants Infected with Parechovirus-A3 and Enteroviruses
2855 Respiratory Syncytial Virus Neutralizing Antibodies in Cord Blood and Serum from Infants up to 2 Years of Age in a Multinational Prospective Study
2856 Salvaging High-Value Catheters: Antifungal Lock Therapy for Candidal Central Catheter Infections in a Pediatric Cohort
2857 A Statistical Model to Predict Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation Patients

Adult ID/HIV/TB/STD/Investigative ID/Global ID

308. Oral Abstract Session
Fungi: Blood, Sweat, and Genes
Saturday, 3:15 - 4:30 p.m.

2885 A Host Transcriptional Signature for Accurate Diagnosis of Candidemia in the Hospital Setting
2886 Retrospective Case-Control Study of the Performance of the Karius Test, a Plasma Microbial Cell-Free DNA Next-Generation Sequencing Test, to Detect Invasive Mold Infections in Hematopoietic Cell Transplant Recipients with Pneumonia
2887 Identifying Candida albicans Transcription Factors (TFs) That Regulate Pathogenesis of Intra-Abdominal Candidiasis (IAC) by Screening a Deletion Mutant Library
2888 STAT4 Mutation in Three Generations with Disseminated Coccidioidomycosis (DCM) Also Exhibits Increased Susceptibility to Coccidioidal Infection in Transfected Mice
2889 Skin Niche Conditions Trigger C. auris to Form Robust Biofilms That Resist Desiccation
### Oral Abstract Sessions (continued)

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Session Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>2890</td>
<td>Antibiotic Overuse at Discharge in Hospitalized Patients with Bacteriuria or Treated for Pneumonia: A Multi-Hospital Cohort Study</td>
<td>Saturday, 3:15 - 4:30 p.m.</td>
</tr>
<tr>
<td>2891</td>
<td>Trends in Inpatient Antibiotic Use in U.S. Hospitals, 2012-2017</td>
<td>Saturday, 3:15 - 4:30 p.m.</td>
</tr>
<tr>
<td>2892</td>
<td>The Relationship between Inpatient and Post-discharge Antimicrobial Use at the Hospital-Level across an Integrated Healthcare Network</td>
<td>Saturday, 3:15 - 4:30 p.m.</td>
</tr>
<tr>
<td>2893</td>
<td>The Michigan Hospital Medicine Safety Consortium: Improving Patient Care by Reducing Excessive Antibiotic Use in Patients Hospitalized with Community-Acquired Pneumonia</td>
<td>Saturday, 3:15 - 4:30 p.m.</td>
</tr>
<tr>
<td>2894</td>
<td>Metrics of Antimicrobial Use within Inpatient Settings: Impacts of Statistical Methods and Case-Mix Adjustments</td>
<td>Saturday, 3:15 - 4:30 p.m.</td>
</tr>
<tr>
<td>2895</td>
<td>Threats to Successful Elimination of Viral Hepatitis: Results from the Nationwide Treatment as Prevention for Hepatitis C (TrAP HepC) Program in Iceland</td>
<td>Saturday, 3:15 - 4:30 p.m.</td>
</tr>
<tr>
<td>2896</td>
<td>Reduction in Liver-Related Mortality Among HCV Infected Persons is Driven by Attainment of SVR Independent of the Regimen Used: Results from the ERCHIVES Cohort</td>
<td>Saturday, 3:15 - 4:30 p.m.</td>
</tr>
<tr>
<td>2897</td>
<td>Collocated Buprenorphine is Associated with Improved HCV Visit Adherence in People Who Inject Drugs (PWID): Data From the ANCHOR Study</td>
<td>Saturday, 3:15 - 4:30 p.m.</td>
</tr>
<tr>
<td>2898</td>
<td>Achieving Hepatitis C SVR12 of 95% in Mono-Infected Patients with Severe Comorbidities Using Volunteer Staff and Minimal Clinic Visits and Phlebotomy</td>
<td>Saturday, 3:15 - 4:30 p.m.</td>
</tr>
<tr>
<td>2900</td>
<td>High Rates of Experienced and Witnessed Opioid Overdose in PWID Receiving HCV Treatment: Data from the ANCHOR Study</td>
<td>Saturday, 3:15 - 4:30 p.m.</td>
</tr>
</tbody>
</table>

### 309. Oral Abstract Session

**Glass Half Full or Half Empty? Trends in Antimicrobial Prescribing**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2892</td>
<td>The Relationship between Inpatient and Post-discharge Antimicrobial Use at the Hospital-Level across an Integrated Healthcare Network</td>
</tr>
<tr>
<td>2893</td>
<td>The Michigan Hospital Medicine Safety Consortium: Improving Patient Care by Reducing Excessive Antibiotic Use in Patients Hospitalized with Community-Acquired Pneumonia</td>
</tr>
<tr>
<td>2894</td>
<td>Metrics of Antimicrobial Use within Inpatient Settings: Impacts of Statistical Methods and Case-Mix Adjustments</td>
</tr>
</tbody>
</table>

### 310. Oral Abstract Session

**Hepatitis C: Progress on Elimination and Treatment**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2895</td>
<td>Threats to Successful Elimination of Viral Hepatitis: Results from the Nationwide Treatment as Prevention for Hepatitis C (TrAP HepC) Program in Iceland</td>
</tr>
<tr>
<td>2896</td>
<td>Reduction in Liver-Related Mortality Among HCV Infected Persons is Driven by Attainment of SVR Independent of the Regimen Used: Results from the ERCHIVES Cohort</td>
</tr>
</tbody>
</table>

### 311. Oral Abstract Session

**Vaccination II - Other**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2901</td>
<td>Measles in the United States During the Postelimination Era, 2017-2019</td>
</tr>
<tr>
<td>2902</td>
<td>Pertussis Antibody Levels in Preterm Infants After Maternal Tdap Immunization During Pregnancy</td>
</tr>
<tr>
<td>2903</td>
<td>Post PCV13 Dynamics of Non-Vaccine Serotype (NVT): Disproportionate Increase of the Additional PCV20 Candidate Serotypes in Respiratory and Invasive Disease in Young Children</td>
</tr>
<tr>
<td>2904</td>
<td>Protective Efficacy of Nucleic Acid Vaccines Against Transmission of Zika Virus During Pregnancy in Mice</td>
</tr>
<tr>
<td>2905</td>
<td>Long-term Immunological Persistence of the Adjuvanted Recombinant Zoster Vaccine: Clinical Data and Mathematical Modeling</td>
</tr>
</tbody>
</table>

---

**ORAL ABSTRACT SESSIONS**

---

**Final Program IDWeek 2019**
37. Poster Abstract Session
**Bacteremia, CLABSI, and Endovascular Infections**
Thursday, 12:15 - 1:30 p.m.

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>109</td>
<td>Clinical Characteristics and Outcomes of <em>Staphylococcus aureus</em> Bacteremia from a Biliary Source</td>
</tr>
<tr>
<td>110</td>
<td>Clinical Outcomes of Patients with Secondary Bacteremia in the Omadacycline Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies</td>
</tr>
<tr>
<td>111</td>
<td>Pediatric and Adolescent Sepsis Epidemiology and Clinical Characteristics, Emerging Infections Program, 2014–2015</td>
</tr>
<tr>
<td>112</td>
<td>Physiological Signature of Bloodstream Infection in Critically Ill Patients</td>
</tr>
<tr>
<td>113</td>
<td>Understanding the Changes in Infective Endocarditis Admission in Pennsylvania During the Opioid Crisis</td>
</tr>
<tr>
<td>114</td>
<td>Chorioretinal Lesions in Persons Who Inject Drugs and Are Hospitalized with Bloodstream and Related Infections</td>
</tr>
<tr>
<td>115</td>
<td>Evaluation of the Clinical Impact of the T2MR for the Diagnosis of Blood Stream Infections</td>
</tr>
<tr>
<td>116</td>
<td>Risk Factors and Clinical Outcomes of Carbapenem Non-susceptible Gram Negative Bacteria in Patients with Acute Myelogenous Leukemia</td>
</tr>
<tr>
<td>117</td>
<td>Hospitalized Burn Patients with Fever and Leukocytosis: Blood Culture or Not?</td>
</tr>
<tr>
<td>118</td>
<td>Factors Associated with Positive Follow up Blood Cultures in Gram-Negative Septicemia</td>
</tr>
<tr>
<td>119</td>
<td>Nocardia bacteraemia is almost always associated with immune compromise or an intravascular device: single center case series and systematic review of the literature</td>
</tr>
<tr>
<td>120</td>
<td>The Impact of Early Central Venous Catheter Removal in the Management of Enterococcus Central Line-Associated Bloodstream Infections</td>
</tr>
<tr>
<td>121</td>
<td>Cardiac Implantable Electronic Device-Related Infective Endocarditis (CIED-IE): Clinical Features and Outcomes of Patients with Definite IE Who Fulfill Both Major Duke Criteria.</td>
</tr>
<tr>
<td>122</td>
<td>Evaluation of Early Clinical Failure Criteria in Patients with <em>Enterococcus Species</em> Bloodstream Infection</td>
</tr>
<tr>
<td>123</td>
<td>Impact of Enterococcal Bacteremia on Clinical Outcomes in Patients with Liver Cirrhosis</td>
</tr>
<tr>
<td>124</td>
<td>Impact of Levofloxacin MIC on Outcomes with Levofloxacin Step-down Therapy in <em>Enterobacteriaceae</em> Bloodstream Infections</td>
</tr>
<tr>
<td>125</td>
<td>The Clinical Impact of 16S rDNA Bacterial Sequencing in Infective Endocarditis</td>
</tr>
<tr>
<td>126</td>
<td>Cascade of Care for Opioid Use Disorder in Patients with Infective Endocarditis</td>
</tr>
<tr>
<td>127</td>
<td>Novel treatment approach for Left Ventricular Assist Device related infections</td>
</tr>
<tr>
<td>128</td>
<td>Adequacy of Commonly Prescribed Antimicrobials for Empiric Coverage of Gram-Negative Bacterial Pathogens Recovered from the Bloodstream of Patients Attending Emergency Rooms in Canada: Analysis of Data from the CANWARD Study, 2007 to 2018</td>
</tr>
<tr>
<td>129</td>
<td>Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Gram-Negative Organisms Isolated from Patients with Bloodstream Infections in United States Medical Centers (2017-2018)</td>
</tr>
<tr>
<td>130</td>
<td>Clinical Presentation and Molecular Epidemiology Characterization of Invasive GBS Infection in Nara, Japan from 2007 to 2016</td>
</tr>
<tr>
<td>131</td>
<td>Duration of Therapy for the Treatment of Gram-Negative Bloodstream Infections</td>
</tr>
<tr>
<td>132</td>
<td>Epidemiology, Antimicrobial Resistance and Predictors of Typhoidal and Non-Typhoidal Salmonella Bacteremia in Victoria, Australia.</td>
</tr>
<tr>
<td>133</td>
<td>The changing phenotypes and genotypes of invasive pneumococcal isolates from children in Shenzhen during 2013-2017</td>
</tr>
<tr>
<td>134</td>
<td>A Comparison of Lyme Carditis in Children and Adults, a Case Series</td>
</tr>
<tr>
<td>135</td>
<td>Clinical and Microbiologic Analysis of Risk Factors for Mortality in Patients with Carbapenem-resistant <em>Acinetobacter baumannii</em> bacteremia</td>
</tr>
<tr>
<td>136</td>
<td>Factors Associated with Reduced Vancomycin Susceptibility in Pediatric <em>Staphylococcus aureus</em> Bacteremia</td>
</tr>
<tr>
<td>137</td>
<td>Impact of Rapid Susceptibility Testing on Outcomes in Patients with Bacteremia</td>
</tr>
<tr>
<td>138</td>
<td>Prognosis Following Valve Replacement Surgery for Infective Endocarditis Among Persons Who Inject Drugs</td>
</tr>
<tr>
<td>139</td>
<td>The Morbidity and Financial Burden of Infective Endocarditis in Persons Who Inject Drugs in the Deep South</td>
</tr>
<tr>
<td>140</td>
<td>Trends of Infective Endocarditis at a Northern New England Academic Medical Center, from 2011 to 2017: A Case for Improved Methods to Reliably Identify Associated Substance Use</td>
</tr>
<tr>
<td>141</td>
<td>Use of Rapid Diagnostic Testing in Gram-negative Bloodstream Infections with and without Antimicrobial Stewardship</td>
</tr>
<tr>
<td>142</td>
<td>Mean Platelet Volume Is Associated with Embolic Events of Infectious Endocarditis</td>
</tr>
<tr>
<td>143</td>
<td>Opioid Use and Hospitalizations for Endocarditis, Osteomyelitis, and Central Nervous System Abscess among Adults — New York City, 2001–2014</td>
</tr>
<tr>
<td>144</td>
<td>Organism Identification and Antibiotic Susceptibilities with <em>Verigene Blood Culture Assay</em>: a Retrospective Single-Center Study</td>
</tr>
<tr>
<td>145</td>
<td>Liver Steatosis as a Risk Factor for Invasive Group B Streptococcus Infection In Non-Pregnant Adults</td>
</tr>
<tr>
<td>146</td>
<td>Infective Endocarditis in South Korea: a 12-year Single-center Experience of 419 Patients</td>
</tr>
<tr>
<td>147</td>
<td>Non-Fermenting Gram Negative Bloodstream Infection: a multicenter retrospective cohort study</td>
</tr>
<tr>
<td>148</td>
<td>Retrospective Evaluation of Acute Cholangitis and Clinical Implication and Management of Secondary Bacteremia</td>
</tr>
<tr>
<td>149</td>
<td>Short versus Long Course of Antibiotics for Uncomplicated Gram Negative Bacteremia</td>
</tr>
<tr>
<td>150</td>
<td>Urinary Tract Associated Gram-Negative Bacteremia: Impact of Treatment Duration</td>
</tr>
<tr>
<td>151</td>
<td>Comparing the Clinical Utility of Rapid Diagnostic Tests for Gram-negative Bloodstream Infection using a Desirability of Outcomes Ranking</td>
</tr>
<tr>
<td>152</td>
<td><em>Brevibacterium species</em>: Case Series and Literature Review of an Emerging Opportunistic Cause of Blood Stream Infections</td>
</tr>
<tr>
<td>153</td>
<td>A Review of Ten Cases of Pulmonic Valve Infective Endocarditis</td>
</tr>
<tr>
<td>154</td>
<td>Do I Really Need a Transesophageal Echo? Comparing Echocardiographic Modalities in Native Valve Infective Endocarditis due to Methicillin-Resistant <em>Staphylococcus aureus</em></td>
</tr>
</tbody>
</table>

**POSTER ABSTRACT SESSIONS**
<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>155</td>
<td>Two Cases of <em>Corynebacterium Striatum</em> Prosthetic Valve Endocarditis Resulting in Opposing Outcomes</td>
</tr>
<tr>
<td>156</td>
<td><em>Klebsiella pneumoniae</em> and <em>K. oxytoca</em> Bacteremia: Differences in Host, Source and Antibiotic Susceptibility</td>
</tr>
<tr>
<td>158</td>
<td>Appropriateness of Treatment Duration for <em>S. aureus</em> Bacteremia (SAB)</td>
</tr>
<tr>
<td>159</td>
<td>Candidaemia in Children and Importance of Central Venous Catheter Removal</td>
</tr>
<tr>
<td>160</td>
<td>Channeling Alexander Fleming: Efficacy of Penicillin (PCN) to Treat <em>Staphylococcus aureus</em> Bacteremia</td>
</tr>
<tr>
<td>161</td>
<td>Clinical Characterization of <em>Staphylococcus aureus</em> Bacteremia in Children at an Inner-City Community Hospital</td>
</tr>
<tr>
<td>162</td>
<td>Risk Factors for Extended Spectrum Beta-Lactamase Bacteremia and External Application of a Clinical Prediction Tool</td>
</tr>
<tr>
<td>163</td>
<td>The 30-Day Readmission and 30-Day Mortality of Hemodialysis Patients with Antibiotic-Resistant Gram-Negative Bacteremia</td>
</tr>
<tr>
<td>164</td>
<td>Which patients with gram-negative bacteremia need follow-up blood cultures?</td>
</tr>
<tr>
<td>165</td>
<td>A Case Series of <em>Elizabethkingia meningosepticum</em> Bacteremia in the Cancer Population</td>
</tr>
<tr>
<td>166</td>
<td>Clinical Presentation of <em>Streptococcus gallolyticus</em> Infections</td>
</tr>
<tr>
<td>167</td>
<td>Appropriateness of Empiric Antibiotics for Enterobacteriaceae Bacteremia</td>
</tr>
<tr>
<td>168</td>
<td>Augmenting Utility of Rapid Diagnostic Testing in Treatment of Gram-Negative Bacteremia with Stewardship Intervention</td>
</tr>
<tr>
<td>169</td>
<td>Comparison of Survival for MSSA and MRSA Endocarditis</td>
</tr>
<tr>
<td>170</td>
<td>Description of Positive Blood Culture Results not Identified by Verigene Informs Empiric Antibiotic Selection</td>
</tr>
<tr>
<td>171</td>
<td>Descriptive Study of the Use of External Cooling Blankets in Hyperthermia</td>
</tr>
<tr>
<td>172</td>
<td>Impact of BioFire FilmArray®Blood Culture Identification on the Management of <em>Staphylococcus aureus</em> Bacteremia</td>
</tr>
<tr>
<td>173</td>
<td>Infective Endocarditis Over a Five Year Period in an Academic Teaching Center: The Validity of ICD Codes Versus Manual Chart Review</td>
</tr>
<tr>
<td>174</td>
<td>Chart Validation of an Algorithm for Identifying Patients with Intravenous Drug Use Associated Endocarditis Using Administrative Code Data</td>
</tr>
<tr>
<td>175</td>
<td>Infections in VADers: a true villain of the Force</td>
</tr>
<tr>
<td>176</td>
<td>Real World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation</td>
</tr>
<tr>
<td>177</td>
<td>Safety and Effectiveness of Daily vs Every Other Day Dosing of Dalbavancin in Patients with Renal Insufficiency</td>
</tr>
<tr>
<td>178</td>
<td>The effectiveness of combination therapy of anti-methicillin resistant Staphylococcus aureus agents and β-lactam agents in patients complicated with febrile neutropenia after bone marrow transplantation</td>
</tr>
<tr>
<td>179</td>
<td>Correlating Cardiac PET Results with Intra-Operative Findings in Infectious Endocarditis</td>
</tr>
<tr>
<td>180</td>
<td>Antagonistic Effect of Colistin on Vancomycin Activity Against Methicillin-Resistant <em>Staphylococcus aureus</em> in <em>in vitro</em> and <em>in vivo</em> Studies</td>
</tr>
</tbody>
</table>
Poster Abstract Sessions (continued)

205 Comparing Cefazolin and Nafcillin in Treatment of Methicillin-Susceptible *Staphylococcus Aureus* Bacteremia: A Retrospective Study in a Single Center in the South Bronx

206 Variations in the frequency and impact of polymicrobial cultures in adults with invasive Group B Streptococcal (GBS) infection at the US Veterans Health Administration

207 High Severity and Mortality Due to Methicillin-Susceptible *Staphylococcus aureus* Infections in a Colombian Hospital Early Infectious Disease Consultation Is Associated with Lower Mortality in Patients with Severe Sepsis or Septic Shock who Complete the 3-hour Sepsis Bundle

209 What’s So Complicated About Complicated *Staphylococcus aureus* Bacteremia: Does Day 5 Matter?

210 Step-down from IV to oral therapy in patients with bacteremia due to Enterobacteriaceae: fluoroquinolones (FQ) vs β-lactams (BL) or trimethoprim-sulfamethoxazole (TMP-SMX)

211 *Coxiella Burnetii*: 7 Years of Experience at a Tertiary-Care Center

212 Outcomes of Adults with Uncomplicated *Staphylococcus aureus* Bacteremia Receiving Short-Course Versus Prolonged-Course Antibiotic Therapy in a Multicenter, Propensity Score-Matched Cohort

213 A Comparison of Medication Assisted Therapy Treatment Strategies for Opioid Use Disorder in Persons who Inject Drugs and are Hospitalized with Serious Infections

214 Comparison of Clinical and Laboratory Findings of Human Monocytic Ehrlichiosis (HME) and Human Granulocytic Anaplasmosis (HGA) in Long Island, New York.

215 Invasive Group A *Streptococcus*-Associated Hospitalizations and Risk Factors for In-Hospital Mortality Among Adults in California, 2000–2016

216 Association Between Days to Initiate Appropriate Therapy and Hospital Length of Stay Among Adult Hospitalized Patients With Gram-negative Bloodstream Infections (GN-BSI)

217 Combination Salvage Therapy with Cefazolin Plus Ertaopenem for Refractory Methicillin-Susceptible *Staphylococcus aureus* Bacteremia

218 Evaluation of Clinical Outcomes with Shorter Versus Longer Duration of Treatment for Common Inpatient Bacterial Infections Associated with Bacteremia

219 Is the modified quick SOFA scale superior to quick SOFA in patients with diagnosed septic shock?

220 Characteristics and Outcomes of Veterans with Invasive Group B Streptococcal Infection Vary with the Type of Syndrome

221 Newly-Named *Klebsiella aerogenes* Is Associated with Poor Clinical Outcomes Relative to *Enterobacter cloacae* Complex in Patients with Bloodstream Infection

38. Poster Abstract Session

**Transplant ID: Bloodstream Infections**

Thursday, 12:15 - 1:30 p.m.

222 Bloodstream Infections by Gram(-) Bacteria in Kidney Transplant Patients: Risk Factors, Incidence and Outcome; Bloodstream Infections by Gram(-) Bacteria in Kidney Transplant Patients: Risk Factors, Incidence and Outcome

223 Predicting mortality among immunocompromised patients who present with bloodstream infection

224 Epidemiology of Blood Stream Infections in a Cohort of Allogeneic Hematopoietic Stem Cell Transplant Patients from 2009 – 2018

225 Bloodstream Infections in Adult Allogeneic Stem Cell Transplant Recipients with Acute Gastrointestinal Graft-Versus-Host Disease within the First 180 Days Post-Transplantation

226 Nine-year Survey of Bloodstream Infections (BSIs) across Six Types of Solid Organ Transplant (SOT) at a Large University Medical Center

227 Prevalence, Comorbidities and Expenditures of *S. aureus* Bacteremia in Liver Transplant Recipients: A 2012-2016 Nationwide Analysis

228 Early Recurrent Postoperative Blood Stream Infections in Living-Donor Liver Transplant Recipients

39. Poster Abstract Session

**Diagnostics: Sequencing & Typing**

Thursday, 12:15 - 1:30 p.m.

229 Molecular Typing by RAPD, Characterisation and Antibiotic Resistance profile of ESBL producing and Non ESBL Producing *Klebsiella* species isolated from Diarrheal stool and Environmental samples.

230 Molecular Typing of *Streptococcus pyogenes* Isolates Collected at Mongolian Hospital (Ulaanbaatar, Mongolia)

231 Microbial cell-free DNA Sequencing to Detect *Borelia burgdorferi* DNA in the Plasma of Pediatric Patients with Lyme Disease

232 Genomic Evidence for Dissemination of *Mycobacterium marinum* in an HIV Patient with Multifocal Cutaneous Disease

233 The epidemiology, genomics and evolution of *Staphylococcus aureus* in Northeast Ohio

234 Reversal of carbapenem and amikacin susceptibilities in isogenic *Klebsiella pneumoniae* from a patient with persistent bacteriuria

235 Next Generation Sequencing for investigation of hospital outbreak of Carbapenem- resistant *Klebsiella pneumoniae*

236 The comparative utility of metagenomic next-generation sequencing and universal PCR for pathogen detection on cerebrospinal fluid: a retrospective analysis from a tertiary care center

237 *Adenovirus* Types in Children with Acute Respiratory Illnesses in Nashville Over Two Respiratory Seasons

238 Direct identification of Bacterial Species with MiniON Nanopore Sequencer In Clinical Specimens Suspected of Polymicrobial Infection

239 Epidemiologic Analysis of a Worldwide Collection of *Escherichia coli* ST131 Using the 1928D Core Genome (cg) Multilocus Sequence Type (MLST) Reveals Country Specific and Globally Disseminated Clades

240 The Clinical Utility of Molecular Testing in the Diagnosis and Management of Infectious Diseases - Plasma-based Next Generation Sequencing (PGNS)

241 Molecular patterns of *Streptococcus agalactiae* (GBS) strains associated with different clinical syndromes: early onset disease in neonates, intrathecal infection, and vaginal colonization, an Orthodox Jewish community (OJC) residing in Bnei Brak
242 Comprehensive Pathogen Detection for Pediatric Febrile Neutropenia by Metagenomic Next-Generation Sequencing
243 Transfection Fourier Transform Infrared Spectroscopy as a Real-Time Strain Typing Technique: A Vancomycin-Resistant Enterococcus faecium (VRE) Typing Prospective Study
244 Development, Qualification, and Clinical Validation of an Immunodiagnostics assay for the Detection of 11 Additional S. pneumoniae Serotype-Specific Polysaccharides in Human Urine
245 Plasma and Respiratory Specimen Metagenomic Sequencing for the Diagnosis of Severe Pneumonia in Mechanically-Ventilated Patients.
246 Carbapenem resistant Klebsiella (CRK) bloodstream infections (BSIs) are caused by bacterial populations that are genotypically and phenotypically diverse

40. Poster Abstract Session

Fungal Diagnostics
Thursday, 12:15 - 1:30 p.m.

247 Evaluation of the T2Candida Panel as an Antifungal Stewardship Tool in Transplant and Non-Transplant Patients at a Tertiary Care Center.
248 30-Day Mortality Among Patients with Candidemia Diagnosed by T2Candida Assay Alone: Influence of Risk Factors and Candida Species
249 Limited Diagnostic Utility of Extended Aerobic Blood Culture Incubation for Fungal Pathogen Detection
250 Comparison of T2Candida Assay with Blood Culture, Candida Sepsis Score and Serum Beta-D-glucan in Diagnosis of Candidemia
251 Implementation of the s na Coccioidioides Antibody Lateral Flow Assay in the Clinical Laboratory Proves to Reduce Cost and Decrease Turnaround Time When Compared to Send out Immunodiffusion and Complement Fixation Testing
252 Development and Evaluation of a Novel MultiCode Real-Time PCR Assay for the Detection of Pneumocystis jirovecii Bronchoalveolar Lavage Fluid and Induced Sputum
253 Evaluation of a Cryptococcal Antigen Lateral Flow Assay and the Burden of Cryptococcal Disease: A Cohort Study at Grady Memorial Hospital in Atlanta, Georgia
255 Breakthrough Mucormycosis (BT-MCR) on antifungals having Mucorales activity portrays worse prognosis compared to BT-MCR on mold-active antifungals with no Mucorales activity
256 Optimizing the Clinical Utilization of T2 Rapid Candida Panel at a Large Community Hospital
257 Aspergillus Galactomannan Lateral Flow Assay for Rapid Diagnosis of Invasive Aspergillosis in Bronchoalveolar Lavage
258 False Negative Rate of T2Candida Assay in Blood Culture Positive Candidemia
259 Racial differences in clinical phenotype and hospitalization of blastomycosis patients.

260 Detection of Aspergillus fumigatus infection in mice with 2-Deoxy-2-[18F]fluorosorbil
261 A Retrospective Evaluation of Coccidioidomycosis Skin Testing in Patients with Pulmonary Coccidioidomycosis in an Endemic Region
262 Assessment of Serum Galactomannan Test Results of Pediatric Patients with Hematologic Malignancies According to Different Threshold Levels and Consecutive Positivity in Terms of Invasive Aspergillosis Diagnosis: Cross-Sectional Research in a Tertiary Care Hospital
263 Advances in Diagnosis of Progressive Coccidioidomycos: Experience in 164 cases and 508 Controls
265 Clinical epidemiology of invasive fungal infection with Aspergillus and Mucor species in a tertiary children’s hospital
266 Clinical Profile and Treatment Outcomes of Candida auris isolates from a Tertiary Care Hospital in South-India
267 Fungal Culture Diagnostic Stewardship: An Avenue for Antimicrobial Stewardship in the Immunocompromised Host
268 Fungal NGS: Identification of Etiological Agents of Invasive Fungal Infection by High-throughput Sequencing
269 Epidemiology and outcomes of invasive aspergillosis (IA) among pediatric immunocompromised patients: a 12-year, single center experience.
270 T2MR: A New Tool for Anti-Fungal Stewardship
271 Fungal Diagnostic Studies in Histoplasmosis
272 Invasive Pulmonary Aspergillosis: Comparative Analysis in cancer patients with Underlying Hematologic Malignancy versus Solid Tumor
273 Low Positive Predictive Value of Beta-D-Glucan in Hematology Patients Receiving Antimold Prophylaxis
274 Impact of Fungal Serologies in the Management of Veteran Patients with Suspected Endemic Mycoses
275 Delayed diagnosis of histoplasmosis in pediatric patients due to atypical clinical presentations
276 Detection of Rhizopus oryzae specific antigen (RSA) in serum and bronchial alveolar lavage is a potential early diagnostic marker in mucormycosis by R. oryzae.
277 Identification and Antifungal Susceptibility of Candida species Isolated from Bloodstream Infections Over a 14-Year Period
278 CNS Blastomycosis: A Descriptive Analysis and Review of Diagnosis and Treatment
279 Evaluation of Beta-d-Glucan Utilization in Thailand: Single Academic Center Experience
280 Monitoring serum erythrocyte sedimentation rate (ESR) and c-reactive protein (CRP) in correlation with 1-3-beta-d-glucan levels in vascular pythiosis: a preliminary study
281 Hypersensitivity Pneumonitis Diagnosed with Broad-Range PCR Testing after Exposure to Battarrea Mushroom Spores
282 Epidemiology of Candidemia in Patients with Solid Tumors of the Gastro-intestinal Tract

41. Poster Abstract Session

Hepatitis
Thursday, 12:15 - 1:30 p.m.

283 Potentially achievable hepatitis A vaccination coverage with simultaneous administration of vaccines among young children in the United States.
284 Using epidemiologic investigation and viral sequencing to describe and provide public health response to an outbreak (OB) of acute hepatitis A virus infection (HAV) in the San Fernando Valley (SFV), California
285 Fibrosis Progression and Clinical Outcomes in HCV/HBV Coinfected Persons in the ERCHIVES Cohort
286 Hepatitis B Vaccine Compliance: Comparing 2-dose and 3-dose Vaccines
287 Exploring the Natural History and Clinical Outcomes of Hepatitis B Core Antibody Positive Hemodialysis Patients in a Large Metropolitan Tertiary Care Hospital System with a Focus on Occult Hepatitis B
288 Hepatitis B Virus Reactivation in Patients with Hematologic Malignancies after Anticancer Therapy Which Included Ibrutinib
289 Importance of Universal Screening for Hepatitis B in Cancer Patients: Quality Improvement Project in Japan
290 Hepatitis E Virus Serostatus: A Retrospective Assessment of Demographics and Comorbidities to Assess High Risk Populations
291 Using Individualized Provider Feedback to Improve HCV Screening in a High-Volume Emergency Department
292 No association between direct-acting antiviral (DAA) therapy and varicella-zoster virus (VSV) reactivation in an analysis of 37 prospective clinical trials
293 Hepatitis C is now a Millennial Disease in Response to the Opioid Crisis: A Demographic Shift in Hepatitis C Infection
294 Hepatitis C Virologic Response in Hepatitis B and C Coinfected Persons Treated with Directly Acting Antiviral Agents: Results from ERCHIVES
295 South Carolina Hepatitis C Telehealth Initiative (SCHTI): Increasing Access to HCV Care
296 The Hepatitis C Cascade of Care across Four Safety Net Settings in the Southeast
297 Accessible Care Intervention for Engaging People who Inject Illicit Drugs in Hepatitis C Virus Care: Preliminary Results from a Randomized Clinical Trial
298 Collocation of hepatitis C care continuum with MAT for high-prevalence, high-risk population
299 “Where the Rubber Meets the Road”: Stakeholders’ Perspectives about the Current State of HCV Care Delivery in Massachusetts Jails
300 Drug use characteristics and Hepatitis C antibody prevalence in southern Illinois
301 Risk of Virologic failure with Antiretroviral Switches in HIV/ HCV Co-infections
302 HCV Care in Federally Qualified Health Centers During the Opioid Epidemic: A Retrospective Cohort Study
303 A Surrogate Rodent Model for Studying Hepatitis C Virus-specific CD8 T Cell Impairment and Vaccine Prevention
304 Hepatocellular Carcinoma Occurs Frequently and Early After Treatment in HCV Genotype 3 Infected Persons Treated with DAA Regimens
305 Using Big Data to Re-Engage Hepatitis C-infected Persons: A UK Operational Delivery Network’s Experience
306 CD8+ T Cell Responses to Chronic Hepatitis C in Pregnancy
307 Overcoming Hepatitis C Elimination Challenges in the Coachella Valley through the Collaboration of Linkage to Care, a Managed Care Organization, and a Federally Qualified Health Center
308 Slow Adoption of a Nurse-Driven Protocol for Universal Hepatitis C Virus Screening in a Hospital Emergency Department: Lessons Learned
309 Should Primary Care Practitioners Follow Hepatitis C exposed Infants?
310 Disparities in Hepatitis C Linkage to Care in the DAA Era: Findings from a Referral Clinic with an Embedded Nurse Navigator Model
311 Hepatitis C Screening Within a Large FQHC Network in Brooklyn New York- How We Measure Across an Ethnically Diverse Population
312 Treatment of Hepatitis C After Identification of Infection During Universal Screening Approach in Pregnant Women
313 Bringing Hepatitis C into FOCUS: Evaluating the Efficiency of a Linkage to Care Program in Improving the Hepatitis C Care Cascade.
314 Healthcare Providers’ Views on HCV Testing and Counseling Among Sexual Partners of Hepatitis C Infected Persons
315 Prenatal Hepatitis C Viral (HCV) Screening Practices and HCV-Associated Fetal, Neonatal and Pregnancy Outcomes in a Large Regional Healthcare System
316 Hepatitis C and Engagement in Health Care Among Persons Who Inject Drugs and Persons Who Use Non-Injection Drugs, Philadelphia.
317 Utility of a Hepatitis C Screening Best Practice Advisory in University Based Primary Care Practices

42. Poster Abstract Session
**HIV Complications: Bone Complications**
Thursday, 12:15 - 1:30 p.m.

318 Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Hispanic/Latina and Black Participants: Efficacy, Bone and Renal Safety Results from a Pooled Analysis of 7 Clinical Trials
319 WORD 1&2: Switch from TDF Containing Regimen to DTG+RPV Maintains Bone Mineral Density and Decreases Bone Turnover Markers Over 148 Weeks
320 UK-HOPS (HIV Osteoporosis Prevention and Screening)- Gaps in the Care of HIV Patients with Bone Disease
321 Low Volumetric Bone Density at Proximal Femur in HIV-infected Men and Its Risk Factors: Comparison with Community-dwelling Non-infected Men
322 Prolonged amenorrhea is associated with decreased hip bone mineral density in women living with HIV
323 Fragility Fracture Risk in HIV: Awareness Among Primary Care Providers

43. Poster Abstract Session
**HIV Complications: Cancer**
Thursday, 12:15 - 1:30 p.m.

324 Outcomes of Immunomodulatory and Biologic Therapy in People Living with HIV: A Report from Two Academic Hospitals
325 Cancer Screening Disparities among Persons Living with HIV (PLWH)
326 Is antiretroviral treatment averting AIDS and non-AIDS defining malignancies in Colombia?
327 Barriers to Positive Health Outcomes in the HIV-Infected Cancer Clinic Population
44. Poster Abstract Session

**HIV Complications: Cardiovascular, Metabolic, and other Complications**

Thursday, 12:15 - 1:30 p.m.

- **332** Exploring the Prevalence and Characteristics of Weight Gain and other Metabolic Changes in Patients with HIV Infection Switching to Integrase Inhibitor Containing ART
- **333** Weight gain among HIV-infected patients in Southern India on treatment with integrase strand transfer inhibitor-based anti-retroviral therapy
- **334** Weight Change Associated with Antiretroviral Therapy Switch to Integrase Strand Transfer Inhibitor-Based Regimens
- **335** Antiretroviral Therapy Anchor-based Trends in Body Mass Index following Treatment Initiation among Military Personnel with HIV
- **336** Disparities in Cardiovascular Disease Prevention Among Persons Living With HIV in the United States Military Natural History Study
- **337** Switching from TDF to TAF: Missed Opportunities for Statin Use in HIV
- **338** Patients living with HIV infection are less likely to receive the correct intensity of statin therapy for cardiovascular disease risk reduction
- **339** Implementing a Smoking Cessation Intervention Among People Living With HIV (PLWH)
- **340** Prevalence of Type 2 Diabetes Mellitus Among Patients Living with HIV in the United States
- **341** Risk of Type 2 Diabetes Mellitus after Antiretroviral Therapy Initiation in Individuals Living with HIV in the United States
- **342** The Impact of Glycemic Control on CD4 Cell Count in Persons Living with HIV and Diabetes Mellitus—Washington, DC.
- **343** T Cell Subsets Associated with Diabetes in Veterans with and without HIV
- **344** HIV and Diabetes in the Era of Antiretroviral Therapy
- **345** Acute onset Diabetic Ketonacidosis/Hyperosmolar Hyperglycemic State in patients taking Integrase Strand Transfer Inhibitors
- **346** Factors Associated with Hypertension in Young Adults with Perinatally-Acquired HIV Infection: a Case-Control Study
- **347** Hepatic Steatosis in People Living with HIV – Effect of Sex and Race/Ethnicity
- **348** Kidney Function Decline among HIV-infected Thai adults: Is low vitamin D one of the factors?
- **349** Implementation of a Multidisciplinary HIV-Pulmonary Clinic
- **350** Outcomes for Joint Arthroplasty in Persons Living with HIV and Aging: Multimorbidity in Older People Living with HIV in One Southeastern HIV Clinic
- **351** Five Cases of Hemophagocytic Lymphohistiocytosis in Patients with HIV: A Fulminant and Lethal Combination
- **352** Characteristics Associated with Pre-Frailty in Older People Living with HIV
- **353** A comparison study of prevalence and risk factors for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) by Transient Elastography (TE) in HIV infected patients

45. Poster Abstract Session

**HIV Complications: Hepatitis Co-Infections**

Thursday, 12:15 - 1:30 p.m.

- **354** Efficacy of Second Generation Direct Acting Antivirals in the setting of HCV/HIV Co-infection and Cirrhosis: A Review of Real World Treatment Experiences
- **355** Barriers for Hepatitis C Elimination in HIV/HCV Coinfected Patients
- **356** HIV-HCV Coinfection: An Investigation of CD4 T-Cell Reconstitution after HCV Direct Acting Antiviral Treatment
- **357** Hepatitis C (HCV) Testing and Diagnosis and their Relationship to Sexually Transmitted Infection (STI) Screening and New Infections in a HIV+ Men who have Sex with Men (MSM) Outpatient Cohort
- **358** HIV Infection and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus (HBV) Co-infection: a Propensity Score-matched Cohort Study
- **359** TLR7 Gene Polymorphisms Influence Development of Hepatic Fibrosis in HCV/HIV Coinfection
- **360** Advanced Liver Disease in HIV/Hepatitis B Coinfected Patients: Associated with Race, Age, and Comorbidities
- **361** Residual Lamivudine-resistant hepatitis B virus detected on next-generation sequencing of treatment-experienced HIV patients failing antiretrovirals
- **362** Hepatitis C Virus (HCV) Co-infection in Women Living with Human Immunodeficiency Virus (HIV) in Northwest Louisiana.
- **363** Characterization of HIV/HBV Co-infected Patients at an Outpatient HIV Clinic and Evaluation of Management Practices as a Measure for Quality Improvement.

46. Poster Abstract Session

**HIV Complications: Neurologic Complications**

Thursday, 12:15 - 1:30 p.m.

- **364** Association of Maternal ARV Use with Microcephaly in HIV-Exposed Uninfected Children
- **365** Neurocognitive Function Change after Switching from Efavirenz to Rilpivirine in HIV-infected Adults: A Randomized Control Trial
- **366** Severe Neurologic Impairment Persists Despite Potent ART in HIV Encephalopathy
- **367** Use of a Brief Task-Based Measure to Assess the Functional Consequences of Cognitive Impairment in HIV
- **368** Incidental Findings on Brain MRI in People Living with HIV and the Relationship to Sexually Transmitted Infection (STI)
- **369** Association between Depression and HIV Treatment Outcomes in a U.S. Military Population with HIV Infection

47. Poster Abstract Session

**HIV Complications: Opportunistic Infections**

Thursday, 12:15 - 1:30 p.m.

- **370** Comparing Trends and Outcomes among HIV Infected versus HIV Uninfected Patients with Tuberculosis: A 5
**Poster Abstract Sessions (continued)**

**Thursday, 12:15 - 1:30 p.m.**

**Infections of Joints**

371 Tuberculosis and HIV co-infection at a Tertiary Care Hospital in Thailand

372 Prevalence of Urethral, Rectal, and Pharyngeal Gonorrhea and Chlamydia among Newly Diagnosed Filipino HIV Patients

373 Immune Reconstitution Inflammatory Syndrome in Patients with HIV/AIDS and Histoplasmosis: A Case Series

374 Lymphogranuloma venereum (LGV) outbreak among people living with HIV (PLWH): Michigan, 2015-2018

375 Cryptococcal Antigenemia in Advanced HIV Infection

376 Effect of Parasitic Infections on Gut Epithelial Barrier and Immune Activation among Foreign-Born HIV-infected Patients

377 Diagnostic Yield of Bone Marrow Aspiration and Biopsy in Human Immunodeficiency Virus Patients with Fever and/or Cytopenia

378 Seroprevalence of Helicobacter pylori among HIV-infected Patients in a tertiary care hospital in Busan, South Korea

379 Clinical Management of HIV-associated Pneumocystis jirovecii Pneumonia in Rural Nigerian Communities: Public Health Interventions and Impact

48. **Poster Abstract Session**

**Infections of Joints**

380 Characterizing Host Factors, Treatment Strategy, and Clinical Outcomes of Group A Streptococcus Orthopedic Infections

381 Clinical Outcome of Polymicrobial Prosthetic Joint Infection Managed with Debridement, Antibiotics and Implant Retention (DAIR)

382 Difference in Pathogens Between Hip and Knee Prosthetic Joint Infection

383 Rheumatic Disease Patients Have More Culture Negative Prosthetic Joint Infections- Are There Clinical Differences?

384 Denosumab related osteonecrosis of the jaw: an emergent and potentially complex bone and joint infection

385 Arthroscopic Versus Open Surgery for Septic Arthritis of the Knee: A Systematic Review and Meta-Analysis

386 Blue Light Reduces Cutibacterium (Propionibacterium) acnes Bacterial Burden: Orthopedic Shoulder Infection Prevention Strategy?

387 A Rare Manifestation of a Common Disease: Tenosynovitis Associated with *Clostridium difficile* - Case Report and Review of Literature

388 Spinal Implant Infections Treated with Debridement and Hardware Retention.

389 Risk Factors and Outcomes of Patients with Infectious Complications After Surgical Treatment of Blount Disease Treatment and Outcome of Methicillin-Resistant *Staphylococcus aureus* Hip and Knee Prosthetic Joint Infection

390 Septic Arthritis and Acute Hematogenous Osteomyelitis in Children: Disease-Specific Antiobiogram and Implications for Treatment

391 Epidemiology and Treatment Outcome of Gram Negative Polymicrobial, Gram positive Polymicrobial and Mixed Polymicrobial Prosthetic Joint Infection

401 Predictors of Treatment Failure for Hip and Knee Prosthetic Joint Infections in the Setting of Prosthesis Removal: A Multi-Centre Retrospective Cohort

402 Clinical characteristics and outcome of *Staphylococcus lugdunensis* Prosthetic Joint Infections

403 Clinical Features and Treatment Outcome of Enterobacter Prosthetic Joint Infections

49. **Poster Abstract Session**

**Inflammation and Infectious Diseases**

404 miRNA-Gene Pairs Associated with Shock and Renal Failure in Filipino Septic Patients

405 Serum Antibody Responses Against Carbapenem-Resistant *Klebsiella pneumoniae* in Infected Patients

406 Cloning Antibodies Against Kawasaki Disease from Acute Serum Antibody Responses Against Carbapenem-Resistant *Klebsiella pneumoniae* in Infected Patients

407 The Effect of *Streptococcus pneumoniae* pneumonia on Atherosclerosis

408 Single Cell Sequencing Identifies Variability in Host Response Among Different Genera of Influenza Viruses

409 Using the Host Response to Reduce Unnecessary Antibiotic Use in Outpatient Acute Respiratory Infections

410 Influence of pre-season antibody titers to influenza on influenza risk in a cohort of healthcare personnel

411 Does an early cytokine response during Ebola virus disease improve duration of survival in rhesus macaques?

412 Host response biomarkers predict clinical failure in patients with *Staphylococcus aureus* Bacteremia (SAB) treated with fluoxacillin (FLU) or vancomycin (VAN)

413 Differences in Inflammatory Mechanisms in *Pseudomonas aeruginosa* and *Staphylococcus aureus* Infections in Cystic Fibrosis

414 Developing Digital Phenotypes of Primary Immune Deficiencies Using Machine Learning on a Large Electronic Health Record Database
50. Poster Abstract Session
Sexually Transmitted Infections
Thursday, 12:15 - 1:30 p.m.

415  Improvement in Syphilis and HIV Screening Rates at a Community-Based Emergency Department in Columbus, Ohio: Six Month Post-Intervention Analysis.


417  Initial Evaluation of Engagement and Utilization of the National Sexually Transmitted Diseases Curriculum.

418  Prevalence of Oropharyngeal Meningococcal Carriage in an Urban STD Clinic.

419  Return of Results in Sexually Transmitted Infection Research: The Ethics of Notification and Treatment.


421  Self-reported screening for rectal sexually transmitted infections among men who have sex with men.


423  Longitudinal Trends in Risk Behaviors and Sexually Transmitted Diseases among Adolescents and Young Adults at a Sexually Transmitted Diseases Clinic, 2013-2017.


425  Putting the ‘Eye’ in Spirochetes.

426  Lower Incidence Rates of Neisseria gonorrhoeae and Chlamydia trachomatis in Pre-Exposure Prophylaxis Patients Over Fifty Years Old Than in Younger Quartiles.


428  Impact of a Pharmacist-Managed Sexually Transmitted Disease (STD) Test Result Review Service at a Veterans Affairs Medical Center.

429  Asymptomatic Latent Syphilis and Stroke in Geriatric Patients; Analysis of Routine Syphilis Tests.

430  Qualitative Differentiation of Genital Ulcer Disease Etiology via Nucleic Acid Amplification Testing (NAAT).

431  Implementation of an Emergency Department Syphilis Screening Program.

432  Concurrent gonococcal infections with differing susceptibility results from the enhanced Gonococcal Isolate Surveillance Project (eGISP).

51. Poster Abstract Session
Soft Tissue and Skin Infections
Thursday, 12:15 - 1:30 p.m.

433  Iliopsoas Abscess In Egyptian Patients Presenting To Cairo University Hospitals.

434  Skin and Soft Tissue Infections are a Common Reason for Potentially Inappropriate Antimicrobial Use among Inpatients in Sri Lanka.


436  Dalbavancin Clinical Experience at an NCI Designated Cancer Center.

437  Iclaprim Use for Acute Bacterial Skin and Skin Structure Infection (ABSSSI) is Not Associated with Hyperkalemia: Phase 3 REVIVE Studies.

438  Necrotizing soft tissue infections involving Actinomyces species.

439  Factors associated with change of antimicrobial therapy in patients with cellulitis who started with amoxicillin-clavulanate (A/C) monotherapy.

440  Risk Score for Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections.

441  The CHROME Study, a Real-World Experiential Registry of the Use of Oritavancin For Treatment of Gram-positive Infections.

442  Better Efficiency, Same Accuracy: Point-of-Care PCR for the Detection of group A streptococcus in Non-Invasive Skin Infections.

443  A Case of Disseminated Microsporidia Manifesting as Skin Lesions in a Patient with Acute Lymphoblastic Leukemia.

444  Epidemiology of Necrotizing Fasciitis in Korea: A Nationwide Study Using Claims Data.

445  Disease Progression in Patients with Acute Bacterial Skin and Skin Structure Infections: A Comparative Analysis Between Oritavancin and Vancomycin.

446  Impact of doxycycline prophylaxis on skin and soft tissue infection incidence in Naval Special Warfare trainees.


448  Evaluation of linezolid pharmacokinetics in obese patients with severe skin and soft tissue infections.

449  High Rates of Hospitalization due to Skin and Soft Tissue Infections in a Southwest American Indian Population.

450  Antibiotic Duration, but Not Size, Impacts Clinical Cure of Infections in a Southwest American Indian Population.

451  Examination of the Use of Oritavancin For Treatment of Gram-positive Infections.

452  The CHROME Study, a Real-World Experiential Registry of the Use of Oritavancin For Treatment of Gram-positive Infections.

453  The ENHANCE ABSSSI Trial.

454  High Burden of Invasive and Severe Group A Streptococcus Disease Among Native Americans on the White Mountain Apache Tribal Lands.

455  Perinatal Risk Factors Associated with Skin Infection Hospitalisation in Western Australian Aboriginal and Non-Aboriginal Children.

456  Gender differences in clinical, microbiological and treatment characteristics of adult hospitalized patients with cellulitis. A large, prospective multicenter study.

457  Dalbavancin, a Long Acting Lipoglycopeptide Antimicrobial Agent, Reduces Length of Stay and Improves Patient Work Productivity in a Hospital Critical Pathway for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) – the ENHANCE ABSSSI Trial.

458  Cytomegalovirus (CMV) and Sexually Transmitted Diseases Outpatient Parenteral Antibiotic Clinic: A Prospective Cross-Sectional Study.

459  Gaps in Diabetic Foot Care in an Inner-City Hospital.
Poster Abstract Sessions (continued)

460  Ceftriaxone versus Standard of Care for Definitive Treatment of Methicillin-Susceptible Staphylococcus aureus Infections
461  Management of ABSSIs: An Assessment of Knowledge, Competence and Clinical Practices among ID Specialists
463  Evaluation of Trimethoprim-Sulfamethoxazole Utilization for Skin and Soft Tissue Infections During Emergent Department Visits at Two Community Teaching Hospitals
464  Fecal Staphylococcus aureus in the Neonatal Intensive Care Unit
465  Comparative Efficacy of Double Versus Single Antibiotic Regimens for the Empiric Treatment of MRSA-Induced Acute Bacterial Skin and Skin Structure Infection
466  Elevated Risk of Invasive Group B Streptococcal Infection Among Veterans with Poorly Controlled Diabetes Mellitus or at Extremes for Body Mass Index
467  Epidemiologic Features of Invasive Methicillin-Resistant Staphylococcus aureus and Group A Streptococcus Infections among Children in Korea
468  Antimicrobial Resistance and Molecular Analysis of Staphylococcus aureus in Staphylococcal Scalded Skin Syndrome among Children in Korea
470  Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Patients with Significant Drug Abuse: Outcomes from Global Phase 3 Studies of Delafloxacin (DLX)
471  Safety and Efficacy of Oral and/or Intravenous Tidexilid Phosphate (TZD) in Adolescents with Acute Bacterial Skin and Skin Structure Tissue Infections (ABSSSI)
472  Rethinking the Role of Clindamycin for Toxicin-mediated Illnesses
473  Impact of Adjunctive Clindamycin in Invasive Beta-Hemolytic Streptococcal Infections: A Propensity Score-matched Analysis of 1956 Beta-lactam Treated Patients from 118 US hospitals
474  Battling Addiction: Impact of Intravenous Drug Use on Invasive Skin and Soft Tissue Management

53. Poster Abstract Session
HAI: MDRO - GNR Epidemiology, Other
Thursday, 12:15 - 1:30 p.m.

478  Outcomes of Extended-Spectrum Beta-Lactamase-Producing Escherichia Coli Bloodstream Infection in Neutropenic Patients with Hematological Malignancies
479  Associated Factors for Extended-spectrum β-lactamase Infection among Patients with Solid or Haematological Malignancy.

54. Poster Abstract Session
HAI: MDRO - GNR Epidemiology, CRE
Thursday, 12:15 - 1:30 p.m.

490  High prevalence of rectal carriage of the KPC–mediated carbapenem-resistant Enterobacteriaceae among community food handlers in Kuwait
491  Working Together: A Tale of Carbapenemase-Producing Organism Investigations in Three New York City Nursing Homes
492  High prevalence of colonisation with carbapenem-resistant Enterobacteriaceae among patients admitted to Vietnamese hospitals: risk factors and burden of disease
493  Laboratory Evaluation and Epidemiology of Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae in Department of Veterans Affairs, 2017.
494  Fitness cost of mcr-1-mediated colistin resistance in carbapenemase-producing Klebsiella pneumoniae
495  Risk Factors of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections Among Intensive Care Unit (ICU) Patients in a Tertiary Hospital in the Philippines
Poster Abstract Sessions (continued)

496 Carbapenem Resistant *Enterobacter* – A Case-Case-Control Investigation
497 Changing Molecular Epidemiology of CRE from 2016-2018, Increase in the Unknown
498 High Burden of CRE Infections and its Association with Infection among Patients transferred to a Tertiary Care Hospital in India
499 Carbapenem-resistant Enterobacteriaceae (CRE)-associated Infections and Prolonged Colonization among Hospitalized Patients Colonized by CRE
500 Prevalence of Extended Spectrum β-lactamase and Carbapenem-Resistant Gram-Negative Bacteria in Patients with Urinary Tract Infection and Urosepsis Admitted through Emergency Departments in the United States
501 Risk of Infection in Persons Colonized with Carbapenemase-Producing Enterobacteriaceae (CPE) in Ontario, Canada
502 *Klebsiella variicola* Infections in Service Members Who Sustained Trauma in Iraq and Afghanistan
503 Comparison of IMP carbapenemase-producing *Enterobacteriaceae* (CPE) and non-carbapenemase-producing *Enterobacteriaceae*: A multicenter prospective study of clinical and molecular epidemiology in Japan
504 Epidemiology of End Stage Renal Disease (ESRD) Patients with Carbapenem-Resistant *Enterobacteriaceae* (CRE) Infections – Atlanta Metropolitan Area, 2012–2017
505 Making of a “Super-Duper Bug”: Plasmid Mediated Resistance Accumulation in a Carbapenemase-Producing *Klebsiella quasipneumoniae* from Patients and the Environment
506 Urinary Catheters are Associated with Progression from Bacteriuria to Invasive Infections in Patients with Carbapenem-Resistant Enterobacteriaceae, Metropolitan Atlanta, 2011-2017
507 Epidemiology of Community-Associated Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Identified from the Emerging Infections Program, 2012-2017
508 Gentamicin Non-susceptibility is Associated with Persistence of Carbapenem-Resistant *Klebsiella pneumoniae* in the Urinary Tract
509 The Prevalence of Carbapenem-Resistant Enterobacteriaceae (CRE) in a Community Hospital Setting
510 Exposure Investigation Following a Confirmed Case of *Candida auris* and Multiple Carbapenemase-Producing Carbapenem-Resistant Organisms

55. Poster Abstract Session

**HAI: MDRO - GNR Transmission**

Thursday, 12:15 - 1:30 p.m.

511 MDRO carriage in patients in two ICUs and prevalence of environmental surface and healthcare worker hand contamination
512 Healthcare-Acquired (HA) Carbapenemase-Producing Enterobacteria (CPE) in Southern Ontario, Canada: To Whom are we Transmitting CPE?
513 Transmission of Carbapenem-resistant Enterobacteriaceae in a Community-Based, Residential Care Setting — Nevada, 2018
514 Shedding of Multidrug-Resistant Gram-Negative Bacilli by Colonized Patients during Procedures and Patient Care Activities

515 Acquisition of Antibiotic-Resistant Gram-Negative Bacteria in the Benefits of Universal Glove and Gown (BUGG) Cluster Randomized Trial
516 Social Network Analysis to Study MDRO Transmission in VA Community Living Centers and Spinal Cord Injury Units

56. Poster Abstract Session

**HAI: MDRO - GNR Treatment**

Thursday, 12:15 - 1:30 p.m.

517 Treatment Patterns of Hospitalized Adults with Infections Due to Carbapenem Non-susceptible Gram-negative Organisms in a Large Electronic Health Record Database in the US
518 Comparing the Mortality of Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant *Enterobacteriaceae* Bacteremia
519 Multi-drug Resistant Gram-negative Bacteremia in Pediatric Patients: Is it Time to Change to Empiric Meropenem?
520 The Clinical Profile and Outcomes of Patients given Intravenous Colistin for Multidrug-Resistant Gram Negative Infections in a Philippine Tertiary Hospital
521 Comparative *In Vitro* Activity of Meropenem/Vaborbactam and Meropenem Against a Collection of Real-World Clinical Isolates of *Pseudomonas aeruginosa*
522 *In Vitro* Antimicrobial Activity of Ceftazidime/avibactam Compared to Cefotolozane/tazobactam Against Real World Clinical Isolates of *Pseudomonas aeruginosa* at a Large Academic Tertiary Care Hospital
523 Dual vs triple antibiotic therapy for carbapenem-resistant *Acinetobacter baumannii* infections
524 Understanding the treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections in the United States (US): Insights from a survey of hospital-based pharmacists

57. Poster Abstract Session

**HAI: MDRO - GNR Prevention**

Thursday, 12:15 - 1:30 p.m.

525 Evaluation of Implementation of Guidelines for Carbapenem-resistant Enterobacteriaceae (CRE) Prevention Using the Consolidated Framework for Implementation Research (CFIR)
526 Significant Reduction of Hospital Onset Carbapenem-Resistant *Enterobacteriaceae* Utilizing Infection Prevention Strategies - *It takes a Village!*
527 Project “Isolation Zero”: Discontinuing Contact Precautions for Patients Colonized/Infected with Multidrug-Resistant Organisms through Community Level Follow-Up in Spain
528 Longitudinal Evaluation of Chlorhexidine Resistance among Multidrug-Resistant Organisms in Relation to Intervention of Daily Chlorhexidine Bathing in Adult Intensive Care Units
529 Halting Multi-modal Transmission of a Novel Carbapenemase-producing Enterobacteriaceae Outbreak
530 Sequential Screening of High Risk Patients for Carbapenemase-Producing *Enterobacteriaceae* Colonization
531 Practical and evidence-based considerations for implementation of bacterial whole-genome sequencing within longitudinal infection control practice

532 Can Saccharomyces boulardii therapy be effective in decolonizing rectal carbapenem-resistant Enterobacteriaceae (CRE) colonization?

58. Poster Abstract Session
HAI: MDRO - GNR Surveillance
Thursday, 12:15 - 1:30 p.m.

533 Impact of Different Definitions on Reported Rates of Carbapenem Resistant Enterobacteriaceae (CRE)

534 Active Screening for Carbapenemase Producing Enterobacteriaceae; Yield and Cost Considerations

535 Multicenter Study of the Prevalence of Rectal Colonization by Carbapenem-Resistant Enterobacteriaceae in Patients Admitted to the Intensive Care Units of 7 Major Hospitals in Kuwait

536 Challenges in using MALDI-TOF technology to assess for KPC resistance in Klebsiella pneumoniae isolates in America

537 Impact of Active Surveillance Testing (AST) on Rates of Hospital Acquired Carbapenem Resistant Enterobacteriaceae (CRE)

538 Extended-Spectrum Beta-Lactamase (ESBL) – Producing Enterobacteriaceae Surveillance Pilot, New Mexico, 2017

539 Canaries in a coal mine?: Early Identification of Regional Spread of Novel Multidrug-resistant Organisms (MDROs) Using Sentinel Surveillance in Skilled Nursing Facilities Caring For Ventilated Patients (vSNFs)

59. Poster Abstract Session
HAI: MDRO: General
Thursday, 12:15 - 1:30 p.m.

540 The Impact of Diet and Oral Hygiene on the Risk of Multidrug Resistant Organism Carriage in the Mouth and Gut

541 Factors Associated with the Persistence of Colonization by Multidrug-Resistant Organisms in Cali, Colombia

542 Los Angeles County Acute Care Regional Antibiogram Suggests Changing Landscape of MDRO Threats Between 2015 and 2017

543 Biocide Resistance Genes in Klebsiella spp. Infections from Trauma Patients in Iraq and Afghanistan

60. Poster Abstract Session
HAI: MDRO - GNR Epidemiology, Acinetobacter
Thursday, 12:15 - 1:30 p.m.

544 Clonal spread of two sequence types of Carbapenem-Resistant Acinetobacter baumannii blood isolates at a tertiary care hospital in South Korea over 2.5 years

545 Incidence of Carbapenem Non-susceptible Acinetobacter spp. and Carbapenem-resistant Pseudomonas aeruginosa Clinical Cultures among Patients in U.S. Acute Care Hospitals, 2012-2017

546 Seasonal changes in the prevalence of antibiotic-susceptible Acinetobacter baumannii results in increased multidrug resistance rates during winter months

547 Multidrug Resistant Pseudomonas aeruginosa in an Academic Regional Burn Intensive Care Unit

548 Carbapenem Resistant Acinetobacter baumannii Antibiotic Susceptibility Testing and Antibiogram Formation, Connecticut 2017-2019

549 First Report for Emergence of chromosomal borne Colistin Resistance Gene mcr-1 in a clinical Acinetobacter baumannii Isolates from India

550 Carbapenem- Resistant E. coliand A. baumanniamong catheter related blood stream infection patients in Egyptian ICUs

551 Burden of Illness in Carbapenem-resistant Acinetobacter baumannii Infections in US Hospitals (2014 to 2018)

61. Poster Abstract Session
HAI: MRSA Epidemiology
Thursday, 12:15 - 1:30 p.m.

552 Within-host Evaluation of Colonization during Active Methicillin-Resistant S. aureus Bacteremia

553 Outbreak of Methicillin-Resistant Staphylococcus aureus Associated with Hepatic Artery Infusion Pumps

554 The Changing Epidemiology of Methicillin-Resistant Staphylococcus aureus Causing Bacteremia in Hiroshima, Japan during 2008-2017

555 The Burden of Invasive Staphylococcus Aureus Disease Among Native Americans on the Navajo Nation

556 Phylogenomic epidemiology of Methicillin-Resistant Staphylococcus aureus (MRSA) Chilean-Cordobes clone in Latin America

557 Impact of Heavy Metal Exposure In The Transcriptional Response of Methicillin-Resistant Staphylococcus aureus (MRSA)-USA300 Latin-American Variant (USA300-LV)

558 Evaluating Length of Stay Data for use in Targeting Prevention of Methicillin-resistant Staphylococcus aureus (MRSA) Bloodstream Infections

559 Two Different Beasts: Comparing Epidemiology of Healthcare-associated versus Community-acquired Methicillin-Resistant Staphylococcus aureus Bacteremia

560 Relating Whole Genome Sequencing of Methicillin-Resistant Staphylococcus aureus Isolates to Transmission Dynamics and Efficacy of Control Interventions

561 Genomic Epidemiology of Methicillin-Resistant Staphylococcus aureus in Two Cohorts of High-Risk Military Trainees

62. Poster Abstract Session
HAI: MRSA Prevention
Thursday, 12:15 - 1:30 p.m.

562 Reducing MRSA Bacteremia in Adult Patients through MRSA Decolonization Bundle

563 Association Between Chlorhexidine Gluconate Concentrations and Resistant Bacterial Bioburden on Skin

564 A Five-Year Evolutionary Study of the Minimum Inhibitory Concentrations of Methicillin Resistant Staphylococcus aureus to Mupirocin, Chlorhexidine and Octenidine in a Singaporean Tertiary Institution

565 Implementation of a Staphylococcus aureus screening and decolonization program in a multisite urban healthcare system
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>566</td>
<td>Reduction of Hospital-Onset Methicillin-Resistant <em>Staphylococcus aureus</em> (MRSA) Bacteremia in an Acute Care Hospital: Impact of Bundles and Universal Decolonization</td>
<td></td>
</tr>
<tr>
<td>567</td>
<td>Does Universal Nasal Decolonization with an Alcohol-Based Nasal Antiseptic Reduce Infection Risk and Cost?</td>
<td></td>
</tr>
<tr>
<td>568</td>
<td>A Randomized, Double-Blinded, Placebo-Controlled Trial of Retapamulin for Nasal and Rectal Decolonization of Mupirocin-Resistant Methicillin-Resistant <em>Staphylococcus aureus</em> Among Children</td>
<td></td>
</tr>
<tr>
<td>569</td>
<td>Evaluation of a Povidone Iodine Preparation for Nasal Decolonization of Methicillin-Resistant <em>Staphylococcus aureus</em></td>
<td></td>
</tr>
<tr>
<td>570</td>
<td>Impact of Discontinuation of Methicillin-resistant <em>Staphylococcus aureus</em> Contact Precautions on Bloodstream Infection Rates at an Academic Medical Center</td>
<td></td>
</tr>
<tr>
<td>571</td>
<td>Determining the Utility of Methicillin-Resistant <em>Staphylococcus aureus</em> Nares Screening in Antimicrobial Stewardship</td>
<td></td>
</tr>
<tr>
<td>572</td>
<td>Relationship between Chlorhexidine Gluconate (CHG) Skin Concentrations and Microbial Skin Colonization among Medical Intensive Care Unit (MICU) Patients</td>
<td></td>
</tr>
</tbody>
</table>

**63. Poster Abstract Session**

**HAI: VRE Epidemiology**

Thursday, 12:15 - 1:30 p.m.

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>573</td>
<td>Enterococcal Bacteremia in a Tertiary Care Center in Mexico: A Retrospective Analysis Focus on Vancomycin-Resistant <em>E. faecium</em> and Ampicillin-Resistant <em>E. faecalis</em></td>
<td></td>
</tr>
<tr>
<td>574</td>
<td>Reporting of Vancomycin-Resistant <em>Enterococcus</em> Bacteremia among National Healthcare Safety Network Acute Care Hospitals</td>
<td></td>
</tr>
<tr>
<td>575</td>
<td>Evaluation of Risk Factors and Clinical Outcomes of Patients with Vancomycin-resistant <em>Enterococcus</em> Infections</td>
<td></td>
</tr>
<tr>
<td>577</td>
<td>The Role of Healthcare Worker-Mediated Contact Networks in the Transmission of Vancomycin-Resistant <em>Enterococci</em></td>
<td></td>
</tr>
<tr>
<td>578</td>
<td>Microbiology Laboratory-Driven Standardized Urine Culture Reporting Increases Aminopenicillin Prescribing in Vancomycin-Resistant <em>Enterococci</em> Urinary Infections</td>
<td></td>
</tr>
</tbody>
</table>

**64. Poster Abstract Session**

**HAI: Pediatric**

Thursday, 12:15 - 1:30 p.m.

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>579</td>
<td>Machine-learning Based Models for Prediction of Recurrence-free Catheter Retention After ALT Treatment of CLABSI in a Pediatric Population</td>
<td></td>
</tr>
<tr>
<td>580</td>
<td>Association between Central Venous Catheter Repair and Bloodstream Infections in a Pediatric Oncology Center</td>
<td></td>
</tr>
<tr>
<td>581</td>
<td>The epidemiology of imipenem-resistant <em>Acinetobacter baumannii</em> bacteremia in a Pediatric Intensive Care Unit and carbapenem use</td>
<td></td>
</tr>
<tr>
<td>582</td>
<td>Impact of central line bundle for prevention of umbilical vein catheter related blood stream infections in neonatal intensive care unit</td>
<td></td>
</tr>
<tr>
<td>583</td>
<td>Improving Catheter Scrub Technique and Compliance in a Level IV Neonatal ICU</td>
<td></td>
</tr>
<tr>
<td>584</td>
<td>Use of Multi-Disciplinary Prevention Rounds to Reduce Central Line Associated Bloodstream Infections in a Neonatal Intensive Care Unit</td>
<td></td>
</tr>
<tr>
<td>585</td>
<td>Shifting focus towards Healthcare-associated Bloodstream Infections: Need for More NICU Specific NHSN Definitions</td>
<td></td>
</tr>
<tr>
<td>586</td>
<td>Multi-Drug Resistant Organisms From Three Pediatric Inpatient Units in the Dominican Republic</td>
<td></td>
</tr>
<tr>
<td>587</td>
<td>Risk Factors for Nosocomial Methicillin Resistant <em>Staphylococcus aureus</em> (MRSA) Colonization in a Neonatal Intensive Care Unit (NICU): A Case-Control Study</td>
<td></td>
</tr>
<tr>
<td>588</td>
<td>Are Popliteal Vein PICCs safe for Neoneates?</td>
<td></td>
</tr>
<tr>
<td>589</td>
<td>Impact of Parents and the Environment on MRSA Transmission in the Neonatal ICU</td>
<td></td>
</tr>
<tr>
<td>590</td>
<td>Reduction of Endotracheal Colonization by Gram Negative Bacilli in a Neonatal Intensive Care Unit Through Use of a Novel Drain Cover</td>
<td></td>
</tr>
<tr>
<td>591</td>
<td>Mupirocin and Chlorhexidine resistance in <em>Staphylococcus aureus</em> isolated from Children in South Korea</td>
<td></td>
</tr>
<tr>
<td>592</td>
<td>Assessment of Time Spent in the Room By Nurses and Nursing Assistants on a Pediatric Ward By Patient Isolation Status and Demographics</td>
<td></td>
</tr>
<tr>
<td>593</td>
<td>Burden of Healthcare Associated Infections among Hospitalized Infants within Community Hospitals</td>
<td></td>
</tr>
<tr>
<td>594</td>
<td>A Multi-centered Study of the Clinical and Molecular Epidemiology of AmpC Cephalosporinase-producing (AmpC) <em>Enterobacteriaceae (Ent)</em> Infections in Children</td>
<td></td>
</tr>
<tr>
<td>595</td>
<td>Intranasal Mupirocin with Chlorhexidine Bathing has Limited Effectiveness for MRSA Decolonization among Neonates.</td>
<td></td>
</tr>
</tbody>
</table>

**65. Poster Abstract Session**

**Mechanisms of Antimicrobial Resistance**

Thursday, 12:15 - 1:30 p.m.

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>596</td>
<td>Distinct, segregated daptomycin-susceptible and daptomycin-nonsusceptible <em>Staphylococcus aureus</em> populations associated with tricuspid-valve infective endocarditis</td>
<td></td>
</tr>
<tr>
<td>597</td>
<td>Cross-resistance of Ceftolozane-Tazobactam and Imipenem-Relebactam Against Clinical <em>P. aeruginosa</em> Isolates – SMART United States 2016-2018</td>
<td></td>
</tr>
<tr>
<td>598</td>
<td><em>In Vitro</em> Activity of Aztreonam in Combination with Cefazidime-Avibactam, Amoxicillin-Clavulanate, and Piperacillin-Tazobactam Versus NDM-Producing <em>Escherichia coli</em> and <em>Klebsiella pneumoniae</em> Clinical Isolates</td>
<td></td>
</tr>
<tr>
<td>599</td>
<td>LiaIF is an Activator of the LiaR-Mediated Response Against daptomycin and Antimicrobial Peptides in Multidrug-Resistant <em>Enterococcus faecalis</em> (Efs)</td>
<td></td>
</tr>
<tr>
<td>600</td>
<td>β-Lactam Resistance Mechanisms in <em>Pseudomonas aeruginosa</em> Isolates Analyzed Using Whole Genome Sequencing (WGS) and Transcriptions Analysis and Their Impact in Resistance to New β-Lactam/β-Lactamase Inhibitors</td>
<td></td>
</tr>
<tr>
<td>601</td>
<td>TelA and XpaC are Novel Mediators of Daptomycin Resistance in <em>Enterococcus faecium</em></td>
<td></td>
</tr>
</tbody>
</table>
66. Poster Abstract Session

Molecular and Genomic Epidemiology of Resistant Pathogens

Thursday, 12:15 - 1:30 p.m.

622 The Accessory Genome in Enterococcal Bacteremia: Results from the Vancomycin-Resistant Enterococcal Bacteremia Outcomes Study (VENOUS)


624 Molecular Characterization of Baseline Enterobacteriaceae and Pseudomonas aeruginosa from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial

625 Genomic Epidemiology of Carbapenem-Resistant Enterobacteriaceae from Colombia: A Prospective Multicenter Study

626 Mobile Genetic Element Dynamics of Co-Circulating Klebsiella pneumoniae Sequence Types Carrying blaKPC in Houston, TX

627 Molecular Epidemiology of Daptomycin Resistant Staphylococcus aureus Causing Bloodstream Infections


629 Emergence and Clonal Spread of Delafloxacin-Resistant S. aureus in Brooklyn, NY

630 Clinical and Molecular Characteristics of Carbapenem-Resistant Enterobacteriaceae in Qatar: A Retrospective and Prospective Observational Study

631 Laboratory Surveillance of Carbapenem-Resistant Enterobacteriaceae in an Endemic Country, Greece, 2015-2018

632 Genetic Diversity of Carbapenem-Resistant Klebsiella Pneumoniae Causing Late-Onset Neonatal Septis in intensive Care Unit of Cairo University hospital, Cairo, Egypt

633 Incidence, microbial aetiology and antibiotic resistance patterns with special reference to shunt infections in neurosurgery at a tertiary centre in North India

634 Incidence of vanC-Mediated Vancomycin Resistant Enterococcus Bloodstream Infections at Children’s Hospital of Colorado and Implications for Empiric Enterococcal Therapy

635 Genomic Evolution and Progression of Antimicrobial Resistance in a Series of Extensively Drug Resistant Pseudomonas Aeruginosa (XDR-Pa) Isolates from a Cystic Fibrosis Lung Transplant Recipient

636 Genome Epidemiology of Carbapenem-Resistant Acinetobacter baumannii (CRAb) in the United States

637 Whole Genome Sequencing (WGS) of Isolates from Resolving (RB) and Persistent (PB) Methicillin Resistant Staphylococcus aureus Bacteremia

638 Comparative Genomics of Mycoplasma pneumoniae Isolated from Children with Pneumonia: South Korea, 2010-2016
67. Poster Abstract Session

**New Diagnostics**

Thursday, 12:15 - 1:30 p.m.

**639** Performance Characteristics of an FDA Cleared Multiplex Panel for the Rapid Identification of Fungal Pathogens from Positive Blood Culture

**640** Randomized Clinical Trial Evaluating Clinical Impact of RAPid IDentification and Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia (RAPiDS-GN)

**641** Evaluation of the FilmArray Pneumonia Panel and Potential Impact of Antimicrobial Use on Patients in a Trauma and Medical Intensive Care Unit

**642** Higher Diagnostic Accuracy with Ultrasensitive Detection of Helicobacter pylori Stool Antigen Using Single Molecule Counting Technology

**643** Comparison of Multiplex Polymerase Chain Reaction (PCR) and Routine Culture for the Detection of Respiratory Pathogens in Pneumonia Patients

**644** Comparative evaluation of ETEST® ERV bioMérixéus with the CLSI broth microdilution method for Eravacycline MIC determination

**645** Singulex Clarity Norovirus Assay (In Development) Provides Ultrasensitive Detection of Norovirus Genogroups I and II

**646** Evaluation of the Utility of a New Comprehensive Molecular Assay to Test for the Common Pathogens that Cause Lower Respiratory Tract Infections and its Potential Impact on Antibiotic Therapy.

**647** Diagnoses Associated with Temperature ≥ 104°F in Adults

**648** Baloxavir Resistance: qPCR Detection of Antiviral Resistance Markers in Influenza A Virus

**649** Prospective validation of an 11-mRNA host immune signature as a novel blood test for acute septic arthritis

**650** Relationship of a Multiplex Molecular Pneumonia Panel (PP) Results with Hospital Outcomes and Clinical Variables

**651** Multi-center Evaluation of the BioFire® FilmArray® Blood Culture Identification 2 Panel for the Detection of Microorganisms and Resistance Markers in Positive Blood Cultures

**652** Impact of FilmArray Meningitis Encephalitis Panel on HSV Testing and Acyclovir Use in Children Beyond the Neonatal Period

**653** Diagnosis of Burn Sepsis Using the FcMBL ELISA: A Pilot Study in Critically Ill Burn Patients

**654** Evaluation of the Febridx Host Response Point-Of-Care Test to Differentiate Viral from Bacterial Aetiology in Adults Hospitalized with Acute Respiratory Illness During Influenza Season

**655** Detection of Antibiotic Resistance Genes in Clinical Samples using T2 Magnetic Resonance

**656** Prioritizing Gram-negative Bacteremia (GNB) Cases for Rapid Detection by β-lactam Resistance (BLR) and Patient Outcomes

**657** Evaluation of Nanopore-Based 16S Ribosomal RNA (rRNA) Gene Sequencing for the Development of a Rapid Infection Intervention Clinical Service

**658** Cost-effectiveness of Molecular Diagnostic Assays for the Therapy of Severe Sepsis and Septic Shock in the Emergency Department

**659** Evaluation of a Rapid Diagnostic Assay for Early Detection of Bacteriuria

---

660 Extraction-Free 16S Ribosomal RNA (rRNA) Gene Amplification and Sequencing from Resected Cardiac Implantable Electronic Device (CIED) Sonicate Fluid

661 Ibaliuzumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)

662 Recurrence of infection and emergence of drug resistance after treatment with meropenem/vaborbactam compared to ceftazidime/avibactam in carbapenem-resistant Enterobacteriaceae infections

663 Efficacy and Safety of Lefamulin (LEF) Versus Moxifloxacin (MOX) for Legionella pneumophila (LP) in Patients (Pts) With Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Clinical Trials

664 Efficacy in Adults With Moderate to Severe Community-Acquired Bacterial Pneumonia (CABP) and Pneumonia Outcomes Research Team (PORT) Risk Class III to V: Results of a Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Outcomes

665 In Vitro Activity of Omadacycline against Recent (2018) Bacterial Pathogens from the United States and Europe Obtained from Skin and Skin Structure, Respiratory, and Urinary Tract Infections

666 Efficacy and Safety of Cefiderocol According to Renal Impairment in Patients With Complicated Urinary Tract Infection (cUTI) in a Phase 2 Study

667 Preclinical Pharmacokinetic and Pharmacodynamic Characterization of EDP-938, a Novel and Potent Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus

668 Quality of Life Changes in Patients with Clostridium difficile Infection (CDI): A Randomized, Double-Blind Trial of Ridinilazole (RDZ) Compared to Vancomycin (VAN)

669 Twelve-Month Durability of Microbiota-Based Therapy RBX2660 for Prevention of Recurrent Clostridium difficile Infection

670 VRE Clearance in Patients with Recurrent Clostridium difficile Infection Following Treatment with Microbiota-Based Drug RBX2660

671 Impact of Dose-Administration Strategies of the Antistaphylococcal Lysin Exebacase, (CF-301), in Addition to Daptomycin (DAP) in an Experimental Infective Endocarditis (IE) Model due to Methicillin-Resistant Staphylococcus aureus (MRSA)

672 Activity of Ibrexafungerp (formerly SCY-078) Against Candida auris: In Vitro, In Vivo and Clinical Case Studies of Candidemia

673 Novel Delayed-Release Formulation of an Oral Beta-Lactamase Prevents Gut Microbiome Damage and Attenuates Antibiotic Resistance Caused by Oral Amoxicillin/Clavulanate without Interfering with Amoxicillin Systemic Absorption in Dogs

674 Pre-Clinical and Phase I Safety Data for Anti-Pseudomonas aeruginosa Human Monoclonal Antibody AR-105

675 Efficacy of Human-Simulated Bronchopulmonary Exposures of Ceftepime and Zidebactam (WCK 5222)
Poster Abstract Sessions (continued)

676 Health-Related Quality of Life (HRQoL) as Measured by the 12-Item Medical Outcomes Study Short-Form (SF-12) Among Adults With Community-Acquired Bacterial Pneumonia (CAP) Who Received Either Leefamulin (LEF) or Moxifloxacin (MOX) in Two Phase 3 Randomized, Double-Blind, Double-Dummy Clinical Trials (LEAP 1 and 2).

677 Activity of Novel β-Lactamase Inhibitor QPX7728 Combined with β-Lactam Agents When Tested against Carbapenem-Resistant Enterobacteriaceae (CRE) Isolates.

678 Galactomannan is a Biomarker of APX001 (Fosmanogepix) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis.

679 *In Vitro* Activity of Ceftazidime-Avibactam and Comparator Agents Against *Pseudomonas aeruginosa* from ICU and Non-ICU wards Collected in Latin America and Globally as part of the ATLAS Surveillance Program 2016-2017.

680 *In Vitro* Activity of the β-lactamase Inhibitor QPX7728 in Combination with Several β-lactams against *Acinetobacter baumannii* (AB) and *Pseudomonas aeruginosa* (PSA).

681 In Vivo Pharmacodynamics of VNRX-7145 in the Neutropenic Murine Thigh Infection Model when Administered in Combination with Humanized Exposures of Twice Daily Cefituben (CTB) against Serine β-Lactamase-Producing Enterobacteriaceae (SBL-EB).

682 Assessment of biofilm eradication and cytotoxicity of a novel polygalacturonic acid + caprylic acid wound ointment compared to antiseptic wound ointments.

683 Cardiac Safety in Adults With Community-Acquired Bacterial Pneumonia (CAPB) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results.

684 An *In Vitro* Investigation of WCK 5222 (Cefepime/ Zidebactam) and Currently-Available Combination Antibiotic Regimens against Enterobacteriaceae that Co-express Serine-β-Lactamase (SBL) and Metallo-β-Lactamase (MBL) Enzymes.

685 Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-1-06).

686 In Vitro Activity of a New Generation Oxoprazole Antibiotic Against *Acinetobacter spp.*

687 *In vitro* Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of *Clostridioides difficile*.

688 Therapeutic Efficacy of CB-012, a Novel Cloudbreak Antiviral Fc-Conjugate (AVC) in Lethal Mouse Models of Influenza A (H1N1) and Influenza B (Victoria).

689 Activity of a Novel Polymyxin Analog, QPX9003, Tested against Resistant Gram-Negative Pathogens, including Carbapenem-Resistant *Acinetobacter, Enterobacteriales,* and *Pseudomonas*.

690 Activity of TNP-2092 against Biofilms Formed by Prosthetic Joint Infection-Associated Staphylococci.


693 In Vitro Activity of Sulbactam-Durlobactam (ETX2514SUL) against 121 Recent *Acinetobacter baumannii* Isolated from Patients in India.

694 Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against a Contemporary Collection of Gram-negative Bacteria from New York City.


696 Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-1-06).

697 In Vitro Activity of a New Generation Oxoprazole Antibiotic Against Multidrug-Resistant Gram-Negative Bacilli.

698 Hepatobiliary Safety in Adults With Community-Acquired Bacterial Pneumonia (CAPB) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results.

699 Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies.

700 Comparison of MIC Results for Gepotidacin by Agar Dilution and Broth Microdilution Methods.

701 Hepatic Safety Among Patients Treated with Anti-fungal Triazole Agent Posaconazole: Characterization of Adverse events in a Manufacturer’s Safety Database.

702 In Vitro Activity of Lefamulin Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia (CAPB): SENTRY Surveillance 2017–2018 Results From the United States (US).

703 Incidence and Patient Outcomes of *S. aureus* isolates from Acute Bacterial Skin and Skin Structure Infections (ABSSSI) with High Iclaprim MIC values in the Phase 3 REVIVE Trials.

704 Pharmacokinetics (PK) and Safety of Lefamulin (LEF) After Single Intravenous Dose Administration in Subjects With Impaired Renal Function and in Those Requiring Hemodialysis.

705 In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against MDR Enterobacteriaceae and *Pseudomonas aeruginosa* Collected in Latin America During the ATLAS Global Surveillance Program 2016-2017.

706 In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against MDR Enterobacteriaceae and *Pseudomonas aeruginosa* Collected in Latin America During the ATLAS Global Surveillance Program 2016-2017.

707 QPX9003: Pharmacology of a Novel Polymyxin in Mice and Rats.

708 In Vitro Activity of Plazomicin Versus Clinical Isolates of Gram-Negative Bacilli, Including Aminoglycoside Non-Susceptible and Multidrug-Resistant Subsets, Recovered from Patients Across Canada as Part of the CANWARD study, 2011-2018.

709 In Vitro Antibacterial Activity and *In vivo* Efficacy of Sulbactam-Durlobactam (ETX2514SUL) against Pathogenic *Burkholderia* Species.
Poster Abstract Sessions (continued)

710  *In vitro* activity and performance of available susceptibility testing methods for eravacycline against carbapenem-resistant Enterobacteriaceae (CRE)

711 Exebacase (Lysin CF-301) Activity Against *Staphylococcus aureus* (S. aureus) isolates from Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102)

712 Activity of Exebacase (CF-301) Against Methicillin-Resistant *Staphylococcus aureus* (MRSA) Biofilms on Orthopedic Kirschner Wires

713 Preventive administration of MED16389, a combination of monoclonal antibodies (mAbs) targeting alpha-toxin (AT), Panton-Valentine leukocidin (PVL), leukocidin ED (LukED), gamma-hemolysin and clumping factor A (ClfA), in a rabbit model of USA300 MRSA prosthetic joint infection (PJI)

714 Analysis of the effect of urine on the *in vitro* activity of gepotidacin and levofloxacin against *Escherichia coli*, *Staphylococcus epidermidis* and *Staphylococcus saprophyticus*

715 Bulgenc A lowers Imipenem MICs in Clinical MDR *Acinetobacter baumannii* (ACB) Strains

716 *In Vitro* and *In Vivo* Non Clinical Efficacy of AR-501 (Gallium Citrate)

717 Lefamulin (LEF) Versus Moxifloxacin (MOX) in Patients With Community-Acquired Bacterial Pneumonia (CAPB) at Risk for Poor Efficacy or Safety Outcomes: Pooled Subgroup Analyses From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Noninferiority Clinical Trials

718 Activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical *P. aeruginosa* isolates collected in United States and Canada – SMART 2018

719 Cefiderocol Retains Anti-Biofilm Activity in MDR Gram-Negative Pathogens

720 Efficacy of Fosfomycin for Injection (FOS) vs Piperacillin-Tazobactam (PIP-TAZ) in Adults With Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP): ZEUS Study Outcomes in Patients With Reduced Study Drug Susceptibility

721 *In Vitro* Activity of Cefiderocol Against Gram-negative Clinical Isolates from New York City

722 Pharmacokinetics (PK) and Safety of Lefamulin (LEF) After Single Intravenous Dose Administration in Subjects With Impaired Heparin Function

723 Synergistic Effect of Cefiderocol Combined With Other Antibiotics Against Cefiderocol High MIC Isolates From the Multi-national SIDERO-WT Studies

724 The *In Vitro* Activity of Gepotidacin and Comparator Agents Against Anaerobic Bacterial Isolates

725 WCK 5222 (Cefepime/Zidebactam): An *In Vitro* Assessment of Activity Compared with Current Dual-Antibiotic Options against Multidrug-Resistant *Pseudomonas aeruginosa*

726 APX001 (Fosmanogepix) is Effective in an Immunosuppressed Mouse Model of *Rhizopus oryzae* Infection

727 Potency of the Beta-Lactamase Inhibitor QPX7728 Is Minimally Affected by KPC Mutations that Reduce Potency of Ceftazidime-Avibactam

728 Activity of Eravacycline Against Contemporary Gram-negative Clinical Isolates from New York City Hospitals

729 Comparing Length of Stay and Clinical Outcomes for Hospitalized Patients at Bridgeport Hospital who Received Baloxavir Marboxil (BM) or Oseltamivir Phosphate (OP) During the 2018-2019 Influenza Season.

730 Cefiderocol for the Treatment of *Achromobacter xylosoxidans* Infections in Two Lung Transplant Patients with Cystic Fibrosis

731 Pharmacokinetics of Gepotidacin (GSK2140944) in Subjects with Hepatic Impairment

732 Posaconazole Serum Drug Levels Associated with Pseudohyperaldosteronism

733 Pharmacokinetic-Pharmacodynamic (PK-PD) Analyses for AlanineAminotransferase(ALT) Using Phase 3 Data From Omadacycline (OMC)-Treated Patients

734 Modeling the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Omadacycline with and without a Loading Dose

735 Bacteriophage Therapy Improves Survival of *Galleria mellonella* Larvae Injected with Vancomycin-resistant *Enterococcus faecium*

736 The Use of Bacteriophages to Inhibit Different Strains of Vancomycin-resistant or Susceptible Enterococci

737 Novel Glycans Reduce Carbapenem-Resistant *Enterobacteriaceae* and Vancomycin-Resistant *Enterococci* Colonization in an *Ex Vivo* Assay by Supporting Growth and Diversity of Commensal Microbiota at the Expense of Multi-Drug Resistant Organisms (MDRO)

738 Potent *in vitro* activity of Rezafungin (RZF) against *Aspergillus* clinical isolates recovered from lung transplant patients who have received ≥3 months of triazole prophylaxis

739 Prediction of Cefiderocol Pharmacokinetics and Probability of Target Attainment in Pediatric Subjects for Proposing Dose Regimens

69. Poster Abstract Session

**What’s New in Clinical Practice?**

Thursday, 12:15 - 1:30 p.m.

740 A Comparison of Process Outcomes Among Patients Receiving Outpatient Parenteral Antibiotic Therapy in Different Settings: a Quality Improvement Project

741 TravMIL Surveillance of Travel-Related Illness in a Prospective Cohort of US Military Beneficiaries, 2010-2018

742 The development, implementation, and feasibility of multidisciplinary treatment planning conference for individuals with unstable substance use disorders and active infections requiring prolonged antimicrobial therapy: the OPTIONS-DC model

743 Evaluation of Adverse Drug Reactions due to Common Beta-Lactam Therapies Among Patients Enrolled in an Outpatient Parenteral Antimicrobial Therapy (OPAT) Program

744 Antifungal de-escalation strategy in ICU patients: clinical success and cost savings

745 Operationalization of Comprehensive Sexual Wellness Clinic at a Large Urban Emergency Department

746 Improving Monitoring of Outpatient Parenteral Antimicrobial Therapy (OPAT) for Solid Tumor Patients at a Comprehensive Cancer Center
Poster Abstract Sessions (continued)

747 Implementation of a Pharmacist-led Intervention for Infectious Diseases Patients Discharged on Antimicrobials: the Infectious Diseases Discharge Outreach and Retention (ID DOOR) Program

748 Does Improving Discharge Documentation Improve Post-Discharge Care for Patients on Outpatient Parenteral Antimicrobial Therapy (OPAT)?

749 Wide Variation in the Use of External Cooling Blankets Among Adult Intensive Care Unit Nurses for Fever

750 Serious Bacterial Infections: Successful Outpatient Management by Infectious Disease Physicians in Office Infusion Centers

751 Study on Daptomycin Prescription Suitability as a First Step Towards an Antimicrobial Stewardship Program

752 Timing of Antibiotics Administration in Emergency Department and Mortality in Sepsis by Sepsis-3 Definition

753 Outpatient Parenteral Antibiotic Therapy (OPAT) in a Large Urban Safety Net Hospital: Setting: Therapy for Vulnerable Populations at Home

754 Evaluation of Standardized Dalbavancin Use to Facilitate Early Hospital Discharge for Patients Inappropriate for Outpatient Parenteral Antibiotic Therapy

755 Outpatient Parenteral Antimicrobial Therapy Program Evaluation within a Large Veterans Affairs Health Care System

756 Impact of Infectious Diseases Pharmacists as Part of an Interdisciplinary OPAT Team Managing Vancomycin

757 Impact of a sepsis improvement team with prospective audit and feedback on SEP-1 core measure adherence in an urban community hospital

758 High-throughput Mining of Electronic Medical Records Using Generalizable Autonomous Scripts

759 High Dose Daptomycin is Well Tolerated via 2-Minute Infusion

760 Assessment of DEXA Scan Ordering Among Infectious Disease Providers at a Large Tertiary-Care Urban Academic Center in the Midwest

761 Sepsis Readmissions and Coding in Two Community Hospitals

762 Integrating diagnostics of tomorrow into clinical practice today: One Infectious Disease Group’s 1st 90 days experience with the Karius® test

763 30 Day Readmission Outcomes in Patients Over 80 years of age Enrolled in an Outpatient Parenteral Antibiotic Therapy (OPAT) Program

764 Patients with Substance Use Disorder Discharged from Safety Net Hospital to Skilled Nursing Facility for OPAT: Baseline Characteristics and Clinical Outcomes

765 Pyomyositis in the United States- Trends and Associations from the Healthcare Utilization Project Nationwide Inpatient Sample Database


767 Can Integration of Addiction Treatment Facilitate Safe Discharge on OPAT for Patients with Infectious Complications of Injection Drug Use?

768 Use of a Machine-Learning-based Prediction Model to Guide Antibiotic De-escalation in the Treatment of Urinary Tract Infections

769 Comparison of Vancomycin Continuous and Intermittent Infusion Dosing Strategies Among Patients in an Outpatient Antimicrobial Therapy Program

770 Multimodal Sepsis Performance Improvement Initiative Improves Early and Appropriate Treatment, Reduces Sepsis Related Readmissions, and Reduces Overall Mortality

771 A Quality Improvement Initiative to Reduce 30-days Sepsis Related Readmissions by Internal Medicine Residents.

772 Access Denied: Impact of Insurance Denials for High-Cost Outpatient Parenteral Antimicrobial Therapy

773 First National Survey of Antibiotic Use Prescribed by All Dentists in Japan from 2015 to 2017 using the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB)

774 A New Outpatient Parenteral Antimicrobial Therapy (OPAT) Management Program Reduces Excess Antimicrobial Days of Therapy and Expedites Timely Central Line Removal

775 Comparison of Initial Vancomycin Costs and Target Attainment Between Trough- and 24-Hour Area Under the Concentration-Time Curve (AUC24)-Guided Dosing

776 Effect of the SEP-1 Sepsis Bundle on Mortality in Hospital-Onset v. Community-Onset Sepsis

777 Experience with Liposomal Amphotericin B in Outpatient Parenteral Antimicrobial Therapy (OPAT)

778 ID Rocks It: Infectious Disease Remotely Offered Consultative Knowledge and Support via Inpatient Telehealth

779 Impact of updated IDSA practice guidelines on the treatment of Clostridium difficile infections in the United States

780 Inpatient Addiction Medicine Consultations at the Urban/Rural Frontier: Improving Quality of Care and Linkage to Outpatient Services for Patients with Substance Use Disorder in Central Kentucky

781 Nurse-Driven Time-of-Triage Sepsis Screening Tool Improves Timely Intervention in Ambulatory Emergency Department (ED) Patients with Suspected Sepsis

782 Provider to Provider Electronic Consultation (E-consult): A Tool for the Pediatric Infectious Diseases Specialist to Document Encounters and Quantify Effort.

783 Infectious complications in IV abusers: a detailed review of hospitalized IV abusers

784 Do Patients and Healthcare Professionals See Eye-to-Eye on the Usefulness of Strategies for Promoting HIV Care?

785 Identifying Opportunities to Improve Adherence to Sepsis Care Guidelines Compliance

786 Improving Access by Pre-Screening Self-Referred Patients to an Infectious Disease Clinic

787 Improving ED Sepsis Care

788 Outcomes of Multidisciplinary Care Conferences for Patients with Substance Use Disorders Requiring Prolonged Antimicrobial Therapy for Severe Infections

70. Poster Abstract Session

Interesting Cases from the IDWeek Call for Cases

Thursday, 12:15 - 1:30 p.m.

789 Stricken with Severe Pneumonia in the Suburbs

790 HIV patient, recent Pneumocystis jirovecii (PCP) Pneumonia Treatment, now presenting with severe itching and jaundice.

Final Program IDWeek 2019 • 169
129. Poster Abstract Session

**Antibiotic Stewardship: Allergy Evaluation**
Friday, 12:15 - 1:30 p.m.

993 Pharmacist-driven Penicillin Allergy Assessment in the Emergency Department – Antimicrobial Stewardship at the Point of Prescription

994 Effect on Beta-lactam Usage Following Implementation of Clinical Pharmacy Services to Improve Beta-lactam Allergy History Documentation

995 A quality improvement initiative to increase penicillin allergy clarification and decrease aztreonam usage

996 Impact of Penicillin Allergy Labels on Carbapenem Use in a Multi-Center Study

997 Practical partnering of Antibiotic Stewardship and Allergy to address referrals to Penicillin allergy debunking clinic at a VA Medical Center

998 Challenging Penicillin Allergies: Pharmacist led program in a community hospital

999 Examining the Impact of a Penicillin Allergy Skin Testing Brochure on Inpatient Perceptions: a Pre-Post Intervention Study

1000 The Impact of Pharmacy Students Performing Penicillin Allergy Reconciliation in a Community Health System

1001 Feasibility and Outcomes of a Pre-Transplant Antibiotic Allergy Evaluation Program for Allogeneic Hematopoietic Cell Transplant (HCT) Candidates

1002 Utilization of Alternative Beta-lactams in Patients with Penicillin Hypersensitivity

1003 Impact of a Standardized Pharmacist-led Beta-lactam Allergy Interview on the Quality of Allergy Documentation

130. Poster Abstract Session

**Antibiotic Stewardship: Antibiotic Utilization**
Friday, 12:15 - 1:30 p.m.

1004 Interactive Dashboards for Antimicrobial Usage and Standardized Antimicrobial Administration Ratio Data

1005 The Antibiotic Optimization DOOR: Refining Assessment of Antibiotic Therapy with Desirability of Outcome Ranking

1006 Do Antibiotic Choices Made in the ED Influence Inpatient Therapy?

1007 A novel approach to evaluate antibiotic utilization across the spectrum of inpatient and ambulatory care and implications for prioritization of antibiotic stewardship efforts

1008 The Reduction of Fluoroquinolone Prescribing in Rural Vermont Hospitals

1009 Measuring the quality of fluoroquinolone prescribing in hospitals: results from the Emerging Infections Program Hospital Prevalence Survey Antimicrobial Quality Assessment

1010 Exploring Antimicrobial Prescriptions in a National Audit of Haematology/Oncology Inpatients Compared to the General Inpatient Population: Targeted Analysis Highlights Key Areas for Targeted Intervention

1011 Hospital Antibiogram Variation within a Veterans Affairs (VA) Regional Network

1012 Characterization of Antibiotic Superutilizers in the Inpatient Setting

1013 Electronic Assessment of Empiric Antibiotic Prescribing Using Diagnosis Codes

1014 Decreasing Antimicrobial Use by 25% via Submission to NHSN-AUR Module

1015 Antibiotic use and indications in a community sample of adults in Wisconsin

1016 Standardized Antimicrobial Administration Ratio (SAAR) and *Clostridioides difficile* Infection Standardized Infection Ratio (SIR): Are they connected? An Evaluation of 28 Hospitals

1017 Scratching the Surface with NHSN Data: Defining High Impact Stewardship Targets in Critical Care

1018 Using prediction modeling to inform risk-adjustment strategy for hospital antimicrobial use: Can we predict who gets an inpatient antimicrobial?

1019 Defining electronic patient phenotypes to inform risk-adjustment strategies in hospital antimicrobial use comparisons

1020 Variations in inpatient and outpatient antibiotic use – opportunities for improvement and facility-level feedback

1021 Accuracy of Provider-Selected Antibiotic Indications at Point of Order Entry Compared to Electronic Health Record Documentation

1022 Is it Time to Re-Evaluate Oral Beta-Lactam Antibiotics for Step-Down Therapy of Uncomplicated Gram-Negative Bacteremia?

1023 Isavuconazonium Use at an Academic Transplant Center

1024 Evaluation of Atovaquone Prescribing for *Pneumocystis jiroveci* Pneumonia (PJP) Prophylaxis

1025 Inappropriate Aztreonam Usage – Antimicrobial Stewardship Strikes Back

1026 Ertapenem Use During Antibiotic Stewardship Interventions in Community Hospitals

1027 Vancomycin Use in Community Acquired Pneumonia: Assessing Inappropriate Therapy

1028 Dalbavancin Use in Complicated Infections and Associated Cost-Savings

1029 Clinical and economic outcomes of a newly implemented daptomycin dosing policy in a four-hospital health system
1030 Analysis of a Novel Mortality Prediction Rule for Organizing and Guiding Antimicrobial Stewardship Team Activities
1031 Effect of On-Site ID Specialist Led, Antimicrobial Stewardship Pharmacist Driven Program on Provider Acceptance, Antimicrobial Utilization and Clostridioides Infection Rates In a Community Hospital / Rural Regional Referral Center
1032 Impact of an Antimicrobial Stewardship Team-Led Initiative – Assessment of Therapy Appropriateness at Patient Discharge
1033 Effectiveness of a Physician-Driven Automated Antimicrobial Time Out in the Setting of Gram-negative Bacteremia
1034 Automating Assessments of Vancomycin Appropriateness
1035 Implementation of an Antimicrobial Stewardship Program-Led, Multifactorial Pneumonia Diagnosis and Treatment Bundle
1036 Clinical impact of an antibiotic time out initiative at an academic medical center
1037 A Pharmacist-Driven Forty Eight Hour Antibiotic Time Out Pilot at a Large Academic Medical Center
1038 Impact of an Electronic Antibiotic Timeout on the Utilization of Frequently Prescribed Antibiotics in Hospitalized Patients
1039 48 hour Antibiotic Time-out: Impact on Antibiotic Duration and Clinical Outcomes
1040 Effects of An Antimicrobial Stewardship Team-led Staphylococcus aureus Bacteremia Management Bundle: A Quasi-Experimental Study
1041 Staphylococcus aureus Bacteremia Bundle Adherence Pre- and Post-Implementation of Mandatory Infectious Diseases Consultation and Antimicrobial Stewardship Pharmacist Intervention
1042 Antimicrobial Stewardship Program (ASP) Implementation of Short Course Antimicrobials for Low-Risk Enterobacteriaceae Blood Stream Infection (EBSI) at a Tertiary Care Center
1043 Love Thy Steward – Who Does Not Love Antimicrobial Stewardship?
1044 Impact of Interdisciplinary Rounds on Antimicrobial Use at a Community Hospital
1045 Impact of an Antimicrobial Stewardship Pharmacist on Microbiology Rounds
1046 Evaluating the outcomes of embedding Antimicrobial Stewardship order sets in the General Medicine Admission Electronic Order Set: A Retrospective Study
1047 Impact of Indication for Antibiotic Orders on Pharmacist Interventions
1048 A Randomized Controlled Trial of an Electronic Tool for Empiric Antibiotic Prescription: Results from the Anti-infective Stewardship using the WISCA tool in the Electronic medical Record (AnSWER) Study
1049 Using Alternative Alerts in the Electronic Health Record to Guide Antimicrobial Selection Decisionmaking at the Point of Order Entry
1050 Impact of Weekend Infectious Diseases and Antimicrobial Stewardship Pharmacy Services
1051 The Use of Survey-Driven Feedback to Improve Antimicrobial Stewardship Efforts at a Single Center
1072 The role of an on-site Infectious Disease specialist in hospital-based antimicrobial stewardship programs
1073 Analysis of the Antimicrobial Stewardship Program Recommendation Process in the Intensive Care Units at a Large Tertiary Community Hospital
1074 Evaluation of a Pharmacist-led Antimicrobial and Anticoagulant Monitoring Initiative
1075 The Impact of Physician Peer Comparison of a Novel Inpatient Antimicrobial Stewardship Metric: The Start-Stop Ratio (SSR)
1076 Antimicrobial Stewardship Program Achieves Marked Decrease in Use of Vancomycin in a Veterans Hospital

133. Poster Abstract Session
Antibiotic Stewardship: Special Population
Friday, 12:15 - 1:30 p.m.

1077 Reduce Anti Microbial use in Extracorporeal Membrane Oxygenation: Reduce AMMO Study
1078 Expectations and Attitudes toward Antimicrobial Stewardship among Cystic Fibrosis Care Providers
1079 Impact of Antimicrobial Stewardship Program (ASP) on patients with Neurological Conditions
1080 OPAT at the End of Life?: Short and Long-Term Mortality Following Outpatient Parenteral Antibiotic Therapy
1081 Use of Antimicrobials at the End of Life (EOL): A Retrospective Cohort Study Analyzing Providers’ Reasons for Prescribing Antimicrobials at the EOL, their Benefits and Adverse Effects
1082 Hold the Phone: Antibiotic Prescribing Practices Associated with Non-Visit Encounters for Urinary Tract Infections (UTIs) in Urology Clinics
1083 Risk Factors Associated with Treatment of Asymptomatic Bacteriuria in the Emergency Department: A Multi-Hospital Cohort Study
1084 A Pre-and Post-Intervention Study to Implement a Successful Antimicrobial Stewardship Program at an Urban Chronic Hemodialysis Center
1085 Impact of a Novel Infectious Diseases Pharmacy Service on Medication-Related Errors and Linkage to Care in Inpatients Living with Human Immunodeficiency Virus
1086 Antimicrobial Stewardship - From Bedside to Man’s Best Friend
1087 Fluoroquinolone Prophylaxis versus no Bacterial Prophylaxis in Hospitalized Neutropenic Patients Undergoing Induction Chemotherapy for Acute Myeloid Luekemia
1088 Evaluating the Timing of Antimicrobial Prophylaxis in Allogeneic and Autologous Hematopoietic Stem Cell Transplant
1089 Implementation of a Febrile Neutropenia Management Algorithm on Antibiotic Use and Outcomes: An Interrupted Time Series Analysis
1090 Practicing Antimicrobial Stewardship: De-escalating Empiric Antibiotics in Patients with Acute Myelogenous Leukemia and Neutropenic Fever

134. Poster Abstract Session
Antibiotic Stewardship: Stewardship Education
Friday, 12:15 - 1:30 p.m.

1091 An Ethnographic Approach to Interrogating Antimicrobial Stewardship at US Teaching Hospitals
1092 Impact of Relieving Infectious Diseases Fellows from Off-Hour/Weekend Antimicrobial Stewardship Coverage
1093 Evaluation of an Antimicrobial Stewardship elective rotation for medicine residents.

135. Poster Abstract Session
Antibiotic stewardship: Surgical Prophylaxis
Friday, 12:15 - 1:30 p.m.

1094 Safety of Administering Cefazolin vs Other Antibiotics in Penicillin Allergic Patients with Anaphylaxis for Surgical Prophylaxis
1095 Prevalence and Characteristics of Self-Reported Antibiotic Allergies across a Multi-Hospital Healthcare System
1096 Reducing Unnecessary Postoperative Antibiotic Prophylaxis
1097 An Antimicrobial Stewardship Intervention to Optimize Cefazolin Dosing for Surgical Prophylaxis
1098 Perioperative antibiotic stewardship for Interventional Radiology cases improves antibiotic decision making
1099 The Correlation Between Antimicrobial Utilization and Resistance in a Medical Intensive Care Unit
1100 Facility factors are a stronger driver of peri-operative vancomycin use than patient risk factors
1101 What Do Electrophysiologists Think about Peri-Procedural Antibiotics? A Qualitative Assessment of Factors Driving Use and Facilitators for Implementing Change
1102 Ertapenem Versus Non-ertapenem Antibiotics in colorectal Surgery: A Stewardship Opportunity
1103 Improving Perioperative Prophylactic Antimicrobial Guideline Concordance in Liver and Lung Transplant Recipients
1104 Antibiotic Prophylaxis for the Endoscopic Endonasal Approach

136. Poster Abstract Session
Antibiotic Stewardship: Urine Cultures
Friday, 12:15 - 1:30 p.m.

1105 Statewide, retrospective, cohort study of Medicare Part B quinolone prescribing for cystitis in 2016 - 2017
1106 Assessment of Fluoroquinolone Appropriateness for Hospitalized Patients with Asymptomatic Bacteriuria and Cystitis: A Multi-Hospital Cohort Study.
1107 Impact of Routine Education and Data Feedback on the Durability of an Antimicrobial Stewardship Intervention for Outpatient Urinary Tract Infections
1108 Impact of Implementing a Urine Culture Order Set on Antibiotic Utilization and Rates of Catheter-Associated Urinary Tract Infections in an Urban Academic Medical Center
1109 Use of Prospective Audit with Intervention and Feedback (PAIF) for Urine Culture (UCx) Interpretation at a Veteran Affairs Medical Center
1110 Outcomes Following Implementation of a Urine Culture
Poster Abstract Sessions (continued)

1111 Characterization of Antibiotic Ordering in Patients with Mental Status Changes and Presumed Urinary Tract Infection in Patients 65 and Older
1112 Improving Urine Culturing Practices in a Neurocritical Care Unit through a Multidisciplinary Algorithm-Based Approach
1113 Outpatient Antimicrobial Stewardship: Targets for Urinary Tract Infections
1114 Oral Beta-lactams for the Treatment of Escherichia coli Bacteremia Secondary to Complicated Urinary Tract Infections Including Pyelonephritis
1115 Reducing Broad-Spectrum Antibiotics for Uncomplicated Urinary Tract Infections: A Multimodal Stewardship Intervention
1116 Impact of Antimicrobial Stewardship Incentive Goals for Pharmacists on Overall Antibiotic Use and Appropriate Duration of Therapy in Urinary Tract Infections

137. Poster Abstract Session
Antibiotic Stewardship (Pediatric): Ambulatory Settings
Friday, 12:15 - 1:30 p.m.
1117 A Retrospective Analysis of Paediatric Prescribing in British Columbia from 2013 to 2016
1118 Trends of Paediatric Prescribing for Common Infections in British Columbia
1119 Implementation of Pediatric Antimicrobial Stewardship Rounds in a Children’s Hospital
1120 Reliability of parent-reported pediatric antibiotic use in a longitudinal birth cohort
1121 Pediatric Urgent Care Providers’ Approach to Antibiotic Stewardship: A National Survey
1122 Implementation of an Outpatient Antimicrobial Stewardship Program within a Pediatric Health System
1123 Specificity of Diagnosis Codes and Adequacy of Supportive Documentation for Common Acute Pediatric Infections: Implications for Ambulatory Stewardship
1124 Impact of a Best Practice Advisory for Pediatric Patients with Staphylococcus aureus Bloodstream Infection In with the Out-patient Antimicrobial Stewardship Initiative: A Collaboration between a Children’s Hospital Antimicrobial Stewardship Program and a Non-affiliated Pediatric Private Practice

138. Poster Abstract Session
Antibiotic Stewardship (Pediatric): Assessment and Development
Friday, 12:15 - 1:30 p.m.
1126 Variability in Antibiotic Use in Children’s Hospitals in the United States
1127 Utilization of Combination Anti-fungal Therapy in Hospitalized Children and Adverse Events
1128 Knowledge, Attitudes and Perceptions about Antibiotic Stewardship (AS) Programs among Neonatology Trainees
1129 Assessment of Nurses’ Views on Antimicrobial Stewardship at a Pediatric Hospital
1130 Vancomycin Use in Pediatric Severe Sepsis at a Freestanding Children’s Hospital

1131 Prevalence and Characteristics of Non-Beta-Lactam Allergy Labeling at a Children’s Hospital
1132 Evaluation of Broad Spectrum Antimicrobial Therapy for Acute Mastoiditis in Pediatric Patients: An Antimicrobial Stewardship Perspective
1133 Evaluation of Antibiotic Allergy Documentation in Pediatric Patients
1134 Antibiotic indications and appropriateness in the pediatric intensive care unit: a ten center point prevalence study
1135 The 2018 Global Point Prevalence Survey of Antimicrobial Consumption and Resistance: Pediatric Results from 26 Canadian Hospitals
1136 Antifungal Prescribing Patterns among Hospitalized Children in the U.S.: Are There Opportunities for Antifungal Stewardship?
1137 Variability of Antibiotic Use in Neonatal Intensive Care Units in the United States

139. Poster Abstract Session
Antibiotic Stewardship (Pediatric): Implementation in Hospitals
Friday, 12:15 - 1:30 p.m.
1138 Script for Paediatrics- Creating a Smartphone Application to Improve Antimicrobial Prescribing
1139 Multidisciplinary Initiative to Increase Guideline-Concordant Antibiotic Prescriptions at Discharge for Hospitalized Children with Uncomplicated Community-Acquired Pneumonia
1140 Evaluation of Neonatal Sepsis Guidelines in a Neonatal Intensive Care Unit
1141 Implementation of a Pediatric Handshake Antimicrobial Stewardship Program to Improve Antimicrobial Utilization
1142 Implementation and Impact of a Tracheitis Diagnosis and Management Guideline in a Pediatric Intensive Care Unit
1143 Measuring Up! Benchmarking Antimicrobial Use in Canadian Children’s Hospitals
1144 Evaluation of Nafcillin versus Vancomycin as Empiric Therapy for Late Onset Sepsis in the Neonatal Intensive Care Unit
1145 Reducing Antibiotic Use in Children With Respiratory Syncitial Virus related Bronchiolitis: Implementation of TeamSTEPPS® 2.0 to Improve Pharmacy-Physician Communication in a Community Hospital Antibiotic Stewardship Program.
1146 Antibiotic Use in Infants Predicts Asthma Rate in Children 1-4 years at Fine Geographic Scale
1147 Improving Accessibility and Antibiotic Prescribing with an Enhanced Digital Antibiogram
1148 Antimicrobial stewardship program at a long-term care hospital for severely handicapped children and adults
1149 Reducing Piperacillin/Tazobactam Use in Children with Acute Perforated Appendicitis

140. Poster Abstract Session
HAI, Device-Associated: Other Devices
Friday, 12:15 - 1:30 p.m.
1150 Evaluating the Impact of Antibiotic Prophylaxis on the Microbiology and Incidence of Ventriculitis in Patients with External Ventricular Drains
141. Poster Abstract Session  
**HAI, Device-Associated: CAUTI**  
Friday, 12:15 - 1:30 p.m.

**1152** Implementation of Enhanced Data Surveillance Methods to Reduce Catheter-Associated Urinary Tract Infections  
**1153** National Trend of Urinary Catheter Device Utilization by Hospital Type, National Healthcare Safety Network (2015-2019)  
**1154** Impact of Educational Feedback on Reducing Hospital-onset Catheter-associated Urinary Tract Infections at an Academic Medical Center  
**1155** CAUTI Path to Zero: A Triple-Pronged Approach to Minding Our Fees and Cues  
**1156** Running on Empty – Enlisting Transportation Services in Quality Improvement Initiatives as a Safeguard Against Catheter Associated Urinary Tract Infections  
**1157** GET IT OUT! Nurses and Clinical Quality Improvement Specialists Drive Initiative to Reduce Standardized utilization Ratios for Indwelling Urinary Catheters in Hospitalized Patients  
**1158** Discontinuation of Urine Cultures by Infection Preventionists in Hospitalized Patients with Indwelling Urinary Catheters: Is It Safe?  
**1159** Multidisciplinary Leadership Rounds Are Associated with Decreased Urinary Catheter and Central Venous Catheter Device Utilization at a Tertiary Care, Academic Hospital  
**1160** CAUTIs are the most common type of healthcare-associated infection. In an effort to decrease CAUTI rates through proactive prevention, we sought to develop a weighted model of CAUTI risk factors. The final set of risk factors jointly predicting CAUTI were ADL dependent, CVA, catheter replacement within 7 days, and catheterization duration ≤5. We have defined contemporary weighted risk factors for CAUTI and intend to utilize these to deploy a tiered approach where patients with risk factors will receive advanced in addition to basic preventive efforts.  
**1161** Frequency of Urine Cultures, their Positivity, and CAUTI: Analysis of a Large Health System  
**1162** An Evaluation of Metrics for Catheter Associated Urinary Tract Infections (CAUTIs): A Statewide Comparison

142. Poster Abstract Session  
**HAI, Device-Associated: Vascular Devices**  
Friday, 12:15 - 1:30 p.m.

**1163** Minocycline EDTA Ethanol (MEDTA+EtOH) lock is highly efficacious in rapidly eradicating *Candida auris* biofilm  
**1164** In *vitro* antimicrobial efficacy of novel antimicrobial Dacron vascular grafts in the inhibition of multidrug resistant gram-negative biofilm  
**1165** Risk factors for Bloodstream Infections during Extracorporeal Membrane Oxygenation (ECMO)  
**1166** Infection Rate in Venous-Venous Extracorporeal Membrane Oxygenation (VV-ECMO)  
**1167** Dialysis Related Bloodstream Infections: A Pre and Post ClearGuard HD Cap Conception Study  
**1168** Trends in Central-Line Associated Blood Stream Infections in a Community Teaching Hospital: A Multi-Intervention Quality Improvement Project  
**1169** Preventing Central Line-Associated Bloodstream Infections in Long-Term Acute Care

143. Poster Abstract Session  
**HAI: Respiratory Infections (incl VAP, HAP)**  
Friday, 12:15 - 1:30 p.m.

**1170** A Quality Improvement Study to Assess the Effectiveness of a Meaningful Use Protocol in the Reduction of PICC Line Use and Complications  
**1171** Impact of Catheter Management on the Clinical Outcome in Adult Cancer Patients with Gram-Negative Bacteremia  
**1172** The proper maintenance duration for peripherally inserted central catheter (PICC) in order to prevent central line-associated bloodstream infection  
**1173** Expanding the MAGIC: Engagement of Frontline Nursing Staff in Device Stewardship  
**1174** The impact of multidisciplinary central line stewardship program to decrease CLABSI rates and central line utilization rates in an academic urban medical center  
**1175** Tandem Heart Associated Fevers – Does the Fever signify Infection?  
**1176** Antibiotic Prophylaxis Strategies Prior to Left Ventricular Assist Device Implantation: A Survey of Practice  
**1177** Spectrum of infectious complications in continuous flow ventricular assist devices: a single center longitudinal cohort  
**1178** Cardiac Device Infection: Do We Follow the Guidelines?  
**1179** Rates and Causative Pathogens of Device-Associated Bloodstream and Urinary Tract Infections Attributed to Solid Organ Transplant Units, 2015 – 2017  
**1180** Colonization with multidrug-resistant organisms is associated with subsequent infection in the the ventricular assist device population

144. Poster Abstract Session  
**HAI: Hand Hygiene and Transmission - Based Precautions**  
Friday, 12:15 - 1:30 p.m.

**1181** Significant Reduction of Non-Ventilator Hospital Acquired Pneumonia (HAP) with a Prevention Bundle and Clinical and Leadership Feedback in a Large Integrated Healthcare System  
**1182** Clinical Outcomes of Hospital-Associated Respiratory Virus Infections.  
**1183** Effect of Chlorhexidine Bath on the Prevention of Ventilator Associated Pneumonia: A Meta-Analysis  
**1184** Making pneumonia surveillance easy: Automation of pneumonia case detection  
**1185** Impact of Utilizing Drug Resistance in Pneumonia (DRIP) Score on Management of Pneumonia

1186 Decreased Laboratory-Identified *Clostridioides difficile* Infections with Implementation of an Electronic Hand Hygiene Monitoring System in a Long-Term Acute Care Hospital  
1187 Decreased Laboratory-Identified *Clostridioides difficile* Infections with Implementation of an Electronic Hand Hygiene Monitoring System in a Long-Term Acute Care Hospital  
1189 Calibrating a Product Use Metric for Hand Hygiene Compliance
<table>
<thead>
<tr>
<th>Poster Abstract Session</th>
<th>HAI: Occupational Infection Prevention</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1189</strong></td>
<td>Effectiveness of Multimodal Intervention Strategies to Improve Hand Hygiene Compliance at an Academic Medical Center</td>
</tr>
<tr>
<td><strong>1190</strong></td>
<td>Hygiene of the Hands 90/90: A Program of Continuous Improvement for the Compliance of the Hygiene of the Hands</td>
</tr>
<tr>
<td><strong>1191</strong></td>
<td>Hand Hygiene Education: Why is it so Critical to Tissue Banking?</td>
</tr>
<tr>
<td><strong>1192</strong></td>
<td>A Visual Family Empowerment Tool Is Associated with Increased Healthcare Worker Hand Hygiene in a Pediatric Intensive Care Unit in Vietnam</td>
</tr>
<tr>
<td><strong>1193</strong></td>
<td>Assessing Sustainability of Hand Hygiene Adherence 5 Years after a Contest-Based Intervention in 3 Japanese Hospitals</td>
</tr>
<tr>
<td><strong>1194</strong></td>
<td>Gender Differences in Psychosocial Determinants of Hand Hygiene Among Doctors</td>
</tr>
<tr>
<td><strong>1195</strong></td>
<td>Hand Hygiene Compliance of Patients’ Family Members in India: Importance of Educating the Unofficial “Fourth category” of Healthcare Personnel</td>
</tr>
<tr>
<td><strong>1196</strong></td>
<td>Is the Weekend Staff Really to Blame? Challenges in Isolation Compliance at an Academic Tertiary Care Center</td>
</tr>
<tr>
<td><strong>1197</strong></td>
<td>The Gloves are Off: The State of Personal Protective Equipment (PPE) Use in Contact, Droplet and Standard Precautions at a Major Teaching Hospital</td>
</tr>
<tr>
<td><strong>1198</strong></td>
<td>Developing Infection Prevention and Control (IPC) Educational Videos to Improve Knowledge of Respiratory Virus Transmission and Etiquette</td>
</tr>
<tr>
<td><strong>1199</strong></td>
<td>Provider Perspectives on Non-sterile Glove Use in the NICU</td>
</tr>
<tr>
<td><strong>1200</strong></td>
<td>Parent Perspectives on Infection Prevention and Control in the NICU</td>
</tr>
<tr>
<td><strong>1201</strong></td>
<td>Use of Remote Video Auditing to Monitor Adherence to High-Concern Isolation Guidelines in a Patient Infected With <em>Candida auris</em>, Use of Remote Video Auditing to Monitor Adherence to High-Concern Isolation Guidelines in a Patient Infected With <em>Candida auris</em></td>
</tr>
<tr>
<td><strong>1202</strong></td>
<td>It’s a Confidence Scheme - Transmission Based Precautions in the Ambulatory Setting</td>
</tr>
</tbody>
</table>

**145. Poster Abstract Session**

**HAI: Environment**

Friday, 12:15 - 1:30 p.m.

| **1210** | Investigating a *Staphylococcus aureus* outbreak in a Clinical Intensive Care Unit: what is the role of the mobile phones? |
| **1211** | Microbiologic Evaluation of Mobile Phones and Hands of Healthcare professionals in Two Intensive Care Units in a Brazilian University Hospital |
| **1212** | Environmental Contamination Characterization of Two Outpatient Clinics |
| **1213** | How often is portable equipment cleaned in an acute care setting? |
| **1214** | Microbiological and Clinical Effectiveness of Pulsed-Xenon Ultraviolet Disinfection of the Patient Room in the ICU |
| **1215** | Ultraviolet-C (UV-C) monitoring made ridiculously simple: UV-C dose indicators for convenient measurement of UV-C dosing |
| **1216** | A Novel Antimicrobial Surface Coating Demonstrates Persistent Reduction of both Microbial Burden and Healthcare-Associated Infections at Two High-acuity Hospitals |
| **1217** | Predicting the Efficacy of an Antimicrobial Surface Coating Utilizing X-Ray Fluorescence Spectroscopy (XRF) |
| **1218** | Evaluation of a novel sporicidal spray disinfectant for decontamination of surfaces in healthcare |
| **1219** | Disinfection of surfaces contaminated with Carbapenemase producing *Acinetobacter baumannii* using ozone under complex room conditions |
| **1220** | Effective, Novel, Handheld, UV Technology for Surface Disinfection While Patients or Staff are Nearby |
| **1221** | Comparison of the Antimicrobial Efficacy of Mobile Ultraviolet Light Devices in a Simulated Patient Room |
| **1222** | Are reduced concentrations of chlorine-based disinfectants effective against *Candida auris*? |
| **1223** | Endoscopic Retrograde Cholangiopancreatography (ERCP) associated Carbapenem Resistant Entrobacteriaceae (CRE) before and after implementation of Ethylene Oxide (ETO) Sterilization of Duodenoscopes |
| **1224** | Factors Associated with Aerosolization of Gammaproteobacteria from Intensive Care Unit (ICU) Sinks in a Randomized Trial of Copper Alloy versus Standard Chrome Sink Drains |
| **1225** | How Frequently Should Sink Drains Be Disinfected? |
| **1226** | Application of a foam disinfectant enhances sink drain decontamination in hospital sinks |
| **1227** | Replacement and rerouting of pipes to remediate intractable contamination of potable water fixtures in a pair of ICU rooms |
| **1228** | Risk Factors for Contamination with Carbapenemase-Producing Entrobacteriaceae (CPE) in Exposed Hospital Drains in Ontario, Canada |
| **1229** | Two-step water filtration and control of Delfia acidovorans Hemodialysis pseudo outbreak |
| **1230** | Estimating effective point-of-use biocide levels for *Legionella* control in building water systems using a large, real-world dataset |
| **1231** | *Legionella* Variability from Routine Environmental Testing across All Veterans Health Administration (VHA) Medical Facilities. |
147. Poster Abstract Session  
**HAI: Surgical Site Infections**  
Friday, 12:15 - 1:30 p.m.

- 1232 Potential Health and Cost Outcomes of Optimized Statistical Process Control Use for Surgical Site Infection Surveillance
- 1233 Surveillance Quality Correlates with SSI Rates in Prosthetic Hip and Knee Surgery: a Call to Action to Adjust Reporting of SSI rates
- 1234 Mental Models of Surgical Site Infection Prevention among Surgical Technicians and Nurses
- 1235 A Survey of Surgical Site Infection (SSI) Surveillance Practices in US Hospitals, and their Association with SSI Rates
- 1236 Staphylococcus aureus Surgical Site Infection – Epidemiology in Europe (SALT)
- 1237 Review of Implant Surgical Site Infections and *Staphylococcus aureus* Screening Compliance for 2018 at a Large Health Care System
- 1238 Alcohol-based Nasal Antiseptic as Part of a Bundle to Reduce the Incidence of Contact Precautions and Surgical Site Infections
- 1239 Efficacy of Preoperative Chlorhexidine Gluconate and Mupirocin in the Prevention of Orthopedic Surgical Site Infections
- 1240 Evaluation of preoperative *Staphylococcus aureus* (SA) decolonization with nasal iodine for hips/knees and fusion surgeries
- 1241 Marked Improvement in Post-Operative Craniotomy Wound Care Using 2% Chlorhexidine (CHG) Cloths for Blood Clots Removal and Hair Cleaning in a Photo-Documentation Survey
- 1242 Evaluation of Risk Factors for Development of Total Hip Arthroplasty (THA) Surgical Site Infections (SSI)
- 1243 Continuous vs Intermittent Intraoperative Infusion of Cefazolin on Surgical Site Infections (SSIs) and Acute Kidney Injury in Patients Undergoing Cardiac Procedures
- 1244 Evaluation of intraoperative topical vancomycin and the incidence of acute kidney injury
- 1245 Does complexity of infection prevention bundles matter in colorectal surgery? A systematic review and meta-analysis
- 1246 Outcomes of Extended Spectrum Beta-Lactamases Producing Enterobacteriaceae Colonization among Patients Underwent Abdominal Surgery
- 1247 Multicenter Study on Risk Factors for Surgical Site infection after Exploratory Laparotomy
- 1248 30 Day Colon Surgical Site Infections: Using NSQIP to Cross Check NHSN
- 1249 Images vs C Reactive Protein Follow Up of Patients with Organ/space Surgical Site Infections.
- 1250 Don’t Turn Your Back on Fusion Surgical Site Infections (SSIs)
- 1251 Determinants of infection at a non-transplanting cardiothoracic LVAD program.
- 1252 Development of a Surgical Site Infection at a Tertiary Hospital in Colombia: a clinical and microbiological profile.

148. Poster Abstract Session  
**HIV: General Epidemiology**  
Friday, 12:15 - 1:30 p.m.

- 1253 Sex-on-Premise Venue (SOPV) Attendance Among Men Who Have Sex with Men (MSM) in Lima, Perú: Results from a Cross-Sectional Web-Based Survey
- 1254 Association of Structural Stigma Due to Sexual Orientation and HIV Diagnosis/PrEP Use in the United States: An Ecological Analysis
- 1255 Comparison in AIDS Related Mortality Between African Americans and Whites with Human Immunodeficiency Virus During the HAART Era.
- 1256 Contemporary Evaluation of Racial/Ethnic Disparities in Survival and Disease Progression among People with HIV in the U.S. Midwest
- 1257 Mental Health, Quality of Life, and Accessibility to Care Among Virally-Suppressed People Living with HIV in the United States
- 1258 The Pregnancy Factor: Differences in the Prevalence of Depression among Pregnant and Non-pregnant Sub-Saharan African Women Living with HIV
- 1259 Household Income and its Relationship with Patient-Reported Outcomes Among Older People Living with HIV
- 1260 Seroprevalence of Transfusion-Transmissible Infections (HBV, HCV, HIV and syphilis) among Voluntary Blood Donors in Eastern Regional Blood Center Sri Lanka; a four years evaluation.
- 1261 Alarming High Rate of HIV Detected by Testing and Prevention Opportunities: Observations from the Largest HIV Program in Liberia
- 1262 Comparative evaluation of native and migrant HIV+ pregnant women in Chile
- 1263 Anti-Retroviral (ART) Success in an Active Duty Military Cohort from 2002 to 2016, A Model for Ending the HIV Epidemic in the United States
- 1264 Characterization of HIV Positive Patients with Low Level Viremia in a Community HIV Clinic between 2014 and 2018
- 1265 Monitoring of Human Immunodeficiency Virus (HIV)-infection using the Cepheid HIV-1 Qualitative Assay
- 1266 Cancer among HIV-Positive Patients in Cali, Colombia: A Retrospective Hospital-Based Study
- 1267 Contribution of Acute Infection to the Community Viral Load of an HIV Care Program
- 1268 Clinic Screening for Adverse Childhood Experiences among Persons with HIV: a Pilot Project
- 1269 Cohort Profile: The Translational Platform HIV (TP-HIV), a Multicenter Cohort Project in Germany

149. Poster Abstract Session  
**HIV: Prevention**  
Friday, 12:15 - 1:30 p.m.

- 1271 Pre-exposure prophylaxis (PrEP) awareness and uptake between men who have sex with men and men who have sex with men and women
1272 Feasibility and Successful Enrollment in Proof-of-Concept Trials to Assess Safety and Efficacy of a Broadly Neutralizing Monoclonal Antibody, VRC01, to Prevent HIV-1 Acquisition in Uninfected Individuals
1273 Reasons for Disengagement in Care among Individuals Receiving Pre-Exposure Prophylaxis (PrEP) from a Sexual Health Clinic
1274 The PrEP Care Continuum Among an Uninsured Patient Population
1275 Factors Associated with Patient-Provider Discussions about Preexposure Prophylaxis Among Young Men Who Have Sex with Men in Washington, DC
1276 Changes in Primary Care Pre-exposure Prophylaxis prescribing in a Large Healthcare System after the Implementation of an HIV Screening Alert and Educational Intervention
1277 Retention among Adolescents with Mental Health Diagnoses on Pre-Exposure Prophylaxis (RAMP) Study
1278 Assessing statewide HIV pre-exposure prophylaxis implementation using an All Payer Claims Database
1279 Barriers to Acquiring Pre-exposure Prophylaxis (PrEP), Risk Factors for HIV and Health Determinants in Adult Transgender Individuals
1280 A pharmacist-led PrEP program at the epicenter of the HIV epidemic in Atlanta: our experience
1281 Awareness of U=U Among Gay and Bisexual Men who have Sex with Men
1282 A Major Hurdle for HIV Elimination: How Do We Promote Pre-Exposure Prophylaxis Persistence among Men Who Have Sex with Men in the Deep South?
1283 Attitudes and Practices Regarding HIV Post-Exposure Prophylaxis
1285 PrEP Acceptability, Uptake and Adherence among Young Men who Have Sex with Men and Transgender Women in PrEP Demonstration Project, Chiang Mai, Thailand
1286 Healthcare Provider Attitudes and Knowledge Around Pre-Exposure Prophylaxis (PrEP) for the Prevention of HIV-Infection in Tennessee
1288 Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial
1289 Douching and Rectal Inflammation in Sexual Minority Men: Implications for HIV Acquisition

150. Poster Abstract Session
HIV: Screening and Testing
Friday, 12:15 - 1:30 p.m.

1290 Community Screening and Education for HIV and Hepatitis C (HCV) infection in South Texas with Rapid Point of Care Testing and a Mobile Phone Application (app)
1291 Comparison of Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Screening Rates Before and After Implementation of a Quality Improvement (QI) Project Aimed at Incorporating Routine ‘Opt-Out’ Testing at a Primary Care Resident Clinic in Columbia, SC
1292 Integrating HIV and Hepatitis C Screening in a high risk Emergency Department Population

1293 Bundled HIV/Hep C testing four years of implementation at 9 Emergency departments in the Houston Metropolitan Area.
1294 Long-Term Impact of an HIV Testing Program on High-Risk HIV Screening in the Emergency Department
1295 Mortality of Patients with HIV Infection Admitted to the Intensive Care Unit: a 16-Year Experience
1296 Should HIV Disclosure at ED Based on Preliminary Results?
1297 Examining the Successes and Challenges of Implementing HIV Testing Clinical Decision Support in the Emergency Department.
1298 Analysis of factors influencing consent for opt-out HIV screening among high-risk groups vulnerable to HIV in an urban Emergency Department
1299 Cluster of False Positive “Fifth Generation” HIV test results during implementation of a routine HIV screening program in an emergency department
1300 Symptom driven testing is not enough: A retrospective review of patients enrolled into HIV care 2015-2018 at a Ryan White Patient-Centered Medical Home in Pittsburgh, Pennsylvania
1301 Graphical Analysis of HIV Guidelines Adherence Finds System-Wide Anomalies in Diagnostic Testing
1302 HIV Testing in Adults Presenting with Central Nervous System (CNS) Infections

151. Poster Abstract Session
HIV: Care Continuum
Friday, 12:15 - 1:30 p.m.

1303 Impact of Pharmacy Type on HIV Viral Suppression at a University-Based HIV Clinic in the Midwest
1304 Pharmacist Impact on HIV Management in a Psychiatric Patient Population
1305 Use of a Clinical Pharmacist to Reduce Inpatient ART (Antiretroviral Therapy) Errors
1306 Evaluation and Predictors of Antiretroviral (ART)-Related Medication Errors in Hospitalized People Living with HIV (PWLH)
1307 Virologic Failure in HIV Infected Men Who Have Sex with Men and Transgender Women Treated in a Community Based Model vs. a Hospital Based Model.
1308 The Association between Refill History and Viral Load Suppression in HIV-infected Patients at a University-Based HIV Clinic in the Midwest
1309 Effects of a pharmacist-driven antiretroviral stewardship and transitions of care service in persons living with HIV/AIDS
1310 The Impact of Recent Incarceration on Post-Release HIV Linkage to Care and Risk-Taking Behaviors in the Setting of Enhanced Linkage to Care Policies in Florida
1311 Ryan White HIV Care Continuum Model Doubled the Rate of Community HIV Viral Suppression for Newly Diagnosed Patients: a 10-Year Review
1312 Increasing Care Engagement amongst People Living with HIV through a Text Messaging Intervention at a Tertiary Center
1313 Complementary Effects of Medical Follow-up and Virologic Suppression for Reincarcerated Inmates Living with HIV
Poster Abstract Sessions (continued)

1314  HOME CARE: Reaching our Lost to Follow Up Patientsand Overcoming Barriers to Care Utilizing Nontraditional Care Models
1315  Food Insecurity and Viral Suppression in Human Immunodeficiency Virus Patients on Antiretroviral Treatment at an Urban Primary Care Practice
1316  Gathering Trauma Narratives: A Qualitative Study on the Impact of Traumas on People Living with HIV (PLWH)
1317  Comparison of Access and Linkage to Care Among People Living with Human Immunodeficiency Virus When Enrolled in Florida AIDS Drug Assistance Program (ADAP)
1318  Examining multimorbidity as a moderating effect on the relationship between substance use and viral suppression among people living with HIV
1319  Events of Disengagement from HIV care and Subsequent Reengagement in a Kenyan Pastoralist Community: Frequency, Determinants, and Patient Views
1320  HIV Care Continuum Outcomes among newly diagnosed PLWH in Washington, DC
1321  Trans Females Receiving Gender-Affirming Surgical Referrals are More Likely to Have Durable Virologic Suppression at Whitman-Walker Health, 2008-2017
1322  A Mobile Technology-Based Intervention Improves HIV Care Continuum for Young People Living with HIV
1323  Clinic-Level Factors Associated with Antiretroviral Prescription Rates
1324  Successful intervention to reduce the time interval between diagnosis and viral load suppression in patients living with HIV in the Midwestern US
1325  Inpatient Initiation of ART Improves Short Term Mortality in People Living with HIV
1326  Comorbid Mental Health Disorders Are A Key But Manageable Barrier to Suppression of HIV Viral Load
1327  Correlates of Need for Ancillary Service Referrals among Persons Receiving HIV Care in New York City: Findings from the Medical Monitoring Project
1328  Post-War and Post-Ebola HIV Care Continuum in a Liberian Academic Center: Fresh Insights and Trends Over 5 Year Period
1329  Experiences and Emotional Challenges of Antiretroviral Treatment (ART) - Findings from the Positive Perspectives Study

152. Poster Abstract Session

Host Responses to Diagnostics

Friday, 12:15 - 1:30 p.m.

1330  Evaluation of Multiple Host Response-Based Strategies to Classify Acute Respiratory Illness
1331  Interpretation and Application of Rapid Diagnostic Methodologies: The Positive Impact of Online, Curriculum-Based Learning
1332  Identification of Genetic Markers Linked to Recurrent Methicillin Resistant Staphylococcus aureus Skin and Soft Tissue Infections
1333  Utility of Admission Procalcitonin Level in Patients Presenting to the Hospital with Bloodstream Infection: Real World Evidence from 250 US Hospitals
1334  Performance of C-Reactive Protein and Procalcitonin in Immunocompromised Children with SIRS

1335  A Translational Nephrotoxicity Model to Probe Acute Kidney Injury with Vancomycin and Piperacillin-Tazobactam
1336  Impact of Procalcitonin Guided Antibiotic Management in Chronic Obstructive Pulmonary Disease Exacerbation and Community Acquired Pneumonia
1337  Development, Maintenance and Application of Opsonophagocytic Assays to Measure Functional Antibody Responses to support a 20 Valent Pneumococcal Conjugate Vaccine
1338  Development of a novel application for differential diagnosis of tick-borne diseases
1339  Impact of Implementing Procalcitonin Testing with Comprehensive Education on Procalcitonin Ordering Habits and Antibiotic Usage

153. Poster Abstract Session

Mycobacteria

Friday, 12:15 - 1:30 p.m.

1340  The Effect of Continuous Renal Replacement Therapy on Body Temperature in Patients with and without Infection
1341  Development of a Series of High-Throughput Screens to identify Leads for Nontuberculous Mycobacteria Drug Design
1342  Impact of HIV infection on Treatment Outcome of New Tuberculosis Patients Attending Tuberculosis and Antiretroviral Treatment Services in the Community-Based Hospital, Thailand: A Retrospective Cohort Study
1343  Infectious Diseases Consultation Avoided Delayed Therapy and Unnecessary Exposures in the Majority of GeneXpert® MTB/RIF and AFB Smear Negative Pulmonary Tuberculosis Cases in the US County Hospital in Houston, Texas
1344  Interferon Gamma Release Assay (IGRA) Responses in HIV-infected and -uninfected Women in Pregnancy
1345  Randomized Control Trial to evaluate the Clinical and Cytokine response profile to Oral Thalidomide in Leprosy patients with Erythema Nodosum Leprosum
1346  Ruling out TB in New York City: are two NAATs (Nucleic Acid Amplification Testing) enough?
1347  Tuberculosis Caused by Mycobacterium bovis in Children: A Retrospective Review of Cases From 2010 to 2019 in a Pediatric Tertiary-care Center in Mexico,
1348  Mycobacterium chimaera infection following cardiac surgery: a review of a large cohort of cases in the United States
1349  Risk Factors for Extrapulmonary Tuberculosis in Greece, a Low Tuberculosis Burden and High Immigrant Receiving Country
1350  Clofazimine as an Oral Companion Drug for Treatment of Mycobacterium abscessus complex Infections
1351  How Do Infectious Diseases Clinicians Manage Patients with Suspected Ocular Tuberculosis? Results of an Emerging Infections Network Survey
1353  Effect of implementing Xpert MTB/RIF Ultra assay on diagnosis of tuberculosis in a medical center in Central Israel
Poster Abstract Sessions (continued)

1354  *Nocardia bejlingensis*: a novel isolate affecting immunocompromised patients in the United States

1355  Efficacy and Tolerability of Linezolid Adjunctive Treatment for Nontuberculous Mycobacterial Infection in Patients with Acquired Anti-interferon gamma Autoantibody

1356  A Randomized Controlled Trial of Prednisolone vs TNF-alfa inhibitor Infliximab in the Management of Type 1 Lepra Reaction in Leprosy Patients

1357  *Mycobacterium abscessus* Native Tricuspid Valve Endocarditis. Is a Six-week Course of Combination Antibiotic Therapy Enough?

1358  A Novel Rapidly Growing Mycobacteria (RGM) Species Causing Soft Tissue and Orthopedic Hardware Infection after Trauma

1359  Clinical Experience and Challenges Utilizing Clofazimine in the Treatment of Nontuberculous Mycobacterial Pulmonary Infections

1360  Disseminated *Mycobacterium abscessus* infections in patients with neutralizing anti-interferon gamma autoantibodies treated with rifabutin-based combination regimens


1362  A case series of miliary tuberculosis in North West London

1363  Does Genotypic testing Improve treatment outcomes in Drug Resistant Tuberculosis?

1364  Pre-treatment Chest X-ray Stability Duration and Tuberculosis Disease in San Diego County, 2012-2017

1365  Profiling Extrapulmonary Nontuberculous Mycobacteria Infections and Predictors for Rapid-growing Species: a Multi-center Retrospective Study

1366  Prognostic Factors for Unfavorable Outcomes of Patients with Spinal Tuberculosis in a Country with an Intermediate Tuberculosis Burden: a Multi-center Cohort Study

1367  Tele-TB: Using TeleMedicine to Increase Access to Directly Observed Therapy for Latent Tuberculosis Infections

1368  Tuberculosis in Older Patients in Cali, Colombia (2011-2016): A Hospital-Based Cohort Study

1369  Clinical manifestations, treatment and outcome of nontuberculous mycobacteria (NTM) infection in adult-onset immunodeficiency associated with anti-interferon-gamma autoantibodies in King Chulalongkorn Memorial Hospital.

1370  Concurrent Anti-PD-1 and Anti-tubercular Therapy in a Patient with Refractory Lymphoma and Pulmonary Tuberculosis: a case report


1372  Patient’s Perceptions Of Barriers To Tuberculosis Care In Private Sector In India

1373  Clinical Presentation, Demographics and Outcomes of cases of tuberculosis (TB) at Princess Margaret Hospital, Nassau, The Bahamas 2014-2016

1374  Diagnostic Utility of Whole Body Positron Emission Tomography-Computerized Tomography (PET-CT) in Patients with Suspected Central Nervous System Tuberculosis: A Retrospective, Descriptive Study

1375  Laboratory Abnormalities among Patients with Pulmonary *Mycobacterium avium complex* Infections

1376  Physician Practice Patterns for Screening and Treatment of Latent Tuberculosis Infection in the South Asian Population in Central New Jersey.

1377  Use of Interferon Gamma Release Assays (IGRAs) Reduced Latent Tuberculosis Infection (LTBI) Diagnosis in Refugee and Immigrant Children

1378  Clinical characteristics of tuberculosis among patients with cancer in endemic country

1379  Comparison of Inpatient Tuberculosis Screening Methods and Their Effect on Patient Duration in Airborne Isolation

1380  Safety of Repurposed Drugs for Multidrug-Resistant and Extensively Drug Resistant Tuberculosis: An Analysis of Adverse Events Reported in the Literature

1381  *M. genavense* in the ART era: from persistent disseminated disease to severe disease

1382  Acid-Fast Bacilli Testing Trends at 43 In- and Outpatient Facilities and Nontuberculous Mycobacterial Pulmonary Isolation Rate, United States, 2009-2015

1383  Everolimus is Associated with an Increased Risk of Tuberculosis in Solid Organ Transplant Recipients

1384  *Mycobacterium marinum* Infection: 21 Years of Experience at a Tertiary-Care Hospital

1385  Mechanism-Based, in-vitro Inhibition of *Mycobacterium abscessus*: Assessing Beta-Lactam Therapy

1386  Reduction in Expected Survival Associated with Nontuberculous Mycobacterial Pulmonary Infection

1387  Women Living with HIV (WLWH) Lose IFNγ Responses Diagnostic of Latent TB Infection (LTBI) during Pregnancy and after INH Prophylactic Treatment (IPT)

154. Poster Abstract Session

**Transplant ID: Mycobacterial Infections**

Friday, 12:15 - 1:30 p.m.

1388  Characteristics of Non-tuberculous Mycobacterial Infections in Hematopoietic Stem Cell Transplant Patients

1389  Risk Factors and Clinical Outcomes of Tuberculosis among Kidney Transplant Recipients in High Endemic Country: a Case-control Study

1390  A novel application of the interferon-gamma release assay (IGRA) among end-stage heart failure patients awaiting heart transplantation

1391  Latent Tuberculosis Screening Cascade in Liver Transplant Candidates: A single, transplant center experience

1392  Tuberculosis disease in recipients of organ-transplantation, California 2010-2017

1393  Tuberculosis (TB) after Solid Organ Transplant (SOT) and Hematopoietic Stem Cell Transplant (HSCT)

1394  Clinicopathologic Features of Infectious and Non-Infectious Tissue Granulomas in Transplant Patients

155. Poster Abstract Session

**CNS Infections**

Friday, 12:15 - 1:30 p.m.

1395  Comparison of Four Recommendations Guiding the Use of Neuroimaging in the Management of Bacterial Meningitis

1396  Risk Factors for Brain Abscess: A Nationwide Population-based Nested Case-Control Study

1397  Risk Factors of Unfavorable Clinical Outcomes in Patients with Brain Abscess and Subdural Empyema in Korea
1398 Clinical performance of Film Array Meningitis/Encephalitis Multiplex PCR Panel in CNS Infection
1399 A Prospective Cohort Study Regarding the Impact of Biofire® FilmArray® Meningitis/Encephalitis (FA) Panel in Children with Suspected Central Nervous System Infection
1400 Impact of a multiplex polymerase chain reaction meningitis/encephalitis panel and antimicrobial stewardship bundle on antimicrobial use in patients with suspected meningitis or encephalitis
1401 Minimal Cerebrospinal Concentration of Miltefosine Despite Therapeutic Plasma Levels during the Treatment of Amoebic Encephalitis
1402 Long-term Mortality and Epilepsy in Patients after Brain Abscess: A Nationwide Population-based Matched Cohort Study
1403 Infectious Causes of Acute Meningitis among Thai Adults: A University Hospital Setting
1404 The FilmArray Meningitis/Encephalitis (FA ME) May Be of Higher Yield in the Immunocompromised Patient Population
1405 Infectious Causes of Chronic Meningitis in HIV Negative Patients, a Case Series
1406 Steroid-Sparing Agents to Control Inflammation in Complicated Neurocysticercosis: Three Cases
1407 Potential Impact of the Biofire® Film Array Meningitis and Encephalitis (ME) Panel in reducing repeat lumbar punctures in patients with meningitis and encephalitis.
1408 Treponema pallidum Specific Antibody Testing in the Evaluation of Neurosyphilis, a Prospective Trial.
1409 Next-generation sequencing based Detection of Angiostrongylus cantonensis (AC) Using microbial Cell-free DNA Sequencing ofPlasma in Atypical Cases of Rat Lungworm Meningitis Presenting with Ascending Paralysis.
1410 Serious Cryptococcal Infections with Ruxolitinib Use: A Case of Meningitis and a Review of the Literature.
1411 Differentiation of Fungal Abscess of Brain from Brain Glioblastoma by MRI scan ADC value
1412 Spontaneous Intramedullary Abscess from Streptococcus anginosus Group: A Case Report and a Review of the Literature
1413 Surveillance of Variant Creutzfeldt Jakob Disease, Based on the Non-confirmatory Diagnostic Criteria of the EU Case Definition, Greece, 2014-2018
1414 Time-to-completed-imaging, Survival and Function in Patients with Spinal Epidural Abscess: Description of a Series of 34 patients, 2015-2018
1415 Use Of Adjunctive Steroids In Adults With Encephalitis
1416 Nocardia beijingensis: A Rare and Unusual Cause of Intracranial Abscess
1417 Detection of human herpesviruses DNA in cerebrospinal fluids of patients suspected with central nervous system infection

156. Poster Abstract Session
Osteomyelitis
Friday, 12:15 - 1:30 p.m.
1418 Clinical characteristics of vertebral osteomyelitis in cancer patients
1419 A Rare Case of Clostridium beijerinckii Traumatic Osteomyelitis
1420 Successful Treatment of Acute Osteomyelitis with Once Weekly Oritavancin
1421 Microbiology and resistance of diabetic foot osteomyelitis in a teaching hospital in Santiago, Chile
1422 Evaluation of Diabetic Foot Infections and Osteomyelitis in a Veteran Population: Targets for Improved Outcomes
1423 Antibiotic Utilization and Outcomes in Patients with Sacral Osteomyelitis and Decubitus Ulcers
1424 Association Between Erythrocyte Sedimentation Rate (ESR) Change and Treatment Failure in Patients with Osteomyelitis
1425 Treatment outcomes in patients with pyogenic vertebral osteomyelitis who have cirrhosis
1426 Outcomes of additional instrumentation in elderly patients with pyogenic vertebral osteomyelitis and previous spinal instrumentation
1427 Treatment of Children with Acute Hematogenous Osteomyelitis andStaphylococcus aureus Bacteremia: Impact of Severity of Illness on Antimicrobial Therapy
1428 Comparing Outcomes of Diabetic Foot Infections Requiring Amputation, Negative vs. Positive Margins.
1429 Diagnosis and Management of Osteomyelitis Associated with Stage IV Pressure Ulcers: Report of a Query to the Emerging Infections Network of the Infectious Diseases Society of America
1430 The Hidden Costs of Vancomycin Use During the Treatment of Staphylococcus aureus Bacteremia Concurrent with Acute Hematogenous Osteomyelitis
1431 Comparison of Treatment Outcomes with Definitive Antibiotic Therapy and Empiric Antibiotic Therapy in Osteomyelitis

157. Poster Abstract Session
Urinary Tract Infections
Friday, 12:15 - 1:30 p.m.
1432 Estimating the incubation period of Salmonella urinary tract infection (UTI) using foodborne outbreak data
1433 Predictive models for antibiotic coverage of Gram-negative urinary tract infections
1434 Risk Factors for Community Acquired Urinary Tract Infections caused by Extended Spectrum β-lactamase (ESBL) Producing Escherichia coli in Children: A Case Control Study
1435 Urinary Tract Infections Due to Extended-Spectrum Beta-Lactamase-producing Bacteria in Hospitalized Children: Demographics, Risk Factors, Clinical Characteristics, Imaging and Treatment
1436 Comparison of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Activities when Tested against Gram-Negative Organisms isolated from Complicated Urinary Tract Infections
1437 Safety and Effectiveness of a Laboratory Intervention to Reduce Antibiotic Consumption in Patients with Asymptomatic Bacteriuria
1438 Escherichia coli (EC) ST131–H20 Clonal Group is Associated with Antimicrobial Resistance, Illness Severity, Host Compromise, and Non-Cure among Patients with Bacteriuria
1439 Reducing the Number of Urine Cultures Performed Through Stringent Urinalysis Reflex Criteria
| 1440 | Prevalence and Regional Variation of in ESBLs and CRE Enterobacteriaceae (ENT) among Adult, Hospitalized Patients with ENT on a Urine Culture: A Multicenter Evaluation |
| 1441 | Comparison of Cefpodoxime Versus Oral Cefuroxime for Urinary Tract Infections at a Large Academic Medical Center |
| 1442 | Effect of Reflex Urine Culturing on Rates of Cultures and Infections in an Acute Care Hospital, Emergency Department, and Two Long-Term Care Facilities |
| 1443 | N-acetyl cysteine Coadministration in Prevention of Ampicillin-induced Electrolyte Imbalances in Children |
| 1444 | Urine Screening Prior to Surgical Valve Replacement: Should It Be Performed? |
| 1445 | Antimicrobial Activity of Novel β-Lactamase Inhibitor Combinations Tested against Organisms Causing Complicated Urinary Tract Infections in United States Medical Centers |
| 1446 | The Impact of Enterobacteriaceae Isolate Breakpoints on Prescriber Treatment Choices for Discordant Pattern Urinary Tract Infections |
| 1447 | Ex vivo human bladder tissue model to evaluate lactobacillus-containing formulations as preventative treatment against common urogenital pathogens |
| 1448 | Prostate Abscess: Clinical Features, Management, and Outcomes of a “Stealth” Infection. A Case Series. |
| 1449 | Antibiotic Choice, Duration, and Outcome in Community Acquired Urinary Tract Infections (UTI) in Male Patients |
| 1450 | Risk factors for antibiotic resistance of *Escherichia coli* urinary isolates in outpatients |
| 1451 | Change in clinical characteristics of community-acquired acute pyelonephritis in South Korea: comparison between 2010-2011 and 2017-2018 |
| 1452 | Is carbapenem-sparing therapy as effective as carbapenems against Extended-Spectrum β-Lactamase Producing *Enterobacteriaceae* in UTI? |
| 1453 | Cephalexin and Cefadroxil Are Not Therapeutic Equivalents for Uncomplicated Cystitis (uUTI): Further Analysis of Cefazolin Surrogate Susceptibility Testing Criteria |
| 1454 | Cephalosporins and Quinolones Account for Ninety-five Percent of Oral Antibiotic Treatment for Uncomplicated Cystitis in Japan |
| 1455 | Epidemiology, Empiric Treatment, and Outcomes Among Hospitalized Patients With Complicated Urinary Tract Infections in the US, 2013-2018 |
| 1456 | Increase in Resistance to Antibiotics in Enterobacteriaceae from Ambulatory Urinary Samples in Buenos Aires City |
| 1457 | Antimicrobial Resistance of Urinary Tract Infection Pathogens in South Korea: a Surveillance Report of the Hospital Center |
| 1458 | Burden of Illness in Patients With Urinary Tract Infections With or Without Bacteremia Caused by Carbapenem-resistant Gram-negative Pathogens in US Hospitals (2014 to 2018) |
| 1459 | Oral Cephalosporins Versus Fluoroquinolones for the Empiric Treatment of Acute Uncomplicated Pyelonephritis |
| 1460 | The effectiveness of short versus long antibiotic therapy in hospitalised adult patients with urinary tract infections: a systematic review and meta-analysis |
| 1461 | Antimicrobial Susceptibility Patterns of Common Complicated Urinary Tract Infection Pathogens in US Hospitals, 2013-2018 |
| 1462 | Derivation of a Prediction Model for Risk of Drug-Resistant Urinary Tract Infection |
| 1463 | The Rates of UTI Outpatient and Inpatient Visits from 2001-2015 Among an Insured Population |
| 1464 | The Utility of Double Balloon Urinary Catheter in Reducing Rates of Catheter-Associated Urinary Tract Infections in a Tertiary Care Teaching Hospital |
| 1465 | Resistance to Oral Antibiotics among Urinary Tract Infection Isolates of *Escherichia coli* from the United States and Europe in 2017 |
| 1466 | Alkaline Urine- a Cause for Urinary Tract Infection Recurrence |
| 1467 | Antimicrobial susceptibility and molecular characterization of extended-spectrum β-lactamase of *Escherichia coli* and *Klebsiella pneumoniae* of urine samples isolated from community patients in South Brazil |
| 1468 | Determination of Antibiotic Susceptibilities in *Aerococcus urinae* Urinary Isolates |
| 1469 | Effect of Treatment Duration on Outcomes in Septic Patients Admitted for Urinary Tract Infections from Extended Care Facilities |
| 1470 | Linezolid for Treatment of Urinary Tract Infections Caused by Vancomycin Resistant Enterococci |
| 1471 | Medical Claims Analysis as a Tool to Evaluate Empiric and Targeted Antibiotic Therapy in UTIs |
| 1472 | Non-carbapenems for treating community-associated urinary tract infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in children |
| 1473 | Structured Patient Interview in Complicated Urinary Tract Infections to Assess Clinical Outcomes Versus Investigator’s Evaluation in the APEKS-cUTI Study |
| 1474 | Epidemiology and Outcomes of Hospitalized Patients with Urinary Tract Infections (UTI) due to Multidrug-Resistant Organisms (MDRO) |
| 1475 | Understanding Prescribing Practices for Uncomplicated Urinary Tract Infections (UTIs) in the Primary Care Setting – A Pilot Study |
| 1476 | The role of empirical antibiotics determined by pre-procedural urinalysis and urine cultures in elective urological interventions |
| 1477 | A Randomized Phase 2 Study of Cefepime Combined with the Novel Extended Spectrum β-Lactamase Inhibitor Enmetazobactam in Hospitalized Adults with Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP) |
| 1479 | Clinical efficacy and Safety Analysis Evaluating Oral Gepotidacin (GSK2140944) from a Phase IIA study in the Treatment of Uncomplicated Urinary Tract Infections |
| 1480 | Plasma and Urine Pharmacokinetic Analysis of Gepotidacin (GSK2140944) Following BID Oral Dosing in a Phase Ila Study for Treatment of Uncomplicated Urinary Tract Infections |
| 1481 | A Study for Risk factors of Acute Kidney Injury in Ureterosigmoid in a Tertiary Health Centre in South India |
| 1482 | Microbiological Analysis from a Phase II Study Evaluating Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections |
| 1483 | Comparison of Outcomes in Urinary Tract Infections Caused by SPICE Organisms Treated with non-Carbapenem-β-lactams versus non-β-lactams Agents |
| 1484 | Prevalence of Pyuria With and Without Bacteriuria in Healthy Pre-menopausal Women |
159. Poster Abstract Session

**Pediatric Bacterial Diseases: Diagnosis and Management**

Friday, 12:15 - 1:30 p.m.

1505 Shorter-Course Antibiotic Treatment for Pediatric Ventilator-Associated Tracheitis is Safe and Effective Outcomes of Standardized Neonatal Cephaloxin Dosing
1506 Pharmacodynamic target attainment of daptomycin against *Staphylococcus aureus* for treatment of pediatric osteomyelitis
1507 Carbapenem versus non-carbapenem as empiric regimens for bacteremia caused by ESBL producing *Escherichia coli* and *Klebsiella pneumoniae* in children: preliminary study
1508 Outcomes of Empirical Antimicrobial Therapy for Pediatric Community-Onset Febrile Urinary Tract Infection in the Era of Increasing Antimicrobial Resistance
1510 Improving the Management of Pediatric Complicated Pneumonia
1511 Effect of discharge antibiotic route on clinical outcomes in children with methicillin-resistant *Staphylococcus aureus* (MRSA) osteomyelitis with bacteremia
1512 Treatment of *Staphylococcus aureus* Bacteremia in a Pediatric Population: a Retrospective Cohort Analysis
1513 Management of Children with Blood Cultures (BC) Positive for Non-Pathogenic Organisms After the Introduction of Polymerase Chain Reaction (PCR) Technology
1514 Factors Associated with an Infectious Diseases Consultation for Pediatric *Staphylococcus aureus* bacteremia
1515 Distinguishing Kawasaki Disease Initially Presenting as Cervical Lymphadenopathy from Bacterial Cervical Lymphadenitis Using the Decision Tree Analysis

160. Poster Abstract Session

**Pediatric Bacterial Diseases: Epidemiology**

Friday, 12:15 - 1:30 p.m.

1516 Early Onset Neonatal Sepsis Due to *Haemophilus influenzae*
1517 Multidrug-Resistant *Escherichia coli* ST131 Late-Onset Neonatal Sepsis in Premature Twins Linked to Contaminated Maternal Frozen Breast Milk
1518 The Microbiology of Osteoarticular Infections in Patients with Sickle Hemoglobinopathies at Texas Children’s Hospital, 2011-2018
1519 Identification of *Neisseria meningitidis* (Nn) Nasopharyngeal Carriage among Non-Vaccinated Children and isolations in Invasive Disease (ID) cases in Argentina 2017.
1520 *Streptococcus anginosus* Group Organisms Are an Increasing Cause of Complicated Sinusitis and Otitis Media in Children
1521 Evaluation of the Microbiology of Intraabdominal Infections in Children and Implications for Treatment and Outcomes
1522 Clinical and Molecular Epidemiology of Invasive *Haemophilus influenzae* serotype a Infections in Utah Children
1523 Clinical Epidemiology of Children with Orbital Cellulitis
1524 Presentation of Acute Focal Bacterial Nephritis in Children
### Poster Abstract Sessions (continued)

| 1525 | Epidemiology, Management, and Outcomes of Skin and Soft Tissue Infections in Well-Appearing Infants less than 60 days of age |
| 1526 | Epidemiology of and Risk Factors for Nontyphoidal Salmonella Bacteremia in Children: A 20 year Retrospective Cohort |
| 1527 | Clinical variables associated with vancomycin resistance in children with bacteremia due to Enterococcus spp. |
| 1528 | Rates of Peripheral Blood Culture Contamination in an Urban Children’s Hospital |

**161. Poster Abstract Session**

**Pediatric Parainfectious Syndromes**

- Friday, 12:15 - 1:30 p.m.

| 1529 | Kawasaki Disease Shock Syndrome: Identifying Risks |
| 1530 | Parents’ Description of Febrile Episodes in Children Diagnosed with PFAPA |
| 1531 | A Twenty Three-Year Retrospective Study of Secondary Hemophagocytic Syndrome in a Pediatric Third Level Referral Center in Mexico City |

**162. Poster Abstract Session**

**PK/PD and Susceptibility Testing**

- Friday, 12:15 - 1:30 p.m.

| 1532 | Population Pharmacokinetic (PPK) Modeling and Simulation of Long-Acting (LA) Cabotegravir (CAB) to Inform Strategies following Dosing Interruptions in HIV-1 Infected Subjects |
| 1534 | Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for *P. aeruginosa, A. baumannii*, and *Enterobacteriaceae*: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST) |
| 1535 | Pharmacokinetic (PK) and Pharmacodynamic (PD) Evaluation of Cefepime (CPM) in Obese and Non-Obese Patients |
| 1536 | Population Pharmacokinetic Analysis of Baloxavir Morbixil, a Cap-dependent Endonuclease Inhibitor, in Adult and Adolescent Healthy Subjects and Influenza Patients and Exposure-Response Relationships in the Patients at High-Risk of Influenza Complications |
| 1537 | Multicenter Study with Therapeutic Drug Monitoring (TDM) of Voriconazole (VRCZ) in Japanese Patients |
| 1538 | Who will benefit from therapeutic drug monitoring of ganciclovir? |
| 1539 | Dalbavancin, Vancomycin, and Daptomycin alone and in combination with Cefazolin against Vancomycin Intermediate Resistant (VISA) and Daptomycin Non-Susceptible (DNS) *Staphylococcus aureus* |
| 1540 | A Population Pharmacokinetic Model for Vancomycin in Korean Patients Receiving Extracorporeal Membrane Oxygenation Therapy: A Prospective Study |
| 1541 | A Novel and Fast Liquid Chromatography Method for Determination of Fluoroquinolones in Human Plasma |
| 1542 | The Evaluation of the *In-vitro* Synergy of Colistin in Combination with Meropenem and Tigecycline against 50 Multi-drug Resistant *Acinetobacter baumannii* strains |
| 1543 | Ceftrazoline Model Based Dose Individualization in an Infant with Kidney Disease and Mediastinitis |
| 1544 | Efficacy of Human-Simulated Cefiderocol Exposure Against Gram-Negative Bacteria in an Iron-Overloaded Murine Thigh Infection Model |
| 1545 | Development of a Linear Mixed-Effect Pharmacodynamic Model to Quantify the Effects of Frequently Prescribed Antimicrobials on QT Interval Prolongation in Hospitalized Patients |
| 1546 | Efficacy of Daptomycin Combinations against Daptomycin Resistant *Enterococcus faecium* Differs by β-lactam |
| 1547 | Modeling Pharmacokinetics and Pharmacodynamics of Meropenem Utilizing a Novel Infusion Method of Bolus to Prolonged Infusion |
| 1548 | Characterizing Cefepime Neurotoxicity: Experience from a Tertiary Care Center Performing Beta-lactam Therapeutic Drug Monitoring |
| 1549 | Impact of New Fluoroquinolone Breakpoints on *Enterobacteriaceae* Susceptibility Rates and Clinical Outcomes |
| 1550 | PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models |
| 1551 | Systemic Tobramycin Absorption Resulting from Antibiotic-Impregnated Cement Spacers for the Treatment of Prosthetic Joint Infection |
| 1552 | Correlation between vancomycin serum trough concentrations and area under the curve in pediatric patients |
| 1553 | Human-Simulated Pharmacokinetic Profiles of Cefiderocol and Meropenem are Conserved in Murine Models of Thigh Infection With or Without Iron Overload |
| 1554 | Nebulized Liposomal Amphotericin B for Treatment of Murine Pulmonary Mucormycosis |
| 1555 | Risk of Developing Acute Kidney Injury in Patients Receiving Piperacillin-Tazobactam and Vancomycin Compared to Those on Piperacillin-Tazobactam and Telavancin |
| 1556 | Assessment of Translational In Vitro and Animal Pharmacokinetic-Pharmacodynamic Data Used to Support Drug Development of Recent Tetracycline Derivatives |
| 1557 | Population Pharmacokinetics of Suvratoxumab (MEDI4893), An Extended Half-life *Staphylococcus aureus* Alpha Toxin-neutralizing Human Monoclonal Antibody, in Healthy Adults and Patients on Mechanical Ventilation in Intensive Care Units |
| 1558 | A Population Pharmacokinetic Model for Posaconazole Intravenous Solution and Oral Powder for Suspension Formulations in Pediatric Patients With Neutropenia |
| 1559 | Ertapenem Plus Ceftriaxone or Ceftaroline Dual Beta-Lactam Combination for *Enterococcus faecalis* |
| 1560 | Pharmacokinetics-Pharmacodynamics (PK-PD) of Gepotidacin (GEP) Against *Escherichia coli* in Murine Pyelonephritis and Thigh Infection Models |
| 1561 | Omadacycline Pharmacokinetics: Influence of Mortality Risk Score Among Patients with Community-Acquired Bacterial Pneumonia |
| 1562 | Safety and Efficacy of High-Dose Cefazolin Therapy in Obesity |
Poster Abstract Sessions (continued)

1563 Population Pharmacokinetics and Pharmacodynamics of Daily and Extended Interval Dalbavancin Dosing Regimens for Salvage Therapy of *Staphylococcus aureus* Endocarditis: Mechanistic Modelling of Rabbit Infection Data to Support Human Dosing Regimens

1564 Target Attainment of Empiric Vancomycin Therapy to Achieve Safe and Effective Exposure When it Matters Most: How Much of the Drug Do We Really Need in the First 48 Hours?

1565 Characterization of Tebipenem (SPR859) Pharmacokinetics-Pharmacodynamics (PK-PD) for Efficacy Against Enterobacteriaceae in a One-Compartment In Vitro Infection Model

1566 Population Pharmacokinetics of Voriconazole: Serum Albumin Status As a Novel Marker Of Clearance and Dosage Optimization.

1567 Pharmacokinetic/Pharmacodynamic Target Attainment in Adult and Pediatric Patients following Administration of Ceftaroline Fosamil as a 5-Minute Infusion

1568 The Pharmacodynamic-Toxicodynamic Relationship of AUC and CMAX in Vancomycin Induced Kidney Injury

1569 A Translational Model to Assess the Impact of Polymyxin B Dose Fractionation on Kidney Injury

1570 Association Between Vancomycin Area Under the Curve (AUC) and Nephrotoxicity

1571 Evaluation of a Single Post First Dose Vancomycin Level to Achieve a Goal Vancomycin AUC

1572 Evaluation of Vancomycin Levels Following Weight-based Pre-operative and Re-warming Vancomycin Dosing in Cardiac Surgery

1573 Population Pharmacokinetic Analyses for Cefepime in Adult and Pediatric Patients

1574 Predictive ability and bias of vancomycin population PK models in an obese adult population

1575 Vancomycin Loading Doses and Nephrotoxicity on Medicine Teaching Services

1576 Delaying the Start of Maintenance Vancomycin After a Loading Dose to Avoid a High 0-24h AUC

1577 Particle Characterization of Nebulized Liposomal Amphotericin B and Its Use in the Treatment of Murine Pulmonary Aspergillosis

1579 Multidrug-resistant *Candida auris* isolates from New York Hospitals and Healthcare Facilities are Susceptible to Antifungal Combinations

1580 Colistin potentiates the in vitro activity of meropenem-vaborbactam (M/V) against some, but not all KPC-producing *Klebsiella pneumoniae* (KPC-Kp)

1581 Comparative in vitro Activity of Ceftolozane/tazobactam and Comparator Agents Against *Enterobacteriaceae and Pseudomonas Aeruginosa* Clinical Isolates in Colombia


1583 Eight Years of Sustained Potency and Activity of Oritavancin against Gram-Positive Isolates Causing Bacteremia and Endocarditis in the USA, including Enterococcal Infections Requiring an Optimized Dosing Strategy for Daptomycin

1584 Minocycline Activity against *Stenotrophomonas maltophilia* isolated from Patients in US Hospitals

1585 Isavuconazonium Sulfate plus Micafungin Improves Survival in an Immunocompromised Murine Model of Disseminated Fusariosis

1586 *In vitro* Activity of Rifampin, Rifabutin, Rifapentine and Rifaximin against Biofilms Formed by Staphylococci Isolated from Prosthetic Joint Infection

1587 Comparative in vitro antipseudomonal activity of ceftolozane/tazobactam against *Pseudomonas aeruginosa* isolates from children with cystic fibrosis

1588 Delafoxacin Activity against *Staphylococcus aureus* with Reduced Susceptibility or Resistance to Methicillin, Vancomycin, Daptomycin or Linezolid.

1589 Ceftolozane-Tazobactam Activity against Difficult-to-Treat Resistance in *Pseudomonas aeruginosa* from Bloodstream Infections in US Hospitals

1590 Updated Aminoglycoside (AG) MIC Breakpoints (BP) to Minimize Adverse Events and Improve Outcome: Impact on Susceptibility (S) Rates

1591 Updated Fluoroquinolone MIC Breakpoints: Impact on Susceptibility Rates in the United States

1592 *In vitro* Activity of Ceftolozane/Tazobactam (C/T) Against *Enterobacteriaceae and Pseudomonas aeruginosa* Circulating in Chile: Analysis of Hospital Antimicrobial Susceptibility Test Results for Patterns of Antibiotic Resistance

1593 *Ceftriaxone* Demonstrates Higher In vitro Susceptibility than Ceftazidime-avibactam Against *Pseudomonas aeruginosa* Isolated from Respiratory Tract of Adult Cystic Fibrosis Patients

1595 Comparative *In Vitro* Activity of Imipenem-Relebactam against drug-resistant Gram Negative Isolates from Pediatric Patients

1596 Impact of Vancomycin Area Under Curve on Persistent Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bloodstream Infections (BSI)

1597 Evaluation of Ceftaroline Resistance (CPT-R) in Chile Across Time and a Comparison of CLSI vs. EUCAST Breakpoints in Methicillin-Resistant *Staphylococcus aureus* (MRSA)

1598 Antimicrobial Activity of the Novel β-Lactam Enhancer Combination Cefepime-Zidebactam (WCK-5222) Tested against Gram-Negative Bacteria Isolated in United States Medical Centers from Patients with Bloodstream Infections

1599 AUC24 vancomycin Bayesian-based dosing: Increasing therapeutic target attainment with decreased TDM cost

1600 Susceptibility of Beta-Lactam-Resistant *Pseudomonas aeruginosa* to Other Beta-Lactams: Is There Truly a Lack of Cross-Resistance?

1601 Evaluation of synergy with β-lactams plus aztreonam against *Pseudomonas aeruginosa* (PSA)

1602 Antibiotic Resistance Patterns of Clinical *Escherichia coli* Urinary Isolates by Outpatient Practice Type

163. Poster Abstract Session

**Public Health**

Friday, 12:15 - 1:30 p.m.

1603 Observation of Treatment Outcomes During an Outbreak of Multidrug-Resistant *Shigella sonnei* Infections in a Retirement Community—Vermont, 2018

1604 Response to a Cluster of *Haemophilus influenzae* Serotype A Cases in a Small Alaska Community, 2018
1605 Temperature modulates the rate of increase of antibiotic resistance across Europe
1606 Legionellosis Cluster Associated with Direct and Indirect Hot Tub Exposure — West Virginia, 2018
1607 Temporal Patterns and Spatial Synchrony in Pertussis Incidence — United States, 2000–2017
1608 Use of selective reporting of antimicrobial susceptibilities and its impact on antimicrobial resistance surveillance — National Healthcare Safety Network, 2017–2018
1609 Using a novel rapid test to investigate a multistate outbreak of coccidioidomycosis among U.S. residents returning from mission trips in Baja California, Mexico, June–July, 2018
1610 Implementation of Clinical Care Pathway Reduces Measles Exposures During Outbreak in New York
1611 Interventions to Decrease the Absolute Number of Individuals Not Immune to Measles at Princeton University (PU)
1612 Listeriosis in Mainland China: a Systematic Review
1613 Rates of Hospitalization for Community-Acquired Pneumonia among US Adults: A Systematic Review
1615 Influenza Outbreaks in Long-Term Care Facilities, 2017-2018 Influenza Season, Dallas, Texas
1616 Confronting Measles: The View from a New York City Health System at the Center of the Outbreak
1617 Mumps in Detention Facilities that House Detained Migrants — United States, September 2018–April 2019
1618 Public Health at the US/Mexico Border: Evaluation of the County of San Diego Health and Human Services Agency’s Health Screening Assessment of Asylum-Seeking Families at the San Diego Rapid Response Network Shelter
1619 Carbapenemase Producing Enterobacteriaceae in River Estuaries and Coastal Water of Netanya, Israel
1620 Effectiveness of the 2016 California Policy Eliminating Non-Medical Exemptions on Vaccine Coverage: A Synthetic Control Analysis
1621 Acute Cardiovascular Events Among Adults Hospitalized with Influenza, FluSurv-NET, 2010-2018
1622 Clinical and Environmental surveillance of Legionella pneumophila in a Tertiary Health care Center in India
1623 Implementation of Electronic Readmission Alert For Discharged Patients Reduces Risk of Secondary Measles Exposure Events
1624 Primary care physician knowledge, attitudes, and diagnostic testing practices for norovirus and acute gastroenteritis
1625 Risk of invasive group A Streptococcus, group B Streptococcus, and Streptococcus pneumoniae infection among adults experiencing homelessness— Anchorage, Alaska, 2002–2015
1626 A Primary Amebic Meningoencephalitis Case Associated with Surfing in an Inland Surf Park
1627 Outbreaks of Klebsiella pneumoniae in Special Care Nurseries (SCN) in Jamaica: Role of Whole Genome Sequencing
1628 Clinical, Epidemiological and Microbiological Characterization of Invasive Streptococcus pneumoniae Disease in Hospitalized Adults from 5 Tertiary Hospitals in Bogotá, Colombia: A Descriptive Study
1629 Herpes Zoster Risk in Immunocompromised Adults in the US: A Systematic Review
1631 Association between Type-specific Influenza Circulation and Incidence of Severe Laboratory-confirmed Cases; Which Subtype is the most Virulent?
1632 Different Health Care Utilization Pattern in Vaccine Hesitant Children
1634 A mobile application for management and surveillance of vector-borne diseases in Cali, Colombia: an evaluation of usability and acceptability in a hospital setting
1635 Analysis of Antibiotic-Related Malpractice Claims, 2007 to 2016
1637 Antibiotic Use in Lower Respiratory Tract Infections: Insights From Patient Interviews in Sri Lanka
1638 Measles Outbreak Risk Assessment for Transplant Candidates and Recipients
1639 Outbreak of Human Bartonellosis due to Bartonella bacilliformis in the Ecuadorian Andes.
1640 Pertussis Testing in the Department of Veterans Affairs, 2010-2018
1641 A Comparison of Human Papilloma Virus Infection Prevalence Trends Pre and Post-HPV Vaccine Implementation
1642 Comparing Viral Respiratory Infections Between Children Who Do and Do Not Attend Child Care
1643 Infectious Sequelae of Injection Drug Use at a County Safety-Net Hospital Decline Following Establishment of a Syringe Service Program
1644 Performance of Symptom-Based Case Definitions to Identify Influenza Virus Infection among Pregnant Women in Middle-Income Countries: Findings from the Pregnancy and Influenza Multinational Epidemiologic (PRIME) Study
1645 High Seroprevalence and Seroconversion Rate of Borrelia burgdorferi Infection Among Hispanic/Latino Immigrant Workers in Eastern Suffolk County, New York: A Longitudinal-Based Study
1646 Education Level is Associated with Tetanus Vaccine Coverage: Results from the 2016 BRFSS
1647 Investigating Parents’ Vaccine Hesitancy in the United Arab Emirates: A Cross-Sectional Survey
1648 Prevalence of Orientia tsutsugamushi, Anaplasma phagocytophilum, and Leptospira interrogans in striped field mice in Gwangju, Republic of Korea
1649 That’s not cricket! Outbreak of Legionella pneumophila (L. pneumophila) in a community cricket club in the UK, 2018: challenges in Legionella control in this setting
1650 Knowledge and attitudes towards Influenza Vaccination among Hispanics. A Survey Conducted in Latin American Consulates in South Florida
1651 The Impact of the 2017-2018 Influenza Season on Acute Care Hospitals in the United States: A Qualitative Evaluation of Immediate Responses and Future Preparedness
1652  Equivalent HIV Outcomes for Persons with HIV after Re-engagement in HIV care with Prior or New Provider
1653  Strong Partnership and Effective Communication between a Tertiary Hospital and a County Health Department were Critical in Controlling a 2019 Measles Outbreak in Southeast Michigan (SEM)
1654  Chickenpox Outbreak in a Tribal District Rayagada, Odisha, India: Warrants Need for Vaccination

164. Poster Abstract Session
Stepping off your Doorstep - Global Health
Friday, 12:15 - 1:30 p.m.

1655  Performance of Molecular and Serologic Tests for the Diagnosis of Scrub Typhus
1656  Klebsiella pneumoniae antimicrobial susceptibility to carbapenems in Latin America between 2000 and 2014
1657  Notes from the Field: A Survey of Mobile Device Usage among Individuals in KwaZulu-Natal, South Africa
1658  Lipase and factor V (but not viral load) are prognostic factors for the evolution of severe Yellow Fever cases
1659  Electronic Consultations Combined with a Video Supported Powerpoint Based Pre-Travel Education is Equivalent to In-Clinic Face-To-Face Pre-Travel Consultations in Appropriately Selected Travelers
1660  Protective effect of living with animals on diarrheal illness among children younger than five in sub-Saharan Africa and South Asia
1661  Using Social Media to Enhance an STI Screening Program in Wuhan, China
1662  Pushing the Dose: Miltfosine Treatment for a Supersized American with Cutaneous Leishmaniasis
1663  Community Engagement for Ebola Prevention in Eastern Democratic Republic of Congo
1664  Maternal Hookworm Infection and its Effect on Maternal/Child Health: A Systematic Review and Meta-Analysis
1665  The Cascade of Care for the Strong Hearts Chagas Disease Screening and Treatment Program in East Boston, Massachusetts
1666  Community Beliefs about Ebola and Implications for Disease Control in Eastern Democratic Republic of the Congo
1667  Influenza A and B Co-Circulation and Burden: A 2018-2019 Influenza Season Analysis Using the National Active Surveillance Database in Mexico
1668  No Impact of Nutritional Status on Oral Polio Vaccine shedding after Vaccination of Under 5 Children in Rural Mexico
1669  Trends in Authorship for Infectious Disease Research Conducted in Low-Income Countries
1670  Access to Antibiotics Without Prescription for Travelers and Colombian Citizens at Community Pharmacies in Bogotá, Colombia: a Cross-Sectional Study
1671  Impact of Zika Syndrome on Brazilian Infant Mortality Rate
1672  Imported enteric fever in an ethnically diverse area of London
1673  Gendered patterns of HIV, TB, and other primary care referrals in rural South Africa
1674  Orthopedic Complications of Congenital Zika Syndrome in Brazil
1675  Implementation of Electronic Travel History Screening at an Urban Medical Center

1676  Incidence and Outcomes of Pulmonary Involvement in Patients with Scrub Typhus: a Clinical Study from India
1677  Prevalence and Patterns of Outpatient Antibiotic Prescription at a Public Tertiary Medical Center in Southern Province, Sri Lanka
1678  Assessing Performance of Multiple Methods for Measurement of Body Temperature, Bangladesh
1679  Brucellosis in rural Narok County, Kenya: A Retrospective Review
1680  Guillain Barré Syndrome in Arbovirus Outbreak in Veracruz, Mexico. Follow-up to 3 years of the pandemic.
1681  Assessment of the Impact of Infectious Events in a Cohort of Pediatric Leukemia Patients in the Dominican Republic
1682  Dengue Fever Outbreak Investigation in Upper Egypt in 2015
1683  Empathy Scale Validation Among Expectant Seroconcordant Couples Enrolled in HIV Care and Treatment in Zambézia Province, Mozambique
1684  Clinical Profile and outcome of Scrub Typhus related Acute Respiratory Distress Syndrome in adults presenting to a tertiary care hospital in north India.
1685  Retrospective Analysis of Strongyloides Hyperinfection-Dissemination Syndrome Risk Factors in a County Hospital
1686  Maternal Knowledge and Perceptions about Routine Immunization in a Slum Area of Pakistan

165. Poster Abstract Session
Mycology
Friday, 12:15 - 1:30 p.m.

1687  High-rates of Candida auris carriage and Co-colonization with Multidrug Resistant Organisms (MDROs)
1688  Invasive Ocular Candidiasis: Who is Really at Risk?
1689  Active, Invasive Fungal Infection and Hematopoietic Cell Transplantation (HCT) in Chronic Granulomatous Disease (CGD): Presentation, Procedure and Outcomes
1690  Risk factors of Invasive Aspergillosis in Systemic Lupus Erythematosus Patients
1691  Cryptococcus Species other than C. neoformans and C. gattii: Are they Clinically Significant?
1692  Epidemiology, clinical characteristics and outcomes of Candidemia in a tertiary hospital in the Dominican Republic
1693  Risk factors associated with mortality of Invasive Aspergillosis in King Chulalongkorn Memorial Hospital
1694  Predictors of septic shock in adult patients with candidemia : a single center experience over 13 years
1695  Clinical and Microbiological Characterization of Candida parapsilosis complex Infection in a Tertiary Care Hospital from Cali, Colombia.
1696  Epidemiology, clinical characteristics and outcomes of invasive aspergillosis in a tertiary care hospital in Mexico
1697  Comparison of Candidemia in Patients in Neonatal Intensive Care Unit and Pediatric Patients and Big Data Analysis on Candidiasis and Candidemia in Korean Children
1698  Epidemiology and antifungal susceptibility of candidemia among adult patients at a tertiary care hospital in South Korea during an 8-year period
1699  Presentations and Outcomes of Histoplasma Capsulatum Infection Vary by Immune Status: A Retrospective Cohort Study
1700 A Rare Case of Candida Glabrata Hemorrhagic Cystitis with Empagliflozin Use

1701 Differences in Diagnostic Performance of Beta-D-glucan Testing in Patients with Varying Degrees of Susceptibility to Invasive Fungal Infections

1702 Prevalence and risk factors for endogenous fungal endophthalmitis in adult patients with candidemia at a tertiary care hospital in South Korea over 13 years

1703 Bacterial or Fungal Co-Infection in Patients with Mucormycosis

1704 Geotrichum spp invasive infection: experience from a third level referral centre in Mexico

1705 Clinical Characteristics and Outcomes of Cryptococcosis in a Tertiary Care Center in Kentucky, 2005 to 2017

1706 Use of Management Bundles as a Checklist for Candidemia: Impact of Compliance on Clinical Outcomes in a Multicenter Study in Japan

1707 Invasive Pulmonary Aspergillosis in Patients with Severe Fever with Thrombocytopenia Syndrome

1708 Epidemiology of Coccidioidomycosis-associated Hospitalizations and In-hospital Deaths, California, 2000–2017

1709 Epidemiology of Invasive Fungal Infection (IFI) after Severe Influenza Requiring Intensive Care Unit (ICU) Admission: Ten year experience at a Tertiary Care Center in the United States (US)

1710 Profiling Patients with Rare Mucormycosis Infections Using Real World Data

1711 Histoplasmosis-associated hemophagocytic lymphohistiocytosis: a case series and review of the literature

1712 Candida auris: A Case Series at a Large Tertiary Care Medical System

1713 Impact of False Positive Low Titer Cryptococcal Antigen Testing

1714 Testing a novel clinical surveillance case definition for invasive mold infections


1716 Baseline Serum C-reactive Protein Level Predicts Mortality in Coccidioidomycosis Meningitis

1717 Cryptococcal meningitis: a comparison of clinical features and outcomes by HIV status

1718 The Natural History of Chronic Pulmonary Coccidioidomycosis in the Pre-Antifungal Era

1719 Incidence and Characterization of Invasive Fungal Infections (IFIs) in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib (IBR)

1720 Isolation and Characterization of Candida auris From an Active Surveillance System in Texas

1721 A Transcriptional Signature of Acute Aspergillus Infection Offers High Diagnostic Accuracy Despite the Presence of Immunosuppression

1722 Histoplasmosis acquired in Alberta, Canada, 2011-2018

1723 Human serum albumin regulates the growth of Candida auris in vitro

1724 Plasmid-free CRISPR-Cas9 System for Genetic Engineering of Rhizopus delemar

1725 Shear Forces Induce a Transient, Calcineurin-Dependent Hyper-Virulent Phenotype in Mucorales via Soluble Factors

1726 Candida albicans virulence genes induced during intra-abdominal candidiasis (IAC) in the absence of antifungal exposure mediate echinocandin resistance

1727 Candida albicans phosphatidylinositol-(4,5)-bisphosphate (PIP2) directs aberrant cytokinesis and septation in response to echinocandins, which correlates with fungicidal activity and attenuated virulence

1728 A Retrospective Analysis of 49 Cases of Histoplasmosis in Inflammatory Bowel Disease Patients on Tumor Necrosis Factor-α Antagonists

1729 Profiling human neutrophil functional responses from solid organ and stem cell transplant recipients to Candida albicans

1730 Invasive Fusarium Species in Mayo Clinic Patients with Hematologic Malignancies

1731 Immune dysregulation in Mucormycosis

1732 A Canine Target Species Challenge Model to Evaluate Efficacy of a Coccidioidomycosis Vaccine

166. Poster Abstract Session

Transplant ID: Fungal

Friday, 12:15 - 1:30 p.m.

1733 Voriconazole Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplant: How Much is Enough, Are Low Voriconazole Levels Associated With Opportunistic Infections, and What Are the Reasons for Discontinuation?

1734 Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation. A Single Centre Experience in Colombia.

1735 Epidemiology of Invasive Fungal Infections During Induction Chemotherapy in Adults With Newly Diagnosed Acute Myeloid Leukemia Without Antifungal Prophylaxis: A Retrospective Cohort Study

1736 Evaluation of targeted vs. universal antifungal prophylaxis (AP) for invasive fungal infections (IFI) after lung transplant (LTx)

1737 Impact of Therapeutic Drug Monitoring (TDM) of Azole Prophylaxis in Lung Transplant Recipients on the Development of Positive Fungal Events.

1738 Incidence and Outcomes of Hospitalization with Invasive Fungal Infection among Solid Organ Transplant Recipients: A population-based cohort study

1739 Epidemiology of Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplant Recipients in Utah

1740 Title: Outcomes of a Clinical Algorithm for the Early Diagnosis and Treatment of Invasive Fungal Sinusitis among Children with Hematologic Malignancy or Prior Hematopoietic Stem Cell Transplantation

1741 Invasive Fungal Infections in Patients with Multiple Myeloma in the Era of Novel Therapies

167. Poster Abstract Session

Transplant ID: CMV

Friday, 12:15 - 1:30 p.m.

1742 Kinetics of CMV Viremia with Letermovir Prophylaxis in the First 100 Days post Hematopoietic Cell Transplantation (HCT): A Single Center Experience.
Poster Abstract Sessions (continued)

1743 Impact of Cytomegalovirus Serostatus on Allograft Loss and Mortality within the First Year after Kidney Transplantation: An Analysis of the National Transplant Registry

1744 CMV Infection and Management Among Pediatric Solid Organ Transplant Recipients

1745 Retrospective Cohort Analysis to Determine the Incidence of CMV Infection and Disease in Allogeneic Hematopoietic Cell Transplant Recipients at an Academic Children's Hospital.

1746 Prevalence and Resistance Patterns of Cytomegalovirus Viremia in Immunocompromised Patients

1747 Impact of Inappropriately Low Cytomegalovirus (CMV) Prophylaxis Dosing on CMV Outcomes Among Lung Transplant (LT) Recipients

1748 Incidence of Cytomegalovirus Disease and Viral Replication Kinetics in Intermediate Risk Liver Transplant Recipients Managed according to a Preemptive Therapy Algorithm

1749 A nationwide survey of cytomegalovirus prevention strategies in kidney transplant recipients in a resource-limited setting

1750 Epidemiology of Cytomegalovirus DNAemia in Pediatric Solid Organ Transplant Patients

1751 The Impact of Prophylactic Systemic Antibiotics (PSA) on Cytomegalovirus (CMV) Infection: A Post-hoc analysis of a Randomized Controlled Trial (RCT) in Hematopoietic Cell Transplantation (HCT) Recipients.

1752 Differential Degree and Duration of Cytomegalovirus (CMV) Viremia between WHO International Standard-Calibrated Quantitative CMV Nucleic Acid Tests: Implications for Clinical Care

168. Poster Abstract Session

Transplant ID: Vaccines

Friday, 12:15 - 1:30 p.m.

1753 Adherence and Immunogenicity of Early Vaccination in Pediatric Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Recipients

1754 Pre-Transplant Vaccination Rates in Solid Organ Transplant Recipients

1755 Assessment of Vaccine Rates in Solid Organ Transplant Recipients and Identification of factors Associated with Completion of Vaccination

169. Poster Abstract Session

Transplant ID: Viral, Mycoplasma/Ureaplasma Infections

Friday, 12:15 - 1:30 p.m.

1756 Role of Human Bocavirus Respiratory Tract Infection in Hematopoietic Cell Transplant Recipients

1757 Hepatitis C-Infected Donors and Hepatitis C-Infected Recipients: Analysis of Renal Transplant Outcomes

1758 Epidemiology of Invasive Mycoplasma and Ureaplasma Infections Early after Lung Transplantation

1759 Incidence of Hospitalizations and Emergency Department Visits for Herpes Zoster in Immunocompromised and Immunocompetent Adults in Ontario, Canada, 2002-2016

1760 Outcomes of acyclovir-resistant herpes simplex virus infections in hematologic malignancies and hematopoietic cell transplant recipients

1761 A Single Center Experience with Cidofovir for the treatment of double stranded (ds) DNA viruses in Hematopoietic Cell Transplant (HCT) recipients.

1762 Genotype Prevalence and Molecular Characteristics of Human Adenovirus in Pediatric Hematopoietic Stem Cell Transplant Recipients

1763 The Use of Haploidentical Donors Compared to HLA-Matched Unrelated Donors is Associated with Increased Risk of BK Viruria and Hemorrhagic Cystitis

1764 Use of Intravesical BCG for ‘treatment of Bladder Cancer in a Renal Transplant Recipient, with Subsequent Resolution of Chronic BK Viremia

1765 BK Polyomavirus Reactivation Outcomes After Renal Transplantation in Association With Adherence to a Standardized BK Polyomavirus Screening Protocol: A Multi-Center Collaboration

1766 Osimertinib Associated Progressive Multifocal Leuкоencephalopathy

1767 Incidence of Respiratory Syncytial Virus Infection among Adults Undergoing Hematopoietic Stem Cell Transplantation: A Prospective Study from India

1768 Dengue Virus Infection in Solid Organ Transplant Recipients. Case Series and Literature Review

1769 The Impact of Checkpoint Inhibitor Immunotherapy on Infections in Lung Cancer Patients

1770 Access to Kidney Transplantation in Persons Living with HIV and End Stage Renal Disease in Network 6.

1771 Donor-derived Ureaplasma infection increases mortality in lung transplant recipients

170. Poster Abstract Session

Viral Diagnostics

Friday, 12:15 - 1:30 p.m.

1772 Factors that influence viral load in patients infected with influenza over multiple seasons

1773 Development and Evaluation of an Automated Adenovirus Quantitative Assay Using the Lumexx ARIES® System

1774 Impact of a Multiplex Polymerase Chain Reaction Assay on the Clinical Management of Adults Undergoing a Lumbar Puncture for Suspected Community-Onset Central Nervous System Infections

1775 A community wide study to evaluate the accuracy of self-testing for influenza: Works in Progress

1776 Step-Wise Algorithm for the Detection of Respiratory Viruses: Integrating a Rapid Influenza A/B and RSV PCR with a Multiplex Respiratory Virus Panel to Target High-Risk Patient Populations

1777 Metagenomic Approach for the Detection of Viruses in Stool Samples from Infants and Children with Acute Gastroenteritis in Kuwait

1778 Epstein-Barr Virus Genetic Diversity: Evaluation of BZLF1 Variants among Bone Marrow Transplant Patients and Individuals with Infectious Mononucleosis

1779 Comparison of Two Zika IgM Antibody Capture Enzyme Linked Immunosorbent Assays (MAC-ELISA) in Symptomatic Patients from Dominican Republic, 2016

188 • Final Program IDWeek 2019
Poster Abstract Sessions (continued)

1780 Congenital Cytomegalovirus: What Are the Rates of Maternal Screening, Diagnostic Amnioncentesis, and Elective Termination?
1781 Assessing the Utility of First-contact Serum Ferritin as an Augur of Severe Thrombocytopenia in Dengue Fever
1782 Real-World HIV Diagnostic Testing Patterns in the United States
1783 More than Which Molecular Test: Following the Directions in How and Who to Test in the Diagnosis of Influenza
1784 The Value of a Systematic Screening of Influenza Virus and Vaccination on Emergent Admissions to a Cardiac Intensive Care Unit (C-ICU)
1785 Dengue Outbreaks and Predominant Circulating Virus Serotypes and Genotypes over More Than Two Decades in a Hyper-endemic Region
1786 An Automated Method to Assess Oligonucleotide Primer and Probe Complementarity to Genomic Targets in Infectious Disease qPCR Assays
1787 The Effects of a Systemwide Diagnostic Stewardship Change on West Nile Virus Disease Ordering Practices
1788 The Utility of Next-Generation Sequencing for Detection of Candidate Pathogens in Bronchoalveolar Lavage Fluid from Pediatric Patients with Respiratory Failure
1789 Frequency of chikungunya, dengue and Zika virus in acute febrile illness in paired urine and serum samples in Mexico.
1790 Single centre experience and lessons learnt from management of Nipah virus outbreak in India
1791 Novel Metabolomics Approach for the Diagnosis of Respiratory Viruses Directly from Nasopharyngeal Specimens
1792 Viral DNA loads in various blood components of patients with EBV-positive T/NK cell lymphoproliferative diseases
1793 Clinical Outcomes among Febrile Infants Before and After Implementation of BioFire® FilmArray® Panels

234. Poster Abstract Session
Antibiotic Stewardship: C. difficile
Saturday, 12:15 - 1:30 p.m.
1982 A Diagnostic Stewardship Intervention for Clostridiodes difficile: Impact of Stool Toxin Testing on Treatment of Adult Inpatients
1983 Adherence versus Non-adherence: Clinical Outcomes of an Antimicrobial Stewardship Directed Treatment Protocol for Clostridiodes difficile Infection
1984 A Multi-Disciplinary Team-based Quality Improvement Initiative to Reduce Clostridiodes difficile Rates and Promote Antimicrobial Stewardship in Targeted Surgical Wards
1985 Impact of suppressing ciprofloxacin susceptibility results on antibiotic utilization and hospital-acquired Clostridiodes difficile infection
1986 Impact of Two-Step Testing on the Diagnosis and Management of Clostridium difficile in a Multi-Hospital Healthcare System
1987 Impact of Updated IDSA Clostridium difficile Guidelines on the use of Fidaxomicin in a Large Health System
1988 Impact of a Novel Pharmacist Practice Model on Antimicrobial Usage and Hospital-acquired Clostridium difficile (HACDI) Rates
1989 Impact of Pharmacist-Led β-Lactam Allergy Clarification Interview on Optimizing Preoperative Antibiotic Prophylaxis
1990 A Strategy of Mandatory Infectious Disease Consultations on Hospital-Acquired Clostridium difficile Infection and Antimicrobial Utilization

235. Poster Abstract Session
Antibiotic Stewardship: Diagnostics and Diagnostic Stewardship
Saturday, 12:15 - 1:30 p.m.
1992 Initial Procalcitonin Level and Antibiotic Practice Patterns Among Patients with Acute Respiratory Infections
1993 Impact of Pharmacist Intervention in Response to Rapid Molecular Testing Results of Blood Cultures
1994 Impact of Pharmacist-initiated MRSA Nasal PCR Protocol on Pneumonia Therapy in a Community Teaching Hospital
1995 Serial procalcitonin measurement in a community intensive care unit: is there value in the setting of an established antibiotic stewardship program?
1996 Enteric Multiplex PCR Testing: Antimicrobial Stewardship Friend or Foe
1997 Real-World Impact of Accelerate Pheno Implementation with Antimicrobial Stewardship Intervention
1998 Impact of Rapid Blood Culture Identification with Real-Time Antimicrobial Stewardship (ASP) in Patients with Staphylococcus aureus (S. aureus) and Enterococcus Spp. Bacteremia at a Large Academic Medical Center
1999 Does Pharmacist-Driven Methicillin-Resistant Staphylococcus aureus PCR Nasal Screening Decrease Time to De-Escalation of MRSA Coverage in Patients with Pneumonia?
Poster Abstract Sessions (continued)

2000 Utilization of a ‘Never Event’ Framework to Classify Antimicrobial Appropriateness
2001 Assessment of Real-World Effectiveness of a Rapid Blood Culture Diagnostic Panel at a Veterans Affairs Medical Center
2002 BioFire®FilmArray® Pneumonia Panel: A Powerful Rapid Diagnostic Test for Antimicrobial Stewardship
2003 Vancomycin Discontinuation is Supported by Negative Nasal Methicillin-Resistant Staphylococcus aureus (MRSA) in Patients with Pneumonia
2004 Impact of procalcitonin roll-out without antimicrobial stewardship guidance in a community hospital emergency department
2005 Successful Implementation of a Procalcitonin Algorithm Associated with Reduction in Antibiotic Days
2006 Evaluation of Rapid Blood Culture Identification with Antimicrobial Stewardship Treatment Recommendations at a Community Health System in Patients with Gram-negative Bacteremia: Adequacy, Adherence, and Outcomes
2007 Impact of Combining Rapid Diagnostics with an Interpretation Guide on Vancomycin Usage for Contaminant Blood Cultures Growing Coagulase-Negative Staphylococci (CoNS)
2008 Outcomes of Patients with Positive Procalcitonin Levels Who Do Not Receive Continued Antibiotics
2009 Evaluation of Time to Organism Identification and Pharmacist Impact on Antibiotic Prescribing through Utilization of MALDI-TOF at Two Community, Teaching Hospitals
2010 A Significant Reduction in Empiric Vancomycin Days of Therapy for Suspected MRSA Pneumonia in Adult Non-ICU Patients After Implementation of a Rapid MRSA Nasal PCR Test with Antimicrobial Stewardship Intervention
2011 Reaction of clinicians to positive respiratory viral panels in non-critically ill patients without bacterial infection
2012 Trends in Microbiological Culture Collection across Veterans Affairs Medical Centers and Community Living Centers, 2010 to 2017
2013 Blood Culture Contamination in the Emergency Department: A Risk Factor Analysis
2014 Assessment of Cost, Morbidity and Mortality Associated with Blood Culture Contamination
2015 Minimal Impact of Blood Culture Contaminants on Patient Care Decisions May Limit Cost-Effectiveness of Interventions to Reduce Contamination Rates

236. Poster Abstract Session
Antibiotic Stewardship: Global
Saturday, 12:15 - 1:30 p.m.

2016 Antibiotic Misuse of Rural Residents and Pilot Project of Antibiotic Take-Back Program
2017 Age-specific Distribution of Antimicrobial days of therapy (DOT) using National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB Japan) ~Comparison with defined daily doses per 1000 inhabitants per day (IDD)
2018 The Global Point Prevalence Survey of Antimicrobial Consumption and Resistance: Quantity and Quality of Antimicrobial Prescribing for Inpatients with Pneumonia in the Philippines in 2018

2019 Multicentric Antimicrobial Point Prevalence Survey in Four Tertiary Care Hospitals in Southern India
2020 Impact of Local Antimicrobial Stewardship Guidelines through a Cellphone app to Lower Hospital Acquired MDR Infections in a Private Hospital in Mexico City
2021 Comparison of Patterns of National Oral Antibiotic Use between All Dentists and Medical Doctors in Japan in 2016 using the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB)
2022 Antibiotic Prescribing Behavior Among Surgeon
2023 Antimicrobial Resistance and Stewardship Knowledge and Perception among Medical and Pharmacy Students in Nigeria
2024 A multifaceted intervention to improve oral antimicrobial prescription at the emergency department in a Japanese tertiary care center
2025 Evaluation of the Impact of an Antimicrobial Stewardship Program in a Tertiary Hospital in Northern Italy: Efficacy of a Persuasive Approach on Antibiotics Consumption and Rate of Clostridium difficile Infection
2026 A current status of antimicrobial stewardship programs in Korean large hospitals: a nationwide survey in 2018
2027 What are the Views Among Pakistani Physicians towards Antimicrobial Resistance and Hospital Antimicrobial Stewardship Programs? A Multi-Site Qualitative Study
2028 A Survey of Antimicrobial Availability, Training and Antimicrobial Recommendations by Staff in Pharmacies and Non-pharmacy Stores in the Dominican Republic
2029 Prevalence of Antibiotic Use and Administration among Hospitalized Adult Patients at a Tertiary Care Hospital in Kilimanjaro, Tanzania
2030 Impact of Education and Antibiotic Guidelines on Dispensing Antibiotics with Community Pharmacists in a Low-and Middle-Income Country
2031 First National Survey of Antimicrobial and Antifungal Stewardship in Japan
2032 A Systematic Review of Systematic Reviews: Procalcitonin in the ICU to Guide Antibiotic Therapy
2033 Standardized point prevalence survey on antibiotic use to inform antimicrobial stewardship strategies in the Caribbean
2034 A Quasi-Experimental Survey Study of Antimicrobial Stewardship Education for Registered Nurses
2035 Clinical and economic outcomes in patients with complicated urinary tract infection (cUTI) and complicated intra-abdominal infection (cIAI) in Perú: Impact of Gram-Negative Organisms (GNO) resistant to antibiotics.
2036 Impact of Local Antimicrobial Stewardship Guidelines through a Cellphone app to Lower Hospital Acquired MDR Infections in a Private Hospital in Mexico City
2037 A Novel Strategy of Antimicrobial Stewardship in Shanghai: Preliminary Practice with Integration of Three Surveillance Networks
2038 Antimicrobial Stewardship (AS) Recognition, Confidence, and Organizational Factors: Multi-center Survey of Bedside Nurses
2039 Antimicrobial Stewardship in Burn and Chronic Wound Centers in Nepal
2040 Evaluation of Inpatient Antimicrobial Prescribing Practices in Cochabamba, Bolivia
2041 Impact of an Infectious Disease Specialist-led Post-prescription Carbapenem Intervention in a Large Japanese Tertiary Hospital: A Before-after Cohort Study
2042 Impact of an antimicrobial stewardship program on the health-care associated infections in a third level hospital in Yucatán, México


237. Poster Abstract Session
Antibiotic Stewardship: Long-Term Care

Saturday, 12:15 - 1:30 p.m.

2044 An Assessment and Feedback Model Bringing Antimicrobial Stewardship Program Expertise to Long-Term Care Facilities

2045 GAIN (Generating Antimicrobial Stewardship Initiatives in Chicago Skilled Nursing Facilities) Collaborative Survey Results: CDC Core Elements of Antimicrobial Stewardship Compliance Assessment in 27 Chicago Skilled Nursing Facilities

2046 A qualitative study on perceived barriers and facilitators of implementing an antimicrobial stewardship intervention in the management of urinary tract infections in a long-term care setting

2047 GAIN (Generating Antimicrobial Stewardship Initiatives in Chicago Skilled Nursing Facilities) Collaborative: Cumulative Results of Point Prevalence Surveys Assessing Antibiotic Appropriateness in Four Chicago Skilled Nursing Facilities

2048 Antibiogram Use in Wisconsin Nursing Homes

2049 Trends in Antibiotic Use and Antibiotic Resistance among Veterans Affairs Community Living Centers from 2011 to 2017

2050 Effect of a Stewardship Intervention on Post-Prescriptive Antibiotic Timeouts in Nursing Homes

2051 Frequency of Inappropriate Antibiotic Prescribing in Nursing Homes

2052 Characterizing Nursing and Provider Social Networks to Develop an Instrument to Improve Antibiotic Stewardship Efforts in Nursing Homes

2053 Information Gaps among Patients Prescribed Antibiotics on Discharge to Nursing Homes

2054 Hospital-initiated Antibiotics in Nursing Homes

2055 Action: A year in the lives of consultant pharmacists working on antimicrobial stewardship in long-term care facilities

2056 Retrospective Analysis of Intravenous Vancomycin Outcomes in Patients Discharged to Skilled Nursing Facilities

238. Poster Abstract Session
Antibiotic Stewardship: Non-Inpatient Settings

Saturday, 12:15 - 1:30 p.m.

2057 Outpatient Antibiotic Stewardship ‘Bundles up’ in Winter with Peer Comparison, URI order set and Education: Is it enough to weather the storm?

2058 Patient Satisfaction Not Impacted by Antibiotic Prescribing for Viral Upper Respiratory Infections

2059 Antimicrobial Stewardship of Community Parenteral Antimicrobial Therapy: A Health System Approach

2060 Evaluation of a pharmacist’s impact on antimicrobial prescribing in an urgent care center

2061 Private Practice Dentists and Orthopedic Surgeons (PPD&OS) Engage in a Novel Stewardship Forum: Consensus to Use Less Antibiotics Achieved


2063 Using Twitter Data and Machine Learning to Identify Outpatient Antibiotic Misuse: a Proof of Concept Study

2064 Applying Human Factors and Ergonomics to Inform a Successful Fluoroquinolone Restriction Intervention: A Mixed Methods Pilot Study

2065 Reducing Inappropriate Antibiotic Prescriptions in the Primary Care Setting

2066 Development and Implementation of Prescribing Algorithms for Antibiotics on Discharge from the Emergency Department

2067 Improving Outpatient Antimicrobial Prescribing for Respiratory Tract Infections

2068 Outpatient Antimicrobial Stewardship: Optimizing Patient Care Via Pharmacist Led Culture Review

2069 A Unique Approach to Outpatient Antibiotic Stewardship in Rural Southern Ohio

2070 Assessing Primary Care Physicians’ Attitudes and Perceptions towards Antibiotic Resistance and Outpatient Antibiotic Stewardship: A National Survey

2071 A Survey of Antibiotic Prescribing Practices Among Adult Primary Care Physicians in Idaho

2072 Do ID and Non-ID Clinicians Agree on IV to PO Switch Criteria? Results from Phase I of the INForming IV to ORal MEdication Report (INFORMER) Project

2073 Apples and Oranges: Comparing Toolkits to Track Antimicrobial Prescribing in Ambulatory Care Settings

2074 A Successful Acute Respiratory Tract Infection Campaign to Improve Antibiotic Prescribing in Outpatient Clinics and an Emergency Department

2075 Transforming Outpatient Antimicrobial Stewardship Through a Clinical Surveillance System

2076 Comparison of Diagnosis and Prescribing Practices between Virtual Visits and Office Visits for Sinusitis within a Primary Care Network

2077 Fluoroquinolone Usage Reduction in the Outpatient Setting

2078 Patterns, Indications, and Appropriateness of Antibiotics Prescribed at a Private Dental Practice

2079 Outpatient Antimicrobial Stewardship Initiative to reduce unnecessary use of antibiotics in patients with Upper Respiratory Infections: Findings shared by a Metropolitan Community Hospital in NYC

2080 Impact of an Emergency Department Post-discharge Blood Culture Follow-up Program

2081 Low 30-Day Hospital Readmission Rates in Medicare Patients receiving Outpatient Parenteral Antimicrobial Therapy (OPAT) in Physician Office Infusion Centers

2082 Evaluation of Outpatient Parenteral Antimicrobial Therapy (OPAT) Processes and Outcomes Among Patients Within an Integrated Health System

2083 A Targeted Remote Audit and Feedback Intervention Utilizing a Local Non-ID Trained Pharmacist
239. Poster Abstract Session
Antibiotic Stewardship: Nursing
Saturday, 12:15 - 1:30 p.m.

2084 Implementation of a diagnostic stewardship algorithm by bedside nurses to reduce unnecessary urinary cultures in hospitalized adult patients.

2085 Bedside nurses improve antimicrobial stewardship and infection prevention outcomes: Results of a 3.5-year study in three hospital telemetry units.

2086 Antimicrobial Stewardship: Why don’t nurses question the white coat?

240. Poster Abstract Session
Antibiotic Stewardship: Regional
Saturday, 12:15 - 1:30 p.m.

2087 Electronic Capture and Feedback of Standardized Antibiotic Clinical Indications Data Among Community Hospitals

2088 Cross sectional analysis of administrative structure and practices for hospital antimicrobial stewardship programs (ASPs) in a large metropolitan city.

2089 Effect of the Duke Antimicrobial Stewardship Outreach Network (DASON): A Multi-Center Time Series Analysis

2090 Are changes in antimicrobial use associated with a decline in hospital pathogen rates in Veterans Affairs Medical Centers?

2091 Use of Telehealth to Expand Antimicrobial Stewardship Capacity among Critical Access Hospitals in Washington State

2092 Acceptability and Effectiveness of Implementation Strategies on Fluoroquinolone (FQ) Prescribing

2093 Prescribing of Antibiotics by Provider Type Across the Veterans Health Administration (VHA), 2015-2017

2094 Acceptability of Antibiotic Substitutions for Fluoroquinolones and Third and Fourth Generation Cephalosporins: a Report from the VA-CDC Practice-Based Research Network (PBRN)

2095 Antimicrobial Stewardship (ASP) in Rural and Critical Access Hospitals (CAHs) Using TeleStewardship Services

2096 System-Wide Multi-Pronged Approach Leads to Successful Reduction of Fluoroquinolone Use Across a Large Health System

2097 Antimicrobial Stewardship Programs in Missouri Hospitals: Facilitators, Barriers, and Complexity of Implementation

2098 Applying Antimicrobial Consumption Metrics to Characterize Inpatient Stewardship Opportunities

241. Poster Abstract Session
Antibiotic Stewardship: Sepsis
Saturday, 12:15 - 1:30 p.m.

2099 Use of Infectious Diseases Source-Specific Electronic Sepsis Order Sets is associated with Improved Survival in Sepsis: An Evaluation of 46 Hospitals in a Large Health Care System

2100 A Retrospective Chart Review of Emergent Antibiotic Use Impact of “Code Sepsis” on Antimicrobial Utilization at an Academic Medical Center

2101 Does Monitoring Procalcitonin Levels in Septic and Septic Shock Patients Decrease Use of Antibiotics and Predict Length of Hospital Stay?

2102 Emergency Department (ED) Stewardship: Stratifying ED Sepsis Order Sets by Penicillin (PCN) Allergy Severity

242. Poster Abstract Session
Antifungals
Saturday, 12:15 - 1:30 p.m.

2104 Susceptibility Trends in Antifungal Resistance (STAR) Study: Preliminary Data from A New Prospective Antifungal Surveillance Study

2105 Liposomal Amphotericin B Use Before and After Implementation of Voriconazole Prophylaxis in Cancer Patients

2106 Evaluation of isavuconazole for the prophylaxis and treatment of invasive fungal infections at a large academic medical center

2107 Azole Therapeutic Drug Monitoring (TDM) in a Multiracial Cohort with Varied Pharmacogenetics

2108 Comparison of Voriconazole versus Itraconazole in the Treatment of Histoplasmosis – A Retrospective Analysis

2109 Liposomal Amphotericin B Associated Nephrotoxicity in Obese and Non-obese Patients

2110 Treatment of Coccidioidomycosis with Isavuconazole

2111 Anidulafungin versus micafungin treatment in adult patients with candidemia: A retrospective study of single center experience

2112 Voriconazole For Primary Prophylaxis: A Decade Of Trends And Outcomes

2113 Evaluation of Empiric Antifungal Therapy in Critically Ill Patients with Liver Disease, Sepsis, and No Evidence of Active Fungal Infection

2114 Correlation Between Antifungal Consumption and the Distribution of Candida Species in a Hospital in Colombia

2115 Activity of a Long-Acting Echinocandin Rezafungin and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2018

2116 Comparative Effectiveness of Amphotericin B, Azoles, and Echinocandins in the Treatment of Candidemia and Invasive Candidiasis: A Systematic Review and Network Meta-Analysis

2117 Fluconazole versus echinocandins as initial therapy for candidemia caused by fluconazole-susceptible species in the era of rapid diagnostic testing

2118 Antifungal Susceptibility Testing of Clinical Isolates of Aspergillus in Mexico

2119 Matched-paired analysis of patients treated for invasive mucormycosis - standard treatment vs. posaconazole new formulations (MoveOn)

2120 Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model

2121 Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients (pts) with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study

2122 Isavuconazonium for invasive fungal therapy: Single-center pediatric experience
# Poster Abstract Sessions (continued)

243. **Poster Abstract Session**  
**Bacterial Diagnostics**  
Saturday, 12:15 - 1:30 p.m.

<table>
<thead>
<tr>
<th>Session No.</th>
<th>Title</th>
<th>Authors</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>2123</td>
<td>Rapid Phenotypic Detection of Gram-negative Bacilli Resistant to Oximinocephalosporins and Carbapenems in Positive Blood Cultures Using a Novel Protocol</td>
<td>[Authors]</td>
<td>A protocol was developed for the rapid detection of resistant bacteria in blood cultures.</td>
</tr>
<tr>
<td>2124</td>
<td>The Epidemiology, Demographics, and Geographical Distribution of Human Non-Tuberculosis Mycobacteria (NTM) Disease in the Endemic Central Florida Region</td>
<td>[Authors]</td>
<td>A study was conducted to understand the spread of NTM disease in Florida.</td>
</tr>
<tr>
<td>2125</td>
<td><em>Staphylococcus</em> Species Identification by Fourier Transform Infrared (FTIR) Spectroscopic Techniques: A Cross-Lab Study</td>
<td>[Authors]</td>
<td>A cross-lab study was conducted to identify <em>Staphylococcus</em> species using FTIR spectroscopy.</td>
</tr>
<tr>
<td>2126</td>
<td>Comparison of Time to Appropriate Antibiotic between Using Microarray Assay and Mass Spectrometry Technique for Identification of Positive Blood Cultures</td>
<td>[Authors]</td>
<td>A comparison was made between using microarray and mass spectrometry for antibiotic identification.</td>
</tr>
<tr>
<td>2127</td>
<td>Parental Acceptance of Over-the-Counter (OTC) testing for Streptococcal Pharyngitis</td>
<td>[Authors]</td>
<td>A study was conducted to assess parental acceptance of OTC testing for pharyngitis.</td>
</tr>
<tr>
<td>2128</td>
<td>Murine typhus and pregnancy: case series and literature review.</td>
<td>[Authors]</td>
<td>A case series and literature review were conducted on murine typhus and pregnancy.</td>
</tr>
<tr>
<td>2129</td>
<td>When is Methicillin Resistant <em>Staphylococcus aureus</em> not Methicillin Resistant <em>Staphylococcus aureus</em>?</td>
<td>[Authors]</td>
<td>A study was conducted to determine the conditions for resistance to methicillin.</td>
</tr>
<tr>
<td>2130</td>
<td>Detection of Carbapenemase-Producing Organisms and Impact on Antimicrobial Utilization for Carbapenem-Resistant Enterobacteriaceae (CRE) Infections</td>
<td>[Authors]</td>
<td>A study was conducted to detect carbapenemase-producing organisms and their impact on antimicrobial utilization.</td>
</tr>
<tr>
<td>2131</td>
<td>Multicenter Evaluation of Meropenem/Vaborbactam MIC Results for <em>Enterobacteriaceae</em> Using MicroScan Dried Gram Negative MIC Panels</td>
<td>[Authors]</td>
<td>A multicenter evaluation was conducted to assess the accuracy of meropenem/vaborbactam MIC results.</td>
</tr>
<tr>
<td>2132</td>
<td>Multicenter Evaluation of Eravacycline MIC Results for <em>Enterobacteriaceae</em> Using MicroScan Dried Gram Negative MIC Panels</td>
<td>[Authors]</td>
<td>A multicenter evaluation was conducted to assess the accuracy of eravacycline MIC results.</td>
</tr>
<tr>
<td>2133</td>
<td>Clinical Impact of Implementation of Rapid Diagnostic Testing of Blood Cultures on Patient Outcomes</td>
<td>[Authors]</td>
<td>A study was conducted to assess the clinical impact of rapid diagnostic testing.</td>
</tr>
<tr>
<td>2134</td>
<td>Differential Changes in Breath Volatile Metabolites to Identify Carbapenem-Resistant Enterobacteriaceae (CRE) in a Murine Pneumonia Model</td>
<td>[Authors]</td>
<td>A study was conducted to identify CRE using breath volatile metabolites.</td>
</tr>
<tr>
<td>2135</td>
<td><em>Streptococcus pneumoniae</em> DNA (lytA) detection in clinical samples sent for respiratory viral polymerase chain reaction- is there bacterial-viral association?</td>
<td>[Authors]</td>
<td>A study was conducted to detect lytA DNA in clinical samples.</td>
</tr>
<tr>
<td>2136</td>
<td>Rapid Antimicrobial Susceptibility Testing using ATP Luminescence and Machine Learning Methods</td>
<td>[Authors]</td>
<td>A study was conducted to assess the accuracy of rapid susceptibility testing using ATP luminescence and machine learning.</td>
</tr>
<tr>
<td>2137</td>
<td>Impact of Accelerate Pheno™ Rapid Blood Culture Detection System with Real Time Notification versus Standard Antibiotic Stewardship on Clinical Outcomes in Bacteremic Patients</td>
<td>[Authors]</td>
<td>A study was conducted to assess the impact of rapid blood culture detection on clinical outcomes.</td>
</tr>
<tr>
<td>2138</td>
<td>Follow-up investigation of antibody titers and diagnostic antibody cut-off values in scrub typhus patients in Korea</td>
<td>[Authors]</td>
<td>A study was conducted to follow-up investigation of antibody titers in scrub typhus patients.</td>
</tr>
<tr>
<td>2139</td>
<td><em>Rickettsia typhi</em> Detection in Clinical Infections by the Karius Test, a Plasma Microbial Cell-free DNA Next-Generation Sequencing Test</td>
<td>[Authors]</td>
<td>A study was conducted to detect <em>Rickettsia typhi</em> using the Karius test.</td>
</tr>
<tr>
<td>2140</td>
<td>Utility of Respiratory Specimen Gram Stain for Predicting Final Culture Result in Patients with Clinically Diagnosed Pneumonia</td>
<td>[Authors]</td>
<td>A study was conducted to assess the utility of respiratory specimen gram stain.</td>
</tr>
<tr>
<td>2141</td>
<td>Potential for harm from Rapid Campylobacter Antigen test: Quality Improvement Process reveals 84% False Positive STATI Campy Stool Antigen Results</td>
<td>[Authors]</td>
<td>A study was conducted to assess the potential harm from rapid campylobacter antigen test.</td>
</tr>
<tr>
<td>2142</td>
<td>Comparison of Molecular-Based Versus Conventional Culture-Based Screening Methods for Detection of Carriers of Extended-Spectrum Beta-Lactamases (ESBL) and Carbapenemases-Producing <em>Enterobacteriaceae</em> (CPE)</td>
<td>[Authors]</td>
<td>A study was conducted to compare molecular and conventional methods for detecting ESBL and CPE.</td>
</tr>
<tr>
<td>2143</td>
<td>Attempting to Add Clarity to “Indeterminates” on a Deployed Rapid Diagnostic with Antimicrobial Stewardship Program (ASP) Intervention</td>
<td>[Authors]</td>
<td>A study was conducted to clarify the use of indeterminates in rapid diagnostic testing.</td>
</tr>
<tr>
<td>2144</td>
<td>Performance of 2019 CLSI Ciprofloxacin Breakpoint Antimicrobial Susceptibility Testing Algorithms for <em>Enterobacteriaceae</em> and <em>Pseudomonas aeruginosa</em> Directly from Positive Blood Culture on the Accelerate Pheno™ System</td>
<td>[Authors]</td>
<td>A study was conducted to assess the performance of CLSI algorithms using the Accelerate Pheno™ system.</td>
</tr>
<tr>
<td>2145</td>
<td>Carbapenem-Resistant Enterobacteriaceae infections at the Maharaj Nakorn Chiang Mai Hospital</td>
<td>[Authors]</td>
<td>A study was conducted to assess carbapenem-resistant infections at a hospital.</td>
</tr>
<tr>
<td>2146</td>
<td>MALDI-TOF Mass Spectrometry Rapid Pathogen Identification and Outcomes of Patients with Bloodstream Infection: a Systematic Review and Meta-analysis</td>
<td>[Authors]</td>
<td>A study was conducted to assess the identification and outcomes of bloodstream infections using MALDI-TOF mass spectrometry.</td>
</tr>
<tr>
<td>2147</td>
<td>Human infections due to <em>Actinotignum</em> species: A five-year retrospective review at Mayo Clinic Rochester, Minnesota</td>
<td>[Authors]</td>
<td>A study was conducted to assess infections due to <em>Actinotignum</em> species.</td>
</tr>
<tr>
<td>2148</td>
<td>Performance of the BioFire FilmArray Gastrointestinal Panel in a Clinical Setting of Infectious Diarrhea</td>
<td>[Authors]</td>
<td>A study was conducted to assess the performance of the BioFire FilmArray panel.</td>
</tr>
<tr>
<td>2149</td>
<td>Performance of a Gradient Diffusion Method (Etest®) on Mueller-Hinton Agar with Sheep Blood for <em>Aerococcus urinae</em> Antimicrobial Susceptibility Testing.</td>
<td>[Authors]</td>
<td>A study was conducted to assess the performance of a diffusion method for <em>Aerococcus urinae</em>.</td>
</tr>
<tr>
<td>2150</td>
<td>Detection and Characterization of Viral and Bacterial Pathogens in Tonsillar Tissues of Children Undergoing Tonsillectomy</td>
<td>[Authors]</td>
<td>A study was conducted to detect and characterize pathogens in tonsillar tissues.</td>
</tr>
<tr>
<td>2152</td>
<td>Detection of Uropathogens Using BD Kiestra™Total Laboratory Automation with Urine Culture Application</td>
<td>[Authors]</td>
<td>A study was conducted to assess the detection of uropathogens using the BD Kiestra™ system.</td>
</tr>
<tr>
<td>2153</td>
<td>Clinical Impact of Addition of Oropharynx MRSA PCR to Anterior Nares MRSA PCR for Patients Admitted with Pneumonia</td>
<td>[Authors]</td>
<td>A study was conducted to assess the clinical impact of oropharynx MRSA PCR.</td>
</tr>
<tr>
<td>2154</td>
<td>Rapid microorganism identification from blood and enrichment fluid cultures using MALDI-TOF mass spectrometry following abbreviated incubation on chocolate agar plates</td>
<td>[Authors]</td>
<td>A study was conducted to assess the rapid identification of microorganisms using MALDI-TOF mass spectrometry.</td>
</tr>
<tr>
<td>2155</td>
<td>Accelerated confirmation of porin loss in carbapenem-resistant <em>Enterobacterales</em>: a MALDI-TOF mass spectrometry-based approach</td>
<td>[Authors]</td>
<td>A study was conducted to assess accelerated confirmation of porin loss using MALDI-TOF mass spectrometry.</td>
</tr>
<tr>
<td>2156</td>
<td>To Evaluate the Role of Kit-Based Loop-Mediated Isothermal Amplification (TB-LAMP) Assay in the Diagnosis of Tubercular Lymphadenitis</td>
<td>[Authors]</td>
<td>A study was conducted to assess the role of TB-LAMP assay in lymphadenitis diagnosis.</td>
</tr>
<tr>
<td>2157</td>
<td>Evaluation of the Utility of the MRSA Nasal PCR Assay in a Community Healthcare System</td>
<td>[Authors]</td>
<td>A study was conducted to assess the utility of the MRSA nasal PCR assay.</td>
</tr>
<tr>
<td>2158</td>
<td>Cost-effectiveness and Budget Impact of a Point-of-Care Nucleic Acid Amplification Test for Diagnosis of Group A Streptococcal Pharyngitis in the United States</td>
<td>[Authors]</td>
<td>A study was conducted to assess the cost-effectiveness of a point-of-care test for streptococcal pharyngitis.</td>
</tr>
<tr>
<td>2159</td>
<td>Accurate carbapenem susceptibility testing within 5-6 hours</td>
<td>[Authors]</td>
<td>A study was conducted to assess accurate carbapenem susceptibility testing.</td>
</tr>
<tr>
<td>2160</td>
<td>Performance of the Cepheid Rapid PCR Test for Patient Screening and Association with Efficacy of Suvratoxumab, a Novel Anti-<em>Staphylococcus aureus</em> Monoclonal Antibody, During the Phase 2 SAATELLITE study</td>
<td>[Authors]</td>
<td>A study was conducted to assess the performance of the Cepheid Rapid PCR test and association with efficacy of Suvratoxumab.</td>
</tr>
<tr>
<td>2161</td>
<td>Organism Specific Turn Around Time Improvement in Urinary Specimens as a Result of Microbiological Laboratory Automation</td>
<td>[Authors]</td>
<td>A study was conducted to assess turn around time improvement in urinary specimens.</td>
</tr>
<tr>
<td>2162</td>
<td>Comparison of Plazomicin Disk Diffusion versus Gradient Diffusion Susceptibility Testing Results Against Drug-Resistant Clinical <em>Enterobacteriaceae</em> Isolates</td>
<td>[Authors]</td>
<td>A study was conducted to compare gradient diffusion with plazomicin disk diffusion.</td>
</tr>
<tr>
<td>2163</td>
<td>Clinical Impact of Inter-site Blood Culture Transport in a Canadian Tertiary Care Center</td>
<td>[Authors]</td>
<td>A study was conducted to assess the clinical impact of inter-site blood culture transport.</td>
</tr>
<tr>
<td>2164</td>
<td>Activity of Fosfomycin (FOF) and Frequency of Nonsusceptible Inner Colonies During Susceptibility Testing of an International Collection of Clinical <em>Pseudomonas aeruginosa</em> (PA) Isolates</td>
<td>[Authors]</td>
<td>A study was conducted to assess the activity of fosfomycin and frequency of nonsusceptible inner colonies during testing.</td>
</tr>
</tbody>
</table>
Poster Abstract Sessions (continued)

2165  *Helicobacter pylori* infections in the Bronx, New York: Whole Genome Sequencing for Rapid Genotypic Susceptibility Testing

2166  Performance Study on the New ETEST® Pipercillin/Tazobactam (P/T) MIC Strip.


2168  Comparison of Rapid Diagnostic Tests for Bloodstream Infections using Desirability of Outcome Ranking Management of Antimicrobial Therapy (DOOR-MAT) and DOOR-MAT

2169  An algorithm based approach reduces overuse of Meningitis/Encephalitis multiplex PCR panel

2170  Xpert Carba-R Assay on Flagged Blood Culture Samples: Clinical Utility in Intensive Care Unit Patients with Gram Negative Bacteremia

2171  Phenotypic Correlations For the Presence of CTX-M in *Enterobacteriaceae* and mecA in *Staphylococcus aureus* using the Verigene® Blood Culture System

2172  True Positivity of Common Blood Culture Contaminants among Pediatric Hospitalizations in the United States, 2009-2016

2173  Detection of *Chlamydia psittaci* by rtPCR in Outbreak Specimens Tested at CDC — 2018


2175  Rapid Detection of Carbapenemase Producing Organisms Directly from Blood Cultures Positive for Gram-Negative Bacilli

2176  A New Rapid Test for Detection of The Cefazolin Inoculum Effect (CIE) in Methicillin-Susceptible *Staphylococcus aureus* (MSSA)

2177  The Impact of the BioFire® FilmArray® Gastrointestinal Syndromic Panel on the Management of Infectious Gastroenteritis due to Diarrheagenic *E. coli* Strains in a Large Community Hospital

2178  Sensitivity of Blood Cultures in Detection of Bacteremia in Febrile Neutropenia.

2179  Detection of Group A Streptococcus in the Saliva of Children Presenting With Pharyngitis Using the cobas®LIA® PCR System

2180  Novel Method for Determining Rapid *E.coli* Antibiotic Susceptibility (AST) Results for Urinary Tract Infections

2181  Yield and Impact of Molecular Diagnostics for Pathogen Detection in Pediatric Patients: 16/18S rRNA PCR and Non-invasive Assays

2182  Harnessing Direct-from-Blood MALDI-TOF (DBM) and Local Blood Stream Infection (BSI) Antibiogram Data to Direct Optimal Therapy for Gram-Negative Rod (GNR) Bacteremia

2183  Survival Impact and Clinical Predictors of Anaerobic Bloodstream Infection

2184  Effect of adjusted CLSI breakpoints on center-wide fluoroquinolone susceptibilities for *Enterobacteriaceae* and *Pseudomonas aeruginosa*: Is it time to restrict empiric fluoroquinolone use?

2185  Group A Streptococcus (GAS) detection by PCR in children with viral acute respiratory illness and healthy children

2186  Differentiation of Severe Fever With Thrombocytopenia Syndrome from Scrub Typhus

2187  Prediction of Patient Outcome During Febrile Neutropenia Despite Anti-infective Treatment Using Machine Learning Algorithms

2188  Provider Education and Rapid Antigen Detection Test Use in Private and Academic Pediatric Clinics

2189  Improving Surveillance of Rocky Mountain spotted fever (RMSF): Implementation of a Multidisciplinary Process

244. Poster Abstract Session

**Bacterial Respiratory Infections**

Saturday, 12:15 - 1:30 p.m.

2190  Influence of Microbiological Culture Results on Antibiotic Choice for Veterans with Hospital-Acquired Pneumonia

2191  The Sputum FilmArray Pneumonia Panel (SFAPP) Outperforms a Diagnostic Bundle in Patients with Community-Acquired Pneumonia (CAP).

2192  Comparative Antimicrobial Susceptibility of Gram-Negative Bacteria Isolated from Patients with Bloodstream Infections and Pneumonia when Tested against Tazobactam Combinations

2193  Factors Impacting the Duration of Antimicrobial Therapy for Community Acquired Pneumonia

2194  Procalcitonin-Guided Antibiotic Strategy for Lower Respiratory Tract Infections: Outcomes and Safety of Withholding Antibiotics

2195  Incidence of Acute Myocardial Infarction in Patients with Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis

2196  Impact of Rapid Discontinuation of Empiric Vancomycin in Patients with Hospital-Acquired or Healthcare-Associated Pneumonia and Absence of Adequate Respiratory Tract Culture Data

2197  Ceftiraxone Monotherapy versus Ceftiraxone plus Azithromycin for the Treatment of Community Acquired Pneumonia in Hospitalized, Non-ICU Patients

2198  Weak Interobserver Reliability in the Clinical Diagnosis of Pneumonia Among Infectious Disease Trained Physicians

2199  The Etiology of Community-acquired Pneumonia with Attention to the Role of Normal Respiratory Flora

2200  Cost Effectiveness of Cefotizolane/Tazobactam for Treating Ventilated Nosocomial Bacterial Pneumonia

2201  Cost of Antimicrobial Use against Upper Respiratory Infection in Japan

2202  Validation of a rabbit model of *Pseudomonas aeruginosa* acute pneumonia

2203  Patient-specific Risk Stratification to Identify Patients at High and Low Risk for *P. aeruginosa* in Community-acquired Pneumonia

2204  Microbiology of Pneumonia Due to Co-Infection in the ICU: Impact of Host Immune Status

2205  Clinical burden of pneumococcal disease in US adults aged 65 years and above with chronic or immunocompromising conditions

2206  Patterns of Care and Outcomes in Elderly Patients Hospitalized with Community Acquired Pneumonia in the United States

2207  Narrowing Antibiotic Spectrum of Activity for Trauma-Associated Pneumonia Through the Use of a Disease Specific Antibigram
Poster Abstract Sessions (continued)

2208 Development and Evaluation of Predictive Models for Estimating Infection Susceptibility to Empiric Treatment Regimens Among Patients with Pneumonia in Intensive Care Units

2209 Charlson Comorbidity Index Scores and in-hospital Prognosis in Severe Acute Respiratory Infections Patients

2210 Nasopharyngeal detection of Streptococcus pneumoniae and clinical disease severity in children with community-acquired pneumonia (CAP)

2211 Impact of Early Fiberoptic Bronchoscopy on Microbiological Diagnostic Rate and Clinical Outcomes of Pneumonia in Acute Leukemia Patients

2212 Burden of Community-Acquired Pneumonia Attributable to Co-morbid Conditions in Adults

2213 Etiology of Community-Acquired Pneumonia (CAP) in Hospitalized Native American Adults

2214 Comparison of Cefepime-Zidebactam (WCK 5222), Ceftazidime-Avibactam, and Ceftolozane-Tazobactam Tested against Gram-Negative Organisms Causing Pneumonia in United States Hospitals in 2018

2215 Diarrheal illness as a risk factor for subsequent respiratory infection among women and infants in Nepal

2216 Pneumonia in the ICU: Epidemiology and Outcomes

2217 Frequency and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers During 2018


2219 Evaluation of Medicare claims to assess burden of pertussis disease in persons aged ≥65 years

2220 Comparative Incidence and Burden of Respiratory Viruses associated with Hospitalization in Adults

2221 Chlamydia pneumoniae (Cpn) induces IFN-γgamma; responses in peripheral blood mononuclear cells (PBMC) from pediatric and adult asthma patients: effects of age and inhaled corticosteroid use.

2222 Impact of Empiric Aminoglycoside Usage on Outcomes in Bacterial Pneumonia

2223 Real time Prediction of Respiratory pathogen infection based on machine learning decision support tool

2224 Reducing Antibiotic Overuse in Adult Lower Respiratory Tract Infections Using Novel Host-Response Based Diagnostics

2225 Are Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis.

2226 Impact of Prior and Concomitant Antibacterial Therapy on Outcomes in the ASPET-NP Randomized, Controlled Trial of Ceftriaxone/Tazobactam (C/T) versus Meropenem (MEM) in Patients (pts) with Ventilated Nosocomial Pneumonia (NP)

2227 Outcomes in Patients with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane-Tazobactam (C/T) Treatment of Nosocomial Pneumonia (ASPET-NP)

2228 Treatment of Community Acquired Bacterial Pneumonia (CABP) in Patients with Diabetes: Outcomes from a Global Phase 3 Study of Delafloxacin (DLX)

2229 Relative Bioavailability of a Single Oral Dose of SUBA-Itraconazole 65mg Capsule Compared to Conventional Itraconazole 100mg Capsule Administered Under Fasted and Fed Conditions in Healthy Adult Volunteers

2230 Analysis of the Microbiological Data from the Delafloxacin (DLX) Phase 3 Community Acquired Bacterial Pneumonia (CABP) Trial

2231 Safety of Nebulized Colistin as Adjunctive Treatment of Lower Respiratory Tract Infections

2232 A Global Phase 3 Study of Delafloxacin (DLX) Compared to Moxifloxacin (MOX) in Patients with Community Acquired Bacterial Pneumonia (CABP)

2233 Efficacy and Symptom Resolution by Visit in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results

2234 Outcomes by Age and Gender from a Global Phase 3 Study of Delafloxacin (DLX) in Community Acquired Bacterial Pneumonia (CABP)

245. Poster Abstract Session

Biomarkers of Infectious Diseases

Saturday, 12:15 - 1:30 p.m.

2235 Fecal Biomarkers for Clostridioides difficile Infection in Cancer Patients

2236 Stool-derived inflammatory mediators serve as biomarkers of severity in Clostridium difficile infection

2237 Early Discontinuation of Antibacterials is Safe for Patients with Community-Acquired Pneumonia (CAP) Who Have a Positive Viral Test, Negative Tests for Bacteria, and Low Procalcitonin

2238 Evaluation of Adjuvant Interferon-gamma Level Assessment to Improve the Performance of Procalcitonin Testing in Hospitalized Bacteremic Patients

2239 Randomized controlled trial of a Procalcitonin-guided antibiotic treatment algorithm plus antibiotic stewardship in the Pediatric Intensive Care Unit (ProPICU)

2240 Can antibiotic duration be reduced by the sequential use of procacetin and endotoxin in patients with sepsis? A Prospective Double-Blind Clinical Trial

2241 Use of a Procalcitonin Assay in Hospitalized Patients for CHF Reduced Subsequent Use of Antibiotics

2242 Using Host Biomarkers and Time to Blood Culture Positivity to Predict Necessity for Echocardiogram in Patients with Staphylococcus aureus Endocarditis

246. Poster Abstract Session

Clinical Outcomes of Infections with Resistant Organisms

Saturday, 12:15 - 1:30 p.m.

2244 Clinical Outcomes with Extended Infusion (EI) versus Intermittent Infusion (II) of Ceftazidime (FEP), Piperacillin/Tazobactam (TZP), and Meropenem (MEM) in Patients with Gram-Negative (GN) Bacteremia

2245 Oral 5-Day Lefamulin for Outpatient Management of Pneumonia Outcomes Research Team (PORT) Risk Class III/IV Community Acquired Bacterial Pneumonia (CABP): Post Hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Phase 3 Study

2246 Improved Outcomes for Cancer Patients Treated With Ceftazidime-Avibactam Versus Polymyxin-Containing Regimens for Carbapenem-Resistant Enterobacteriaceae Bacteremia
2247  Real-world Experience with Meropenem-vaborbactam (M/V) for Treatment of Carbapenem-resistant Enterobacteriaceae (CRE) Infections

2248  Clinical and Microbiological Outcomes Associated with Real World Use of Ceftolozane/Tazobactam

2249  Impact of Minimum Inhibitory Concentration on Clinical Outcomes of Daptomycin for VRE Bloodstream Infection among Neutropenic Oncology Patients

2250  Combination Vancocycin Plus Cefazolin for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

2251  Estimating the Need for Novel Gram-Negative Active Antibiotics in US Hospitals

2252  Patient Preferences for Triazole Antifungals in the Treatment of Invasive Mold Infection: a Discrete Choice Experiment

2253  Comparison of Outcomes between Patients with and without Cystic Fibrosis Treated with Ceftolozane-Tazobactam for Pseudomonas aeruginosa Infections

2254  Multicenter Evaluation of Ceftazidime-Avibactam for Multidrug-Resistant Pseudomonas aeruginosa Infections

2255  The Use of Dalbavancin for Staphylococcus Aureus Bacteremia in Persons Who Inject Drugs (PWID)

2256  Baloxavir marboxil in Combination with Oseltamivir in Two critically ill Patients with Influenza A (H1N1; 2009 strain) on Veno-venous Extra-Corporal Membranous Oxygenation

2257  BDG-Guided Management of Empirical Antifungal Therapy: a Real Life Experience in a Hospital-Wide Context with High Incidence of Non-albicans Candida Infection

2258  Correlation of Electroencephalogram Findings and Dose Relative to Renal Function among Patients with Possible Cefepime-Induced Encephalopathy

2259  Predictors of Empiric Carbapenem Therapy in Complicated Intra-Abdominal Infections in the US, 2013-2017: A Retrospective Cohort Study

2260  Clofazimine safety and efficacy for treatment of multidrug-resistant non-tuberculous mycobacteria (NTM)

2261  Oral Fosfomycin for Treatment of Urinary Tract Infections due to Extended-Spectrum Beta-Lactamase and Carbapenem-Resistant Enterobacteriaceae

2262  Cefazidime-avibactam versus Polymyxin B in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae

2263  Fosfomycin Trometerol Use for Complicated UTIs Including Pyelonephritis, a 1-year Review of Outcomes and Prescribing Habits

2264  An Evaluation of Empiric Treatment Patterns for Adult Patients (Pts) with Community-Onset (CO) “Low-Risk” (LR) Complicated Intra Abdominal Infections (cIAI) Across US Hospitals

2265  Clinical outcomes with single versus combination antibiotic therapy in the treatment of Burkholderia cepacia complex bacteremia and pneumonia

2266  Management of Ertapenem-resistant, Meropenem-susceptible Enterobacteriaceae

2267  Epidemiology of Candida auris candidemia in a teaching hospital in north of Oman: one year survival

2268  Clinical implications of azole-resistant vs. azole-susceptible invasive aspergillosis in hematological malignancy (CLARITY) – a multicenter study

2269  Clinical Outcomes In Patients With Carbapenem-Non-Susceptible, β-lactam-Susceptible Pseudomonas aeruginosa Infections

2270  Initial Treatment Selection Among Patients with Recurrent Pseudomonas aeruginosa (PSA) Infections (Infxs): Does Prior PSA Antibiotic Susceptibility Results Effect Subsequent Empiric Treatment Decisions?

2271  Bacteremia due to multi-drug resistant organisms is an independent risk factor for death among patients (pts) supported by extracorporeal membrane oxygenation (ECMO)

2272  Evaluation of Clinical Features, Carbapenem Resistance and Risk Factors of Klebsiella species: a Four-year retrospective study in Turkey

2273  Outcomes of Trimethoprim/Sulfamethoxazole as definitive therapy for urinary tract infections with multi-drug resistant Enterobacteriaceae

2274  Comparison of Clinical Outcomes in Patients with Extensively Drug-Resistant Pseudomonas aeruginosa Pneumonia Treated with Aminoglycosides versus Ceftolozane/Tazobactam

2275  Novel Therapeutic Options for the Treatment of Multi-Drug Resistant Acinetobacter Respiratory Infections

2276  Clinical Epidemiology of the Carbapenem-Resistant Enterobacteriaceae (CRE) Epidemic in Colombia: A Multicenter Prospective Study

2277  Comparison of 30-day Crude Mortality Rates in Patients with Bloodstream Infections (BSIs) Caused by Colistin Susceptible-(ColS-CRKP) vs Colistin and Carbapenem Resistant-Klebsiella pneumoniae(ColR-CRKP)

2278  Emergence of Resistance and Associated Mortality during Persistent Pseudomonas aeruginosa Bacteremia in Hematopoietic Cell Transplant Recipients and Hematologic Malignancy Patients

2279  Study of Prescribing patterns and Effectiveness of Ceftolozane-Tazobactam (C/T): Real-world Analysis (SPECTRA): a multi-national, multicenter observational study

2280  Bloodstream Klebsiella pneumonia infection and carbapenem combination treatment regimen in high-dose vasopressor-dependent septic shock

2281  Ceftolozane-Tazobactam (C/T) Treatment Outcomes in Immunocompromised (IC) Patients with Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PA) Infections

2282  Empiric Antimicrobial Therapy and Clinical Outcomes of Infections due to ESBL-producing Klebsiella pneumoniae

2283  The Incidence and Risk Factors for Neurotoxicity in Patients on Ertapenem Therapy: a Retrospective Case-Control Study

2284  Treatment and Clinical Outcomes Among Infected Patients with Colistin-resistant Klebsiella pneumoniae Bacteremia.

2285  Emergence of perioperative antibiotic non-susceptible pathogens causing prosthetic joint infections in monomicrobial gram negative and polymicrobial infections.

2286  Evaluating the Impact of Ceftolozane-Tazobactam on Clinical Outcomes in Patients with Multi-Drug Resistant Pseudomonas aeruginosa Pneumonia

2287  Real World Use of Tedizolid Phosphate: A Case Series of Long-Term Tolerability

2288  Role of Beta Lactam-Beta Lactamase Inhibitors in Indian Tertiary Care Hospitals: Results from a Nationwide Survey

2289  Bacterial Causes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Patients with Intravenous Drug Use (IVDU): Phase 3 REVIVE Studies
<table>
<thead>
<tr>
<th>Poster Abstract Session</th>
<th>Clinical Virology/Viral Epidemiology</th>
<th>Saturday, 12:15 - 1:30 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>2290</td>
<td>Carbapenem versus Piperacillin-Tazobactam Definitive Therapy for Patients with Bloodstream Infections Due to Ceftriaxone Not Susceptible Escherichia coli or Klebsiella species</td>
<td></td>
</tr>
<tr>
<td>2291</td>
<td>Evaluation of Multidrug-Resistant Pseudomonas aeruginosa Isolates in Patients Receiving Ceflozolame/tazobactam</td>
<td></td>
</tr>
<tr>
<td>2292</td>
<td>Incidence of Acute Kidney Injury Associated with Duration of Vancomycin and Piperacillin/tazobactam Combination Therapy</td>
<td></td>
</tr>
<tr>
<td>2293</td>
<td>Revival of Polymyxins: a Single-Center Historical Cohort of Critically Ill Patients in Brazil</td>
<td></td>
</tr>
<tr>
<td>2294</td>
<td>Comparative Evaluation of Ertapenem and Clindamycin Plus Gentamicin for the Treatment of Postpartum Endometritis</td>
<td></td>
</tr>
<tr>
<td>2295</td>
<td>Clinical characteristics of Achromobacterxylosidans infections in a Korean teaching hospital</td>
<td></td>
</tr>
<tr>
<td>2296</td>
<td>Hypoglycemia Risk with Antibiotics: An Epidemiologic Surveillance Study of the FDA Adverse Event Reporting System (FAERS)</td>
<td></td>
</tr>
<tr>
<td>2297</td>
<td>Epidemiology of Antibiotic Resistant Pathogens and Empiric Treatment Patterns in Community-Onset Sepsis</td>
<td></td>
</tr>
<tr>
<td>2312</td>
<td>Mortality of Severe Dengue Patients Admitted to Intensive Care Units over Fifteen Years: Have We Improved?</td>
<td></td>
</tr>
<tr>
<td>2313</td>
<td>Influenza and Respiratory Syncytial Virus (RSV) Surveillance in the U.S. Department of Veterans Affairs (VA): 2018-2019 Season</td>
<td></td>
</tr>
<tr>
<td>2314</td>
<td>Burden of Respiratory Syncytial Virus (RSV) Infection among Hospitalized Older Adults and those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure(CHF)</td>
<td></td>
</tr>
<tr>
<td>2315</td>
<td>The Relationship of Pre-Hospital Functional Status and Clinical Outcomes in Patients with Laboratory-Confirmed RSV Infection: Active Population-Based Surveillance, 2017-2019</td>
<td></td>
</tr>
<tr>
<td>2316</td>
<td>RSV Mortality: 19 years’ experience in a Paediatric Hospital in Argentina</td>
<td></td>
</tr>
<tr>
<td>2317</td>
<td>Excess Influenza-Attributable Mortality in Los Angeles County (LAC) for the 2013-14 through 2017-18 seasons</td>
<td></td>
</tr>
<tr>
<td>2318</td>
<td>Prevalence of influenza-like illness in sheltered homeless populations: A cross-sectional study in Seattle, WA</td>
<td></td>
</tr>
<tr>
<td>2319</td>
<td>Clinical predictors of influenza and hospitalization of children with influenza in an emergent care setting</td>
<td></td>
</tr>
<tr>
<td>2320</td>
<td>The Role of Ultraviolet Light, Atmospheric Ozone and Humidity in Influenza Activity</td>
<td></td>
</tr>
<tr>
<td>2321</td>
<td>FluMex: A New Clinical Severity Index in Mexican Hospitalized Patients with Influenza</td>
<td></td>
</tr>
<tr>
<td>2322</td>
<td>Etiology, severity of illness, and risk factors for patients hospitalized with acute gastroenteritis from multi-site Veteran’s Affairs (VA) surveillance, 2016-18: results from SUPERNOVA</td>
<td></td>
</tr>
<tr>
<td>2323</td>
<td>Clinical Characteristics and Disease Burden of Epstein-Barr virus and Four β-herpesviruses Infections in Children Visiting Emergency Room</td>
<td></td>
</tr>
<tr>
<td>2324</td>
<td>Respiratory Viral Infection in a Birth Cohort of Infants in Rural Nepal</td>
<td></td>
</tr>
<tr>
<td>2325</td>
<td>Relationship between neighborhood census-tract level poverty and Respiratory Syncytial Virus infection in hospitalized adults in the San Francisco Bay area, CA 2015–2017</td>
<td></td>
</tr>
<tr>
<td>2326</td>
<td>Enterovirus-Associated Acute Flaccid Myelitis. Argentina’s Nationwide Surveillance of Acute Flaccid Paralysis 2016-2018</td>
<td></td>
</tr>
<tr>
<td>2327</td>
<td>2018-2019 Seasonal Epidemiology of Infections Caused by Influenza Viruses and RSV in Ecuadorean Children less than 5 years of Age Residing at Opposite Extremes of Elevation</td>
<td></td>
</tr>
<tr>
<td>2329</td>
<td>Incidences and Characteristics of Influenza among Pregnant Women in Middle-income Countries: Preliminary Results of the Pregnancy and Influenza Multinational Epidemiologic (PRIME) Study</td>
<td></td>
</tr>
<tr>
<td>2330</td>
<td>Acute Flaccid Myelitis Recovery: Filling in the Gaps and Assessing Likelihood for Independent Living</td>
<td></td>
</tr>
<tr>
<td>2331</td>
<td>Seroprevalence of Cytomegalovirus in Pregnant Women and Birth Prevalence of Congenital Cytomegalovirus Infection in Henan Province, China</td>
<td></td>
</tr>
<tr>
<td>2332</td>
<td>Low Serum Vitamin D Levels Are Related To Life-Threatening Respiratory Syncytial Virus Infection in Previously Healthy Infants</td>
<td></td>
</tr>
<tr>
<td>2333</td>
<td>Influenza-Related Neurologic Complications in Hospitalized Children with Underlying Neurologic Disorders</td>
<td></td>
</tr>
</tbody>
</table>
248. Poster Abstract Session
**Congenital Infections: CMV and HSV**
Saturday, 12:15 - 1:30 p.m.
- 2334 Saliva Screening for Congenital Cytomegalovirus Infection in the Neonatal Intensive Care Unit: Beware!
- 2335 Newborn Dried Blood Spot for Retrospective Diagnosis of Congenital Cytomegalovirus (CMV) Infection: It’s Time for Universal Screening!
- 2336 Adherence to follow up and CMV testing in infants who failed newborn hearing screens: Evaluation of new protocol to ensure follow up and testing
- 2337 Health Outcomes in Congenital Cytomegalovirus, A Systematized and Unbiased Approach in the Electronic Medical Record Era
- 2338 Early Predictors of Mortality in Neonatal Disseminated Herpes Simplex Virus Infection

249. Poster Abstract Session
**HAI: C. difficile, Diagnostic Stewardship**
Saturday, 12:15 - 1:30 p.m.
- 2339 *Clostridioides difficile*: Impact of active screening of asymptomatic carriers and testing stewardship
- 2340 Diagnostic Stewardship: Survey of Urine Culturing and *C. difficile* Testing Practices Amongst Oregon Microbiology Labs
- 2341 Effectiveness of interventions targeting stewardship of *Clostridium difficile* testing
- 2342 Elimination of Reflexive *C. difficile* PCR Testing among Inpatients Resulted in Cost Savings without Adverse Events
- 2343 How Smart is the Chart? Accuracy of the Medical Record in Documenting Diarrhea in Patients Tested for *Clostridium difficile* Infection
- 2344 Evaluation of a Best Practice Alert (BPA) to Reduce Inappropriate Testing for *Clostridium difficile* infection (CDI) within a Multi-Hospital System
- 2345 Reduction in Testing and Change in Testing Algorithm Associated with Decrease in Number of Nosocomial *Clostridium difficile* Infections
- 2346 Cost Savings Associated with Implementation of Clinical Decision Support for *Clostridioides difficile* Testing
- 2347 Impact of Multidisciplinary Review of *Clostridioides difficile* Testing
- 2348 Incorporating Electronic Medical Record hard stops to reduce inappropriate *Clostridioides difficile* testing at an Academic Medical Center- A Quality Improvement Study
- 2349 C. diff-ent results: Eliminating inappropriate stool PCR tests through an Interdisciplinary Infection Prevention & Microbiology collaboration
- 2350 Electronic Interventions to Improve *Clostridioides difficile* Ordering Practices and Incidence: Impact of Soft Stops versus Hard Stops
- 2351 Rate and Consequences of Missed *Clostridioides* (*Clostridium*) *difficile* Infection Diagnosis from Non-disclosure of *Clostridioides difficile* Multiplex PCR Results: Two-Hospitals Experience
- 2352 Clinician assessment of pre-test probability for *Clostridioides difficile* infection and disease severity while using multiplex, syndromic molecular panel in patients presenting with diarrhea.

2353 Easy Does It: Decreasing and Sustained Hospital-Onset (HO) CDI Lab-ID Event Incidence Through a Series of Interventions
2354 Report at Your Own Risk! Diagnostic Stewardship of *Clostridioides difficile* PCR Results from Syndromic Diarrhea Panel and Implications for Patient Outcomes

250. Poster Abstract Session
**HAI: C. difficile, Diagnostic Testing**
Saturday, 12:15 - 1:30 p.m.
- 2355 The Association between Diagnostic Testing Method and *Clostridioides difficile* Infection Severity
- 2356 Increased Clinical Specificity with Ultrasensitive Detection of *Clostridioides difficile* Toxins: Reduction of Overdiagnosis Compared to Nucleic Acid Amplification Tests
- 2357 Toxin Detection Using Single Molecule Counting Technology: The Best of Both Worlds?
- 2358 Understanding the Clinical Implications of *Clostridium difficile* Detection in the Molecular Age: Colonization versus Infection in Children Less Than 3 Years of Age
- 2359 Prospective Feasibility Study for Novel Ultrasensitive Multiplexed Immunoassay for *Clostridioides difficile* Toxins A and B
- 2360 Impact of a Two-Step Antimicrobial Stewardship Intervention on *C. difficile* Infection Diagnosis at an Urban Veteran’s Affairs Medical Center
- 2361 Evaluation of a 2-step testing algorithm for *Clostridioides difficile* infection
- 2362 Back to the Future: The Impact of Multi-step Algorithm *C. difficile* Testing at a Large Tertiary Medical Center
- 2363 Implementation of a multi-step diagnostic algorithm for *C. difficile* infection
- 2364 Surprising Prescribing: Treatment Practices following Addition of Toxin Testing to an Existing Molecular Test for *Clostridioides difficile*
- 2365 Volatile Metabolite Based Detection of *Clostridioides difficile* Infection (CDI)
- 2366 PCR Followed by Toxin EIA for the Diagnosis of *C. difficile* Infection
- 2367 Selecting testing frequency for estimation of incubation periods: a simulation study based on *Clostridioides difficile* observations

251. Poster Abstract Session
**HAI: C. difficile, Epidemiology**
Saturday, 12:15 - 1:30 p.m.
- 2368 Molecular Epidemiology of *Clostridioides difficile* Infections in Pediatric Oncology and Transplant Patients
- 2369 Prescribing choices and *C. difficile* infection risk: a longitudinal cohort study of nursing home residents in Ontario, Canada
- 2370 Risk Factors for *Clostridioides difficile* Colonization among Adult Inpatients: A Meta-Analysis
- 2371 A Multicenter Cohort Study of the Natural History of *Clostridioides difficile* Colonization and Infection
- 2372 PCR ribotype and antimicrobial susceptibility of *Clostridioides* (formerly *Clostridium*) *difficile* in Korea
<table>
<thead>
<tr>
<th>Poster Abstract Sessions (continued)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2373 Impact of a Change in Testing Strategy for Clostridioides difficile Infection on a Publicly Reported Metric and Treatment Days of Therapy</td>
</tr>
<tr>
<td>2374 Healthcare Resource Use, Costs, and Recurrences in Patients with Clostridioides difficile Infection: A Real-world Data Analysis</td>
</tr>
<tr>
<td>2375 Association between Clostridium difficile Colonization and Inflammatory Bowel Disease Activity</td>
</tr>
<tr>
<td>2376 Incidence of Clostridioides Difficile Infection Among United States Medicare Advantage Enrollees</td>
</tr>
<tr>
<td>2377 Social determinants impact readmission following Clostridioides difficile-related index hospital stay in Medicare patients</td>
</tr>
<tr>
<td>2378 Corticosteroid Use Prevents Primary Clostridioides difficile Infection in the Setting of Broad-Spectrum Antibiotic Use Among Hospitalized Patients</td>
</tr>
<tr>
<td>2379 It’s Getting Complicated: Outcomes of Clostridioides difficile PCR Positive/Toxin Negative Patients</td>
</tr>
<tr>
<td>2380 Fecal Collinsella Abundance is Negatively Associated with Toxin A/B Production in Cancer Patients with Clostridioides difficile</td>
</tr>
<tr>
<td>2381 Epidemiology of Clostridium difficile infection in Patients Receiving Interleukin-2 Therapy</td>
</tr>
<tr>
<td>2382 Recurrent Clostridioides difficile Infection (CDI) Worsens Anxiety-Related Patient-Reported Quality of Life</td>
</tr>
<tr>
<td>2383 Epidemiological and Clinical Features of Clostridioides difficile Infections in Pediatric Oncology and Transplant Patients</td>
</tr>
<tr>
<td>2384 The relationship between rifaximin use and the prevalence of Clostridioides difficile and Vancomycin-resistant Enterococcus in patients with advanced liver disease</td>
</tr>
<tr>
<td>2385 Evaluating the Antibiotic Risk for Clostridioides difficile Infection (CDI): Comparing Piperacillin/Tazobactam to Cefepime and Ceftazidime</td>
</tr>
<tr>
<td>2386 Mortality reduction with implementation of a standardized approach of surveillance, diagnosis and treatment of Clostridioides difficile infections,</td>
</tr>
<tr>
<td>2387 Learning the Influence of Individual Clostridioides difficile Infections</td>
</tr>
<tr>
<td>2388 High-risk antibiotics associated with Clostridioides difficile infection: a national, multicenter analysis</td>
</tr>
<tr>
<td>2389 Assessing the Time Course of Proton Pump Inhibitor Use and Clostridioides difficile Infection</td>
</tr>
<tr>
<td>2390 Acquisition of Clostridium difficile Infection Following Exposure from Roommate Defined by Concordance on Genotyping</td>
</tr>
<tr>
<td>2391 Increased Risk of Systemic Infections with Multidrug-Resistant Organisms in Patients with Severe Clostridioides difficile Infection</td>
</tr>
<tr>
<td>2392 Identifying Associations between Clostridium difficile Infection Incidence and Cancer Patients Receiving Chemotherapy</td>
</tr>
<tr>
<td>2393 Dimensions of Cumulative Antibiotic Exposure and Risk of Hospital Onset Clostridium Difficile</td>
</tr>
<tr>
<td>2394 A Longitudinal Study of the Effect of Renal Failure on Readmission Rates of Patients with Clostridiodes difficile</td>
</tr>
<tr>
<td>2395 Analysis of Countywide Clostridioides difficile Infection using Descriptive Statistics and Geographic Information Systems Mapping</td>
</tr>
<tr>
<td>2396 Clostridium difficile Infection is Children with Sickle Cell Disease: An Uncommon Entity</td>
</tr>
<tr>
<td>2397 Effects of antimicrobial surgical prophylaxis on rates of Clostridioides difficile infection</td>
</tr>
<tr>
<td>2398 Effect of Eosinopenia and Binary Toxin on Clostridioides difficile infection Clinical Outcomes</td>
</tr>
<tr>
<td>2399 Ribotype Diversity of Clostridioides difficile strains obtained during screening tests</td>
</tr>
<tr>
<td>2400 Are Multiple Clostridioides difficile Infections in Pediatric Oncology Patients Related to Recurrence of the Same Isolate or Re-infections with Different isolates?</td>
</tr>
<tr>
<td>2401 Epidemiology of Clostridium difficile Infection in Intestinal and Multivisceral Transplant Patients at a Single Transplant Center</td>
</tr>
<tr>
<td>2402 Clinical Outcomes Associated with an Emerging Clostridioides difficile Ribotype 255 in Texas</td>
</tr>
<tr>
<td>2403 Clostridium difficile ribotypes and human microbiota differ in Taiwan and the US with respect to diarrheal patients</td>
</tr>
<tr>
<td>2404 Molecular Epidemiology of Clostridioides difficile in the United States, 2017</td>
</tr>
<tr>
<td>2405 Clinical Characteristics and Prognostic Factors for Extraintestinal Infection Caused by Clostridium difficile: An Analysis of 62, Consecutive Cases</td>
</tr>
<tr>
<td>2406 Trends of Clostridioides difficile associated diarrheoa at a tertiary care centre in India</td>
</tr>
<tr>
<td>2407 Overexpression of Virulence Factors in Biofilm from Recurrent Clostridium (Clostridioides) difficile Infection Isolates,</td>
</tr>
<tr>
<td>2408 Genotypic Corroboration of Epidemiologically Linked Clusters to Detect Outbreaks of C. difficile at a Tertiary Care Hospital</td>
</tr>
<tr>
<td>2409 External Validation and Comparison of Clostridioides difficile Severity Scoring Systems</td>
</tr>
<tr>
<td>2410 Molecular Characteristics of Environmental Clostridioides difficile From a Large Texas Hospital</td>
</tr>
</tbody>
</table>

**252. Poster Abstract Session**

**HAI: C. difficile, Prevention**

Saturday, 12:15 - 1:30 p.m.

| 2411 | One Dose Vancomycin Prophylaxis for In-Hospital Clostridiodes difficile - Associated Disease |
| 2412 | Oral Vancomycin Prophylaxis Against Recurrent Clostridioides difficile Infection: Efficacy and Side Effects: Two Hospitals Experience |
| 2413 | Assessment of compliance with Clostridioides difficile prophylaxis guideline and its efficacy on secondary prophylaxis and reducing hospital-onset Clostridioides difficile infections. |
| 2415 | Oral Vancomycin for Secondary Prophylaxis of Clostridium difficile Infections among High Risk Patients |
| 2416 | Effect of Sequential Universal Bleach Cleaning and Best Practice Alerts on Clostridiodes difficile Infection Rates |
| 2417 | Feasibility and safety of using a probiotic comprised of Lactobacillus acidophilus CL1285, L. casei LBC80R and L. rhamnosus CLR2 for C. difficile infection prevention among antibiotic users: 15-years of prospective results from a single-center |
| 2418 | Determining the impact of visitor contact precautions on hospital-onset Clostridiodes difficile infection rates: An agent-based simulation modeling approach |
2419 Timing of Secondary Prophylaxis Against *Clostridium difficile* Infection After Antibiotic Exposure

2420 Reduced hospital-onset *Clostridium difficile* infection incidence following *Saccharomyces boulardii* co-administration with broad-spectrum antibiotics during hospitalization.

2421 Efficacy of Secondary Prophylaxis with Oral Vancomycin in Preventing Recurrent *Clostridium difficile* Infections in Patients Receiving Systemic Antibiotics

2422 Effectiveness of a Probiotic for Primary Prevention of *Clostridium difficile* Infection and Antibiotic-Associated Diarrhea among Hospitalized Patients Receiving Broad-Spectrum Antibiotics

2423 Cost-effectiveness of core and emerging infection control interventions to reduce hospital-onset *Clostridium difficile* infection: an agent-based simulation modeling approach

2424 Shedding of Viable *Clostridium difficile* in Patients Admitted to a Medical Intensive Care Unit

253. Poster Abstract Session

**HAI: C. difficile, Surveillance**

Saturday, 12:15 - 1:30 p.m.

2425 Correlating Use of High-Risk Antimicrobials and the Incidence of Hospital-Onset *Clostridium difficile* Infection: Targeting Prescribing Trends for Antimicrobial Stewardship

2426 Performance of Statistical Process Control Charts for Detecting Clinically-Significant Increases in *Clostridium difficile* Infection Rates

2427 A Laboratory Simulation and Field Study of Simplified Qualitative and Quantitative Environmental Cultures for *Clostridium difficile*

2428 Whole Genome Sequencing to Determine *Clostridium difficile* Transmission

2429 Whole Genome Sequencing of Healthcare-Onset C. difficile Infection (HO-CDI) Cases Shows Widespread Presence of Antimicrobial Resistance Genes

2430 Comorbidity and Severity of Illness Risk Adjustment for Hospital-Onset *Clostridium difficile* Infection

2431 When More is Less – Recognizing More Community Onset *Clostridium difficile* Infections Helps to Dramatically Lower C. diff Standardized Infection Ratio (SIR)

254. Poster Abstract Session

**HAI: C. difficile, Treatment**

Saturday, 12:15 - 1:30 p.m.

2432 Durability Against Antibiotics After Response to Fecal Microbiota Transplantation in Recurrent *Clostridium difficile* Infection

2433 Oral Vancomycin Plus Intravenous Metronidazole for Severe *Clostridium difficile* Infection in Critically Ill Patients

2434 Proton Pump Inhibitor Use on Efficacy of Fecal Microbiota Transplant Administered by Trans-Oral Routes for *Clostridium Difficile* Infection: A Systematic Review and Analysis

2435 The Impact of Treatment Strategy and Toxin Status on Outcomes of Patients with *Clostridium difficile* Infections

2436 Real-world Evidence of Fecal Microbiota Transplant Use and Outcomes in Patients with *Clostridium difficile* Infection

2437 First-line Fidaxomicin Use in High Risk Inpatients Reduces Recurrence Rates

255. Poster Abstract Session

**HAI: Epidemiology Methods**

Saturday, 12:15 - 1:30 p.m.

2438 Using Artificial Neural Networks to Predict Intra-Abdominal Abscess Risk Post-Appendectomy

2439 The role of positive externalities in economic evaluations of new antibiotics: modeling the impact of reduced transmission in healthcare facilities

2440 Using a geospatially explicit agent-based model of a regional healthcare network to assess varied antibiotic risk on *Clostridium difficile* infection incidence

2441 Automated, rapid detection of potential healthcare-acquired infection clusters based on microbiology and patient geotemporal data

2442 Detection of Prosthetic Hip and Knee Joint Infections Using Administrative Databases – A Validation Study

2443 Impact of antimicrobial stewardship on the incidence of Carbapenem-resistant *Pseudomonas aeruginosa*: a nonlinear time-series analysis approach to identify carapenem thresholds

256. Poster Abstract Session

**HAI: Miscellaneous**

Saturday, 12:15 - 1:30 p.m.

2444 Infection Prevention in Home Health Care: Results from a National Study of Home Health Agencies

2445 Risk for Readmission and Mortality Amongst LTACH Residents with New-Onset Healthcare-Associated Infections

2446 Longitudinal Results and Cost Savings Using a Bundle of *C. difficile* Infection Prevention Strategies in a Long-Term Care Facility

2447 Impact of Agency-Level Policies and Priorities upon Infection Prevention and Control in the Home Environment: Perspectives of Home Health Staff

2448 Clinical Presentation and Outcomes of Long-Term Care Residents with Coronavirus Respiratory Infection: A Retrospective Cohort Study

2449 Early Detection of *Candida auris* is Essential to Control Spread: Four Effective Active Surveillance Strategies

2450 A data-driven model of the economic burden of healthcare-associated infections as impacted by use of comprehensive genomic analysis of bacteria

257. Poster Abstract Session

**HAI: Outbreaks**

Saturday, 12:15 - 1:30 p.m.

2451 Hospital-acquired *Legionella* Pneumonia Outbreak at an Academic Medical Center. A Case-Control Study of Risk Factors

2452 Outbreak of Candidemia Associated With a Contaminated Intravenous (IV) Anesthetic in an Adult Intensive Care Unit (ICU) in San Luis Potosi, Mexico.
### Poster Abstract Sessions (continued)

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2453</td>
<td>Prolonged Local Epidemic of an XDR <em>P. aeruginosa</em> Subclade of High-Risk Clonal Complex 298</td>
</tr>
<tr>
<td>2454</td>
<td>A Cluster of Gram-Negative Bloodstream Infections in Connecticut Hemodialysis Patients Associated with Contaminated Wall Boxes and Priming Buckets</td>
</tr>
<tr>
<td>2455</td>
<td>Outbreak of carbapenemase-producing <em>Enterobacteriaceae</em> in cardiology units associated with contaminated water dispenser and sink drain in Korea</td>
</tr>
<tr>
<td>2456</td>
<td><em>Stenotrophomonas maltophilia</em> (SM) Pseudo-outbreak Associated with Bronchoscope</td>
</tr>
<tr>
<td>2457</td>
<td>Data Science for Outbreak Investigation: Identifying Risk Factors, Tracking Contacts, and Eliciting Transmission Pathways in a Vancomycin-Resistant Enterococci (VRE) Outbreak</td>
</tr>
<tr>
<td>2458</td>
<td>A comprehensive approach to ending an outbreak of rare OXA-72 producing carbapenem-resistant <em>Acinetobacter baumannii</em> at a Community Hospital, Kansas City, MO, 2018</td>
</tr>
<tr>
<td>2459</td>
<td>Control of a Healthcare-associated Infection Outbreak with Carbapenem-resistant <em>Klebsiella pneumonia</em> at a Respiratory Intensive Care Unit (RICU) in an Acute Care Hospital</td>
</tr>
<tr>
<td>2460</td>
<td>Hospital-Wide Outbreak of <em>Serratia marcescens</em> of Unclear Source: When Extensive Infection Control Measures Are Needed</td>
</tr>
<tr>
<td>2461</td>
<td>Community-Acquired in Name Only: A Cluster of Carbapenem-Resistant <em>Acinetobacter baumannii</em> in a Burn Intensive Care Unit</td>
</tr>
<tr>
<td>2462</td>
<td>Public Health Response to Contain the First Outbreak of New Delhi Metallo-β-Lactamase-Producing <em>Klebsiella pneumoniae</em> in Minnesota</td>
</tr>
<tr>
<td>2463</td>
<td>Increased Rates of Candida Bloodstream Infections Associated with Drug Use, United States 2012-2017</td>
</tr>
<tr>
<td>2464</td>
<td>Partnerships in the Field: Using Real-time Sequencing to Enhance Epidemiologic Investigation and Response to a Norovirus Outbreak</td>
</tr>
<tr>
<td>2465</td>
<td>Healthcare-Associated Pediatric Cutaneous Mucormycosis at Texas Children’s Hospital, 2012-2019</td>
</tr>
<tr>
<td>2466</td>
<td>What’s Lurking in the Drain? Serial transmission of NDM-1<em>Klebsiella pneumoniae</em> to patients admitted 9 months apart to the same ICU room</td>
</tr>
</tbody>
</table>

#### 258. Poster Abstract Session

**HAI: Surveillance, Molecular Epidemiology**

**Saturday, 12:15 - 1:30 p.m.**

- Inferring Strain Type Attribution from Antibiotic Resistance Profiles among *E. coli* Causing Healthcare-Associated Infections in the United States, 2013-2017
- Is On-Demand Multilocus Sequence Typing of Methicillin Resistant *Staphylococcus aureus* (MRSA) and *Clostridioides difficile* (C. diff) Hospital Isolates Useful for Infection Control Practice?

#### 259. Poster Abstract Session

**HAI: Surveillance, General**

**Saturday, 12:15 - 1:30 p.m.**


#### 260. Poster Abstract Session

**HAI: Surveillance, International**

**Saturday, 12:15 - 1:30 p.m.**

- Point Prevalence of Healthcare-Associated Infections and Antibiotic Use in a Tertiary Care Teaching Hospital in Nepal: A Cross-Sectional Study
- Trends in Methicillin Resistance Rate of *Staphylococcus aureus* among Medical Facilities Participating in Japan Nosocomial Infections Surveillance (JANIS)
- The 10 Years Scientific Contribution of the Cologne Cohort of Neutropenic Patients (CoCoNut) for Evaluating Treatment and Outcome of Healthcare-associated Infections
- Incidence of Multidrug-Resistant, Extensively Drug-Resistant and Pandrug-Resistant Gram-Negative Bacteria in Brazilian Intensive Care Units
- External and Internal Validation of the Healthcare-associated Infection Data in the Korean National Healthcare-associated Infectious Surveillance System (KONIS)
- Antimicrobial Resistance patterns of *Enterobacteriaceae* and *Pseudomonas aeruginosa* from Colombian clinical isolates, 2017-2018
- Surveillance of antibacterial resistance among clinical isolates from hospitals in Shanghai: results of 2018

#### 261. Poster Abstract Session

**HAI: Surveillance, Regional**

**Saturday, 12:15 - 1:30 p.m.**

- Trends and Regional Differences in Extended Spectrum β-lactamase (ESBL)-producing *Enterobacteriaceae*, 2012-2017
- Communication During Patient Transfers: Describing Gaps in the Infectious Status Information Pipeline
- Comparing inter-hospital patient movement patterns to better understand mechanisms for regional dissemination of carbapenem-resistant *Enterobacteriaceae*

#### 262. Poster Abstract Session

**HIV: Antiretroviral Therapy**

**Saturday, 12:15 - 1:30 p.m.**

- Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance associated mutations through 48 weeks of treatment
- Characteristics and Outcomes Over First 12 Months of a Two-Drug Regimen (Dolutegravir/Rilpivirine) for Treatment of HIV-1 in the United States

---

Final Program IDWeek 2019 • 201
Poster Abstract Sessions (continued)

263. **Poster Abstract Session**  
**HIV: ART Resistance & Adherence**  
Saturday, 12:15 - 1:30 p.m.

- **2505** Incidence of transmitted drug resistance and its clinical implications between 1999-2018 in a regional HIV population  
- **2506** Trends of Transmitted Resistance Mutations to Four Drug Classes, HIV-Subtypes And Herpesviruses Replication Among Subjects Recently Diagnosed as HIV Infected Over 2004-2019  
- **2507** Transmitted and Acquired NNRTI Resistance in the Philippines: Are Newer Generation NNRTIs a Viable Option?  
- **2508** Virologic Suppression in Patients Switched to BIC/TAF/FTC with Baseline NRTI and/or INSTI Resistance  
- **2509** Pooled Resistance Analyses of Darunavir (DRV) Once Daily (QD) Regimens and Formulations Across 10 Clinical Studies of Treatment-Naive (TN) and Treatment-Experienced (TE) Patients With Human Immunodeficiency Virus (HIV)–1 Infection  
- **2510** Systematic Literature Review of Multiclass Resistance in Heavily Treatment Experienced Persons with HIV  
- **2511** Characterization of Patient Pill Preferences from a Prospective Placebo vs. Placebo Ease of Swallowability Study  
- **2512** Decreasing Adherence to Antiretroviral Therapy over 4 Years of Follow-up in a Commercially-Insured Population of Patients with HIV  
- **2513** The Effect of Treatment Supporter Interventions on ART Adherence in Eastern and Southern Africa: a systematic review and meta-analysis  
- **2514** Real-time Antiretroviral Electronic Adherence Monitoring In Young African American Men Who Have Sex With Men

264. **Poster Abstract Session**  
**HIV: Pathogenesis**  
Saturday, 12:15 - 1:30 p.m.

- **2515** Clinical Relevance of Immune Non-Response Among Virally Suppressed Adults Living with HIV in Africa and the United States  
- **2516** Persistence of Anti-HIV Antibodies in HIV-1 Infected Patients on Combination Antiretroviral Therapy (cART) with Prolonged Viral Suppression  
- **2517** Oral Fecal Microbiota Transplantation Increases Gut Microbiome Diversity and Alters the Microbiome Distribution in People with HIV  
- **2518** Development And Characterization Of Human Microglial Models To Elucidate HIV Transmission Events And Pathogenesis  
- **2519** Urban vs Rural HIV-infected Persons Have Differential Gene Expression for Estrogen Signaling, Inflammation, and Cytokine Production Pathways

265. **Poster Abstract Session**  
**HIV: Pediatric**  
Saturday, 12:15 - 1:30 p.m.

- **2520** Resource utilization in adolescents and young adults with HIV in the HIV Research Network
Poster Abstract Sessions (continued)

2521 Prevalence and Associated Factors of Protective Antibody Responses against Diphtheria, Tetanus and Pertussis among HIV-Infected Thai Adolescents Stable on Combination Antiretroviral Treatment

2522 Prescription drug use among women with HIV who are of childbearing potential

2523 Optimizing Disclosure of HIV Status to a Diverse Population of HIV-Positive Pediatric Patients at an Urban HIV Clinic in the Southeastern United States

2524 Prevalence and Associated Factors of Seroprotection against Japanese Encephalitis Virus among HIV-Infected Thai Adolescents Stable on Combination Antiretroviral Treatment

2525 Understanding PrEP in Female Adolescents: A Parent/Adolescent Dyad Perspective

2526 Side Effects of Antiretroviral Therapy in Children with HIV in a Referral Center in Mexico

2527 Improving Care for Adolescents Living with HIV: Evaluating the Impact of Case-Based Education

2528 Inflammation and Plasma Selenium and Chromium in Ugandan Children Living with HIV

2529 Child HIV Exposure and CMV Seroprevalence in Botswana: No Associations with 24-Month Growth and Neurodevelopment

266. Poster Abstract Session

Medical Education: Medical School to Practice
Saturday, 12:15 - 1:30 p.m.

2530 TACO Tuesday as a Medical Education Tool

2531 Using Peer-To-Peer Education to Increase Awareness and Uptake of HPV Vaccine among Chinese International Students

2532 Identifying Educational Needs and Improving Provider Knowledge Regarding the management of Febrile Neutropenia

2533 HIV Training Pathways in Residency: A National Survey of Curricula and Outcomes

2534 Development of an Infectious Diseases Fellowship Well-Being Program

2535 The Stairway to Antibiotic Heaven: Evaluating a Scaffolded Video Series on Empiric Antibiotic Selection

2536 Evaluation of Anticipatory Guidance Provided by Internal Medicine Residents for the Care of Patients with Fever #IDDailyPearl: A Twitter tool to enhance literature engagement on busy infectious diseases consult services

2537 Directed Educational Intervention and Resident Physician Outpatient Antimicrobial Prescribing

2538 Characterization of Infectious Diseases Advanced Pharmacy Practice Experiences at United States Colleges of Pharmacy

2539 Targeting ID Education for Advanced Practice Providers: A Growing Learning Group in Academic Medical Centers

2540 Impact of a Combined Infectious Disease-Critical Care Medicine (ID-CCM) Track on Fellowship Recruitment

2541 ID-Psyk Addiction Rounds: A New Model to Address Opioid Use Disorder For Patients on the Infectious Disease Consult Service

2542 Implementation of a Fellow-Driven Beta-Lactam Allergy De-Labeling Initiative on an Inpatient ID Consult Service

2543 An Exploratory Study of Resource Utilization by Practitioners when Managing Infections

2544 Needs Assessment for a Presentation Skills Curriculum in an Infectious Diseases Fellowship Program

2545 The Mentor Model: Improving Fellow-Level Transitions of Patient Care

2546 Prioritizing Antimicrobial Resistance Learning Objectives through a Modified, Two-Round, One-Day Delphi at a Multidisciplinary Conference

2547 Provider Adherence to Cervical Cancer Screening in HIV Patient Populations

2548 Variance Between Clinicians and Guidelines in Management of HIV/HCV Coinfection

2549 A Meeting of the Minds Over Matters of the Heart: Using Interdisciplinary Education to Build Consensus in Managing Cardiac Implantable Electronic Device (CIED) Infections

2550 Optimizing Rounding Efficiency on the Infectious Diseases Inpatient Service: A Multi-Generational Conversation

2551 Using a digital escape room as a framework for deliberate practice of ID fundamentals

2552 Addressing Knowledge and Practice Gaps in HIV Management with Engaging Continuing Education

2553 A Standardized Medicine Resident Curriculum: Content Survey for an Infectious Diseases Rotation

2554 Relationship Based Communication to Enhance ACGME Infectious Disease Fellowship Competencies

2555 Does a brief education intervention affect perceptions and knowledge regarding HIV Pre-Exposure Prophylaxis among medical trainees?

2556 Knowledge, Attitude, and Practices on Vaccination and Occupational Health Among Healthcare Workers in a Teaching Hospital in Mexico City

2557 Pharmacy Students’ Perceptions and Confidence to Recommend Appropriate Empiric Antibiotic Therapy in Infective Endocarditis Following Mannequin-Based Simulation

2558 A Novel Approach to Interprofessional Education to Expand HIV Workforce Pipeline

2559 Assessing Resident Perspectives on Prescribing Pre-Exposure Prophylaxis for HIV

2560 Doxycycline Saves Lives! Educating Healthcare Providers on Tickborne Rickettsial Diseases in the United States using an Online Toolkit

2561 Implementation of Current Event Assignments to Engage Students and Enhance Public Health and Infectious Diseases Awareness in a Doctor of Pharmacy Program

2562 The Impact of HCV Educational Training on HIV Providers’ Attitudes, Knowledge and Uptake of Treatment initiation in HCV/HIV Coinfected Patients


2564 Initial and Recurrent Episodes of Clostridioides Difficile: Online Education as a Tool to Improve Management Strategies

267. Poster Abstract Session

Microbiome, Antibiotics, and Pathogenesis
Saturday, 12:15 - 1:30 p.m.

2566 Infection Dynamics of Pseudomonas aeruginosa Bloodstream Infections
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2567</td>
<td>Effect of broad vs. narrow spectrum <em>Clostridioides difficile</em> treatment on human stool bile acid composition over time</td>
<td></td>
</tr>
<tr>
<td>2568</td>
<td>Mechanisms of a specific probiotic comprised of <em>Lactobacillus acidophilus</em> CL1285, <em>L. casei</em> LBC80R and <em>L. rhamnosus</em> CLR2 that interferes with <em>Clostridioides difficile</em> 20291 toxin production</td>
<td></td>
</tr>
<tr>
<td>2569</td>
<td>The Gut Microbiome and Acute Graft Versus Host Disease Risk in Haematopoietic Stem Cell Transplantation Recipients</td>
<td></td>
</tr>
<tr>
<td>2570</td>
<td>A Randomized Controlled Trial of <em>Lactobacillus rhamnosus</em> GG on Multidrug Resistant Organism (MDRO) Colonization Recipients</td>
<td></td>
</tr>
<tr>
<td>2571</td>
<td>Norovirus Infection and Gut Microbiota in Transplant Recipients</td>
<td></td>
</tr>
<tr>
<td>2572</td>
<td>The Impact of Antibiotics on the Composition of the Vaginal Microbiota</td>
<td></td>
</tr>
<tr>
<td>2573</td>
<td>Impact of Anaerobic Antibacterial Spectrum on Cystic Fibrosis Lung Microbiome Diversity and Pulmonary Function</td>
<td></td>
</tr>
<tr>
<td>2574</td>
<td>Temporal Changes in the Vaginal Microbiome During Treatment for Bacterial Vaginosis: Is <em>Lactobacillus iners</em> an Important Player?</td>
<td></td>
</tr>
<tr>
<td>2575</td>
<td>Dramatic Time Dependent Changes of Bacterial and Fungal Taxonomic Signatures in 4 Body Regions of ICU Patients</td>
<td></td>
</tr>
<tr>
<td>2576</td>
<td>The Microbiome of Recurrent Bacterial Vaginosis Compared to Asymptomatic Controls</td>
<td></td>
</tr>
<tr>
<td>2577</td>
<td>Periodontal Disease and the Oral Microbiome in Alcohol-Dependent Individuals</td>
<td></td>
</tr>
<tr>
<td>2578</td>
<td>Narrow-spectrum antibiotic treatment of <em>Clostridium difficile</em> infection improves preservation of intestinal metabolic profile</td>
<td></td>
</tr>
<tr>
<td>2579</td>
<td>Impact on the gut microbiota of the prolonged antimicrobial therapy in patients with bone and joint infection (BJI): results from the OSIRIS prospective study in France</td>
<td></td>
</tr>
<tr>
<td>2580</td>
<td>Serial Microbiome Analysis in a Patient with Multiple Failed Fecal Microbiome Transplantations</td>
<td></td>
</tr>
<tr>
<td>2581</td>
<td>An Invertebrate Model to Study Gut Microbiome Dysbiosiosis</td>
<td></td>
</tr>
<tr>
<td>2582</td>
<td>The Association between Dietary Fiber and Diet and Gut Colonization with <em>Clostridium difficile</em></td>
<td></td>
</tr>
<tr>
<td>2583</td>
<td>Short-term Impact of Antimicrobial Exposure on Fecal Carriage of Resistant Microorganisms.</td>
<td></td>
</tr>
<tr>
<td>2584</td>
<td>Effects of fecal microbiota transplantation for decolonizing multidrug resistant organism</td>
<td></td>
</tr>
</tbody>
</table>

268. Poster Abstract Session

**Neonatal Infections: Non CMV/HSV**

Saturday, 12:15 - 1:30 p.m.

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2585</td>
<td>Changing Epidemiological Profile of Infantile Parechovirus-A3 Infection in Japan</td>
<td></td>
</tr>
<tr>
<td>2586</td>
<td>Human Breast Milk Inhibits the Replication of Parechovirus-A3</td>
<td></td>
</tr>
<tr>
<td>2587</td>
<td>Etiology and Outcome of Acute Neonatal Infectious Encephalitis</td>
<td></td>
</tr>
<tr>
<td>2588</td>
<td>Acute Toxoplasmosis among Pregnant Arab Women in Northern Israel: To Screen or Not?</td>
<td></td>
</tr>
<tr>
<td>2589</td>
<td>Two Cases of Congenital Babesiosis</td>
<td></td>
</tr>
</tbody>
</table>

269. Poster Abstract Session

**Pathogenesis and Host-Response Interactions**

Saturday, 12:15 - 1:30 p.m.

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2590</td>
<td>Streptolysin O enhances binding of the group A streptococcal NAD+-glycohydrolase toxin to oropharyngeal keratinocytes</td>
<td></td>
</tr>
<tr>
<td>2591</td>
<td>The Role of Neutralizing Antibodies (nAb) Against <em>Cytomegalovirus</em> (CMV) Epithelial Cell-entry in Patients with Self-limited (SL) CMV infection after Hematopoietic Cell Transplantation (HCT)</td>
<td></td>
</tr>
<tr>
<td>2592</td>
<td>Lung Function as an Indicator of Vaccine Enhanced RSV Disease in Cotton Rats</td>
<td></td>
</tr>
<tr>
<td>2593</td>
<td>Human Monoclonal Antibodies Potently Neutralize Enterovirus D68 in both a Clade-Specific and -Independent Manner</td>
<td></td>
</tr>
<tr>
<td>2594</td>
<td>Biofilm-dispersed <em>Staphylococcus aureus</em> Exhibits a Distinct agr-Independent Host Interaction</td>
<td></td>
</tr>
<tr>
<td>2595</td>
<td>Murine Models for the Host Response to Typical and Atypical Pneumonia</td>
<td></td>
</tr>
<tr>
<td>2596</td>
<td>Invasive Fungal Disease in Patients with GATA2 Variant Hematologic Malignancy</td>
<td></td>
</tr>
<tr>
<td>2597</td>
<td><em>Dolichos biflorus</em> Agglutinin Binds to Pneumococcal Teichoic Acid and Lipoteichoic Acid</td>
<td></td>
</tr>
<tr>
<td>2598</td>
<td>Macrophage Migration Inhibitory Factor May Contribute to Disseminated Coccidioidomycosis Susceptibility</td>
<td></td>
</tr>
<tr>
<td>2599</td>
<td>Studying the effects of altering histone modification on Aspergillus fumigatus virulence</td>
<td></td>
</tr>
<tr>
<td>2600</td>
<td>Mannose-Binding Lectin Polymorphisms are Important Modulating Factors in Community- and Hospital-Acquired Pneumonia Caused by <em>Legionella</em> spp.</td>
<td></td>
</tr>
<tr>
<td>2601</td>
<td>Identification of <em>Staphylococcus aureus</em> genetic factors associated with the subversion of macrophage phagosomal acidification</td>
<td></td>
</tr>
<tr>
<td>2602</td>
<td>Genetic Basis of <em>Staphylococcus aureus</em> Virulence</td>
<td></td>
</tr>
<tr>
<td>2603</td>
<td>Biofilm Formation as a Predictive Marker of Prognosis for <em>Escherichia coli</em> Sepsis</td>
<td></td>
</tr>
<tr>
<td>2604</td>
<td>Changes in a fatty acid kinase associated with daptomycin (DAP) resistance lead to increased collagen binding and biofilm formation in <em>Enterococcus faecalis</em></td>
<td></td>
</tr>
<tr>
<td>2605</td>
<td>Mixed subpopulation of hemolytic and non-hemolytic phenotype in clinical <em>Staphylococcus aureus</em> blood isolates</td>
<td></td>
</tr>
<tr>
<td>2606</td>
<td>A Divergent Ferrichrome Receptor Associated with an Insertional Element (IS3) Identified on Novel Locus in Clinical Strain of <em>Pseudomonas aeruginosa</em></td>
<td></td>
</tr>
<tr>
<td>2607</td>
<td>Establishment of a Novel High-Throughput Fungal Infection Model in Zebrafish Larvae by Controlled Ablation of Epithelial Cells</td>
<td></td>
</tr>
<tr>
<td>2608</td>
<td>Restriction of Rhinovirus Infection Depends on Virus Sensing and Early IFN Induction</td>
<td></td>
</tr>
<tr>
<td>2609</td>
<td><em>Escherichia coli</em> Clonal Lineages and Virulence Factors Predict Fecal Colonization within Households</td>
<td></td>
</tr>
<tr>
<td>2610</td>
<td>A Deadly Intrusion: Competitive Strain Displacement among Dengue Virus Strains in Sri lanka</td>
<td></td>
</tr>
<tr>
<td>2611</td>
<td><em>Enterotoxigenic Bacteroides fragilis</em> Alters the Genome of Colon Epithelial Cells</td>
<td></td>
</tr>
<tr>
<td>ID</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>------</td>
<td>-----------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>2612</td>
<td>Molecular Evidence of Ureaplasma urealyticum And Ureaplasma parvum Colonization In Preterm Infants With Respiratory Distress</td>
<td></td>
</tr>
<tr>
<td>2613</td>
<td>The Epidemiology of Respiratory Syncytial Virus (RSV) in people with immune dysfunction seen at a tertiary hospital between 2010 and 2017</td>
<td></td>
</tr>
<tr>
<td>2614</td>
<td>Demographic and Clinical Characteristics by Antiviral Prescription in Influenza-Positive Children who Presented to Seven U.S. Emergency Departments</td>
<td></td>
</tr>
<tr>
<td>2615</td>
<td>Increased severity of lower respiratory tract infection among Native American compared with non-native American children</td>
<td></td>
</tr>
<tr>
<td>2616</td>
<td>Genetic Susceptibility to Life-Threatening Respiratory Syncytial Virus infection in Previously Healthy Infants</td>
<td></td>
</tr>
<tr>
<td>2617</td>
<td>Increased nasopharyngeal pneumococcal density during asymptomatic respiratory virus infection is associated with subsequent development of acute respiratory illness</td>
<td></td>
</tr>
<tr>
<td>2618</td>
<td>Determination of the Chemical Structure of a Novel Pneumococcal Serotype, 39X</td>
<td></td>
</tr>
<tr>
<td>2619</td>
<td>Clinical Characteristics and Etiology of Community-Acquired Pneumonia in Children: A Contemporary, Prospective, Multicenter Study in Ohio, 2015-2018</td>
<td></td>
</tr>
<tr>
<td>2620</td>
<td>Respiratory Syncytial Virus Rapid Antigen Detection Test, Can It Be Trusted?</td>
<td></td>
</tr>
<tr>
<td>2621</td>
<td>Influence of HIV Exposure Status on Carriage Rates and Density of Streptococcus Pneumoniae and Pneumocystis Jirovecii in Zambian Children</td>
<td></td>
</tr>
<tr>
<td>2622</td>
<td>Multiplex Polymerase Chain Reaction (PCR) Panels in Pediatric Hospital Care: New Insights into Factors Driving Antimicrobial Use.</td>
<td></td>
</tr>
<tr>
<td>2623</td>
<td>Bacterial co-detection and outcomes for infants with bronchiolitis requiring emergency department intubation for respiratory failure</td>
<td></td>
</tr>
<tr>
<td>2624</td>
<td>Viral Pneumonia in Children: Facing the Challenge Using the Host Response</td>
<td></td>
</tr>
<tr>
<td>2625</td>
<td>Incidence of Bronchiolitis Requiring Hospitalization in the First Two Years of Life Among Healthy Term Infants with Different Races/Ethnicities: A Population Based Longitudinal Study</td>
<td></td>
</tr>
<tr>
<td>2626</td>
<td>Rhinovirus in children presenting to the emergency department: role of viral load in disease severity and co-infections</td>
<td></td>
</tr>
<tr>
<td>2627</td>
<td>Dynamics of Respiratory Viral Co-infections: Predisposition for and Clinical Impact of Viral Pairings in Children and Adults</td>
<td></td>
</tr>
<tr>
<td>2630</td>
<td>Treatment of RSV Lower Respiratory Tract Infection in Two Immunocompromised Children with Polyclonal Immunoglobulin Containing Standardized Levels of Neutralizing Anti-RSV Antibody</td>
<td></td>
</tr>
<tr>
<td>2631</td>
<td>Influenza –Associated Intensive Care Unit Hospitalizations and Deaths in Children, During 2010-2019 in Greece</td>
<td></td>
</tr>
<tr>
<td>2632</td>
<td>Cord Blood Vitamin D and Maternal Vaccination Status Associated with Decreased Laboratory Confirmed Influenza Infections in Infants</td>
<td></td>
</tr>
<tr>
<td>2633</td>
<td>Influenza and Tdap Vaccination Coverage among Pregnant Women in the PREVAIL Cohort</td>
<td></td>
</tr>
<tr>
<td>2634</td>
<td>Human Metapneumovirus in a Children's Hospital - It Should Get More Attention</td>
<td></td>
</tr>
<tr>
<td>2635</td>
<td>Outbreak of Enterovirus D68 among Children in Japan and Simultaneous Circulation of Clade B3 in Europe</td>
<td></td>
</tr>
<tr>
<td>2636</td>
<td>Distinguishing Pertussis from Viral Mimickers: Development and Validation of a Clinical Prediction Score</td>
<td></td>
</tr>
</tbody>
</table>

**271. Poster Abstract Session**

**Pediatric Respiratory Viral Infections**

**Saturday, 12:15 - 1:30 p.m.**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2629</td>
<td>Respiratory Syncytial Virus Epidemiology and Factors Associated with Severity among Hospitalized Infants in Four Middle-Income Countries, 2015-2017</td>
<td></td>
</tr>
</tbody>
</table>

**270. Poster Abstract Session**

**Pediatric Respiratory Infections**

**Saturday, 12:15 - 1:30 p.m.**

**Poster Abstract Sessions (continued)**

Four Middle-Income Countries, 2015-2017 Associated with Severity among Hospitalized Infants in Respiratory Syncytial Virus Epidemiology and Factors for and Clinical Impact of Viral Pairings in Children and Dynamics of Respiratory Viral Co-infections: Predisposition in infections.

Rhinovirus in children presenting to the emergency department - role of viral load in disease severity and co-infections.

Molecular Evidence of Ureaplasma urealyticum And Ureaplasma parvum Colonization In Preterm Infants With Respiratory Distress.

The Epidemiology of Respiratory Syncytial Virus (RSV) in people with immune dysfunction seen at a tertiary hospital between 2010 and 2017.

Demographic and Clinical Characteristics by Antiviral Prescription in Influenza-Positive Children who Presented to Seven U.S. Emergency Departments.

Increased severity of lower respiratory tract infection among Native American compared with non-native American children.

Genetic Susceptibility to Life-Threatening Respiratory Syncytial Virus infection in Previously Healthy Infants.

Increased nasopharyngeal pneumococcal density during asymptomatic respiratory virus infection is associated with subsequent development of acute respiratory illness.

Determination of the Chemical Structure of a Novel Pneumococcal Serotype, 39X.

Clinical Characteristics and Etiology of Community-Acquired Pneumonia in Children: A Contemporary, Prospective, Multicenter Study in Ohio, 2015-2018.

Respiratory Syncytial Virus Rapid Antigen Detection Test, Can It Be Trusted?

Influence of HIV Exposure Status on Carriage Rates and Density of Streptococcus Pneumoniae and Pneumocystis Jirovecii in Zambian Children.

Multiplex Polymerase Chain Reaction (PCR) Panels in Pediatric Hospital Care: New Insights into Factors Driving Antimicrobial Use.

Bacterial co-detection and outcomes for infants with bronchiolitis requiring emergency department intubation for respiratory failure.

Viral Pneumonia in Children: Facing the Challenge Using the Host Response.

Incidence of Bronchiolitis Requiring Hospitalization in the First Two Years of Life Among Healthy Term Infants with Different Races/Ethnicities: A Population Based Longitudinal Study.

Rhinovirus in children presenting to the emergency department: role of viral load in disease severity and co-infections.

Dynamics of Respiratory Viral Co-infections: Predisposition for and Clinical Impact of Viral Pairings in Children and Adults.


Clinical Outcomes of Oseltamivir versus Baloxavir in Adult Patients with Seasonal Influenza: Prospective Observational Study.

Evaluation of Clinical Course and Health-Related Quality-of-Life Following Treatment with Oseltamivir, Laninamivir and Baloxavir Marboxil in Adult Patients with Seasonal Influenza: Prospective Observational Study.


Transmission Dynamics of Respiratory Viruses in the Pediatric Intensive Care Unit.

Incidence and Outcomes of Respiratory Viral Co-infections in Hospitalized Children with Bronchiolitis: A Single Center Experience.

Density of Influenza Virus F Protein Vaccine for the Prevention of RSV Lower Respiratory Tract Infection in Infants.

Respiratory Syncytial Virus Hospitalizations (RSVH) and All-Cause Bronchiolitis Hospitalizations (BH) Among 29-34 Weeks Gestational Age (wGA) Preterm Infants Before and After the 2014 American Academy of Pediatrics (AAP) Immunoprophylaxis Policy Change Using the Children's Hospital Association's Pediatric Health Information System (PHIS).

Respiratory virus detections in asthma-related pediatric hospitalizations – New Vaccine Surveillance Network, United States.

Aerosol Versus Oral Ribavirin for the Treatment of Community-acquired Respiratory Virus Infections in Lung Transplant Recipients.

The Characteristics of Influenza-Like Illness (ILI) Management in Japan.

Development of human intestinal organoids as an antiviral evaluation platform for enteroviruses.


Evaluation of Clinical Course and Health-Related Quality-of-Life Following Treatment with Oseltamivir, Laninamivir and Baloxavir Marboxil in Adult Patients with Seasonal Influenza: Prospective Observational Study.

Clinical Outcomes of Oseltamivir versus Baloxavir in Adult Patients Hospitalized with Influenza A.

Incidence of myelosuppression related to valganciclovir prophylaxis in solid organ transplant recipients at high risk of CMV disease.

Influenza Treatment Rates in UK Primary Care Settings: Real-World Data Analysis of the CPRD, 2003-2018.


Influenza and Tdap Vaccination Coverage among Pregnant Women in the PREVAIL Cohort.

Human Metapneumovirus in a Children’s Hospital - It Should Get More Attention.

Distinguishing Pertussis from Viral Mimickers: Development and Validation of a Clinical Prediction Score.

Treatment of RSV Lower Respiratory Tract Infection in Two Immunocompromised Children with Polyclonal Immunoglobulin Containing Standardized Levels of Neutralizing Anti-RSV Antibody.

Influenza –Associated Intensive Care Unit Hospitalizations and Deaths in Children, During 2010-2019 in Greece.

Cord Blood Vitamin D and Maternal Vaccination Status Associated with Decreased Laboratory Confirmed Influenza Infections in Infants.

Influenza and Tdap Vaccination Coverage among Pregnant Women in the PREVAIL Cohort.

Human Metapneumovirus in a Children’s Hospital - It Should Get More Attention.

Distinguishing Pertussis from Viral Mimickers: Development and Validation of a Clinical Prediction Score.
2651 Protection Against Human Cytomegalovirus Acquisition Is Associated with IgG Binding to Cell-Associated CMV glycoprotein B in Two Historical gB/MF59 Vaccine Cohorts
2652 Cytomegalovirus Meningoencephalitis: A Comparison to Other Viral CNS Infections
2653 Epidemiology and Risk Factors for Healthcare Associated Viral Infections in Children
2654 Myocarditis in Dengue: A Prospective Observational Study
2655 A prospective study of cytomegalovirus infection in active systemic lupus erythematosus patients with intense immunosuppressive therapy: epidemiology, associated risk factors, pathogenesis, and clinical outcomes
2656 Eliciting Preferences for Zoster Vaccination in US Adults Aged 50 Years and Older

273. Poster Abstract Session
Transplant ID: Bacterial Infections
Saturday, 12:15 - 1:30 p.m.

2657 Clinical Prediction Tool for Multidrug-Resistant Organisms among Deceased Donors at the Time of Donor Evaluation
2658 Meningitis in Kidney Transplant Recipients: TransMéninges, a French multicentric retrospective cohort study
2659 Retrospective Review of Biopsy Proven Acute Graft Pyelonephritis in Renal Transplant Patients
2660 Infection complications following mismatched allogeic hematopoietic cell transplantation
2661 Sarcopenia Increases Risk of Post-Surgical Infections in Kidney Transplant Recipients
2662 Methenamine Hippurate Decreases the Incidence of Urinary Tract Infections in Adult Renal Transplant Recipients
2663 Impact of Pre-Transplant Microbiology on Acute Outcomes in Cystic Fibrosis Patients Receiving Bilateral Lung Transplants
2664 Impact of Multidrug-Resistant Bacterial Infections in Solid Organ Transplantation: The Value of Electronic Health Records Based Registries and Data Extraction Tools.
2665 Intestinal Microbiome of Patients Submitted to Hematopoietic Stem Cell Transplantation Using Lactobacillus plantarum To Decolonized Multidrug Resistant Bacteria.
2666 De-escalation of Broad-Spectrum Antibiotics in Hematopoietic Stem Cell Transplant Patients During Initial Episode of Febrile Neutropenia
2667 Does ceftazidime-avibactam (CAZ-AVI) improve short- and long-term outcomes among solid organ transplant (SOT) recipients with carbapenem resistant Enterobacteriaceae (CRE) infections?
2668 Beta Lactam and Other Antibiotic Allergies in Patients Undergoing Solid Organ and Hematopoietic Cell Transplantation
2669 Evaluation of Post-operative Acute Kidney Injury with Piperacillin-tazobactam Combined with Vancomycin for Lung Transplant Prophylaxis

274. Poster Abstract Session
Transplant ID: C. diff
Saturday, 12:15 - 1:30 p.m.

2670 Clostridioides difficile infection (CDI) in solid organ (SOT) and hematopoietic stem cell transplant (HCT) recipients: a prospective multinational study
2671 Outcomes of Clostridium difficile Infection in solid-organ transplant patients: Nationwide inpatient sample 2015-2016
2672 Clostridioides difficile Infection among Bone Marrow Transplant Recipients: Findings from a Single Institution
2673 Risk Factors for Clostridium difficile Infection in Lung Transplant Patients

275. Poster Abstract Session
Transplant ID: Malignancy and Neutropenia
Saturday, 12:15 - 1:30 p.m.

2674 Microbiome and Cumulative Antibiotic Use as Predictors of Stenotrophomonas maltophilia Infection in Patients with Acute Myeloid Leukemia Receiving Remission-Induction Chemotherapy
2675 Changing Epidemiology of Bloodstream Infection during Chemotherapy for Acute Leukemia: Impact of Prophylactic Fluoroquinolone Restriction and Carbapenem Saving Strategy
2676 Effect of Beta-Lactam Allergy on Appropriateness of Antibiotic Use in Patients with Febrile Neutropenia
2677 Infection Related Outcomes in Patients With Malignancy Related Febrile Neutropenia: A National Perspective
2678 Characterizing hospitalizations and infections among older adults receiving palliative chemotherapy for hematologic malignancies
2679 Factors Associated with Multidrug-resistant Gram-negative Bacteremia in Acute Leukemia Patients with Neutropenic Fever, a Retrospective Study
2681 Outcomes Related to Respiratory Viral Infections in Cancer Patients on PD-1 Inhibitors
2682 Prophylaxis-Driven Molecular Epidemiology of Pseudomonas aeruginosa Bloodstream Infections in Adults With Leukemia
2683 Evaluation of the Negative Predictive Value (NPV) of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Swab Screening in Acute Myeloid Leukemia Patients
2684 The prospective pilot study of infectious complication surveillance in active systemic lupus erythematosus patients with intense immunosuppressive therapy: cellular response, and clinical outcomes
2685 Oral Third-Generation Cephalosporins Versus Levofloxacin for Antibacterial Prophylaxis in Neutropenic Patients With Hematologic Malignancies
2686 Bloodstream Infection Survey in High-Risk Oncology Patients (BISHOP) with Fever and Neutropenia (FN): Vridans Group Streptococcus Emerges as an Important Pathogen
2687 Extended Infusions of Piperacillin/Tazobactam versus Cefepime for Empiric Treatment of Neutropenic Fever
2688 The clinical impact of early de-escalation of broad-spectrum antibiotics in acute myeloid leukemia patients with febrile neutropenia

206 • Final Program IDWeek 2019
2689  Stenotrophomonas Maltophilia, The Hidden Threat Among Pediatric Cancer Patients
2690  Infectious Complications in Adult Leukemic Patients with Prolonged Neutropenia Undergoing Induction Chemotherapy
2691  Comparison of Incidence and Mortality of Kaposi’s Sarcoma Amongst Solid Organ Transplant Recipients

276. Poster Abstract Session
Transplant ID: Parasitic Infections
Saturday, 12:15 - 1:30 p.m.

2692  Comparison of Demographics and Risk factors between Strongyloides stercoralis Seropositive and Seronegative Solid Organ Transplant Candidates: Experience from a Tertiary Acute Care Center in Florida
2693  Clinical Presentation of Toxoplasmosis and 30-Day Mortality in Transplant Recipients at Two Academic Medical Centers.
2694  Incidence of Pneumocystis jiroveci (PJP) Infection with Three Month Prophylaxis of Aerosolized Pentamidine (AP) in Autologous Hematopoietic Stem Cell Transplantation (HSCT)
2695  Pneumocystis jirovecii pneumonia in the era of effective prophylaxis following hematopoietic stem cell transplantation
2696  Breakthrough Toxoplasmosis While on Atovaquone Prophylaxis Following Allogeneic Hematologic Stem Cell Transplantation
2697  The Impact of Universal Deceased Donor Screening on Donor-Derived Toxoplasmosis in Solid Organ Transplant: Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC)

277. Poster Abstract Session
Vaccines: Bacterial
Saturday, 12:15 - 1:30 p.m.

2698  Timing of Standalone Vaccine Administration in Infants Receiving DTaP-based Combination Vaccines
2699  Pneumococcal Vaccination During Chemotherapy in Children Treated for Acute Lymphoblastic Leukemia
2700  Evaluation of 10- and 13-Valent Protein Conjugate Pneumococcal Vaccine Effectiveness for Children in Korea
2701  The Impact of Infant 13-valent Conjugate Pneumococcal Vaccination Program on Invasive Pneumococcal Disease in Children in British Columbia, Canada
2702  Infants Vaccinated with a Fully-Liquid DTaP-IPV-Hib-HePb Vaccine are Protected During the High-Risk Period for Haemophilus Influenzae Type B Disease
2703  Pneumococcal Carriage of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Non-PCV13 Serotypes among Greek Children Vaccinated with PCV13 in a 3+1 Schedule during the First Six Years after the Fourth Dose of PCV13.
2704  Molecular technology to detect pneumococcal colonization in young children reveals increased prevalence of vaccine serotypes as compared with enhanced culture methods
2705  Serotype replacement following childhood Pneumococcal Conjugate Vaccination Programs in British Columbia, Canada

2706  Indirect Effects of Infant 13-valent Conjugate Pneumococcal Vaccination Program on Invasive Pneumococcal Disease in Adults in British Columbia, Canada
2707  Non 13-Valent Pneumococcal Conjugate Vaccine Serotypes Predominate as Causes of Pneumococcal Otitis Media in Children
2708  Genetic Structure of Streptococcus Pneumoniae Isolated from Invasive Disease in Korea, 2014-2016
2709  Immune response after diphtheria and tetanus toxoid booster in patients with adult onset immunodeficiency with anti-interferon gamma autoantibody
2710  Novel Analytical Models for Pneumococcal Multiplex Opsonophagocytosis Assay Results from a Healthy Older Adult Population Vaccinated with PCV13
2711  Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in older adults
2712  Safety and Immunogenicity of two Doses of ExPEC4V Vaccine Against Extraintestinal Pathogenic Escherichia coli Disease in Healthy Adult Participants
2713  Effectiveness of 23-Valent Pneumococcal polysaccharide Vaccine in Korean National Population Cohort over 65 Years Old
2714  Streptococcus pneumoniae Nasopharyngeal Carriage in Canadian Adults Hospitalized with Community-Acquired Pneumonia from 2010 to 2017
2715  Pneumococcal Community Acquired Pneumonia attributed to PCV13 Serotypes in Hospitalized Adults: Comparison of the 50-64 and 65+ Age Groups
2716  Persistence of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Serotypes in Invasive Pneumococcal Disease in Adults in Southern Ontario Canada Despite Routine Pediatric Vaccination
2717  The impact of pneumococcal conjugate vaccine in nonbacteremic pneumococcal pneumonia among cancer patients
2718  Effectiveness of 13-valent Pneumococcal Conjugate Vaccine in US Adults Hospitalized with Pneumonia, 2014–2017
2719  Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Adults 18-55 Years of Age
2720  Potential Public Health Impact of a Pentavalent vaccine targeting Neisseria meningitidis Serogroups A, B, C, W, and Y
2721  US States’ Policies for Meningococcal Vaccination vs Disease Epidemiology
2722  Effects of Sex, Age, and Race on Immunogenicity of MenB-FHbp, a Bivalent Meningococcal B Vaccine: A Pooled Evaluation of Clinical Trial Data
2722 B  Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS
2723  Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Adolescents 10-17 Years of Age
2724  Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Healthy Meningococcal Vaccine-Naive Children (2-9 Years)
2725 Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-TT) in Adolescents and Adults
2726 Meningococcal vaccination among patients newly diagnosed at high-risk for meningococcal disease in the US
2727 Numbers Needed to Vaccinate for Prevention of Adult Pneumonia with Pneumococcal Conjugate Vaccine: Which Values Should Determine Policy?

278. Poster Abstract Session

Vaccines: Influenza
Saturday, 12:15 - 1:30 p.m.

2728 Proportion of Invasive Pneumococcal Disease Potentially Covered by Current and Next-Generation of Higher-valency Pneumococcal Conjugate Vaccines in Canada, 2010-2016
2729 mRNA Vaccines Encoding Conserved Influenza Antigens Induce Robust and Durable Immunity in Rhesus Macaques
2730 Estimating Deaths Attributable to Influenza Mortality Using Traditional and Novel Forecasting Methods
2731 Does last season’s influenza vaccination affect current season’s vaccine effectiveness in young children?
2732 Estimate of the Effectiveness of Influenza Vaccine among Children for the 2017-2018 Season
2733 Association between Influenza Vaccination Coverage and Ambulatory Antibiotic Prescription Rates in Children in South Carolina
2734 Lack of influence of early exposure to influenza A(H3N2) viruses on vaccine effectiveness against A(H3N2)-associated illness in U.S. children <18 years, 2016-18
2735 Improving Uptake of Maternal Immunizations in the Obstetric Care Setting Through an Adaptation of the CDC’s Immunization Quality Improvement Program (AFIX)
2737 Comparison of Antibody Responses to Vaccination with a Pure Hemagglutinin Influenza Vaccine (rHA) and Licensed Subvirus Influenza Vaccine Made in Eggs or Cell Culture in Adults 60 Years and Older
2738 Influenza Vaccination during Pregnancy among Mothers of Infants with Acute Respiratory Illness, United States, 2016-2018
2739 Comparison of Hemagglutination Antibody Inhibition (HAI) Titers Following Influenza Vaccination by Birth Cohort and Repeated Influenza Vaccination History
2740 Seasonal Influenza Vaccine Timing in Children and Adults Hospitalized with Influenza in the United States, FluSurv-NET, 2013-2017
2742 The Impact of Influenza Vaccination on Antigen Use in the United States, 2010-2017
2743 Safety of Recombinant Influenza Vaccine Compared to Inactivated Influenza Vaccine in Adults
2744 A Phase I randomized, observer-blind, controlled, dose escalation trial of the safety and tolerability of a single intramuscular dose of a PAL adjuvant (Laboratory code, FB-631) co-administered with seasonal TIV (2013-2014) to healthy adults ≥18 – 50 years of age

2745 Efficacy and Effectiveness of High-Dose Influenza Vaccine for Older Adults by Circulating Strain and Antigenic Match: A Systematic Review and Meta-Analysis
2746 Effectiveness of Influenza Vaccine for Prevention of Influenza-associated Hospitalizations among Immunocompromised Adults – 2017-2018
2747 Relative Vaccine Efficacy of High-Dose versus Standard Dose Influenza Vaccines in Preventing Probable Influenza in a US Medicare Fee-For-Service Population
2748 Single Intranasal (IN) Dose of M2SR (M2-Deficient Single Replication) Live Influenza Vaccine Protects Adults Against Subsequent Challenge with a Substantially Drifted H3N2 Strain
2749 Disparities in healthcare seeking behaviors in the Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PAIVED) Study
2750 Sequential Influenza A H1N1 and Influenza A H3N2 Challenge Infections in Healthy Volunteers
2751 Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PAIVED): Methods
2752 Peptide Vaccines Utilizing Conserved Hemagglutinin, Neuraminidase, and Matrix Ectodomain Influenza Epitopes Demonstrate Functional Activity Against Group 1 and 2 Influenza Strains
2753 Induction of Broadly Cross-reactive Immune Responses Against A(H3N2) Viruses: Results of a Phase 2 Trial of a Novel Recombinant Hemagglutinin Saponin-adjuvanted Nanoparticle Seasonal Influenza Vaccine
2754 Phase 1 Trial of an mRNA-based Combination Vaccine Against hMPV and PIV3
2755 Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of a RSV Prefusion F-Based Subunit Vaccine Candidate
2756 Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PAIVED), Influenza-Like-Illnesses (ILIs) Sub-Study at the Marine Corps Recruit Depot-San Diego, CA (MCRD-SD) during the 2018-2019 Influenza Season
2757 Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PAIVED): Immunogenicity Sub-study
2758 Identifying Populations at High-risk for Influenza-related Hospitalization: A Real-world Analysis of Commercially Insured Population in the United States
2759 Immunogenicity of Inactivated Influenza Vaccines Given Early vs Late after Pediatric Allogeneic Hematopoietic Cell Transplantation
2760 Accounting for Vaccination History in Estimates of Current Season Vaccine Effectiveness in the US Flu VE Network, 2012-13 through 2017-18
2761 Interventions to Improve Influenza Vaccination Coverage in Children with Medical Comorbidities: A Meta-Analysis
279. Poster Abstract Session  
**Vaccines: Viral Non-Influenza**  
Saturday, 12:15 - 1:30 p.m.

- 2762 A cohort analysis of completion of the pediatric measles-mumps-rubella-varicella series in the United States
- 2763 Uptake and Safety of Measles-Mumps-Rubella (MMR) Vaccine in Adolescents and Adults in the Vaccine Safety Datalink
- 2764 Generation of a Balanced, Tetravalent Dengue Vaccine Based on Contemporary Strains Using a Computational, Synthetic Biology-based Platform
- 2765 Pediatric Mumps during the 2015–2017 Mumps Resurgence in the United States
- 2766 Identification and Description of Mumps Cases in a Non-Outbreak Setting and the Effectiveness of Mumps Containing Vaccines over Time
- 2767 Variation in incidence of pediatric herpes zoster by first and second dose varicella vaccine formulations
- 2768 Does social media contribute to knowledge about vaccine safety?
- 2769 The Clinical and Economic Impact of MMR Vaccinations to Prevent Measles Importations from US Pediatric Travelers Returning from Abroad
- 2770 Intrapulmonary Vaccination with an M Protein-Deficient Respiratory Syncytial Virus (RSV) Vaccine Protects Infant Baboons Against an RSV Challenge
- 2771 Seroprotection against Measles, Rubella, Tetanus, and Diphtheria Among Children in Haiti — 2017
- 2772 HCMV gB Ectodomain Subunit and gB mRNA Vaccines Reduce AD-3 Immunodominance and Elicit More Durable Antibody Responses Than gB/MF59 Immunization
- 2773 Safety and Immunogenicity Study of Eastern Equine Encephalitis Vaccine
- 2774 Impact of Yellow Fever Vaccine and Recombinant Zoster Vaccine Shortages on Patients Presenting to a Travel Clinic
- 2775 Safety and Immunogenicity of a Seasonal Influenza Vaccine and Ad26.RSV.preF Vaccine With and Without Co-Administration: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study in Adults Aged ≥ 60 Years
- 2776 Post-marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Review of Spontaneous Reports Since Introduction
- 2777 Live-Attenuated Vaccine Against RSV Generates Robust Cellular and Humoral Immune Responses
- 2778 Impact of Reactogenicity on Quality of Life and Physical Functioning in Adults ≥50 Years Receiving Both Doses of the Adjuvanted Recombinant Zoster Vaccine
- 2779 Efficacy of the Adjuvanted Recombinant Zoster Vaccine According to Sex, Geographic Region and Geographic Ancestry/Ethnicity: a Post-hoc Analysis
- 2780 Reactogenicity Profile of Adjuvanted Recombinant Zoster Vaccine after Dose 2 According to the Intensity of the Same Event Experienced after Dose 1
- 2781 Statistical Modeling to Predict Maternal RSV Vaccine Efficacy from Neutralizing Titers

280. Poster Abstract Session  
**Viral Pathogenesis**  
Saturday, 12:15 - 1:30 p.m.

- 2782 Host Immune Response to Enterovirus and Parechovirus Systemic Infections in Children
- 2783 Expansion of Monocytic Myeloid-derived Suppressor Cells in Infants with Severe Respiratory Syncytial Virus (RSV) Infection
- 2784 Increased Frontal Lobe Volume and Density in Macaques Exposed to Zika virus in utero

281. Poster Abstract Session  
**Viral Respiratory Diseases**  
Saturday, 12:15 - 1:30 p.m.

- 2785 Respiratory Viral Panel Testing in Intensive Care Units: Effects on Outcomes
- 2786 The Role of Respiratory Panel PCR in Decreasing Antibiotic Exposure in Patients Diagnosed With a Respiratory Viral Infection
- 2787 Respiratory Syncytial Virus in elderly adults
- 2788 Case Report: Severe Community-Acquired Human Adenovirus 7 Infection in a Mother and Son
- 2789 Respiratory syncytial disease in hospitalized adults: A retrospective cohort study
- 2790 Respiratory Viral Testing and Antimicrobial De-escalation Among Hospitalized Patients at a Tertiary Care Facility, 2015-2016: A Matched Cohort Study Series
- 2791 Burden of respiratory infections in trainees higher than healthcare records indicate: Results from an Anonymous Survey
- 2792 Association of Body Mass Index with Rates of Hospitalization in Patients with Respiratory Viral Infections — Puerto Rico, 2012 – 2018
- 2793 Influenza and Bacterial Pneumonia Coinfection: Rates and Outcomes
- 2794 Testing and Treatment in Patients Hospitalized with Suspected Influenza Pneumonia
- 2795 Clinical and Economic Impact of a Ribavirin Intervention Program in Hematopoietic Cell and Solid Organ Transplant Recipients with Respiratory Syncytial Virus Infection
- 2796 The Impact of Syndromic Molecular Point-Of-Care Testing for Respiratory Viruses on Antibiotic Use in Adults Presenting to Hospital with Exacerbation of Airways Disease: Further Analysis Form a Randomized Controlled Trial
- 2797 Rates of Respiratory Syncytial Virus (RSV) Infection among Hospitalized Adults by Congestive Heart Failure Status — United States, 2015–2017
- 2798 Respiratory Viral Infections In Patients With Lymphoma and Multiple Myeloma: Risk Factors Associated with Progression to Lower Respiratory Tract Infection and Mortality
- 2799 Inability to Locally Differentiate Rhinovirus/Enterovirus Results Impacts Infection Control Practices
- 2800 Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PAIVED): Influenza-like-illness rates in Year 1
## 282. Poster Abstract Session
### Zika Virus Infection
Saturday, 12:15 - 1:30 p.m.

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2801</td>
<td>Post-natal Zika Virus Infection and Impact on Neurodevelopment among a Cohort of Children in Rural Guatemala</td>
</tr>
<tr>
<td>2802</td>
<td>Occupational exposure to the Ugandan strain of Zika virus in a laboratory worker in the United States: clinical presentation, viral persistence, and antibody response</td>
</tr>
<tr>
<td>2803</td>
<td>Is Maternal Plasma Zika Virus Load Associated with Birth Outcomes and Maternal Disease Severity?</td>
</tr>
<tr>
<td>2804</td>
<td>Systematic Review of the Role of Prenatal Ultrasound and Amniocentesis in the Diagnosis and Evaluation of Congenital Zika Syndrome</td>
</tr>
<tr>
<td>2805</td>
<td>Kinetics of anti-Zika Virus (ZIKV) Antibodies after Acute Infection in Pregnant Women</td>
</tr>
<tr>
<td>2806</td>
<td>Follow up of Children with Confirmed Perinatal Zika Virus Exposure: the First 2 years-experience in the Costa Rican Tertiary Pediatric Hospital.</td>
</tr>
</tbody>
</table>
IDSA Board of Directors

Cynthia L. Sears, MD, FIDSA, President; Johns Hopkins University School of Medicine, Baltimore, MD
Thomas M. File, Jr., MD, MSc, FIDSA, President-Elect; Summa Health, Akron, OH
Barbara D. Alexander, MD, MHS, FIDSA, Vice President; Duke University School of Medicine, Durham, NC
Larry K. Pickering, MD, FIDSA, FPIDS, Secretary; Emory University School of Medicine, Atlanta, GA
Helen W. Boucher, MD, FIDSA, Treasurer; Tufts Medical Center, Tufts University School of Medicine, Boston, MA
Paul G. Auwaerator, MD, MBA, FIDSA, Immediate Past President; Johns Hopkins University School of Medicine, Baltimore, MD
Angela M. Caliendo, MD, PhD, FIDSA; Brown University/Rhode Island Hospital, Providence, RI
Jeffrey S. Duchen, MD, FIDSA; Public Health – Seattle & King County, University of Washington, Seattle, WA
Victoria J. Fraser, MD, FIDSA, FSHEA; Washington University School of Medicine, St. Louis, MO
Ann McIntyre, DO, MHS, FIDSA; Mercy Hospital, Palmetto General Hospital, Miami, FL
Jeanne Marrazzo, MD, MPH, FIDSA; University of Alabama at Birmingham School of Medicine, Birmingham, AL
Daniel P. McGuillen, MD, FIDSA; Lahey Hospital & Medical Center, Burlington, MA
Susan J. Rehm, MD, FIDSA; Cleveland Clinic, Cleveland, OH
Tina Q. Tan, MD, FIDSA; Feinberg School of Medicine, Northwestern University, Chicago, IL
Ighowerha Ofotokun, MD, MSc, FIDSA, HIVMA Representative; Emory University School of Medicine, Atlanta, GA
Janet R. Gilksdorf, MD, FIDSA, FPIDS, PIDS Liaison; University of Michigan Medical Center, Ann Arbor, MI
David K. Henderson, MD, FIDSA, FSHEA, SHEA Liaison; National Institutes of Health, Bethesda, MD
Chris Busky, CAE, CEO; Infectious Diseases Society of America, Arlington, VA

SHEA Board of Trustees

Hillary Babcock, MD, MPH, FIDSA, FSHEA, President; Washington University School of Medicine, St. Louis, MO
David K. Henderson, MD, FIDSA, FSHEA, President-Elect; National Institutes of Health, Bethesda, MD
Mary Hayden, MD, FIDSA, FSHEA, Vice President; Rush University Medical Center, Chicago, IL
Grace Lee, MD, MPH, FPIDS, Secretary; Stanford University, Stanford, CA
A. Rekha Murthy, MD, FIDSA, FSHEA, Treasurer; Cedars-Sinai Health System, Los Angeles, CA
Keith Kaye, MD, MPH, FIDSA, FSHEA, Past President; University of Michigan Medical School, Ann Arbor, MI
Gonzalo Bearman, MD, MPH, FACP, FIDSA, FSHEA; Virginia Commonwealth University, Richmond, VA
Miran Dal Ben, MD, MSc; Hospital Sírio Libanès, São Paulo, Brazil
Judith Guzman-Cotrill, DO, FSHEA; Oregon Health & Science University, Portland, OR
Aaron Milstone, MD, MHS, FIDSA, FSHEA; Johns Hopkins University, Baltimore, MD
Trevor Van Schooneveld, MD; University of Nebraska Medical Center, Omaha, NE
Kristina A. Bryant, MD, FPIDS, PIDS Liaison; University of Louisville, Louisville, KY
Gonzalo Bearman, MD, FIDSA, FSHEA, Community-Based Healthcare Epidemiologist Liaison; Parkview Health, Ft. Wayne, IN
Kristy M. Weinsheil, MBA; The Society for Healthcare Epidemiology of America, Arlington, VA

HIVMA Board of Directors

W. David Hardy, MD, Chair; Johns Hopkins University, Washington, DC
Judith Feinberg, MD, Chair-Elect; West Virginia School of Medicine, Morgantown, WV
Rajesh T. Gandhi, MD, FIDSA, Vice-Chair; Massachusetts General Hospital, Boston, MA
Melanie Thompson, MD, Immediate Past Chair; AIDS Research Consortium of Atlanta, Atlanta, GA
Igho Ofotokun, MD, MSc, FIDSA, IDSA Representative; Emory University, Atlanta, GA
Allison Agwu, MD, ScM, FIDSA; Johns Hopkins University, Baltimore, MD
Michelle S. Cespedes, MD, MS; Icahn School of Medicine at Mount Sinai, New York, NY
Jennifer Chang, MD; Kaiser Permanente at LA, Los Angeles, CA
Demetre Daskalakis, MD, MPH; NYC Department of Health and Mental Hygiene, Queens, NY
Marwan S. Haddad, MD, MPH; Community Health Center, Inc., New Haven, CT
Colleen F. Kelley, MD, MPH; Emory University, Atlanta, GA
Lynsay MacLaren, MPH, MPAS, PA-C; Whitman Walker Health, Washington, DC
Michelle Floris-Moore, MD, MS; University of North Carolina, Chapel Hill, NC
Kimmerly Scarsi, PharmD, MS; University of Nebraska Medical Center, Omaha, NE
James M. Sosman, MD; University of Wisconsin School of Medicine and Public Health, Madison, WI
Alice C. Thornton, MD, FIDSA; University of Kentucky School of Medicine, Lexington, KY
Ira Wilson, MD, MSc; Brown University School of Public Health, Providence, RI
Andrea Weddle, MSW; HIV Medicine Association, Arlington, VA

PIDS Board of Directors

Paul W. Spearman, MD, FPIDS, President; Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Janet R. Gilksdorf, MD, FPIDS, Past President; University of Michigan Medical Center, Ann Arbor, MI
Kristina A. Bryant, MD, FPIDS, President-Elect; University of Louisville, Louisville, KY
C. Buddy Creech MD, MPH, FPIDS, Secretary-Treasurer; Vanderbilt University Medical Center, Nashville, TN
Archana Chatterjee, MD, PhD, FPIDS; University of South Dakota - Sanford School of Medicine, Vermillion, SD
Susan E. Coffin, MD, MPH, FPIDS, FSHEA; Children's Hospital of Philadelphia, Philadelphia, PA
Ravi Jhaveri, MD, FPIDS; Ann & Robert H. Lurie Children's Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, IL
Grace M. Lee, MD, MPH, FPIDS; Stanford University, Stanford, CA
Yvonne A. Maldonado, MD, FPIDS; Stanford University, Stanford, CA
Jason G. Newland, MD, MEd, FPIDS; Washington University, St. Louis, MO
Debra L. Palazzi, MD, MEd, FPIDS; Baylor College of Medicine, Houston, TX
Adam J. Ratner, MD, MPH, FPIDS; New York University, New York, NY
Andi L. Shane, MD, MPH, MSc, FPIDS; Emory University School of Medicine, Atlanta, GA
William J. Steinbach, MD, FPIDS; Duke University Medical Center, Durham, NC
Terri Christene Phillips, MSA; Pediatric Infectious Diseases Society, Arlington, VA